{"293abc6b35a4e05e88ae452ef19e257dec0fbfda": [["The fact that these many different systems have complex carbohydrates as a common theme has given rise to the term \"glycobiology,\" which has been defined as \"a study of the structure and function of the carbohydrate modifications on different types of macromolecules\" (9) .", [["carbohydrates", "CHEMICAL", 56, 69], ["carbohydrate", "CHEMICAL", 203, 215], ["a study", "TEST", 158, 165], ["the carbohydrate modifications", "TREATMENT", 199, 229]]]], "671d14a9553ecce89589ccef31aed7cbe079361a": [["IntroductionType I interferon (IFN) cytokines are the first-line of defense against viral infections.", [["viral infections", "DISEASE", 84, 100], ["Type I interferon", "GENE_OR_GENE_PRODUCT", 12, 29], ["IFN", "GENE_OR_GENE_PRODUCT", 31, 34], ["Type I interferon (IFN) cytokines", "PROTEIN", 12, 45], ["IntroductionType I interferon (IFN) cytokines", "TREATMENT", 0, 45], ["viral infections", "PROBLEM", 84, 100], ["viral", "OBSERVATION_MODIFIER", 84, 89], ["infections", "OBSERVATION", 90, 100]]], ["They act through the immune system by rapidly inducting cellular modulators, thus inhibiting viral replication and spreading (Burke et al., 2014) .", [["immune system", "ANATOMY", 21, 34], ["cellular", "ANATOMY", 56, 64], ["cellular", "CELL", 56, 64], ["rapidly inducting cellular modulators", "PROBLEM", 38, 75], ["inhibiting viral replication", "PROBLEM", 82, 110], ["cellular modulators", "OBSERVATION", 56, 75]]], ["Viral infections yield highly conserved pathogen-associated molecular patterns (PAMPs), such as double-stranded RNA (dsRNA).", [["Viral infections", "DISEASE", 0, 16], ["pathogen-associated molecular patterns", "GENE_OR_GENE_PRODUCT", 40, 78], ["pathogen-associated molecular patterns", "PROTEIN", 40, 78], ["PAMPs", "PROTEIN", 80, 85], ["double-stranded RNA", "RNA", 96, 115], ["Viral infections", "PROBLEM", 0, 16], ["double-stranded RNA (dsRNA)", "PROBLEM", 96, 123], ["infections", "OBSERVATION", 6, 16], ["pathogen", "OBSERVATION_MODIFIER", 40, 48], ["stranded RNA", "OBSERVATION_MODIFIER", 103, 115]]], ["Viral RNA contains short hairpin dsRNA with triphosphorylated 5 0 end (5 0 pppRNA) that preferentially activates host's pattern recognition receptors (PRRs), including the retinoic acid inducible gene-I (RIG-I) receptor (Ng and Gommerman, 2013) .", [["retinoic acid", "CHEMICAL", 172, 185], ["pattern recognition receptors", "GENE_OR_GENE_PRODUCT", 120, 149], ["PRRs", "GENE_OR_GENE_PRODUCT", 151, 155], ["retinoic acid inducible gene-I", "GENE_OR_GENE_PRODUCT", 172, 202], ["RIG-I) receptor", "GENE_OR_GENE_PRODUCT", 204, 219], ["Viral RNA", "RNA", 0, 9], ["triphosphorylated 5 0 end", "DNA", 44, 69], ["pattern recognition receptors", "PROTEIN", 120, 149], ["PRRs", "PROTEIN", 151, 155], ["retinoic acid inducible gene-I (RIG-I) receptor", "PROTEIN", 172, 219], ["Ng", "DNA", 221, 223], ["2013", "DNA", 239, 243], ["Viral RNA", "PROBLEM", 0, 9], ["short hairpin dsRNA", "PROBLEM", 19, 38], ["triphosphorylated", "TREATMENT", 44, 61], ["the retinoic acid", "TEST", 168, 185], ["RNA", "OBSERVATION", 6, 9], ["short hairpin", "OBSERVATION_MODIFIER", 19, 32]]], ["Tripartite motif (TRIM) proteins, TRIM25 (Gack et al., 2007) and TRIM4 (Yan et al., 2014) , play a critical role in RIG-I activation through K63-linked ubiquitination.", [["TRIM", "GENE_OR_GENE_PRODUCT", 18, 22], ["TRIM25", "GENE_OR_GENE_PRODUCT", 34, 40], ["RIG-I", "GENE_OR_GENE_PRODUCT", 116, 121], ["K63", "GENE_OR_GENE_PRODUCT", 141, 144], ["Tripartite motif (TRIM) proteins", "PROTEIN", 0, 32], ["TRIM25", "PROTEIN", 34, 40], ["TRIM4", "PROTEIN", 65, 70], ["K63", "PROTEIN", 141, 144], ["ubiquitination", "OBSERVATION", 152, 166]]], ["The activated RIG-I further interacts with mitochondrial antiviral-signaling protein (MAVS) and stimulates transcription factor, IFN regulatory factor-3/7 (IRF-3/7) to induce IFN gene expression (Wilkins and Gale, 2010) .", [["mitochondrial", "ANATOMY", 43, 56], ["RIG-I", "GENE_OR_GENE_PRODUCT", 14, 19], ["mitochondrial", "CELLULAR_COMPONENT", 43, 56], ["antiviral-signaling protein", "GENE_OR_GENE_PRODUCT", 57, 84], ["MAVS", "GENE_OR_GENE_PRODUCT", 86, 90], ["IFN regulatory factor-3/7", "GENE_OR_GENE_PRODUCT", 129, 154], ["IRF-3/7", "GENE_OR_GENE_PRODUCT", 156, 163], ["IFN", "GENE_OR_GENE_PRODUCT", 175, 178], ["RIG-I", "PROTEIN", 14, 19], ["mitochondrial antiviral-signaling protein", "PROTEIN", 43, 84], ["MAVS", "PROTEIN", 86, 90], ["transcription factor", "PROTEIN", 107, 127], ["IFN regulatory factor-3/7", "PROTEIN", 129, 154], ["IRF-3/7", "PROTEIN", 156, 163], ["IFN gene", "DNA", 175, 183], ["mitochondrial antiviral", "TREATMENT", 43, 66], ["signaling protein (MAVS)", "TREATMENT", 67, 91], ["transcription factor", "TEST", 107, 127], ["IFN regulatory factor", "TEST", 129, 150], ["IRF", "TEST", 156, 159]]], ["IFNs, secreted from virus-infected cells, bind to the IFN receptor (IFNAR) on the cell surface to initiate the JAK-STAT pathway.", [["cells", "ANATOMY", 35, 40], ["cell surface", "ANATOMY", 82, 94], ["IFNs", "GENE_OR_GENE_PRODUCT", 0, 4], ["cells", "CELL", 35, 40], ["IFN receptor", "GENE_OR_GENE_PRODUCT", 54, 66], ["IFNAR", "GENE_OR_GENE_PRODUCT", 68, 73], ["cell surface", "CELLULAR_COMPONENT", 82, 94], ["JAK", "GENE_OR_GENE_PRODUCT", 111, 114], ["STAT", "GENE_OR_GENE_PRODUCT", 115, 119], ["IFNs", "PROTEIN", 0, 4], ["virus-infected cells", "CELL_TYPE", 20, 40], ["IFN receptor", "PROTEIN", 54, 66], ["IFNAR", "PROTEIN", 68, 73], ["JAK", "PROTEIN", 111, 114], ["STAT", "PROTEIN", 115, 119], ["IFNs", "PROBLEM", 0, 4], ["virus", "PROBLEM", 20, 25], ["infected cells", "PROBLEM", 26, 40], ["the cell surface", "TREATMENT", 78, 94], ["the JAK", "TREATMENT", 107, 114], ["infected cells", "OBSERVATION", 26, 40]]], ["This upregulates hundreds of IFN-stimulated gene products (ISGs) and suppresses viral infection (Carty et al., 2014; Schneider et al., 2014) .", [["viral infection", "DISEASE", 80, 95], ["IFN-stimulated gene products", "GENE_OR_GENE_PRODUCT", 29, 57], ["IFN-stimulated gene products", "PROTEIN", 29, 57], ["ISGs", "PROTEIN", 59, 63], ["IFN-stimulated gene products", "TREATMENT", 29, 57], ["viral infection", "PROBLEM", 80, 95]]], ["RIG-I agonists have been shown to induce IFN's expression and multiple innate antiviral response to control a number of viral infections.", [["viral infections", "DISEASE", 120, 136], ["RIG-I", "GENE_OR_GENE_PRODUCT", 0, 5], ["IFN", "GENE_OR_GENE_PRODUCT", 41, 44], ["IFN", "PROTEIN", 41, 44], ["RIG-I agonists", "TREATMENT", 0, 14], ["IFN's expression", "TREATMENT", 41, 57], ["multiple innate antiviral response", "TREATMENT", 62, 96], ["viral infections", "PROBLEM", 120, 136], ["viral infections", "OBSERVATION", 120, 136]]], ["These include, vesicular stomatitis virus (VSV) of the family Rhabdoviridae (Goulet et al., 2013) , hepatitis C virus (HCV) of the family Flaviviridae (Goulet et al., 2013) , influenza virus of the family Orthomyxoviridae (Chiang et al., 2015) , and herpes simplex virus type 1 (HSV-1) of the family Herpesviridae (Liu et al., 2016) .", [["vesicular stomatitis", "DISEASE", 15, 35], ["hepatitis C", "DISEASE", 100, 111], ["influenza virus", "DISEASE", 175, 190], ["herpes simplex virus", "DISEASE", 250, 270], ["vesicular stomatitis virus", "ORGANISM", 15, 41], ["VSV", "ORGANISM", 43, 46], ["hepatitis C virus", "ORGANISM", 100, 117], ["HCV", "ORGANISM", 119, 122], ["Flaviviridae", "ORGANISM", 138, 150], ["influenza virus", "ORGANISM", 175, 190], ["herpes simplex virus type 1", "ORGANISM", 250, 277], ["HSV-1", "ORGANISM", 279, 284], ["stomatitis virus", "SPECIES", 25, 41], ["hepatitis C virus", "SPECIES", 100, 117], ["influenza virus", "SPECIES", 175, 190], ["herpes simplex virus type 1", "SPECIES", 250, 277], ["HSV-1", "SPECIES", 279, 284], ["vesicular stomatitis virus", "SPECIES", 15, 41], ["VSV", "SPECIES", 43, 46], ["hepatitis C virus", "SPECIES", 100, 117], ["HCV", "SPECIES", 119, 122], ["herpes simplex virus type 1", "SPECIES", 250, 277], ["HSV-1", "SPECIES", 279, 284], ["vesicular stomatitis virus", "PROBLEM", 15, 41], ["hepatitis C virus", "PROBLEM", 100, 117], ["herpes simplex virus type", "PROBLEM", 250, 275], ["vesicular stomatitis virus", "OBSERVATION", 15, 41]]], ["Viral infections, including rhabdovirus (Masatani et al., 2010) , paramyxovirus (Ling et al., 2009 ), orthomyxovirus (Tawaratsumida et al., 2014 , coronavirus (Xing et al., 2013) , and herpesvirus (Xing et al., 2012) , may counteract RIG-I-dependent IFN antiviral response.", [["Viral infections", "DISEASE", 0, 16], ["Viral", "ORGANISM", 0, 5], ["herpesvirus", "ORGANISM", 185, 196], ["RIG-I-", "GENE_OR_GENE_PRODUCT", 234, 240], ["IFN", "GENE_OR_GENE_PRODUCT", 250, 253], ["RIG", "PROTEIN", 234, 237], ["IFN", "PROTEIN", 250, 253], ["Viral infections", "PROBLEM", 0, 16], ["rhabdovirus", "PROBLEM", 28, 39], ["Masatani et al.", "TEST", 41, 56], ["paramyxovirus", "PROBLEM", 66, 79], ["orthomyxovirus (Tawaratsumida et al.", "TEST", 102, 138], ["coronavirus", "TEST", 147, 158], ["herpesvirus", "PROBLEM", 185, 196], ["RIG", "TEST", 234, 237], ["I-dependent IFN antiviral response", "PROBLEM", 238, 272], ["infections", "OBSERVATION", 6, 16], ["paramyxovirus", "ANATOMY", 66, 79], ["I-dependent", "OBSERVATION_MODIFIER", 238, 249], ["antiviral response", "OBSERVATION", 254, 272]]], ["It has also been reported that viruses utilize the host cell's deubiqutinases and ubiquitin ligases to antagonize RIG-I-mediated innate immune response and succeed in viral replication.", [["cell", "ANATOMY", 56, 60], ["host cell", "CELL", 51, 60], ["deubiqutinases", "GENE_OR_GENE_PRODUCT", 63, 77], ["RIG-I", "GENE_OR_GENE_PRODUCT", 114, 119], ["deubiqutinases", "PROTEIN", 63, 77], ["ubiquitin ligases", "PROTEIN", 82, 99], ["RIG-I", "PROTEIN", 114, 119], ["viruses", "PROBLEM", 31, 38], ["the host cell's deubiqutinases", "TREATMENT", 47, 77], ["ubiquitin ligases", "TREATMENT", 82, 99], ["viral replication", "TREATMENT", 167, 184], ["viruses", "OBSERVATION", 31, 38], ["host cell", "OBSERVATION", 51, 60], ["viral replication", "OBSERVATION", 167, 184]]], ["Cellular ubiquitin-specific proteases, USP21 (Fan et al., 2014) , USP3 (Cui et al., 2014) and USP15 (Zhang et al., 2015) , a subfamily of deubiqutinase (Reyes-Turcu et al., 2009) , remove K63-linked polyubiquitin chains from RIG-I and block it to induce IFN-b.", [["USP21", "GENE_OR_GENE_PRODUCT", 39, 44], ["deubiqutinase", "GENE_OR_GENE_PRODUCT", 138, 151], ["RIG-I", "GENE_OR_GENE_PRODUCT", 225, 230], ["IFN", "GENE_OR_GENE_PRODUCT", 254, 257], ["Cellular ubiquitin-specific proteases", "PROTEIN", 0, 37], ["USP21", "PROTEIN", 39, 44], ["K63", "PROTEIN", 188, 191], ["polyubiquitin chains", "PROTEIN", 199, 219], ["RIG-I", "PROTEIN", 225, 230], ["IFN", "PROTEIN", 254, 257], ["Cellular ubiquitin", "TEST", 0, 18], ["specific proteases", "TEST", 19, 37], ["USP21", "TEST", 39, 44], ["K63", "TREATMENT", 188, 191], ["polyubiquitin chains", "OBSERVATION", 199, 219]]], ["Moreover, a cellular protein antagonizes the activation of RIG-I and participates in the innate immune response during viral infection.", [["cellular", "ANATOMY", 12, 20], ["viral infection", "DISEASE", 119, 134], ["cellular", "CELL", 12, 20], ["RIG-I", "GENE_OR_GENE_PRODUCT", 59, 64], ["cellular protein", "PROTEIN", 12, 28], ["RIG-I", "PROTEIN", 59, 64], ["viral infection", "PROBLEM", 119, 134], ["cellular protein", "OBSERVATION", 12, 28], ["viral infection", "OBSERVATION", 119, 134]]], ["Such as Syndecan-4 (SDC4) and NOD-like receptor family CARD domain containing 5 (NLRC5) protein can interact with RIG-I to negatively regulate type I IFN antiviral response (Cui et al., 2010; Lin et al., 2016) .", [["Syndecan-4", "GENE_OR_GENE_PRODUCT", 8, 18], ["SDC4", "GENE_OR_GENE_PRODUCT", 20, 24], ["NOD-like receptor family CARD domain containing 5", "GENE_OR_GENE_PRODUCT", 30, 79], ["NLRC5", "GENE_OR_GENE_PRODUCT", 81, 86], ["RIG-I", "GENE_OR_GENE_PRODUCT", 114, 119], ["type I IFN", "GENE_OR_GENE_PRODUCT", 143, 153], ["Syndecan-4 (SDC4) and NOD-like receptor family CARD domain containing 5 (NLRC5) protein", "PROTEIN", 8, 95], ["RIG-I", "PROTEIN", 114, 119], ["IFN", "PROTEIN", 150, 153], ["Syndecan", "TEST", 8, 16], ["receptor family CARD domain containing 5 (NLRC5) protein", "TREATMENT", 39, 95], ["type I IFN antiviral response", "PROBLEM", 143, 172]]], ["The level of antiviral cytokines is significantly higher in USP21/SDC4-deficient mice.", [["USP21", "GENE_OR_GENE_PRODUCT", 60, 65], ["SDC4", "GENE_OR_GENE_PRODUCT", 66, 70], ["antiviral cytokines", "PROTEIN", 13, 32], ["USP21", "PROTEIN", 60, 65], ["SDC4", "PROTEIN", 66, 70], ["mice", "SPECIES", 81, 85], ["mice", "SPECIES", 81, 85], ["antiviral cytokines", "TEST", 13, 32], ["antiviral cytokines", "OBSERVATION", 13, 32]]], ["It should be noted that USP21/SDC4deficient mice are more resistant to viral infection as compared with the control mice (Fan et al., 2014; Lin et al., 2016) .", [["viral infection", "DISEASE", 71, 86], ["USP21", "GENE_OR_GENE_PRODUCT", 24, 29], ["SDC4deficient mice", "ORGANISM", 30, 48], ["mice", "ORGANISM", 116, 120], ["USP21", "PROTEIN", 24, 29], ["mice", "SPECIES", 44, 48], ["mice", "SPECIES", 116, 120], ["mice", "SPECIES", 44, 48], ["mice", "SPECIES", 116, 120], ["USP21", "TEST", 24, 29], ["SDC4deficient mice", "PROBLEM", 30, 48], ["viral infection", "PROBLEM", 71, 86], ["viral", "OBSERVATION_MODIFIER", 71, 76], ["infection", "OBSERVATION", 77, 86]]], ["It can thus be inferred that the depression of endogenous negative regulators of type I IFN exhibits a potential antiviral effect.IntroductionGlioma tumor suppressor candidate region gene 2 protein (GLTSCR2) is a nucleolar protein that contains multiple nucleolar localization sequences (Kalt et al., 2012) .", [["Glioma tumor", "ANATOMY", 142, 154], ["nucleolar", "ANATOMY", 213, 222], ["nucleolar", "ANATOMY", 254, 263], ["depression", "DISEASE", 33, 43], ["Glioma tumor", "DISEASE", 142, 154], ["type I IFN", "GENE_OR_GENE_PRODUCT", 81, 91], ["Glioma tumor", "CANCER", 142, 154], ["suppressor candidate region gene 2", "GENE_OR_GENE_PRODUCT", 155, 189], ["GLTSCR2", "GENE_OR_GENE_PRODUCT", 199, 206], ["nucleolar", "CELLULAR_COMPONENT", 213, 222], ["nucleolar", "CELLULAR_COMPONENT", 254, 263], ["endogenous negative regulators", "PROTEIN", 47, 77], ["type I IFN", "PROTEIN", 81, 91], ["Glioma tumor suppressor candidate region gene 2 protein", "PROTEIN", 142, 197], ["GLTSCR2", "PROTEIN", 199, 206], ["nucleolar protein", "PROTEIN", 213, 230], ["nucleolar localization sequences", "DNA", 254, 286], ["the depression of endogenous negative regulators of type I IFN", "PROBLEM", 29, 91], ["a potential antiviral effect", "PROBLEM", 101, 129], ["IntroductionGlioma tumor suppressor candidate", "TREATMENT", 130, 175], ["a nucleolar protein", "PROBLEM", 211, 230], ["antiviral effect", "OBSERVATION", 113, 129], ["Glioma tumor", "OBSERVATION", 142, 154], ["nucleolar protein", "OBSERVATION", 213, 230]]], ["GLTSCR2 physically interacts with phosphatase and tensin homolog deleted on chromosome 10 (PTEN), and modulates programmed cell death (Okahara et al., 2004; Yim et al., 2007) .", [["cell", "ANATOMY", 123, 127], ["death", "DISEASE", 128, 133], ["GLTSCR2", "GENE_OR_GENE_PRODUCT", 0, 7], ["phosphatase and tensin homolog deleted on chromosome 10", "GENE_OR_GENE_PRODUCT", 34, 89], ["PTEN", "GENE_OR_GENE_PRODUCT", 91, 95], ["cell", "CELL", 123, 127], ["GLTSCR2", "PROTEIN", 0, 7], ["phosphatase and tensin homolog", "PROTEIN", 34, 64], ["chromosome 10", "DNA", 76, 89], ["PTEN", "DNA", 91, 95], ["phosphatase and tensin homolog", "TREATMENT", 34, 64], ["cell death", "OBSERVATION", 123, 133]]], ["Our previous study showed that viral infection induces translocation of GLTSCR2 from the nucleus to the cytoplasm.", [["nucleus", "ANATOMY", 89, 96], ["cytoplasm", "ANATOMY", 104, 113], ["viral infection", "DISEASE", 31, 46], ["GLTSCR2", "GENE_OR_GENE_PRODUCT", 72, 79], ["nucleus", "CELLULAR_COMPONENT", 89, 96], ["cytoplasm", "ORGANISM_SUBSTANCE", 104, 113], ["GLTSCR2", "PROTEIN", 72, 79], ["Our previous study", "TEST", 0, 18], ["viral infection", "PROBLEM", 31, 46], ["viral", "OBSERVATION_MODIFIER", 31, 36], ["infection", "OBSERVATION", 37, 46], ["nucleus", "ANATOMY", 89, 96], ["cytoplasm", "OBSERVATION_MODIFIER", 104, 113]]], ["Cytoplasmic GLTSCR2 blocks IFN-b induction and deactivates RIG-I by negatively regulating it via K63-linked ubiquitination (Wang et al., 2016a) .", [["Cytoplasmic", "ANATOMY", 0, 11], ["GLTSCR2", "GENE_OR_GENE_PRODUCT", 12, 19], ["IFN-b", "GENE_OR_GENE_PRODUCT", 27, 32], ["RIG-I", "GENE_OR_GENE_PRODUCT", 59, 64], ["K63", "GENE_OR_GENE_PRODUCT", 97, 100], ["GLTSCR2", "PROTEIN", 12, 19], ["IFN", "PROTEIN", 27, 30], ["RIG-I", "PROTEIN", 59, 64], ["K63", "PROTEIN", 97, 100], ["Cytoplasmic GLTSCR2 blocks", "PROBLEM", 0, 26], ["IFN", "TEST", 27, 30], ["b induction", "TREATMENT", 31, 42]]], ["In present study, we find that purified G4-T, which mimics GLTSCR2 protein, promotes efficient proliferation of DNA and RNA viruses of distinct genera.", [["G4-T", "GENE_OR_GENE_PRODUCT", 40, 44], ["GLTSCR2", "GENE_OR_GENE_PRODUCT", 59, 66], ["DNA", "CELLULAR_COMPONENT", 112, 115], ["G4", "PROTEIN", 40, 42], ["GLTSCR2 protein", "PROTEIN", 59, 74], ["GLTSCR2 protein", "PROBLEM", 59, 74], ["DNA", "PROBLEM", 112, 115], ["RNA viruses of distinct genera", "PROBLEM", 120, 150], ["efficient proliferation", "OBSERVATION", 85, 108], ["RNA viruses", "OBSERVATION", 120, 131], ["distinct", "OBSERVATION_MODIFIER", 135, 143], ["genera", "OBSERVATION_MODIFIER", 144, 150]]], ["We also develop a short hairpin RNA (shRNA) plasmid that targets a specific GLTSCR2 gene.", [["GLTSCR2", "GENE_OR_GENE_PRODUCT", 76, 83], ["short hairpin RNA (shRNA) plasmid", "DNA", 18, 51], ["GLTSCR2 gene", "DNA", 76, 88], ["a short hairpin RNA (shRNA) plasmid", "PROBLEM", 16, 51], ["short hairpin", "OBSERVATION_MODIFIER", 18, 31]]], ["Treatment of GLTSCR2-specific shRNA is found to significantly inhibit in vitro and in vivo infections.", [["infections", "DISEASE", 91, 101], ["GLTSCR2", "GENE_OR_GENE_PRODUCT", 13, 20], ["GLTSCR2", "PROTEIN", 13, 20], ["GLTSCR2", "TEST", 13, 20], ["specific shRNA", "PROBLEM", 21, 35], ["vivo infections", "PROBLEM", 86, 101], ["infections", "OBSERVATION", 91, 101]]], ["This paper provides solid evidence that GLTSCR2 is a valuable target for developing cell-based antivirals.CellsHEp-2, HeLa, Vero, HEK293T, MDCK, and chicken embryo fibroblast DF-1 cells are cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 2 mM L-glutamine, nonessential amino acids, sodium pyruvate, 5% or 10% heat-inactivated fetal bovine serum (FBS), 100 U/ml penicillin and 100 mg/ml streptomycin (all reagents are purchased from Gibco Invitrogen).", [["cell", "ANATOMY", 84, 88], ["CellsHEp-2", "ANATOMY", 106, 116], ["HeLa", "ANATOMY", 118, 122], ["Vero", "ANATOMY", 124, 128], ["HEK293T", "ANATOMY", 130, 137], ["MDCK", "ANATOMY", 139, 143], ["embryo fibroblast DF-1 cells", "ANATOMY", 157, 185], ["fetal bovine serum", "ANATOMY", 350, 368], ["FBS", "ANATOMY", 370, 373], ["L-glutamine", "CHEMICAL", 267, 278], ["amino acids", "CHEMICAL", 293, 304], ["sodium pyruvate", "CHEMICAL", 306, 321], ["penicillin", "CHEMICAL", 385, 395], ["streptomycin", "CHEMICAL", 410, 422], ["L-glutamine", "CHEMICAL", 267, 278], ["amino acids", "CHEMICAL", 293, 304], ["sodium pyruvate", "CHEMICAL", 306, 321], ["penicillin", "CHEMICAL", 385, 395], ["streptomycin", "CHEMICAL", 410, 422], ["GLTSCR2", "GENE_OR_GENE_PRODUCT", 40, 47], ["cell", "CELL", 84, 88], ["CellsHEp-2", "CELL", 106, 116], ["HeLa", "CELL", 118, 122], ["Vero", "CELL", 124, 128], ["HEK293T", "CELL", 130, 137], ["MDCK", "CELL", 139, 143], ["chicken", "ORGANISM", 149, 156], ["embryo fibroblast DF-1 cells", "CELL", 157, 185], ["L-glutamine", "SIMPLE_CHEMICAL", 267, 278], ["amino acids", "AMINO_ACID", 293, 304], ["sodium", "SIMPLE_CHEMICAL", 306, 312], ["pyruvate", "SIMPLE_CHEMICAL", 313, 321], ["bovine", "ORGANISM", 356, 362], ["serum", "ORGANISM_SUBSTANCE", 363, 368], ["FBS", "ORGANISM_SUBSTANCE", 370, 373], ["penicillin", "SIMPLE_CHEMICAL", 385, 395], ["streptomycin", "SIMPLE_CHEMICAL", 410, 422], ["GLTSCR2", "PROTEIN", 40, 47], ["CellsHEp-2", "CELL_LINE", 106, 116], ["HeLa", "CELL_LINE", 118, 122], ["Vero", "CELL_LINE", 124, 128], ["HEK293T", "CELL_LINE", 130, 137], ["MDCK", "CELL_LINE", 139, 143], ["chicken embryo fibroblast DF-1 cells", "CELL_LINE", 149, 185], ["chicken", "SPECIES", 149, 156], ["bovine", "SPECIES", 356, 362], ["chicken", "SPECIES", 149, 156], ["bovine", "SPECIES", 356, 362], ["developing cell-based antivirals", "TREATMENT", 73, 105], ["CellsHEp", "TEST", 106, 114], ["HeLa", "TEST", 118, 122], ["Vero", "TEST", 124, 128], ["HEK293T", "TEST", 130, 137], ["MDCK", "TEST", 139, 143], ["chicken embryo fibroblast DF", "TEST", 149, 177], ["Dulbecco", "TEST", 202, 210], ["2 mM L-glutamine", "TREATMENT", 262, 278], ["nonessential amino acids", "TEST", 280, 304], ["sodium pyruvate", "TEST", 306, 321], ["fetal bovine serum", "TEST", 350, 368], ["FBS", "TEST", 370, 373], ["penicillin", "TREATMENT", 385, 395], ["streptomycin", "TREATMENT", 410, 422], ["all reagents", "TREATMENT", 424, 436]]], ["Human hepatocellular liver carcinoma cell lines Huh7.5.1 are provided by Dr. Francis Chisari at Scripps Research Institute, Florida, USA.", [["hepatocellular liver carcinoma cell lines Huh7.5.1", "ANATOMY", 6, 56], ["hepatocellular liver carcinoma", "DISEASE", 6, 36], ["Human", "ORGANISM", 0, 5], ["hepatocellular liver carcinoma cell lines Huh7.5.1", "CELL", 6, 56], ["Human hepatocellular liver carcinoma cell lines", "CELL_LINE", 0, 47], ["Huh7.5.1", "CELL_LINE", 48, 56], ["Human", "SPECIES", 0, 5], ["Human hepatocellular liver carcinoma cell lines Huh7", "TREATMENT", 0, 52], ["hepatocellular", "OBSERVATION_MODIFIER", 6, 20], ["liver", "ANATOMY", 21, 26], ["carcinoma", "OBSERVATION", 27, 36], ["cell lines", "OBSERVATION", 37, 47]]], ["All cells are cultured at 37 C in a humidified incubator with 5% CO 2 .VirusesEnterovirus A71 (EV-A71) strain BC08 , avian influenza virus (AIV) strain H9-WD (Wang et al., 2016b) , canine distemper virus (CDV) strain MD77 (Lan et al., 2005) , Newcastle disease virus (NDV) strain Lasota and infectious bronchitis virus (IBV) strain M41 (Li et al., 2013) , porcine epidemic diarrhea virus (PEDV) strain CV777 (Sun et al., 2015) , VSV strain Indiana (Wang et al., 2016a) , HSV-1 strain F (Wang et al., 2011) and HCV strain JFH-1 (Xu et al., 2014) are reproduced in RD, MDCK, Vero, HeLa, Vero, HeLa, HEK293T, HeLa and Huh7.5.1 cells respectively, according to the reports indicated above.", [["cells", "ANATOMY", 4, 9], ["MDCK", "ANATOMY", 567, 571], ["HeLa", "ANATOMY", 579, 583], ["Vero", "ANATOMY", 585, 589], ["HeLa", "ANATOMY", 591, 595], ["HEK293T", "ANATOMY", 597, 604], ["HeLa", "ANATOMY", 606, 610], ["Huh7", "ANATOMY", 615, 619], ["5.1 cells", "ANATOMY", 620, 629], ["avian influenza virus", "DISEASE", 117, 138], ["canine distemper", "DISEASE", 181, 197], ["Newcastle disease", "DISEASE", 243, 260], ["infectious bronchitis virus", "DISEASE", 291, 318], ["porcine epidemic diarrhea virus", "DISEASE", 356, 387], ["CO 2", "CHEMICAL", 65, 69], ["cells", "CELL", 4, 9], ["VirusesEnterovirus A71", "ORGANISM", 71, 93], ["EV-A71) strain BC08 ,", "ORGANISM", 95, 116], ["avian influenza virus", "ORGANISM", 117, 138], ["AIV", "ORGANISM", 140, 143], ["strain H9-WD", "ORGANISM", 145, 157], ["canine distemper virus", "ORGANISM", 181, 203], ["CDV", "ORGANISM", 205, 208], ["Newcastle disease virus (NDV) strain Lasota", "ORGANISM", 243, 286], ["infectious bronchitis virus", "ORGANISM", 291, 318], ["IBV", "ORGANISM", 320, 323], ["porcine epidemic diarrhea virus", "ORGANISM", 356, 387], ["VSV strain Indiana", "ORGANISM", 429, 447], ["HSV-1 strain F", "ORGANISM", 471, 485], ["HCV", "ORGANISM", 510, 513], ["MDCK", "CELL", 567, 571], ["Vero", "CELL", 573, 577], ["HeLa", "CELL", 579, 583], ["Vero", "CELL", 585, 589], ["HeLa", "CELL", 591, 595], ["HEK293T", "CELL", 597, 604], ["HeLa", "CELL", 606, 610], ["Huh7", "CELL", 615, 619], ["5.1 cells", "CELL", 620, 629], ["RD", "CELL_LINE", 563, 565], ["MDCK", "CELL_LINE", 567, 571], ["Vero", "CELL_LINE", 573, 577], ["HeLa", "CELL_LINE", 579, 583], ["Vero", "CELL_LINE", 585, 589], ["HeLa", "CELL_LINE", 591, 595], ["HEK293T", "CELL_LINE", 597, 604], ["HeLa", "CELL_LINE", 606, 610], ["Huh7", "CELL_LINE", 615, 619], ["avian influenza virus", "SPECIES", 117, 138], ["canine distemper virus", "SPECIES", 181, 203], ["NDV", "SPECIES", 268, 271], ["infectious bronchitis virus", "SPECIES", 291, 318], ["porcine epidemic diarrhea virus", "SPECIES", 356, 387], ["HSV-1", "SPECIES", 471, 476], ["VirusesEnterovirus A71 (EV-A71) strain BC08 , avian influenza virus", "SPECIES", 71, 138], ["AIV", "SPECIES", 140, 143], ["canine distemper virus", "SPECIES", 181, 203], ["CDV", "SPECIES", 205, 208], ["Newcastle disease virus", "SPECIES", 243, 266], ["NDV", "SPECIES", 268, 271], ["infectious bronchitis virus", "SPECIES", 291, 318], ["IBV", "SPECIES", 320, 323], ["porcine epidemic diarrhea virus", "SPECIES", 356, 387], ["PEDV", "SPECIES", 389, 393], ["HSV-1", "SPECIES", 471, 476], ["HCV strain JFH-1", "SPECIES", 510, 526], ["a humidified incubator", "TREATMENT", 34, 56], ["VirusesEnterovirus", "TEST", 71, 89], ["EV", "TEST", 95, 97], ["strain BC08", "PROBLEM", 103, 114], ["avian influenza virus", "PROBLEM", 117, 138], ["canine distemper virus", "PROBLEM", 181, 203], ["Newcastle disease virus (NDV) strain Lasota", "PROBLEM", 243, 286], ["infectious bronchitis virus", "PROBLEM", 291, 318], ["porcine epidemic diarrhea virus (PEDV) strain", "PROBLEM", 356, 401], ["HSV", "TEST", 471, 474], ["HCV strain JFH", "TEST", 510, 524], ["Xu et al.", "TEST", 528, 537], ["MDCK", "TEST", 567, 571], ["Vero", "TEST", 573, 577], ["HeLa", "TEST", 579, 583], ["Vero", "TEST", 585, 589], ["HeLa", "TEST", 591, 595], ["HEK293T", "TEST", 597, 604], ["HeLa", "TEST", 606, 610], ["Huh7", "TEST", 615, 619], ["infectious", "OBSERVATION_MODIFIER", 291, 301], ["bronchitis", "OBSERVATION", 302, 312], ["Huh7", "ANATOMY", 615, 619]]], ["GFP-NDV strain NA-1 is generated by inserting an additional transcription cassette coding for the enhanced GFP between the P and M genes of the NDV genome (Wang et al., 2015) .", [["GFP", "GENE_OR_GENE_PRODUCT", 0, 3], ["NA-1", "GENE_OR_GENE_PRODUCT", 15, 19], ["GFP", "GENE_OR_GENE_PRODUCT", 107, 110], ["NDV", "ORGANISM", 144, 147], ["transcription cassette", "DNA", 60, 82], ["GFP", "DNA", 107, 110], ["P and M genes", "DNA", 123, 136], ["NDV genome", "DNA", 144, 154], ["NDV strain NA-1", "SPECIES", 4, 19], ["NDV", "SPECIES", 144, 147], ["GFP", "TEST", 0, 3], ["NDV strain NA", "TEST", 4, 17], ["an additional transcription cassette", "TREATMENT", 46, 82], ["the enhanced GFP", "PROBLEM", 94, 110], ["NDV", "ANATOMY", 144, 147]]], ["The HCV genotype 1b repliconcontaining cell line (2\u00c03\u00fe) is provided by Dr. Stanley Lemon at University of Texas Medical Branch, USA (Yi and Lemon, 2004) .AntibodiesRabbit polyclonal antibody to GLTSCR2 (used at 1:1000) is acquired from abcam.", [["cell line", "ANATOMY", 39, 48], ["HCV", "ORGANISM", 4, 7], ["cell line", "CELL", 39, 48], ["2\u00c03\u00fe", "CELL", 50, 54], ["GLTSCR2", "GENE_OR_GENE_PRODUCT", 194, 201], ["abcam", "GENE_OR_GENE_PRODUCT", 236, 241], ["HCV genotype 1b repliconcontaining cell line", "CELL_LINE", 4, 48], ["2\u00c03\u00fe", "CELL_LINE", 50, 54], ["Rabbit polyclonal antibody", "PROTEIN", 164, 190], ["GLTSCR2", "PROTEIN", 194, 201], ["abcam", "PROTEIN", 236, 241], ["Rabbit", "SPECIES", 164, 170], ["HCV", "SPECIES", 4, 7], ["Rabbit", "SPECIES", 164, 170], ["The HCV genotype 1b repliconcontaining cell line", "TREATMENT", 0, 48], ["Antibodies", "TEST", 154, 164], ["Rabbit polyclonal antibody", "TEST", 164, 190], ["GLTSCR2", "TEST", 194, 201], ["HCV", "OBSERVATION", 4, 7], ["cell line", "OBSERVATION", 39, 48]]], ["The anti NDV-P (1:1000), CDV-N (1:1000), VSV-G (1:200) mouse monoclonal antibodies are obtained from Santa Cruz.", [["NDV", "ORGANISM", 9, 12], ["CDV", "ORGANISM", 25, 28], ["VSV", "ORGANISM", 41, 44], ["-G", "SIMPLE_CHEMICAL", 44, 46], ["mouse", "ORGANISM", 55, 60], ["VSV-G (1:200) mouse monoclonal antibodies", "PROTEIN", 41, 82], ["Santa Cruz", "PROTEIN", 101, 111], ["mouse", "SPECIES", 55, 60], ["mouse", "SPECIES", 55, 60], ["The anti NDV", "TEST", 0, 12], ["CDV", "TEST", 25, 28], ["VSV-G", "TEST", 41, 46], ["mouse monoclonal antibodies", "TEST", 55, 82]]], ["The antibodies to actin (1:1000) and His (1:1000) are obtained from Beyotime Biotechnology.", [["His", "CHEMICAL", 37, 40], ["actin", "GENE_OR_GENE_PRODUCT", 18, 23], ["antibodies", "PROTEIN", 4, 14], ["actin", "PROTEIN", 18, 23], ["1:1000", "PROTEIN", 25, 31], ["1:1000", "PROTEIN", 42, 48], ["The antibodies", "TEST", 0, 14]]], ["The antibody to HCV-core (1:400) is preserved in our laboratory.", [["HCV", "ORGANISM", 16, 19], ["HCV", "SPECIES", 16, 19], ["The antibody", "TEST", 0, 12], ["HCV", "TEST", 16, 19]]], ["Antibodies are diluted in PBS containing 5% skim milk (pH 7.3).Protein production and purificationG4-T, in which HIV-derived cell-penetrating Tat peptide (Reissmann, 2014; Rizzuti et al., 2015) is conjugated at the C-terminal of G4, is constructed and cloned into the expression vector pET-28a NdeI-EcoRI restriction sites.", [["milk", "ANATOMY", 49, 53], ["cell", "ANATOMY", 125, 129], ["milk", "ORGANISM_SUBSTANCE", 49, 53], ["HIV", "ORGANISM", 113, 116], ["cell", "CELL", 125, 129], ["pET-28a", "GENE_OR_GENE_PRODUCT", 286, 293], ["G4", "PROTEIN", 229, 231], ["expression vector pET-28a NdeI-EcoRI restriction sites", "DNA", 268, 322], ["HIV", "SPECIES", 113, 116], ["Antibodies", "TREATMENT", 0, 10], ["pH", "TEST", 55, 57], ["Protein production", "TEST", 63, 81], ["NdeI-EcoRI restriction sites", "TREATMENT", 294, 322]]], ["Escherichia coli strain BL21(DE3) transformed with the recombinant His-tagged G4-T plasmid is grown at 37 C in LB to an optical density of 0.8 (OD at 590 nm) before being induced with 1 mM IPTG for 4 h.", [["IPTG", "CHEMICAL", 189, 193], ["IPTG", "CHEMICAL", 189, 193], ["Escherichia coli", "ORGANISM", 0, 16], ["strain BL21", "ORGANISM", 17, 28], ["DE3", "GENE_OR_GENE_PRODUCT", 29, 32], ["recombinant His-tagged G4-T plasmid", "DNA", 55, 90], ["Escherichia coli strain BL21", "SPECIES", 0, 28], ["Escherichia coli", "SPECIES", 0, 16], ["BL21", "SPECIES", 24, 28], ["DE3", "SPECIES", 29, 32], ["Escherichia coli strain BL21", "PROBLEM", 0, 28], ["an optical density", "TEST", 117, 135], ["1 mM IPTG", "TREATMENT", 184, 193], ["coli", "OBSERVATION", 12, 16]]], ["Bacterial cells are harvested in PBS (pH 7.3) by centrifugation at 6000g for 20 min at 4 C. The pellet is resuspended in 10 vol of pellet of lysis buffer (20 mM Tris-HCl, 100 mM NaCl, pH 8.0) in the presence of the protease inhibitor cocktail (Roche).", [["Bacterial cells", "ANATOMY", 0, 15], ["Tris-HCl", "CHEMICAL", 161, 169], ["NaCl", "CHEMICAL", 178, 182], ["Tris-HCl", "CHEMICAL", 161, 169], ["NaCl", "CHEMICAL", 178, 182], ["Bacterial cells", "CELL", 0, 15], ["Tris-HCl", "SIMPLE_CHEMICAL", 161, 169], ["Bacterial cells", "CELL_TYPE", 0, 15], ["Bacterial cells", "PROBLEM", 0, 15], ["pH", "TEST", 38, 40], ["centrifugation", "TEST", 49, 63], ["lysis buffer", "TREATMENT", 141, 153], ["NaCl", "TEST", 178, 182], ["pH", "TEST", 184, 186], ["the protease inhibitor cocktail", "TREATMENT", 211, 242], ["cells", "OBSERVATION", 10, 15]]], ["After sonication, the cell suspension is fractionated by centrifugation at 6000g for 20 min at 4 C. Supernatants (soluble fractions) are passed over to nickelnitrilotriacetic acid (Ni-NTA) columns.", [["cell", "ANATOMY", 22, 26], ["Supernatants", "ANATOMY", 100, 112], ["nickelnitrilotriacetic acid", "CHEMICAL", 152, 179], ["Ni-NTA", "CHEMICAL", 181, 187], ["nickelnitrilotriacetic acid", "CHEMICAL", 152, 179], ["Ni-NTA", "CHEMICAL", 181, 187], ["cell", "CELL", 22, 26], ["nickelnitrilotriacetic acid", "SIMPLE_CHEMICAL", 152, 179], ["Ni-NTA", "SIMPLE_CHEMICAL", 181, 187], ["sonication", "TREATMENT", 6, 16], ["the cell suspension", "TREATMENT", 18, 37], ["Supernatants (soluble fractions", "TREATMENT", 100, 131], ["nickelnitrilotriacetic acid (Ni-NTA) columns", "TREATMENT", 152, 196]]], ["Following the binding to column, the column is washed with lysis buffer containing increasing concentrations of imidazole (10, 20, 50, and 200 mM).", [["imidazole", "CHEMICAL", 112, 121], ["imidazole", "CHEMICAL", 112, 121], ["imidazole", "SIMPLE_CHEMICAL", 112, 121], ["lysis buffer", "TREATMENT", 59, 71], ["increasing concentrations of imidazole", "TREATMENT", 83, 121], ["column", "ANATOMY", 37, 43]]], ["His-fused protein G4-T is eluted and concentrated by ultrafiltration of 5 K membranes (Millipore), and stored at \u00c080 C.Gel-filtration analysisThe purified G4-T protein eluted from His-Ni column is loaded onto the Superdex G200 column in a solution buffer of 20 mM Tris-HCl, pH 8.0.", [["His-Ni", "CHEMICAL", 180, 186], ["Tris-HCl", "CHEMICAL", 264, 272], ["His", "CHEMICAL", 0, 3], ["His", "CHEMICAL", 180, 183], ["Ni", "CHEMICAL", 184, 186], ["Tris-HCl", "CHEMICAL", 264, 272], ["G4-T", "GENE_OR_GENE_PRODUCT", 155, 159], ["Tris-HCl", "SIMPLE_CHEMICAL", 264, 272], ["G4", "PROTEIN", 18, 20], ["purified G4-T protein", "PROTEIN", 146, 167], ["filtration analysis", "TEST", 123, 142], ["The purified G4-T protein", "TEST", 142, 167], ["His-Ni column", "TREATMENT", 180, 193], ["a solution buffer", "TREATMENT", 237, 254], ["pH", "TEST", 274, 276]]], ["The analytical column is calibrated with a series of individual runs of standard molecular mass proteins as markers, including bovine serum albumin (68 kDa), egg white albumin (43 kDa), and ribose nucleotidase (13.7 kDa).", [["serum", "ANATOMY", 134, 139], ["ribose", "CHEMICAL", 190, 196], ["ribose", "CHEMICAL", 190, 196], ["bovine", "ORGANISM", 127, 133], ["serum", "ORGANISM_SUBSTANCE", 134, 139], ["albumin", "GENE_OR_GENE_PRODUCT", 140, 147], ["egg white albumin", "GENE_OR_GENE_PRODUCT", 158, 175], ["ribose nucleotidase", "GENE_OR_GENE_PRODUCT", 190, 209], ["standard molecular mass proteins", "PROTEIN", 72, 104], ["bovine serum albumin", "PROTEIN", 127, 147], ["egg white albumin", "PROTEIN", 158, 175], ["ribose nucleotidase", "PROTEIN", 190, 209], ["bovine", "SPECIES", 127, 133], ["standard molecular mass proteins", "PROBLEM", 72, 104], ["bovine serum albumin", "TEST", 127, 147], ["kDa", "TEST", 152, 155], ["egg white albumin", "TEST", 158, 175], ["kDa", "TEST", 180, 183], ["ribose nucleotidase", "TEST", 190, 209], ["mass", "OBSERVATION", 91, 95]]], ["The peak protein is collected and analyzed on 10% SDS-PAGE.Chemical cross-linkingPurified protein G4-T is incubated at 4 C in the presence of 0.05% Glutaraldehyde (GA, MP Biomedicals) for 15 min.", [["G4-T", "CHEMICAL", 98, 102], ["Glutaraldehyde", "CHEMICAL", 148, 162], ["GA", "CHEMICAL", 164, 166], ["SDS", "CHEMICAL", 50, 53], ["Glutaraldehyde", "CHEMICAL", 148, 162], ["Glutaraldehyde", "SIMPLE_CHEMICAL", 148, 162], ["GA", "SIMPLE_CHEMICAL", 164, 166], ["G4", "PROTEIN", 98, 100], ["The peak protein", "TEST", 0, 16], ["0.05% Glutaraldehyde (GA, MP Biomedicals", "TREATMENT", 142, 182], ["peak protein", "OBSERVATION", 4, 16], ["cross-linking", "OBSERVATION", 68, 81]]], ["The reaction is terminated by the addition of 200 mM Tris-HCl buffer, pH 8.0.", [["Tris-HCl", "CHEMICAL", 53, 61], ["Tris-HCl", "CHEMICAL", 53, 61], ["Tris-HCl", "SIMPLE_CHEMICAL", 53, 61], ["200 mM Tris-HCl buffer", "TREATMENT", 46, 68], ["pH", "TEST", 70, 72]]], ["Cross-linking products are analyzed by 10% SDS-PAGE and Western blotting.Circular dichroism (CD) spectra analysisThe highly purified G4-T by the gel-filtration is incubated at the final concentration of 30 mM in PBS, with 0%, 25%, or 50% 2,2,2trifluoroethanol (TFE).", [["2,2,2trifluoroethanol", "CHEMICAL", 238, 259], ["TFE", "CHEMICAL", 261, 264], ["2,2,2trifluoroethanol", "CHEMICAL", 238, 259], ["TFE", "CHEMICAL", 261, 264], ["2,2,2trifluoroethanol", "SIMPLE_CHEMICAL", 238, 259], ["TFE", "SIMPLE_CHEMICAL", 261, 264], ["Circular dichroism", "TEST", 73, 91], ["spectra analysis", "TEST", 97, 113], ["the gel-filtration", "TREATMENT", 141, 159], ["PBS", "TEST", 212, 215]]], ["The wavelength-dependence of molar ellipticity [q] is monitored at 25 C as the average of eight scans in a spectropolarimeter (Model J-710, JASCO), equipped with a thermoelectric temperature controller.", [["molar ellipticity", "PROBLEM", 29, 46], ["eight scans", "TEST", 90, 101], ["a thermoelectric temperature controller", "TREATMENT", 162, 201], ["wavelength", "OBSERVATION_MODIFIER", 4, 14], ["dependence", "OBSERVATION_MODIFIER", 15, 25], ["molar", "OBSERVATION_MODIFIER", 29, 34], ["ellipticity", "OBSERVATION_MODIFIER", 35, 46]]], ["The thermal denaturation temperature (Tm) is measured at 222 nm by recording the CD signal in the temperature range of 20e75 C with a scan rate of 1 C/ min.Quantitative real-time PCR (RT-PCR)Replicate cultures are harvested and total RNA is extracted with Trizol (Invitrogen).", [["The thermal denaturation temperature", "TEST", 0, 36], ["the CD signal", "TEST", 77, 90], ["the temperature range", "TEST", 94, 115], ["a scan rate", "TEST", 132, 143], ["Quantitative real-time PCR", "TEST", 156, 182], ["RT-PCR", "TEST", 184, 190], ["Replicate cultures", "TEST", 191, 209], ["total RNA", "TREATMENT", 228, 237], ["Trizol (Invitrogen", "TREATMENT", 256, 274], ["thermal", "OBSERVATION_MODIFIER", 4, 11], ["denaturation", "OBSERVATION_MODIFIER", 12, 24]]], ["A two-step RT-PCR (SYBR Green I technology, Applied Roche) is performed using SYBR green supermix (Toyobo) according to the manufacturer's protocol to measure transcription levels for several genes of interest.", [["A two-step RT-PCR", "TREATMENT", 0, 17], ["the manufacturer's protocol", "TREATMENT", 120, 147], ["transcription levels", "TEST", 159, 179]]], ["The primers used are as follows.", [["The primers", "TREATMENT", 0, 11]]], ["IFN-b: 5 0 -CCT ACA AAG AAG CAG CAA-3 0 (forward), 5 0 -TCC TCA GGG ATG TCA AAG -3 0 (reverse).", [["TCA AAG -3 0", "CHEMICAL", 72, 84], ["5 0 -CCT", "SIMPLE_CHEMICAL", 7, 15], ["IFN-b: 5 0 -CCT ACA AAG AAG CAG CAA-3 0", "DNA", 0, 39], ["TCC", "DNA", 56, 59], ["ATG TCA AAG -3 0", "DNA", 68, 84], ["IFN", "TEST", 0, 3], ["CCT ACA AAG AAG", "TEST", 12, 27], ["CAG", "TEST", 28, 31], ["CAA", "TEST", 32, 35], ["TCA AAG", "TEST", 72, 79], ["ACA AAG", "ANATOMY", 16, 23]]], ["PKR: 5 0 -TAC GCC TGA CCA CAA CTA -3 0 (forward), 5 0 -GGT ATT CCT TCC CGT CTA -3 0 (reverse).", [["PKR", "GENE_OR_GENE_PRODUCT", 0, 3], ["PKR: 5 0 -TAC GCC TGA CCA CAA CTA -3 0 (forward), 5 0 -GGT ATT CCT TCC CGT CTA -3 0", "DNA", 0, 83], ["PKR", "TEST", 0, 3], ["TAC GCC", "TEST", 10, 17], ["TGA", "TEST", 18, 21], ["CAA CTA", "TEST", 26, 33], ["GGT ATT CCT TCC CGT CTA", "TEST", 55, 78]]], ["ISG56: 5 0 -CAC CCA CTT CTG TCT TACT -3 0 (forward), 5 0 -ACA TTC TTG CCA GGT CTA -3 0 (reverse).", [["ISG56: 5 0 -CAC CCA", "DNA", 0, 19], ["TCT TACT -3 0 (forward), 5 0 -ACA TTC", "DNA", 28, 65], ["CCA GGT CTA -3 0", "DNA", 70, 86], ["CTT", "TEST", 20, 23], ["CTG", "TEST", 24, 27], ["TCT", "TEST", 28, 31], ["TACT", "TEST", 32, 36], ["ACA TTC TTG", "TEST", 58, 69], ["GGT CTA", "TEST", 74, 81], ["CCA", "ANATOMY", 16, 19]]], ["NDV-N: 5 0 -TGA TGA CCC AGA AGA TAG ATG GAG -3 0 (forward), 5 0 -CTG TGA GTG GGA GCA TAA AAG AGA -3 0 (reverse).", [["AGA -3 0", "CHEMICAL", 93, 101], ["NDV", "ORGANISM", 0, 3], ["NDV-N: 5 0 -TGA TGA CCC AGA AGA TAG ATG GAG -3 0 (forward), 5 0 -CTG TGA GTG GGA GCA TAA AAG AGA -3 0", "DNA", 0, 101], ["NDV", "TEST", 0, 3], ["TGA", "TEST", 12, 15], ["AGA", "TEST", 28, 31], ["ATG", "TEST", 36, 39], ["GAG", "TEST", 40, 43], ["CTG TGA", "TEST", 65, 72], ["GGA", "TEST", 77, 80], ["GCA", "TEST", 81, 84], ["AAG", "TEST", 89, 92], ["AGA", "TEST", 93, 96]]], ["ICP8: 5 0 -GAC GGG CAA TCA GCG GTT CGC -3 0 (forward), 5 0 -TCG TCC AGG TCG TCG TCA TCC -3 0 (reverse).", [["CAA", "CHEMICAL", 19, 22], ["TCA TCC -3 0", "CHEMICAL", 80, 92], ["ICP8: 5 0 -GAC GGG CAA TCA GCG GTT CGC -3 0 (forward), 5 0 -TCG TCC AGG TCG TCG TCA TCC -3 0", "DNA", 0, 92], ["ICP8", "TEST", 0, 4], ["GAC GGG", "TEST", 11, 18], ["CAA", "TEST", 19, 22], ["TCA", "TEST", 23, 26], ["GCG", "TEST", 27, 30], ["GTT", "TEST", 31, 34], ["CGC", "TEST", 35, 38], ["TCG", "TEST", 60, 63], ["TCC", "TEST", 64, 67], ["AGG", "TEST", 68, 71], ["TCG", "TEST", 72, 75], ["TCG", "TEST", 76, 79], ["TCA TCC", "TEST", 80, 87]]], ["HCV-NS5A: 5 0 -TAG GTG CTG GGT CCA AATC -3 0 (forward), 5 0 -TAT GCT GGC GAG GCT TAT -3 0 (reverse).", [["HCV-NS5A", "ORGANISM", 0, 8], ["HCV-NS5A: 5 0 -TAG GTG CTG GGT CCA AATC -3 0", "DNA", 0, 44], ["TAT", "DNA", 61, 64], ["HCV", "SPECIES", 0, 3], ["HCV", "TEST", 0, 3], ["NS5A", "TEST", 4, 8], ["CTG", "TEST", 23, 26], ["GGT", "TEST", 27, 30], ["CCA", "TEST", 31, 34], ["AATC", "TEST", 35, 39], ["TAT", "TEST", 81, 84], ["NS5A", "OBSERVATION", 4, 8]]], ["IBV-N: 5 0 -GGT TGC TGCT AAG GGT GC-3 0 (forward), 5 0 -GCC TTT GTA ATG CGG GAG-3 0 (reverse).", [["IBV", "ORGANISM", 0, 3], ["IBV", "TEST", 0, 3], ["GGT TGC TGCT", "TEST", 12, 24], ["AAG", "TEST", 25, 28], ["GGT", "TEST", 29, 32], ["GC", "TEST", 33, 35], ["GCC TTT GTA ATG CGG GAG", "TEST", 56, 79]]], ["GAPDH: 5 0 -CTG GTG ACC CGT GCT GCT T-3 0 (forward), 5 0 -TTG CCG CCT TCT GCC TTA-3 0 (reverse).", [["GAPDH", "GENE_OR_GENE_PRODUCT", 0, 5], ["GAPDH: 5 0 -CTG GTG ACC", "DNA", 0, 23], ["GAPDH", "TEST", 0, 5], ["CTG GTG", "TEST", 12, 19], ["ACC", "TEST", 20, 23], ["GCT", "TEST", 28, 31], ["GCT", "TEST", 32, 35], ["T", "TEST", 36, 37], ["TTG CCG CCT TCT GCC TTA", "TEST", 58, 81]]], ["Relative fold changes are automatically calculated by the Step One Plus real-time PCR system software (Applied Biosystems), following the DDC T method.", [["fold", "ANATOMY", 9, 13], ["Relative fold changes", "PROBLEM", 0, 21], ["the DDC T method", "TREATMENT", 134, 150], ["fold", "OBSERVATION_MODIFIER", 9, 13], ["changes", "OBSERVATION", 14, 21]]], ["GAPDH is also determined and used as internal control.LDH assay for toxicity analysisProtein cytotoxicity is assessed using a lactate dehydrogenase (LDH) assay according to the manufacturer's instructions by means of a Cytotoxicity Detection Kit PLUS (Roche).ELISA for IFN-bHEK293T cells are infected with VSV at a MOI of 0.1 for indicated times, in the presence or absence of G4-T.", [["-bHEK293T cells", "ANATOMY", 272, 287], ["toxicity", "DISEASE", 68, 76], ["lactate", "CHEMICAL", 126, 133], ["lactate", "CHEMICAL", 126, 133], ["GAPDH", "GENE_OR_GENE_PRODUCT", 0, 5], ["LDH", "GENE_OR_GENE_PRODUCT", 54, 57], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 126, 147], ["LDH", "GENE_OR_GENE_PRODUCT", 149, 152], ["IFN-bHEK293T cells", "CELL", 269, 287], ["VSV", "ORGANISM", 306, 309], ["GAPDH", "PROTEIN", 0, 5], ["LDH", "PROTEIN", 54, 57], ["lactate dehydrogenase", "PROTEIN", 126, 147], ["LDH", "PROTEIN", 149, 152], ["IFN-bHEK293T cells", "CELL_LINE", 269, 287], ["VSV", "SPECIES", 306, 309], ["GAPDH", "PROBLEM", 0, 5], ["LDH assay", "TEST", 54, 63], ["toxicity analysis", "TEST", 68, 85], ["Protein cytotoxicity", "TEST", 85, 105], ["a lactate dehydrogenase", "TEST", 124, 147], ["LDH", "TEST", 149, 152], ["ELISA", "TEST", 259, 264], ["IFN-bHEK293T cells", "TREATMENT", 269, 287], ["VSV", "TREATMENT", 306, 309]]], ["The supernatants are harvested for ELISA (PBL Biomedical Laboratories) with a commercial sandwich kit (TFB), according to the manufacturer's instructions.Preparation of cell lysates and immunoblotsThe cells are harvested and dissolved in 200 ml lysis buffer (pH 7.5 20 mM Tris-HCl, 150 mM NaCl, 1% Triton X-100, 1 mM EDTA, 2.5 mM Sodium pyrophosphate, 1 mM b-Glycerrophosphate, 1 mM Sodium orthovanadate, 1 mg/ml Leupeptin) in the presence of the protease inhibitor cocktail for 30 min at 4 C and finally disrupted by sonication.", [["supernatants", "ANATOMY", 4, 16], ["cell lysates", "ANATOMY", 169, 181], ["cells", "ANATOMY", 201, 206], ["Tris-HCl", "CHEMICAL", 272, 280], ["NaCl", "CHEMICAL", 289, 293], ["Triton X-100", "CHEMICAL", 298, 310], ["Sodium pyrophosphate", "CHEMICAL", 330, 350], ["b-Glycerrophosphate", "CHEMICAL", 357, 376], ["Sodium orthovanadate", "CHEMICAL", 383, 403], ["Leupeptin", "CHEMICAL", 413, 422], ["Tris-HCl", "CHEMICAL", 272, 280], ["NaCl", "CHEMICAL", 289, 293], ["EDTA", "CHEMICAL", 317, 321], ["Sodium pyrophosphate", "CHEMICAL", 330, 350], ["b-Glycerrophosphate", "CHEMICAL", 357, 376], ["Sodium orthovanadate", "CHEMICAL", 383, 403], ["Leupeptin", "CHEMICAL", 413, 422], ["cell lysates", "CELL", 169, 181], ["cells", "CELL", 201, 206], ["Tris-HCl", "SIMPLE_CHEMICAL", 272, 280], ["Triton X-100", "SIMPLE_CHEMICAL", 298, 310], ["EDTA", "SIMPLE_CHEMICAL", 317, 321], ["Sodium pyrophosphate", "SIMPLE_CHEMICAL", 330, 350], ["b-Glycerrophosphate", "SIMPLE_CHEMICAL", 357, 376], ["Sodium orthovanadate", "SIMPLE_CHEMICAL", 383, 403], ["Leupeptin", "SIMPLE_CHEMICAL", 413, 422], ["a commercial sandwich kit (TFB", "TREATMENT", 76, 106], ["cell lysates", "TREATMENT", 169, 181], ["immunoblots", "TEST", 186, 197], ["pH", "TEST", 259, 261], ["Tris", "TEST", 272, 276], ["HCl", "TEST", 277, 280], ["NaCl", "TEST", 289, 293], ["EDTA", "TEST", 317, 321], ["2.5 mM Sodium pyrophosphate", "TREATMENT", 323, 350], ["Glycerrophosphate", "TREATMENT", 359, 376], ["1 mM Sodium orthovanadate", "TREATMENT", 378, 403], ["Leupeptin", "TREATMENT", 413, 422], ["the protease inhibitor cocktail", "TREATMENT", 443, 474], ["cell lysates", "OBSERVATION", 169, 181], ["cells", "ANATOMY", 201, 206], ["harvested", "OBSERVATION", 211, 220]]], ["After then, the cell suspension is fractionated by centrifugation at 6000g for 20 min at 4 C. Solubilized proteins are harvested, electrophoresed in denaturing polyacrylamide gels, transferred to a polyvinylidene fluoride membrane and reacted with the antibodies indicated.", [["cell", "ANATOMY", 16, 20], ["polyvinylidene fluoride", "CHEMICAL", 198, 221], ["polyacrylamide", "CHEMICAL", 160, 174], ["polyvinylidene fluoride", "CHEMICAL", 198, 221], ["cell", "CELL", 16, 20], ["antibodies", "PROTEIN", 252, 262], ["the cell suspension", "TREATMENT", 12, 31], ["Solubilized proteins", "TREATMENT", 94, 114], ["denaturing polyacrylamide gels", "TREATMENT", 149, 179], ["a polyvinylidene fluoride membrane", "TREATMENT", 196, 230], ["the antibodies", "TEST", 248, 262], ["harvested", "OBSERVATION", 119, 128]]], ["Protein bands are detected with secondary antibody conjugated to horseradish peroxidase (HRP), and actin is used as a loading control.Determination of TCID 50Cells are mock-infected or exposed to viruses in mixture supplemented with DMEM.", [["horseradish peroxidase", "SIMPLE_CHEMICAL", 65, 87], ["HRP", "GENE_OR_GENE_PRODUCT", 89, 92], ["actin", "GENE_OR_GENE_PRODUCT", 99, 104], ["TCID 50Cells", "GENE_OR_GENE_PRODUCT", 151, 163], ["secondary antibody", "PROTEIN", 32, 50], ["horseradish peroxidase", "PROTEIN", 65, 87], ["HRP", "PROTEIN", 89, 92], ["actin", "PROTEIN", 99, 104], ["TCID 50Cells", "PROTEIN", 151, 163], ["horseradish", "SPECIES", 65, 76], ["Protein bands", "TEST", 0, 13], ["secondary antibody", "PROBLEM", 32, 50], ["horseradish peroxidase", "TREATMENT", 65, 87], ["a loading control", "TREATMENT", 116, 133]]], ["After 90 min the inoculum is replaced with DMEM containing 2% FBS and incubated for 48 h or 72 h (only for HSV-1).", [["FBS", "ANATOMY", 62, 65], ["FBS", "ORGANISM_SUBSTANCE", 62, 65], ["HSV-1", "SPECIES", 107, 112], ["DMEM", "TREATMENT", 43, 47], ["2% FBS", "TREATMENT", 59, 65], ["HSV", "TEST", 107, 110]]], ["Virus titration is performed in cells cultured in 96-well plate at 10 4 cells/well 24 h prior to the assay to achieve 80% confluency.Determination of TCID 50Ten-fold serial dilutions are prepared for each sample and 100 ml/ well of each dilution are added to the cells in quadruplicates.", [["cells", "ANATOMY", 32, 37], ["cells", "ANATOMY", 72, 77], ["sample", "ANATOMY", 205, 211], ["cells", "ANATOMY", 263, 268], ["Virus", "ORGANISM", 0, 5], ["cells", "CELL", 32, 37], ["cells", "CELL", 72, 77], ["TCID 50Ten", "GENE_OR_GENE_PRODUCT", 150, 160], ["cells", "CELL", 263, 268], ["50Ten", "PROTEIN", 155, 160], ["Virus titration", "TREATMENT", 0, 15], ["the assay", "TEST", 97, 106], ["TCID 50Ten-fold serial dilutions", "TREATMENT", 150, 182], ["each dilution", "TREATMENT", 232, 245]]], ["Wells with cytopathic effect are scored as positive for virus growth and log 10 TCID 50 /ml is determined by the method of Reed and Muench.Reed and Muench methodLog 10 50% end point dilution \u00bc log 10 of dilution showing a mortality next above 50% -(difference of logarithms \u00c2 logarithm of dilution factor).", [["dilution factor", "PROTEIN", 289, 304], ["cytopathic effect", "PROBLEM", 11, 28], ["virus growth", "PROBLEM", 56, 68], ["cytopathic", "OBSERVATION_MODIFIER", 11, 21]]], ["Generally, the following formula is used to calculate \"difference of logarithms\" (difference of logarithms is also His.", [["His", "CHEMICAL", 115, 118]]], ["(C) CD spectra of the purified G4-T in PBS solution with 0%, 25%, and 50% TFE.", [["G4-T", "CHEMICAL", 31, 35], ["TFE", "CHEMICAL", 74, 77], ["TFE", "CHEMICAL", 74, 77], ["TFE", "SIMPLE_CHEMICAL", 74, 77], ["50% TFE", "TREATMENT", 70, 77]]], ["A typical a-helix secondary structure is showed with double minima at 208 and 222 nm.", [["A typical a-helix secondary structure", "PROBLEM", 0, 37], ["secondary structure", "OBSERVATION", 18, 37]]], ["(D)Reed and Muench methodThermal denaturation of G4-T at wavelength of 222 nm. known as \"proportionate distance\" or \"interpolated value\"): Difference of logarithms \u00bc [(mortality at dilution next above 50%)-50%]/[(mortality next above 50%)-(mortality next below 50%)].HCV infectivityHCV infectivity titers are determined by focus-forming units (FFU) assay.", [["G4-T", "CHEMICAL", 49, 53], ["HCV", "ORGANISM", 267, 270], ["HCV", "SPECIES", 267, 270], ["HCV infectivityHCV infectivity titers", "PROBLEM", 267, 304]]], ["In brief, Huh7.5.1 cells seeded in a 96-well plate are infected with indicated MOI of HCV for different times.", [["Huh7", "ANATOMY", 10, 14], ["5.1 cells", "ANATOMY", 15, 24], ["Huh7", "CELL", 10, 14], ["cells", "CELL", 19, 24], ["HCV", "ORGANISM", 86, 89], ["Huh7", "CELL_LINE", 10, 14], ["HCV", "SPECIES", 86, 89], ["cells seeded", "OBSERVATION", 19, 31], ["infected", "OBSERVATION", 55, 63]]], ["The number of FFU is counted automatically by an ImmunoSpot Series 5 UV Analyzer with customized software (CTL Europe GmbH).", [["an ImmunoSpot Series", "TEST", 46, 66], ["number", "OBSERVATION_MODIFIER", 4, 10]]], ["The viral infectivity titers in FFU/ml are averages from three independent assays.siRNA interferenceCells in T-25 flask grown to 30e40% confluency are transfected with 200 pmol of siRNA (Santa Cruz) by using Lipofectamine\u2122 2000 (Invitrogen) according to manufacturer's protocols.Design of shRNAInvitrogen BLOCK-iT\u2122 RNAi (https://rnaidesigner.thermofisher. com) is used to design siRNAs targeting Gallus GLTSCR2.", [["Lipofectamine\u2122", "CHEMICAL", 208, 222], ["Lipofectamine\u2122 2000", "CHEMICAL", 208, 227], ["shRNAInvitrogen BLOCK", "SIMPLE_CHEMICAL", 289, 310], ["Gallus", "ORGANISM", 396, 402], ["GLTSCR2", "GENE_OR_GENE_PRODUCT", 403, 410], ["Santa Cruz", "PROTEIN", 187, 197], ["Gallus GLTSCR2", "PROTEIN", 396, 410], ["T-25", "SPECIES", 109, 113], ["Gallus", "SPECIES", 396, 402], ["The viral infectivity titers", "TEST", 0, 28], ["T", "TEST", 109, 110], ["Lipofectamine\u2122", "TREATMENT", 208, 222], ["Design of shRNAInvitrogen BLOCK", "TREATMENT", 279, 310], ["design siRNAs targeting Gallus GLTSCR2", "PROBLEM", 372, 410], ["viral", "OBSERVATION_MODIFIER", 4, 9], ["infectivity titers", "OBSERVATION", 10, 28]]], ["Based on the siRNA screening results, shRNA-158, siRNA-243, and siRNA-1370 are predicted to have the best suppression effect and are selected to design shRNA.", [["siRNA-243", "CHEMICAL", 49, 58], ["siRNA-1370", "CHEMICAL", 64, 74], ["shRNA-158", "GENE_OR_GENE_PRODUCT", 38, 47], ["siRNA-243", "GENE_OR_GENE_PRODUCT", 49, 58], ["siRNA-1370", "GENE_OR_GENE_PRODUCT", 64, 74], ["shRNA-158, siRNA-243", "DNA", 38, 58], ["siRNA-1370", "DNA", 64, 74], ["the siRNA screening", "TEST", 9, 28], ["shRNA", "TEST", 38, 43], ["siRNA", "TEST", 49, 54], ["siRNA", "TEST", 64, 69]]], ["The shRNA sequences targeting Gallus GLTSCR2 are as follows (5 0 -3 0 ; only the sense strand is shown). shRNA-158: GCG ATT TCC TCG AGG ATG TGA; shRNA-243: GGA TAC GGG CAA TGC TGA GAA; shRNA-1370: GCC TGA AGT ACG TGG AGA AGA.", [["shRNA-1370", "CHEMICAL", 185, 195], ["Gallus", "ORGANISM", 30, 36], ["GLTSCR2", "GENE_OR_GENE_PRODUCT", 37, 44], ["shRNA sequences", "DNA", 4, 19], ["Gallus GLTSCR2", "DNA", 30, 44], ["shRNA-243", "DNA", 145, 154], ["shRNA-1370: GCC TGA AGT ACG TGG AGA AGA", "DNA", 185, 224], ["Gallus", "SPECIES", 30, 36], ["The shRNA sequences", "TEST", 0, 19], ["Gallus GLTSCR2", "TEST", 30, 44], ["shRNA", "TEST", 105, 110], ["GCG ATT TCC", "TEST", 116, 127], ["TCG", "TEST", 128, 131], ["AGG", "TEST", 132, 135], ["ATG", "TEST", 136, 139], ["TGA", "TEST", 140, 143], ["shRNA", "TEST", 145, 150], ["GGA", "TEST", 156, 159], ["TGA GAA", "TEST", 176, 183], ["shRNA", "TEST", 185, 190], ["GCC TGA", "TEST", 197, 204], ["AGA", "TEST", 221, 224], ["Gallus", "ANATOMY", 30, 36]]], ["The shRNA expression vector pGPU6/GFP/Neo is selected to be the parental plasmid.", [["plasmid", "ANATOMY", 73, 80], ["pGPU6", "GENE_OR_GENE_PRODUCT", 28, 33], ["GFP", "GENE_OR_GENE_PRODUCT", 34, 37], ["Neo", "GENE_OR_GENE_PRODUCT", 38, 41], ["shRNA expression vector", "DNA", 4, 27], ["pGPU6", "DNA", 28, 33], ["GFP", "DNA", 34, 37], ["Neo", "DNA", 38, 41], ["parental plasmid", "DNA", 64, 80], ["The shRNA expression vector", "TREATMENT", 0, 27], ["GFP/Neo", "TREATMENT", 34, 41], ["the parental plasmid", "TREATMENT", 60, 80]]], ["All these DNA oligonucleotides are chemically synthesized by Invitrogen.Transfection of shRNA plasmidsCells grown to 60e80% confluency are transfected with plasmid-based shRNA by using Lipofectamine\u2122 2000 according to manufacturer's protocols. normalized to the internal control (glyceraldehyde-3-phosphate dehydrogenase [GAPDH] ) and expressed as relative fold changes over the control.", [["Cells", "ANATOMY", 102, 107], ["Lipofectamine\u2122", "CHEMICAL", 185, 199], ["glyceraldehyde-3-phosphate", "CHEMICAL", 280, 306], ["glyceraldehyde-3-phosphate", "CHEMICAL", 280, 306], ["DNA", "CELLULAR_COMPONENT", 10, 13], ["Invitrogen", "GENE_OR_GENE_PRODUCT", 61, 71], ["Cells", "CELL", 102, 107], ["glyceraldehyde-3-phosphate dehydrogenase", "GENE_OR_GENE_PRODUCT", 280, 320], ["GAPDH", "GENE_OR_GENE_PRODUCT", 322, 327], ["shRNA plasmids", "DNA", 88, 102], ["plasmid", "DNA", 156, 163], ["glyceraldehyde-3-phosphate dehydrogenase", "PROTEIN", 280, 320], ["GAPDH", "PROTEIN", 322, 327], ["All these DNA oligonucleotides", "TREATMENT", 0, 30], ["Transfection of shRNA plasmids", "TREATMENT", 72, 102], ["Cells", "TEST", 102, 107], ["plasmid-based shRNA", "TREATMENT", 156, 175], ["Lipofectamine\u2122", "TREATMENT", 185, 199], ["glyceraldehyde", "TEST", 280, 294], ["relative fold changes", "PROBLEM", 348, 369], ["DNA oligonucleotides", "OBSERVATION", 10, 30]]], ["Statistical analysis was evaluated by one-way analysis of variance with Dunnett's multiple-comparison test. p < 0.01, p < 0.001 compared with PBS-treated group.", [["Statistical analysis", "TEST", 0, 20], ["Dunnett", "TEST", 72, 79], ["comparison test", "TEST", 91, 106], ["p", "TEST", 108, 109], ["PBS", "TEST", 142, 145]]], ["(F) HEK293T cells were infected with VSV at a MOI of 0.1 in the presence of G4-T (20 mg/ml) (lanes 2e3) and commercially available IFN-b (10 ng/ml) (lanes 3e4), the virus yields were determined 48 h later, as log 10 TCID 50 /ml.", [["HEK293T cells", "ANATOMY", 4, 17], ["G4-T", "CHEMICAL", 76, 80], ["F) HEK293T cells", "CELL", 1, 17], ["VSV", "ORGANISM", 37, 40], ["G4-T", "SIMPLE_CHEMICAL", 76, 80], ["IFN-b", "GENE_OR_GENE_PRODUCT", 131, 136], ["HEK293T cells", "CELL_LINE", 4, 17], ["IFN", "PROTEIN", 131, 134], ["VSV", "SPECIES", 37, 40], ["VSV", "TREATMENT", 37, 40], ["a MOI", "TEST", 44, 49], ["G4-T", "TREATMENT", 76, 80]]], ["Statistical analysis was evaluated by one-way analysis of variance with Dunnett's multiple-comparison test. **p < 0.01 compared with untreated group.", [["Statistical analysis", "TEST", 0, 20], ["Dunnett", "TEST", 72, 79], ["comparison test", "TEST", 91, 106]]], ["Under the same experimental condition, electrophoretically separated proteins were analyzed by immunoblotting with specific antibody to viral protein VSV-G, with actin as a control (right).SPF chicken embryo assayFor each inoculation, a mixture of shRNA plasmid (10 mg), Lipofectamine (10 ml), NDV (50 PFU, 50 ml) or AIV (500 PFU, 100 ml) is injected into the allantoic cavity of 9-day chicken eggs.", [["embryo", "ANATOMY", 201, 207], ["allantoic cavity", "ANATOMY", 360, 376], ["eggs", "ANATOMY", 394, 398], ["Lipofectamine", "CHEMICAL", 271, 284], ["NDV", "CHEMICAL", 294, 297], ["VSV-G", "GENE_OR_GENE_PRODUCT", 150, 155], ["actin", "GENE_OR_GENE_PRODUCT", 162, 167], ["chicken", "ORGANISM", 193, 200], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 201, 207], ["Lipofectamine", "SIMPLE_CHEMICAL", 271, 284], ["NDV", "ORGANISM", 294, 297], ["AIV", "ORGANISM", 317, 320], ["allantoic cavity", "MULTI-TISSUE_STRUCTURE", 360, 376], ["chicken", "ORGANISM", 386, 393], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 394, 398], ["electrophoretically separated proteins", "PROTEIN", 39, 77], ["viral protein VSV-G", "PROTEIN", 136, 155], ["actin", "PROTEIN", 162, 167], ["shRNA plasmid", "DNA", 248, 261], ["chicken", "SPECIES", 193, 200], ["chicken", "SPECIES", 386, 393], ["chicken", "SPECIES", 193, 200], ["NDV", "SPECIES", 294, 297], ["AIV", "SPECIES", 317, 320], ["chicken", "SPECIES", 386, 393], ["electrophoretically separated proteins", "TREATMENT", 39, 77], ["immunoblotting", "TEST", 95, 109], ["specific antibody", "TEST", 115, 132], ["viral protein VSV", "TREATMENT", 136, 153], ["SPF chicken embryo assay", "TREATMENT", 189, 213], ["a mixture of shRNA plasmid", "TREATMENT", 235, 261], ["Lipofectamine", "TREATMENT", 271, 284], ["NDV", "TREATMENT", 294, 297], ["AIV", "TREATMENT", 317, 320], ["right", "ANATOMY_MODIFIER", 182, 187], ["allantoic cavity", "ANATOMY", 360, 376]]], ["Eggs are incubated for different times, and allantoic fluid is harvested to measure virus titer.", [["Eggs", "ANATOMY", 0, 4], ["allantoic fluid", "ANATOMY", 44, 59], ["Eggs", "ORGANISM_SUBSTANCE", 0, 4], ["allantoic fluid", "ORGANISM_SUBSTANCE", 44, 59], ["Eggs", "TREATMENT", 0, 4], ["allantoic fluid", "TREATMENT", 44, 59]]], ["All the embryos infected with NDV (50 PFU) or AIV (500 PFU) alive under the experimental condition.Hemagglutination (HA) assayEach allantoic fluid is collected and two-fold serially diluted in sterile saline; each dilution of 50 ml is reacted against an equal volume of 1% of washed red blood cells (RBC) of chicken.", [["embryos", "ANATOMY", 8, 15], ["red blood cells", "ANATOMY", 283, 298], ["RBC", "ANATOMY", 300, 303], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 8, 15], ["NDV", "ORGANISM", 30, 33], ["red blood cells", "CELL", 283, 298], ["RBC", "CELL", 300, 303], ["chicken", "ORGANISM", 308, 315], ["washed red blood cells", "CELL_TYPE", 276, 298], ["RBC", "CELL_TYPE", 300, 303], ["chicken", "SPECIES", 308, 315], ["NDV", "SPECIES", 30, 33], ["AIV", "SPECIES", 46, 49], ["chicken", "SPECIES", 308, 315], ["NDV", "TREATMENT", 30, 33], ["AIV", "PROBLEM", 46, 49], ["Hemagglutination (HA) assayEach allantoic fluid", "PROBLEM", 99, 146], ["sterile saline", "TREATMENT", 193, 207], ["an equal volume", "TEST", 251, 266], ["red blood cells", "TEST", 283, 298], ["RBC", "TEST", 300, 303], ["embryos", "ANATOMY", 8, 15], ["infected", "OBSERVATION", 16, 24], ["allantoic", "ANATOMY", 131, 140], ["fluid", "OBSERVATION", 141, 146]]], ["The maximum dilution of allantoic fluid that still results in complete agglutination of RBC suspension is recorded as HA unit (HAU).", [["allantoic fluid", "ANATOMY", 24, 39], ["RBC", "ANATOMY", 88, 91], ["allantoic fluid", "ORGANISM_SUBSTANCE", 24, 39], ["RBC", "CELL", 88, 91], ["The maximum dilution of allantoic fluid", "TREATMENT", 0, 39], ["RBC suspension", "TREATMENT", 88, 102], ["maximum", "OBSERVATION_MODIFIER", 4, 11], ["allantoic fluid", "OBSERVATION", 24, 39], ["agglutination", "OBSERVATION", 71, 84], ["RBC suspension", "OBSERVATION", 88, 102]]], ["An experiment is performed three times, and the viral infectivity titers in HAU value are averages from two independent assays.Recombinant protein G4-T folds in an a-helical dimer structurePreviously, we showed that the C-terminal region G4 (amino acids 241e478) of GLTSCR2 participates in optimal VSV replication (Wang et al., 2016a ).", [["amino acids", "CHEMICAL", 242, 253], ["C", "CHEMICAL", 220, 221], ["amino acids", "CHEMICAL", 242, 253], ["amino acids 241e478", "AMINO_ACID", 242, 261], ["GLTSCR2", "GENE_OR_GENE_PRODUCT", 266, 273], ["VSV", "ORGANISM", 298, 301], ["Recombinant protein G4-T folds", "PROTEIN", 127, 157], ["a-helical dimer structure", "PROTEIN", 164, 189], ["C-terminal region G4", "DNA", 220, 240], ["amino acids 241e478", "PROTEIN", 242, 261], ["GLTSCR2", "PROTEIN", 266, 273], ["VSV", "SPECIES", 298, 301], ["the viral infectivity titers", "TEST", 44, 72], ["Recombinant protein", "TEST", 127, 146], ["the C-terminal region", "PROBLEM", 216, 237], ["amino acids", "TEST", 242, 253], ["GLTSCR2", "TREATMENT", 266, 273], ["viral infectivity", "OBSERVATION", 48, 65], ["terminal", "ANATOMY_MODIFIER", 222, 230], ["VSV replication", "OBSERVATION", 298, 313]]], ["In the current study, His-fusion protein G4-T is produced, in which cell-penetrating peptide Tat (GGSRYGRKKRRQRRR) is conjugated at the C-terminal of G4.", [["cell", "ANATOMY", 68, 72], ["C", "CHEMICAL", 136, 137], ["G4-T", "GENE_OR_GENE_PRODUCT", 41, 45], ["cell", "CELL", 68, 72], ["Tat", "GENE_OR_GENE_PRODUCT", 93, 96], ["GGSRYGRKKRRQRRR", "GENE_OR_GENE_PRODUCT", 98, 113], ["His-fusion protein G4", "PROTEIN", 22, 43], ["T", "PROTEIN", 44, 45], ["cell-penetrating peptide Tat", "PROTEIN", 68, 96], ["GGSRYGRKKRRQRRR", "PROTEIN", 98, 113], ["C-terminal of G4", "PROTEIN", 136, 152], ["the current study", "TEST", 3, 20], ["His-fusion protein G4", "TEST", 22, 43], ["penetrating peptide Tat (GGSRYGRKKRRQRRR)", "TREATMENT", 73, 114]]], ["Recombinant protein G4-T is purified by Ni-column and eluted with a Tris-HCl buffer containing imidazole at concentrations of 10, 20, 50, or 200 mM.", [["Tris-HCl", "CHEMICAL", 68, 76], ["imidazole", "CHEMICAL", 95, 104], ["Tris-HCl", "CHEMICAL", 68, 76], ["imidazole", "CHEMICAL", 95, 104], ["G4-T", "GENE_OR_GENE_PRODUCT", 20, 24], ["Ni-column", "SIMPLE_CHEMICAL", 40, 49], ["Tris-HCl", "SIMPLE_CHEMICAL", 68, 76], ["imidazole", "SIMPLE_CHEMICAL", 95, 104], ["Recombinant protein G4-T", "PROTEIN", 0, 24], ["Recombinant protein G4", "TEST", 0, 22], ["a Tris-HCl buffer", "TREATMENT", 66, 83], ["imidazole", "TREATMENT", 95, 104]]], ["Results show that G4-T is highly soluble in 20 mM imidazole with over 85% purity at a concentration of about 1 mg/ml (Fig. 1A, lane 5) .", [["G4-T", "CHEMICAL", 18, 22], ["imidazole", "CHEMICAL", 50, 59], ["imidazole", "CHEMICAL", 50, 59], ["G4-T", "SIMPLE_CHEMICAL", 18, 22], ["imidazole", "SIMPLE_CHEMICAL", 50, 59]]], ["G4-T is then passed over a Superdex G200 column.", [["a Superdex G200 column", "TREATMENT", 25, 47]]], ["This results in the selfassociation of G4-T into a dimer structure with a molecular mass of 52 kDa in a Tris-HCl buffer (Fig. 1B) .", [["G4-T", "CHEMICAL", 39, 43], ["Tris-HCl", "CHEMICAL", 104, 112], ["Tris-HCl", "CHEMICAL", 104, 112], ["Tris-HCl", "SIMPLE_CHEMICAL", 104, 112], ["G4", "PROTEIN", 39, 41], ["dimer structure", "PROTEIN", 51, 66], ["a molecular mass", "PROBLEM", 72, 88], ["a Tris-HCl buffer", "TREATMENT", 102, 119], ["mass", "OBSERVATION", 84, 88]]], ["Chemical cross-linking analysis confirms the formation of dimers of G4-T in the presence of 0.05% Glutaraldehyde (GA) (lane 4).Recombinant protein G4-T folds in an a-helical dimer structureCircular dichroism (CD) spectrometry is performed to study the secondary structural changes in PBS with and without 2,2,2trifluoroethanol (TFE).", [["G4-T", "CHEMICAL", 68, 72], ["Glutaraldehyde", "CHEMICAL", 98, 112], ["GA", "CHEMICAL", 114, 116], ["2,2,2trifluoroethanol", "CHEMICAL", 305, 326], ["TFE", "CHEMICAL", 328, 331], ["Glutaraldehyde", "CHEMICAL", 98, 112], ["2,2,2trifluoroethanol", "CHEMICAL", 305, 326], ["TFE", "CHEMICAL", 328, 331], ["G4-T", "SIMPLE_CHEMICAL", 68, 72], ["Glutaraldehyde", "SIMPLE_CHEMICAL", 98, 112], ["GA", "SIMPLE_CHEMICAL", 114, 116], ["PBS", "SIMPLE_CHEMICAL", 284, 287], ["2,2,2trifluoroethanol", "SIMPLE_CHEMICAL", 305, 326], ["TFE", "SIMPLE_CHEMICAL", 328, 331], ["Recombinant protein G4", "PROTEIN", 127, 149], ["Chemical cross-linking analysis", "TEST", 0, 31], ["0.05% Glutaraldehyde (GA", "TREATMENT", 92, 116], ["Recombinant protein", "TEST", 127, 146], ["the secondary structural changes in PBS", "PROBLEM", 248, 287], ["2,2,2trifluoroethanol (TFE", "TREATMENT", 305, 331]]], ["TFE is widely used in conformational studies because it promotes intramolecular hydrogen bonds in spite of intermolecular interactions with water molecules, and thus, lowers the polarity of the solution .", [["TFE", "CHEMICAL", 0, 3], ["TFE", "CHEMICAL", 0, 3], ["hydrogen", "CHEMICAL", 80, 88], ["TFE", "SIMPLE_CHEMICAL", 0, 3], ["TFE", "TREATMENT", 0, 3], ["conformational studies", "TEST", 22, 44], ["intramolecular hydrogen bonds", "PROBLEM", 65, 94], ["intramolecular", "OBSERVATION", 65, 79], ["hydrogen bonds", "OBSERVATION", 80, 94]]], ["ResultsRecombinant protein G4-T folds in an a-helical dimer structureshow that G4-T protein exhibits a tendency to form a a-helical secondary structure in a PBS buffer solution.", [["G4-T", "GENE_OR_GENE_PRODUCT", 79, 83], ["ResultsRecombinant protein G4-T folds", "PROTEIN", 0, 37], ["G4", "PROTEIN", 79, 81], ["T protein", "PROTEIN", 82, 91], ["a-helical secondary structure", "PROTEIN", 122, 151], ["ResultsRecombinant protein G4", "TEST", 0, 29], ["G4-T protein", "TEST", 79, 91], ["a tendency", "PROBLEM", 101, 111], ["a PBS buffer solution", "TREATMENT", 155, 176]]], ["The tendency to form a-helical secondary structure for G4-T protein in the presence of 25% and 50% TFE is more obvious than that in the absence of TFE (Fig. 1C) .", [["G4-T", "CHEMICAL", 55, 59], ["TFE", "CHEMICAL", 99, 102], ["TFE", "CHEMICAL", 147, 150], ["TFE", "CHEMICAL", 99, 102], ["TFE", "CHEMICAL", 147, 150], ["G4-T", "GENE_OR_GENE_PRODUCT", 55, 59], ["TFE", "SIMPLE_CHEMICAL", 99, 102], ["TFE", "SIMPLE_CHEMICAL", 147, 150], ["G4", "PROTEIN", 55, 57], ["T protein", "PROTEIN", 58, 67], ["G4-T protein", "TEST", 55, 67], ["more obvious", "OBSERVATION_MODIFIER", 106, 118]]], ["This result indicates that there is no effect of polarity on (10 ng/ml), or PBS for 48 h.", [["PBS", "TREATMENT", 76, 79], ["no", "UNCERTAINTY", 36, 38]]], ["Virus titer was presented as log 10 FFU/ml.", [["Virus", "ORGANISM", 0, 5], ["Virus titer", "TEST", 0, 11]]], ["Statistical analysis was evaluated by two-way analysis of variance with Dunnett's multiple-comparison test.", [["Statistical analysis", "TEST", 0, 20], ["Dunnett", "TEST", 72, 79], ["comparison test", "TEST", 91, 106]]], ["(B) Huh7.5.1 cells were exposed to HCV at a MOI of 0.1 for indicated times, in the presence of G4-T, IFN-b, or PBS.", [["Huh7", "ANATOMY", 4, 8], ["5.1 cells", "ANATOMY", 9, 18], ["G4-T", "CHEMICAL", 95, 99], ["B) Huh7", "CELL", 1, 8], ["5.1 cells", "CELL", 9, 18], ["HCV", "ORGANISM", 35, 38], ["G4-T", "GENE_OR_GENE_PRODUCT", 95, 99], ["IFN-b", "GENE_OR_GENE_PRODUCT", 101, 106], ["PBS", "SIMPLE_CHEMICAL", 111, 114], ["(B) Huh7", "CELL_LINE", 0, 8], ["IFN", "PROTEIN", 101, 104], ["HCV", "SPECIES", 35, 38], ["5.1 cells", "PROBLEM", 9, 18], ["HCV", "PROBLEM", 35, 38], ["a MOI", "TEST", 42, 47], ["IFN", "TEST", 101, 104], ["PBS", "PROBLEM", 111, 114], ["HCV", "OBSERVATION_MODIFIER", 35, 38]]], ["Total RNA was isolated; HCV-NS5A mRNA was quantified by RT-PCR, and assessed as described in Fig. 2A .", [["HCV", "ORGANISM", 24, 27], ["NS5A", "GENE_OR_GENE_PRODUCT", 28, 32], ["2A", "GENE_OR_GENE_PRODUCT", 98, 100], ["HCV-NS5A mRNA", "RNA", 24, 37], ["HCV", "SPECIES", 24, 27], ["Total RNA", "TEST", 0, 9], ["HCV", "PROBLEM", 24, 27], ["NS5A mRNA", "TEST", 28, 37], ["PCR", "TEST", 59, 62]]], ["Statistical analysis was evaluated by two-way analysis of variance with Dunnett's multiple-comparison test.", [["Statistical analysis", "TEST", 0, 20], ["Dunnett", "TEST", 72, 79], ["comparison test", "TEST", 91, 106]]], ["(C) Huh7.5.1 cells were transfected with the linear Jc1-Luc HCV plasmid for 48 h, in the presence of G4-T, IFN-b, or PBS.", [["Huh7", "ANATOMY", 4, 8], ["5.1 cells", "ANATOMY", 9, 18], ["G4-T", "CHEMICAL", 101, 105], ["Huh7", "CELL", 4, 8], ["5.1 cells", "CELL", 9, 18], ["Jc1", "GENE_OR_GENE_PRODUCT", 52, 55], ["G4-T", "GENE_OR_GENE_PRODUCT", 101, 105], ["IFN-b", "GENE_OR_GENE_PRODUCT", 107, 112], ["PBS", "SIMPLE_CHEMICAL", 117, 120], ["(C) Huh7", "CELL_LINE", 0, 8], ["linear Jc1-Luc HCV plasmid", "DNA", 45, 71], ["IFN", "PROTEIN", 107, 110], ["HCV", "SPECIES", 60, 63], ["the linear Jc1", "TREATMENT", 41, 55], ["Luc HCV plasmid", "TREATMENT", 56, 71], ["IFN", "TEST", 107, 110], ["linear", "OBSERVATION_MODIFIER", 45, 51]]], ["The cells were lysed and assayed with luciferase assay system in a Modulus Microplate Luminometer.", [["cells", "ANATOMY", 4, 9], ["cells", "CELL", 4, 9], ["luciferase", "GENE_OR_GENE_PRODUCT", 38, 48], ["luciferase", "PROTEIN", 38, 48], ["luciferase assay system", "TEST", 38, 61], ["a Modulus Microplate Luminometer", "TREATMENT", 65, 97]]], ["We typically obtain counts ranging from 10,000e900,000, whereas the background signal from bald virus infected sample is usually below 100.", [["bald virus", "ORGANISM", 91, 101], ["bald virus", "SPECIES", 91, 101], ["counts", "TEST", 20, 26], ["the background signal", "TEST", 64, 85], ["bald virus infected sample", "PROBLEM", 91, 117]]], ["Statistical analysis was evaluated by one-way analysis of variance with Dunnett's multiple-comparison test. *p < 0.05, p < 0.001 compared with negative shRNA-treated eggs.", [["eggs", "ANATOMY", 166, 170], ["Statistical analysis", "TEST", 0, 20], ["Dunnett", "TEST", 72, 79], ["comparison test", "TEST", 91, 106]]], ["(B) Specific fluorescence in DF-1 cells infected with GFP-NDV was imaged by fluorescence microscopy (magnification of 100\u00c2), one image is representative of three.", [["DF-1 cells", "ANATOMY", 29, 39], ["DF-1 cells", "CELL", 29, 39], ["GFP-NDV", "ORGANISM", 54, 61], ["DF-1 cells", "CELL_LINE", 29, 39], ["GFP", "PROTEIN", 54, 57], ["NDV", "SPECIES", 58, 61], ["Specific fluorescence in DF", "TEST", 4, 31], ["GFP", "TEST", 54, 57], ["fluorescence microscopy", "TEST", 76, 99], ["one image", "TEST", 125, 134]]], ["The description (1:10 5 and 1:10 6 ) indicated the dilution of NDV-infected allantoic fluid used for inoculation of cells.Discussionprotein is expected to treat viruses in clinical samples that are fastidious and difficult to cultivate, and vaccine strains from wildtype isolates.", [["allantoic fluid", "ANATOMY", 76, 91], ["cells", "ANATOMY", 116, 121], ["samples", "ANATOMY", 181, 188], ["NDV", "ORGANISM", 63, 66], ["allantoic fluid", "ORGANISM_SUBSTANCE", 76, 91], ["cells", "CELL", 116, 121], ["wildtype isolates", "ORGANISM", 262, 279], ["NDV", "SPECIES", 63, 66], ["the dilution", "TEST", 47, 59], ["NDV", "PROBLEM", 63, 66], ["infected allantoic fluid", "TREATMENT", 67, 91], ["inoculation of cells", "PROBLEM", 101, 121], ["viruses in clinical samples", "PROBLEM", 161, 188], ["fastidious", "PROBLEM", 198, 208], ["vaccine strains from wildtype isolates", "PROBLEM", 241, 279], ["infected", "OBSERVATION_MODIFIER", 67, 75], ["allantoic fluid", "OBSERVATION", 76, 91]]], ["Our study highlights the potential of the cellular protein GLTSCR2 to be a valuable target for the development of broad-spectrum class of antivirals.DiscussionOver the past 10 years numerous applications have successfully used the RNA interference (RNAi) technology.", [["cellular", "ANATOMY", 42, 50], ["cellular", "CELL", 42, 50], ["GLTSCR2", "GENE_OR_GENE_PRODUCT", 59, 66], ["cellular protein", "PROTEIN", 42, 58], ["GLTSCR2", "PROTEIN", 59, 66], ["Our study", "TEST", 0, 9], ["the cellular protein GLTSCR2", "PROBLEM", 38, 66], ["antivirals", "TREATMENT", 138, 148], ["cellular protein GLTSCR2", "OBSERVATION", 42, 66]]], ["It is based on the fact that small interfering RNA (siRNA) molecules or short hairpin RNAs (shRNAs) target viral and cellular mRNA, which results in the degradation and suppression of specific gene expressions (Bosher and Labouesse, 2000; Das et al., 2006) .", [["cellular", "ANATOMY", 117, 125], ["short hairpin RNAs", "GENE_OR_GENE_PRODUCT", 72, 90], ["shRNAs", "GENE_OR_GENE_PRODUCT", 92, 98], ["cellular", "CELL", 117, 125], ["small interfering RNA (siRNA) molecules", "RNA", 29, 68], ["short hairpin RNAs", "RNA", 72, 90], ["shRNAs", "RNA", 92, 98], ["viral and cellular mRNA", "RNA", 107, 130], ["small interfering RNA (siRNA) molecules", "PROBLEM", 29, 68], ["short hairpin RNAs (shRNAs) target viral and cellular mRNA", "PROBLEM", 72, 130], ["the degradation", "PROBLEM", 149, 164], ["small", "OBSERVATION_MODIFIER", 29, 34], ["interfering", "OBSERVATION", 35, 46], ["cellular mRNA", "OBSERVATION", 117, 130]]], ["The development of the plasmid-based technology to produce shRNA, driven by the U6 promoter, has made long term and inducible gene silencing possible (Sui et al., 2002) .", [["U6", "GENE_OR_GENE_PRODUCT", 80, 82], ["plasmid", "DNA", 23, 30], ["shRNA", "DNA", 59, 64], ["U6 promoter", "DNA", 80, 91], ["shRNA", "PROBLEM", 59, 64], ["long term and inducible gene silencing", "PROBLEM", 102, 140], ["U6 promoter", "OBSERVATION", 80, 91]]], ["A number of studies have demonstrated that RNAi-mediated gene suppression of pathogenic viruses to be highly effective against many human and animal viruses both in vitro and in vivo (Burnett et al., 2011; DeVincenzo, 2012; Huang, 2008; Jain and Jain, 2015; Spurgers et al., 2008) .", [["human", "ORGANISM", 132, 137], ["human", "SPECIES", 132, 137], ["human", "SPECIES", 132, 137], ["studies", "TEST", 12, 19], ["RNAi", "TEST", 43, 47], ["pathogenic viruses", "PROBLEM", 77, 95], ["many human and animal viruses", "PROBLEM", 127, 156], ["pathogenic viruses", "OBSERVATION", 77, 95], ["viruses", "OBSERVATION", 149, 156]]], ["The siRNA-and shRNA-mediated knockdown can inhibit viral replication of NDV and AIV in chicken cells and embryos.", [["cells", "ANATOMY", 95, 100], ["embryos", "ANATOMY", 105, 112], ["NDV", "ORGANISM", 72, 75], ["AIV", "ORGANISM", 80, 83], ["chicken", "ORGANISM", 87, 94], ["cells", "CELL", 95, 100], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 105, 112], ["chicken cells", "CELL_TYPE", 87, 100], ["chicken", "SPECIES", 87, 94], ["NDV", "SPECIES", 72, 75], ["AIV", "SPECIES", 80, 83], ["chicken", "SPECIES", 87, 94], ["The siRNA", "TEST", 0, 9], ["shRNA-mediated knockdown", "TREATMENT", 14, 38], ["viral replication", "TREATMENT", 51, 68], ["NDV", "PROBLEM", 72, 75], ["AIV in chicken cells", "TREATMENT", 80, 100], ["embryos", "PROBLEM", 105, 112], ["siRNA", "ANATOMY", 4, 9], ["chicken cells", "OBSERVATION", 87, 100]]], ["The plasmid-based shRNA that targets matrix protein M of NDV (Yin et al., 2010) and nucleocapsid protein NP of AIV (Abrahamyan et al., 2009) leads to a yield reduction of 80 and 400 folds in cells, respectively.", [["cells", "ANATOMY", 191, 196], ["NDV", "ORGANISM", 57, 60], ["nucleocapsid protein NP", "GENE_OR_GENE_PRODUCT", 84, 107], ["cells", "CELL", 191, 196], ["plasmid", "DNA", 4, 11], ["matrix protein M", "PROTEIN", 37, 53], ["nucleocapsid protein NP", "PROTEIN", 84, 107], ["NDV", "SPECIES", 57, 60], ["The plasmid-based shRNA", "TREATMENT", 0, 23], ["matrix protein M", "TEST", 37, 53], ["NDV", "TEST", 57, 60], ["nucleocapsid protein NP", "TEST", 84, 107], ["a yield reduction", "TEST", 150, 167]]], ["Furthermore, shRNA targets NP of NDV that is delivered into the chicken embryos and reduces HA value by 10 folds in virus titer (Yue et al., 2009) , while siRNA targets NP of AIV and reduces HAU value by 8 folds (Ge et al., 2003) .DiscussionIn this study, GLTSCR2-specific shRNA-1370 is evaluated for antiviral activity against NDV and AIV by means of virus titration in chicken cells and embryos.", [["embryos", "ANATOMY", 72, 79], ["cells", "ANATOMY", 379, 384], ["embryos", "ANATOMY", 389, 396], ["shRNA-1370", "CHEMICAL", 273, 283], ["NDV", "ORGANISM", 33, 36], ["chicken", "ORGANISM", 64, 71], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 72, 79], ["AIV", "ORGANISM", 175, 178], ["GLTSCR2", "SIMPLE_CHEMICAL", 256, 263], ["NDV", "ORGANISM", 328, 331], ["AIV", "ORGANISM", 336, 339], ["chicken", "ORGANISM", 371, 378], ["cells", "CELL", 379, 384], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 389, 396], ["HAU", "PROTEIN", 191, 194], ["GLTSCR2", "DNA", 256, 263], ["chicken cells", "CELL_TYPE", 371, 384], ["chicken", "SPECIES", 64, 71], ["NDV", "SPECIES", 328, 331], ["chicken", "SPECIES", 371, 378], ["NDV", "SPECIES", 33, 36], ["chicken", "SPECIES", 64, 71], ["AIV", "SPECIES", 175, 178], ["NDV", "SPECIES", 328, 331], ["AIV", "SPECIES", 336, 339], ["chicken", "SPECIES", 371, 378], ["NDV", "PROBLEM", 33, 36], ["the chicken embryos", "TREATMENT", 60, 79], ["HA value", "PROBLEM", 92, 100], ["this study", "TEST", 244, 254], ["GLTSCR2", "TEST", 256, 263], ["antiviral activity", "TREATMENT", 301, 319], ["NDV", "PROBLEM", 328, 331], ["AIV", "PROBLEM", 336, 339], ["virus titration", "TREATMENT", 352, 367], ["chicken cells", "TREATMENT", 371, 384], ["NDV", "OBSERVATION", 33, 36]]], ["Our results show that plasmid-based shRNA-1370 induces up to 1000-fold decrease in the infective titer in cells infected with NDV (Fig. 5) .", [["cells", "ANATOMY", 106, 111], ["shRNA-1370", "CHEMICAL", 36, 46], ["cells", "CELL", 106, 111], ["NDV", "ORGANISM", 126, 129], ["Fig. 5", "ORGANISM", 131, 137], ["plasmid", "DNA", 22, 29], ["NDV", "SPECIES", 126, 129], ["plasmid-based shRNA", "TEST", 22, 41], ["fold decrease", "PROBLEM", 66, 79], ["the infective titer in cells", "PROBLEM", 83, 111], ["decrease", "OBSERVATION_MODIFIER", 71, 79], ["infective titer", "OBSERVATION_MODIFIER", 87, 102]]], ["In our chicken embryo experiments, NDV of 50 PFU in 50 ml has been selected to inject into the allantoic cavity of 9-day chicken eggs.", [["embryo", "ANATOMY", 15, 21], ["allantoic cavity", "ANATOMY", 95, 111], ["eggs", "ANATOMY", 129, 133], ["chicken", "ORGANISM", 7, 14], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 15, 21], ["NDV", "ORGANISM", 35, 38], ["allantoic cavity", "MULTI-TISSUE_STRUCTURE", 95, 111], ["chicken", "ORGANISM", 121, 128], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 129, 133], ["chicken", "SPECIES", 7, 14], ["chicken", "SPECIES", 121, 128], ["chicken", "SPECIES", 7, 14], ["NDV", "SPECIES", 35, 38], ["chicken", "SPECIES", 121, 128], ["our chicken embryo experiments", "TREATMENT", 3, 33], ["NDV", "TREATMENT", 35, 38], ["allantoic cavity", "ANATOMY", 95, 111]]], ["Infected eggs are stored immediately at 4 C for 12 h, and all eggs are harvested and analyzed simultaneously for consistency.", [["eggs", "ANATOMY", 9, 13], ["eggs", "ANATOMY", 62, 66], ["Infected eggs", "PROBLEM", 0, 13], ["all eggs", "TREATMENT", 58, 66], ["eggs", "OBSERVATION", 9, 13], ["harvested", "OBSERVATION", 71, 80]]], ["Under this experimental condition, NDV titer reaches the peak at 96 h.p.i.", [["NDV", "ORGANISM", 35, 38], ["NDV", "SPECIES", 35, 38], ["NDV titer", "TEST", 35, 44]]], ["6e8, application of shRNA-1370 substantially reduces viral replication of NDV and AIV in chicken embryo fibroblasts.", [["embryo fibroblasts", "ANATOMY", 97, 115], ["shRNA-1370", "CHEMICAL", 20, 30], ["NDV", "ORGANISM", 74, 77], ["AIV", "ORGANISM", 82, 85], ["chicken", "ORGANISM", 89, 96], ["embryo fibroblasts", "CELL", 97, 115], ["chicken embryo fibroblasts", "CELL_TYPE", 89, 115], ["chicken", "SPECIES", 89, 96], ["NDV", "SPECIES", 74, 77], ["AIV", "SPECIES", 82, 85], ["chicken", "SPECIES", 89, 96], ["application of shRNA", "TREATMENT", 5, 25], ["viral replication", "TREATMENT", 53, 70], ["NDV", "PROBLEM", 74, 77], ["AIV", "PROBLEM", 82, 85], ["chicken embryo fibroblasts", "PROBLEM", 89, 115], ["viral replication", "OBSERVATION", 53, 70], ["chicken embryo fibroblasts", "OBSERVATION", 89, 115]]], ["There are two time milestones that are noteworthy.", [["two", "OBSERVATION_MODIFIER", 10, 13], ["time", "OBSERVATION_MODIFIER", 14, 18], ["milestones", "OBSERVATION", 19, 29]]], ["At 96 h.p.i, the case with a shRNA-1370 treatment simultaneously or 24 h prior to infection with NDV substantially reduces the virus titer in TCID 50 by over 60 folds, and in HAU value by 3 folds for AIV.", [["shRNA-1370", "CHEMICAL", 29, 39], ["infection", "DISEASE", 82, 91], ["NDV", "ORGANISM", 97, 100], ["HAU", "CANCER", 175, 178], ["NDV", "SPECIES", 97, 100], ["AIV", "SPECIES", 200, 203], ["a shRNA", "TREATMENT", 27, 34], ["infection", "PROBLEM", 82, 91], ["NDV", "PROBLEM", 97, 100], ["the virus titer", "PROBLEM", 123, 138], ["AIV", "PROBLEM", 200, 203], ["infection", "OBSERVATION", 82, 91]]], ["It is suggested that the shRNA-1370 treatment has substantial effect on viral replication.", [["shRNA-1370", "CHEMICAL", 25, 35], ["shRNA-1370", "GENE_OR_GENE_PRODUCT", 25, 35], ["the shRNA", "TREATMENT", 21, 30], ["treatment", "TREATMENT", 36, 45], ["viral replication", "TREATMENT", 72, 89], ["viral replication", "OBSERVATION", 72, 89]]], ["The impact is stronger with increasing treatment time.", [["increasing treatment time", "TREATMENT", 28, 53], ["stronger", "OBSERVATION_MODIFIER", 14, 22]]], ["At 72 h.p.i, beyond our expectation, a simultaneous shRNA-1370 treatment with NDV infection reduces the virus titer in TCID 50 by 29 folds, and in HAU value by 4 folds for AIV.", [["shRNA-1370", "CHEMICAL", 52, 62], ["NDV infection", "DISEASE", 78, 91], ["NDV", "ORGANISM", 78, 81], ["HAU", "CANCER", 147, 150], ["NDV", "SPECIES", 78, 81], ["AIV", "SPECIES", 172, 175], ["a simultaneous shRNA", "TREATMENT", 37, 57], ["treatment", "TREATMENT", 63, 72], ["NDV infection", "PROBLEM", 78, 91], ["the virus titer", "TREATMENT", 100, 115], ["AIV", "PROBLEM", 172, 175], ["infection", "OBSERVATION", 82, 91]]], ["The antiviral effect at 72 h.p.i. is more prominent than that at 48, 60, and 84 h.p.i.", [["The antiviral effect", "PROBLEM", 0, 20], ["antiviral effect", "OBSERVATION", 4, 20], ["more prominent", "OBSERVATION_MODIFIER", 37, 51]]], ["There is limited literature describing shRNA plasmid-based platforms that target cellular proteins utilized by viruses for in vivo proliferation.", [["cellular", "ANATOMY", 81, 89], ["cellular", "CELL", 81, 89], ["shRNA plasmid", "DNA", 39, 52], ["cellular proteins", "PROTEIN", 81, 98], ["shRNA plasmid", "TREATMENT", 39, 52], ["target cellular proteins", "PROBLEM", 74, 98], ["vivo proliferation", "OBSERVATION", 126, 144]]], ["Our study provides a model for the screening and identification of cell-based antivirals.", [["cell", "ANATOMY", 67, 71], ["cell", "CELL", 67, 71], ["Our study", "TEST", 0, 9], ["the screening", "TEST", 31, 44], ["cell-based antivirals", "TREATMENT", 67, 88]]], ["This work also provides a new idea for the design of an intervention strategy against multiple viruses by targeting negative feedback regulators of type I IFN.DiscussionColon and esophageal cancers in humans that harbor low levels of GLTSCR2 show a better 5-year survival rate than patients whose cancers have high GLTSCR2 levels (Sasaki et al., 2011) .", [["esophageal cancers", "ANATOMY", 179, 197], ["cancers", "ANATOMY", 297, 304], ["esophageal cancers", "DISEASE", 179, 197], ["cancers", "DISEASE", 297, 304], ["type I IFN", "GENE_OR_GENE_PRODUCT", 148, 158], ["esophageal cancers", "CANCER", 179, 197], ["humans", "ORGANISM", 201, 207], ["GLTSCR2", "GENE_OR_GENE_PRODUCT", 234, 241], ["patients", "ORGANISM", 282, 290], ["cancers", "CANCER", 297, 304], ["GLTSCR2", "GENE_OR_GENE_PRODUCT", 315, 322], ["negative feedback regulators", "PROTEIN", 116, 144], ["type I IFN", "PROTEIN", 148, 158], ["GLTSCR2", "PROTEIN", 234, 241], ["GLTSCR2", "PROTEIN", 315, 322], ["humans", "SPECIES", 201, 207], ["patients", "SPECIES", 282, 290], ["humans", "SPECIES", 201, 207], ["an intervention strategy", "TREATMENT", 53, 77], ["multiple viruses", "PROBLEM", 86, 102], ["DiscussionColon and esophageal cancers", "PROBLEM", 159, 197], ["high GLTSCR2 levels", "PROBLEM", 310, 329], ["esophageal", "ANATOMY", 179, 189], ["cancers", "OBSERVATION", 190, 197], ["cancers", "OBSERVATION", 297, 304]]], ["Therefore, small molecule inhibitors that are designed based on GLTSCR2specific shRNA are expected to act as broad therapy against viral infection, without cytotoxicity and side-effects on host cells.", [["cells", "ANATOMY", 194, 199], ["viral infection", "DISEASE", 131, 146], ["host cells", "CELL", 189, 199], ["GLTSCR2specific shRNA", "DNA", 64, 85], ["host cells", "CELL_TYPE", 189, 199], ["small molecule inhibitors", "TREATMENT", 11, 36], ["GLTSCR2specific shRNA", "TREATMENT", 64, 85], ["broad therapy", "TREATMENT", 109, 122], ["viral infection", "PROBLEM", 131, 146], ["cytotoxicity", "PROBLEM", 156, 168], ["host cells", "PROBLEM", 189, 199], ["small", "OBSERVATION_MODIFIER", 11, 16], ["molecule inhibitors", "OBSERVATION", 17, 36], ["infection", "OBSERVATION", 137, 146], ["host cells", "OBSERVATION", 189, 199]]], ["We are currently investigating structure-based design of small molecule antagonist.Author contributionsC.C.L., H.J.D., P.W., W.M. and X.J.W. analyzed data; all performed research; and X.J.W. designed research and wrote the paper.", [["small molecule antagonist", "TREATMENT", 57, 82], ["small", "OBSERVATION_MODIFIER", 57, 62], ["molecule antagonist", "OBSERVATION", 63, 82]]]], "PMC7485592": [["INTRODUCTIONIn recent years, Centers for Medicare & Medicaid Services (CMS) and other payers have invested significant resources in testing the patient-centered medical home (PCMH) model as a means to improve the organization and delivery of primary health care and reduce health care expenditures.", [["patient", "ORGANISM", 144, 151], ["patient", "SPECIES", 144, 151], ["primary health care", "TREATMENT", 242, 261]]], ["Goals of the PCMH model are to improve patient access to care, improve coordination and quality of care, and increase patient participation in health-related decision-making and self-management.1, 2 Understanding how the PCMH model affects patient experience with care is essential to assessing the model\u2019s overall impact and identifying areas in need of improvement.", [["patient", "ORGANISM", 39, 46], ["patient", "ORGANISM", 118, 125], ["patient", "ORGANISM", 240, 247], ["patient", "SPECIES", 39, 46], ["patient", "SPECIES", 118, 125], ["patient", "SPECIES", 240, 247], ["the PCMH model", "TREATMENT", 9, 23], ["self-management", "TREATMENT", 178, 193]]], ["Quantitative studies to date have shown mixed but promising results.3\u20137 Qualitative research allows for more in-depth exploration and deeper understanding of patients\u2019 experiences of care, but little work has been done in this area.INTRODUCTIONThe Multi-Payer Advanced Primary Care Practice (MAPCP) Demonstration provides an opportunity to explore the effects of PCMH transformation across a broad variety of populations, health care systems, and geographic areas.", [["PCMH", "CHEMICAL", 363, 367], ["patients", "ORGANISM", 158, 166], ["patients", "SPECIES", 158, 166], ["Quantitative studies", "TEST", 0, 20], ["depth exploration", "TEST", 112, 129], ["PCMH transformation", "PROBLEM", 363, 382]]], ["By the end of 2014, 857 advanced primary care practices were participating in the demonstration.INTRODUCTIONThis paper describes the perspectives of patients and patient caregivers from practices participating in the MAPCP Demonstration regarding their experiences with aspects of their care that are expectations for a PCMH (i.e., enhanced access to care, high-quality and coordinated care, support for shared decision-making and patient self-management, and solicitation of patient input) and how their care had changed since their practices\u2019 PCMH transformation.Sampling and Recruitment ::: METHODSThe study design was to hold 12 focus groups in each of the eight MAPCP Demonstration states\u2014one group for each of six categories in two separate geographical regions, including both rural and urban areas.", [["PCMH", "DISEASE", 320, 324], ["patients", "ORGANISM", 149, 157], ["patient", "ORGANISM", 162, 169], ["patient", "ORGANISM", 431, 438], ["patient", "ORGANISM", 476, 483], ["patients", "SPECIES", 149, 157], ["patient", "SPECIES", 162, 169], ["patient", "SPECIES", 431, 438], ["patient", "SPECIES", 476, 483], ["METHODSThe study", "TEST", 594, 610]]], ["The six categories were Medicare high-risk (defined as having a Hierarchical Condition Category score \u2265 1.22), Medicare low-risk, Medicaid, Medicare/Medicaid dually eligible beneficiaries, caregivers of Medicaid or Medicare beneficiaries, and caregivers of Medicaid children (in Vermont, groups were conducted with participants of the Support and Services at Home [SASH] program, which provided support services and care coordination to Medicare beneficiaries living in subsidized housing and the surrounding communities, instead of caregivers of Medicaid children).", [["children", "ORGANISM", 266, 274], ["children", "ORGANISM", 556, 564], ["children", "SPECIES", 266, 274], ["participants", "SPECIES", 315, 327], ["children", "SPECIES", 556, 564]]], ["We aimed to recruit 10 people per group, with the goal of having 6\u20138 participants.Sampling and Recruitment ::: METHODSWe recruited participants by mailing letters to Medicare, Medicaid, and dually eligible beneficiaries inviting them or their caregivers to participate.", [["people", "ORGANISM", 23, 29], ["people", "SPECIES", 23, 29], ["participants", "SPECIES", 69, 81], ["participants", "SPECIES", 131, 143]]], ["To identify Medicaid beneficiaries and the caregivers of children with Medicaid, four practices in each state generated a random sample of Medicaid beneficiaries who had received care at those practices over the prior 12 months and mailed the recruitment letter to the sample on the study\u2019s behalf.Sampling and Recruitment ::: METHODSThe recruitment letter asked beneficiaries to call to be screened for eligibility.", [["children", "ORGANISM", 57, 65], ["children", "SPECIES", 57, 65], ["care", "TREATMENT", 179, 183], ["the study", "TEST", 279, 288]]], ["To ensure that beneficiaries and caregivers had sufficient experience with the practice to be able to speak knowledgably about it and that they would be able to address questions about coordination with specialists, they also had to have seen a specialist at least once in the prior year and have a chronic condition.Sampling and Recruitment ::: METHODSBecause contact information for beneficiaries\u2019 caregivers was not available, the recruitment letters to beneficiaries also invited caregivers to call and be screened for eligibility.", [["a chronic condition", "PROBLEM", 297, 316], ["chronic", "OBSERVATION_MODIFIER", 299, 306]]], ["A caregiver was defined as the main person responsible for the beneficiary\u2019s health care who usually or always took the beneficiary to appointments at his or her primary care practice.", [["person", "SPECIES", 36, 42]]], ["To capture a broader variety of experiences, we did not recruit both a beneficiary and their caregiver.Sampling and Recruitment ::: METHODSIf we did not receive a sufficient number of incoming calls to recruit 10 participants for any of the Medicare and dually eligible groups, we called beneficiaries from among those who received recruitment letters to identify additional participants.", [["participants", "SPECIES", 213, 225], ["participants", "SPECIES", 375, 387], ["recruitment letters", "TREATMENT", 332, 351]]], ["All participants read and signed an informed consent form.", [["participants", "SPECIES", 4, 16]]], ["The moderator followed a discussion guide that explored participants\u2019 awareness of the PCMH concept and their experiences with care related to key PCMH constructs.", [["PCMH constructs", "DNA", 147, 162], ["participants", "SPECIES", 56, 68]]], ["For example, related to access to care, participants were asked about the ease or difficulty of getting an appointment when they needed one; how they could schedule appointments and their satisfaction with those methods; wait times; if they had used a patient portal and if so, their experience with it; and whether the practice had taken any steps to help them reduce use of the emergency room.", [["patient", "ORGANISM", 252, 259], ["participants", "SPECIES", 40, 52], ["patient", "SPECIES", 252, 259], ["portal", "ANATOMY", 260, 266]]], ["Participants were also asked whether they had experienced any changes in any of these areas in the previous few years.", [["Participants", "SPECIES", 0, 12]]], ["Groups lasted 1.5 h on average, and participants were given a $50 Visa gift card for their participation.", [["participants", "SPECIES", 36, 48]]], ["Each group was audio-recorded and transcribed.Data Collection and Analysis ::: METHODSTo guide our analysis of the data, we developed a coding scheme based on a priori theoretical constructs as well as on themes that emerged from a review of the focus group transcripts.", [["focus group transcripts", "RNA", 246, 269], ["the data", "TEST", 111, 119], ["a coding scheme", "PROBLEM", 134, 149]]], ["Though some distinctions were found across the eight states, our analysis focuses on the comprehensive findings from all the states, with differences noted by focus group type when applicable.", [["our analysis", "TEST", 61, 73]]], ["When summarizing the frequency with which specific views were expressed, we use \u201cfew\u201d for fewer than 10% of participants; \u201csome\u201d for 10 to 25%; \u201cmany\u201d for 25 to 50%; and \u201cmost\u201d for more than 50%.Access to Care ::: RESULTSMost participants reported convenient access to care during office hours, and some thought that it had improved in recent years: wait times were short and they could typically get a same-day appointment when needed (although usually not with their primary care providers [PCPs]).", [["participants", "SPECIES", 108, 120], ["participants", "SPECIES", 226, 238]]], ["After-hours access was more problematic, however: most participants said that their practices\u2019 hours were limited to weekdays during the day, forcing participants to visit an urgent care facility or the emergency department when they had an urgent health care need after hours.Access to Care ::: RESULTSThe biggest recent change in access described by participants was the addition of patient portals.", [["patient", "ORGANISM", 385, 392], ["participants", "SPECIES", 55, 67], ["participants", "SPECIES", 150, 162], ["participants", "SPECIES", 352, 364], ["patient", "SPECIES", 385, 392], ["change", "OBSERVATION_MODIFIER", 322, 328]]], ["Participants who had used the portal were enthusiastic about its ability to help them make appointments, check test results, and communicate with their PCPs.", [["Participants", "SPECIES", 0, 12], ["portal", "ANATOMY", 30, 36]]], ["However, most participants had not used the portal, and many were not even aware of it.", [["participants", "SPECIES", 14, 26], ["portal", "ANATOMY", 44, 50]]], ["In the words of one participant, \u201cI like to talk to people when I make appointments, not hit buttons on a computer\u201d(dually eligible, Vermont).Coordination of Care ::: RESULTSParticipants\u2019 experiences with coordination of care varied widely.", [["participant", "SPECIES", 20, 31], ["people", "SPECIES", 52, 58]]], ["Most said that information was readily shared between their PCPs, specialists, and hospitals\u2014for example, their PCP knew if they had been in the hospital and was able to access test results from their specialists.", [["PCP", "DISEASE", 112, 115]]], ["Many said that their PCP either visited them in the hospital or called to follow up after they were discharged.", [["PCP", "DISEASE", 21, 24], ["PCP", "CHEMICAL", 21, 24]]], ["Some participants, however, said that information did not readily transfer between the PCP and the hospital or specialists, particularly if they were in different systems.", [["PCP", "DISEASE", 87, 90], ["participants", "SPECIES", 5, 17]]], ["Some said their PCP did not know when they had been in the hospital, or that the PCP did not have access to lab results from the hospital and would order the same tests again.Coordination of Care ::: RESULTSMost participants thought that the transfer of information had improved in recent years, particularly with the introduction of EHRs.", [["PCP", "DISEASE", 16, 19], ["PCP", "DISEASE", 81, 84], ["PCP", "CHEMICAL", 16, 19], ["PCP", "CHEMICAL", 81, 84], ["participants", "SPECIES", 212, 224], ["the same tests", "TEST", 154, 168]]], ["However, some participants noted that the transfer of information did not necessarily mean that their PCPs were coordinating their care for them: they were not sure to what extent their PCPs actually digested the information, and some caregivers, in particular, said that they still felt that they were the ones who had to take the lead in coordinating the care for their loved ones: \u201cThe information is there, but I always feel like I have to be the advocate for my mom to say, \u2018Well, she had this and the results came back that way, so does that mean we need to do something?\u2019\u201d (caregiver, New York).Coordination of Care ::: RESULTSSome participants mentioned that their practices were providing more assistance in scheduling appointments with specialists than they had in the past.", [["participants", "SPECIES", 14, 26], ["participants", "SPECIES", 639, 651]]], ["Some Medicaid and dually eligible participants reported, however, that the specialists their PCPs referred them to often would not accept their insurance, so they ended up having to find specialists on their own.", [["participants", "SPECIES", 34, 46]]], ["A few participants mentioned that their PCPs seemed more willing to provide referrals to specialists than in the past; some considered this an improvement, but some wished the PCP would provide more care themselves, rather than sending them to specialists.Coordination of Care ::: RESULTSA final change in coordination of care noted by some participants was that during hospital stays, care was increasingly provided by hospitalists, and their PCPs, who knew them best, were not involved with their care.", [["PCP", "DISEASE", 176, 179], ["participants", "SPECIES", 6, 18], ["participants", "SPECIES", 341, 353], ["few", "OBSERVATION_MODIFIER", 2, 5]]], ["They felt that this practice reduced coordination of care.Patient-Centered Care ::: RESULTSMost participants thought that their PCPs communicated well with them: listened carefully, explained things thoroughly and in terms they understood, and spent as much time as needed to address all their concerns.", [["Patient", "SPECIES", 58, 65], ["participants", "SPECIES", 96, 108]]], ["On the other hand, some participants (most of whom were in Medicaid or dually eligible groups) said that their PCPs rushed them, allowed them to discuss only one or two concerns per appointment, did not address their emotional or mental health needs, or made assumptions about their needs.Patient-Centered Care ::: RESULTSMost participants were also pleased with the office staff at their practices, describing them as friendly, helpful, professional, courteous, and efficient, and a few thought that the staff had become more efficient and friendlier in recent years.", [["participants", "SPECIES", 24, 36], ["Patient", "SPECIES", 289, 296], ["participants", "SPECIES", 327, 339]]], ["A few participants had complaints, however, including that staff were rude, were inefficient, did not respect confidentiality, did not transmit messages to their PCPs, or made it difficult to reach the PCP.", [["PCP", "DISEASE", 202, 205], ["PCP", "CHEMICAL", 202, 205], ["participants", "SPECIES", 6, 18], ["few", "OBSERVATION_MODIFIER", 2, 5]]], ["Again, most of the participants who had negative experiences were in Medicaid or dually eligible groups.", [["participants", "ORGANISM", 19, 31], ["participants", "SPECIES", 19, 31]]], ["As one said, \u201c[The staff] act like they are doing you a favor by taking your Medicaid\u201d (Medicaid, Pennsylvania).Patient-Centered Care ::: RESULTSThe primary changes that participants noted in patient-centered care related to the introduction of EHRs.", [["patient", "ORGANISM", 192, 199], ["Patient", "SPECIES", 112, 119], ["participants", "SPECIES", 170, 182], ["patient", "SPECIES", 192, 199]]], ["Participants said that the EHRs helped to ensure that their PCPs remembered their medical information, facilitated filling prescriptions, and shortened the wait time for getting test results.", [["Participants", "SPECIES", 0, 12]]], ["Many participants had started receiving a printout at the end of their appointments summarizing key information, which most appreciated.", [["participants", "SPECIES", 5, 17]]], ["One drawback of EHRs mentioned by some participants, however, was that their PCPs were now typing on the computer during their time with them, and they felt that this made for less personal communication \u201cSometimes I think they spend more time looking at the computer than looking at you\u201d (low-risk Medicare, Pennsylvania).Patient-Centered Care ::: RESULTSA few participants mentioned other changes.", [["participants", "SPECIES", 39, 51], ["Patient", "SPECIES", 323, 330], ["participants", "SPECIES", 362, 374]]], ["Others said that the practice seemed to be taking a more proactive approach to care, including administering screeners to assess depression or other health risks, calling patients to remind them about appointments or to tell them when they were due for a test or an appointment, and providing support for non-medical issues, such as transportation or food access.", [["depression", "DISEASE", 129, 139], ["patients", "ORGANISM", 171, 179], ["patients", "SPECIES", 171, 179], ["depression", "PROBLEM", 129, 139]]], ["Finally, a few participants noticed a new team-based approach to care\u2014for example, that a nurse would ask them questions before they saw their PCPs; some appreciated this because it made more efficient use of their time with the PCP, but others were frustrated that they had to repeat the same information.Shared Decision-Making ::: RESULTSMost participants viewed their relationships with their PCPs as partnerships and said that their PCP respected their opinions and preferences and involved them in making decisions about their treatment.", [["PCP", "DISEASE", 229, 232], ["PCP", "DISEASE", 437, 440], ["participants", "SPECIES", 15, 27], ["participants", "SPECIES", 345, 357], ["their treatment", "TREATMENT", 526, 541]]], ["Some, however (primarily Medicaid and dually eligible beneficiaries), felt that their PCPs disregarded their perspectives by not focusing on the health concerns most important to them, not taking their health concerns seriously, or pushing them to have treatments or tests they did not want: \u201cI just don\u2019t think they listen to me sometimes\u2026.", [["treatments", "TREATMENT", 253, 263]]], ["Some participants commented that they thought that, in general, patients need to advocate for themselves to make sure that their concerns are addressed.", [["patients", "ORGANISM", 64, 72], ["participants", "SPECIES", 5, 17], ["patients", "SPECIES", 64, 72]]], ["In the words of one participant, \u201cIt seems like I have to take the lead in asking [my PCP] questions about my\u2026 diabetes.", [["diabetes", "DISEASE", 111, 119], ["participant", "SPECIES", 20, 31], ["diabetes", "PROBLEM", 111, 119], ["diabetes", "OBSERVATION", 111, 119]]], ["I have to be very assertive\u2026 in getting information from her about diet or medication, things of that sort\u201d(low-risk Medicare, Rhode Island).Shared Decision-Making ::: RESULTSA few participants noted some changes in shared decision-making.", [["participants", "SPECIES", 181, 193], ["medication", "TREATMENT", 75, 85]]], ["Others noted a general shift in approach: \u201cI think [they now] want you to be an active part of the team and not just sit back and be told what to do\u201d (low-risk Medicare, Minnesota).Self-Management Support ::: RESULTSMost participants said that their PCPs talked to them about things they could do to improve their health, but almost none reported having a written care plan and few indicated that they had set specific health-related goals with their PCPs.", [["participants", "SPECIES", 221, 233]]], ["Moreover, a few participants said their PCPs talked to them about managing their health only if they, the patients, brought it up, and they wished that the PCPs spent more time discussing prevention.", [["patients", "ORGANISM", 106, 114], ["participants", "SPECIES", 16, 28], ["patients", "SPECIES", 106, 114]]], ["On the other hand, some participants said that their PCPs had given up talking to them about behavior change, because they knew that it would be \u201cin one ear and out the other\u201d (Medicaid, Michigan).Self-Management Support ::: RESULTSParticipants reported receiving varying levels of support for managing their health.", [["ear", "ANATOMY", 153, 156], ["ear", "ORGAN", 153, 156], ["participants", "SPECIES", 24, 36], ["varying levels of support", "TREATMENT", 264, 289]]], ["Only a few, all of whom were either Medicaid or dually eligible participants, had care managers through their PCPs, who helped with needs such as home care, housework, transportation, housing, employment, emotional support, reviewing medications, setting up appointments, and obtaining needed medical equipment.", [["participants", "SPECIES", 64, 76], ["emotional support", "TREATMENT", 205, 222], ["medications", "TREATMENT", 234, 245], ["medical equipment", "TREATMENT", 293, 310], ["few", "OBSERVATION_MODIFIER", 7, 10]]], ["Nearly all participants who received these services found them to be very helpful.", [["participants", "ORGANISM", 11, 23], ["participants", "SPECIES", 11, 23]]], ["Some participants said that their PCPs had referred them to classes on topics such as smoking cessation, diabetes control, or weight loss.", [["diabetes", "DISEASE", 105, 113], ["weight loss", "DISEASE", 126, 137], ["participants", "SPECIES", 5, 17], ["diabetes control", "PROBLEM", 105, 121], ["weight loss", "PROBLEM", 126, 137]]], ["A few participants said that their PCPs had offered other supports, such as referring them to a dietitian or nutritionist to help support healthy eating or setting them up with a blood pressure cuff and logbooks to monitor their blood pressure.", [["blood", "ANATOMY", 179, 184], ["blood", "ANATOMY", 229, 234], ["blood", "ORGANISM_SUBSTANCE", 179, 184], ["blood", "ORGANISM_SUBSTANCE", 229, 234], ["participants", "SPECIES", 6, 18], ["a blood pressure cuff", "TREATMENT", 177, 198], ["logbooks", "TREATMENT", 203, 211], ["their blood pressure", "TEST", 223, 243]]], ["Some commented, though, that the only support their PCPs gave them to aid behavior change was written information such as a pamphlet, which they found inadequate: \u201cNothing\u2019s been said to either [me or my wife] about diet, especially me being diabetic.", [["diabetic", "DISEASE", 242, 250], ["diabetic", "PROBLEM", 242, 250]]], ["I was just handed a pamphlet\u201d (dually eligible, North Carolina).Solicitation of Patient Input and Awareness of Medical Home ::: RESULTSThe extent to which participants reported that their practices solicited feedback from them varied.", [["Patient", "SPECIES", 80, 87], ["participants", "SPECIES", 155, 167]]], ["Many said that their practice administered patient surveys or had other mechanisms for soliciting patient input; some participants said that this solicitation of feedback was new.Solicitation of Patient Input and Awareness of Medical Home ::: RESULTSAlmost no participants were familiar with the term \u201cmedical home.\u201d", [["patient", "ORGANISM", 43, 50], ["patient", "ORGANISM", 98, 105], ["patient", "SPECIES", 43, 50], ["patient", "SPECIES", 98, 105], ["participants", "SPECIES", 118, 130], ["Patient", "SPECIES", 195, 202], ["participants", "SPECIES", 260, 272]]], ["Some participants expressed concerns about the medical home concept, however.", [["participants", "SPECIES", 5, 17]]], ["Others were concerned that the medical home concept could increase bureaucracy, restrict patients\u2019 access to providers, increase costs to patients, or threaten patient privacy.", [["patients", "ORGANISM", 89, 97], ["patients", "ORGANISM", 138, 146], ["patient", "ORGANISM", 160, 167], ["patients", "SPECIES", 89, 97], ["patients", "SPECIES", 138, 146], ["patient", "SPECIES", 160, 167]]], ["Our findings suggest that from the patient perspective, most of the practices participating in the MAPCP Demonstration were delivering care in a way that was largely consistent with PCMH principles.", [["patient", "ORGANISM", 35, 42], ["patient", "SPECIES", 35, 42], ["PCMH principles", "TREATMENT", 182, 197], ["consistent with", "UNCERTAINTY", 166, 181]]], ["Most participants described having accessible, well-coordinated, and high-quality care and appropriate engagement in shared decision-making.", [["participants", "SPECIES", 5, 17]]], ["These findings are similar to earlier, smaller qualitative studies of patient perspectives on PCMH care.8, 9DISCUSSIONOur findings also highlight several areas that may require enhanced transformation from the patient perspective.", [["patient", "ORGANISM", 70, 77], ["patient", "ORGANISM", 210, 217], ["patient", "SPECIES", 70, 77], ["patient", "SPECIES", 210, 217], ["PCMH care", "TREATMENT", 94, 103], ["enhanced transformation", "PROBLEM", 177, 200], ["several", "OBSERVATION_MODIFIER", 146, 153], ["may require", "UNCERTAINTY", 165, 176], ["enhanced transformation", "OBSERVATION", 177, 200]]], ["Relatively few participants used patient portals, indicating that practices\u2019 investments in new technologies may have limited effect when patients are not aware of their existence, cannot access them, or do not want to use them.", [["patient", "ORGANISM", 33, 40], ["patients", "ORGANISM", 138, 146], ["participants", "SPECIES", 15, 27], ["patient", "SPECIES", 33, 40], ["patients", "SPECIES", 138, 146]]], ["Despite practices\u2019 efforts to expand access to care, participants still struggled to reach their PCPs and receive care when facing emergencies during nights and weekends, suggesting the need for additional effort in this area.", [["participants", "SPECIES", 53, 65]]], ["Participants rarely received written plans or set specific goals with their physicians, which are critical tools for supporting patients\u2019 self-management of chronic conditions.", [["patients", "ORGANISM", 128, 136], ["Participants", "SPECIES", 0, 12], ["patients", "SPECIES", 128, 136], ["chronic conditions", "PROBLEM", 157, 175]]], ["Participants noted that although care was generally well-coordinated within a health care system, practices still need to improve coordination of care across systems, including the transfer EHR information and allowing for their PCPs to be engaged in their care when they were in the hospital.", [["Participants", "SPECIES", 0, 12]]], ["As primary care practices function within the realities of limited financial and staffing resources, adoption of PCMH components may require strategic prioritization.", [["PCMH components", "TREATMENT", 113, 128], ["strategic prioritization", "TREATMENT", 141, 165]]], ["The need for prioritization is likely to escalate in the aftermath of COVID-19 pandemic, as many primary care practices may struggle to maintain PCMH functions that they have put in place and introduce new ones.DISCUSSIONPatients\u2019 perspectives also revealed persistent disparities and the need to enhance the paradigm of patient-centered care.", [["patient", "ORGANISM", 321, 328], ["patient", "SPECIES", 321, 328], ["prioritization", "TREATMENT", 13, 27], ["persistent disparities", "PROBLEM", 258, 280], ["persistent", "OBSERVATION_MODIFIER", 258, 268], ["disparities", "OBSERVATION", 269, 280]]], ["Some participants from Medicaid and dually eligible groups reported feeling stigmatized or that their health concerns were not taken seriously, and some experienced challenges with coordination of care because many specialists would not accept their insurance.", [["participants", "SPECIES", 5, 17]]], ["These findings are consistent with previous research, which has shown that people who are uninsured or who have Medicaid insurance often feel that they are treated poorly by their health care providers10, 11 and that many providers are unwilling to accept patients with Medicaid coverage.12\u201314 These challenges suggest the need for enhanced focus on provider training in cultural competencies, re-evaluation of effectiveness of cultural competency trainings across existing programs, and incentives to serve Medicaid beneficiaries and dually eligible.DISCUSSIONAs reported in other recent qualitative studies describing patient experiences with PCMHs,9 we also found that most participants did not know what a medical home was and were not aware that their practices were participating in an initiative seeking to enhance patient centeredness of care.", [["people", "ORGANISM", 75, 81], ["patients", "ORGANISM", 256, 264], ["patient", "ORGANISM", 620, 627], ["patient", "ORGANISM", 822, 829], ["people", "SPECIES", 75, 81], ["patients", "SPECIES", 256, 264], ["patient", "SPECIES", 620, 627], ["participants", "SPECIES", 677, 689], ["patient", "SPECIES", 822, 829], ["Medicaid coverage", "TREATMENT", 270, 287], ["provider training", "TREATMENT", 350, 367], ["cultural competency trainings", "TREATMENT", 428, 457], ["consistent with", "UNCERTAINTY", 19, 34]]], ["In addition, few participants said that their practices had taken any steps to solicit their feedback.", [["participants", "SPECIES", 17, 29]]], ["While practice improvement is a responsibility of practice staff, meaningful transformation cannot be achieved in the absence of patient engagement and buy-in.", [["patient", "ORGANISM", 129, 136], ["patient", "SPECIES", 129, 136], ["meaningful transformation", "PROBLEM", 66, 91]]], ["More recent iterations of CMS valued based care initiatives such as Accountable Care Organizations and the Comprehensive Primary Care Plus initiative require more structured patient engagement in organizational operations than those required in MAPCP, such as patient representation on organizational boards and advisory councils,15 which may help to improve practices\u2019 responsiveness to patient needs and concerns.", [["patient", "ORGANISM", 174, 181], ["patient", "ORGANISM", 260, 267], ["patient", "ORGANISM", 388, 395], ["patient", "SPECIES", 174, 181], ["patient", "SPECIES", 260, 267], ["patient", "SPECIES", 388, 395], ["organizational operations", "TREATMENT", 196, 221]]], ["While seeking patient input and feedback is an important and necessary step forward, it is the willingness of practices and providers to act on patient input and recommendations that will facilitate change.DISCUSSIONThis study is subject to several limitations.", [["patient", "ORGANISM", 14, 21], ["patient", "ORGANISM", 144, 151], ["patient", "SPECIES", 14, 21], ["patient", "SPECIES", 144, 151]]], ["First, the selection criteria for the study (that participants be Medicaid, Medicare, or dually eligible beneficiaries or caregivers of beneficiaries in eight select states and speak English fluently) led to a sample that was primarily non-Hispanic White, over age 60, and English-speaking; results may not be generalizable to other demographic groups.", [["participants", "SPECIES", 50, 62], ["the study", "TEST", 34, 43]]], ["We were also unable to summarize the experiences of children enrolled in Medicaid because we were unable to recruit a sufficient number of caregivers of Medicaid children.", [["children", "ORGANISM", 52, 60], ["children", "ORGANISM", 162, 170], ["children", "SPECIES", 52, 60], ["children", "SPECIES", 162, 170]]], ["However, because participants were drawn from eight different states, including both urban and rural areas, the study represents a much greater breadth of experiences than previous studies, and the high number of Medicaid and dually eligible beneficiaries ensures that perspectives of low-income and disabled populations are reflected.", [["participants", "SPECIES", 17, 29], ["the study", "TEST", 108, 117], ["previous studies", "TEST", 172, 188], ["low-income and disabled populations", "PROBLEM", 285, 320]]], ["Second, because we collected data only from patients of practices that were participating in the MAPCP Demonstration, we cannot assess the extent to which their experiences may differ from those whose practices were not participating in the MAPCP Demonstration.", [["patients", "ORGANISM", 44, 52], ["patients", "SPECIES", 44, 52]]], ["Third, because the focus groups were conducted at one point in time, approximately 2.5 years after the MAPCP Demonstration began, we can only indirectly assess the extent to which patient experiences changed after their practices began their PCMH transformation.", [["patient", "ORGANISM", 180, 187], ["patient", "SPECIES", 180, 187]]], ["Finally, because each focus group included participants from more than one practice, it was not possible to link the comments from participants in specific focus groups to individual practices.", [["participants", "SPECIES", 43, 55], ["participants", "SPECIES", 131, 143]]], ["As a result, we were unable to assess which practices had been most successful in achieving PCMH transformation or to what extent patient perceptions of care aligned with practice transformation efforts.DISCUSSIONAdditional research is needed to further understand PCMH transformation from the patient perspective.", [["patient", "ORGANISM", 130, 137], ["patient", "ORGANISM", 294, 301], ["patient", "SPECIES", 130, 137], ["patient", "SPECIES", 294, 301], ["practice transformation efforts", "TREATMENT", 171, 202]]], ["Research that links patient experiences to specific practices, including characteristics of the practices (e.g., practice culture, leadership, and physician engagement) and the PCMH transformation strategies the practices have implemented, could help elucidate how practice characteristics or strategies influence patient experiences.", [["patient", "ORGANISM", 20, 27], ["patient", "ORGANISM", 314, 321], ["patient", "SPECIES", 20, 27], ["patient", "SPECIES", 314, 321], ["practice culture", "TEST", 113, 129], ["the PCMH transformation strategies", "TREATMENT", 173, 207]]]], "6976a825ba6f320b5c7811b88b585d2d26584548": [["D ipeptidyl peptidase-4 (DPP4) is a ubiquitous serine protease that exists as either a membrane localised protein, or as a soluble form (sDPP4) that lacks transmembrane and cytosolic domains but retains catalytic activity and is found widely distributed in plasma and body fluids 1 .", [["membrane", "ANATOMY", 87, 95], ["transmembrane", "ANATOMY", 155, 168], ["cytosolic", "ANATOMY", 173, 182], ["plasma", "ANATOMY", 257, 263], ["body fluids", "ANATOMY", 268, 279], ["serine", "CHEMICAL", 47, 53], ["D ipeptidyl peptidase-4", "GENE_OR_GENE_PRODUCT", 0, 23], ["DPP4", "GENE_OR_GENE_PRODUCT", 25, 29], ["serine", "AMINO_ACID", 47, 53], ["membrane", "CELLULAR_COMPONENT", 87, 95], ["sDPP4", "GENE_OR_GENE_PRODUCT", 137, 142], ["transmembrane", "CELLULAR_COMPONENT", 155, 168], ["plasma", "ORGANISM_SUBSTANCE", 257, 263], ["ipeptidyl peptidase-4", "PROTEIN", 2, 23], ["DPP4", "PROTEIN", 25, 29], ["ubiquitous serine protease", "PROTEIN", 36, 62], ["membrane localised protein", "PROTEIN", 87, 113], ["soluble form", "PROTEIN", 123, 135], ["sDPP4", "PROTEIN", 137, 142], ["transmembrane and cytosolic domains", "PROTEIN", 155, 190], ["D ipeptidyl peptidase", "TREATMENT", 0, 21], ["a ubiquitous serine protease", "TREATMENT", 34, 62], ["a membrane localised protein", "PROBLEM", 85, 113], ["transmembrane and cytosolic domains", "PROBLEM", 155, 190], ["cytosolic domains", "OBSERVATION", 173, 190], ["catalytic activity", "OBSERVATION", 203, 221], ["widely", "OBSERVATION_MODIFIER", 235, 241]]], ["The aminopeptidase activity of DPP4 enables cleavage of dipeptides from the amino terminus of oligopeptides or small proteins, thereby modifying their activity.", [["dipeptides", "CHEMICAL", 56, 66], ["amino", "CHEMICAL", 76, 81], ["aminopeptidase", "GENE_OR_GENE_PRODUCT", 4, 18], ["DPP4", "GENE_OR_GENE_PRODUCT", 31, 35], ["amino", "AMINO_ACID", 76, 81], ["aminopeptidase", "PROTEIN", 4, 18], ["DPP4", "PROTEIN", 31, 35], ["amino terminus", "PROTEIN", 76, 90], ["small proteins", "PROTEIN", 111, 125], ["The aminopeptidase activity of DPP4", "TREATMENT", 0, 35], ["cleavage of dipeptides", "TREATMENT", 44, 66], ["the amino terminus of oligopeptides", "TREATMENT", 72, 107], ["small proteins", "PROBLEM", 111, 125]]], ["Notably, DPP4 cleaves and inactivates the incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), terminating their ability to stimulate glucose-dependent insulin secretion 2, 3 .", [["glucose", "CHEMICAL", 97, 104], ["glucose", "CHEMICAL", 188, 195], ["glucose", "CHEMICAL", 97, 104], ["glucose", "CHEMICAL", 188, 195], ["DPP4", "GENE_OR_GENE_PRODUCT", 9, 13], ["incretin hormones", "GENE_OR_GENE_PRODUCT", 42, 59], ["glucagon-like peptide-1", "GENE_OR_GENE_PRODUCT", 61, 84], ["GLP-1", "GENE_OR_GENE_PRODUCT", 86, 91], ["glucose-dependent insulinotropic polypeptide", "GENE_OR_GENE_PRODUCT", 97, 141], ["GIP", "GENE_OR_GENE_PRODUCT", 143, 146], ["glucose", "SIMPLE_CHEMICAL", 188, 195], ["insulin", "GENE_OR_GENE_PRODUCT", 206, 213], ["DPP4", "PROTEIN", 9, 13], ["DPP4 cleaves", "TREATMENT", 9, 21], ["the incretin hormones", "TEST", 38, 59], ["glucagon", "TEST", 61, 69], ["peptide", "TEST", 75, 82], ["GLP", "TEST", 86, 89], ["glucose", "TEST", 97, 104], ["insulinotropic polypeptide", "TREATMENT", 115, 141], ["glucose", "TEST", 188, 195], ["dependent insulin secretion", "PROBLEM", 196, 223]]], ["Notwithstanding the putative importance of DPP4 for cleavage of multiple substrates with pleiotropic biological activities 4,5 , multiple DPP4 inhibitors are now widely used for the treatment of type 2 diabetes (T2D) 6 .", [["type 2 diabetes", "DISEASE", 195, 210], ["T2D", "DISEASE", 212, 215], ["DPP4", "GENE_OR_GENE_PRODUCT", 43, 47], ["DPP4", "GENE_OR_GENE_PRODUCT", 138, 142], ["DPP4", "PROTEIN", 43, 47], ["DPP4", "TREATMENT", 43, 47], ["pleiotropic biological activities", "TREATMENT", 89, 122], ["multiple DPP4 inhibitors", "TREATMENT", 129, 153], ["type 2 diabetes (T2D)", "PROBLEM", 195, 216]]]], "16989134ea5ebc0adb1c24a9cb1d5be37f0a9fad": [["IntroductionThe newly emergent coronavirus (2019-nCoV, now known as SARS-CoV-2) was first identified in Wuhan in December 2019 and spread rapidly to all provinces and cities in China [1] .", [["coronavirus", "ORGANISM", 31, 42], ["2019-nCoV", "ORGANISM", 44, 53], ["SARS-CoV-2", "ORGANISM", 68, 78], ["coronavirus", "SPECIES", 31, 42], ["SARS-CoV-2", "SPECIES", 68, 78]]], ["Current research suggests that efficient transmission of SARS-CoV-2 from infected individuals (both symptomatic and asymptomatic) to uninfected contacts can result from respiratory droplets, aerosols, and direct contact.", [["respiratory droplets", "ANATOMY", 169, 189], ["SARS", "DISEASE", 57, 61], ["SARS-CoV-2", "ORGANISM", 57, 67], ["SARS-CoV", "SPECIES", 57, 65], ["SARS", "PROBLEM", 57, 61], ["CoV", "TEST", 62, 65], ["infected individuals", "PROBLEM", 73, 93], ["symptomatic", "PROBLEM", 100, 111], ["asymptomatic", "PROBLEM", 116, 128]]], ["The main clinical symptoms of SARS-CoV-2 infection (known as COVID-19) are fever, fatigue, and cough leading to pneumonia that can develop into acute respiratory distress syndrome [2, 3] .", [["respiratory", "ANATOMY", 150, 161], ["SARS-CoV-2 infection", "DISEASE", 30, 50], ["fever", "DISEASE", 75, 80], ["fatigue", "DISEASE", 82, 89], ["cough", "DISEASE", 95, 100], ["pneumonia", "DISEASE", 112, 121], ["acute respiratory distress syndrome", "DISEASE", 144, 179], ["SARS-CoV-2", "ORGANISM", 30, 40], ["CoV-", "SPECIES", 35, 39], ["SARS-CoV-2", "SPECIES", 30, 40], ["The main clinical symptoms", "PROBLEM", 0, 26], ["SARS", "PROBLEM", 30, 34], ["CoV-2 infection", "PROBLEM", 35, 50], ["COVID", "TEST", 61, 66], ["fever", "PROBLEM", 75, 80], ["fatigue", "PROBLEM", 82, 89], ["cough", "PROBLEM", 95, 100], ["pneumonia", "PROBLEM", 112, 121], ["acute respiratory distress syndrome", "PROBLEM", 144, 179], ["main", "OBSERVATION_MODIFIER", 4, 8], ["pneumonia", "OBSERVATION", 112, 121], ["acute", "OBSERVATION_MODIFIER", 144, 149], ["respiratory distress", "OBSERVATION", 150, 170]]], ["There are currently several documented cases of patients diagnosed with COVID-19 that had digestive findings as the first sign of disease [4] .", [["digestive", "ANATOMY", 90, 99], ["patients", "ORGANISM", 48, 56], ["digestive", "ORGAN", 90, 99], ["patients", "SPECIES", 48, 56], ["COVID", "TEST", 72, 77], ["digestive findings", "PROBLEM", 90, 108], ["disease", "PROBLEM", 130, 137], ["disease", "OBSERVATION", 130, 137]]], ["We present a case of COVID-19 that presented to our hospital with a chief complaint of hematochezia.Case reportAn 83-year-old man presented with chief complaint of dark-red bloody stools.", [["hematochezia", "DISEASE", 87, 99], ["hematochezia", "PATHOLOGICAL_FORMATION", 87, 99], ["man", "ORGANISM", 126, 129], ["bloody", "ORGANISM_SUBDIVISION", 173, 179], ["stools", "ORGANISM_SUBSTANCE", 180, 186], ["man", "SPECIES", 126, 129], ["hematochezia", "PROBLEM", 87, 99], ["dark-red bloody stools", "PROBLEM", 164, 186], ["hematochezia", "OBSERVATION", 87, 99], ["bloody stools", "OBSERVATION", 173, 186]]], ["He reported stool volume of approximately 200 mL 2-3 times per day, fatigue, and poor appetite beginning one day prior to presentation.", [["stool", "ANATOMY", 12, 17], ["fatigue", "DISEASE", 68, 75], ["He", "ORGANISM", 0, 2], ["stool", "ORGANISM_SUBSTANCE", 12, 17], ["stool volume", "PROBLEM", 12, 24], ["fatigue", "PROBLEM", 68, 75], ["poor appetite", "PROBLEM", 81, 94], ["stool", "OBSERVATION", 12, 17]]], ["He was admitted to the Gastrointestinal Ward 1 of Luoyang Central Hospital on January 27, 2020 for evaluation and follow-up.", [["evaluation", "TEST", 99, 109], ["Gastrointestinal", "ANATOMY", 23, 39]]], ["At admission the patient was oriented but in low spirits.", [["patient", "ORGANISM", 17, 24], ["patient", "SPECIES", 17, 24]]], ["He was eating and sleeping poorly and was oliguric although no significant weight loss was observed.Case reportOn the second day of admission, the patient excreted bloody stools several times during the day.", [["oliguric", "DISEASE", 42, 50], ["weight loss", "DISEASE", 75, 86], ["bloody stools", "DISEASE", 164, 177], ["He", "ORGANISM", 0, 2], ["patient", "ORGANISM", 147, 154], ["patient", "SPECIES", 147, 154], ["oliguric", "PROBLEM", 42, 50], ["significant weight loss", "PROBLEM", 63, 86], ["bloody stools", "PROBLEM", 164, 177], ["oliguric", "OBSERVATION", 42, 50], ["no", "UNCERTAINTY", 60, 62], ["significant", "OBSERVATION_MODIFIER", 63, 74], ["weight loss", "OBSERVATION", 75, 86], ["bloody", "OBSERVATION", 164, 170]]], ["He received initial symptomatic treatment with oral pantoprazole enteric-coated capsule, once a day.", [["oral", "ANATOMY", 47, 51], ["capsule", "ANATOMY", 80, 87], ["pantoprazole", "CHEMICAL", 52, 64], ["pantoprazole", "CHEMICAL", 52, 64], ["oral", "ORGANISM_SUBDIVISION", 47, 51], ["pantoprazole", "SIMPLE_CHEMICAL", 52, 64], ["initial symptomatic treatment", "TREATMENT", 12, 41], ["oral pantoprazole enteric-coated capsule", "TREATMENT", 47, 87]]], ["Abdominal computerized tomography (CT) scan performed on the third day of admission suggested the presence of a spaceoccupying lesion at the right adrenal gland; the diagnosis of adrenal tumor was considered.", [["lesion", "ANATOMY", 127, 133], ["right adrenal gland", "ANATOMY", 141, 160], ["adrenal tumor", "ANATOMY", 179, 192], ["adrenal tumor", "DISEASE", 179, 192], ["lesion", "CANCER", 127, 133], ["adrenal gland", "ORGAN", 147, 160], ["adrenal tumor", "CANCER", 179, 192], ["Abdominal computerized tomography (CT) scan", "TEST", 0, 43], ["a spaceoccupying lesion at the right adrenal gland", "PROBLEM", 110, 160], ["adrenal tumor", "PROBLEM", 179, 192], ["spaceoccupying", "OBSERVATION_MODIFIER", 112, 126], ["lesion", "OBSERVATION", 127, 133], ["right", "ANATOMY_MODIFIER", 141, 146], ["adrenal gland", "ANATOMY", 147, 160], ["adrenal", "ANATOMY", 179, 186], ["tumor", "OBSERVATION", 187, 192]]], ["As the patient was elderly and not specifically symptomatic, follow-up observation was recommended.", [["patient", "ORGANISM", 7, 14], ["patient", "SPECIES", 7, 14], ["symptomatic", "PROBLEM", 48, 59], ["follow-up observation", "TEST", 61, 82]]], ["A magnetic resonance imaging (MRI) examination revealed abnormal signals within the seminal vesicle, suggesting the possibility of internal hemorrhage; follow-up prostate MRI was recommended.Case reporthttps://doi.org/10.1016/j.medmal.2020.03.005 0399-077X/\u00a9 2020 Elsevier Masson SAS.", [["seminal vesicle", "ANATOMY", 84, 99], ["prostate", "ANATOMY", 162, 170], ["internal hemorrhage", "DISEASE", 131, 150], ["seminal vesicle", "MULTI-TISSUE_STRUCTURE", 84, 99], ["prostate", "ORGAN", 162, 170], ["A magnetic resonance imaging (MRI) examination", "TEST", 0, 46], ["abnormal signals within the seminal vesicle", "PROBLEM", 56, 99], ["internal hemorrhage", "PROBLEM", 131, 150], ["follow-up prostate MRI", "TEST", 152, 174], ["abnormal signals", "OBSERVATION", 56, 72], ["seminal vesicle", "ANATOMY", 84, 99], ["suggesting the possibility of", "UNCERTAINTY", 101, 130], ["internal", "OBSERVATION_MODIFIER", 131, 139], ["hemorrhage", "OBSERVATION", 140, 150]]], ["All rights reserved.Table 1Laboratory data including complete blood count (CBC).MeasureReference range Hospital day 1 Hospital day 6MeasureWhite blood cell count (109/L) 3.5-9.5 6.62 5.15 Red blood cell count (10 12 /L) 10-12 3.77 a 3.66 a Absolute neutrophil count (10 9 /L) 1.8-6.3 5.61 4.42 Absolute lymphocyte count (10 9 /L) 1.", [["blood", "ANATOMY", 62, 67], ["blood cell", "ANATOMY", 145, 155], ["Red blood cell", "ANATOMY", 188, 202], ["neutrophil", "ANATOMY", 249, 259], ["lymphocyte", "ANATOMY", 303, 313], ["blood", "ORGANISM_SUBSTANCE", 62, 67], ["blood cell", "CELL", 145, 155], ["blood cell", "CELL", 192, 202], ["neutrophil", "CELL", 249, 259], ["lymphocyte", "CELL", 303, 313], ["complete blood count", "TEST", 53, 73], ["CBC", "TEST", 75, 78], ["blood cell count", "TEST", 145, 161], ["Red blood cell count", "TEST", 188, 208], ["a Absolute neutrophil count", "TEST", 238, 265], ["Absolute lymphocyte count", "TEST", 294, 319]]], ["Colonoscopy was also recommended to clarify the acute colorectal findings and to identify the source of bleeding.MeasureOn the fifth day of admission, the patient's condition remained stable.", [["colorectal", "ANATOMY", 54, 64], ["bleeding", "DISEASE", 104, 112], ["colorectal", "MULTI-TISSUE_STRUCTURE", 54, 64], ["patient", "ORGANISM", 155, 162], ["patient", "SPECIES", 155, 162], ["Colonoscopy", "TEST", 0, 11], ["the acute colorectal findings", "PROBLEM", 44, 73], ["bleeding", "PROBLEM", 104, 112], ["acute", "OBSERVATION_MODIFIER", 48, 53], ["colorectal", "OBSERVATION", 54, 64], ["bleeding", "OBSERVATION", 104, 112], ["stable", "OBSERVATION", 184, 190]]], ["Colonoscopy revealed three polyps in the colon, but no tumors or hemorrhagic sites were identified.", [["polyps", "ANATOMY", 27, 33], ["colon", "ANATOMY", 41, 46], ["tumors", "ANATOMY", 55, 61], ["sites", "ANATOMY", 77, 82], ["polyps in the colon", "DISEASE", 27, 46], ["tumors", "DISEASE", 55, 61], ["hemorrhagic", "DISEASE", 65, 76], ["polyps", "PATHOLOGICAL_FORMATION", 27, 33], ["colon", "ORGAN", 41, 46], ["tumors", "CANCER", 55, 61], ["Colonoscopy", "TEST", 0, 11], ["three polyps in the colon", "PROBLEM", 21, 46], ["tumors", "PROBLEM", 55, 61], ["hemorrhagic sites", "PROBLEM", 65, 82], ["three", "OBSERVATION_MODIFIER", 21, 26], ["polyps", "OBSERVATION", 27, 33], ["colon", "ANATOMY", 41, 46], ["no", "UNCERTAINTY", 52, 54], ["tumors", "OBSERVATION", 55, 61], ["hemorrhagic", "OBSERVATION_MODIFIER", 65, 76]]], ["Therefore, hematochezia secondary to infection was considered.", [["hematochezia", "DISEASE", 11, 23], ["infection", "DISEASE", 37, 46], ["hematochezia", "PATHOLOGICAL_FORMATION", 11, 23], ["hematochezia", "PROBLEM", 11, 23], ["infection", "PROBLEM", 37, 46], ["hematochezia", "OBSERVATION", 11, 23], ["infection", "OBSERVATION", 37, 46]]], ["On this same day, the bloody stools disappeared, but the patient suddenly developed a fever, with peak body temperature measured at 39 \u2022 C (Fig. 1) .", [["bloody stools", "ANATOMY", 22, 35], ["body", "ANATOMY", 103, 107], ["fever", "DISEASE", 86, 91], ["bloody stools", "ORGANISM_SUBSTANCE", 22, 35], ["patient", "ORGANISM", 57, 64], ["body", "ORGANISM_SUBDIVISION", 103, 107], ["patient", "SPECIES", 57, 64], ["the bloody stools", "PROBLEM", 18, 35], ["a fever", "PROBLEM", 84, 91], ["peak body temperature", "TEST", 98, 119], ["fever", "OBSERVATION", 86, 91]]], ["The patient denied any symptoms including chest tightness, cough, expectoration, or dyspnea.", [["chest", "ANATOMY", 42, 47], ["chest tightness", "DISEASE", 42, 57], ["cough", "DISEASE", 59, 64], ["expectoration", "DISEASE", 66, 79], ["dyspnea", "DISEASE", 84, 91], ["patient", "ORGANISM", 4, 11], ["chest", "ORGANISM_SUBDIVISION", 42, 47], ["patient", "SPECIES", 4, 11], ["any symptoms", "PROBLEM", 19, 31], ["chest tightness", "PROBLEM", 42, 57], ["cough", "PROBLEM", 59, 64], ["expectoration", "PROBLEM", 66, 79], ["dyspnea", "PROBLEM", 84, 91], ["chest", "ANATOMY", 42, 47], ["cough", "OBSERVATION", 59, 64], ["expectoration", "OBSERVATION", 66, 79]]], ["The physical examination on this day was notable for bilateral rough breath sounds and moist rales in the lower right lung.", [["breath", "ANATOMY", 69, 75], ["lower right lung", "ANATOMY", 106, 122], ["lung", "ORGAN", 118, 122], ["The physical examination", "TEST", 0, 24], ["bilateral rough breath sounds", "PROBLEM", 53, 82], ["moist rales in the lower right lung", "PROBLEM", 87, 122], ["bilateral", "ANATOMY_MODIFIER", 53, 62], ["rough", "OBSERVATION_MODIFIER", 63, 68], ["breath sounds", "OBSERVATION", 69, 82], ["moist", "OBSERVATION_MODIFIER", 87, 92], ["rales", "OBSERVATION", 93, 98], ["lower", "ANATOMY_MODIFIER", 106, 111], ["right", "ANATOMY_MODIFIER", 112, 117], ["lung", "ANATOMY", 118, 122]]], ["He was treated with dexamethasone injection, and the fever disappeared.MeasureLaboratory tests on and during admission revealed a white blood cell count within the normal range, but the number of lymphocytes and platelets as well as red blood cell count, hemoglobin, and hematocrit levels all decreased gradually during the hospital stay ( Table 1 ).", [["white blood cell", "ANATOMY", 130, 146], ["lymphocytes", "ANATOMY", 196, 207], ["platelets", "ANATOMY", 212, 221], ["red blood cell", "ANATOMY", 233, 247], ["dexamethasone", "CHEMICAL", 20, 33], ["fever", "DISEASE", 53, 58], ["dexamethasone", "CHEMICAL", 20, 33], ["He", "ORGANISM", 0, 2], ["dexamethasone", "SIMPLE_CHEMICAL", 20, 33], ["blood cell", "CELL", 136, 146], ["lymphocytes", "CELL", 196, 207], ["platelets", "CELL", 212, 221], ["red blood cell", "CELL", 233, 247], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 255, 265], ["hematocrit", "GENE_OR_GENE_PRODUCT", 271, 281], ["lymphocytes", "CELL_TYPE", 196, 207], ["platelets", "CELL_TYPE", 212, 221], ["hemoglobin", "PROTEIN", 255, 265], ["dexamethasone injection", "TREATMENT", 20, 43], ["the fever", "PROBLEM", 49, 58], ["MeasureLaboratory tests", "TEST", 71, 94], ["a white blood cell count", "TEST", 128, 152], ["lymphocytes", "TEST", 196, 207], ["platelets", "TEST", 212, 221], ["red blood cell count", "TEST", 233, 253], ["hemoglobin", "TEST", 255, 265], ["hematocrit levels", "TEST", 271, 288], ["normal range", "OBSERVATION_MODIFIER", 164, 176], ["lymphocytes", "OBSERVATION", 196, 207], ["decreased", "OBSERVATION_MODIFIER", 293, 302], ["gradually", "OBSERVATION_MODIFIER", 303, 312]]], ["The rapid antigen test was negative for both influenza A and B and blood cultures were negative.", [["blood cultures", "ANATOMY", 67, 81], ["B", "CELL", 61, 62], ["blood cultures", "CELL", 67, 81], ["The rapid antigen test", "TEST", 0, 22], ["both influenza A", "PROBLEM", 40, 56], ["blood cultures", "TEST", 67, 81]]], ["On hospital days six and seven, throat swabs obtained from the patient tested positive for SARS-CoV-2 by real-time RT-PCR.", [["throat swabs", "ANATOMY", 32, 44], ["patient", "ORGANISM", 63, 70], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 91, 101], ["patient", "SPECIES", 63, 70], ["SARS-CoV", "SPECIES", 91, 99], ["throat swabs", "TEST", 32, 44], ["SARS", "PROBLEM", 91, 95], ["CoV", "TEST", 96, 99]]], ["CT scan images on admission showed no abnormality (Fig. 2) , but when repeated on the fifth day after admission, the CT scan revealed infiltrates in the lower right lung (Fig. 3) .MeasureUpon questioning, the patient disclosed his granddaughter had contact with people who had returned from Wuhan.", [["lower right lung", "ANATOMY", 153, 169], ["lung", "ORGAN", 165, 169], ["patient", "ORGANISM", 209, 216], ["people", "ORGANISM", 262, 268], ["patient", "SPECIES", 209, 216], ["people", "SPECIES", 262, 268], ["CT scan images", "TEST", 0, 14], ["abnormality", "PROBLEM", 38, 49], ["the CT scan", "TEST", 113, 124], ["infiltrates in the lower right lung", "PROBLEM", 134, 169], ["no", "UNCERTAINTY", 35, 37], ["abnormality", "OBSERVATION", 38, 49], ["infiltrates", "OBSERVATION", 134, 145], ["lower", "ANATOMY_MODIFIER", 153, 158], ["right", "ANATOMY_MODIFIER", 159, 164], ["lung", "ANATOMY", 165, 169], ["Fig", "OBSERVATION_MODIFIER", 171, 174]]], ["At that time, his granddaughter had no symptom, although his daughter had developed a fever but did not have any sign or symptom of pneumonia.MeasureBased on the epidemiological history, detection of SARS-CoV-2 by real-time RT-PCR, and the chest CT scan findings, the patient was diagnosed with COVID-19.", [["fever", "DISEASE", 86, 91], ["pneumonia", "DISEASE", 132, 141], ["SARS", "DISEASE", 200, 204], ["patient", "ORGANISM", 268, 275], ["patient", "SPECIES", 268, 275], ["SARS-CoV", "SPECIES", 200, 208], ["symptom", "PROBLEM", 39, 46], ["a fever", "PROBLEM", 84, 91], ["pneumonia", "PROBLEM", 132, 141], ["SARS", "TEST", 200, 204], ["CoV", "TEST", 205, 208], ["RT-PCR", "TEST", 224, 230], ["the chest CT scan findings", "TEST", 236, 262], ["COVID", "TEST", 295, 300], ["fever", "OBSERVATION", 86, 91], ["pneumonia", "OBSERVATION", 132, 141], ["chest", "ANATOMY", 240, 245]]], ["On his seventh day of admission, he was transferred to the first affiliated hospital of Henan University of Science and Technology for further evaluation and treatment.", [["further evaluation", "TEST", 135, 153], ["treatment", "TREATMENT", 158, 167]]], ["On January 29, computerized tomography (CT) scan images revealed no acute intrathoracic abnormalities.DiscussionThe patient was an 83-year-old man who developed hematochezia three days after indirect contact with individuals returning from Wuhan.", [["intrathoracic", "ANATOMY", 74, 87], ["hematochezia", "DISEASE", 161, 173], ["patient", "ORGANISM", 116, 123], ["man", "ORGANISM", 143, 146], ["patient", "SPECIES", 116, 123], ["man", "SPECIES", 143, 146], ["computerized tomography (CT) scan images", "TEST", 15, 55], ["acute intrathoracic abnormalities", "PROBLEM", 68, 101], ["hematochezia", "PROBLEM", 161, 173], ["no", "UNCERTAINTY", 65, 67], ["acute", "OBSERVATION_MODIFIER", 68, 73], ["intrathoracic", "ANATOMY", 74, 87], ["abnormalities", "OBSERVATION", 88, 101], ["hematochezia", "OBSERVATION", 161, 173]]], ["Nine days later, he developed fever and lung inflammation with throat swabs that tested positive for SARS-CoV-2.", [["lung", "ANATOMY", 40, 44], ["throat swabs", "ANATOMY", 63, 75], ["fever", "DISEASE", 30, 35], ["lung inflammation", "DISEASE", 40, 57], ["lung", "ORGAN", 40, 44], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 101, 111], ["SARS-CoV", "SPECIES", 101, 109], ["fever", "PROBLEM", 30, 35], ["lung inflammation", "PROBLEM", 40, 57], ["throat swabs", "TEST", 63, 75], ["SARS", "PROBLEM", 101, 105], ["CoV", "TEST", 106, 109], ["fever", "OBSERVATION", 30, 35], ["lung", "ANATOMY", 40, 44], ["inflammation", "OBSERVATION", 45, 57], ["throat", "ANATOMY", 63, 69]]], ["As such, he was diagnosed with COVID-19.", [["COVID-19", "CHEMICAL", 31, 39], ["COVID", "TEST", 31, 36]]], ["No source of bleeding was identified by colonoscopy or abdominal CT scan and as such, we considered the possibility that hematochezia might be secondary to infection with SARS-CoV-2 pathogen.", [["abdominal", "ANATOMY", 55, 64], ["bleeding", "DISEASE", 13, 21], ["hematochezia", "DISEASE", 121, 133], ["infection", "DISEASE", 156, 165], ["SARS", "DISEASE", 171, 175], ["abdominal", "ORGANISM_SUBDIVISION", 55, 64], ["hematochezia", "PATHOLOGICAL_FORMATION", 121, 133], ["SARS-CoV-2 pathogen", "ORGANISM", 171, 190], ["bleeding", "PROBLEM", 13, 21], ["colonoscopy", "TEST", 40, 51], ["abdominal CT scan", "TEST", 55, 72], ["hematochezia", "PROBLEM", 121, 133], ["infection", "PROBLEM", 156, 165], ["SARS", "PROBLEM", 171, 175], ["CoV-2 pathogen", "PROBLEM", 176, 190], ["source of", "UNCERTAINTY", 3, 12], ["bleeding", "OBSERVATION", 13, 21], ["abdominal", "ANATOMY", 55, 64], ["infection", "OBSERVATION", 156, 165]]], ["Unfortunately, we did not determine whether SARS-CoV-2 could be detected in stool specimens, which may have provided further direct evidence in this case.", [["stool specimens", "ANATOMY", 76, 91], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 44, 54], ["stool specimens", "ORGANISM_SUBSTANCE", 76, 91], ["SARS-CoV", "SPECIES", 44, 52], ["SARS", "PROBLEM", 44, 48], ["CoV", "TEST", 49, 52], ["stool specimens", "TEST", 76, 91]]], ["At this writing, there are several reports of diarrhea associated with the presentation of SARS-CoV-2 infection [4] , but to the best of our knowledge, this is the first report of hematochezia as the presenting symptom and chief complaint.DiscussionUpon diagnosis, the patient was transferred to the first affiliated hospital of Henan University of Science and Technology, and as such we have no additional follow-up information.DiscussionSix days after the patient left our hospital (February 7, 2020), another 63-year-old male patient -who had been on the same ward with underlying diagnoses of intestinal obstruction and postoperative recurrence of rectal carcinoma -developed fever and was also diagnosed with COVID-19.", [["intestinal", "ANATOMY", 597, 607], ["rectal carcinoma", "ANATOMY", 652, 668], ["diarrhea", "DISEASE", 46, 54], ["SARS-CoV-2 infection", "DISEASE", 91, 111], ["hematochezia", "DISEASE", 180, 192], ["intestinal obstruction", "DISEASE", 597, 619], ["rectal carcinoma", "DISEASE", 652, 668], ["fever", "DISEASE", 680, 685], ["SARS-CoV-2", "ORGANISM", 91, 101], ["hematochezia", "PATHOLOGICAL_FORMATION", 180, 192], ["patient", "ORGANISM", 269, 276], ["patient", "ORGANISM", 458, 465], ["patient", "ORGANISM", 529, 536], ["intestinal", "ORGAN", 597, 607], ["rectal carcinoma", "CANCER", 652, 668], ["patient", "SPECIES", 269, 276], ["patient", "SPECIES", 458, 465], ["patient", "SPECIES", 529, 536], ["SARS-CoV-2", "SPECIES", 91, 101], ["diarrhea", "PROBLEM", 46, 54], ["SARS", "PROBLEM", 91, 95], ["CoV-2 infection", "PROBLEM", 96, 111], ["hematochezia", "PROBLEM", 180, 192], ["the presenting symptom", "PROBLEM", 196, 218], ["intestinal obstruction", "PROBLEM", 597, 619], ["postoperative recurrence", "PROBLEM", 624, 648], ["rectal carcinoma", "PROBLEM", 652, 668], ["fever", "PROBLEM", 680, 685], ["COVID", "TEST", 714, 719], ["diarrhea", "OBSERVATION", 46, 54], ["hematochezia", "OBSERVATION", 180, 192], ["intestinal", "ANATOMY", 597, 607], ["obstruction", "OBSERVATION", 608, 619], ["rectal", "ANATOMY", 652, 658], ["carcinoma", "OBSERVATION", 659, 668], ["fever", "OBSERVATION", 680, 685]]], ["The ward was emptied and sterilized repeatedly; the Center for Disease Control (CDC) collected samples from numerous surfaces including the desktop, bed sheets, and quilt covers.", [["Disease Control (CDC)", "PROBLEM", 63, 84], ["the desktop, bed sheets", "TREATMENT", 136, 159], ["numerous", "OBSERVATION_MODIFIER", 108, 116], ["surfaces", "OBSERVATION_MODIFIER", 117, 125]]], ["SARS-CoV-2 was detected on these surfaces even after repeated attempts at sterilization.", [["SARS", "DISEASE", 0, 4], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["repeated attempts at sterilization", "TREATMENT", 53, 87]]], ["These results suggest that these patients may have carried high viral loads.DiscussionTaken together, our findings with respect to this case patient suggest that fever and respiratory findings may not be the only presenting signs and symptoms of SARS-CoV-2 infection.", [["respiratory", "ANATOMY", 172, 183], ["fever", "DISEASE", 162, 167], ["SARS", "DISEASE", 246, 250], ["infection", "DISEASE", 257, 266], ["patients", "ORGANISM", 33, 41], ["patient", "ORGANISM", 141, 148], ["SARS-CoV-2", "ORGANISM", 246, 256], ["patients", "SPECIES", 33, 41], ["patient", "SPECIES", 141, 148], ["SARS-CoV-2", "SPECIES", 246, 256], ["high viral loads", "PROBLEM", 59, 75], ["fever", "PROBLEM", 162, 167], ["respiratory findings", "PROBLEM", 172, 192], ["symptoms", "PROBLEM", 234, 242], ["SARS", "PROBLEM", 246, 250], ["CoV", "PROBLEM", 251, 254], ["2 infection", "PROBLEM", 255, 266], ["viral loads", "OBSERVATION", 64, 75], ["infection", "OBSERVATION", 257, 266]]], ["Presentations including diarrhea and hematochezia may be secondary to an alternate point of entry.", [["diarrhea", "DISEASE", 24, 32], ["hematochezia", "DISEASE", 37, 49], ["diarrhea", "PROBLEM", 24, 32], ["hematochezia", "PROBLEM", 37, 49], ["diarrhea", "OBSERVATION", 24, 32], ["hematochezia", "OBSERVATION", 37, 49]]], ["This point needs to be clarified as quickly as possible.Human and animal rightsThe authors declare that the work described has been carried out in accordance with the Declaration of Helsinki of the World Medical Association revised in 2013 for experiments involving humans as well as in accordance with the EU Directive 2010/63/EU for animal experiments.", [["Human", "ORGANISM", 56, 61], ["humans", "ORGANISM", 266, 272], ["Human", "SPECIES", 56, 61], ["humans", "SPECIES", 266, 272], ["Human", "SPECIES", 56, 61], ["humans", "SPECIES", 266, 272]]]], "fb616b384c73d1a6cd540445e1eca0ea821dc9db": [["AssociAted signsRegardless of the underlying cause, abdominal enlargement is most likely to be associated with increased respiratory effort, usually characterized as tachypnea (increased respiratory rate).", [["abdominal", "ANATOMY", 52, 61], ["respiratory", "ANATOMY", 121, 132], ["respiratory", "ANATOMY", 187, 198], ["abdominal enlargement", "DISEASE", 52, 73], ["tachypnea", "DISEASE", 166, 175], ["abdominal", "ORGANISM_SUBDIVISION", 52, 61], ["the underlying cause", "PROBLEM", 30, 50], ["abdominal enlargement", "PROBLEM", 52, 73], ["increased respiratory effort", "PROBLEM", 111, 139], ["tachypnea", "PROBLEM", 166, 175], ["increased respiratory rate", "PROBLEM", 177, 203], ["abdominal", "ANATOMY", 52, 61], ["enlargement", "OBSERVATION", 62, 73], ["most likely to be", "UNCERTAINTY", 77, 94], ["increased", "OBSERVATION_MODIFIER", 111, 120], ["respiratory effort", "OBSERVATION", 121, 139], ["tachypnea", "OBSERVATION", 166, 175], ["increased", "OBSERVATION_MODIFIER", 177, 186], ["respiratory rate", "OBSERVATION", 187, 203]]], ["Dogs are more likely than cats to vocalize during expiration (grunt).", [["Dogs", "ORGANISM", 0, 4], ["cats", "ORGANISM", 26, 30], ["cats", "SPECIES", 26, 30], ["more likely", "UNCERTAINTY", 9, 20]]], ["Increased heart rate, lethargy, diminished appetite, and orthopnea (positional breathing) are variably observed.AssociAted signsdifferentiAl diAgnosis diAgnostic PlAns 1.", [["heart", "ANATOMY", 10, 15], ["lethargy", "DISEASE", 22, 30], ["orthopnea", "DISEASE", 57, 66], ["heart", "ORGAN", 10, 15], ["Increased heart rate", "PROBLEM", 0, 20], ["lethargy", "PROBLEM", 22, 30], ["diminished appetite", "PROBLEM", 32, 51], ["orthopnea (positional breathing)", "PROBLEM", 57, 89], ["heart", "ANATOMY", 10, 15], ["rate", "OBSERVATION_MODIFIER", 16, 20], ["lethargy", "OBSERVATION", 22, 30], ["diminished", "OBSERVATION_MODIFIER", 32, 42]]], ["Establish duration and progression of abdominal enlargement; in females, establish whether or not pregnancy is possible.", [["abdominal", "ANATOMY", 38, 47], ["abdominal enlargement", "DISEASE", 38, 59], ["abdominal", "ORGANISM_SUBDIVISION", 38, 47], ["abdominal enlargement", "PROBLEM", 38, 59], ["progression", "OBSERVATION_MODIFIER", 23, 34], ["abdominal", "ANATOMY", 38, 47], ["enlargement", "OBSERVATION", 48, 59]]], ["Abdominal palpation.", [["Abdominal", "ANATOMY", 0, 9], ["Abdominal palpation", "TEST", 0, 19], ["palpation", "OBSERVATION", 10, 19]]], ["Note: Preferably accomplished with the patient in right lateral recumbency.", [["patient", "ORGANISM", 39, 46], ["patient", "SPECIES", 39, 46], ["right", "ANATOMY_MODIFIER", 50, 55], ["lateral", "ANATOMY_MODIFIER", 56, 63], ["recumbency", "OBSERVATION", 64, 74]]], ["Examination is carried out using two hands simultaneously.", [["Examination", "TEST", 0, 11]]], ["Abdominal ballottement.", [["Abdominal", "ANATOMY", 0, 9], ["Abdominal ballottement", "TREATMENT", 0, 22], ["ballottement", "OBSERVATION", 10, 22]]], ["Manipulate the abdominal wall in an attempt to determine whether or not an accumulation of fluid exists within the abdomen.", [["abdominal wall", "ANATOMY", 15, 29], ["fluid", "ANATOMY", 91, 96], ["abdomen", "ANATOMY", 115, 122], ["abdominal wall", "MULTI-TISSUE_STRUCTURE", 15, 29], ["fluid", "ORGANISM_SUBSTANCE", 91, 96], ["abdomen", "ORGAN", 115, 122], ["the abdominal wall", "TREATMENT", 11, 29], ["an accumulation of fluid exists within the abdomen", "PROBLEM", 72, 122], ["abdominal", "ANATOMY", 15, 24], ["wall", "ANATOMY_MODIFIER", 25, 29], ["accumulation", "OBSERVATION_MODIFIER", 75, 87], ["fluid", "OBSERVATION", 91, 96], ["abdomen", "ANATOMY", 115, 122]]], ["Imaging.", [["Imaging", "TEST", 0, 7]]], ["Abdominal radiograph or abdominal ultrasound.", [["Abdominal", "ANATOMY", 0, 9], ["abdominal", "ANATOMY", 24, 33], ["abdominal", "ORGANISM_SUBDIVISION", 24, 33], ["Abdominal radiograph", "TEST", 0, 20], ["abdominal ultrasound", "TEST", 24, 44], ["abdominal", "ANATOMY", 24, 33]]], ["Laboratory profile.", [["Laboratory profile", "TEST", 0, 18]]], ["Generally conducted to assess patient overall health status.", [["patient", "ORGANISM", 30, 37], ["patient", "SPECIES", 30, 37]]], ["Fine needle aspiration and cytology.", [["Fine needle aspiration", "TEST", 0, 22], ["cytology", "TEST", 27, 35], ["needle", "OBSERVATION_MODIFIER", 5, 11], ["aspiration", "OBSERVATION", 12, 22]]], ["Aspiration of solid organs or masses may be indicated.", [["solid organs", "ANATOMY", 14, 26], ["masses", "ANATOMY", 30, 36], ["solid organs", "ORGAN", 14, 26], ["masses", "CANCER", 30, 36], ["Aspiration of solid organs", "PROBLEM", 0, 26], ["masses", "PROBLEM", 30, 36], ["solid organs", "OBSERVATION", 14, 26], ["masses", "OBSERVATION", 30, 36]]], ["Exploratory surgery.", [["Exploratory surgery", "TREATMENT", 0, 19], ["surgery", "OBSERVATION", 12, 19]]], ["Laparoscopy may be a necessary alternative.Aggression definitionAggression is a condition (either normal or abnormal) in the dog or cat characterized by threatening, destructive, or attacking behavior.", [["Aggression", "DISEASE", 43, 53], ["dog", "ORGANISM", 125, 128], ["cat", "ORGANISM", 132, 135], ["dog", "SPECIES", 125, 128], ["Laparoscopy", "TREATMENT", 0, 11], ["destructive", "PROBLEM", 166, 177], ["attacking behavior", "PROBLEM", 182, 200], ["destructive", "OBSERVATION_MODIFIER", 166, 177]]], ["Furthermore, aggression can be categorized as offensive or defensive.", [["aggression", "DISEASE", 13, 23]]], ["Specific knowledge of the pattern and type of aggression is critical if effective intervention is to be accomplished.", [["aggression", "DISEASE", 46, 56], ["effective intervention", "TREATMENT", 72, 94]]], ["For the criteria of this definition to be met, it is assumed that organic causes of aggression (e.g., pain or intracranial mass) have been ruled out.", [["intracranial mass", "ANATOMY", 110, 127], ["aggression", "DISEASE", 84, 94], ["pain", "DISEASE", 102, 106], ["aggression", "PROBLEM", 84, 94], ["pain", "PROBLEM", 102, 106], ["intracranial mass", "PROBLEM", 110, 127], ["intracranial", "ANATOMY", 110, 122], ["mass", "OBSERVATION", 123, 127]]], ["Hematuria is the presence of blood in the urine; the presence of trace amounts of blood in the urine will not be obvious on gross appearance of a urine sample.", [["blood", "ANATOMY", 29, 34], ["urine", "ANATOMY", 42, 47], ["blood", "ANATOMY", 82, 87], ["urine", "ANATOMY", 95, 100], ["urine sample", "ANATOMY", 146, 158], ["Hematuria", "DISEASE", 0, 9], ["blood", "ORGANISM_SUBSTANCE", 29, 34], ["urine", "ORGANISM_SUBSTANCE", 42, 47], ["blood", "ORGANISM_SUBSTANCE", 82, 87], ["urine", "ORGANISM_SUBSTANCE", 95, 100], ["urine", "ORGANISM_SUBSTANCE", 146, 151], ["Hematuria", "PROBLEM", 0, 9], ["blood in the urine", "PROBLEM", 29, 47], ["trace amounts of blood in the urine", "PROBLEM", 65, 100], ["a urine sample", "TEST", 144, 158], ["blood", "OBSERVATION", 29, 34], ["urine", "OBSERVATION", 42, 47], ["trace", "OBSERVATION_MODIFIER", 65, 70], ["amounts", "OBSERVATION_MODIFIER", 71, 78], ["blood", "OBSERVATION", 82, 87]]], ["Therefore any noticeable change in the color of urine observed by the owner is likely to be interpreted as \"blood in the urine.\"", [["urine", "ANATOMY", 48, 53], ["blood", "ANATOMY", 108, 113], ["urine", "ANATOMY", 121, 126], ["urine", "ORGANISM_SUBSTANCE", 48, 53], ["blood", "ORGANISM_SUBSTANCE", 108, 113], ["urine", "ORGANISM_SUBSTANCE", 121, 126], ["any noticeable change in the color of urine", "PROBLEM", 10, 53], ["blood in the urine", "PROBLEM", 108, 126], ["noticeable", "OBSERVATION_MODIFIER", 14, 24], ["change", "OBSERVATION", 25, 31], ["urine", "OBSERVATION", 48, 53]]], ["Further evaluation of the patient is necessary to determine whether or not the discoloration is associated with small blood clots in recently voided urine, blood-tinged urine, or brown or red urine.", [["blood clots", "ANATOMY", 118, 129], ["urine", "ANATOMY", 149, 154], ["blood", "ANATOMY", 156, 161], ["urine", "ANATOMY", 169, 174], ["red urine", "ANATOMY", 188, 197], ["patient", "ORGANISM", 26, 33], ["blood clots", "ORGANISM_SUBSTANCE", 118, 129], ["urine", "ORGANISM_SUBSTANCE", 149, 154], ["blood", "ORGANISM_SUBSTANCE", 156, 161], ["urine", "ORGANISM_SUBSTANCE", 169, 174], ["brown", "ORGANISM_SUBDIVISION", 179, 184], ["red urine", "ORGANISM_SUBSTANCE", 188, 197], ["patient", "SPECIES", 26, 33], ["Further evaluation", "TEST", 0, 18], ["the discoloration", "PROBLEM", 75, 92], ["small blood clots", "PROBLEM", 112, 129], ["voided urine", "TEST", 142, 154], ["blood-tinged urine", "TEST", 156, 174], ["brown or red urine", "PROBLEM", 179, 197], ["discoloration", "OBSERVATION", 79, 92], ["clots", "OBSERVATION", 124, 129]]], ["The presence of blood in the urine, whether gross or occult, is most often indicative of upper or lower urinary tract bleeding, although systemic coagulopathies and reproductive tract disorders may also cause hematuria.", [["blood", "ANATOMY", 16, 21], ["urine", "ANATOMY", 29, 34], ["lower urinary tract", "ANATOMY", 98, 117], ["urinary tract bleeding", "DISEASE", 104, 126], ["systemic coagulopathies", "DISEASE", 137, 160], ["reproductive tract disorders", "DISEASE", 165, 193], ["hematuria", "DISEASE", 209, 218], ["blood", "ORGANISM_SUBSTANCE", 16, 21], ["urine", "ORGANISM_SUBSTANCE", 29, 34], ["upper", "ORGANISM_SUBDIVISION", 89, 94], ["lower", "ORGANISM_SUBDIVISION", 98, 103], ["urinary tract", "ORGANISM_SUBDIVISION", 104, 117], ["tract", "ORGANISM_SUBDIVISION", 178, 183], ["blood in the urine", "PROBLEM", 16, 34], ["gross or occult", "PROBLEM", 44, 59], ["upper or lower urinary tract bleeding", "PROBLEM", 89, 126], ["systemic coagulopathies", "PROBLEM", 137, 160], ["reproductive tract disorders", "PROBLEM", 165, 193], ["hematuria", "PROBLEM", 209, 218], ["blood", "OBSERVATION", 16, 21], ["urine", "ANATOMY", 29, 34], ["gross", "OBSERVATION_MODIFIER", 44, 49], ["occult", "OBSERVATION", 53, 59], ["most often indicative of", "UNCERTAINTY", 64, 88], ["upper", "ANATOMY_MODIFIER", 89, 94], ["lower", "ANATOMY_MODIFIER", 98, 103], ["urinary tract", "ANATOMY", 104, 117], ["bleeding", "OBSERVATION", 118, 126], ["systemic", "OBSERVATION_MODIFIER", 137, 145], ["coagulopathies", "OBSERVATION", 146, 160], ["hematuria", "OBSERVATION", 209, 218]]], ["The presence of hemoglobin in urine (hemoglobinuria) is not necessarily a reflection of urinary tract disease.", [["urine", "ANATOMY", 30, 35], ["urinary tract", "ANATOMY", 88, 101], ["hemoglobinuria", "DISEASE", 37, 51], ["urinary tract disease", "DISEASE", 88, 109], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 16, 26], ["urine", "ORGANISM_SUBSTANCE", 30, 35], ["urinary tract", "ORGANISM_SUBDIVISION", 88, 101], ["hemoglobin", "PROTEIN", 16, 26], ["hemoglobin in urine (hemoglobinuria", "PROBLEM", 16, 51], ["urinary tract disease", "PROBLEM", 88, 109], ["hemoglobin", "OBSERVATION", 16, 26], ["not necessarily", "UNCERTAINTY", 56, 71], ["urinary tract", "ANATOMY", 88, 101], ["disease", "OBSERVATION", 102, 109]]], ["Systemic disorders (e.g., those leading to intravascular hemolysis) can be associated with significant hemoglobinuria in the presence of a normal urinary system.", [["intravascular", "ANATOMY", 43, 56], ["urinary system", "ANATOMY", 146, 160], ["Systemic disorders", "DISEASE", 0, 18], ["intravascular hemolysis", "DISEASE", 43, 66], ["hemoglobinuria", "DISEASE", 103, 117], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 43, 56], ["urinary", "ORGANISM_SUBDIVISION", 146, 153], ["Systemic disorders", "PROBLEM", 0, 18], ["intravascular hemolysis", "PROBLEM", 43, 66], ["significant hemoglobinuria", "PROBLEM", 91, 117], ["disorders", "OBSERVATION", 9, 18], ["hemolysis", "OBSERVATION", 57, 66], ["significant", "OBSERVATION_MODIFIER", 91, 102], ["hemoglobinuria", "OBSERVATION", 103, 117], ["normal", "OBSERVATION", 139, 145], ["urinary system", "ANATOMY", 146, 160]]], ["Owners are likely to interpret this clinical sign to be \"blood in the urine. \"", [["blood", "ANATOMY", 57, 62], ["urine", "ANATOMY", 70, 75], ["blood", "ORGANISM_SUBSTANCE", 57, 62], ["urine", "ORGANISM_SUBSTANCE", 70, 75], ["blood in the urine", "PROBLEM", 57, 75]]], ["In true hemoglobinuria, without hematuria, microscopic examination will reveal the absence of red blood cells (RBCs).Aggression definitionDistinguishing hemoglobinuria from hematuria is an important diagnostic consideration.", [["red blood cells", "ANATOMY", 94, 109], ["RBCs", "ANATOMY", 111, 115], ["hemoglobinuria", "DISEASE", 8, 22], ["hematuria", "DISEASE", 32, 41], ["Aggression", "DISEASE", 117, 127], ["hemoglobinuria", "DISEASE", 153, 167], ["hematuria", "DISEASE", 173, 182], ["red blood cells", "CELL", 94, 109], ["RBCs", "CELL", 111, 115], ["red blood cells", "CELL_TYPE", 94, 109], ["RBCs", "CELL_TYPE", 111, 115], ["true hemoglobinuria", "PROBLEM", 3, 22], ["hematuria", "PROBLEM", 32, 41], ["microscopic examination", "TEST", 43, 66], ["red blood cells", "TEST", 94, 109], ["RBCs", "TEST", 111, 115], ["Aggression definition", "TEST", 117, 138], ["hemoglobinuria", "PROBLEM", 153, 167], ["hematuria", "PROBLEM", 173, 182], ["true", "OBSERVATION_MODIFIER", 3, 7], ["hemoglobinuria", "OBSERVATION", 8, 22], ["without", "UNCERTAINTY", 24, 31], ["hematuria", "OBSERVATION", 32, 41], ["hemoglobinuria", "OBSERVATION", 153, 167], ["hematuria", "OBSERVATION", 173, 182], ["important diagnostic consideration", "UNCERTAINTY", 189, 223]]], ["Conventional urine test strips (dipsticks) do not differentiate between the two; therefore microscopic examination of urine sediment for the presence of significant numbers of RBCs is critical.Aggression definitionMyoglobinuria is characterized by brown to dark-red urine, the absence of RBCs in the urine sediment, and a positive finding on testing for occult blood.", [["urine", "ANATOMY", 13, 18], ["urine sediment", "ANATOMY", 118, 132], ["RBCs", "ANATOMY", 176, 180], ["urine", "ANATOMY", 266, 271], ["RBCs", "ANATOMY", 288, 292], ["urine sediment", "ANATOMY", 300, 314], ["blood", "ANATOMY", 361, 366], ["Aggression", "DISEASE", 193, 203], ["Myoglobinuria", "DISEASE", 214, 227], ["urine", "ORGANISM_SUBSTANCE", 13, 18], ["urine", "ORGANISM_SUBSTANCE", 118, 123], ["RBCs", "CELL", 176, 180], ["urine", "ORGANISM_SUBSTANCE", 266, 271], ["RBCs", "CELL", 288, 292], ["urine sediment", "ORGANISM_SUBSTANCE", 300, 314], ["blood", "ORGANISM_SUBSTANCE", 361, 366], ["RBCs", "CELL_TYPE", 176, 180], ["RBCs", "CELL_TYPE", 288, 292], ["Conventional urine test strips (dipsticks", "TEST", 0, 41], ["microscopic examination", "TEST", 91, 114], ["urine sediment", "TEST", 118, 132], ["significant numbers of RBCs", "PROBLEM", 153, 180], ["Aggression definitionMyoglobinuria", "PROBLEM", 193, 227], ["brown to dark-red urine", "PROBLEM", 248, 271], ["RBCs", "PROBLEM", 288, 292], ["the urine sediment", "TEST", 296, 314], ["testing", "TEST", 342, 349], ["occult blood", "PROBLEM", 354, 366], ["Myoglobinuria", "OBSERVATION", 214, 227], ["brown to dark-red", "OBSERVATION_MODIFIER", 248, 265], ["urine", "OBSERVATION", 266, 271], ["urine", "ANATOMY", 300, 305], ["sediment", "OBSERVATION", 306, 314]]], ["Bilirubinuria can also cause dark-brown to dark-orange urine but alone will not produce a test result positive for occult blood.", [["urine", "ANATOMY", 55, 60], ["blood", "ANATOMY", 122, 127], ["Bilirubinuria", "CHEMICAL", 0, 13], ["urine", "ORGANISM_SUBSTANCE", 55, 60], ["blood", "ORGANISM_SUBSTANCE", 122, 127], ["dark-brown to dark-orange urine", "PROBLEM", 29, 60], ["a test result", "TEST", 88, 101], ["occult blood", "PROBLEM", 115, 127], ["brown to dark", "OBSERVATION_MODIFIER", 34, 47]]], ["Myoglobinuria is a serious sign and denotes generalized muscle disease.AssociAted signsHematuria associated with the urinary tract may not be associated with any other clinical signs.", [["muscle", "ANATOMY", 56, 62], ["urinary tract", "ANATOMY", 117, 130], ["Myoglobinuria", "DISEASE", 0, 13], ["muscle disease", "DISEASE", 56, 70], ["Hematuria", "DISEASE", 87, 96], ["muscle", "ORGAN", 56, 62], ["urinary tract", "ORGANISM_SUBDIVISION", 117, 130], ["Myoglobinuria", "PROBLEM", 0, 13], ["a serious sign", "PROBLEM", 17, 31], ["generalized muscle disease", "PROBLEM", 44, 70], ["AssociAted signsHematuria", "PROBLEM", 71, 96], ["the urinary tract", "PROBLEM", 113, 130], ["any other clinical signs", "PROBLEM", 158, 182], ["generalized", "OBSERVATION_MODIFIER", 44, 55], ["muscle", "ANATOMY", 56, 62], ["disease", "OBSERVATION", 63, 70], ["Hematuria", "OBSERVATION", 87, 96], ["urinary tract", "ANATOMY", 117, 130]]], ["In patients with significant bleeding of renal origin, evidence of systemic illness may be present but is unlikely to localize the source of hematuria.", [["renal", "ANATOMY", 41, 46], ["bleeding", "DISEASE", 29, 37], ["systemic illness", "DISEASE", 67, 83], ["hematuria", "DISEASE", 141, 150], ["patients", "ORGANISM", 3, 11], ["renal", "ORGAN", 41, 46], ["patients", "SPECIES", 3, 11], ["significant bleeding of renal origin", "PROBLEM", 17, 53], ["systemic illness", "PROBLEM", 67, 83], ["hematuria", "PROBLEM", 141, 150], ["significant", "OBSERVATION_MODIFIER", 17, 28], ["bleeding", "OBSERVATION", 29, 37], ["renal", "ANATOMY", 41, 46], ["origin", "ANATOMY_MODIFIER", 47, 53], ["evidence of", "UNCERTAINTY", 55, 66], ["systemic", "OBSERVATION_MODIFIER", 67, 75], ["illness", "OBSERVATION", 76, 83], ["hematuria", "OBSERVATION", 141, 150]]], ["Hematuria originating from the bladder is more likely to be associated with clinical signs, particularly pollakiuria and dysuria.", [["bladder", "ANATOMY", 31, 38], ["Hematuria originating from the bladder", "DISEASE", 0, 38], ["pollakiuria", "DISEASE", 105, 116], ["dysuria", "DISEASE", 121, 128], ["bladder", "ORGAN", 31, 38], ["Hematuria", "PROBLEM", 0, 9], ["clinical signs", "PROBLEM", 76, 90], ["pollakiuria", "PROBLEM", 105, 116], ["dysuria", "PROBLEM", 121, 128], ["bladder", "ANATOMY", 31, 38], ["more likely", "UNCERTAINTY", 42, 53], ["dysuria", "OBSERVATION", 121, 128]]], ["Reproductive tract disorders (e.g., prostatitis and vaginitis) can also cause significant hematuria.", [["tract", "ANATOMY", 13, 18], ["Reproductive tract disorders", "DISEASE", 0, 28], ["prostatitis", "DISEASE", 36, 47], ["vaginitis", "DISEASE", 52, 61], ["hematuria", "DISEASE", 90, 99], ["tract", "ORGANISM_SUBDIVISION", 13, 18], ["Reproductive tract disorders", "PROBLEM", 0, 28], ["prostatitis", "PROBLEM", 36, 47], ["vaginitis", "PROBLEM", 52, 61], ["significant hematuria", "PROBLEM", 78, 99], ["prostatitis", "OBSERVATION", 36, 47], ["vaginitis", "OBSERVATION", 52, 61], ["significant", "OBSERVATION_MODIFIER", 78, 89], ["hematuria", "OBSERVATION", 90, 99]]], ["Patients with hematuria or hemoglobinuria should be examined carefully for evidence of systemic bleeding, coagulopathies, and neoplasia.", [["neoplasia", "ANATOMY", 126, 135], ["hematuria", "DISEASE", 14, 23], ["hemoglobinuria", "DISEASE", 27, 41], ["bleeding", "DISEASE", 96, 104], ["coagulopathies", "DISEASE", 106, 120], ["neoplasia", "DISEASE", 126, 135], ["Patients", "ORGANISM", 0, 8], ["neoplasia", "CANCER", 126, 135], ["Patients", "SPECIES", 0, 8], ["hematuria", "PROBLEM", 14, 23], ["hemoglobinuria", "PROBLEM", 27, 41], ["systemic bleeding", "PROBLEM", 87, 104], ["coagulopathies", "PROBLEM", 106, 120], ["neoplasia", "PROBLEM", 126, 135], ["hematuria", "OBSERVATION", 14, 23], ["hemoglobinuria", "OBSERVATION", 27, 41], ["systemic", "OBSERVATION_MODIFIER", 87, 95], ["bleeding", "OBSERVATION", 96, 104], ["coagulopathies", "OBSERVATION", 106, 120], ["neoplasia", "OBSERVATION", 126, 135]]], ["Complete urinalysis.", [["Complete urinalysis", "TEST", 0, 19]]], ["Using a fresh sample, include assessment of gross appearance, specific gravity, biochemical reagent strips (dipsticks), and microscopic examination of urine sediment.", [["sample", "ANATOMY", 14, 20], ["urine sediment", "ANATOMY", 151, 165], ["urine", "ORGANISM_SUBSTANCE", 151, 156], ["a fresh sample", "TEST", 6, 20], ["assessment", "TEST", 30, 40], ["specific gravity", "TEST", 62, 78], ["biochemical reagent strips", "TEST", 80, 106], ["dipsticks", "TEST", 108, 117], ["microscopic examination", "TEST", 124, 147], ["urine sediment", "PROBLEM", 151, 165], ["urine sediment", "OBSERVATION", 151, 165]]], ["Ideally, two samples should be collected: a voided urine sample followed by a urine sample collected by cystocentesis.", [["samples", "ANATOMY", 13, 20], ["urine sample", "ANATOMY", 51, 63], ["urine sample", "ANATOMY", 78, 90], ["urine", "ORGANISM_SUBSTANCE", 51, 56], ["urine", "ORGANISM_SUBSTANCE", 78, 83], ["a voided urine sample", "TEST", 42, 63], ["a urine sample", "TEST", 76, 90]]], ["Culture and sensitivity, if bacteria are present.", [["Culture", "TEST", 0, 7], ["sensitivity", "TEST", 12, 23], ["bacteria", "PROBLEM", 28, 36]]], ["Routine laboratory profile, to include hematology and biochemistry panel.", [["Routine laboratory profile", "TEST", 0, 26], ["biochemistry panel", "TEST", 54, 72]]], ["Coagulation profile, if hemoglobinuria is present.", [["hemoglobinuria", "DISEASE", 24, 38], ["Coagulation profile", "TEST", 0, 19], ["hemoglobinuria", "PROBLEM", 24, 38], ["hemoglobinuria", "OBSERVATION", 24, 38]]], ["Abdominal radiographs, for evidence of calculi, prostatic enlargement, and soft tissue masses.", [["Abdominal", "ANATOMY", 0, 9], ["calculi", "ANATOMY", 39, 46], ["prostatic", "ANATOMY", 48, 57], ["soft tissue masses", "ANATOMY", 75, 93], ["calculi", "DISEASE", 39, 46], ["prostatic enlargement", "DISEASE", 48, 69], ["calculi", "PATHOLOGICAL_FORMATION", 39, 46], ["prostatic", "ORGAN", 48, 57], ["soft tissue masses", "CANCER", 75, 93], ["Abdominal radiographs", "TEST", 0, 21], ["calculi", "PROBLEM", 39, 46], ["prostatic enlargement", "PROBLEM", 48, 69], ["soft tissue masses", "PROBLEM", 75, 93], ["calculi", "OBSERVATION", 39, 46], ["prostatic", "ANATOMY", 48, 57], ["enlargement", "OBSERVATION", 58, 69], ["soft tissue", "OBSERVATION_MODIFIER", 75, 86], ["masses", "OBSERVATION", 87, 93]]], ["Contrast radiography of the upper and lower urinary tracts.", [["upper", "ANATOMY", 28, 33], ["lower urinary tracts", "ANATOMY", 38, 58], ["upper", "ORGANISM_SUBDIVISION", 28, 33], ["lower urinary", "ORGANISM_SUBDIVISION", 38, 51], ["Contrast radiography", "TEST", 0, 20], ["upper", "ANATOMY_MODIFIER", 28, 33], ["lower", "ANATOMY_MODIFIER", 38, 43], ["urinary tracts", "ANATOMY", 44, 58]]], ["Ultrasound examination of the prostate, urinary bladder, and kidneys.", [["prostate", "ANATOMY", 30, 38], ["urinary bladder", "ANATOMY", 40, 55], ["kidneys", "ANATOMY", 61, 68], ["prostate", "CANCER", 30, 38], ["urinary bladder", "MULTI-TISSUE_STRUCTURE", 40, 55], ["kidneys", "ORGAN", 61, 68], ["Ultrasound examination of the prostate, urinary bladder", "TEST", 0, 55], ["prostate", "ANATOMY", 30, 38], ["urinary bladder", "ANATOMY", 40, 55], ["kidneys", "ANATOMY", 61, 68]]], ["Exploratory laparotomy (if coagulation profile is normal).comA: loss of consciousness definitionComa is a state of complete reversible or irreversible unconsciousness that can result from neurologic as well as nonneurologic disease (drug overdose, especially in dogs).", [["neurologic", "ANATOMY", 188, 198], ["loss of consciousness", "DISEASE", 64, 85], ["definitionComa", "DISEASE", 86, 100], ["unconsciousness", "DISEASE", 151, 166], ["nonneurologic disease", "DISEASE", 210, 231], ["drug overdose", "DISEASE", 233, 246], ["dogs", "ORGANISM", 262, 266], ["dogs", "SPECIES", 262, 266], ["Exploratory laparotomy", "TEST", 0, 22], ["coagulation profile", "TEST", 27, 46], ["comA", "PROBLEM", 58, 62], ["loss of consciousness definitionComa", "PROBLEM", 64, 100], ["complete reversible or irreversible unconsciousness", "PROBLEM", 115, 166], ["nonneurologic disease (drug overdose", "PROBLEM", 210, 246], ["laparotomy", "OBSERVATION", 12, 22]]], ["Coma can be a consequence of diffuse or multifocal lesions of the cerebrum or a lesion affecting the rostral brainstem and ascending reticular activating system.", [["lesions", "ANATOMY", 51, 58], ["cerebrum", "ANATOMY", 66, 74], ["lesion", "ANATOMY", 80, 86], ["rostral brainstem", "ANATOMY", 101, 118], ["reticular", "ANATOMY", 133, 142], ["Coma", "DISEASE", 0, 4], ["lesions", "CANCER", 51, 58], ["cerebrum", "ORGAN", 66, 74], ["lesion", "CANCER", 80, 86], ["brainstem", "ORGAN", 109, 118], ["reticular", "IMMATERIAL_ANATOMICAL_ENTITY", 133, 142], ["Coma", "PROBLEM", 0, 4], ["diffuse or multifocal lesions of the cerebrum", "PROBLEM", 29, 74], ["a lesion affecting the rostral brainstem and ascending reticular activating system", "PROBLEM", 78, 160], ["diffuse", "OBSERVATION_MODIFIER", 29, 36], ["multifocal", "OBSERVATION_MODIFIER", 40, 50], ["lesions", "OBSERVATION", 51, 58], ["cerebrum", "ANATOMY", 66, 74], ["lesion", "OBSERVATION", 80, 86], ["rostral", "ANATOMY_MODIFIER", 101, 108], ["brainstem", "ANATOMY", 109, 118], ["ascending", "ANATOMY_MODIFIER", 123, 132], ["reticular", "ANATOMY_MODIFIER", 133, 142]]], ["A variety of organic central nervous system (CNS) diseases leading to metabolic or toxic encephalopathy can also produce coma.AssociAted signsDespite the fact that the comatose patient is unconscious, a complete neuroophthalmologic examination should be completed.", [["central nervous system", "ANATOMY", 21, 43], ["CNS", "ANATOMY", 45, 48], ["organic central nervous system (CNS) diseases", "DISEASE", 13, 58], ["encephalopathy", "DISEASE", 89, 103], ["coma", "DISEASE", 121, 125], ["comatose", "DISEASE", 168, 176], ["central nervous system", "ANATOMICAL_SYSTEM", 21, 43], ["CNS", "ANATOMICAL_SYSTEM", 45, 48], ["patient", "ORGANISM", 177, 184], ["patient", "SPECIES", 177, 184], ["organic central nervous system (CNS) diseases", "PROBLEM", 13, 58], ["toxic encephalopathy", "PROBLEM", 83, 103], ["coma", "PROBLEM", 121, 125], ["unconscious", "PROBLEM", 188, 199], ["a complete neuroophthalmologic examination", "TEST", 201, 243], ["variety", "OBSERVATION_MODIFIER", 2, 9], ["organic", "ANATOMY_MODIFIER", 13, 20], ["central", "ANATOMY_MODIFIER", 21, 28], ["nervous system", "ANATOMY", 29, 43], ["toxic encephalopathy", "OBSERVATION", 83, 103]]], ["Altered pupil size and pupillary light responses usually indicate brainstem disease.", [["pupil", "ANATOMY", 8, 13], ["brainstem", "ANATOMY", 66, 75], ["brainstem disease", "DISEASE", 66, 83], ["pupil", "MULTI-TISSUE_STRUCTURE", 8, 13], ["brainstem disease", "CANCER", 66, 83], ["Altered pupil size", "PROBLEM", 0, 18], ["pupillary light responses", "TEST", 23, 48], ["brainstem disease", "PROBLEM", 66, 83], ["pupil", "OBSERVATION_MODIFIER", 8, 13], ["size", "OBSERVATION_MODIFIER", 14, 18], ["pupillary light", "OBSERVATION", 23, 38], ["brainstem", "ANATOMY", 66, 75], ["disease", "OBSERVATION", 76, 83]]], ["Emergency cardiac assessment of the unconscious patient justifies an electrocardiogram (ECG) and thoracic radiographs.", [["cardiac", "ANATOMY", 10, 17], ["thoracic", "ANATOMY", 97, 105], ["cardiac", "ORGAN", 10, 17], ["patient", "ORGANISM", 48, 55], ["patient", "SPECIES", 48, 55], ["Emergency cardiac assessment", "TEST", 0, 28], ["an electrocardiogram", "TEST", 66, 86], ["ECG", "TEST", 88, 91], ["thoracic radiographs", "TEST", 97, 117], ["thoracic", "ANATOMY", 97, 105]]], ["Laboratory assessment of the comatose patient includes hepatic enzymes and, when feasible, hepatic function, electrolytes, and glucose level.", [["hepatic", "ANATOMY", 55, 62], ["hepatic", "ANATOMY", 91, 98], ["comatose", "DISEASE", 29, 37], ["glucose", "CHEMICAL", 127, 134], ["glucose", "CHEMICAL", 127, 134], ["patient", "ORGANISM", 38, 45], ["hepatic", "ORGAN", 55, 62], ["hepatic", "MULTI-TISSUE_STRUCTURE", 91, 98], ["glucose", "SIMPLE_CHEMICAL", 127, 134], ["hepatic enzymes", "PROTEIN", 55, 70], ["patient", "SPECIES", 38, 45], ["Laboratory assessment", "TEST", 0, 21], ["hepatic enzymes", "TEST", 55, 70], ["hepatic function", "TEST", 91, 107], ["electrolytes", "TEST", 109, 121], ["glucose level", "TEST", 127, 140], ["hepatic", "ANATOMY", 55, 62], ["hepatic", "ANATOMY", 91, 98]]], ["Critical: Assessment of vital signs to evaluate airway, breathing, and circulation (pulse, heartbeat, and ECG).", [["airway", "ANATOMY", 48, 54], ["airway", "MULTI-TISSUE_STRUCTURE", 48, 54], ["vital signs", "TEST", 24, 35], ["airway", "TEST", 48, 54], ["breathing", "TEST", 56, 65], ["pulse", "TEST", 84, 89], ["heartbeat", "TEST", 91, 100], ["ECG", "TEST", 106, 109], ["airway", "ANATOMY", 48, 54]]], ["Take thoracic radiographs if indicated.", [["thoracic", "ANATOMY", 5, 13], ["thoracic radiographs", "TEST", 5, 25], ["thoracic", "ANATOMY", 5, 13]]], ["If cerebral edema is suspected, administer ventilation support, intravenous hyperosmotic agents (e.g., mannitol 20%, 1 to 2 g/kg of body weight q6h), and glucocorticoids.", [["cerebral", "ANATOMY", 3, 11], ["intravenous", "ANATOMY", 64, 75], ["body", "ANATOMY", 132, 136], ["cerebral edema", "DISEASE", 3, 17], ["mannitol", "CHEMICAL", 103, 111], ["glucocorticoids", "CHEMICAL", 154, 169], ["mannitol", "CHEMICAL", 103, 111], ["cerebral edema", "PATHOLOGICAL_FORMATION", 3, 17], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 64, 75], ["mannitol", "SIMPLE_CHEMICAL", 103, 111], ["body", "ORGANISM_SUBDIVISION", 132, 136], ["glucocorticoids", "SIMPLE_CHEMICAL", 154, 169], ["cerebral edema", "PROBLEM", 3, 17], ["ventilation support", "TREATMENT", 43, 62], ["intravenous hyperosmotic agents", "TREATMENT", 64, 95], ["mannitol", "TREATMENT", 103, 111], ["glucocorticoids", "TREATMENT", 154, 169], ["cerebral", "ANATOMY", 3, 11], ["edema", "OBSERVATION", 12, 17]]], ["Conduct careful neurologic examination directed toward evaluation of brainstem function, including motor function, pupillary light responses (or lack thereof), and eye movement.", [["neurologic", "ANATOMY", 16, 26], ["brainstem", "ANATOMY", 69, 78], ["eye", "ANATOMY", 164, 167], ["brainstem", "ANATOMICAL_SYSTEM", 69, 78], ["eye", "ORGAN", 164, 167], ["careful neurologic examination", "TEST", 8, 38], ["evaluation of brainstem function", "TEST", 55, 87], ["motor function", "TEST", 99, 113], ["pupillary light responses", "TEST", 115, 140], ["eye", "ANATOMY", 164, 167]]], ["Comprehensive laboratory profile, to include hematology, biochemical profile, and urinalysis.", [["biochemical profile", "TEST", 57, 76], ["urinalysis", "TEST", 82, 92]]], ["Special diagnostic tests as appropriate:AssociAted signsa.", [["Special diagnostic tests", "TEST", 0, 24]]], ["Metabolic coma: Serum ammonia, bile acids, glucose, blood and urine lead levels b.", [["Serum", "ANATOMY", 16, 21], ["blood", "ANATOMY", 52, 57], ["urine", "ANATOMY", 62, 67], ["coma", "DISEASE", 10, 14], ["ammonia", "CHEMICAL", 22, 29], ["bile acids", "CHEMICAL", 31, 41], ["glucose", "CHEMICAL", 43, 50], ["ammonia", "CHEMICAL", 22, 29], ["bile acids", "CHEMICAL", 31, 41], ["glucose", "CHEMICAL", 43, 50], ["Serum", "ORGANISM_SUBSTANCE", 16, 21], ["ammonia", "SIMPLE_CHEMICAL", 22, 29], ["bile acids", "SIMPLE_CHEMICAL", 31, 41], ["glucose", "SIMPLE_CHEMICAL", 43, 50], ["blood", "ORGANISM_SUBSTANCE", 52, 57], ["urine", "ORGANISM_SUBSTANCE", 62, 67], ["Metabolic coma", "PROBLEM", 0, 14], ["Serum ammonia", "TEST", 16, 29], ["bile acids", "TEST", 31, 41], ["glucose", "TEST", 43, 50], ["blood", "TEST", 52, 57], ["urine lead levels", "TEST", 62, 79], ["coma", "OBSERVATION", 10, 14], ["bile", "ANATOMY", 31, 35]]], ["Neurologic coma: Skull radiographs, cerebral spinal fluid analysis, electroencephalography c.", [["cerebral spinal fluid", "ANATOMY", 36, 57], ["Neurologic coma", "DISEASE", 0, 15], ["Neurologic coma", "TEST", 0, 15], ["Skull radiographs", "TEST", 17, 34], ["cerebral spinal fluid analysis", "TEST", 36, 66], ["electroencephalography c.", "TEST", 68, 93], ["Skull", "ANATOMY", 17, 22], ["cerebral spinal", "ANATOMY", 36, 51]]], ["Assessment of response to intravenous mannitol.constiPAtion (obstiPAtion)See also Straining to Defecate: Dyschezia.constiPAtion (obstiPAtion)definition Constipation is the infrequent or difficult passage of feces.", [["intravenous", "ANATOMY", 26, 37], ["feces", "ANATOMY", 207, 212], ["mannitol", "CHEMICAL", 38, 46], ["Constipation", "DISEASE", 152, 164], ["mannitol", "CHEMICAL", 38, 46], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 26, 37], ["mannitol", "SIMPLE_CHEMICAL", 38, 46], ["feces", "ORGANISM_SUBSTANCE", 207, 212], ["intravenous mannitol", "TREATMENT", 26, 46], ["constiPAtion (obstiPAtion", "PROBLEM", 47, 72], ["constiPAtion (obstiPAtion)definition", "PROBLEM", 115, 151], ["Constipation", "PROBLEM", 152, 164], ["difficult passage of feces", "PROBLEM", 186, 212]]], ["Obstipation is intractable constipation resulting in fecal impaction through the rectum and possibly the colon.", [["fecal", "ANATOMY", 53, 58], ["rectum", "ANATOMY", 81, 87], ["colon", "ANATOMY", 105, 110], ["Obstipation", "DISEASE", 0, 11], ["constipation", "DISEASE", 27, 39], ["fecal impaction through the rectum and possibly the colon", "DISEASE", 53, 110], ["fecal", "ORGANISM_SUBDIVISION", 53, 58], ["rectum", "ORGAN", 81, 87], ["colon", "ORGAN", 105, 110], ["Obstipation", "PROBLEM", 0, 11], ["intractable constipation", "PROBLEM", 15, 39], ["fecal impaction through the rectum and possibly the colon", "PROBLEM", 53, 110], ["intractable", "OBSERVATION_MODIFIER", 15, 26], ["constipation", "OBSERVATION", 27, 39], ["fecal impaction", "OBSERVATION", 53, 68], ["rectum", "ANATOMY", 81, 87], ["colon", "ANATOMY", 105, 110]]], ["The act of straining to defecate or painful defecation, the likely manifestation of constipation or obstipation, typically represents the reason for which a constipated dog or cat is presented (see also Straining to Defecate: Dyschezia).constiPAtion (obstiPAtion)There is no strict definition of bowel regularity; therefore there is no \"normal\" number of daily or weekly bowel movements, deviations from which constitutes constipation.", [["bowel", "ANATOMY", 296, 301], ["bowel", "ANATOMY", 371, 376], ["painful defecation", "DISEASE", 36, 54], ["constipation", "DISEASE", 84, 96], ["obstipation", "DISEASE", 100, 111], ["bowel movements", "DISEASE", 371, 386], ["constipation", "DISEASE", 422, 434], ["dog", "ORGANISM", 169, 172], ["cat", "ORGANISM", 176, 179], ["bowel", "ORGAN", 296, 301], ["bowel", "ORGAN", 371, 376], ["dog", "SPECIES", 169, 172], ["straining to defecate", "PROBLEM", 11, 32], ["painful defecation", "PROBLEM", 36, 54], ["constipation", "PROBLEM", 84, 96], ["obstipation", "PROBLEM", 100, 111], ["a constipated dog", "PROBLEM", 155, 172], ["constiPAtion (obstiPAtion", "PROBLEM", 237, 262], ["bowel regularity", "PROBLEM", 296, 312], ["constipation", "PROBLEM", 422, 434], ["likely manifestation of", "UNCERTAINTY", 60, 83], ["constipation", "OBSERVATION", 84, 96], ["obstipation", "OBSERVATION", 100, 111], ["no", "UNCERTAINTY", 272, 274], ["strict definition", "OBSERVATION_MODIFIER", 275, 292], ["bowel", "ANATOMY", 296, 301], ["regularity", "OBSERVATION", 302, 312], ["no", "UNCERTAINTY", 333, 335], ["bowel", "ANATOMY", 371, 376], ["movements", "OBSERVATION", 377, 386]]], ["Practically, constipation can be considered to exist when a significant delay in frequency of passing formed stools has been noted or when the stool is observed to be of unusually hard or dry consistency.", [["constipation", "DISEASE", 13, 25], ["stools", "ORGANISM_SUBSTANCE", 109, 115], ["stool", "ORGANISM_SUBSTANCE", 143, 148], ["constipation", "PROBLEM", 13, 25], ["a significant delay", "PROBLEM", 58, 77], ["passing formed stools", "PROBLEM", 94, 115], ["unusually hard or dry consistency", "PROBLEM", 170, 203], ["constipation", "OBSERVATION", 13, 25], ["significant", "OBSERVATION_MODIFIER", 60, 71], ["delay", "OBSERVATION_MODIFIER", 72, 77]]], ["Constipation is categorized under one of the following headings: neurogenic; mechanical (physical); muscular (smooth muscle); or iatrogenic (drug-induced).constiPAtion (obstiPAtion)The owner who perceives a pet as straining to defecate may, in fact, be observing a pet that is straining to urinate.", [["muscular", "ANATOMY", 100, 108], ["smooth muscle", "ANATOMY", 110, 123], ["Constipation", "DISEASE", 0, 12], ["muscular", "TISSUE", 100, 108], ["smooth muscle", "TISSUE", 110, 123], ["Constipation", "PROBLEM", 0, 12], ["neurogenic", "PROBLEM", 65, 75], ["mechanical (physical)", "PROBLEM", 77, 98], ["muscular (smooth muscle)", "PROBLEM", 100, 124], ["iatrogenic (drug-induced)", "PROBLEM", 129, 154], ["constiPAtion", "PROBLEM", 155, 167], ["straining to urinate", "PROBLEM", 277, 297], ["neurogenic", "OBSERVATION", 65, 75], ["muscular", "ANATOMY", 100, 108], ["smooth muscle", "ANATOMY", 110, 123]]], ["This is particularly true in cats with disorders of the lower urinary tract, such as feline urologic syndrome (FUS).", [["lower urinary tract", "ANATOMY", 56, 75], ["disorders of the lower urinary tract", "DISEASE", 39, 75], ["feline urologic syndrome", "DISEASE", 85, 109], ["FUS", "DISEASE", 111, 114], ["cats", "ORGANISM", 29, 33], ["lower", "ORGANISM_SUBDIVISION", 56, 61], ["urinary tract", "ORGANISM_SUBDIVISION", 62, 75], ["feline", "ORGANISM", 85, 91], ["cats", "SPECIES", 29, 33], ["feline", "SPECIES", 85, 91], ["disorders of the lower urinary tract", "PROBLEM", 39, 75], ["feline urologic syndrome", "PROBLEM", 85, 109], ["true", "OBSERVATION_MODIFIER", 21, 25], ["cats", "OBSERVATION", 29, 33], ["lower", "ANATOMY_MODIFIER", 56, 61], ["urinary tract", "ANATOMY", 62, 75], ["urologic syndrome", "OBSERVATION", 92, 109]]], ["In the context of this discussion, dyschezia is discussed only insofar as it is associated with constipation and obstipation ( Figure 3 -2).AssociAted signsAssessment of the patient presented because of constipation or obstipation can represent a significant medical challenge because of the complex and varied pathogenic mechanisms involved.", [["dyschezia", "DISEASE", 35, 44], ["constipation", "DISEASE", 96, 108], ["obstipation", "DISEASE", 113, 124], ["constipation", "DISEASE", 203, 215], ["obstipation", "DISEASE", 219, 230], ["dyschezia", "CANCER", 35, 44], ["patient", "ORGANISM", 174, 181], ["patient", "SPECIES", 174, 181], ["constipation", "PROBLEM", 96, 108], ["obstipation", "PROBLEM", 113, 124], ["constipation", "PROBLEM", 203, 215], ["obstipation", "PROBLEM", 219, 230], ["a significant medical challenge", "PROBLEM", 245, 276], ["obstipation", "OBSERVATION", 113, 124]]], ["Animals with neurogenic causes of constipation may have significant perianal or rectal pain associated with focal lesions.", [["perianal", "ANATOMY", 68, 76], ["rectal", "ANATOMY", 80, 86], ["focal lesions", "ANATOMY", 108, 121], ["constipation", "DISEASE", 34, 46], ["perianal or rectal pain", "DISEASE", 68, 91], ["Animals", "ORGANISM", 0, 7], ["perianal", "PATHOLOGICAL_FORMATION", 68, 76], ["rectal", "ORGANISM_SUBDIVISION", 80, 86], ["focal lesions", "PATHOLOGICAL_FORMATION", 108, 121], ["neurogenic causes", "PROBLEM", 13, 30], ["constipation", "PROBLEM", 34, 46], ["significant perianal or rectal pain", "PROBLEM", 56, 91], ["focal lesions", "PROBLEM", 108, 121], ["neurogenic", "OBSERVATION", 13, 23], ["constipation", "OBSERVATION", 34, 46], ["significant", "OBSERVATION_MODIFIER", 56, 67], ["perianal", "ANATOMY", 68, 76], ["rectal", "ANATOMY", 80, 86], ["pain", "OBSERVATION", 87, 91], ["focal", "OBSERVATION_MODIFIER", 108, 113], ["lesions", "OBSERVATION", 114, 121]]], ["Other patients may have nonpainful neurologic disease or long-term complications stemming from previous pelvic or spinal trauma.AssociAted signsMechanical causes are either extraluminal or intraluminal.", [["neurologic", "ANATOMY", 35, 45], ["pelvic", "ANATOMY", 104, 110], ["spinal", "ANATOMY", 114, 120], ["extraluminal", "ANATOMY", 173, 185], ["intraluminal", "ANATOMY", 189, 201], ["neurologic disease", "DISEASE", 35, 53], ["pelvic or spinal trauma", "DISEASE", 104, 127], ["patients", "ORGANISM", 6, 14], ["pelvic", "ORGANISM_SUBDIVISION", 104, 110], ["patients", "SPECIES", 6, 14], ["nonpainful neurologic disease", "PROBLEM", 24, 53], ["long-term complications stemming", "PROBLEM", 57, 89], ["previous pelvic or spinal trauma", "PROBLEM", 95, 127], ["AssociAted signsMechanical causes", "PROBLEM", 128, 161], ["long-term", "OBSERVATION_MODIFIER", 57, 66], ["pelvic", "ANATOMY", 104, 110], ["spinal", "ANATOMY", 114, 120], ["trauma", "OBSERVATION", 121, 127], ["extraluminal", "OBSERVATION_MODIFIER", 173, 185], ["intraluminal", "OBSERVATION_MODIFIER", 189, 201]]], ["Abdominal and rectal palpation is indicated in both male and female dogs and cats.", [["Abdominal", "ANATOMY", 0, 9], ["rectal", "ANATOMY", 14, 20], ["Abdominal", "MULTI-TISSUE_STRUCTURE", 0, 9], ["rectal", "ORGAN", 14, 20], ["dogs", "ORGANISM", 68, 72], ["cats", "ORGANISM", 77, 81], ["dogs", "SPECIES", 68, 72], ["cats", "SPECIES", 77, 81], ["Abdominal and rectal palpation", "TEST", 0, 30], ["rectal", "ANATOMY", 14, 20], ["palpation", "OBSERVATION", 21, 30]]], ["Narrow or blood-tinged feces may signal the presence of an intraluminal lesion, whereas in patients with extraluminal lesions, associated clinical signs may not be present.AssociAted signsMuscular causes are the least common and are generally the result of extreme metabolic aberrations.", [["blood", "ANATOMY", 10, 15], ["feces", "ANATOMY", 23, 28], ["intraluminal lesion", "ANATOMY", 59, 78], ["extraluminal lesions", "ANATOMY", 105, 125], ["blood", "ORGANISM_SUBSTANCE", 10, 15], ["feces", "ORGANISM_SUBSTANCE", 23, 28], ["intraluminal lesion", "PATHOLOGICAL_FORMATION", 59, 78], ["patients", "ORGANISM", 91, 99], ["extraluminal lesions", "PATHOLOGICAL_FORMATION", 105, 125], ["patients", "SPECIES", 91, 99], ["Narrow or blood-tinged feces", "PROBLEM", 0, 28], ["an intraluminal lesion", "PROBLEM", 56, 78], ["extraluminal lesions", "PROBLEM", 105, 125], ["associated clinical signs", "PROBLEM", 127, 152], ["AssociAted signsMuscular causes", "PROBLEM", 172, 203], ["extreme metabolic aberrations", "PROBLEM", 257, 286], ["blood", "ANATOMY", 10, 15], ["tinged feces", "OBSERVATION", 16, 28], ["intraluminal", "OBSERVATION_MODIFIER", 59, 71], ["lesion", "OBSERVATION", 72, 78], ["extraluminal", "OBSERVATION_MODIFIER", 105, 117], ["lesions", "OBSERVATION", 118, 125], ["may not be", "UNCERTAINTY", 153, 163], ["signsMuscular", "OBSERVATION_MODIFIER", 183, 196], ["causes", "OBSERVATION", 197, 203], ["extreme", "OBSERVATION_MODIFIER", 257, 264], ["metabolic aberrations", "OBSERVATION", 265, 286]]], ["Idiopathic colonic atony is reported, but constipation may also result from severe catabolic states.", [["colonic", "ANATOMY", 11, 18], ["Idiopathic colonic atony", "DISEASE", 0, 24], ["constipation", "DISEASE", 42, 54], ["colonic", "ORGAN", 11, 18], ["Idiopathic colonic atony", "PROBLEM", 0, 24], ["constipation", "PROBLEM", 42, 54], ["severe catabolic states", "PROBLEM", 76, 99], ["colonic", "ANATOMY", 11, 18], ["atony", "OBSERVATION", 19, 24], ["severe", "OBSERVATION_MODIFIER", 76, 82], ["catabolic states", "OBSERVATION", 83, 99]]], ["Laboratory evidence of endocrine disease and electrolyte abnormalities should be assessed.cough definitionA cough is a sudden, forceful expiratory response to irritating stimuli (e.g., secretions) situated in the tracheobronchial tree.", [["endocrine", "ANATOMY", 23, 32], ["secretions", "ANATOMY", 185, 195], ["tracheobronchial tree", "ANATOMY", 213, 234], ["endocrine disease", "DISEASE", 23, 40], ["electrolyte abnormalities", "DISEASE", 45, 70], ["cough", "DISEASE", 90, 95], ["cough", "DISEASE", 108, 113], ["endocrine", "ANATOMICAL_SYSTEM", 23, 32], ["tracheobronchial tree", "MULTI-TISSUE_STRUCTURE", 213, 234], ["endocrine disease", "PROBLEM", 23, 40], ["electrolyte abnormalities", "PROBLEM", 45, 70], ["cough definitionA cough", "PROBLEM", 90, 113], ["a sudden", "PROBLEM", 117, 125], ["forceful expiratory response", "PROBLEM", 127, 155], ["irritating stimuli", "TEST", 159, 177], ["secretions", "PROBLEM", 185, 195], ["evidence of", "UNCERTAINTY", 11, 22], ["endocrine disease", "OBSERVATION", 23, 40], ["electrolyte abnormalities", "OBSERVATION", 45, 70], ["tracheobronchial", "ANATOMY", 213, 229], ["tree", "ANATOMY_MODIFIER", 230, 234]]], ["Cough is the most frequent clinical presentation (followed by dyspnea and hemoptysis) that is referrable to the lower respiratory tract.", [["lower respiratory tract", "ANATOMY", 112, 135], ["Cough", "DISEASE", 0, 5], ["dyspnea", "DISEASE", 62, 69], ["hemoptysis", "DISEASE", 74, 84], ["lower", "ORGANISM_SUBDIVISION", 112, 117], ["respiratory tract", "ORGANISM_SUBDIVISION", 118, 135], ["Cough", "PROBLEM", 0, 5], ["dyspnea", "PROBLEM", 62, 69], ["hemoptysis", "PROBLEM", 74, 84], ["hemoptysis", "OBSERVATION", 74, 84], ["lower", "ANATOMY_MODIFIER", 112, 117], ["respiratory tract", "ANATOMY", 118, 135]]], ["At presentation, cough should be characterized as \"acute-onset\" (duration of only a few days) or \"chronic\" (duration longer than 2 weeks).", [["cough", "DISEASE", 17, 22], ["cough", "PROBLEM", 17, 22], ["cough", "OBSERVATION", 17, 22], ["acute", "OBSERVATION_MODIFIER", 51, 56], ["chronic", "OBSERVATION_MODIFIER", 98, 105]]], ["Attempting to characterize cough as productive or nonproductive is difficult in animals and therefore has little value in the overall diagnostic plan.AssociAted signsAlthough cough is a principal sign of lower respiratory tract disease, particularly lower airway (tracheal and bronchial) disease, it may also occur in animals with nonpulmonary disease, particularly cardiac and intrathoracic diseases.", [["lower respiratory tract", "ANATOMY", 204, 227], ["lower airway", "ANATOMY", 250, 262], ["tracheal", "ANATOMY", 264, 272], ["bronchial", "ANATOMY", 277, 286], ["nonpulmonary", "ANATOMY", 331, 343], ["cardiac", "ANATOMY", 366, 373], ["intrathoracic", "ANATOMY", 378, 391], ["cough", "DISEASE", 27, 32], ["cough", "DISEASE", 175, 180], ["lower respiratory tract disease", "DISEASE", 204, 235], ["lower airway (tracheal and bronchial) disease", "DISEASE", 250, 295], ["nonpulmonary disease", "DISEASE", 331, 351], ["cardiac and intrathoracic diseases", "DISEASE", 366, 400], ["lower", "ORGANISM_SUBDIVISION", 204, 209], ["respiratory tract", "ORGANISM_SUBDIVISION", 210, 227], ["lower airway", "ORGANISM_SUBDIVISION", 250, 262], ["tracheal", "MULTI-TISSUE_STRUCTURE", 264, 272], ["bronchial", "MULTI-TISSUE_STRUCTURE", 277, 286], ["cardiac", "ORGAN", 366, 373], ["intrathoracic", "ORGAN", 378, 391], ["cough", "PROBLEM", 27, 32], ["AssociAted signsAlthough cough", "PROBLEM", 150, 180], ["lower respiratory tract disease", "PROBLEM", 204, 235], ["lower airway (tracheal and bronchial) disease", "PROBLEM", 250, 295], ["nonpulmonary disease", "PROBLEM", 331, 351], ["cardiac and intrathoracic diseases", "PROBLEM", 366, 400], ["cough", "OBSERVATION", 27, 32], ["cough", "OBSERVATION", 175, 180], ["lower", "ANATOMY_MODIFIER", 204, 209], ["respiratory tract", "ANATOMY", 210, 227], ["disease", "OBSERVATION", 228, 235], ["lower", "ANATOMY_MODIFIER", 250, 255], ["airway", "ANATOMY", 256, 262], ["tracheal", "ANATOMY", 264, 272], ["bronchial", "ANATOMY", 277, 286], ["disease", "OBSERVATION", 288, 295], ["may also occur", "UNCERTAINTY", 300, 314], ["nonpulmonary", "ANATOMY", 331, 343], ["disease", "OBSERVATION", 344, 351], ["cardiac", "ANATOMY", 366, 373], ["intrathoracic", "ANATOMY", 378, 391], ["diseases", "OBSERVATION", 392, 400]]], ["Associated signs, therefore, may include a wide spectrum of findings; there may also be no associated signs.", [["Associated signs", "PROBLEM", 0, 16], ["associated signs", "PROBLEM", 91, 107], ["may also be no", "UNCERTAINTY", 76, 90], ["signs", "OBSERVATION", 102, 107]]], ["Particular attention should be given to determining the character of the cough: it can be paroxysmal and severe, which usually indicates the need for immediate intervention, or mild but persistent.", [["cough", "DISEASE", 73, 78], ["paroxysmal", "DISEASE", 90, 100], ["the cough", "PROBLEM", 69, 78], ["paroxysmal", "PROBLEM", 90, 100], ["immediate intervention", "TREATMENT", 150, 172], ["cough", "OBSERVATION", 73, 78], ["severe", "OBSERVATION_MODIFIER", 105, 111], ["mild", "OBSERVATION_MODIFIER", 177, 181], ["persistent", "OBSERVATION_MODIFIER", 186, 196]]], ["Animals in need of immediate attention are those with cough associated with syncope, dyspnea, or hemoptysis.", [["cough", "DISEASE", 54, 59], ["syncope", "DISEASE", 76, 83], ["dyspnea", "DISEASE", 85, 92], ["hemoptysis", "DISEASE", 97, 107], ["Animals", "ORGANISM", 0, 7], ["cough", "PROBLEM", 54, 59], ["syncope", "PROBLEM", 76, 83], ["dyspnea", "PROBLEM", 85, 92], ["hemoptysis", "PROBLEM", 97, 107], ["hemoptysis", "OBSERVATION", 97, 107]]], ["Orthopnea, the inability to breathe without assuming a particular (usually upright) position, is a serious sign that suggests compromised respiratory function and also warrants immediate attention.", [["respiratory", "ANATOMY", 138, 149], ["Orthopnea", "DISEASE", 0, 9], ["Orthopnea", "PROBLEM", 0, 9], ["the inability to breathe", "PROBLEM", 11, 35], ["compromised respiratory function", "PROBLEM", 126, 158], ["compromised", "OBSERVATION_MODIFIER", 126, 137], ["respiratory function", "OBSERVATION", 138, 158]]], ["Nasal discharge, tachypnea, and hyperpnea are less commonly associated with cough.", [["Nasal", "ANATOMY", 0, 5], ["tachypnea", "DISEASE", 17, 26], ["hyperpnea", "DISEASE", 32, 41], ["cough", "DISEASE", 76, 81], ["Nasal", "MULTI-TISSUE_STRUCTURE", 0, 5], ["Nasal discharge", "PROBLEM", 0, 15], ["tachypnea", "PROBLEM", 17, 26], ["hyperpnea", "PROBLEM", 32, 41], ["cough", "PROBLEM", 76, 81], ["tachypnea", "OBSERVATION", 17, 26], ["hyperpnea", "OBSERVATION", 32, 41], ["less", "OBSERVATION_MODIFIER", 46, 50], ["cough", "OBSERVATION", 76, 81]]], ["Cough can be misinterpreted by the owner as vomiting, particularly in dogs with infectious airway disease.definitionHemoptysis is the expectoration, during cough, of blood.", [["airway", "ANATOMY", 91, 97], ["blood", "ANATOMY", 166, 171], ["Cough", "DISEASE", 0, 5], ["vomiting", "DISEASE", 44, 52], ["infectious airway disease", "DISEASE", 80, 105], ["Hemoptysis", "DISEASE", 116, 126], ["cough", "DISEASE", 156, 161], ["dogs", "ORGANISM", 70, 74], ["airway", "ORGAN", 91, 97], ["blood", "ORGANISM_SUBSTANCE", 166, 171], ["dogs", "SPECIES", 70, 74], ["Cough", "PROBLEM", 0, 5], ["vomiting", "PROBLEM", 44, 52], ["infectious airway disease", "PROBLEM", 80, 105], ["Hemoptysis", "PROBLEM", 116, 126], ["the expectoration", "PROBLEM", 130, 147], ["cough", "PROBLEM", 156, 161], ["blood", "PROBLEM", 166, 171], ["infectious airway disease", "OBSERVATION", 80, 105], ["Hemoptysis", "OBSERVATION", 116, 126], ["expectoration", "OBSERVATION", 134, 147]]], ["Seldom is the volume of blood loss sufficient to cause anemia; however, once confirmed, hemoptysis is a severe clinical finding indicative of bleeding into or from the lower airways.", [["blood", "ANATOMY", 24, 29], ["lower airways", "ANATOMY", 168, 181], ["blood loss", "DISEASE", 24, 34], ["anemia", "DISEASE", 55, 61], ["hemoptysis", "DISEASE", 88, 98], ["bleeding", "DISEASE", 142, 150], ["blood", "ORGANISM_SUBSTANCE", 24, 29], ["lower airways", "ORGANISM_SUBDIVISION", 168, 181], ["blood loss", "PROBLEM", 24, 34], ["anemia", "PROBLEM", 55, 61], ["hemoptysis", "PROBLEM", 88, 98], ["a severe clinical finding", "PROBLEM", 102, 127], ["bleeding", "PROBLEM", 142, 150], ["volume", "OBSERVATION_MODIFIER", 14, 20], ["blood loss", "OBSERVATION", 24, 34], ["anemia", "OBSERVATION", 55, 61], ["hemoptysis", "OBSERVATION", 88, 98], ["severe", "OBSERVATION_MODIFIER", 104, 110], ["indicative of", "UNCERTAINTY", 128, 141], ["bleeding", "OBSERVATION", 142, 150], ["lower", "ANATOMY_MODIFIER", 168, 173], ["airways", "ANATOMY", 174, 181]]], ["Hemoptysis can be attributed to direct injury of the pulmonary or, less commonly, the tracheobronchial blood vessels; pulmonary hypertension; or coagulopathy.", [["pulmonary", "ANATOMY", 53, 62], ["tracheobronchial blood vessels", "ANATOMY", 86, 116], ["pulmonary", "ANATOMY", 118, 127], ["Hemoptysis", "DISEASE", 0, 10], ["pulmonary hypertension", "DISEASE", 118, 140], ["coagulopathy", "DISEASE", 145, 157], ["pulmonary", "ORGAN", 53, 62], ["tracheobronchial blood vessels", "MULTI-TISSUE_STRUCTURE", 86, 116], ["pulmonary", "ORGAN", 118, 127], ["Hemoptysis", "PROBLEM", 0, 10], ["direct injury of the pulmonary", "PROBLEM", 32, 62], ["the tracheobronchial blood vessels", "PROBLEM", 82, 116], ["pulmonary hypertension", "PROBLEM", 118, 140], ["coagulopathy", "PROBLEM", 145, 157], ["injury", "OBSERVATION", 39, 45], ["pulmonary", "ANATOMY", 53, 62], ["tracheobronchial", "ANATOMY", 86, 102], ["blood vessels", "ANATOMY", 103, 116], ["pulmonary", "ANATOMY", 118, 127], ["hypertension", "OBSERVATION", 128, 140], ["coagulopathy", "OBSERVATION", 145, 157]]], ["Although an uncommon presenting sign, hemoptysis is more prevalent in dogs than in cats.", [["hemoptysis", "DISEASE", 38, 48], ["dogs", "ORGANISM", 70, 74], ["cats", "ORGANISM", 83, 87], ["dogs", "SPECIES", 70, 74], ["cats", "SPECIES", 83, 87], ["hemoptysis", "PROBLEM", 38, 48], ["hemoptysis", "OBSERVATION", 38, 48]]], ["Because vomiting can be mistaken by the owner for coughing, it becomes essential to differentiate between hemoptysis and hematemesis during the initial examination.", [["vomiting", "DISEASE", 8, 16], ["coughing", "DISEASE", 50, 58], ["hemoptysis", "DISEASE", 106, 116], ["hematemesis", "DISEASE", 121, 132], ["vomiting", "PROBLEM", 8, 16], ["coughing", "PROBLEM", 50, 58], ["hemoptysis", "PROBLEM", 106, 116], ["hematemesis", "PROBLEM", 121, 132], ["the initial examination", "TEST", 140, 163], ["hemoptysis", "OBSERVATION", 106, 116], ["hematemesis", "OBSERVATION", 121, 132]]], ["Hemoptysis is regarded as an emergency presentation.AssociAted signsThe most common, and least significant, sign associated with hemoptysis is melena, or dark-red or black discoloration of stool that occurs subsequent to swallowing expectorated blood.", [["stool", "ANATOMY", 189, 194], ["blood", "ANATOMY", 245, 250], ["Hemoptysis", "DISEASE", 0, 10], ["hemoptysis", "DISEASE", 129, 139], ["melena", "DISEASE", 143, 149], ["melena", "PATHOLOGICAL_FORMATION", 143, 149], ["stool", "ORGANISM_SUBSTANCE", 189, 194], ["blood", "ORGANISM_SUBSTANCE", 245, 250], ["Hemoptysis", "PROBLEM", 0, 10], ["AssociAted signs", "PROBLEM", 52, 68], ["hemoptysis", "PROBLEM", 129, 139], ["melena", "PROBLEM", 143, 149], ["dark-red or black discoloration of stool", "PROBLEM", 154, 194], ["swallowing expectorated blood", "PROBLEM", 221, 250], ["most common", "OBSERVATION_MODIFIER", 72, 83], ["significant", "OBSERVATION_MODIFIER", 95, 106], ["hemoptysis", "OBSERVATION", 129, 139], ["melena", "OBSERVATION", 143, 149], ["black", "OBSERVATION_MODIFIER", 166, 171], ["discoloration", "OBSERVATION_MODIFIER", 172, 185], ["stool", "OBSERVATION", 189, 194]]], ["More serious associated signs include coughing, hyperpnea, orthopnea, and cyanosis.", [["coughing", "DISEASE", 38, 46], ["hyperpnea", "DISEASE", 48, 57], ["orthopnea", "DISEASE", 59, 68], ["cyanosis", "DISEASE", 74, 82], ["coughing", "PROBLEM", 38, 46], ["hyperpnea", "PROBLEM", 48, 57], ["orthopnea", "PROBLEM", 59, 68], ["cyanosis", "PROBLEM", 74, 82], ["coughing", "OBSERVATION", 38, 46], ["orthopnea", "OBSERVATION", 59, 68], ["cyanosis", "OBSERVATION", 74, 82]]], ["Apparent episodic weakness and collapse may also be reported. differentiAl diAgnosis diAgnostic PlAns 1.", [["episodic weakness", "DISEASE", 9, 26], ["episodic weakness", "PROBLEM", 9, 26], ["collapse", "PROBLEM", 31, 39], ["episodic", "OBSERVATION_MODIFIER", 9, 17], ["weakness", "OBSERVATION", 18, 26], ["collapse", "OBSERVATION", 31, 39], ["may also be", "UNCERTAINTY", 40, 51]]], ["Thorough history and physical examination.", [["physical examination", "TEST", 21, 41]]], ["In addition, an attempt should be made to determine that the sign for which the patient was presented is, in fact, expectoration of blood during coughing and not bloody vomitus.", [["blood", "ANATOMY", 132, 137], ["patient", "ORGANISM", 80, 87], ["blood", "ORGANISM_SUBSTANCE", 132, 137], ["patient", "SPECIES", 80, 87], ["expectoration of blood", "PROBLEM", 115, 137], ["coughing", "PROBLEM", 145, 153], ["bloody vomitus", "PROBLEM", 162, 176]]], ["Routine laboratory profile, to assess the patient's overall health status.", [["patient", "ORGANISM", 42, 49], ["patient", "SPECIES", 42, 49], ["Routine laboratory profile", "TEST", 0, 26]]], ["Emphasis should be placed on the fecal examination and heartworm tests.", [["fecal", "ANATOMY", 33, 38], ["fecal", "ORGANISM_SUBDIVISION", 33, 38], ["the fecal examination", "TEST", 29, 50], ["heartworm tests", "TEST", 55, 70], ["fecal", "ANATOMY", 33, 38], ["heartworm", "ANATOMY", 55, 64]]], ["Multiple attempts to locate parasite ova in the stool should be made, because lung parasites may be few in number and ova shed intermittently.", [["ova", "ANATOMY", 37, 40], ["stool", "ANATOMY", 48, 53], ["lung", "ANATOMY", 78, 82], ["lung parasites", "DISEASE", 78, 92], ["stool", "ORGANISM_SUBSTANCE", 48, 53], ["lung", "ORGAN", 78, 82], ["parasite ova in the stool", "TREATMENT", 28, 53], ["lung parasites", "PROBLEM", 78, 92], ["parasite", "OBSERVATION_MODIFIER", 28, 36], ["ova", "OBSERVATION", 37, 40], ["stool", "OBSERVATION", 48, 53], ["lung", "ANATOMY", 78, 82], ["parasites", "OBSERVATION", 83, 92], ["few", "OBSERVATION_MODIFIER", 100, 103]]], ["Thoracic radiographs (especially for evidence of advanced heartworm disease in dogs).", [["heartworm disease", "DISEASE", 58, 75], ["heartworm", "ORGANISM_SUBDIVISION", 58, 67], ["dogs", "ORGANISM", 79, 83], ["dogs", "SPECIES", 79, 83], ["Thoracic radiographs", "TEST", 0, 20], ["advanced heartworm disease in dogs", "PROBLEM", 49, 83], ["advanced", "OBSERVATION_MODIFIER", 49, 57], ["heartworm", "OBSERVATION", 58, 67]]], ["Coagulation profile, particularly in those animals with significant bleeding from other sites.", [["bleeding", "DISEASE", 68, 76], ["Coagulation profile", "TEST", 0, 19], ["significant bleeding from other sites", "PROBLEM", 56, 93], ["significant", "OBSERVATION_MODIFIER", 56, 67], ["bleeding", "OBSERVATION", 68, 76]]], ["Transtracheal aspiration with cytologic studies or bacterial culture and sensitivity tests, or both.", [["Transtracheal aspiration", "TEST", 0, 24], ["cytologic studies", "TEST", 30, 47], ["bacterial culture", "TEST", 51, 68], ["sensitivity tests", "TEST", 73, 90], ["aspiration", "OBSERVATION", 14, 24]]], ["Special procedures, including ultrasonography of the lung, particularly when discrete masses are seen on radiographs; echocardiography; blood gas analysis; bronchoscopy; bronchography; and angiography.deAfness or heAring loss definitionDeafness is the detectable lack or loss (complete or partial) of the sense of hearing.", [["lung", "ANATOMY", 53, 57], ["masses", "ANATOMY", 86, 92], ["blood", "ANATOMY", 136, 141], ["Deafness", "DISEASE", 236, 244], ["lung", "ORGAN", 53, 57], ["masses", "CANCER", 86, 92], ["blood", "ORGANISM_SUBSTANCE", 136, 141], ["Special procedures", "TEST", 0, 18], ["ultrasonography of the lung", "TEST", 30, 57], ["discrete masses", "PROBLEM", 77, 92], ["radiographs", "TEST", 105, 116], ["echocardiography", "TEST", 118, 134], ["blood gas analysis", "TEST", 136, 154], ["bronchoscopy", "TEST", 156, 168], ["bronchography", "TEST", 170, 183], ["angiography", "TEST", 189, 200], ["Deafness", "PROBLEM", 236, 244], ["lung", "ANATOMY", 53, 57], ["masses", "OBSERVATION", 86, 92]]], ["Deafness can result from abnormalities at any one of several levels from the ear to the brain.", [["ear", "ANATOMY", 77, 80], ["brain", "ANATOMY", 88, 93], ["Deafness", "DISEASE", 0, 8], ["ear", "ORGAN", 77, 80], ["brain", "ORGAN", 88, 93], ["Deafness", "PROBLEM", 0, 8], ["abnormalities", "PROBLEM", 25, 38], ["ear", "ANATOMY", 77, 80], ["brain", "ANATOMY", 88, 93]]], ["Peripheral deafness is categorized as either conduction deafness, involving abnormalities of the transduction apparatus (external ear canal, tympanic membrane, auditory ossicles in the middle ear), or nerve deafness, involving the hearing receptors in the cochlea or the auditory branch of the eighth cranial nerve.", [["ear canal", "ANATOMY", 130, 139], ["tympanic membrane", "ANATOMY", 141, 158], ["ossicles", "ANATOMY", 169, 177], ["middle ear", "ANATOMY", 185, 195], ["nerve", "ANATOMY", 201, 206], ["cochlea", "ANATOMY", 256, 263], ["auditory branch", "ANATOMY", 271, 286], ["eighth cranial nerve", "ANATOMY", 294, 314], ["Peripheral deafness", "DISEASE", 0, 19], ["conduction deafness", "DISEASE", 45, 64], ["nerve deafness", "DISEASE", 201, 215], ["ear canal", "MULTI-TISSUE_STRUCTURE", 130, 139], ["tympanic membrane", "MULTI-TISSUE_STRUCTURE", 141, 158], ["auditory ossicles", "MULTI-TISSUE_STRUCTURE", 160, 177], ["ear", "ORGAN", 192, 195], ["nerve", "ORGAN", 201, 206], ["cochlea", "ORGAN", 256, 263], ["auditory branch", "MULTI-TISSUE_STRUCTURE", 271, 286], ["cranial nerve", "MULTI-TISSUE_STRUCTURE", 301, 314], ["hearing receptors", "PROTEIN", 231, 248], ["Peripheral deafness", "PROBLEM", 0, 19], ["conduction deafness", "PROBLEM", 45, 64], ["abnormalities of the transduction apparatus", "PROBLEM", 76, 119], ["tympanic membrane, auditory ossicles in the middle ear)", "PROBLEM", 141, 196], ["nerve deafness", "PROBLEM", 201, 215], ["the hearing receptors", "PROBLEM", 227, 248], ["deafness", "OBSERVATION", 11, 19], ["conduction deafness", "OBSERVATION", 45, 64], ["transduction apparatus", "OBSERVATION", 97, 119], ["external", "ANATOMY_MODIFIER", 121, 129], ["ear canal", "ANATOMY", 130, 139], ["tympanic membrane", "ANATOMY", 141, 158], ["auditory ossicles", "OBSERVATION", 160, 177], ["middle ear", "ANATOMY", 185, 195], ["nerve", "ANATOMY", 201, 206], ["deafness", "OBSERVATION", 207, 215], ["cochlea", "ANATOMY", 256, 263], ["auditory", "ANATOMY_MODIFIER", 271, 279], ["branch", "ANATOMY_MODIFIER", 280, 286], ["eighth cranial nerve", "ANATOMY", 294, 314]]], ["Congenital deafness is usually nerve deafness and is the result of abnormal development of the middle and/or inner ear.", [["nerve", "ANATOMY", 31, 36], ["middle", "ANATOMY", 95, 101], ["inner ear", "ANATOMY", 109, 118], ["Congenital deafness", "DISEASE", 0, 19], ["nerve deafness", "DISEASE", 31, 45], ["nerve", "MULTI-TISSUE_STRUCTURE", 31, 36], ["inner", "TISSUE", 109, 114], ["ear", "ORGAN", 115, 118], ["Congenital deafness", "PROBLEM", 0, 19], ["nerve deafness", "PROBLEM", 31, 45], ["abnormal development of the middle and/or inner ear", "PROBLEM", 67, 118], ["deafness", "OBSERVATION", 11, 19], ["nerve", "ANATOMY", 31, 36], ["deafness", "OBSERVATION", 37, 45], ["abnormal", "OBSERVATION_MODIFIER", 67, 75], ["middle", "ANATOMY_MODIFIER", 95, 101], ["inner", "ANATOMY_MODIFIER", 109, 114], ["ear", "ANATOMY", 115, 118]]], ["Central hearing loss (intracranial cause) is uncommon.", [["intracranial", "ANATOMY", 22, 34], ["hearing loss", "DISEASE", 8, 20], ["Central hearing loss (intracranial cause", "PROBLEM", 0, 40], ["hearing loss", "OBSERVATION", 8, 20]]], ["Loss of hearing, either complete or partial, in one or both ears does occur in both dogs and cats but is particularly difficult to confirm.", [["ears", "ANATOMY", 60, 64], ["Loss of hearing", "DISEASE", 0, 15], ["ears", "ORGAN", 60, 64], ["dogs", "ORGANISM", 84, 88], ["cats", "ORGANISM", 93, 97], ["dogs", "SPECIES", 84, 88], ["cats", "SPECIES", 93, 97], ["Loss of hearing", "PROBLEM", 0, 15], ["hearing", "OBSERVATION", 8, 15]]], ["Partial loss of hearing occurs most commonly in older animals and is noted by owners as decreased response to voice or noise (e.g., thunder).AssociAted signsAlthough rare, invasive lesions or panencephalitis could conceivably cause central hearing loss.", [["invasive lesions", "ANATOMY", 172, 188], ["loss of hearing", "DISEASE", 8, 23], ["panencephalitis", "DISEASE", 192, 207], ["hearing loss", "DISEASE", 240, 252], ["lesions", "CANCER", 181, 188], ["Partial loss of hearing", "PROBLEM", 0, 23], ["invasive lesions", "PROBLEM", 172, 188], ["panencephalitis", "PROBLEM", 192, 207], ["central hearing loss", "PROBLEM", 232, 252], ["loss", "OBSERVATION_MODIFIER", 8, 12], ["hearing", "OBSERVATION", 16, 23], ["rare", "OBSERVATION_MODIFIER", 166, 170], ["invasive", "OBSERVATION_MODIFIER", 172, 180], ["lesions", "OBSERVATION", 181, 188], ["panencephalitis", "OBSERVATION", 192, 207], ["hearing loss", "OBSERVATION", 240, 252]]], ["However, the associated neurologic signs would be extensive, and hearing loss becomes a secondary or insignificant clinical issue.AssociAted signsAnimals with peripheral hearing loss caused by acquired unilateral lesions (severe otitis externa) may manifest a variety of signs referable to the inner ear, particularly head tilt and, less often, circling.", [["neurologic", "ANATOMY", 24, 34], ["lesions", "ANATOMY", 213, 220], ["otitis externa", "ANATOMY", 229, 243], ["inner ear", "ANATOMY", 294, 303], ["head", "ANATOMY", 318, 322], ["hearing loss", "DISEASE", 65, 77], ["peripheral hearing loss", "DISEASE", 159, 182], ["otitis externa", "DISEASE", 229, 243], ["lesions", "PATHOLOGICAL_FORMATION", 213, 220], ["ear", "ORGAN", 300, 303], ["head", "ORGANISM_SUBDIVISION", 318, 322], ["the associated neurologic signs", "PROBLEM", 9, 40], ["hearing loss", "PROBLEM", 65, 77], ["insignificant clinical issue", "PROBLEM", 101, 129], ["AssociAted signsAnimals", "PROBLEM", 130, 153], ["peripheral hearing loss", "PROBLEM", 159, 182], ["acquired unilateral lesions", "PROBLEM", 193, 220], ["severe otitis externa", "PROBLEM", 222, 243], ["circling", "PROBLEM", 345, 353], ["extensive", "OBSERVATION_MODIFIER", 50, 59], ["insignificant", "OBSERVATION_MODIFIER", 101, 114], ["peripheral", "ANATOMY_MODIFIER", 159, 169], ["hearing loss", "OBSERVATION", 170, 182], ["unilateral", "OBSERVATION_MODIFIER", 202, 212], ["lesions", "OBSERVATION", 213, 220], ["severe", "OBSERVATION_MODIFIER", 222, 228], ["otitis", "OBSERVATION", 229, 235], ["inner", "ANATOMY_MODIFIER", 294, 299], ["ear", "ANATOMY", 300, 303], ["head", "ANATOMY", 318, 322]]], ["Pain or increased sensitivity may be associated with infectious lesions affecting hearing in either ear.", [["lesions", "ANATOMY", 64, 71], ["ear", "ANATOMY", 100, 103], ["Pain", "DISEASE", 0, 4], ["lesions", "PATHOLOGICAL_FORMATION", 64, 71], ["ear", "ORGAN", 100, 103], ["Pain", "PROBLEM", 0, 4], ["increased sensitivity", "PROBLEM", 8, 29], ["infectious lesions affecting hearing in either ear", "PROBLEM", 53, 103], ["may be associated with", "UNCERTAINTY", 30, 52], ["infectious", "OBSERVATION_MODIFIER", 53, 63], ["lesions", "OBSERVATION", 64, 71], ["ear", "ANATOMY", 100, 103]]], ["Physical evidence of otitis externa is readily detected during routine examinations.", [["otitis externa", "ANATOMY", 21, 35], ["otitis externa", "DISEASE", 21, 35], ["otitis externa", "PROBLEM", 21, 35], ["routine examinations", "TEST", 63, 83], ["otitis", "OBSERVATION", 21, 27]]], ["Severe swelling associated with a chronic inflammation, a ruptured or damaged tympanic membrane, and infections of the middle ear may effectively decrease hearing acuity.", [["tympanic membrane", "ANATOMY", 78, 95], ["middle ear", "ANATOMY", 119, 129], ["swelling", "DISEASE", 7, 15], ["inflammation", "DISEASE", 42, 54], ["infections", "DISEASE", 101, 111], ["tympanic membrane", "MULTI-TISSUE_STRUCTURE", 78, 95], ["ear", "ORGAN", 126, 129], ["Severe swelling", "PROBLEM", 0, 15], ["a chronic inflammation", "PROBLEM", 32, 54], ["a ruptured or damaged tympanic membrane", "PROBLEM", 56, 95], ["infections of the middle ear", "PROBLEM", 101, 129], ["decrease hearing acuity", "PROBLEM", 146, 169], ["swelling", "OBSERVATION", 7, 15], ["chronic", "OBSERVATION_MODIFIER", 34, 41], ["inflammation", "OBSERVATION", 42, 54], ["ruptured", "OBSERVATION", 58, 66], ["damaged", "OBSERVATION_MODIFIER", 70, 77], ["tympanic membrane", "ANATOMY", 78, 95], ["infections", "OBSERVATION", 101, 111], ["middle ear", "ANATOMY", 119, 129], ["decrease", "OBSERVATION_MODIFIER", 146, 154], ["hearing acuity", "OBSERVATION", 155, 169]]], ["Hypothyroidism may also be associated with degeneration of the cochlea and subsequent decrease in hearing acuity.", [["cochlea", "ANATOMY", 63, 70], ["Hypothyroidism", "DISEASE", 0, 14], ["degeneration of the cochlea", "DISEASE", 43, 70], ["cochlea", "ORGAN", 63, 70], ["Hypothyroidism", "PROBLEM", 0, 14], ["degeneration of the cochlea", "PROBLEM", 43, 70], ["subsequent decrease in hearing acuity", "PROBLEM", 75, 112], ["may also be associated with", "UNCERTAINTY", 15, 42], ["degeneration", "OBSERVATION", 43, 55], ["cochlea", "ANATOMY", 63, 70], ["decrease", "OBSERVATION_MODIFIER", 86, 94], ["hearing acuity", "OBSERVATION", 98, 112]]], ["The clinical history is important and should include any prior exposure to drugs known to be toxic to the cochlear nerve and organ of Corti (e.g., aminoglycoside therapy).AssociAted signsCongenital (hereditary) deafness is associated with a white or merle hair coat in both dogs and cats.", [["cochlear nerve", "ANATOMY", 106, 120], ["organ", "ANATOMY", 125, 130], ["Corti", "ANATOMY", 134, 139], ["hair", "ANATOMY", 256, 260], ["aminoglycoside", "CHEMICAL", 147, 161], ["hereditary) deafness", "DISEASE", 199, 219], ["aminoglycoside", "CHEMICAL", 147, 161], ["cochlear nerve", "MULTI-TISSUE_STRUCTURE", 106, 120], ["organ", "ORGAN", 125, 130], ["Corti", "ORGAN", 134, 139], ["aminoglycoside", "SIMPLE_CHEMICAL", 147, 161], ["dogs", "ORGANISM", 274, 278], ["cats", "ORGANISM", 283, 287], ["dogs", "SPECIES", 274, 278], ["cats", "SPECIES", 283, 287], ["drugs", "TREATMENT", 75, 80], ["Corti (e.g., aminoglycoside therapy", "TREATMENT", 134, 169], ["AssociAted signsCongenital (hereditary) deafness", "PROBLEM", 171, 219], ["a white or merle hair coat in both dogs and cats", "PROBLEM", 239, 287], ["cochlear nerve", "ANATOMY", 106, 120], ["organ", "ANATOMY", 125, 130], ["Corti", "ANATOMY", 134, 139], ["hereditary", "OBSERVATION_MODIFIER", 199, 209], ["deafness", "OBSERVATION", 211, 219]]], ["In dogs, the highest incidence occurs in the Dalmatian.", [["dogs", "ORGANISM", 3, 7], ["dogs", "SPECIES", 3, 7], ["highest", "OBSERVATION_MODIFIER", 13, 20]]], ["However, several breeds are reported to be affected.decreAsed urine Production: oliguriA And AnuriA definitionOliguria is a reduced amount of urine production and output in relation to fluid intake.", [["urine", "ANATOMY", 62, 67], ["urine", "ANATOMY", 142, 147], ["fluid", "ANATOMY", 185, 190], ["AnuriA", "CHEMICAL", 93, 99], ["urine", "ORGANISM_SUBSTANCE", 62, 67], ["oliguriA", "SIMPLE_CHEMICAL", 80, 88], ["AnuriA", "SIMPLE_CHEMICAL", 93, 99], ["urine", "ORGANISM_SUBSTANCE", 142, 147], ["fluid", "ORGANISM_SUBSTANCE", 185, 190], ["decreAsed urine Production", "PROBLEM", 52, 78], ["oliguriA", "PROBLEM", 80, 88], ["AnuriA definitionOliguria", "PROBLEM", 93, 118], ["a reduced amount of urine production", "PROBLEM", 122, 158], ["fluid intake", "TEST", 185, 197], ["several", "OBSERVATION_MODIFIER", 9, 16], ["breeds", "OBSERVATION", 17, 23], ["urine Production", "OBSERVATION", 62, 78], ["oliguriA", "OBSERVATION", 80, 88], ["AnuriA", "OBSERVATION", 93, 99], ["reduced", "OBSERVATION_MODIFIER", 124, 131], ["amount", "OBSERVATION_MODIFIER", 132, 138], ["urine production", "OBSERVATION", 142, 158], ["output", "OBSERVATION_MODIFIER", 163, 169], ["fluid intake", "OBSERVATION", 185, 197]]], ["Patients in which urine production ceases have anuria and are considered to be anuric.", [["urine", "ANATOMY", 18, 23], ["anuria", "DISEASE", 47, 53], ["anuric", "DISEASE", 79, 85], ["Patients", "ORGANISM", 0, 8], ["urine", "ORGANISM_SUBSTANCE", 18, 23], ["Patients", "SPECIES", 0, 8], ["anuria", "PROBLEM", 47, 53], ["anuric", "PROBLEM", 79, 85], ["anuria", "OBSERVATION", 47, 53], ["anuric", "OBSERVATION", 79, 85]]], ["In contrast to polyuric states, neither oliguria nor anuria is likely to be the primary problem for which a dog or cat is presented.", [["oliguria", "DISEASE", 40, 48], ["anuria", "DISEASE", 53, 59], ["dog", "ORGANISM", 108, 111], ["cat", "ORGANISM", 115, 118], ["dog", "SPECIES", 108, 111], ["oliguria", "PROBLEM", 40, 48], ["anuria", "PROBLEM", 53, 59], ["oliguria", "OBSERVATION", 40, 48], ["anuria", "OBSERVATION", 53, 59], ["likely to be", "UNCERTAINTY", 63, 75]]], ["The metabolic consequences of decreased urine production are severe and generally represent significant compromises in renal blood flow or in the functional status of a critical nephron mass.", [["urine", "ANATOMY", 40, 45], ["renal blood", "ANATOMY", 119, 130], ["nephron mass", "ANATOMY", 178, 190], ["urine", "ORGANISM_SUBSTANCE", 40, 45], ["renal", "MULTI-TISSUE_STRUCTURE", 119, 124], ["blood", "ORGANISM_SUBSTANCE", 125, 130], ["nephron", "TISSUE", 178, 185], ["decreased urine production", "PROBLEM", 30, 56], ["significant compromises in renal blood flow", "PROBLEM", 92, 135], ["a critical nephron mass", "PROBLEM", 167, 190], ["metabolic", "OBSERVATION_MODIFIER", 4, 13], ["decreased", "OBSERVATION_MODIFIER", 30, 39], ["urine production", "OBSERVATION", 40, 56], ["severe", "OBSERVATION_MODIFIER", 61, 67], ["significant", "OBSERVATION_MODIFIER", 92, 103], ["compromises", "OBSERVATION", 104, 115], ["renal", "ANATOMY", 119, 124], ["blood flow", "OBSERVATION", 125, 135], ["nephron", "ANATOMY", 178, 185], ["mass", "OBSERVATION", 186, 190]]], ["The daily urine volume at which oliguria begin is a function of solute load and renal concentrating ability.", [["urine", "ANATOMY", 10, 15], ["renal", "ANATOMY", 80, 85], ["oliguria", "DISEASE", 32, 40], ["urine", "ORGANISM_SUBSTANCE", 10, 15], ["renal", "ORGAN", 80, 85], ["The daily urine volume", "TEST", 0, 22], ["oliguria", "PROBLEM", 32, 40], ["solute load", "TREATMENT", 64, 75], ["oliguria", "OBSERVATION", 32, 40], ["renal", "ANATOMY", 80, 85]]], ["In general, oliguria exists when daily urine production is reduced by 75% or more.", [["urine", "ANATOMY", 39, 44], ["oliguria", "DISEASE", 12, 20], ["urine", "ORGANISM_SUBSTANCE", 39, 44], ["oliguria", "PROBLEM", 12, 20], ["urine production", "TEST", 39, 55], ["oliguria", "OBSERVATION", 12, 20], ["reduced", "OBSERVATION_MODIFIER", 59, 66]]], ["Production of 0.5 to 1.0 mL of urine per kilogram per hour indicates adequate renal perfusion in the dog.", [["urine", "ANATOMY", 31, 36], ["renal", "ANATOMY", 78, 83], ["urine", "ORGANISM_SUBSTANCE", 31, 36], ["renal", "ORGAN", 78, 83], ["dog", "ORGANISM", 101, 104], ["dog", "SPECIES", 101, 104], ["adequate", "OBSERVATION", 69, 77], ["renal", "ANATOMY", 78, 83], ["perfusion", "OBSERVATION", 84, 93]]], ["Anuria begins or terminates with oliguria; therefore early detection and treatment of the underlying cause are critical to the overall prognosis.AssociAted signsThe problem(s) for which an oliguric or anuric patient is presented will likely be related to the metabolic consequences of compromised renal function.", [["renal", "ANATOMY", 297, 302], ["Anuria", "DISEASE", 0, 6], ["oliguria", "DISEASE", 33, 41], ["oliguric", "DISEASE", 189, 197], ["patient", "ORGANISM", 208, 215], ["renal", "ORGAN", 297, 302], ["patient", "SPECIES", 208, 215], ["Anuria", "PROBLEM", 0, 6], ["oliguria", "PROBLEM", 33, 41], ["early detection", "TEST", 53, 68], ["treatment", "TREATMENT", 73, 82], ["an oliguric", "PROBLEM", 186, 197], ["compromised renal function", "PROBLEM", 285, 311], ["oliguria", "OBSERVATION", 33, 41], ["oliguric", "OBSERVATION", 189, 197], ["anuric", "OBSERVATION", 201, 207], ["renal", "ANATOMY", 297, 302], ["function", "OBSERVATION", 303, 311]]], ["Uremia, characterized by vomiting, hematemesis, diarrhea, lethargy, or anorexia, predominates.", [["Uremia", "DISEASE", 0, 6], ["vomiting", "DISEASE", 25, 33], ["hematemesis", "DISEASE", 35, 46], ["diarrhea", "DISEASE", 48, 56], ["lethargy", "DISEASE", 58, 66], ["anorexia", "DISEASE", 71, 79], ["Uremia", "PROBLEM", 0, 6], ["vomiting", "PROBLEM", 25, 33], ["hematemesis", "PROBLEM", 35, 46], ["diarrhea", "PROBLEM", 48, 56], ["lethargy", "PROBLEM", 58, 66], ["anorexia", "PROBLEM", 71, 79], ["anorexia", "OBSERVATION", 71, 79]]], ["Any one or a combination of signs may present at the time of initial examination.", [["signs", "PROBLEM", 28, 33], ["initial examination", "TEST", 61, 80]]], ["Some patients may be presented in a comatose or semiconscious state, in which case it is essential that renal function and urinary output be established immediately.", [["renal", "ANATOMY", 104, 109], ["urinary", "ANATOMY", 123, 130], ["comatose", "DISEASE", 36, 44], ["patients", "ORGANISM", 5, 13], ["renal", "ORGAN", 104, 109], ["urinary", "ORGANISM_SUBSTANCE", 123, 130], ["patients", "SPECIES", 5, 13], ["urinary output", "TEST", 123, 137], ["renal", "ANATOMY", 104, 109]]], ["Because acute renal failure (ARF) is the principal differential diagnosis in oliguria and anuria, once it has been established the clinician must obtain a thorough clinical history and laboratory profile, including urinalysis if possible, in an attempt to determine the cause of renal failure and to institute corrective therapy.", [["renal", "ANATOMY", 14, 19], ["renal", "ANATOMY", 279, 284], ["acute renal failure", "DISEASE", 8, 27], ["ARF", "DISEASE", 29, 32], ["oliguria", "DISEASE", 77, 85], ["anuria", "DISEASE", 90, 96], ["renal failure", "DISEASE", 279, 292], ["renal", "ORGAN", 14, 19], ["renal", "ORGAN", 279, 284], ["acute renal failure", "PROBLEM", 8, 27], ["ARF", "PROBLEM", 29, 32], ["oliguria", "PROBLEM", 77, 85], ["anuria", "PROBLEM", 90, 96], ["laboratory profile", "TEST", 185, 203], ["urinalysis", "TEST", 215, 225], ["renal failure", "PROBLEM", 279, 292], ["corrective therapy", "TREATMENT", 310, 328], ["acute", "OBSERVATION_MODIFIER", 8, 13], ["renal", "ANATOMY", 14, 19], ["failure", "OBSERVATION", 20, 27], ["ARF", "OBSERVATION", 29, 32], ["oliguria", "OBSERVATION", 77, 85], ["anuria", "OBSERVATION", 90, 96], ["renal", "ANATOMY", 279, 284], ["failure", "OBSERVATION", 285, 292]]], ["White, blue-eyed cats (may be unilateral or bilateral) Several breeds affected, particularly those with a white or merle hair coat differentiAl diAgnosis diAgnostic PlAns 1.", [["cats", "ORGANISM", 17, 21], ["cats", "SPECIES", 17, 21], ["blue-eyed cats", "SPECIES", 7, 21], ["Several breeds affected", "PROBLEM", 55, 78], ["bilateral", "ANATOMY_MODIFIER", 44, 53], ["breeds", "OBSERVATION", 63, 69]]], ["Initiation of fluid therapy and placement of an indwelling urinary catheter, to establish the rate of urine production.", [["fluid", "ANATOMY", 14, 19], ["urinary", "ANATOMY", 59, 66], ["urine", "ANATOMY", 102, 107], ["urinary", "ORGANISM_SUBDIVISION", 59, 66], ["urine", "ORGANISM_SUBSTANCE", 102, 107], ["fluid therapy", "TREATMENT", 14, 27], ["an indwelling urinary catheter", "TREATMENT", 45, 75], ["fluid therapy", "OBSERVATION", 14, 27], ["indwelling", "OBSERVATION", 48, 58], ["urinary", "ANATOMY", 59, 66], ["catheter", "OBSERVATION", 67, 75]]], ["History, to address any possible exposure to toxins, particularly antifreeze, as well as recent drug treatment.", [["toxins", "TREATMENT", 45, 51], ["antifreeze", "TREATMENT", 66, 76], ["recent drug treatment", "TREATMENT", 89, 110]]], ["Radiographs of the abdomen.", [["abdomen", "ANATOMY", 19, 26], ["abdomen", "ORGAN", 19, 26], ["Radiographs of the abdomen", "TEST", 0, 26], ["abdomen", "ANATOMY", 19, 26]]], ["These may reveal enlarged kidneys, thereby supporting a diagnosis of ARF.", [["kidneys", "ANATOMY", 26, 33], ["ARF", "DISEASE", 69, 72], ["kidneys", "ORGAN", 26, 33], ["ARF", "GENE_OR_GENE_PRODUCT", 69, 72], ["enlarged kidneys", "PROBLEM", 17, 33], ["ARF", "PROBLEM", 69, 72], ["enlarged", "OBSERVATION", 17, 25], ["kidneys", "ANATOMY", 26, 33], ["ARF", "OBSERVATION", 69, 72]]], ["Do not rule out the diagnosis of ARF if kidney size appears normal.", [["kidney", "ANATOMY", 40, 46], ["ARF", "DISEASE", 33, 36], ["ARF", "GENE_OR_GENE_PRODUCT", 33, 36], ["kidney", "ORGAN", 40, 46], ["ARF", "PROBLEM", 33, 36], ["ARF", "OBSERVATION", 33, 36], ["kidney", "ANATOMY", 40, 46], ["size", "OBSERVATION_MODIFIER", 47, 51], ["normal", "OBSERVATION", 60, 66]]], ["Ultrasound imaging of kidneys is also helpful in establishing diagnosis.", [["kidneys", "ANATOMY", 22, 29], ["kidneys", "ORGAN", 22, 29], ["Ultrasound imaging of kidneys", "TEST", 0, 29], ["kidneys", "ANATOMY", 22, 29]]], ["Complete blood count (CBC).", [["blood", "ANATOMY", 9, 14], ["blood", "ORGANISM_SUBSTANCE", 9, 14], ["Complete blood count", "TEST", 0, 20], ["CBC", "TEST", 22, 25]]], ["The biochemical profile should include electrolytes as well as blood urea nitrogen (BUN) and creatinine levels.", [["blood", "ANATOMY", 63, 68], ["blood urea nitrogen", "CHEMICAL", 63, 82], ["creatinine", "CHEMICAL", 93, 103], ["urea", "CHEMICAL", 69, 73], ["nitrogen", "CHEMICAL", 74, 82], ["creatinine", "CHEMICAL", 93, 103], ["blood", "ORGANISM_SUBSTANCE", 63, 68], ["urea nitrogen", "SIMPLE_CHEMICAL", 69, 82], ["BUN", "SIMPLE_CHEMICAL", 84, 87], ["creatinine", "SIMPLE_CHEMICAL", 93, 103], ["The biochemical profile", "TEST", 0, 23], ["electrolytes", "TEST", 39, 51], ["blood urea nitrogen", "TEST", 63, 82], ["BUN", "TEST", 84, 87], ["creatinine levels", "TEST", 93, 110]]], ["Urinalysis (must include urine specific gravity) with microscopic examination of sediment for evidence of crystalluria, RBCs, white blood cells (WBCs), and casts is essential even if only a small volume of urine can be obtained.", [["urine", "ANATOMY", 25, 30], ["RBCs", "ANATOMY", 120, 124], ["white blood cells", "ANATOMY", 126, 143], ["WBCs", "ANATOMY", 145, 149], ["urine", "ANATOMY", 206, 211], ["crystalluria", "DISEASE", 106, 118], ["urine", "ORGANISM_SUBSTANCE", 25, 30], ["RBCs", "CELL", 120, 124], ["white blood cells", "CELL", 126, 143], ["WBCs", "CELL", 145, 149], ["urine", "ORGANISM_SUBSTANCE", 206, 211], ["RBCs", "CELL_TYPE", 120, 124], ["white blood cells", "CELL_TYPE", 126, 143], ["WBCs", "CELL_TYPE", 145, 149], ["Urinalysis", "TEST", 0, 10], ["urine specific gravity", "TEST", 25, 47], ["microscopic examination", "TEST", 54, 77], ["crystalluria", "PROBLEM", 106, 118], ["RBCs", "TEST", 120, 124], ["white blood cells", "TEST", 126, 143], ["WBCs", "TEST", 145, 149], ["casts", "TEST", 156, 161], ["a small volume of urine", "PROBLEM", 188, 211], ["crystalluria", "OBSERVATION", 106, 118]]], ["Blood gases, to assess for metabolic acidosis, which may be severe in ARF.", [["Blood", "ANATOMY", 0, 5], ["metabolic acidosis", "DISEASE", 27, 45], ["ARF", "DISEASE", 70, 73], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["ARF", "GENE_OR_GENE_PRODUCT", 70, 73], ["Blood gases", "TEST", 0, 11], ["metabolic acidosis", "PROBLEM", 27, 45], ["ARF", "PROBLEM", 70, 73], ["acidosis", "OBSERVATION", 37, 45], ["may be", "UNCERTAINTY", 53, 59], ["severe", "OBSERVATION_MODIFIER", 60, 66], ["ARF", "OBSERVATION", 70, 73]]], ["Urine protein-creatinine ratio, to assess proteinuria.", [["Urine", "ANATOMY", 0, 5], ["creatinine", "CHEMICAL", 14, 24], ["proteinuria", "DISEASE", 42, 53], ["creatinine", "CHEMICAL", 14, 24], ["Urine", "ORGANISM_SUBSTANCE", 0, 5], ["creatinine", "SIMPLE_CHEMICAL", 14, 24], ["Urine protein", "PROTEIN", 0, 13], ["Urine protein", "TEST", 0, 13], ["creatinine ratio", "TEST", 14, 30], ["proteinuria", "PROBLEM", 42, 53], ["proteinuria", "OBSERVATION", 42, 53]]], ["If possible, determinations of serum osmolality and serum osmolar gap.", [["serum", "ANATOMY", 31, 36], ["serum", "ANATOMY", 52, 57], ["serum", "ORGANISM_SUBSTANCE", 31, 36], ["serum", "ORGANISM_SUBSTANCE", 52, 57], ["osmolar", "IMMATERIAL_ANATOMICAL_ENTITY", 58, 65], ["serum osmolality", "TEST", 31, 47], ["serum osmolar gap", "TEST", 52, 69]]], ["Special diagnostics: intravenous pyelogram (IVP), renal biopsy, and determinations of lead and other heavy metals in the blood as indicated.diArrheA, Acute-onset definitionA definition of acute-onset diarrhea is probably unnecessary; when it happens, you know it!", [["intravenous", "ANATOMY", 21, 32], ["renal", "ANATOMY", 50, 55], ["blood", "ANATOMY", 121, 126], ["diarrhea", "DISEASE", 200, 208], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 21, 32], ["renal biopsy", "MULTI-TISSUE_STRUCTURE", 50, 62], ["blood", "ORGANISM_SUBSTANCE", 121, 126], ["intravenous pyelogram", "TREATMENT", 21, 42], ["renal biopsy", "TEST", 50, 62], ["the blood", "TEST", 117, 126], [".diArrheA", "PROBLEM", 139, 148], ["acute-onset diarrhea", "PROBLEM", 188, 208], ["renal", "ANATOMY", 50, 55], ["biopsy", "OBSERVATION", 56, 62], ["Acute", "OBSERVATION_MODIFIER", 150, 155], ["acute", "OBSERVATION_MODIFIER", 188, 193], ["-onset", "OBSERVATION_MODIFIER", 193, 199], ["diarrhea", "OBSERVATION", 200, 208], ["probably", "UNCERTAINTY", 212, 220]]], ["The condition involves a sudden change in bowel pattern, characterized as increased fluidity, frequency, or volume, that is sustained despite empiric or supportive therapy (see also Diarrhea, Chronic).", [["bowel", "ANATOMY", 42, 47], ["Diarrhea", "DISEASE", 182, 190], ["bowel", "ORGAN", 42, 47], ["a sudden change in bowel pattern", "PROBLEM", 23, 55], ["increased fluidity", "PROBLEM", 74, 92], ["volume", "PROBLEM", 108, 114], ["supportive therapy", "TREATMENT", 153, 171], ["Diarrhea", "PROBLEM", 182, 190], ["bowel", "ANATOMY", 42, 47], ["increased", "OBSERVATION_MODIFIER", 74, 83], ["fluidity", "OBSERVATION_MODIFIER", 84, 92], ["Chronic", "OBSERVATION_MODIFIER", 192, 199]]], ["Fundamentally, diarrhea occurs when the amount of water and other intestinal contents reaching the colon exceed the ability of the colon to store the feces and adequately remove the excess water.", [["intestinal", "ANATOMY", 66, 76], ["colon", "ANATOMY", 99, 104], ["colon", "ANATOMY", 131, 136], ["feces", "ANATOMY", 150, 155], ["diarrhea", "DISEASE", 15, 23], ["intestinal", "ORGAN", 66, 76], ["colon", "ORGAN", 99, 104], ["colon", "ORGAN", 131, 136], ["feces", "ORGANISM_SUBSTANCE", 150, 155], ["diarrhea", "PROBLEM", 15, 23], ["diarrhea", "OBSERVATION", 15, 23], ["intestinal", "ANATOMY", 66, 76], ["contents", "OBSERVATION", 77, 85], ["colon", "ANATOMY", 99, 104], ["colon", "ANATOMY", 131, 136]]], ["The pathogenesis of acute diarrhea may be classified as osmotic diarrhea, abnormal gut permeability, secretory diarrhea, or abnormal bowel motility.", [["gut", "ANATOMY", 83, 86], ["bowel", "ANATOMY", 133, 138], ["diarrhea", "DISEASE", 26, 34], ["diarrhea", "DISEASE", 64, 72], ["diarrhea", "DISEASE", 111, 119], ["abnormal bowel motility", "DISEASE", 124, 147], ["gut", "ORGANISM_SUBDIVISION", 83, 86], ["bowel", "ORGAN", 133, 138], ["acute diarrhea", "PROBLEM", 20, 34], ["osmotic diarrhea", "PROBLEM", 56, 72], ["abnormal gut permeability", "PROBLEM", 74, 99], ["secretory diarrhea", "PROBLEM", 101, 119], ["abnormal bowel motility", "PROBLEM", 124, 147], ["acute", "OBSERVATION_MODIFIER", 20, 25], ["diarrhea", "OBSERVATION", 26, 34], ["osmotic", "OBSERVATION_MODIFIER", 56, 63], ["diarrhea", "OBSERVATION", 64, 72], ["gut permeability", "OBSERVATION_MODIFIER", 83, 99], ["diarrhea", "OBSERVATION", 111, 119], ["abnormal", "OBSERVATION_MODIFIER", 124, 132], ["bowel motility", "OBSERVATION", 133, 147]]], ["In the patient with acute diarrhea, it is conceivable that only one of these mechanisms is involved.", [["diarrhea", "DISEASE", 26, 34], ["patient", "ORGANISM", 7, 14], ["patient", "SPECIES", 7, 14], ["acute diarrhea", "PROBLEM", 20, 34], ["acute", "OBSERVATION_MODIFIER", 20, 25], ["diarrhea", "OBSERVATION", 26, 34]]], ["However, the longer the underlying cause of the diarrhea persists, the more likely that homeostatic and compensatory mechanisms will be overwhelmed.", [["diarrhea", "DISEASE", 48, 56], ["the diarrhea", "PROBLEM", 44, 56], ["diarrhea", "OBSERVATION", 48, 56], ["more likely", "UNCERTAINTY", 71, 82]]], ["The pathogenesis of the patient's diarrhea is then related to a combination of events.AssociAted signsAcute diarrhea is a common presenting sign for which multitudes of diagnostic possibilities exist.", [["diarrhea", "DISEASE", 34, 42], ["diarrhea", "DISEASE", 108, 116], ["patient", "ORGANISM", 24, 31], ["patient", "SPECIES", 24, 31], ["the patient's diarrhea", "PROBLEM", 20, 42], ["events", "PROBLEM", 79, 85], ["AssociAted signsAcute diarrhea", "PROBLEM", 86, 116], ["signsAcute", "OBSERVATION_MODIFIER", 97, 107], ["diarrhea", "OBSERVATION", 108, 116]]], ["The list of associated signs can be, in the clinical setting, extensive.", [["associated signs", "PROBLEM", 12, 28], ["extensive", "OBSERVATION_MODIFIER", 62, 71]]], ["Among the most common signs encountered in an animal presented with acute diarrhea are vomiting, dehydration, slight weight loss, and hematochezia.", [["diarrhea", "DISEASE", 74, 82], ["vomiting", "DISEASE", 87, 95], ["dehydration", "DISEASE", 97, 108], ["weight loss", "DISEASE", 117, 128], ["hematochezia", "DISEASE", 134, 146], ["acute diarrhea", "PROBLEM", 68, 82], ["vomiting", "PROBLEM", 87, 95], ["dehydration", "PROBLEM", 97, 108], ["slight weight loss", "PROBLEM", 110, 128], ["hematochezia", "PROBLEM", 134, 146], ["acute", "OBSERVATION_MODIFIER", 68, 73], ["diarrhea", "OBSERVATION", 74, 82], ["slight", "OBSERVATION_MODIFIER", 110, 116], ["weight loss", "OBSERVATION", 117, 128], ["hematochezia", "OBSERVATION", 134, 146]]], ["Abdominal pain, halitosis, flatulence, and borborygmus are other gut-associated signs.", [["Abdominal", "ANATOMY", 0, 9], ["gut", "ANATOMY", 65, 68], ["Abdominal pain", "DISEASE", 0, 14], ["halitosis", "DISEASE", 16, 25], ["flatulence", "DISEASE", 27, 37], ["borborygmus", "DISEASE", 43, 54], ["gut", "ORGANISM_SUBDIVISION", 65, 68], ["Abdominal pain", "PROBLEM", 0, 14], ["halitosis", "PROBLEM", 16, 25], ["flatulence", "PROBLEM", 27, 37], ["borborygmus", "PROBLEM", 43, 54], ["pain", "OBSERVATION", 10, 14], ["halitosis", "OBSERVATION", 16, 25], ["flatulence", "OBSERVATION", 27, 37], ["signs", "OBSERVATION", 80, 85]]], ["However, not all patients with acute diarrhea have primary intestinal disease, such as those with renal or hepatic failure or hypoadrenocorticism; icterus, oral ulcers, muscle weakness, and so on may also be encountered.", [["intestinal", "ANATOMY", 59, 69], ["renal", "ANATOMY", 98, 103], ["hepatic", "ANATOMY", 107, 114], ["oral", "ANATOMY", 156, 160], ["muscle", "ANATOMY", 169, 175], ["diarrhea", "DISEASE", 37, 45], ["primary intestinal disease", "DISEASE", 51, 77], ["renal or hepatic failure", "DISEASE", 98, 122], ["hypoadrenocorticism", "DISEASE", 126, 145], ["icterus", "DISEASE", 147, 154], ["ulcers", "DISEASE", 161, 167], ["muscle weakness", "DISEASE", 169, 184], ["patients", "ORGANISM", 17, 25], ["intestinal", "ORGAN", 59, 69], ["renal", "ORGAN", 98, 103], ["hepatic", "ORGAN", 107, 114], ["oral", "ORGANISM_SUBDIVISION", 156, 160], ["ulcers", "PATHOLOGICAL_FORMATION", 161, 167], ["muscle", "ORGAN", 169, 175], ["patients", "SPECIES", 17, 25], ["acute diarrhea", "PROBLEM", 31, 45], ["primary intestinal disease", "PROBLEM", 51, 77], ["renal or hepatic failure", "PROBLEM", 98, 122], ["hypoadrenocorticism", "PROBLEM", 126, 145], ["icterus", "PROBLEM", 147, 154], ["oral ulcers", "PROBLEM", 156, 167], ["muscle weakness", "PROBLEM", 169, 184], ["acute", "OBSERVATION_MODIFIER", 31, 36], ["diarrhea", "OBSERVATION", 37, 45], ["intestinal", "ANATOMY", 59, 69], ["disease", "OBSERVATION", 70, 77], ["renal", "ANATOMY", 98, 103], ["hepatic", "ANATOMY", 107, 114], ["failure", "OBSERVATION", 115, 122], ["icterus", "OBSERVATION_MODIFIER", 147, 154], ["oral", "ANATOMY", 156, 160], ["ulcers", "OBSERVATION", 161, 167], ["muscle", "ANATOMY", 169, 175], ["weakness", "OBSERVATION", 176, 184]]], ["Fever, anorexia, and lethargy may also accompany acute diarrhea in the dog and cat.diArrheA, chronic definitionChronic diarrhea is a persistent or gradual change in bowel pattern, characterized by increased fluidity, frequency, or volume of stool, that is sustained for more than 1 to 2 weeks despite empiric or supportive therapy (see also Diarrhea, Acute-Onset).", [["bowel", "ANATOMY", 165, 170], ["stool", "ANATOMY", 241, 246], ["Fever", "DISEASE", 0, 5], ["anorexia", "DISEASE", 7, 15], ["lethargy", "DISEASE", 21, 29], ["diarrhea", "DISEASE", 55, 63], ["diarrhea", "DISEASE", 119, 127], ["Diarrhea", "DISEASE", 341, 349], ["dog", "ORGANISM", 71, 74], ["bowel", "ORGAN", 165, 170], ["stool", "ORGANISM_SUBSTANCE", 241, 246], ["dog", "SPECIES", 71, 74], ["Fever", "PROBLEM", 0, 5], ["anorexia", "PROBLEM", 7, 15], ["lethargy", "PROBLEM", 21, 29], ["acute diarrhea in the dog and cat.diArrheA", "PROBLEM", 49, 91], ["chronic definition", "PROBLEM", 93, 111], ["Chronic diarrhea", "PROBLEM", 111, 127], ["a persistent or gradual change in bowel pattern", "PROBLEM", 131, 178], ["increased fluidity", "PROBLEM", 197, 215], ["volume of stool", "PROBLEM", 231, 246], ["supportive therapy", "TREATMENT", 312, 330], ["Diarrhea", "PROBLEM", 341, 349], ["anorexia", "OBSERVATION", 7, 15], ["acute", "OBSERVATION_MODIFIER", 49, 54], ["diarrhea", "OBSERVATION", 55, 63], ["chronic", "OBSERVATION_MODIFIER", 93, 100], ["Chronic", "OBSERVATION_MODIFIER", 111, 118], ["diarrhea", "OBSERVATION", 119, 127], ["persistent", "OBSERVATION_MODIFIER", 133, 143], ["gradual", "OBSERVATION_MODIFIER", 147, 154], ["change", "OBSERVATION", 155, 161], ["bowel pattern", "ANATOMY", 165, 178], ["increased", "OBSERVATION_MODIFIER", 197, 206], ["fluidity", "OBSERVATION_MODIFIER", 207, 215], ["stool", "OBSERVATION", 241, 246], ["sustained", "OBSERVATION_MODIFIER", 256, 265]]], ["In the clinical setting, the clinical history and associated signs should be used to further characterize chronic diarrhea as large-bowel or small-bowel diarrhea.AssociAted signsClinical differentiation of small-bowel and large-bowel diarrhea is fundamentally important for the diagnosis and treatment of chronic diarrhea (Table 3-1) .", [["bowel", "ANATOMY", 132, 137], ["bowel", "ANATOMY", 147, 152], ["bowel", "ANATOMY", 212, 217], ["bowel", "ANATOMY", 228, 233], ["diarrhea", "DISEASE", 114, 122], ["diarrhea", "DISEASE", 153, 161], ["diarrhea", "DISEASE", 234, 242], ["diarrhea", "DISEASE", 313, 321], ["bowel", "ORGAN", 132, 137], ["bowel", "ORGAN", 147, 152], ["bowel", "ORGAN", 212, 217], ["bowel", "ORGAN", 228, 233], ["associated signs", "PROBLEM", 50, 66], ["chronic diarrhea", "PROBLEM", 106, 122], ["small-bowel diarrhea", "PROBLEM", 141, 161], ["small-bowel and large-bowel diarrhea", "PROBLEM", 206, 242], ["chronic diarrhea", "PROBLEM", 305, 321], ["chronic", "OBSERVATION_MODIFIER", 106, 113], ["diarrhea", "OBSERVATION", 114, 122], ["large", "OBSERVATION_MODIFIER", 126, 131], ["bowel", "ANATOMY", 132, 137], ["small", "OBSERVATION_MODIFIER", 141, 146], ["bowel", "ANATOMY", 147, 152], ["diarrhea", "OBSERVATION", 153, 161], ["differentiation", "OBSERVATION_MODIFIER", 187, 202], ["small", "OBSERVATION_MODIFIER", 206, 211], ["bowel", "ANATOMY", 212, 217], ["large", "OBSERVATION_MODIFIER", 222, 227], ["bowel", "ANATOMY", 228, 233], ["diarrhea", "OBSERVATION", 234, 242], ["chronic", "OBSERVATION_MODIFIER", 305, 312], ["diarrhea", "OBSERVATION", 313, 321]]], ["Less specific signs associated with chronic diarrheal diseases include dehydration, poorquality hair coat, and fever.", [["hair", "ANATOMY", 96, 100], ["diarrheal diseases", "DISEASE", 44, 62], ["dehydration", "DISEASE", 71, 82], ["fever", "DISEASE", 111, 116], ["chronic diarrheal diseases", "PROBLEM", 36, 62], ["dehydration", "PROBLEM", 71, 82], ["poorquality hair coat", "PROBLEM", 84, 105], ["fever", "PROBLEM", 111, 116], ["chronic", "OBSERVATION_MODIFIER", 36, 43], ["diarrheal diseases", "OBSERVATION", 44, 62], ["dehydration", "OBSERVATION", 71, 82], ["poorquality hair coat", "OBSERVATION", 84, 105], ["fever", "OBSERVATION", 111, 116]]], ["On abdominal palpation, discrete masses, thickened bowel loops, pain, or gas may occasionally be detected.", [["abdominal", "ANATOMY", 3, 12], ["masses", "ANATOMY", 33, 39], ["bowel", "ANATOMY", 51, 56], ["pain", "DISEASE", 64, 68], ["abdominal", "ORGANISM_SUBDIVISION", 3, 12], ["masses", "CANCER", 33, 39], ["bowel", "ORGAN", 51, 56], ["abdominal palpation", "TEST", 3, 22], ["discrete masses", "PROBLEM", 24, 39], ["thickened bowel loops", "PROBLEM", 41, 62], ["pain", "PROBLEM", 64, 68], ["gas", "PROBLEM", 73, 76], ["abdominal", "ANATOMY", 3, 12], ["palpation", "OBSERVATION", 13, 22], ["discrete", "OBSERVATION_MODIFIER", 24, 32], ["masses", "OBSERVATION", 33, 39], ["thickened", "OBSERVATION", 41, 50], ["bowel loops", "ANATOMY", 51, 62], ["pain", "OBSERVATION", 64, 68], ["gas", "OBSERVATION", 73, 76]]], ["Edema, ascites, and pleural effusion in patients with chronic diarrhea suggest substantial protein losses through the bowel.", [["Edema", "ANATOMY", 0, 5], ["ascites", "ANATOMY", 7, 14], ["pleural effusion", "ANATOMY", 20, 36], ["bowel", "ANATOMY", 118, 123], ["Edema", "DISEASE", 0, 5], ["ascites", "DISEASE", 7, 14], ["pleural effusion", "DISEASE", 20, 36], ["diarrhea", "DISEASE", 62, 70], ["pleural effusion", "PATHOLOGICAL_FORMATION", 20, 36], ["patients", "ORGANISM", 40, 48], ["bowel", "ORGAN", 118, 123], ["patients", "SPECIES", 40, 48], ["Edema", "PROBLEM", 0, 5], ["ascites", "PROBLEM", 7, 14], ["pleural effusion", "PROBLEM", 20, 36], ["chronic diarrhea", "PROBLEM", 54, 70], ["substantial protein losses through the bowel", "PROBLEM", 79, 123], ["ascites", "OBSERVATION", 7, 14], ["pleural", "ANATOMY", 20, 27], ["effusion", "OBSERVATION", 28, 36], ["chronic", "OBSERVATION_MODIFIER", 54, 61], ["diarrhea", "OBSERVATION", 62, 70], ["substantial", "OBSERVATION_MODIFIER", 79, 90], ["protein losses", "OBSERVATION", 91, 105], ["bowel", "ANATOMY", 118, 123]]], ["The patient with pallor should be assessed for intestinal bleeding, as well as for an anemia of chronic inflammatory disease.AssociAted signsHematologic signs of greatest significance include eosinophilia (allergic or inflammatory) and significant lymphopenia (lymphangiectasia).", [["intestinal", "ANATOMY", 47, 57], ["pallor", "DISEASE", 17, 23], ["intestinal bleeding", "DISEASE", 47, 66], ["anemia", "DISEASE", 86, 92], ["chronic inflammatory disease", "DISEASE", 96, 124], ["eosinophilia", "DISEASE", 192, 204], ["allergic", "DISEASE", 206, 214], ["lymphopenia", "DISEASE", 248, 259], ["lymphangiectasia", "DISEASE", 261, 277], ["patient", "ORGANISM", 4, 11], ["intestinal", "ORGAN", 47, 57], ["lymphangiectasia", "PATHOLOGICAL_FORMATION", 261, 277], ["patient", "SPECIES", 4, 11], ["pallor", "PROBLEM", 17, 23], ["intestinal bleeding", "PROBLEM", 47, 66], ["an anemia", "PROBLEM", 83, 92], ["chronic inflammatory disease", "PROBLEM", 96, 124], ["AssociAted signsHematologic signs", "PROBLEM", 125, 158], ["eosinophilia", "PROBLEM", 192, 204], ["allergic", "PROBLEM", 206, 214], ["inflammatory)", "PROBLEM", 218, 231], ["significant lymphopenia (lymphangiectasia", "PROBLEM", 236, 277], ["intestinal", "ANATOMY", 47, 57], ["bleeding", "OBSERVATION", 58, 66], ["anemia", "OBSERVATION", 86, 92], ["chronic", "OBSERVATION_MODIFIER", 96, 103], ["inflammatory", "OBSERVATION", 104, 116], ["greatest", "OBSERVATION_MODIFIER", 162, 170], ["eosinophilia", "OBSERVATION", 192, 204], ["allergic", "OBSERVATION_MODIFIER", 206, 214], ["inflammatory", "OBSERVATION_MODIFIER", 218, 230], ["significant", "OBSERVATION_MODIFIER", 236, 247], ["lymphopenia", "OBSERVATION", 248, 259], ["lymphangiectasia", "OBSERVATION", 261, 277]]], ["Hypoproteinemia is associated with extreme malnutrition, protein-losing enteropathies, and enteric blood loss.", [["blood", "ANATOMY", 99, 104], ["Hypoproteinemia", "DISEASE", 0, 15], ["malnutrition", "DISEASE", 43, 55], ["protein-losing enteropathies", "DISEASE", 57, 85], ["enteric blood loss", "DISEASE", 91, 109], ["blood", "ORGANISM_SUBSTANCE", 99, 104], ["Hypoproteinemia", "PROBLEM", 0, 15], ["extreme malnutrition", "PROBLEM", 35, 55], ["protein-losing enteropathies", "PROBLEM", 57, 85], ["enteric blood loss", "PROBLEM", 91, 109], ["associated with", "UNCERTAINTY", 19, 34], ["extreme", "OBSERVATION_MODIFIER", 35, 42], ["malnutrition", "OBSERVATION", 43, 55], ["losing enteropathies", "OBSERVATION", 65, 85], ["enteric blood loss", "OBSERVATION", 91, 109]]], ["Hyperglobulinemia is associated with Basenji enteropathy and feline infectious peritonitis (FIP). proglottids, a zinc sulfate flotation test for Giardia and Coccidia cysts, a saline suspension for protozoan trophozoites, and a sedimentation or Baermann determination for Strongyloides larvae.", [["Coccidia cysts", "ANATOMY", 157, 171], ["trophozoites", "ANATOMY", 207, 219], ["Hyperglobulinemia", "DISEASE", 0, 17], ["Basenji enteropathy", "DISEASE", 37, 56], ["feline infectious peritonitis", "DISEASE", 61, 90], ["FIP", "DISEASE", 92, 95], ["zinc sulfate", "CHEMICAL", 113, 125], ["Giardia and Coccidia cysts", "DISEASE", 145, 171], ["protozoan trophozoites", "DISEASE", 197, 219], ["Strongyloides larvae", "DISEASE", 271, 291], ["zinc sulfate", "CHEMICAL", 113, 125], ["proglottids", "SIMPLE_CHEMICAL", 98, 109], ["zinc sulfate", "SIMPLE_CHEMICAL", 113, 125], ["Strongyloides larvae", "ORGANISM", 271, 291], ["feline", "SPECIES", 61, 67], ["Hyperglobulinemia", "PROBLEM", 0, 17], ["Basenji enteropathy", "PROBLEM", 37, 56], ["feline infectious peritonitis", "PROBLEM", 61, 90], ["proglottids", "TREATMENT", 98, 109], ["a zinc sulfate flotation test", "TEST", 111, 140], ["Giardia", "PROBLEM", 145, 152], ["Coccidia cysts", "PROBLEM", 157, 171], ["a saline suspension", "TREATMENT", 173, 192], ["protozoan trophozoites", "PROBLEM", 197, 219], ["a sedimentation", "PROBLEM", 225, 240], ["Baermann determination", "TREATMENT", 244, 266], ["Strongyloides larvae", "PROBLEM", 271, 291], ["associated with", "UNCERTAINTY", 21, 36], ["Basenji enteropathy", "OBSERVATION", 37, 56], ["feline", "OBSERVATION_MODIFIER", 61, 67], ["infectious", "OBSERVATION_MODIFIER", 68, 78], ["peritonitis", "OBSERVATION", 79, 90], ["FIP", "OBSERVATION_MODIFIER", 92, 95], ["Coccidia cysts", "OBSERVATION", 157, 171], ["protozoan trophozoites", "OBSERVATION", 197, 219]]], ["Adult whipworms can be seen in the colon on colonoscopy.", [["whipworms", "ANATOMY", 6, 15], ["colon", "ANATOMY", 35, 40], ["colon", "ORGAN", 35, 40], ["Adult whipworms", "PROBLEM", 0, 15], ["colonoscopy", "TEST", 44, 55], ["colon", "ANATOMY", 35, 40]]], ["Additional fecal studies.", [["Additional fecal studies", "TEST", 0, 24], ["fecal", "ANATOMY", 11, 16]]], ["Beyond routine fecal flotation and direct examination, several other fecal tests are indicated, including microscopic examinations for fat (Sudan preparation), starch (iodine preparation), and cytologic staining (Gram stain and Wright stain) to assess for presence of leukocytes and infectious agents.", [["fecal", "ANATOMY", 15, 20], ["fecal", "ANATOMY", 69, 74], ["fat", "ANATOMY", 135, 138], ["leukocytes", "ANATOMY", 268, 278], ["iodine", "CHEMICAL", 168, 174], ["iodine", "CHEMICAL", 168, 174], ["fecal", "ORGANISM_SUBSTANCE", 15, 20], ["fat", "TISSUE", 135, 138], ["starch", "SIMPLE_CHEMICAL", 160, 166], ["iodine", "SIMPLE_CHEMICAL", 168, 174], ["leukocytes", "CELL", 268, 278], ["leukocytes", "CELL_TYPE", 268, 278], ["routine fecal flotation", "TEST", 7, 30], ["direct examination", "TEST", 35, 53], ["several other fecal tests", "TEST", 55, 80], ["microscopic examinations", "TEST", 106, 130], ["fat (Sudan preparation", "TREATMENT", 135, 157], ["starch (iodine preparation", "TREATMENT", 160, 186], ["cytologic staining", "TEST", 193, 211], ["Gram stain", "TEST", 213, 223], ["Wright stain", "TEST", 228, 240], ["leukocytes", "PROBLEM", 268, 278], ["infectious agents", "TREATMENT", 283, 300], ["fecal", "ANATOMY", 15, 20], ["leukocytes", "OBSERVATION", 268, 278], ["infectious", "OBSERVATION", 283, 293]]], ["Malassimilation can be assessed through quantitative fecal fat analysis and fecal weight (daily output), although in clinical practice these tests are seldom performed.", [["fecal fat", "ANATOMY", 53, 62], ["fecal", "ANATOMY", 76, 81], ["fat", "TISSUE", 59, 62], ["fecal", "ORGANISM_SUBDIVISION", 76, 81], ["Malassimilation", "TREATMENT", 0, 15], ["quantitative fecal fat analysis", "TEST", 40, 71], ["fecal weight (daily output", "TEST", 76, 102], ["these tests", "TEST", 135, 146]]], ["Several special biochemical and physical tests can also be carried out on feces: fecal water content, nitrogen content (for azotorrhea and malassimilation), electrolytes, pH, osmolality, fecal occult blood, and cultures for both fungi and bacteria.", [["feces", "ANATOMY", 74, 79], ["fecal", "ANATOMY", 81, 86], ["blood", "ANATOMY", 200, 205], ["nitrogen", "CHEMICAL", 102, 110], ["nitrogen", "CHEMICAL", 102, 110], ["feces", "ORGANISM_SUBDIVISION", 74, 79], ["fecal", "ORGANISM_SUBDIVISION", 81, 86], ["water", "SIMPLE_CHEMICAL", 87, 92], ["nitrogen", "SIMPLE_CHEMICAL", 102, 110], ["fecal", "ORGANISM_SUBSTANCE", 187, 192], ["blood", "ORGANISM_SUBSTANCE", 200, 205], ["physical tests", "TEST", 32, 46], ["nitrogen content", "TEST", 102, 118], ["azotorrhea", "PROBLEM", 124, 134], ["malassimilation", "TEST", 139, 154], ["electrolytes", "TEST", 157, 169], ["pH", "TEST", 171, 173], ["osmolality", "TEST", 175, 185], ["fecal occult blood", "TEST", 187, 205], ["cultures", "TEST", 211, 219], ["both fungi", "PROBLEM", 224, 234], ["bacteria", "PROBLEM", 239, 247], ["fecal", "ANATOMY", 81, 86], ["fecal", "ANATOMY", 187, 192]]], ["Tests of absorptive and digestive function, such as trypsin-like immunoreactivity (TLI), serum folate, and vitamin B 12 assay.", [["digestive", "ANATOMY", 24, 33], ["serum", "ANATOMY", 89, 94], ["folate", "CHEMICAL", 95, 101], ["vitamin B", "CHEMICAL", 107, 116], ["folate", "CHEMICAL", 95, 101], ["vitamin B 12", "CHEMICAL", 107, 119], ["digestive", "ORGAN", 24, 33], ["trypsin", "GENE_OR_GENE_PRODUCT", 52, 59], ["serum", "ORGANISM_SUBSTANCE", 89, 94], ["folate", "SIMPLE_CHEMICAL", 95, 101], ["vitamin B 12", "GENE_OR_GENE_PRODUCT", 107, 119], ["trypsin", "PROTEIN", 52, 59], ["absorptive and digestive function", "PROBLEM", 9, 42], ["trypsin", "TEST", 52, 59], ["TLI", "TEST", 83, 86], ["serum folate", "TEST", 89, 101], ["vitamin B 12 assay", "TEST", 107, 125], ["digestive function", "OBSERVATION", 24, 42]]], ["Gastrointestinal (GI) radiography and ultrasonography.", [["Gastrointestinal", "ANATOMY", 0, 16], ["Gastrointestinal", "MULTI-TISSUE_STRUCTURE", 0, 16], ["Gastrointestinal (GI) radiography", "TEST", 0, 33], ["ultrasonography", "TEST", 38, 53], ["GI", "ANATOMY", 18, 20]]], ["GI endoscopy (gastroscopy, duodenoscopy, and colonoscopy), with biopsy of intestinal mucosa.", [["intestinal mucosa", "ANATOMY", 74, 91], ["intestinal mucosa", "MULTI-TISSUE_STRUCTURE", 74, 91], ["GI endoscopy", "TEST", 0, 12], ["gastroscopy", "TEST", 14, 25], ["duodenoscopy", "TEST", 27, 39], ["colonoscopy", "TEST", 45, 56], ["biopsy", "TEST", 64, 70], ["intestinal mucosa", "PROBLEM", 74, 91], ["intestinal mucosa", "ANATOMY", 74, 91]]], ["Duodenal intubation and aspiration can be performed to obtain specimens for cytologic examination and culture.", [["Duodenal", "ANATOMY", 0, 8], ["specimens", "ANATOMY", 62, 71], ["Duodenal", "MULTI-TISSUE_STRUCTURE", 0, 8], ["Duodenal intubation", "TREATMENT", 0, 19], ["aspiration", "TREATMENT", 24, 34], ["specimens", "TEST", 62, 71], ["cytologic examination", "TEST", 76, 97], ["culture", "TEST", 102, 109], ["intubation", "OBSERVATION", 9, 19], ["aspiration", "OBSERVATION", 24, 34]]], ["Exploratory laparotomy and intestinal biopsy.", [["intestinal", "ANATOMY", 27, 37], ["intestinal biopsy", "MULTI-TISSUE_STRUCTURE", 27, 44], ["Exploratory laparotomy", "TEST", 0, 22], ["intestinal biopsy", "TEST", 27, 44], ["laparotomy", "OBSERVATION", 12, 22], ["intestinal", "ANATOMY", 27, 37], ["biopsy", "OBSERVATION", 38, 44]]], ["Response to empiric treatment: Enzyme replacement or treatment of occult parasite infections.difficulty breAthing or resPirAtory distress: cyAnosis definitionCyanosis is a bluish discoloration of the skin and mucous membranes resulting from excessive concentration (> 5 g/dL) of reduced hemoglobin in the blood.", [["skin", "ANATOMY", 200, 204], ["mucous membranes", "ANATOMY", 209, 225], ["blood", "ANATOMY", 305, 310], ["occult parasite infections", "DISEASE", 66, 92], ["resPirAtory distress", "DISEASE", 117, 137], ["cyAnosis", "DISEASE", 139, 147], ["Cyanosis", "DISEASE", 158, 166], ["skin", "ORGAN", 200, 204], ["mucous membranes", "MULTI-TISSUE_STRUCTURE", 209, 225], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 287, 297], ["blood", "ORGANISM_SUBSTANCE", 305, 310], ["hemoglobin", "PROTEIN", 287, 297], ["empiric treatment", "TREATMENT", 12, 29], ["Enzyme replacement", "TREATMENT", 31, 49], ["treatment", "TREATMENT", 53, 62], ["occult parasite infections", "PROBLEM", 66, 92], ["difficulty breAthing", "PROBLEM", 93, 113], ["resPirAtory distress", "PROBLEM", 117, 137], ["cyAnosis definitionCyanosis", "PROBLEM", 139, 166], ["a bluish discoloration of the skin", "PROBLEM", 170, 204], ["mucous membranes", "PROBLEM", 209, 225], ["excessive concentration", "PROBLEM", 241, 264], ["reduced hemoglobin in the blood", "PROBLEM", 279, 310], ["occult", "OBSERVATION_MODIFIER", 66, 72], ["parasite infections", "OBSERVATION", 73, 92], ["resPirAtory distress", "OBSERVATION", 117, 137], ["cyAnosis", "OBSERVATION", 139, 147], ["Cyanosis", "OBSERVATION", 158, 166], ["bluish", "OBSERVATION_MODIFIER", 172, 178], ["discoloration", "OBSERVATION", 179, 192], ["skin", "ANATOMY", 200, 204], ["mucous membranes", "ANATOMY", 209, 225], ["excessive", "OBSERVATION_MODIFIER", 241, 250], ["concentration", "OBSERVATION_MODIFIER", 251, 264], ["reduced", "OBSERVATION_MODIFIER", 279, 286], ["hemoglobin", "OBSERVATION", 287, 297], ["blood", "ANATOMY", 305, 310]]], ["In dogs and cats, cyanosis may develop acutely in hypoxic states or may be chronic.", [["cyanosis", "DISEASE", 18, 26], ["dogs", "ORGANISM", 3, 7], ["cats", "ORGANISM", 12, 16], ["dogs", "SPECIES", 3, 7], ["cats", "SPECIES", 12, 16], ["cyanosis", "PROBLEM", 18, 26], ["hypoxic", "OBSERVATION", 50, 57], ["may be", "UNCERTAINTY", 68, 74], ["chronic", "OBSERVATION_MODIFIER", 75, 82]]], ["Although cyanosis can develop during hypoxia, the terms are not synonymous.Note:The increased concentration of reduced hemoglobin in blood is the result of either an increase in the quantity of venous blood in the cutaneous tissues (passive venous congestion) or a decrease in oxygen saturation in capillary blood.", [["blood", "ANATOMY", 133, 138], ["venous blood", "ANATOMY", 194, 206], ["cutaneous tissues", "ANATOMY", 214, 231], ["venous", "ANATOMY", 241, 247], ["capillary blood", "ANATOMY", 298, 313], ["cyanosis", "DISEASE", 9, 17], ["hypoxia", "DISEASE", 37, 44], ["oxygen", "CHEMICAL", 277, 283], ["oxygen", "CHEMICAL", 277, 283], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 119, 129], ["blood", "ORGANISM_SUBSTANCE", 133, 138], ["venous blood", "ORGANISM_SUBSTANCE", 194, 206], ["cutaneous tissues", "TISSUE", 214, 231], ["venous", "MULTI-TISSUE_STRUCTURE", 241, 247], ["oxygen", "SIMPLE_CHEMICAL", 277, 283], ["capillary blood", "ORGANISM_SUBSTANCE", 298, 313], ["hemoglobin", "PROTEIN", 119, 129], ["cyanosis", "PROBLEM", 9, 17], ["hypoxia", "PROBLEM", 37, 44], ["reduced hemoglobin in blood", "PROBLEM", 111, 138], ["venous blood in the cutaneous tissues", "PROBLEM", 194, 231], ["passive venous congestion", "PROBLEM", 233, 258], ["a decrease in oxygen saturation in capillary blood", "PROBLEM", 263, 313], ["cyanosis", "OBSERVATION", 9, 17], ["increased", "OBSERVATION_MODIFIER", 84, 93], ["concentration", "OBSERVATION_MODIFIER", 94, 107], ["reduced", "OBSERVATION_MODIFIER", 111, 118], ["hemoglobin", "OBSERVATION", 119, 129], ["increase", "OBSERVATION_MODIFIER", 166, 174], ["quantity", "OBSERVATION_MODIFIER", 182, 190], ["venous", "ANATOMY", 194, 200], ["blood", "OBSERVATION", 201, 206], ["cutaneous tissues", "ANATOMY", 214, 231], ["venous", "ANATOMY", 241, 247], ["congestion", "OBSERVATION", 248, 258], ["decrease", "OBSERVATION_MODIFIER", 265, 273], ["oxygen saturation", "OBSERVATION", 277, 294], ["capillary blood", "OBSERVATION", 298, 313]]], ["It is the absolute, rather than the relative, amount of reduced hemoglobin that actually causes the cyanosis to develop.", [["cyanosis", "DISEASE", 100, 108], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 64, 74], ["hemoglobin", "PROTEIN", 64, 74], ["reduced hemoglobin", "PROBLEM", 56, 74], ["the cyanosis", "PROBLEM", 96, 108], ["absolute", "OBSERVATION_MODIFIER", 10, 18], ["reduced", "OBSERVATION_MODIFIER", 56, 63], ["hemoglobin", "OBSERVATION", 64, 74], ["cyanosis", "OBSERVATION", 100, 108]]], ["If the concentration of hemoglobin is also reduced, the absolute concentration of reduced hemoglobin is also decreased.", [["hemoglobin", "GENE_OR_GENE_PRODUCT", 24, 34], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 90, 100], ["hemoglobin", "PROTEIN", 24, 34], ["hemoglobin", "PROTEIN", 90, 100], ["the concentration of hemoglobin", "PROBLEM", 3, 34], ["reduced hemoglobin", "PROBLEM", 82, 100], ["hemoglobin", "OBSERVATION", 24, 34], ["reduced", "OBSERVATION_MODIFIER", 43, 50], ["absolute concentration", "OBSERVATION_MODIFIER", 56, 78], ["reduced", "OBSERVATION_MODIFIER", 82, 89], ["hemoglobin", "OBSERVATION", 90, 100], ["decreased", "OBSERVATION_MODIFIER", 109, 118]]], ["Therefore even in severe anemia, cyanosis is not evident.", [["anemia", "DISEASE", 25, 31], ["cyanosis", "DISEASE", 33, 41], ["severe anemia", "PROBLEM", 18, 31], ["cyanosis", "PROBLEM", 33, 41], ["severe", "OBSERVATION_MODIFIER", 18, 24], ["anemia", "OBSERVATION", 25, 31], ["cyanosis", "OBSERVATION", 33, 41], ["not evident", "UNCERTAINTY", 45, 56]]], ["On the other hand, patients with an elevated RBC mass, or polycythemia, tend to be cyanotic at higher levels of arterial oxygen saturation than patients with a normal RBC mass.", [["RBC mass", "ANATOMY", 45, 53], ["arterial", "ANATOMY", 112, 120], ["RBC", "ANATOMY", 167, 170], ["polycythemia", "DISEASE", 58, 70], ["cyanotic", "DISEASE", 83, 91], ["oxygen", "CHEMICAL", 121, 127], ["oxygen", "CHEMICAL", 121, 127], ["patients", "ORGANISM", 19, 27], ["RBC", "CELL", 45, 48], ["arterial", "MULTI-TISSUE_STRUCTURE", 112, 120], ["oxygen", "SIMPLE_CHEMICAL", 121, 127], ["patients", "ORGANISM", 144, 152], ["RBC", "CELL", 167, 170], ["patients", "SPECIES", 19, 27], ["patients", "SPECIES", 144, 152], ["an elevated RBC mass", "PROBLEM", 33, 53], ["polycythemia", "PROBLEM", 58, 70], ["cyanotic", "PROBLEM", 83, 91], ["arterial oxygen saturation", "TEST", 112, 138], ["a normal RBC mass", "PROBLEM", 158, 175], ["RBC", "ANATOMY", 45, 48], ["mass", "OBSERVATION", 49, 53], ["polycythemia", "OBSERVATION", 58, 70], ["cyanotic", "OBSERVATION", 83, 91], ["arterial", "ANATOMY", 112, 120], ["oxygen saturation", "OBSERVATION", 121, 138], ["normal RBC mass", "OBSERVATION", 160, 175]]], ["Cyanosis also occurs when functional abnormalities of hemoglobin (e.g., methemoglobinemia [darkbrown blood]) exist.", [["blood", "ANATOMY", 101, 106], ["Cyanosis", "DISEASE", 0, 8], ["methemoglobinemia", "DISEASE", 72, 89], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 54, 64], ["blood", "ORGANISM_SUBSTANCE", 101, 106], ["hemoglobin", "PROTEIN", 54, 64], ["Cyanosis", "PROBLEM", 0, 8], ["functional abnormalities of hemoglobin", "PROBLEM", 26, 64], ["methemoglobinemia [darkbrown blood", "PROBLEM", 72, 106]]], ["In the dog and cat, disorders affecting the oxygen-carrying capacity of hemoglobin are usually drug-or chemical-induced.", [["oxygen", "CHEMICAL", 44, 50], ["oxygen", "CHEMICAL", 44, 50], ["dog", "ORGANISM", 7, 10], ["cat", "ORGANISM", 15, 18], ["oxygen", "SIMPLE_CHEMICAL", 44, 50], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 72, 82], ["hemoglobin", "PROTEIN", 72, 82], ["dog", "SPECIES", 7, 10], ["cat", "SPECIES", 15, 18], ["disorders", "PROBLEM", 20, 29], ["the oxygen", "TREATMENT", 40, 50]]], ["As little as 1.5 g of methemoglobin per deciliter or 0.5 g of sulfhemoglobin per deciliter will produce cyanosis.AssociAted signsCyanosis can result from disorders affecting the cardiovascular system, ventilation, or oxygen-carrying capacity of RBCs.", [["cardiovascular system", "ANATOMY", 178, 199], ["RBCs", "ANATOMY", 245, 249], ["methemoglobin", "CHEMICAL", 22, 35], ["sulfhemoglobin", "CHEMICAL", 62, 76], ["cyanosis", "DISEASE", 104, 112], ["signsCyanosis", "DISEASE", 124, 137], ["disorders affecting the cardiovascular system", "DISEASE", 154, 199], ["oxygen", "CHEMICAL", 217, 223], ["methemoglobin", "CHEMICAL", 22, 35], ["sulfhemoglobin", "CHEMICAL", 62, 76], ["oxygen", "CHEMICAL", 217, 223], ["methemoglobin", "SIMPLE_CHEMICAL", 22, 35], ["sulfhemoglobin", "SIMPLE_CHEMICAL", 62, 76], ["cardiovascular", "ANATOMICAL_SYSTEM", 178, 192], ["system", "ANATOMICAL_SYSTEM", 193, 199], ["oxygen", "SIMPLE_CHEMICAL", 217, 223], ["RBCs", "CELL", 245, 249], ["RBCs", "CELL_TYPE", 245, 249], ["methemoglobin", "TEST", 22, 35], ["sulfhemoglobin", "TREATMENT", 62, 76], ["cyanosis", "PROBLEM", 104, 112], ["AssociAted signsCyanosis", "PROBLEM", 113, 137], ["disorders affecting the cardiovascular system", "PROBLEM", 154, 199], ["ventilation", "TREATMENT", 201, 212], ["cyanosis", "OBSERVATION", 104, 112], ["cardiovascular system", "ANATOMY", 178, 199]]], ["Several cardiovascular diseases, particularly those that compromise cardiac output or are associated with right-to-left vascular shunts, predispose to cyanosis.", [["cardiovascular", "ANATOMY", 8, 22], ["cardiac", "ANATOMY", 68, 75], ["left vascular", "ANATOMY", 115, 128], ["cardiovascular diseases", "DISEASE", 8, 31], ["cardiac output", "DISEASE", 68, 82], ["cyanosis", "DISEASE", 151, 159], ["cardiovascular", "ANATOMICAL_SYSTEM", 8, 22], ["cardiac", "ORGAN", 68, 75], ["vascular", "MULTI-TISSUE_STRUCTURE", 120, 128], ["Several cardiovascular diseases", "PROBLEM", 0, 31], ["compromise cardiac output", "PROBLEM", 57, 82], ["cyanosis", "PROBLEM", 151, 159], ["cardiovascular", "ANATOMY", 8, 22], ["diseases", "OBSERVATION", 23, 31], ["output", "OBSERVATION_MODIFIER", 76, 82], ["right", "ANATOMY_MODIFIER", 106, 111], ["left", "ANATOMY_MODIFIER", 115, 119], ["vascular", "ANATOMY", 120, 128], ["shunts", "OBSERVATION", 129, 135], ["cyanosis", "OBSERVATION", 151, 159]]], ["Therefore animals with both acquired and congenital cardiac disease are susceptible.", [["cardiac", "ANATOMY", 52, 59], ["congenital cardiac disease", "DISEASE", 41, 67], ["cardiac", "ORGAN", 52, 59], ["congenital cardiac disease", "PROBLEM", 41, 67], ["congenital", "OBSERVATION_MODIFIER", 41, 51], ["cardiac", "ANATOMY", 52, 59], ["disease", "OBSERVATION", 60, 67]]], ["Associated signs include cough, respiratory distress, and syncope.", [["respiratory", "ANATOMY", 32, 43], ["cough", "DISEASE", 25, 30], ["respiratory distress", "DISEASE", 32, 52], ["syncope", "DISEASE", 58, 65], ["Associated signs", "PROBLEM", 0, 16], ["cough", "PROBLEM", 25, 30], ["respiratory distress", "PROBLEM", 32, 52], ["syncope", "PROBLEM", 58, 65], ["cough", "OBSERVATION", 25, 30], ["respiratory distress", "OBSERVATION", 32, 52], ["syncope", "OBSERVATION", 58, 65]]], ["The most common congenital heart defects associated with right-to-left shunts are (1) pulmonary valve stenosis as seen in tetralogy of Fallot, stenosis, and ventricular septal defect (VSD) and (2) pulmonary hypertension as seen in patent ductus arteriosus (PDA) and VSD.", [["heart", "ANATOMY", 27, 32], ["right-", "ANATOMY", 57, 63], ["pulmonary valve", "ANATOMY", 86, 101], ["ventricular septal", "ANATOMY", 157, 175], ["pulmonary", "ANATOMY", 197, 206], ["heart defects", "DISEASE", 27, 40], ["pulmonary valve stenosis", "DISEASE", 86, 110], ["tetralogy of Fallot", "DISEASE", 122, 141], ["stenosis", "DISEASE", 143, 151], ["ventricular septal defect", "DISEASE", 157, 182], ["pulmonary hypertension", "DISEASE", 197, 219], ["patent ductus arteriosus", "DISEASE", 231, 255], ["heart", "ORGAN", 27, 32], ["pulmonary valve", "MULTI-TISSUE_STRUCTURE", 86, 101], ["ventricular septal", "MULTI-TISSUE_STRUCTURE", 157, 175], ["pulmonary", "ORGAN", 197, 206], ["ductus arteriosus", "MULTI-TISSUE_STRUCTURE", 238, 255], ["The most common congenital heart defects", "PROBLEM", 0, 40], ["pulmonary valve stenosis", "PROBLEM", 86, 110], ["tetralogy of Fallot", "PROBLEM", 122, 141], ["stenosis", "PROBLEM", 143, 151], ["ventricular septal defect (VSD)", "PROBLEM", 157, 188], ["pulmonary hypertension", "PROBLEM", 197, 219], ["patent ductus arteriosus", "PROBLEM", 231, 255], ["VSD", "PROBLEM", 266, 269], ["most", "OBSERVATION_MODIFIER", 4, 8], ["common", "OBSERVATION_MODIFIER", 9, 15], ["heart", "ANATOMY", 27, 32], ["defects", "OBSERVATION", 33, 40], ["right", "ANATOMY_MODIFIER", 57, 62], ["to-", "ANATOMY_MODIFIER", 63, 66], ["left", "ANATOMY_MODIFIER", 66, 70], ["shunts", "OBSERVATION", 71, 77], ["pulmonary valve", "ANATOMY", 86, 101], ["stenosis", "OBSERVATION", 102, 110], ["Fallot", "OBSERVATION", 135, 141], ["stenosis", "OBSERVATION", 143, 151], ["ventricular septal", "ANATOMY", 157, 175], ["defect", "OBSERVATION", 176, 182], ["VSD", "OBSERVATION", 184, 187], ["pulmonary", "ANATOMY", 197, 206], ["hypertension", "OBSERVATION", 207, 219], ["patent", "OBSERVATION", 231, 237], ["ductus arteriosus", "ANATOMY", 238, 255], ["PDA", "OBSERVATION_MODIFIER", 257, 260], ["VSD", "OBSERVATION", 266, 269]]], ["Respiratory disorders affecting ventilation predispose to cyanosis.", [["Respiratory", "ANATOMY", 0, 11], ["Respiratory disorders", "DISEASE", 0, 21], ["cyanosis", "DISEASE", 58, 66], ["Respiratory disorders", "PROBLEM", 0, 21], ["cyanosis", "PROBLEM", 58, 66], ["cyanosis", "OBSERVATION", 58, 66]]], ["Severe infiltrative lung disease (e.g., neoplasia, pulmonary edema, or generalized pneumonia) can produce cyanosis associated with increased respiratory effort.AssociAted signsAnimals with cyanosis not associated with clinical signs other than increased respiratory rate may have abnormal hemoglobin levels, which, if present in sufficient concentration, will cause cyanosis.", [["lung", "ANATOMY", 20, 24], ["neoplasia", "ANATOMY", 40, 49], ["pulmonary", "ANATOMY", 51, 60], ["respiratory", "ANATOMY", 141, 152], ["respiratory", "ANATOMY", 254, 265], ["infiltrative lung disease", "DISEASE", 7, 32], ["neoplasia", "DISEASE", 40, 49], ["pulmonary edema", "DISEASE", 51, 66], ["pneumonia", "DISEASE", 83, 92], ["cyanosis", "DISEASE", 106, 114], ["cyanosis", "DISEASE", 189, 197], ["cyanosis", "DISEASE", 366, 374], ["lung", "ORGAN", 20, 24], ["neoplasia", "CANCER", 40, 49], ["pulmonary", "ORGAN", 51, 60], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 289, 299], ["hemoglobin", "PROTEIN", 289, 299], ["Severe infiltrative lung disease", "PROBLEM", 0, 32], ["neoplasia", "PROBLEM", 40, 49], ["pulmonary edema", "PROBLEM", 51, 66], ["generalized pneumonia", "PROBLEM", 71, 92], ["cyanosis", "PROBLEM", 106, 114], ["increased respiratory effort", "PROBLEM", 131, 159], ["AssociAted signsAnimals", "PROBLEM", 160, 183], ["cyanosis", "PROBLEM", 189, 197], ["clinical signs", "PROBLEM", 218, 232], ["increased respiratory rate", "PROBLEM", 244, 270], ["abnormal hemoglobin levels", "PROBLEM", 280, 306], ["cyanosis", "PROBLEM", 366, 374], ["infiltrative", "OBSERVATION_MODIFIER", 7, 19], ["lung", "ANATOMY", 20, 24], ["disease", "OBSERVATION", 25, 32], ["neoplasia", "OBSERVATION", 40, 49], ["pulmonary", "ANATOMY", 51, 60], ["edema", "OBSERVATION", 61, 66], ["generalized", "OBSERVATION_MODIFIER", 71, 82], ["pneumonia", "OBSERVATION", 83, 92], ["cyanosis", "OBSERVATION", 106, 114], ["increased", "OBSERVATION_MODIFIER", 131, 140], ["respiratory effort", "OBSERVATION", 141, 159], ["cyanosis", "OBSERVATION", 189, 197], ["respiratory rate", "OBSERVATION", 254, 270]]], ["Associated signs include methemoglobinuria and methemoglobinemia.AssociAted signsCentral cyanosis is defined as compromised oxygen saturation or abnormal hemoglobin; peripheral cyanosis is compromised blood flow.difficulty breAthing or resPirAtory distress: dysPneA definitionDyspnea is pathologic breathlessness and labored breathing most commonly associated with cardiac or pulmonary disease.", [["blood", "ANATOMY", 201, 206], ["cardiac", "ANATOMY", 365, 372], ["pulmonary", "ANATOMY", 376, 385], ["methemoglobinuria", "DISEASE", 25, 42], ["methemoglobinemia", "DISEASE", 47, 64], ["cyanosis", "DISEASE", 89, 97], ["oxygen", "CHEMICAL", 124, 130], ["peripheral cyanosis", "DISEASE", 166, 185], ["breathlessness", "DISEASE", 298, 312], ["cardiac or pulmonary disease", "DISEASE", 365, 393], ["oxygen", "CHEMICAL", 124, 130], ["oxygen", "SIMPLE_CHEMICAL", 124, 130], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 154, 164], ["blood", "ORGANISM_SUBSTANCE", 201, 206], ["cardiac", "ORGAN", 365, 372], ["pulmonary", "ORGAN", 376, 385], ["hemoglobin", "PROTEIN", 154, 164], ["methemoglobinuria", "PROBLEM", 25, 42], ["methemoglobinemia", "PROBLEM", 47, 64], ["AssociAted signsCentral cyanosis", "PROBLEM", 65, 97], ["compromised oxygen saturation", "PROBLEM", 112, 141], ["abnormal hemoglobin", "PROBLEM", 145, 164], ["peripheral cyanosis", "PROBLEM", 166, 185], ["compromised blood flow", "PROBLEM", 189, 211], ["difficulty breAthing", "PROBLEM", 212, 232], ["resPirAtory distress", "PROBLEM", 236, 256], ["dysPneA definitionDyspnea", "PROBLEM", 258, 283], ["pathologic breathlessness", "PROBLEM", 287, 312], ["labored breathing", "PROBLEM", 317, 334], ["cardiac or pulmonary disease", "PROBLEM", 365, 393], ["methemoglobinuria", "OBSERVATION", 25, 42], ["methemoglobinemia", "OBSERVATION", 47, 64], ["cyanosis", "OBSERVATION", 89, 97], ["abnormal", "OBSERVATION_MODIFIER", 145, 153], ["hemoglobin", "OBSERVATION_MODIFIER", 154, 164], ["peripheral", "ANATOMY_MODIFIER", 166, 176], ["cyanosis", "OBSERVATION", 177, 185], ["flow", "OBSERVATION_MODIFIER", 207, 211], ["resPirAtory distress", "OBSERVATION", 236, 256], ["pulmonary", "ANATOMY", 376, 385], ["disease", "OBSERVATION", 386, 393]]], ["What actually is and is not true breathlessness in veterinary medicine can be difficult to define in clinical practice.", [["breathlessness", "DISEASE", 33, 47], ["true breathlessness", "PROBLEM", 28, 47]]], ["Serious respiratory distress associated with substantive respiratory compromise may appear, to the owner at least, as only a minor problem.", [["respiratory", "ANATOMY", 8, 19], ["respiratory", "ANATOMY", 57, 68], ["respiratory distress", "DISEASE", 8, 28], ["Serious respiratory distress", "PROBLEM", 0, 28], ["substantive respiratory compromise", "PROBLEM", 45, 79], ["a minor problem", "PROBLEM", 123, 138], ["distress", "OBSERVATION", 20, 28], ["respiratory compromise", "OBSERVATION", 57, 79], ["minor", "OBSERVATION_MODIFIER", 125, 130], ["problem", "OBSERVATION", 131, 138]]], ["Physical examination and patient assessment are critical to the recognition and interpretation of this clinical sign.difficulty breAthing or resPirAtory distress: dysPneA definitionDyspnea may result from (1) the need for oxygen, (2) metabolic aberrations leading to acidosis (a compensatory mechanism), (3) high environmental temperatures (heat stroke), (4) CNS disease, (5) disorders affecting motor innervation to the muscles of respiration, and (6) pain.", [["CNS", "ANATOMY", 359, 362], ["muscles", "ANATOMY", 421, 428], ["Dyspnea", "DISEASE", 181, 188], ["oxygen", "CHEMICAL", 222, 228], ["acidosis", "DISEASE", 267, 275], ["stroke", "DISEASE", 346, 352], ["CNS disease", "DISEASE", 359, 370], ["pain", "DISEASE", 453, 457], ["oxygen", "CHEMICAL", 222, 228], ["patient", "ORGANISM", 25, 32], ["oxygen", "SIMPLE_CHEMICAL", 222, 228], ["CNS", "ANATOMICAL_SYSTEM", 359, 362], ["muscles", "ORGAN", 421, 428], ["patient", "SPECIES", 25, 32], ["Physical examination", "TEST", 0, 20], ["patient assessment", "TEST", 25, 43], ["this clinical sign", "TEST", 98, 116], ["difficulty breAthing", "PROBLEM", 117, 137], ["resPirAtory distress", "PROBLEM", 141, 161], ["dysPneA definition", "PROBLEM", 163, 181], ["Dyspnea", "PROBLEM", 181, 188], ["oxygen", "TREATMENT", 222, 228], ["metabolic aberrations", "PROBLEM", 234, 255], ["acidosis", "PROBLEM", 267, 275], ["a compensatory mechanism)", "PROBLEM", 277, 302], ["high environmental temperatures (heat stroke)", "PROBLEM", 308, 353], ["CNS disease, (5) disorders", "PROBLEM", 359, 385], ["pain", "PROBLEM", 453, 457], ["acidosis", "OBSERVATION", 267, 275], ["CNS", "ANATOMY", 359, 362], ["disease", "OBSERVATION", 363, 370], ["muscles", "ANATOMY", 421, 428]]], ["In any event, once confirmed, diagnostic evaluation of the patient presented in respiratory distress should not be delayed.AssociAted signsThe most common respiratory signs that characterize distress or dyspnea include (1) tachypnea (increased respiratory rate), (2) hyperpnea (increased respiratory rate and depth), (3) orthopnea, and (4) cough.", [["respiratory", "ANATOMY", 80, 91], ["respiratory", "ANATOMY", 155, 166], ["respiratory", "ANATOMY", 244, 255], ["respiratory", "ANATOMY", 288, 299], ["respiratory distress", "DISEASE", 80, 100], ["dyspnea", "DISEASE", 203, 210], ["tachypnea", "DISEASE", 223, 232], ["hyperpnea", "DISEASE", 267, 276], ["orthopnea", "DISEASE", 321, 330], ["cough", "DISEASE", 340, 345], ["patient", "ORGANISM", 59, 66], ["patient", "SPECIES", 59, 66], ["diagnostic evaluation", "TEST", 30, 51], ["respiratory distress", "PROBLEM", 80, 100], ["AssociAted signs", "PROBLEM", 123, 139], ["The most common respiratory signs", "PROBLEM", 139, 172], ["distress", "PROBLEM", 191, 199], ["dyspnea", "PROBLEM", 203, 210], ["tachypnea", "PROBLEM", 223, 232], ["increased respiratory rate)", "PROBLEM", 234, 261], ["hyperpnea", "PROBLEM", 267, 276], ["increased respiratory rate and depth)", "PROBLEM", 278, 315], ["orthopnea", "PROBLEM", 321, 330], ["cough", "PROBLEM", 340, 345], ["respiratory distress", "OBSERVATION", 80, 100], ["increased", "OBSERVATION_MODIFIER", 278, 287], ["respiratory rate", "OBSERVATION", 288, 304], ["cough", "OBSERVATION", 340, 345]]], ["In obstructive upper airway diseases, stridor (laryngeal) and stertor (pharyngeal) abnormalities may be present (patient must be examined under anesthesia).AssociAted signsFluid accumulation in the thoracic cavity may be accompanied by ascites and hepatomegaly.", [["upper airway", "ANATOMY", 15, 27], ["laryngeal", "ANATOMY", 47, 56], ["pharyngeal", "ANATOMY", 71, 81], ["thoracic cavity", "ANATOMY", 198, 213], ["ascites", "ANATOMY", 236, 243], ["obstructive upper airway diseases", "DISEASE", 3, 36], ["stridor", "DISEASE", 38, 45], ["laryngeal) and stertor (pharyngeal) abnormalities", "DISEASE", 47, 96], ["ascites", "DISEASE", 236, 243], ["hepatomegaly", "DISEASE", 248, 260], ["airway", "MULTI-TISSUE_STRUCTURE", 21, 27], ["laryngeal", "ORGAN", 47, 56], ["pharyngeal", "ORGAN", 71, 81], ["patient", "ORGANISM", 113, 120], ["thoracic cavity", "ORGAN", 198, 213], ["patient", "SPECIES", 113, 120], ["obstructive upper airway diseases", "PROBLEM", 3, 36], ["stridor (laryngeal) and stertor (pharyngeal) abnormalities", "PROBLEM", 38, 96], ["anesthesia", "TREATMENT", 144, 154], ["AssociAted signsFluid accumulation in the thoracic cavity", "PROBLEM", 156, 213], ["ascites", "PROBLEM", 236, 243], ["hepatomegaly", "PROBLEM", 248, 260], ["obstructive", "OBSERVATION_MODIFIER", 3, 14], ["upper", "ANATOMY_MODIFIER", 15, 20], ["airway", "ANATOMY", 21, 27], ["diseases", "OBSERVATION", 28, 36], ["stridor", "OBSERVATION", 38, 45], ["laryngeal", "ANATOMY", 47, 56], ["pharyngeal", "ANATOMY", 71, 81], ["signs", "OBSERVATION_MODIFIER", 167, 172], ["Fluid accumulation", "OBSERVATION", 172, 190], ["thoracic cavity", "ANATOMY", 198, 213], ["ascites", "OBSERVATION", 236, 243], ["hepatomegaly", "OBSERVATION", 248, 260]]], ["Physical evidence of hyperadrenocorticism supports thromboembolic pulmonary disease.", [["pulmonary", "ANATOMY", 66, 75], ["hyperadrenocorticism", "DISEASE", 21, 41], ["thromboembolic pulmonary disease", "DISEASE", 51, 83], ["pulmonary", "ORGAN", 66, 75], ["hyperadrenocorticism", "PROBLEM", 21, 41], ["thromboembolic pulmonary disease", "PROBLEM", 51, 83], ["hyperadrenocorticism", "OBSERVATION", 21, 41], ["thromboembolic", "OBSERVATION_MODIFIER", 51, 65], ["pulmonary", "ANATOMY", 66, 75], ["disease", "OBSERVATION", 76, 83]]], ["Cyanosis, pallor, evidence of physical trauma, shock, and coma are serious signs often associated with respiratory distress. differentiAl diAgnosis diAgnostic PlAns 1.", [["respiratory", "ANATOMY", 103, 114], ["Cyanosis", "DISEASE", 0, 8], ["pallor", "DISEASE", 10, 16], ["physical trauma", "DISEASE", 30, 45], ["shock", "DISEASE", 47, 52], ["coma", "DISEASE", 58, 62], ["respiratory distress", "DISEASE", 103, 123], ["Cyanosis", "PROBLEM", 0, 8], ["pallor", "PROBLEM", 10, 16], ["physical trauma", "PROBLEM", 30, 45], ["shock", "PROBLEM", 47, 52], ["coma", "PROBLEM", 58, 62], ["serious signs", "PROBLEM", 67, 80], ["respiratory distress", "PROBLEM", 103, 123], ["pallor", "OBSERVATION", 10, 16], ["physical", "OBSERVATION_MODIFIER", 30, 38], ["trauma", "OBSERVATION", 39, 45], ["shock", "OBSERVATION", 47, 52], ["respiratory distress", "OBSERVATION", 103, 123]]], ["Physical examination is a priority to establish need for supplemental oxygen administration.", [["oxygen", "CHEMICAL", 70, 76], ["oxygen", "CHEMICAL", 70, 76], ["oxygen", "SIMPLE_CHEMICAL", 70, 76], ["Physical examination", "TEST", 0, 20], ["supplemental oxygen administration", "TREATMENT", 57, 91]]], ["Patient stabilization, as required, must be accomplished.", [["Patient", "SPECIES", 0, 7], ["stabilization", "OBSERVATION", 8, 21]]], ["Historical information relevant to duration, progression, past illnesses, and exposure to noxious substances or trauma is indicated.", [["trauma", "DISEASE", 112, 118], ["past illnesses", "PROBLEM", 58, 72], ["noxious substances", "TREATMENT", 90, 108], ["trauma", "PROBLEM", 112, 118]]], ["Knowledge of all current medications, including heartworm preventative, must be established.", [["all current medications", "TREATMENT", 13, 36], ["heartworm preventative", "TREATMENT", 48, 70]]], ["Laboratory profile, to include a CBC, biochemistry panel, urinalysis, heartworm test (in dogs), and FeLV and FIV tests (in cats).", [["dogs", "ORGANISM", 89, 93], ["FeLV", "ORGANISM", 100, 104], ["FIV", "ORGANISM", 109, 112], ["cats", "ORGANISM", 123, 127], ["dogs", "SPECIES", 89, 93], ["cats", "SPECIES", 123, 127], ["FeLV", "SPECIES", 100, 104], ["FIV", "SPECIES", 109, 112], ["Laboratory profile", "TEST", 0, 18], ["a CBC", "TEST", 31, 36], ["biochemistry panel", "TEST", 38, 56], ["urinalysis", "TEST", 58, 68], ["heartworm test", "TEST", 70, 84], ["FeLV", "PROBLEM", 100, 104], ["FIV tests", "TEST", 109, 118]]], ["Cytologic, bacteriologic, and biochemical assessments of body cavity effusions are indicated.", [["body cavity effusions", "ANATOMY", 57, 78], ["effusions", "DISEASE", 69, 78], ["body cavity effusions", "CANCER", 57, 78], ["Cytologic", "TEST", 0, 9], ["bacteriologic", "TEST", 11, 24], ["biochemical assessments", "TEST", 30, 53], ["body cavity effusions", "PROBLEM", 57, 78], ["effusions", "OBSERVATION", 69, 78]]], ["Thoracic and cervical radiographs.", [["Thoracic", "ANATOMY", 0, 8], ["cervical", "ANATOMY", 13, 21], ["Thoracic", "MULTI-TISSUE_STRUCTURE", 0, 8], ["cervical", "ORGAN", 13, 21], ["Thoracic and cervical radiographs", "TEST", 0, 33], ["cervical", "ANATOMY", 13, 21]]], ["Presence of a heart murmur, cardiac arrhythmia, or both should be further evaluated by electrocardiography and echocardio graphy.", [["heart", "ANATOMY", 14, 19], ["cardiac", "ANATOMY", 28, 35], ["heart murmur", "DISEASE", 14, 26], ["cardiac arrhythmia", "DISEASE", 28, 46], ["heart", "ORGAN", 14, 19], ["cardiac", "ORGAN", 28, 35], ["a heart murmur", "PROBLEM", 12, 26], ["cardiac arrhythmia", "PROBLEM", 28, 46], ["electrocardiography", "TEST", 87, 106], ["echocardio graphy", "TEST", 111, 128], ["heart", "ANATOMY", 14, 19], ["murmur", "OBSERVATION", 20, 26], ["cardiac", "ANATOMY", 28, 35], ["arrhythmia", "OBSERVATION", 36, 46]]], ["Swallowing is a complex reflex requiring coordination of multiple muscular and neurologic reactions involving the tongue, palate, pharynx, larynx, esophagus, and gastroesophageal junction.", [["muscular", "ANATOMY", 66, 74], ["neurologic", "ANATOMY", 79, 89], ["tongue", "ANATOMY", 114, 120], ["palate", "ANATOMY", 122, 128], ["pharynx", "ANATOMY", 130, 137], ["larynx", "ANATOMY", 139, 145], ["esophagus", "ANATOMY", 147, 156], ["gastroesophageal junction", "ANATOMY", 162, 187], ["muscular and neurologic reactions", "DISEASE", 66, 99], ["muscular", "ORGAN", 66, 74], ["tongue", "ORGAN", 114, 120], ["palate", "ORGAN", 122, 128], ["pharynx", "ORGAN", 130, 137], ["larynx", "ORGAN", 139, 145], ["esophagus", "ORGAN", 147, 156], ["gastroesophageal junction", "MULTI-TISSUE_STRUCTURE", 162, 187], ["a complex reflex", "PROBLEM", 14, 30], ["multiple muscular and neurologic reactions involving the tongue, palate, pharynx, larynx, esophagus, and gastroesophageal junction", "PROBLEM", 57, 187], ["muscular", "ANATOMY", 66, 74], ["neurologic reactions", "OBSERVATION", 79, 99], ["tongue", "ANATOMY", 114, 120], ["palate", "ANATOMY", 122, 128], ["pharynx", "ANATOMY", 130, 137], ["larynx", "ANATOMY", 139, 145], ["esophagus", "ANATOMY", 147, 156], ["gastroesophageal junction", "ANATOMY", 162, 187]]], ["Dysphagia may occur as a result of disorders affecting any one of the three swallowing phases: oropharyngeal, esophageal, and gastroesophageal.", [["oropharyngeal", "ANATOMY", 95, 108], ["esophageal", "ANATOMY", 110, 120], ["gastroesophageal", "ANATOMY", 126, 142], ["Dysphagia", "DISEASE", 0, 9], ["oropharyngeal", "ORGANISM_SUBDIVISION", 95, 108], ["esophageal", "ORGAN", 110, 120], ["gastroesophageal", "ORGAN", 126, 142], ["Dysphagia", "PROBLEM", 0, 9], ["disorders", "PROBLEM", 35, 44], ["oropharyngeal, esophageal, and gastroesophageal", "PROBLEM", 95, 142], ["oropharyngeal", "ANATOMY", 95, 108], ["esophageal", "ANATOMY", 110, 120], ["gastroesophageal", "ANATOMY", 126, 142]]], ["Disorders affecting the oropharyngeal phase of swallowing are responsible for causing pronounced dysphagia, whereas disorders affecting the esophageal and gastroesophageal phases of swallowing are associated with regurgitation.AssociAted signsDysphagia is observed in young animals, particularly in association with congenital esophageal motility disorders and as an acquired condition in older animals.", [["oropharyngeal", "ANATOMY", 24, 37], ["esophageal", "ANATOMY", 140, 150], ["gastroesophageal", "ANATOMY", 155, 171], ["esophageal", "ANATOMY", 327, 337], ["dysphagia", "DISEASE", 97, 106], ["signsDysphagia", "DISEASE", 238, 252], ["congenital esophageal motility disorders", "DISEASE", 316, 356], ["oropharyngeal", "ORGANISM_SUBDIVISION", 24, 37], ["esophageal", "ORGAN", 140, 150], ["gastroesophageal", "ORGAN", 155, 171], ["esophageal", "ORGAN", 327, 337], ["Disorders", "PROBLEM", 0, 9], ["the oropharyngeal phase of swallowing", "PROBLEM", 20, 57], ["pronounced dysphagia", "PROBLEM", 86, 106], ["whereas disorders", "PROBLEM", 108, 125], ["the esophageal and gastroesophageal phases of swallowing", "PROBLEM", 136, 192], ["regurgitation", "PROBLEM", 213, 226], ["AssociAted signsDysphagia", "PROBLEM", 227, 252], ["congenital esophageal motility disorders", "PROBLEM", 316, 356], ["an acquired condition", "PROBLEM", 364, 385], ["oropharyngeal phase", "OBSERVATION_MODIFIER", 24, 43], ["pronounced", "OBSERVATION_MODIFIER", 86, 96], ["dysphagia", "OBSERVATION", 97, 106], ["esophageal", "ANATOMY", 140, 150], ["gastroesophageal phases", "ANATOMY", 155, 178], ["regurgitation", "OBSERVATION", 213, 226], ["signsDysphagia", "OBSERVATION", 238, 252], ["esophageal", "ANATOMY", 327, 337], ["motility disorders", "OBSERVATION", 338, 356]]], ["This is more common as a presenting sign in dogs than in cats.AssociAted signsPrehension of food in animals presented with dysphagia is characteristically normal.", [["dysphagia", "DISEASE", 123, 132], ["dogs", "ORGANISM", 44, 48], ["cats", "ORGANISM", 57, 61], ["dogs", "SPECIES", 44, 48], ["cats", "SPECIES", 57, 61], ["dysphagia", "PROBLEM", 123, 132], ["more common", "OBSERVATION_MODIFIER", 8, 19], ["signs", "OBSERVATION_MODIFIER", 73, 78], ["Prehension", "OBSERVATION_MODIFIER", 78, 88], ["dysphagia", "OBSERVATION", 123, 132], ["characteristically", "OBSERVATION_MODIFIER", 136, 154], ["normal", "OBSERVATION", 155, 161]]], ["Hypersalivation may occasionally be reported, particularly in animals with nasal discharge associated with regurgitation.AssociAted signsRegurgitation is an inconsistent sign associated with dysphagia that does not necessarily correlate with the severity of the underlying disorder.", [["nasal", "ANATOMY", 75, 80], ["Hypersalivation", "DISEASE", 0, 15], ["signsRegurgitation", "DISEASE", 132, 150], ["dysphagia", "DISEASE", 191, 200], ["nasal", "ORGANISM_SUBDIVISION", 75, 80], ["Hypersalivation", "PROBLEM", 0, 15], ["nasal discharge", "PROBLEM", 75, 90], ["regurgitation", "PROBLEM", 107, 120], ["AssociAted signsRegurgitation", "PROBLEM", 121, 150], ["dysphagia", "PROBLEM", 191, 200], ["the underlying disorder", "PROBLEM", 258, 281], ["nasal", "ANATOMY", 75, 80], ["regurgitation", "OBSERVATION", 107, 120], ["signsRegurgitation", "OBSERVATION", 132, 150], ["dysphagia", "OBSERVATION", 191, 200], ["disorder", "OBSERVATION", 273, 281]]], ["Generally, regurgitation is a consequence of abnormalities of the esophageal and gastroesophageal phases of swallowing.", [["esophageal", "ANATOMY", 66, 76], ["gastroesophageal", "ANATOMY", 81, 97], ["esophageal", "ORGAN", 66, 76], ["gastroesophageal", "ORGAN", 81, 97], ["regurgitation", "PROBLEM", 11, 24], ["abnormalities of the esophageal and gastroesophageal phases of swallowing", "PROBLEM", 45, 118], ["regurgitation", "OBSERVATION", 11, 24], ["esophageal", "ANATOMY", 66, 76], ["gastroesophageal phases", "ANATOMY", 81, 104]]], ["Although most dysphagic patients have a normal to increased appetite (polyphagia), anorexia, weight loss, and coughing may be associated with severe or chronic obstructive esophageal disease or esophageal ulceration.AssociAted signsCaution: Assessment of affected patients for evidence of neurologic signs is of paramount importance, because dysphagia is a principal neurologic complication associated with rabies virus infection. hAir loss: AloPeciA definition Alopecia is the loss or absence of hair coat in any amounts and any distribution.", [["esophageal", "ANATOMY", 172, 182], ["esophageal", "ANATOMY", 194, 204], ["neurologic", "ANATOMY", 289, 299], ["neurologic", "ANATOMY", 367, 377], ["hair coat", "ANATOMY", 497, 506], ["dysphagic", "DISEASE", 14, 23], ["polyphagia", "DISEASE", 70, 80], ["anorexia", "DISEASE", 83, 91], ["weight loss", "DISEASE", 93, 104], ["coughing", "DISEASE", 110, 118], ["obstructive esophageal disease", "DISEASE", 160, 190], ["esophageal ulceration", "DISEASE", 194, 215], ["dysphagia", "DISEASE", 342, 351], ["rabies virus infection", "DISEASE", 407, 429], ["Alopecia", "DISEASE", 462, 470], ["patients", "ORGANISM", 24, 32], ["esophageal", "ORGAN", 172, 182], ["esophageal ulceration", "PATHOLOGICAL_FORMATION", 194, 215], ["patients", "ORGANISM", 264, 272], ["rabies virus", "ORGANISM", 407, 419], ["hAir", "GENE_OR_GENE_PRODUCT", 431, 435], ["hair coat", "MULTI-TISSUE_STRUCTURE", 497, 506], ["patients", "SPECIES", 24, 32], ["patients", "SPECIES", 264, 272], ["rabies virus", "SPECIES", 407, 419], ["increased appetite (polyphagia)", "PROBLEM", 50, 81], ["anorexia", "PROBLEM", 83, 91], ["weight loss", "PROBLEM", 93, 104], ["coughing", "PROBLEM", 110, 118], ["severe or chronic obstructive esophageal disease", "PROBLEM", 142, 190], ["esophageal ulceration", "PROBLEM", 194, 215], ["neurologic signs", "PROBLEM", 289, 305], ["dysphagia", "PROBLEM", 342, 351], ["a principal neurologic complication", "PROBLEM", 355, 390], ["rabies virus infection", "PROBLEM", 407, 429], ["hAir loss", "PROBLEM", 431, 440], ["AloPeciA definition", "PROBLEM", 442, 461], ["Alopecia", "PROBLEM", 462, 470], ["the loss", "PROBLEM", 474, 482], ["hair coat in any amounts", "PROBLEM", 497, 521], ["anorexia", "OBSERVATION", 83, 91], ["weight loss", "OBSERVATION", 93, 104], ["severe", "OBSERVATION_MODIFIER", 142, 148], ["chronic", "OBSERVATION_MODIFIER", 152, 159], ["obstructive", "OBSERVATION_MODIFIER", 160, 171], ["esophageal", "ANATOMY", 172, 182], ["disease", "OBSERVATION", 183, 190], ["esophageal", "ANATOMY", 194, 204], ["ulceration", "OBSERVATION", 205, 215], ["AloPeciA", "OBSERVATION", 442, 450]]], ["Physiologic loss of hair (e.g., normal shedding or hereditary hair loss such as in the Rex cat breed) is excluded from this definition.", [["hair", "ANATOMY", 20, 24], ["hair", "ANATOMY", 62, 66], ["loss of hair", "DISEASE", 12, 24], ["hereditary hair loss", "DISEASE", 51, 71], ["hair", "ORGAN", 20, 24], ["hair", "ORGAN", 62, 66], ["cat", "ORGANISM", 91, 94], ["Physiologic loss of hair (e.g.", "PROBLEM", 0, 30], ["hereditary hair loss", "PROBLEM", 51, 71], ["loss", "OBSERVATION_MODIFIER", 12, 16], ["hair", "OBSERVATION_MODIFIER", 20, 24]]], ["In clinical practice, hair loss, with and without pruritus, is among the most common reasons a cat or dog is presented.", [["hair", "ANATOMY", 22, 26], ["hair loss", "DISEASE", 22, 31], ["pruritus", "DISEASE", 50, 58], ["hair", "MULTI-TISSUE_STRUCTURE", 22, 26], ["cat", "ORGANISM", 95, 98], ["dog", "ORGANISM", 102, 105], ["dog", "SPECIES", 102, 105], ["hair loss", "PROBLEM", 22, 31], ["pruritus", "PROBLEM", 50, 58], ["hair loss", "OBSERVATION", 22, 31]]], ["In most cases the loss of hair is secondary to some underlying disorder rather than being a primary event.", [["hair", "ANATOMY", 26, 30], ["hair", "ORGAN", 26, 30], ["the loss of hair", "PROBLEM", 14, 30], ["some underlying disorder", "PROBLEM", 47, 71], ["a primary event", "PROBLEM", 90, 105], ["disorder", "OBSERVATION", 63, 71]]], ["The distribution of hair loss is important in that it can be characteristic of the underlying cause.", [["hair", "ANATOMY", 20, 24], ["hair loss", "DISEASE", 20, 29], ["hair", "ORGAN", 20, 24], ["hair loss", "PROBLEM", 20, 29], ["distribution", "OBSERVATION_MODIFIER", 4, 16], ["hair loss", "OBSERVATION", 20, 29]]], ["Alopecia can be classified on the basis of distribution as (1) diffuse, (2) regional, (3) multifocal, and (4) focal.", [["Alopecia", "DISEASE", 0, 8], ["Alopecia", "PROBLEM", 0, 8], ["diffuse, (2) regional, (3) multifocal, and (4) focal", "PROBLEM", 63, 115], ["diffuse", "OBSERVATION_MODIFIER", 63, 70], ["multifocal", "OBSERVATION_MODIFIER", 90, 100], ["focal", "OBSERVATION_MODIFIER", 110, 115]]], ["The causes for hair loss are varied and often complex.", [["hair", "ANATOMY", 15, 19], ["hair loss", "DISEASE", 15, 24], ["hair", "ORGAN", 15, 19], ["hair loss", "PROBLEM", 15, 24], ["hair loss", "OBSERVATION", 15, 24], ["varied", "OBSERVATION_MODIFIER", 29, 35]]], ["Abnormalities of follicular structure may be inherited, ranging from complete absence of hair follicles to selective absence of follicles that produce hair of a specific color.", [["follicular structure", "ANATOMY", 17, 37], ["hair follicles", "ANATOMY", 89, 103], ["follicles", "ANATOMY", 128, 137], ["hair", "ANATOMY", 151, 155], ["follicular structure", "MULTI-TISSUE_STRUCTURE", 17, 37], ["hair follicles", "MULTI-TISSUE_STRUCTURE", 89, 103], ["follicles", "MULTI-TISSUE_STRUCTURE", 128, 137], ["hair", "ORGAN", 151, 155], ["Abnormalities of follicular structure", "PROBLEM", 0, 37], ["hair follicles", "PROBLEM", 89, 103], ["follicular structure", "OBSERVATION", 17, 37], ["may be", "UNCERTAINTY", 38, 44], ["ranging", "OBSERVATION_MODIFIER", 56, 63], ["hair follicles", "OBSERVATION", 89, 103], ["follicles", "OBSERVATION", 128, 137]]], ["Inflammatory skin diseases that incorporate the hair follicle may disrupt hair growth and maintenance.", [["skin", "ANATOMY", 13, 17], ["hair follicle", "ANATOMY", 48, 61], ["hair", "ANATOMY", 74, 78], ["skin diseases", "DISEASE", 13, 26], ["skin", "ORGAN", 13, 17], ["hair follicle", "MULTI-TISSUE_STRUCTURE", 48, 61], ["hair", "MULTI-TISSUE_STRUCTURE", 74, 78], ["Inflammatory skin diseases", "PROBLEM", 0, 26], ["the hair follicle", "PROBLEM", 44, 61], ["hair growth", "PROBLEM", 74, 85], ["skin", "ANATOMY", 13, 17], ["diseases", "OBSERVATION", 18, 26], ["growth", "OBSERVATION_MODIFIER", 79, 85]]], ["Bacterial folliculitis, demodectic mange, and follicular hyperkeratosis are examples.AssociAted signsDisorders that disrupt the normal follicular cycles can interrupt hair growth without loss or injury to the hair follicle.", [["follicular hyperkeratosis", "ANATOMY", 46, 71], ["follicular", "ANATOMY", 135, 145], ["hair", "ANATOMY", 167, 171], ["hair follicle", "ANATOMY", 209, 222], ["folliculitis", "DISEASE", 10, 22], ["demodectic mange", "DISEASE", 24, 40], ["follicular hyperkeratosis", "DISEASE", 46, 71], ["follicular hyperkeratosis", "PATHOLOGICAL_FORMATION", 46, 71], ["hair", "MULTI-TISSUE_STRUCTURE", 167, 171], ["hair follicle", "MULTI-TISSUE_STRUCTURE", 209, 222], ["Bacterial folliculitis", "PROBLEM", 0, 22], ["demodectic mange", "PROBLEM", 24, 40], ["follicular hyperkeratosis", "PROBLEM", 46, 71], ["AssociAted signsDisorders", "PROBLEM", 85, 110], ["hair growth", "PROBLEM", 167, 178], ["loss or injury to the hair follicle", "PROBLEM", 187, 222], ["folliculitis", "OBSERVATION", 10, 22], ["follicular hyperkeratosis", "OBSERVATION", 46, 71], ["normal follicular cycles", "OBSERVATION", 128, 152], ["injury", "OBSERVATION", 195, 201], ["hair follicle", "OBSERVATION", 209, 222]]], ["The cycle is as follows: anagen (growth phase), catagen (transitional phase), and telogen (resting phase).AssociAted signsThe complex pathogenesis of alopecia supports a multitude of associated clinical signs in any animal presented with hair loss.", [["hair", "ANATOMY", 238, 242], ["alopecia", "DISEASE", 150, 158], ["hair loss", "DISEASE", 238, 247], ["alopecia", "PATHOLOGICAL_FORMATION", 150, 158], ["hair", "ORGAN", 238, 242], ["anagen (growth phase", "TEST", 25, 45], ["catagen (transitional phase", "TEST", 48, 75], ["telogen (resting phase", "TEST", 82, 104], ["AssociAted signs", "PROBLEM", 106, 122], ["alopecia", "PROBLEM", 150, 158], ["associated clinical signs", "PROBLEM", 183, 208], ["hair loss", "PROBLEM", 238, 247], ["complex", "OBSERVATION_MODIFIER", 126, 133], ["pathogenesis", "OBSERVATION", 134, 146], ["alopecia", "OBSERVATION", 150, 158], ["hair loss", "OBSERVATION", 238, 247]]], ["Pruritus is an important associated sign if present.", [["Pruritus", "DISEASE", 0, 8], ["Pruritus", "PROBLEM", 0, 8]]], ["Allergic, inflammatory, and parasitic skin diseases are likely to cause pruritus.", [["skin", "ANATOMY", 38, 42], ["parasitic skin diseases", "DISEASE", 28, 51], ["pruritus", "DISEASE", 72, 80], ["skin", "ORGAN", 38, 42], ["Allergic", "PROBLEM", 0, 8], ["inflammatory", "PROBLEM", 10, 22], ["parasitic skin diseases", "PROBLEM", 28, 51], ["pruritus", "PROBLEM", 72, 80], ["inflammatory", "OBSERVATION_MODIFIER", 10, 22], ["parasitic", "OBSERVATION_MODIFIER", 28, 37], ["skin", "ANATOMY", 38, 42], ["diseases", "OBSERVATION", 43, 51], ["likely to cause", "UNCERTAINTY", 56, 71], ["pruritus", "OBSERVATION", 72, 80]]], ["Secondary traumatic excoriation of the skin may further provoke cutaneous injury, thereby intensifying the pruritus.", [["skin", "ANATOMY", 39, 43], ["cutaneous", "ANATOMY", 64, 73], ["cutaneous injury", "DISEASE", 64, 80], ["pruritus", "DISEASE", 107, 115], ["skin", "ORGAN", 39, 43], ["cutaneous", "ORGANISM_SUBDIVISION", 64, 73], ["Secondary traumatic excoriation of the skin", "PROBLEM", 0, 43], ["cutaneous injury", "PROBLEM", 64, 80], ["the pruritus", "PROBLEM", 103, 115], ["traumatic", "OBSERVATION_MODIFIER", 10, 19], ["excoriation", "OBSERVATION", 20, 31], ["skin", "ANATOMY", 39, 43], ["may further provoke", "UNCERTAINTY", 44, 63], ["cutaneous", "ANATOMY", 64, 73], ["injury", "OBSERVATION", 74, 80], ["pruritus", "OBSERVATION", 107, 115]]], ["Alopecia caused by endocrine, genetic, and metabolic factors is less likely to be associated with pruritus, although pruritus may become a factor if the exposed skin becomes particularly dry or sunburned.", [["endocrine", "ANATOMY", 19, 28], ["skin", "ANATOMY", 161, 165], ["Alopecia", "DISEASE", 0, 8], ["pruritus", "DISEASE", 98, 106], ["pruritus", "DISEASE", 117, 125], ["endocrine", "ANATOMICAL_SYSTEM", 19, 28], ["skin", "ORGAN", 161, 165], ["Alopecia", "PROBLEM", 0, 8], ["pruritus", "PROBLEM", 98, 106], ["pruritus", "PROBLEM", 117, 125], ["the exposed skin", "PROBLEM", 149, 165], ["skin", "ANATOMY", 161, 165]]], ["Immune-mediated diseases leading to alopecia are variably pruritic, depending on the distribution and type of skin injury.", [["skin", "ANATOMY", 110, 114], ["alopecia", "DISEASE", 36, 44], ["skin injury", "DISEASE", 110, 121], ["skin", "ORGAN", 110, 114], ["Immune-mediated diseases", "PROBLEM", 0, 24], ["alopecia", "PROBLEM", 36, 44], ["variably pruritic", "PROBLEM", 49, 66], ["skin injury", "PROBLEM", 110, 121], ["diseases", "OBSERVATION", 16, 24], ["alopecia", "OBSERVATION", 36, 44], ["variably", "OBSERVATION_MODIFIER", 49, 57], ["pruritic", "OBSERVATION_MODIFIER", 58, 66], ["skin", "ANATOMY", 110, 114], ["injury", "OBSERVATION", 115, 121]]], ["Nutritional alopecia is rarely confirmed but can be a source of dermatitis and associated pruritus.AssociAted signsAlopecia without pruritus may be associated with dramatic physical signs resulting from endocrine or metabolic disorders.", [["endocrine", "ANATOMY", 203, 212], ["alopecia", "DISEASE", 12, 20], ["dermatitis", "DISEASE", 64, 74], ["pruritus", "DISEASE", 90, 98], ["Alopecia", "DISEASE", 115, 123], ["pruritus", "DISEASE", 132, 140], ["endocrine or metabolic disorders", "DISEASE", 203, 235], ["endocrine", "ANATOMICAL_SYSTEM", 203, 212], ["Nutritional alopecia", "PROBLEM", 0, 20], ["dermatitis", "PROBLEM", 64, 74], ["associated pruritus", "PROBLEM", 79, 98], ["AssociAted signsAlopecia", "PROBLEM", 99, 123], ["pruritus", "PROBLEM", 132, 140], ["dramatic physical signs", "PROBLEM", 164, 187], ["endocrine or metabolic disorders", "PROBLEM", 203, 235], ["alopecia", "OBSERVATION", 12, 20], ["dermatitis", "OBSERVATION", 64, 74], ["pruritus", "OBSERVATION", 90, 98], ["signs", "OBSERVATION_MODIFIER", 110, 115], ["Alopecia", "OBSERVATION", 115, 123], ["without", "UNCERTAINTY", 124, 131], ["pruritus", "OBSERVATION", 132, 140], ["metabolic disorders", "OBSERVATION", 216, 235]]], ["Dermatologic signs include thickened skin, hyperpigmentation, and dry and brittle hair coat (hypothyroidism).", [["skin", "ANATOMY", 37, 41], ["hair", "ANATOMY", 82, 86], ["hyperpigmentation", "DISEASE", 43, 60], ["dry and brittle hair coat", "DISEASE", 66, 91], ["hypothyroidism", "DISEASE", 93, 107], ["skin", "ORGAN", 37, 41], ["Dermatologic signs", "TEST", 0, 18], ["thickened skin", "PROBLEM", 27, 41], ["hyperpigmentation", "PROBLEM", 43, 60], ["dry and brittle hair coat (hypothyroidism)", "PROBLEM", 66, 108], ["thickened", "OBSERVATION_MODIFIER", 27, 36], ["skin", "ANATOMY", 37, 41], ["hyperpigmentation", "OBSERVATION", 43, 60], ["dry", "OBSERVATION", 66, 69], ["brittle hair", "OBSERVATION_MODIFIER", 74, 86], ["coat", "OBSERVATION_MODIFIER", 87, 91], ["hypothyroidism", "OBSERVATION", 93, 107]]], ["On the other hand, skin may appear thin and lack elasticity (canine Cushing syndrome, Sertoli cell tumor).", [["skin", "ANATOMY", 19, 23], ["Sertoli cell tumor", "ANATOMY", 86, 104], ["Cushing syndrome", "DISEASE", 68, 84], ["Sertoli cell tumor", "DISEASE", 86, 104], ["skin", "ORGAN", 19, 23], ["Sertoli cell tumor", "CANCER", 86, 104], ["thin and lack elasticity (canine Cushing syndrome", "PROBLEM", 35, 84], ["Sertoli cell tumor", "PROBLEM", 86, 104], ["skin", "ANATOMY", 19, 23], ["may appear", "UNCERTAINTY", 24, 34], ["thin", "OBSERVATION", 35, 39], ["lack elasticity", "OBSERVATION_MODIFIER", 44, 59], ["Sertoli cell tumor", "OBSERVATION", 86, 104]]], ["Gynecomastia, skin softness, calcinosis cutis, and pigmented macules are other dermatologic signs associated with alopecia.differentiAl diAgnosisVirtually all dogs and cats with primary skin disease manifest some degree of alopecia.", [["skin", "ANATOMY", 14, 18], ["pigmented macules", "ANATOMY", 51, 68], ["skin", "ANATOMY", 186, 190], ["Gynecomastia", "DISEASE", 0, 12], ["skin softness", "DISEASE", 14, 27], ["calcinosis cutis", "DISEASE", 29, 45], ["pigmented macules", "DISEASE", 51, 68], ["alopecia", "DISEASE", 114, 122], ["primary skin disease", "DISEASE", 178, 198], ["alopecia", "DISEASE", 223, 231], ["skin", "ORGAN", 14, 18], ["pigmented macules", "PATHOLOGICAL_FORMATION", 51, 68], ["dogs", "ORGANISM", 159, 163], ["cats", "ORGANISM", 168, 172], ["skin", "ORGAN", 186, 190], ["alopecia", "PATHOLOGICAL_FORMATION", 223, 231], ["dogs", "SPECIES", 159, 163], ["cats", "SPECIES", 168, 172], ["Gynecomastia", "PROBLEM", 0, 12], ["skin softness", "PROBLEM", 14, 27], ["calcinosis cutis", "PROBLEM", 29, 45], ["pigmented macules", "PROBLEM", 51, 68], ["other dermatologic signs", "PROBLEM", 73, 97], ["alopecia", "PROBLEM", 114, 122], ["all dogs and cats", "PROBLEM", 155, 172], ["primary skin disease", "PROBLEM", 178, 198], ["alopecia", "PROBLEM", 223, 231], ["skin", "ANATOMY", 14, 18], ["softness", "OBSERVATION_MODIFIER", 19, 27], ["calcinosis cutis", "OBSERVATION", 29, 45], ["pigmented", "OBSERVATION_MODIFIER", 51, 60], ["macules", "OBSERVATION", 61, 68], ["alopecia", "OBSERVATION", 114, 122], ["skin", "ANATOMY", 186, 190], ["disease", "OBSERVATION", 191, 198], ["degree", "OBSERVATION_MODIFIER", 213, 219], ["alopecia", "OBSERVATION", 223, 231]]], ["The pattern of hair loss is typically asymmetric, and primary skin disease can appear to be symmetric (e.g., parasitic dermatosis).", [["hair", "ANATOMY", 15, 19], ["skin", "ANATOMY", 62, 66], ["hair loss", "DISEASE", 15, 24], ["primary skin disease", "DISEASE", 54, 74], ["parasitic dermatosis", "DISEASE", 109, 129], ["hair", "ORGAN", 15, 19], ["skin", "ORGAN", 62, 66], ["hair loss", "PROBLEM", 15, 24], ["primary skin disease", "PROBLEM", 54, 74], ["parasitic dermatosis", "PROBLEM", 109, 129], ["hair loss", "OBSERVATION", 15, 24], ["asymmetric", "OBSERVATION_MODIFIER", 38, 48], ["skin", "ANATOMY", 62, 66], ["disease", "OBSERVATION", 67, 74], ["symmetric", "OBSERVATION_MODIFIER", 92, 101], ["parasitic", "OBSERVATION_MODIFIER", 109, 118], ["dermatosis", "OBSERVATION", 119, 129]]], ["In pursuing the diagnosis in dogs or cats presented with hair loss, thorough systemic and skin examinations are indicated.", [["hair", "ANATOMY", 57, 61], ["skin", "ANATOMY", 90, 94], ["hair loss", "DISEASE", 57, 66], ["dogs", "ORGANISM", 29, 33], ["cats", "ORGANISM", 37, 41], ["hair", "MULTI-TISSUE_STRUCTURE", 57, 61], ["skin", "ORGAN", 90, 94], ["dogs", "SPECIES", 29, 33], ["cats", "SPECIES", 37, 41], ["hair loss", "PROBLEM", 57, 66], ["thorough systemic and skin examinations", "TEST", 68, 107], ["skin", "ANATOMY", 90, 94]]], ["The clinician may find it helpful to characterize a patient's hair loss according to various etiologic categories, as follows.incoordinAtion: AtAxiA definitionAtaxia is the loss of coordination without spasticity, paresis, or involuntary movement.", [["hair", "ANATOMY", 62, 66], ["hair loss", "DISEASE", 62, 71], ["loss of coordination", "DISEASE", 173, 193], ["spasticity", "DISEASE", 202, 212], ["paresis", "DISEASE", 214, 221], ["involuntary movement", "DISEASE", 226, 246], ["patient", "ORGANISM", 52, 59], ["hair", "ORGAN", 62, 66], ["patient", "SPECIES", 52, 59], ["a patient's hair loss", "PROBLEM", 50, 71], ["incoordinAtion", "PROBLEM", 126, 140], ["AtAxiA definitionAtaxia", "PROBLEM", 142, 165], ["the loss of coordination", "PROBLEM", 169, 193], ["spasticity", "PROBLEM", 202, 212], ["paresis", "PROBLEM", 214, 221], ["involuntary movement", "PROBLEM", 226, 246], ["AtAxiA", "OBSERVATION", 142, 148], ["paresis", "OBSERVATION", 214, 221]]], ["In practice, however, it is possible for ataxia to be accompanied by additional neurologic signs.", [["neurologic", "ANATOMY", 80, 90], ["ataxia", "DISEASE", 41, 47], ["ataxia", "PROBLEM", 41, 47], ["additional neurologic signs", "PROBLEM", 69, 96]]], ["Ataxia is the result of disorders of the conscious or unconscious proprioceptive system, disorders of the cerebellum, or disorders of the vestibular system.AssociAted signsIn the spectrum of disorders causing ataxia, lesions of the vestibular system predominate.", [["proprioceptive system", "ANATOMY", 66, 87], ["cerebellum", "ANATOMY", 106, 116], ["vestibular system", "ANATOMY", 138, 155], ["lesions", "ANATOMY", 217, 224], ["vestibular system", "ANATOMY", 232, 249], ["Ataxia", "DISEASE", 0, 6], ["disorders of the conscious or unconscious proprioceptive system", "DISEASE", 24, 87], ["disorders of the cerebellum", "DISEASE", 89, 116], ["disorders of the vestibular system", "DISEASE", 121, 155], ["ataxia", "DISEASE", 209, 215], ["lesions of the vestibular system", "DISEASE", 217, 249], ["cerebellum", "ORGAN", 106, 116], ["vestibular system", "MULTI-TISSUE_STRUCTURE", 138, 155], ["lesions", "CANCER", 217, 224], ["vestibular system", "MULTI-TISSUE_STRUCTURE", 232, 249], ["Ataxia", "PROBLEM", 0, 6], ["disorders of the conscious or unconscious proprioceptive system", "PROBLEM", 24, 87], ["disorders of the cerebellum", "PROBLEM", 89, 116], ["disorders of the vestibular system", "PROBLEM", 121, 155], ["AssociAted signs", "PROBLEM", 156, 172], ["disorders", "PROBLEM", 191, 200], ["ataxia", "PROBLEM", 209, 215], ["lesions of the vestibular system", "PROBLEM", 217, 249], ["cerebellum", "ANATOMY", 106, 116], ["vestibular system", "ANATOMY", 138, 155], ["ataxia", "OBSERVATION", 209, 215], ["lesions", "OBSERVATION", 217, 224], ["vestibular system", "ANATOMY", 232, 249]]], ["However, vestibular signs may result from other brain disorders and spinal cord syndromes.", [["vestibular", "ANATOMY", 9, 19], ["brain", "ANATOMY", 48, 53], ["spinal cord", "ANATOMY", 68, 79], ["vestibular signs", "DISEASE", 9, 25], ["brain disorders", "DISEASE", 48, 63], ["cord syndromes", "DISEASE", 75, 89], ["brain", "ORGAN", 48, 53], ["spinal cord", "ORGAN", 68, 79], ["vestibular signs", "PROBLEM", 9, 25], ["other brain disorders", "PROBLEM", 42, 63], ["spinal cord syndromes", "PROBLEM", 68, 89], ["brain", "ANATOMY", 48, 53], ["disorders", "OBSERVATION", 54, 63], ["spinal cord", "ANATOMY", 68, 79], ["syndromes", "OBSERVATION", 80, 89]]], ["Associated signs include head tilt, nystagmus, circling, and hemiparesis.", [["head", "ANATOMY", 25, 29], ["nystagmus", "DISEASE", 36, 45], ["hemiparesis", "DISEASE", 61, 72], ["head", "ORGANISM_SUBDIVISION", 25, 29], ["head tilt", "PROBLEM", 25, 34], ["nystagmus", "PROBLEM", 36, 45], ["circling", "PROBLEM", 47, 55], ["hemiparesis", "PROBLEM", 61, 72], ["head tilt", "OBSERVATION", 25, 34], ["nystagmus", "OBSERVATION", 36, 45], ["hemiparesis", "OBSERVATION", 61, 72]]], ["Patients with cerebellar lesions typically have symmetric signs: hypermetria, abnormally long range of movement (goose-stepping gait); hypometria, abnormally short range of movement; or tremor, particularly of the head.", [["cerebellar lesions", "ANATOMY", 14, 32], ["head", "ANATOMY", 214, 218], ["cerebellar lesions", "DISEASE", 14, 32], ["hypermetria", "DISEASE", 65, 76], ["hypometria", "DISEASE", 135, 145], ["tremor", "DISEASE", 186, 192], ["Patients", "ORGANISM", 0, 8], ["cerebellar lesions", "CANCER", 14, 32], ["head", "ORGANISM_SUBDIVISION", 214, 218], ["Patients", "SPECIES", 0, 8], ["cerebellar lesions", "PROBLEM", 14, 32], ["hypermetria", "PROBLEM", 65, 76], ["abnormally long range of movement", "PROBLEM", 78, 111], ["hypometria", "PROBLEM", 135, 145], ["abnormally short range of movement", "PROBLEM", 147, 181], ["tremor", "PROBLEM", 186, 192], ["cerebellar", "ANATOMY", 14, 24], ["lesions", "OBSERVATION", 25, 32], ["symmetric", "OBSERVATION_MODIFIER", 48, 57], ["abnormally", "OBSERVATION_MODIFIER", 78, 88], ["long range", "OBSERVATION_MODIFIER", 89, 99], ["short range", "OBSERVATION_MODIFIER", 158, 169], ["head", "ANATOMY", 214, 218]]], ["In practice, polyuria (PU) and polydipsia (PD), also abbreviated PU/PD, are loosely interpreted to mean an increase in urination and water consumption, respectively.", [["polyuria", "DISEASE", 13, 21], ["PU", "DISEASE", 23, 25], ["polydipsia", "DISEASE", 31, 41], ["PD", "DISEASE", 43, 45], ["PD", "DISEASE", 68, 70], ["water", "SIMPLE_CHEMICAL", 133, 138], ["polyuria (PU)", "PROBLEM", 13, 26], ["polydipsia", "PROBLEM", 31, 41], ["abbreviated PU/PD", "PROBLEM", 53, 70], ["an increase in urination", "PROBLEM", 104, 128], ["polyuria", "OBSERVATION", 13, 21], ["polydipsia", "OBSERVATION", 31, 41], ["increase", "OBSERVATION_MODIFIER", 107, 115]]], ["True PU, however, is an abnormal increase in urine production, usually of low specific gravity.", [["urine", "ANATOMY", 45, 50], ["urine", "ORGANISM_SUBSTANCE", 45, 50], ["an abnormal increase in urine production", "PROBLEM", 21, 61], ["PU", "OBSERVATION", 5, 7], ["abnormal", "OBSERVATION_MODIFIER", 24, 32], ["increase", "OBSERVATION_MODIFIER", 33, 41], ["urine production", "OBSERVATION", 45, 61]]], ["Although PD is an abnormal or absolute increase in water consumption usually associated with increased thirst, water intake is seldom quantitated.", [["PD", "DISEASE", 9, 11], ["water", "SIMPLE_CHEMICAL", 51, 56], ["water", "SIMPLE_CHEMICAL", 111, 116], ["PD", "PROBLEM", 9, 11], ["an abnormal", "PROBLEM", 15, 26], ["water consumption", "PROBLEM", 51, 68], ["increased thirst", "PROBLEM", 93, 109], ["abnormal", "OBSERVATION_MODIFIER", 18, 26], ["absolute", "OBSERVATION_MODIFIER", 30, 38], ["increase", "OBSERVATION_MODIFIER", 39, 47], ["water consumption", "OBSERVATION_MODIFIER", 51, 68], ["increased", "OBSERVATION_MODIFIER", 93, 102], ["thirst", "OBSERVATION", 103, 109]]], ["Use of the terms polyuria and polydipsia is usually justified when a client presents a dog or cat with subjective increases in urination frequency and water intake as the primary problem.", [["polyuria", "DISEASE", 17, 25], ["polydipsia", "DISEASE", 30, 40], ["dog", "ORGANISM", 87, 90], ["cat", "ORGANISM", 94, 97], ["urination", "ORGANISM_SUBDIVISION", 127, 136], ["water", "SIMPLE_CHEMICAL", 151, 156], ["the terms polyuria", "PROBLEM", 7, 25], ["polydipsia", "PROBLEM", 30, 40], ["subjective increases in urination frequency", "PROBLEM", 103, 146], ["polydipsia", "OBSERVATION", 30, 40]]], ["When clear evidence of increased urination and increased thirst is not present, actual documentation of 24-hour urinary output and water intake may be necessary.", [["urinary", "ANATOMY", 112, 119], ["urinary", "ORGANISM_SUBSTANCE", 112, 119], ["water", "SIMPLE_CHEMICAL", 131, 136], ["increased urination", "PROBLEM", 23, 42], ["increased thirst", "PROBLEM", 47, 63], ["urinary output", "TEST", 112, 126], ["increased", "OBSERVATION_MODIFIER", 23, 32], ["urination", "OBSERVATION", 33, 42], ["increased", "OBSERVATION_MODIFIER", 47, 56], ["thirst", "OBSERVATION", 57, 63]]], ["PD is a compensatory sign that develops subsequent to PU.", [["PD", "DISEASE", 0, 2], ["a compensatory sign", "PROBLEM", 6, 25], ["PU", "OBSERVATION", 54, 56]]], ["Primary PD with compensatory PU is uncommon.", [["PD", "DISEASE", 8, 10], ["compensatory PU", "PROBLEM", 16, 31], ["compensatory", "OBSERVATION_MODIFIER", 16, 28], ["PU", "OBSERVATION", 29, 31]]], ["Primary PD subsequent to increased thirst can cause secondary PU but is an uncommon clinical finding.", [["PD", "DISEASE", 8, 10], ["PU", "DISEASE", 62, 64], ["Primary PD", "PROBLEM", 0, 10], ["increased thirst", "PROBLEM", 25, 41], ["secondary PU", "PROBLEM", 52, 64], ["secondary PU", "OBSERVATION", 52, 64], ["uncommon", "OBSERVATION_MODIFIER", 75, 83]]], ["Compulsive water drinking (pseudopsychogenic PD) is probably the most important type of primary PD, although the underlying cause is not known.", [["PD", "DISEASE", 45, 47], ["primary PD", "DISEASE", 88, 98], ["primary PD", "PROBLEM", 88, 98], ["probably the", "UNCERTAINTY", 52, 64], ["most important", "OBSERVATION_MODIFIER", 65, 79]]], ["Hypothalamic lesions, hypercalcemia, and increased levels of plasma renin are less common causes of primary PD.AssociAted signsSigns associated with PU or PD are varied and dependent on the underlying disease.", [["Hypothalamic lesions", "ANATOMY", 0, 20], ["plasma", "ANATOMY", 61, 67], ["Hypothalamic lesions", "DISEASE", 0, 20], ["hypercalcemia", "DISEASE", 22, 35], ["primary PD", "DISEASE", 100, 110], ["PD", "DISEASE", 155, 157], ["Hypothalamic lesions", "PATHOLOGICAL_FORMATION", 0, 20], ["plasma", "ORGANISM_SUBSTANCE", 61, 67], ["renin", "GENE_OR_GENE_PRODUCT", 68, 73], ["plasma renin", "PROTEIN", 61, 73], ["Hypothalamic lesions", "PROBLEM", 0, 20], ["hypercalcemia", "PROBLEM", 22, 35], ["increased levels of plasma renin", "PROBLEM", 41, 73], ["primary PD", "PROBLEM", 100, 110], ["AssociAted signsSigns", "PROBLEM", 111, 132], ["PU", "PROBLEM", 149, 151], ["PD", "PROBLEM", 155, 157], ["the underlying disease", "PROBLEM", 186, 208], ["lesions", "OBSERVATION", 13, 20], ["hypercalcemia", "OBSERVATION", 22, 35], ["increased", "OBSERVATION_MODIFIER", 41, 50], ["PU", "OBSERVATION", 149, 151], ["dependent", "OBSERVATION_MODIFIER", 173, 182], ["disease", "OBSERVATION", 201, 208]]], ["Generalized signs include weakness, decreased appetite, weight loss, diarrhea, and fever.", [["weakness", "DISEASE", 26, 34], ["decreased appetite", "DISEASE", 36, 54], ["weight loss", "DISEASE", 56, 67], ["diarrhea", "DISEASE", 69, 77], ["fever", "DISEASE", 83, 88], ["Generalized signs", "PROBLEM", 0, 17], ["weakness", "PROBLEM", 26, 34], ["decreased appetite", "PROBLEM", 36, 54], ["weight loss", "PROBLEM", 56, 67], ["diarrhea", "PROBLEM", 69, 77], ["fever", "PROBLEM", 83, 88], ["weakness", "OBSERVATION", 26, 34], ["decreased", "OBSERVATION_MODIFIER", 36, 45], ["diarrhea", "OBSERVATION", 69, 77], ["fever", "OBSERVATION", 83, 88]]], ["Polyphagia with weight loss occurs in animals with diabetes mellitus and in cats with associated with wheal-and-flare reaction.", [["Polyphagia", "DISEASE", 0, 10], ["weight loss", "DISEASE", 16, 27], ["diabetes mellitus", "DISEASE", 51, 68], ["cats", "ORGANISM", 76, 80], ["cats", "SPECIES", 76, 80], ["Polyphagia", "PROBLEM", 0, 10], ["weight loss", "PROBLEM", 16, 27], ["diabetes mellitus", "PROBLEM", 51, 68], ["wheal-and-flare reaction", "PROBLEM", 102, 126], ["weight loss", "OBSERVATION", 16, 27], ["flare", "OBSERVATION", 112, 117]]], ["Histamine-mediated itching cannot be completely inhibited by either H 1 -or H 2 -receptor antagonists (blockers).", [["Histamine", "CHEMICAL", 0, 9], ["itching", "DISEASE", 19, 26], ["Histamine", "CHEMICAL", 0, 9], ["Histamine", "SIMPLE_CHEMICAL", 0, 9], ["H 1", "SIMPLE_CHEMICAL", 68, 71], ["H 2 -receptor antagonists", "SIMPLE_CHEMICAL", 76, 101], ["Histamine-mediated itching", "PROBLEM", 0, 26], ["receptor antagonists (blockers", "TREATMENT", 81, 111], ["itching", "OBSERVATION", 19, 26]]], ["The close association between itching and inflammation of the skin is attributed to the fact that many of the endogenous mediators and potentiators are released in situ during inflammatory events.", [["skin", "ANATOMY", 62, 66], ["itching", "DISEASE", 30, 37], ["inflammation", "DISEASE", 42, 54], ["skin", "ORGAN", 62, 66], ["endogenous mediators", "PROTEIN", 110, 130], ["itching", "PROBLEM", 30, 37], ["inflammation of the skin", "PROBLEM", 42, 66], ["inflammatory events", "PROBLEM", 176, 195], ["itching", "OBSERVATION", 30, 37], ["inflammation", "OBSERVATION", 42, 54], ["skin", "ANATOMY", 62, 66], ["inflammatory", "OBSERVATION_MODIFIER", 176, 188]]], ["Itching, although a protective response, can become more harmful than helpful.", [["Itching", "PROBLEM", 0, 7]]], ["As a feature of dermatitis, itch mediators cannot be removed by the patient.", [["dermatitis", "DISEASE", 16, 26], ["itch", "DISEASE", 28, 32], ["patient", "ORGANISM", 68, 75], ["patient", "SPECIES", 68, 75], ["dermatitis", "PROBLEM", 16, 26], ["itch mediators", "PROBLEM", 28, 42], ["dermatitis", "OBSERVATION", 16, 26]]], ["In fact, scratching and biting eventually promote more inflammation and subsequently perpetuate the itching.AssociAted signsSkin lesions are commonly associated with pruritus; however, it becomes important to characterize the lesions and to distinguish those that are primary from those that are secondary to scratching or biting.", [["Skin lesions", "ANATOMY", 124, 136], ["lesions", "ANATOMY", 226, 233], ["inflammation", "DISEASE", 55, 67], ["itching", "DISEASE", 100, 107], ["Skin lesions", "DISEASE", 124, 136], ["pruritus", "DISEASE", 166, 174], ["scratching", "DISEASE", 309, 319], ["Skin lesions", "CANCER", 124, 136], ["lesions", "PATHOLOGICAL_FORMATION", 226, 233], ["scratching", "PROBLEM", 9, 19], ["biting", "PROBLEM", 24, 30], ["more inflammation", "PROBLEM", 50, 67], ["the itching", "PROBLEM", 96, 107], ["AssociAted signsSkin lesions", "PROBLEM", 108, 136], ["pruritus", "PROBLEM", 166, 174], ["the lesions", "PROBLEM", 222, 233], ["scratching", "PROBLEM", 309, 319], ["biting", "PROBLEM", 323, 329], ["scratching", "OBSERVATION_MODIFIER", 9, 19], ["inflammation", "OBSERVATION", 55, 67], ["itching", "OBSERVATION", 100, 107], ["signs", "OBSERVATION_MODIFIER", 119, 124], ["Skin", "ANATOMY", 124, 128], ["lesions", "OBSERVATION", 129, 136], ["lesions", "OBSERVATION", 226, 233]]], ["Papules and pustules are characteristic primary lesions that may ultimately develop into secondary lesions, such as crusts, ulcers, scale in collarettes, and pigmented macules.", [["Papules", "ANATOMY", 0, 7], ["pustules", "ANATOMY", 12, 20], ["primary lesions", "ANATOMY", 40, 55], ["lesions", "ANATOMY", 99, 106], ["crusts", "ANATOMY", 116, 122], ["ulcers", "ANATOMY", 124, 130], ["collarettes", "ANATOMY", 141, 152], ["macules", "ANATOMY", 168, 175], ["Papules", "DISEASE", 0, 7], ["pustules", "DISEASE", 12, 20], ["crusts", "DISEASE", 116, 122], ["ulcers", "DISEASE", 124, 130], ["collarettes", "DISEASE", 141, 152], ["macules", "DISEASE", 168, 175], ["pustules", "PATHOLOGICAL_FORMATION", 12, 20], ["lesions", "CANCER", 48, 55], ["lesions", "PATHOLOGICAL_FORMATION", 99, 106], ["ulcers", "PATHOLOGICAL_FORMATION", 124, 130], ["pigmented macules", "PATHOLOGICAL_FORMATION", 158, 175], ["Papules", "PROBLEM", 0, 7], ["pustules", "PROBLEM", 12, 20], ["primary lesions", "PROBLEM", 40, 55], ["secondary lesions", "PROBLEM", 89, 106], ["crusts", "PROBLEM", 116, 122], ["ulcers", "PROBLEM", 124, 130], ["scale in collarettes", "TEST", 132, 152], ["pigmented macules", "PROBLEM", 158, 175], ["pustules", "OBSERVATION", 12, 20], ["primary", "OBSERVATION_MODIFIER", 40, 47], ["lesions", "OBSERVATION", 48, 55], ["secondary", "OBSERVATION_MODIFIER", 89, 98], ["lesions", "OBSERVATION", 99, 106], ["crusts", "OBSERVATION_MODIFIER", 116, 122], ["ulcers", "OBSERVATION", 124, 130], ["pigmented", "OBSERVATION_MODIFIER", 158, 167], ["macules", "OBSERVATION", 168, 175]]], ["Vesicles and bullae, plaques, and urticaria (wheals) can also occur as primary skin lesions.", [["Vesicles", "ANATOMY", 0, 8], ["bullae", "ANATOMY", 13, 19], ["plaques", "ANATOMY", 21, 28], ["skin lesions", "ANATOMY", 79, 91], ["plaques", "DISEASE", 21, 28], ["urticaria", "DISEASE", 34, 43], ["primary skin lesions", "DISEASE", 71, 91], ["Vesicles", "ORGANISM_SUBSTANCE", 0, 8], ["bullae", "PATHOLOGICAL_FORMATION", 13, 19], ["skin lesions", "CANCER", 79, 91], ["Vesicles", "PROBLEM", 0, 8], ["bullae", "PROBLEM", 13, 19], ["plaques", "PROBLEM", 21, 28], ["urticaria", "PROBLEM", 34, 43], ["primary skin lesions", "PROBLEM", 71, 91], ["bullae", "OBSERVATION", 13, 19], ["plaques", "OBSERVATION", 21, 28], ["urticaria", "OBSERVATION", 34, 43], ["skin", "ANATOMY", 79, 83], ["lesions", "OBSERVATION", 84, 91]]], ["Linear crusts, irregular ulceration, lichenification, diffuse scaling and pigmentation, and patchy alopecia are characteristic lesions that develop secondary to excoriation.AssociAted signsPruritus can also occur without primary lesions (i.e., \"essential\" pruritus).", [["lesions", "ANATOMY", 127, 134], ["primary lesions", "ANATOMY", 221, 236], ["lichenification", "DISEASE", 37, 52], ["alopecia", "DISEASE", 99, 107], ["pruritus", "DISEASE", 256, 264], ["lesions", "PATHOLOGICAL_FORMATION", 127, 134], ["lesions", "PATHOLOGICAL_FORMATION", 229, 236], ["Linear crusts", "PROBLEM", 0, 13], ["irregular ulceration", "PROBLEM", 15, 35], ["lichenification", "PROBLEM", 37, 52], ["diffuse scaling and pigmentation", "PROBLEM", 54, 86], ["patchy alopecia", "PROBLEM", 92, 107], ["characteristic lesions", "PROBLEM", 112, 134], ["excoriation", "PROBLEM", 161, 172], ["AssociAted signsPruritus", "PROBLEM", 173, 197], ["primary lesions", "PROBLEM", 221, 236], ["essential\" pruritus", "PROBLEM", 245, 264], ["crusts", "OBSERVATION_MODIFIER", 7, 13], ["irregular", "OBSERVATION_MODIFIER", 15, 24], ["ulceration", "OBSERVATION", 25, 35], ["lichenification", "OBSERVATION_MODIFIER", 37, 52], ["diffuse", "OBSERVATION_MODIFIER", 54, 61], ["scaling", "OBSERVATION_MODIFIER", 62, 69], ["pigmentation", "OBSERVATION_MODIFIER", 74, 86], ["patchy", "OBSERVATION_MODIFIER", 92, 98], ["alopecia", "OBSERVATION", 99, 107], ["characteristic", "OBSERVATION_MODIFIER", 112, 126], ["lesions", "OBSERVATION", 127, 134], ["excoriation", "OBSERVATION", 161, 172], ["without", "UNCERTAINTY", 213, 220], ["primary", "OBSERVATION_MODIFIER", 221, 228], ["lesions", "OBSERVATION", 229, 236], ["essential", "OBSERVATION_MODIFIER", 245, 254], ["\"", "OBSERVATION_MODIFIER", 254, 255], ["pruritus", "OBSERVATION", 256, 264]]], ["This type of itching is a manifestation of systemic disease, although mediation may be central or cutaneous.", [["cutaneous", "ANATOMY", 98, 107], ["itching", "DISEASE", 13, 20], ["systemic disease", "DISEASE", 43, 59], ["itching", "PROBLEM", 13, 20], ["systemic disease", "PROBLEM", 43, 59], ["itching", "OBSERVATION", 13, 20], ["systemic", "OBSERVATION_MODIFIER", 43, 51], ["disease", "OBSERVATION", 52, 59], ["may be", "UNCERTAINTY", 80, 86], ["central", "OBSERVATION_MODIFIER", 87, 94], ["cutaneous", "OBSERVATION", 98, 107]]], ["Causes include atopy, dry skin, and neurogenic and psychogenic disorders.", [["skin", "ANATOMY", 26, 30], ["atopy", "DISEASE", 15, 20], ["dry skin", "DISEASE", 22, 30], ["neurogenic and psychogenic disorders", "DISEASE", 36, 72], ["skin", "ORGAN", 26, 30], ["atopy", "PROBLEM", 15, 20], ["dry skin", "PROBLEM", 22, 30], ["neurogenic", "PROBLEM", 36, 46], ["psychogenic disorders", "PROBLEM", 51, 72], ["atopy", "OBSERVATION", 15, 20], ["dry", "OBSERVATION_MODIFIER", 22, 25], ["skin", "ANATOMY", 26, 30], ["neurogenic", "ANATOMY", 36, 46], ["psychogenic disorders", "OBSERVATION", 51, 72]]], ["A spectrum of renal, hepatic, hematopoietic, allergic, and endocrine diseases are associated with essential pruritus.Joint swelling: ArthroPAthy definitionJoint swelling, or joint enlargement, is any abnormal increase in size, either visible or palpable, of any joint that is not directly caused by a proliferation of tissue.", [["renal", "ANATOMY", 14, 19], ["hepatic", "ANATOMY", 21, 28], ["hematopoietic", "ANATOMY", 30, 43], ["endocrine", "ANATOMY", 59, 68], ["joint", "ANATOMY", 174, 179], ["joint", "ANATOMY", 262, 267], ["tissue", "ANATOMY", 318, 324], ["renal, hepatic, hematopoietic, allergic, and endocrine diseases", "DISEASE", 14, 77], ["pruritus", "DISEASE", 108, 116], ["swelling", "DISEASE", 123, 131], ["swelling", "DISEASE", 161, 169], ["joint enlargement", "DISEASE", 174, 191], ["renal", "CANCER", 14, 19], ["hepatic", "MULTI-TISSUE_STRUCTURE", 21, 28], ["endocrine", "ANATOMICAL_SYSTEM", 59, 68], ["joint", "MULTI-TISSUE_STRUCTURE", 174, 179], ["joint", "MULTI-TISSUE_STRUCTURE", 262, 267], ["tissue", "TISSUE", 318, 324], ["allergic", "PROBLEM", 45, 53], ["endocrine diseases", "PROBLEM", 59, 77], ["essential pruritus", "PROBLEM", 98, 116], ["Joint swelling", "PROBLEM", 117, 131], ["ArthroPAthy definition", "PROBLEM", 133, 155], ["Joint swelling", "PROBLEM", 155, 169], ["joint enlargement", "PROBLEM", 174, 191], ["any abnormal increase in size", "PROBLEM", 196, 225], ["a proliferation of tissue", "PROBLEM", 299, 324], ["renal", "ANATOMY", 14, 19], ["hepatic", "ANATOMY", 21, 28], ["hematopoietic", "ANATOMY", 30, 43], ["allergic", "OBSERVATION", 45, 53], ["endocrine diseases", "OBSERVATION", 59, 77], ["essential", "OBSERVATION_MODIFIER", 98, 107], ["pruritus", "OBSERVATION", 108, 116], ["swelling", "OBSERVATION", 123, 131], ["ArthroPAthy", "OBSERVATION", 133, 144], ["Joint", "ANATOMY", 155, 160], ["swelling", "OBSERVATION", 161, 169], ["joint", "ANATOMY", 174, 179], ["enlargement", "OBSERVATION", 180, 191], ["abnormal", "OBSERVATION_MODIFIER", 200, 208], ["increase", "OBSERVATION_MODIFIER", 209, 217], ["size", "OBSERVATION_MODIFIER", 221, 225], ["visible", "OBSERVATION_MODIFIER", 234, 241], ["palpable", "OBSERVATION", 245, 253], ["joint", "ANATOMY", 262, 267], ["not directly caused", "UNCERTAINTY", 276, 295], ["proliferation", "OBSERVATION", 301, 314], ["tissue", "OBSERVATION", 318, 324]]], ["In practice, joint swelling is the primary presenting sign only occasionally.", [["joint", "ANATOMY", 13, 18], ["swelling", "DISEASE", 19, 27], ["joint", "MULTI-TISSUE_STRUCTURE", 13, 18], ["joint swelling", "PROBLEM", 13, 27], ["joint", "ANATOMY", 13, 18], ["swelling", "OBSERVATION", 19, 27]]], ["Pain and associated lameness are more likely causes for presentation, whereas actual enlargement of a joint is detected during physical examination.", [["joint", "ANATOMY", 102, 107], ["Pain", "DISEASE", 0, 4], ["lameness", "DISEASE", 20, 28], ["joint", "MULTI-TISSUE_STRUCTURE", 102, 107], ["Pain", "PROBLEM", 0, 4], ["associated lameness", "PROBLEM", 9, 28], ["actual enlargement of a joint", "PROBLEM", 78, 107], ["physical examination", "TEST", 127, 147], ["lameness", "OBSERVATION", 20, 28], ["more likely", "UNCERTAINTY", 33, 44], ["enlargement", "OBSERVATION", 85, 96], ["joint", "ANATOMY", 102, 107]]], ["However, there is not necessarily an association between joint swelling and pain.Joint swelling: ArthroPAthy definitionJoint swelling, or effusion, occurs subsequent to injury to the synovial membrane in which there is not only an increase in volume of synovial fluid produced, but quantitative biochemical and cellular changes as well.", [["joint", "ANATOMY", 57, 62], ["synovial membrane", "ANATOMY", 183, 200], ["synovial fluid", "ANATOMY", 253, 267], ["cellular", "ANATOMY", 311, 319], ["joint swelling", "DISEASE", 57, 71], ["pain", "DISEASE", 76, 80], ["swelling", "DISEASE", 87, 95], ["swelling", "DISEASE", 125, 133], ["effusion", "DISEASE", 138, 146], ["joint", "ORGANISM_SUBDIVISION", 57, 62], ["synovial membrane", "MULTI-TISSUE_STRUCTURE", 183, 200], ["synovial fluid", "ORGANISM_SUBSTANCE", 253, 267], ["cellular", "CELL", 311, 319], ["joint swelling", "PROBLEM", 57, 71], ["pain", "PROBLEM", 76, 80], ["Joint swelling", "PROBLEM", 81, 95], ["ArthroPAthy", "PROBLEM", 97, 108], ["Joint swelling", "PROBLEM", 119, 133], ["effusion", "PROBLEM", 138, 146], ["injury to the synovial membrane", "PROBLEM", 169, 200], ["an increase in volume of synovial fluid", "PROBLEM", 228, 267], ["quantitative biochemical and cellular changes", "PROBLEM", 282, 327], ["not necessarily", "UNCERTAINTY", 18, 33], ["joint", "ANATOMY", 57, 62], ["swelling", "OBSERVATION", 63, 71], ["pain", "OBSERVATION", 76, 80], ["swelling", "OBSERVATION", 87, 95], ["ArthroPAthy", "OBSERVATION", 97, 108], ["Joint", "ANATOMY", 119, 124], ["swelling", "OBSERVATION", 125, 133], ["effusion", "OBSERVATION", 138, 146], ["injury", "OBSERVATION", 169, 175], ["synovial membrane", "ANATOMY", 183, 200], ["not only", "UNCERTAINTY", 219, 227], ["increase", "OBSERVATION_MODIFIER", 231, 239], ["volume", "OBSERVATION_MODIFIER", 243, 249], ["synovial fluid", "OBSERVATION", 253, 267], ["biochemical", "OBSERVATION_MODIFIER", 295, 306], ["cellular changes", "OBSERVATION", 311, 327]]], ["Most joint swelling is attributed to inflammation of the synovial membrane, or synovitis.", [["joint", "ANATOMY", 5, 10], ["synovial membrane", "ANATOMY", 57, 74], ["swelling", "DISEASE", 11, 19], ["inflammation", "DISEASE", 37, 49], ["synovitis", "DISEASE", 79, 88], ["joint", "MULTI-TISSUE_STRUCTURE", 5, 10], ["synovial membrane", "MULTI-TISSUE_STRUCTURE", 57, 74], ["Most joint swelling", "PROBLEM", 0, 19], ["inflammation of the synovial membrane", "PROBLEM", 37, 74], ["synovitis", "PROBLEM", 79, 88], ["joint", "ANATOMY", 5, 10], ["swelling", "OBSERVATION", 11, 19], ["attributed to", "UNCERTAINTY", 23, 36], ["inflammation", "OBSERVATION", 37, 49], ["synovial membrane", "ANATOMY", 57, 74], ["synovitis", "OBSERVATION", 79, 88]]], ["Abnormal synovial fluid accumulation (effusion) may be classified as serous, fibrinous, purulent, septic, or hemorrhagic.AssociAted signsAlthough lameness is the most common clinical sign associated with joint swelling, it is not consistently present.", [["synovial fluid", "ANATOMY", 9, 23], ["serous", "ANATOMY", 69, 75], ["fibrinous", "ANATOMY", 77, 86], ["joint", "ANATOMY", 204, 209], ["effusion", "DISEASE", 38, 46], ["septic", "DISEASE", 98, 104], ["hemorrhagic", "DISEASE", 109, 120], ["lameness", "DISEASE", 146, 154], ["joint swelling", "DISEASE", 204, 218], ["synovial fluid", "TISSUE", 9, 23], ["serous", "ORGANISM_SUBSTANCE", 69, 75], ["joint", "ORGANISM_SUBDIVISION", 204, 209], ["Abnormal synovial fluid accumulation", "PROBLEM", 0, 36], ["effusion", "PROBLEM", 38, 46], ["serous", "PROBLEM", 69, 75], ["fibrinous", "PROBLEM", 77, 86], ["purulent", "PROBLEM", 88, 96], ["septic", "PROBLEM", 98, 104], ["hemorrhagic", "PROBLEM", 109, 120], ["AssociAted signs", "PROBLEM", 121, 137], ["lameness", "PROBLEM", 146, 154], ["joint swelling", "PROBLEM", 204, 218], ["synovial", "ANATOMY", 9, 17], ["fluid accumulation", "OBSERVATION", 18, 36], ["effusion", "OBSERVATION", 38, 46], ["serous", "OBSERVATION_MODIFIER", 69, 75], ["fibrinous", "OBSERVATION_MODIFIER", 77, 86], ["purulent", "OBSERVATION_MODIFIER", 88, 96], ["septic", "OBSERVATION_MODIFIER", 98, 104], ["hemorrhagic", "OBSERVATION_MODIFIER", 109, 120], ["lameness", "OBSERVATION", 146, 154], ["most common", "OBSERVATION_MODIFIER", 162, 173], ["joint", "ANATOMY", 204, 209], ["swelling", "OBSERVATION", 210, 218], ["not consistently", "UNCERTAINTY", 226, 242]]], ["Joint swelling may also be associated with, or mistaken for, hyperplasia, metaplasia, or neoplasia of the synovium, joint capsule, articular cartilage, or periarticular bone.", [["Joint", "ANATOMY", 0, 5], ["metaplasia", "ANATOMY", 74, 84], ["neoplasia", "ANATOMY", 89, 98], ["synovium", "ANATOMY", 106, 114], ["joint capsule", "ANATOMY", 116, 129], ["articular cartilage", "ANATOMY", 131, 150], ["periarticular bone", "ANATOMY", 155, 173], ["swelling", "DISEASE", 6, 14], ["hyperplasia", "DISEASE", 61, 72], ["metaplasia", "DISEASE", 74, 84], ["neoplasia", "DISEASE", 89, 98], ["Joint", "MULTI-TISSUE_STRUCTURE", 0, 5], ["metaplasia", "CANCER", 74, 84], ["neoplasia", "CANCER", 89, 98], ["synovium", "TISSUE", 106, 114], ["joint capsule", "TISSUE", 116, 129], ["articular cartilage", "TISSUE", 131, 150], ["periarticular bone", "TISSUE", 155, 173], ["Joint swelling", "PROBLEM", 0, 14], ["hyperplasia", "PROBLEM", 61, 72], ["metaplasia", "PROBLEM", 74, 84], ["neoplasia of the synovium, joint capsule, articular cartilage, or periarticular bone", "PROBLEM", 89, 173], ["swelling", "OBSERVATION", 6, 14], ["hyperplasia", "OBSERVATION", 61, 72], ["metaplasia", "OBSERVATION", 74, 84], ["neoplasia", "OBSERVATION", 89, 98], ["synovium", "ANATOMY", 106, 114], ["joint capsule", "ANATOMY", 116, 129], ["articular cartilage", "ANATOMY", 131, 150], ["periarticular bone", "ANATOMY", 155, 173]]], ["Hemorrhagic joint effusion (hemarthrosis) may be associated with coagulopathy and spontaneous bleeding from the respiratory, GI, or urinary tract.", [["joint", "ANATOMY", 12, 17], ["respiratory", "ANATOMY", 112, 123], ["GI", "ANATOMY", 125, 127], ["urinary tract", "ANATOMY", 132, 145], ["Hemorrhagic joint effusion", "DISEASE", 0, 26], ["hemarthrosis", "DISEASE", 28, 40], ["coagulopathy", "DISEASE", 65, 77], ["bleeding", "DISEASE", 94, 102], ["respiratory, GI, or urinary tract", "DISEASE", 112, 145], ["joint", "PATHOLOGICAL_FORMATION", 12, 17], ["GI", "ORGANISM_SUBDIVISION", 125, 127], ["urinary tract", "ORGANISM_SUBDIVISION", 132, 145], ["Hemorrhagic joint effusion", "PROBLEM", 0, 26], ["hemarthrosis", "PROBLEM", 28, 40], ["coagulopathy", "PROBLEM", 65, 77], ["spontaneous bleeding from the respiratory, GI, or urinary tract", "PROBLEM", 82, 145], ["joint", "ANATOMY", 12, 17], ["effusion", "OBSERVATION", 18, 26], ["hemarthrosis", "OBSERVATION", 28, 40], ["may be associated with", "UNCERTAINTY", 42, 64], ["coagulopathy", "OBSERVATION", 65, 77], ["spontaneous", "OBSERVATION_MODIFIER", 82, 93], ["bleeding", "OBSERVATION", 94, 102], ["respiratory", "ANATOMY", 112, 123], ["GI", "ANATOMY", 125, 127], ["urinary tract", "ANATOMY", 132, 145]]], ["Subluxation or fracture of a carpus, tarsus, or stifle may also be associated with detectable joint swelling.", [["carpus", "ANATOMY", 29, 35], ["tarsus", "ANATOMY", 37, 43], ["joint", "ANATOMY", 94, 99], ["Subluxation", "DISEASE", 0, 11], ["fracture", "DISEASE", 15, 23], ["swelling", "DISEASE", 100, 108], ["carpus", "TISSUE", 29, 35], ["tarsus", "ORGANISM_SUBDIVISION", 37, 43], ["stifle", "ORGANISM_SUBDIVISION", 48, 54], ["joint", "ORGANISM_SUBDIVISION", 94, 99], ["Subluxation", "PROBLEM", 0, 11], ["fracture of a carpus, tarsus", "PROBLEM", 15, 43], ["detectable joint swelling", "PROBLEM", 83, 108], ["fracture", "OBSERVATION", 15, 23], ["carpus", "ANATOMY", 29, 35], ["tarsus", "ANATOMY", 37, 43], ["stifle", "OBSERVATION", 48, 54], ["may also be associated with", "UNCERTAINTY", 55, 82], ["detectable", "OBSERVATION_MODIFIER", 83, 93], ["joint", "ANATOMY", 94, 99], ["swelling", "OBSERVATION", 100, 108]]], ["Arthritis associated with systemic disease (e.g., infectious or immune mediated) can also be accompanied by significant joint swelling.loss of APPetite: AnorexiA definitionStrictly speaking, anorexia is the complete lack or loss of appetite.", [["joint", "ANATOMY", 120, 125], ["Arthritis", "DISEASE", 0, 9], ["systemic disease", "DISEASE", 26, 42], ["swelling", "DISEASE", 126, 134], ["anorexia", "DISEASE", 191, 199], ["joint", "ORGANISM_SUBDIVISION", 120, 125], ["APPetite", "SIMPLE_CHEMICAL", 143, 151], ["Arthritis", "PROBLEM", 0, 9], ["systemic disease", "PROBLEM", 26, 42], ["infectious", "PROBLEM", 50, 60], ["significant joint swelling", "PROBLEM", 108, 134], ["loss of APPetite", "PROBLEM", 135, 151], ["AnorexiA", "PROBLEM", 153, 161], ["anorexia", "PROBLEM", 191, 199], ["loss of appetite", "PROBLEM", 224, 240], ["systemic", "OBSERVATION_MODIFIER", 26, 34], ["disease", "OBSERVATION", 35, 42], ["significant", "OBSERVATION_MODIFIER", 108, 119], ["joint", "ANATOMY", 120, 125], ["swelling", "OBSERVATION", 126, 134]]], ["In addition, part of the difficulty in assessing the patient that is presented with loss of appetite is grounded in owner expectation of what is and what is not a normal appetite in a dog or cat.", [["loss of appetite", "DISEASE", 84, 100], ["patient", "ORGANISM", 53, 60], ["dog", "ORGANISM", 184, 187], ["cat", "ORGANISM", 191, 194], ["patient", "SPECIES", 53, 60], ["dog", "SPECIES", 184, 187], ["loss of appetite", "PROBLEM", 84, 100]]], ["Although domesticated pets do tend to eat at regular intervals throughout the day, some do experience transient periods of sustained inappetence that may, in fact, be entirely normal and not associated with underlying disease.", [["inappetence", "DISEASE", 133, 144], ["sustained inappetence", "PROBLEM", 123, 144], ["underlying disease", "PROBLEM", 207, 225], ["sustained", "OBSERVATION_MODIFIER", 123, 132], ["inappetence", "OBSERVATION", 133, 144], ["normal", "OBSERVATION", 176, 182], ["not associated with", "UNCERTAINTY", 187, 206], ["disease", "OBSERVATION", 218, 225]]], ["When assessing a dog or cat for partial loss of appetite, careful history and physical evaluation are indicated to determine whether or not underlying disease may be the cause of this vague clinical sign.", [["dog", "ORGANISM", 17, 20], ["cat", "ORGANISM", 24, 27], ["dog", "SPECIES", 17, 20], ["dog", "SPECIES", 17, 20], ["partial loss of appetite", "PROBLEM", 32, 56], ["physical evaluation", "TEST", 78, 97], ["underlying disease", "PROBLEM", 140, 158], ["this vague clinical sign", "PROBLEM", 179, 203], ["disease", "OBSERVATION", 151, 158]]], ["In addition, the clinical history must establish the duration of the anorexia and whether the loss of appetite is complete or partial.AssociAted signsAnorexia is regarded as a low-yield clinical sign that may be associated with numerous underlying disorders.", [["anorexia", "DISEASE", 69, 77], ["loss of appetite", "DISEASE", 94, 110], ["Anorexia", "DISEASE", 150, 158], ["the anorexia", "PROBLEM", 65, 77], ["the loss of appetite", "PROBLEM", 90, 110], ["AssociAted signsAnorexia", "PROBLEM", 134, 158], ["a low-yield clinical sign", "PROBLEM", 174, 199], ["numerous underlying disorders", "PROBLEM", 228, 257], ["Anorexia", "OBSERVATION", 150, 158], ["may be associated with", "UNCERTAINTY", 205, 227]]], ["Historical evidence of a significant change in the pet's environment (e.g., a new child in the family) or daily routine (e.g., the dog is home alone during the day Note: What makes anorexia such an important clinical sign is the fact that loss of appetite (either complete or partial) is often the first outward sign an owner may notice when a pet is ill.AssociAted signsfor the first time) is important to assess.", [["anorexia", "DISEASE", 181, 189], ["loss of appetite", "DISEASE", 239, 255], ["dog", "ORGANISM", 131, 134], ["a significant change in the pet's environment", "PROBLEM", 23, 68], ["anorexia", "PROBLEM", 181, 189], ["loss of appetite", "PROBLEM", 239, 255], ["significant", "OBSERVATION_MODIFIER", 25, 36], ["change", "OBSERVATION", 37, 43]]], ["Knowledge of current drug therapy, whether the pet eats sticks or other foreign material, whether or not the pet food type recently changed or may not be fresh (moldy canned and dry food will generally not be consumed) is important.", [["current drug therapy", "TREATMENT", 13, 33], ["the pet eats sticks", "TREATMENT", 43, 62], ["other foreign material", "PROBLEM", 66, 88]]], ["Physical examination should determine overall body conformation, body weight, extent of weight loss (if present), and any obvious external injuries that might contribute.", [["body", "ANATOMY", 46, 50], ["body", "ANATOMY", 65, 69], ["weight loss", "DISEASE", 88, 99], ["body", "ORGANISM_SUBDIVISION", 46, 50], ["body", "ORGANISM_SUBDIVISION", 65, 69], ["Physical examination", "TEST", 0, 20], ["body weight", "TEST", 65, 76], ["weight loss", "PROBLEM", 88, 99], ["any obvious external injuries", "PROBLEM", 118, 147], ["weight loss", "OBSERVATION", 88, 99], ["injuries", "OBSERVATION", 139, 147]]], ["Age is an important factor in the assessment of anorexia.", [["anorexia", "DISEASE", 48, 56], ["the assessment", "TEST", 30, 44], ["anorexia", "PROBLEM", 48, 56], ["anorexia", "OBSERVATION", 48, 56]]], ["Diminished sense of smell, neoplasia, joint disease, and dental disease are common age-related disorders that may contribute to anorexia.differentiAl diAgnosisDifferential diagnoses associated with anorexia are too numerous to be of assistance in resolving to a diagnosis.", [["neoplasia", "ANATOMY", 27, 36], ["joint", "ANATOMY", 38, 43], ["neoplasia", "DISEASE", 27, 36], ["joint disease", "DISEASE", 38, 51], ["dental disease", "DISEASE", 57, 71], ["anorexia", "DISEASE", 128, 136], ["anorexia", "DISEASE", 198, 206], ["neoplasia", "CANCER", 27, 36], ["joint", "MULTI-TISSUE_STRUCTURE", 38, 43], ["Diminished sense of smell", "PROBLEM", 0, 25], ["neoplasia", "PROBLEM", 27, 36], ["joint disease", "PROBLEM", 38, 51], ["dental disease", "PROBLEM", 57, 71], ["related disorders", "PROBLEM", 87, 104], ["anorexia", "PROBLEM", 128, 136], ["anorexia", "PROBLEM", 198, 206], ["smell", "OBSERVATION", 20, 25], ["neoplasia", "OBSERVATION", 27, 36], ["joint", "ANATOMY", 38, 43], ["disease", "OBSERVATION", 44, 51], ["dental", "ANATOMY", 57, 63], ["disease", "OBSERVATION", 64, 71], ["anorexia", "OBSERVATION", 128, 136], ["anorexia", "OBSERVATION", 198, 206]]], ["The clinician faced with a patient that has only anorexia is faced with a significant clinical challenge in defining the underlying disorder.", [["anorexia", "DISEASE", 49, 57], ["patient", "ORGANISM", 27, 34], ["patient", "SPECIES", 27, 34], ["anorexia", "PROBLEM", 49, 57], ["the underlying disorder", "PROBLEM", 117, 140]]], ["Even the categories of disease that could be associated with inappetence are wide ranging and include psychologic, metabolic, orthopedic, infectious, inflammatory, and neoplastic causes.Careful observation of the patient on and off the examination table is important.", [["neoplastic", "ANATOMY", 168, 178], ["inappetence", "DISEASE", 61, 72], ["patient", "ORGANISM", 213, 220], ["patient", "SPECIES", 213, 220], ["disease", "PROBLEM", 23, 30], ["inappetence", "PROBLEM", 61, 72], ["psychologic, metabolic, orthopedic, infectious, inflammatory", "PROBLEM", 102, 162], ["neoplastic causes", "PROBLEM", 168, 185], ["Careful observation", "TEST", 186, 205], ["the examination table", "TEST", 232, 253], ["disease", "OBSERVATION", 23, 30], ["infectious", "OBSERVATION", 138, 148], ["inflammatory", "OBSERVATION_MODIFIER", 150, 162], ["neoplastic", "OBSERVATION_MODIFIER", 168, 178]]], ["A methodical physical examination.", [["A methodical physical examination", "TEST", 0, 33]]], ["A standard laboratory profile to include hematology, biochemistry, and urinalysis (fecalis optional depending on the presenting signs).", [["A standard laboratory profile", "TEST", 0, 29], ["biochemistry", "TEST", 53, 65], ["urinalysis", "TEST", 71, 81]]], ["Radiography or other imaging study is indicated if the pain can be localized to a discrete region of the body (e.g., abdominal cavity).", [["body", "ANATOMY", 105, 109], ["abdominal cavity", "ANATOMY", 117, 133], ["pain", "DISEASE", 55, 59], ["body", "ORGANISM_SUBDIVISION", 105, 109], ["abdominal cavity", "MULTI-TISSUE_STRUCTURE", 117, 133], ["Radiography", "TEST", 0, 11], ["other imaging study", "TEST", 15, 34], ["the pain", "PROBLEM", 51, 59], ["body", "ANATOMY", 105, 109], ["abdominal cavity", "ANATOMY", 117, 133]]], ["Special diagnostic tests are indicated if specific abnormalities can be detected (e.g., biopsy, aspiration and cytopathology, myelography).lymPh node enlArgement: lymPhAdenomegAly definitionLymphadenomegaly refers to those lymph nodes that are larger than expected with or without commensurate changes in consistency.", [["lymPh node", "ANATOMY", 139, 149], ["lymph nodes", "ANATOMY", 223, 234], ["lymPh node", "MULTI-TISSUE_STRUCTURE", 139, 149], ["Aly", "GENE_OR_GENE_PRODUCT", 176, 179], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 223, 234], ["Special diagnostic tests", "TEST", 0, 24], ["specific abnormalities", "PROBLEM", 42, 64], ["biopsy", "TEST", 88, 94], ["aspiration", "TEST", 96, 106], ["cytopathology", "TEST", 111, 124], ["myelography", "TEST", 126, 137], ["lymPh node enlArgement", "PROBLEM", 139, 161], ["Aly definitionLymphadenomegaly", "PROBLEM", 176, 206], ["those lymph nodes", "PROBLEM", 217, 234], ["commensurate changes in consistency", "PROBLEM", 281, 316], ["node enlArgement", "OBSERVATION", 145, 161], ["definitionLymphadenomegaly", "OBSERVATION", 180, 206], ["lymph nodes", "OBSERVATION", 223, 234], ["larger", "OBSERVATION_MODIFIER", 244, 250]]], ["Involved nodes may be unusually soft, firm, or painful, suggestive of inflammation, whereas enlarged, firm, nonpainful lymph nodes suggest neoplasia.", [["nodes", "ANATOMY", 9, 14], ["lymph nodes", "ANATOMY", 119, 130], ["neoplasia", "ANATOMY", 139, 148], ["inflammation", "DISEASE", 70, 82], ["neoplasia", "DISEASE", 139, 148], ["nodes", "MULTI-TISSUE_STRUCTURE", 9, 14], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 119, 130], ["neoplasia", "CANCER", 139, 148], ["firm", "PROBLEM", 38, 42], ["painful", "PROBLEM", 47, 54], ["inflammation", "PROBLEM", 70, 82], ["nonpainful lymph nodes", "PROBLEM", 108, 130], ["neoplasia", "PROBLEM", 139, 148], ["nodes", "OBSERVATION", 9, 14], ["firm", "OBSERVATION", 38, 42], ["suggestive of", "UNCERTAINTY", 56, 69], ["inflammation", "OBSERVATION", 70, 82], ["enlarged", "OBSERVATION_MODIFIER", 92, 100], ["firm", "OBSERVATION_MODIFIER", 102, 106], ["nonpainful", "OBSERVATION_MODIFIER", 108, 118], ["lymph nodes", "OBSERVATION", 119, 130], ["suggest", "UNCERTAINTY", 131, 138], ["neoplasia", "OBSERVATION", 139, 148]]], ["Lymphadenomegaly is usually not a presenting problem, with the possible exception of generalized enlargement of all superficial lymph nodes.", [["superficial lymph nodes", "ANATOMY", 116, 139], ["Lymphadenomegaly", "DISEASE", 0, 16], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 128, 139], ["Lymphadenomegaly", "PROBLEM", 0, 16], ["generalized enlargement of all superficial lymph nodes", "PROBLEM", 85, 139], ["generalized", "OBSERVATION_MODIFIER", 85, 96], ["enlargement", "OBSERVATION", 97, 108], ["all", "OBSERVATION_MODIFIER", 112, 115], ["superficial", "ANATOMY_MODIFIER", 116, 127], ["lymph nodes", "OBSERVATION", 128, 139]]], ["Lymph nodes become enlarged as a result of inflammation (pyogenic or granulomatous), reactive lymphoid hyperplasia, or neoplasia (primary or neoplastic).", [["Lymph nodes", "ANATOMY", 0, 11], ["granulomatous", "ANATOMY", 69, 82], ["lymphoid hyperplasia", "ANATOMY", 94, 114], ["neoplasia", "ANATOMY", 119, 128], ["primary", "ANATOMY", 130, 137], ["neoplastic", "ANATOMY", 141, 151], ["inflammation", "DISEASE", 43, 55], ["pyogenic", "DISEASE", 57, 65], ["reactive lymphoid hyperplasia", "DISEASE", 85, 114], ["neoplasia", "DISEASE", 119, 128], ["Lymph nodes", "MULTI-TISSUE_STRUCTURE", 0, 11], ["lymphoid", "PATHOLOGICAL_FORMATION", 94, 102], ["neoplasia", "CANCER", 119, 128], ["Lymph nodes", "PROBLEM", 0, 11], ["enlarged", "PROBLEM", 19, 27], ["inflammation (pyogenic or granulomatous)", "PROBLEM", 43, 83], ["reactive lymphoid hyperplasia", "PROBLEM", 85, 114], ["neoplasia", "PROBLEM", 119, 128], ["Lymph nodes", "OBSERVATION", 0, 11], ["enlarged", "OBSERVATION_MODIFIER", 19, 27], ["inflammation", "OBSERVATION", 43, 55], ["pyogenic", "OBSERVATION_MODIFIER", 57, 65], ["granulomatous", "OBSERVATION_MODIFIER", 69, 82], ["reactive", "OBSERVATION_MODIFIER", 85, 93], ["lymphoid hyperplasia", "OBSERVATION", 94, 114], ["neoplasia", "OBSERVATION", 119, 128], ["neoplastic", "OBSERVATION_MODIFIER", 141, 151]]], ["In pyogenic inflammation, neutrophils dilate and engorge the sinuses, whereas in granulomatous inflammation an infiltrate or macrophages are present (e.g., systemic mycoses).", [["neutrophils", "ANATOMY", 26, 37], ["sinuses", "ANATOMY", 61, 68], ["macrophages", "ANATOMY", 125, 136], ["inflammation", "DISEASE", 12, 24], ["inflammation", "DISEASE", 95, 107], ["mycoses", "DISEASE", 165, 172], ["neutrophils", "CELL", 26, 37], ["sinuses", "ORGAN", 61, 68], ["macrophages", "CELL", 125, 136], ["neutrophils", "CELL_TYPE", 26, 37], ["macrophages", "CELL_TYPE", 125, 136], ["pyogenic inflammation", "PROBLEM", 3, 24], ["neutrophils dilate", "TEST", 26, 44], ["engorge the sinuses", "PROBLEM", 49, 68], ["granulomatous inflammation", "PROBLEM", 81, 107], ["an infiltrate", "PROBLEM", 108, 121], ["macrophages", "PROBLEM", 125, 136], ["systemic mycoses", "PROBLEM", 156, 172], ["pyogenic", "OBSERVATION_MODIFIER", 3, 11], ["inflammation", "OBSERVATION", 12, 24], ["neutrophils dilate", "OBSERVATION", 26, 44], ["sinuses", "ANATOMY", 61, 68], ["granulomatous", "OBSERVATION_MODIFIER", 81, 94], ["inflammation", "OBSERVATION_MODIFIER", 95, 107], ["infiltrate", "OBSERVATION", 111, 121], ["macrophages", "OBSERVATION", 125, 136], ["systemic", "OBSERVATION_MODIFIER", 156, 164], ["mycoses", "OBSERVATION", 165, 172]]], ["Reactive lymphoid hyperplasia is associated with an increase in the number of germinal centers within the lymph node and an infiltrate of plasma cells.", [["lymphoid hyperplasia", "ANATOMY", 9, 29], ["germinal centers", "ANATOMY", 78, 94], ["lymph node", "ANATOMY", 106, 116], ["plasma cells", "ANATOMY", 138, 150], ["lymphoid hyperplasia", "DISEASE", 9, 29], ["lymphoid hyperplasia", "PATHOLOGICAL_FORMATION", 9, 29], ["germinal centers", "MULTI-TISSUE_STRUCTURE", 78, 94], ["lymph node", "MULTI-TISSUE_STRUCTURE", 106, 116], ["plasma cells", "CELL", 138, 150], ["plasma cells", "CELL_TYPE", 138, 150], ["Reactive lymphoid hyperplasia", "PROBLEM", 0, 29], ["germinal centers within the lymph node", "PROBLEM", 78, 116], ["an infiltrate of plasma cells", "PROBLEM", 121, 150], ["lymphoid hyperplasia", "OBSERVATION", 9, 29], ["increase", "OBSERVATION_MODIFIER", 52, 60], ["number", "OBSERVATION_MODIFIER", 68, 74], ["germinal centers", "OBSERVATION", 78, 94], ["lymph node", "OBSERVATION", 106, 116], ["infiltrate", "OBSERVATION", 124, 134], ["plasma cells", "OBSERVATION", 138, 150]]], ["In neoplastic lymph nodes, tumor cells may invade the sinuses (metastatic), gradually destroying the normal node architecture, or the architecture of the lymph node is entirely replaced by malignant lymphocytes (lymphosarsoma)-that is, histologically the sinuses are obliterated and germinal centers cannot be found.AssociAted signsCharacterize the consistency and number of affected nodes as well as their location (i.e., generalized or regional).", [["neoplastic lymph nodes", "ANATOMY", 3, 25], ["tumor cells", "ANATOMY", 27, 38], ["sinuses", "ANATOMY", 54, 61], ["node", "ANATOMY", 108, 112], ["lymph node", "ANATOMY", 154, 164], ["malignant lymphocytes", "ANATOMY", 189, 210], ["lymphosarsoma", "ANATOMY", 212, 225], ["sinuses", "ANATOMY", 255, 262], ["germinal centers", "ANATOMY", 283, 299], ["nodes", "ANATOMY", 384, 389], ["tumor", "DISEASE", 27, 32], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 14, 25], ["tumor cells", "CELL", 27, 38], ["sinuses", "ORGAN", 54, 61], ["node architecture", "MULTI-TISSUE_STRUCTURE", 108, 125], ["lymph node", "MULTI-TISSUE_STRUCTURE", 154, 164], ["malignant lymphocytes", "CELL", 189, 210], ["lymphosarsoma", "CANCER", 212, 225], ["sinuses", "CANCER", 255, 262], ["nodes", "MULTI-TISSUE_STRUCTURE", 384, 389], ["tumor cells", "CELL_TYPE", 27, 38], ["malignant lymphocytes", "CELL_TYPE", 189, 210], ["neoplastic lymph nodes", "PROBLEM", 3, 25], ["tumor cells", "PROBLEM", 27, 38], ["malignant lymphocytes (lymphosarsoma)", "PROBLEM", 189, 226], ["AssociAted signs", "PROBLEM", 316, 332], ["affected nodes", "PROBLEM", 375, 389], ["neoplastic", "OBSERVATION_MODIFIER", 3, 13], ["lymph nodes", "OBSERVATION", 14, 25], ["tumor cells", "OBSERVATION", 27, 38], ["sinuses", "ANATOMY", 54, 61], ["metastatic", "OBSERVATION_MODIFIER", 63, 73], ["normal", "OBSERVATION_MODIFIER", 101, 107], ["node", "OBSERVATION", 108, 112], ["architecture", "OBSERVATION_MODIFIER", 113, 125], ["lymph node", "OBSERVATION", 154, 164], ["malignant", "OBSERVATION_MODIFIER", 189, 198], ["lymphocytes", "OBSERVATION", 199, 210], ["sinuses", "ANATOMY", 255, 262], ["obliterated", "OBSERVATION", 267, 278], ["germinal centers", "OBSERVATION", 283, 299], ["cannot be found", "UNCERTAINTY", 300, 315], ["consistency", "OBSERVATION_MODIFIER", 349, 360], ["number", "OBSERVATION_MODIFIER", 365, 371], ["affected", "OBSERVATION_MODIFIER", 375, 383], ["nodes", "OBSERVATION", 384, 389], ["generalized", "OBSERVATION_MODIFIER", 423, 434], ["regional", "OBSERVATION_MODIFIER", 438, 446]]], ["Lymph node pain is an inconsistent finding usually associated with inflammatory disease (lymphadenitis) rather than neoplasia (lymphoma).", [["Lymph node", "ANATOMY", 0, 10], ["neoplasia", "ANATOMY", 116, 125], ["lymphoma", "ANATOMY", 127, 135], ["Lymph node pain", "DISEASE", 0, 15], ["lymphadenitis", "DISEASE", 89, 102], ["neoplasia", "DISEASE", 116, 125], ["lymphoma", "DISEASE", 127, 135], ["Lymph node", "MULTI-TISSUE_STRUCTURE", 0, 10], ["neoplasia", "CANCER", 116, 125], ["lymphoma", "CANCER", 127, 135], ["Lymph node pain", "PROBLEM", 0, 15], ["inflammatory disease", "PROBLEM", 67, 87], ["lymphadenitis", "PROBLEM", 89, 102], ["neoplasia (lymphoma)", "PROBLEM", 116, 136], ["node", "OBSERVATION", 6, 10], ["inflammatory", "OBSERVATION_MODIFIER", 67, 79], ["disease", "OBSERVATION", 80, 87], ["lymphadenitis", "OBSERVATION", 89, 102], ["neoplasia", "OBSERVATION", 116, 125], ["lymphoma", "OBSERVATION", 127, 135]]], ["Associated 3 signs are likely to be regional, as is the lymph node enlargement (i.e., tissue injury or infection).", [["lymph node", "ANATOMY", 56, 66], ["tissue", "ANATOMY", 86, 92], ["lymph node enlargement", "DISEASE", 56, 78], ["infection", "DISEASE", 103, 112], ["lymph node", "MULTI-TISSUE_STRUCTURE", 56, 66], ["tissue", "TISSUE", 86, 92], ["the lymph node enlargement", "PROBLEM", 52, 78], ["tissue injury", "PROBLEM", 86, 99], ["infection", "PROBLEM", 103, 112], ["likely to be", "UNCERTAINTY", 23, 35], ["regional", "OBSERVATION_MODIFIER", 36, 44], ["lymph node enlargement", "OBSERVATION", 56, 78], ["tissue", "OBSERVATION_MODIFIER", 86, 92], ["injury", "OBSERVATION", 93, 99], ["infection", "OBSERVATION", 103, 112]]], ["Patients with generalized lymphadenomegaly may not have associated signs, or there may be nonspecific signs, including weight loss, fever, decreased appetite, and lassitude as a result of systemic illness.PAin definitionPain is the perception of an unpleasant sensation; it may be generalized or localized.", [["lymphadenomegaly", "DISEASE", 26, 42], ["weight loss", "DISEASE", 119, 130], ["fever", "DISEASE", 132, 137], ["decreased appetite", "DISEASE", 139, 157], ["systemic illness", "DISEASE", 188, 204], ["Patients", "ORGANISM", 0, 8], ["PAin", "GENE_OR_GENE_PRODUCT", 205, 209], ["Patients", "SPECIES", 0, 8], ["generalized lymphadenomegaly", "PROBLEM", 14, 42], ["nonspecific signs", "PROBLEM", 90, 107], ["weight loss", "PROBLEM", 119, 130], ["fever", "PROBLEM", 132, 137], ["decreased appetite", "PROBLEM", 139, 157], ["systemic illness", "PROBLEM", 188, 204], ["PAin definitionPain", "PROBLEM", 205, 224], ["an unpleasant sensation", "PROBLEM", 246, 269], ["generalized", "OBSERVATION_MODIFIER", 14, 25], ["lymphadenomegaly", "OBSERVATION", 26, 42], ["may be", "UNCERTAINTY", 83, 89], ["nonspecific", "OBSERVATION_MODIFIER", 90, 101], ["weight loss", "OBSERVATION", 119, 130]]], ["Although pain may be the single most common presenting complaint of humans who seek medical attention from a physician, the ability of a dog or cat to communicate pain and the ability of the owner to interpret the signs correctly make this a particularly complex clinical sign in animals.", [["pain", "DISEASE", 9, 13], ["pain", "DISEASE", 163, 167], ["humans", "ORGANISM", 68, 74], ["dog", "ORGANISM", 137, 140], ["cat", "ORGANISM", 144, 147], ["humans", "SPECIES", 68, 74], ["dog", "SPECIES", 137, 140], ["humans", "SPECIES", 68, 74], ["pain", "PROBLEM", 9, 13], ["pain", "PROBLEM", 163, 167]]], ["However, the inability of an animal to communicate pain must not be interpreted to mean there is an absence of pain.", [["pain", "DISEASE", 51, 55], ["pain", "DISEASE", 111, 115], ["pain", "PROBLEM", 51, 55], ["pain", "PROBLEM", 111, 115]]], ["Animals do experience averse sensation and awareness of tissue injury.", [["tissue", "ANATOMY", 56, 62], ["tissue injury", "DISEASE", 56, 69], ["Animals", "ORGANISM", 0, 7], ["tissue", "TISSUE", 56, 62], ["averse sensation", "PROBLEM", 22, 38], ["tissue injury", "PROBLEM", 56, 69], ["tissue", "ANATOMY", 56, 62], ["injury", "OBSERVATION", 63, 69]]], ["In animals, pain can be acute (e.g., trauma) or chronic (neuropathic pain associated with sustained tissue injury or disease).AssociAted signsThe actual perception and manifestation of pain varies from one animal to another.", [["tissue", "ANATOMY", 100, 106], ["pain", "DISEASE", 12, 16], ["trauma", "DISEASE", 37, 43], ["neuropathic pain", "DISEASE", 57, 73], ["tissue injury", "DISEASE", 100, 113], ["pain", "DISEASE", 185, 189], ["tissue", "TISSUE", 100, 106], ["pain", "PROBLEM", 12, 16], ["trauma", "PROBLEM", 37, 43], ["chronic (neuropathic pain", "PROBLEM", 48, 73], ["sustained tissue injury", "PROBLEM", 90, 113], ["disease", "PROBLEM", 117, 124], ["AssociAted signs", "PROBLEM", 126, 142], ["pain", "PROBLEM", 185, 189], ["acute", "OBSERVATION_MODIFIER", 24, 29], ["chronic", "OBSERVATION_MODIFIER", 48, 55], ["neuropathic", "OBSERVATION_MODIFIER", 57, 68], ["injury", "OBSERVATION", 107, 113]]], ["Fundamental to the ability to interpret the presence of pain in an animal is the ability to recognize a change in behavior.", [["pain", "DISEASE", 56, 60], ["pain", "PROBLEM", 56, 60], ["a change in behavior", "PROBLEM", 102, 122], ["pain", "OBSERVATION", 56, 60]]], ["Pain associated with acute injury can be relatively simple to ascertain.", [["Pain", "DISEASE", 0, 4], ["Pain", "PROBLEM", 0, 4], ["acute injury", "PROBLEM", 21, 33], ["acute", "OBSERVATION_MODIFIER", 21, 26], ["injury", "OBSERVATION", 27, 33]]], ["However, chronic pain emanating from a specific organ or tissue (e.g., liver or bone) can be difficult to characterize and localize.", [["organ", "ANATOMY", 48, 53], ["tissue", "ANATOMY", 57, 63], ["liver", "ANATOMY", 71, 76], ["bone", "ANATOMY", 80, 84], ["pain", "DISEASE", 17, 21], ["organ", "ORGAN", 48, 53], ["tissue", "TISSUE", 57, 63], ["liver", "ORGAN", 71, 76], ["bone", "TISSUE", 80, 84], ["chronic pain", "PROBLEM", 9, 21], ["a specific organ or tissue (e.g., liver or bone)", "PROBLEM", 37, 85], ["chronic", "OBSERVATION_MODIFIER", 9, 16], ["pain", "OBSERVATION", 17, 21], ["tissue", "OBSERVATION", 57, 63], ["liver", "ANATOMY", 71, 76], ["bone", "ANATOMY", 80, 84]]], ["Other signs that may be associated with pain include sleeplessness; unusual posture; decreased activity; decreased appetite; reluctance to play, walk, or run; agitation; altered gait; and decreased grooming.", [["pain", "DISEASE", 40, 44], ["sleeplessness", "DISEASE", 53, 66], ["agitation", "DISEASE", 159, 168], ["Other signs", "PROBLEM", 0, 11], ["pain", "PROBLEM", 40, 44], ["sleeplessness", "PROBLEM", 53, 66], ["unusual posture", "PROBLEM", 68, 83], ["decreased activity", "PROBLEM", 85, 103], ["decreased appetite", "PROBLEM", 105, 123], ["agitation", "PROBLEM", 159, 168], ["altered gait", "PROBLEM", 170, 182], ["decreased grooming", "PROBLEM", 188, 206]]], ["Physical findings differentiAl diAgnosis for lymPhAdenomegAly gEnEralizEd Lymphosarcoma Diffuse, generalized skin disease Infectious diseases (numerous infections are known to cause lymph node enlargement) Parasitic (especially severe ectoparasitism, e.g., demodicosis with secondary pyoderma) Recent (within days) vaccination localizEd Any of the causes of generalized lymphadenomegaly (above) Localized infection, especially in the skin or subcutaneous tissues Cutaneous neoplasia other than lymphoma are also highly varied and may include hypersalivation, mydriasis, tachycardia, shivering, or increased respiratory rate.", [["skin", "ANATOMY", 109, 113], ["lymph node", "ANATOMY", 182, 192], ["skin", "ANATOMY", 434, 438], ["subcutaneous tissues Cutaneous neoplasia", "ANATOMY", 442, 482], ["lymphoma", "ANATOMY", 494, 502], ["respiratory", "ANATOMY", 607, 618], ["lymPhAdenomeg", "CHEMICAL", 45, 58], ["skin disease", "DISEASE", 109, 121], ["Infectious diseases", "DISEASE", 122, 141], ["infections", "DISEASE", 152, 162], ["lymph node enlargement", "DISEASE", 182, 204], ["ectoparasitism", "DISEASE", 235, 249], ["demodicosis", "DISEASE", 257, 268], ["pyoderma", "DISEASE", 284, 292], ["lymphadenomegaly", "DISEASE", 370, 386], ["infection", "DISEASE", 405, 414], ["Cutaneous neoplasia", "DISEASE", 463, 482], ["lymphoma", "DISEASE", 494, 502], ["hypersalivation", "DISEASE", 542, 557], ["mydriasis", "DISEASE", 559, 568], ["tachycardia", "DISEASE", 570, 581], ["shivering", "DISEASE", 583, 592], ["lymPhAdenomeg", "CHEMICAL", 45, 58], ["skin", "ORGAN", 109, 113], ["lymph node", "MULTI-TISSUE_STRUCTURE", 182, 192], ["skin", "ORGAN", 434, 438], ["subcutaneous tissues", "TISSUE", 442, 462], ["Cutaneous neoplasia", "CANCER", 463, 482], ["lymphoma", "CANCER", 494, 502], ["lymPhAdenomeg", "PROBLEM", 45, 58], ["Lymphosarcoma", "PROBLEM", 74, 87], ["generalized skin disease Infectious diseases", "PROBLEM", 97, 141], ["numerous infections", "PROBLEM", 143, 162], ["lymph node enlargement", "PROBLEM", 182, 204], ["Parasitic (especially severe ectoparasitism", "PROBLEM", 206, 249], ["demodicosis", "PROBLEM", 257, 268], ["secondary pyoderma", "PROBLEM", 274, 292], ["vaccination", "TREATMENT", 315, 326], ["generalized lymphadenomegaly", "PROBLEM", 358, 386], ["Localized infection", "PROBLEM", 395, 414], ["subcutaneous tissues Cutaneous neoplasia", "PROBLEM", 442, 482], ["lymphoma", "PROBLEM", 494, 502], ["hypersalivation", "PROBLEM", 542, 557], ["mydriasis", "PROBLEM", 559, 568], ["tachycardia", "PROBLEM", 570, 581], ["shivering", "PROBLEM", 583, 592], ["increased respiratory rate", "PROBLEM", 597, 623], ["EralizEd Lymphosarcoma", "OBSERVATION", 65, 87], ["Diffuse", "OBSERVATION_MODIFIER", 88, 95], ["generalized", "OBSERVATION_MODIFIER", 97, 108], ["skin", "ANATOMY", 109, 113], ["disease", "OBSERVATION", 114, 121], ["infections", "OBSERVATION", 152, 162], ["lymph node enlargement", "OBSERVATION", 182, 204], ["Parasitic", "OBSERVATION_MODIFIER", 206, 215], ["severe", "OBSERVATION_MODIFIER", 228, 234], ["pyoderma", "OBSERVATION", 284, 292], ["generalized", "OBSERVATION_MODIFIER", 358, 369], ["lymphadenomegaly", "OBSERVATION", 370, 386], ["Localized", "OBSERVATION_MODIFIER", 395, 404], ["infection", "OBSERVATION", 405, 414], ["skin", "ANATOMY", 434, 438], ["subcutaneous tissues", "ANATOMY", 442, 462], ["Cutaneous", "ANATOMY", 463, 472], ["neoplasia", "OBSERVATION", 473, 482], ["lymphoma", "OBSERVATION", 494, 502], ["may include", "UNCERTAINTY", 530, 541], ["hypersalivation", "OBSERVATION", 542, 557], ["increased", "OBSERVATION_MODIFIER", 597, 606], ["respiratory rate", "OBSERVATION", 607, 623]]], ["Unfortunately, despite efforts to establish pain \"scales, \" there are still no standardized, objective pain test for animals.differentiAl diAgnosisPain can be associated with many disorders; therefore developing a list of differential diagnoses becomes impractical.", [["pain", "DISEASE", 44, 48], ["pain", "DISEASE", 103, 107], ["pain \"scales", "PROBLEM", 44, 56], ["objective pain test", "TEST", 93, 112], ["many disorders", "PROBLEM", 175, 189], ["can be associated with", "UNCERTAINTY", 152, 174]]], ["Because pain is characteristically associated with inflammation or tissue trauma, every effort should be made to localize the source of the pain in order to focus the diagnostic search.", [["tissue", "ANATOMY", 67, 73], ["pain", "DISEASE", 8, 12], ["inflammation", "DISEASE", 51, 63], ["trauma", "DISEASE", 74, 80], ["pain", "DISEASE", 140, 144], ["tissue", "TISSUE", 67, 73], ["pain", "PROBLEM", 8, 12], ["inflammation", "PROBLEM", 51, 63], ["tissue trauma", "PROBLEM", 67, 80], ["the pain", "PROBLEM", 136, 144], ["characteristically associated with", "UNCERTAINTY", 16, 50], ["inflammation", "OBSERVATION", 51, 63], ["tissue", "ANATOMY", 67, 73], ["trauma", "OBSERVATION", 74, 80]]], ["Localizing acute-onset pain is generally less problematic than localizing chronic pain.", [["pain", "DISEASE", 23, 27], ["chronic pain", "DISEASE", 74, 86], ["Localizing acute-onset pain", "PROBLEM", 0, 27], ["localizing chronic pain", "PROBLEM", 63, 86], ["acute", "OBSERVATION_MODIFIER", 11, 16], ["onset", "OBSERVATION_MODIFIER", 17, 22], ["pain", "OBSERVATION", 23, 27], ["less problematic", "OBSERVATION_MODIFIER", 41, 57], ["chronic", "OBSERVATION_MODIFIER", 74, 81], ["pain", "OBSERVATION", 82, 86]]], ["Particularly in the patient with nonlocalizing, chronic pain, developing a clear diagnostic plan is essential in establishing a diagnosis.diAgnostic PlAns1.", [["pain", "DISEASE", 56, 60], ["patient", "ORGANISM", 20, 27], ["PlAns1", "PROTEIN", 149, 155], ["patient", "SPECIES", 20, 27], ["chronic pain", "PROBLEM", 48, 60], ["chronic", "OBSERVATION_MODIFIER", 48, 55], ["pain", "OBSERVATION", 56, 60]]], ["Careful observation of the patient as it moves, stands, sits, lies down, and so on is critical.", [["patient", "ORGANISM", 27, 34], ["patient", "SPECIES", 27, 34], ["Careful observation", "TEST", 0, 19]]], ["Acute pain: Physical examination addresses the physiologic (objective) assessment of the patient (e.g., heart rate, blood pressure, respiratory rate, pupils [dilation]).", [["heart", "ANATOMY", 104, 109], ["blood", "ANATOMY", 116, 121], ["respiratory", "ANATOMY", 132, 143], ["pain", "DISEASE", 6, 10], ["patient", "ORGANISM", 89, 96], ["heart", "ORGAN", 104, 109], ["blood", "ORGANISM_SUBSTANCE", 116, 121], ["patient", "SPECIES", 89, 96], ["Acute pain", "PROBLEM", 0, 10], ["Physical examination", "TEST", 12, 32], ["assessment", "TEST", 71, 81], ["heart rate", "TEST", 104, 114], ["blood pressure", "TEST", 116, 130], ["respiratory rate", "TEST", 132, 148], ["pain", "OBSERVATION", 6, 10], ["heart", "ANATOMY", 104, 109]]], ["When feasible, effort should be made to localize the origin of the pain.", [["pain", "DISEASE", 67, 71], ["the pain", "PROBLEM", 63, 71], ["pain", "OBSERVATION", 67, 71]]], ["Acute pain: Physical examination should also address the behavioral (subjective) assessment of pain (e.g., attitude, mentation, posture, awareness of surroundings).", [["pain", "DISEASE", 6, 10], ["pain", "DISEASE", 95, 99], ["Acute pain", "PROBLEM", 0, 10], ["Physical examination", "TEST", 12, 32], ["pain", "PROBLEM", 95, 99], ["pain", "OBSERVATION", 6, 10]]], ["A standard laboratory profile to include hematology, biochemistry, and urinalysis (fecal is optional depending on the presenting signs).", [["fecal", "ORGANISM_SUBSTANCE", 83, 88], ["A standard laboratory profile", "TEST", 0, 29], ["biochemistry", "TEST", 53, 65], ["urinalysis", "TEST", 71, 81]]], ["Radiography or other imaging study is indicated if the pain can be localized to a discrete region of the body (e.g., abdominal cavity).", [["body", "ANATOMY", 105, 109], ["abdominal cavity", "ANATOMY", 117, 133], ["pain", "DISEASE", 55, 59], ["body", "ORGANISM_SUBDIVISION", 105, 109], ["abdominal cavity", "MULTI-TISSUE_STRUCTURE", 117, 133], ["Radiography", "TEST", 0, 11], ["other imaging study", "TEST", 15, 34], ["the pain", "PROBLEM", 51, 59], ["body", "ANATOMY", 105, 109], ["abdominal cavity", "ANATOMY", 117, 133]]], ["Special diagnostic tests are indicated if specific abnormalities can be detected (e.g., biopsy, aspiration and cytopathology, myelography).", [["Special diagnostic tests", "TEST", 0, 24], ["specific abnormalities", "PROBLEM", 42, 64], ["biopsy", "TEST", 88, 94], ["aspiration", "TEST", 96, 106], ["cytopathology", "TEST", 111, 124], ["myelography", "TEST", 126, 137]]], ["In some patients, empiric treatment with analgesics or nonsteroidal antiinflammatory drugs may be indicated (see Table 1 -18).", [["nonsteroidal", "ANATOMY", 55, 67], ["patients", "ORGANISM", 8, 16], ["patients", "SPECIES", 8, 16], ["empiric treatment", "TREATMENT", 18, 35], ["analgesics", "TREATMENT", 41, 51], ["nonsteroidal antiinflammatory drugs", "TREATMENT", 55, 90]]], ["However, using this method for managing pain requires the ability to provide follow-up care to that patient.definitionRegurgitation is retrograde esophageal transport of ingesta subsequent to a mechanical, neurogenic, or myogenic swallowing disorder.", [["esophageal", "ANATOMY", 146, 156], ["pain", "DISEASE", 40, 44], ["definitionRegurgitation", "DISEASE", 108, 131], ["swallowing disorder", "DISEASE", 230, 249], ["patient", "ORGANISM", 100, 107], ["esophageal", "ORGAN", 146, 156], ["patient", "SPECIES", 100, 107], ["this method", "TREATMENT", 15, 26], ["managing pain", "PROBLEM", 31, 44], ["definitionRegurgitation", "PROBLEM", 108, 131], ["retrograde esophageal transport of ingesta", "PROBLEM", 135, 177], ["a mechanical, neurogenic", "PROBLEM", 192, 216], ["myogenic swallowing disorder", "PROBLEM", 221, 249], ["esophageal", "ANATOMY", 146, 156], ["neurogenic", "OBSERVATION", 206, 216], ["swallowing disorder", "OBSERVATION", 230, 249]]], ["Owners most often describe regurgitation as \"vomiting. \"", [["vomiting", "DISEASE", 45, 53], ["regurgitation", "PROBLEM", 27, 40], ["vomiting", "PROBLEM", 45, 53], ["regurgitation", "OBSERVATION", 27, 40]]], ["Both regurgitation and vomiting imply a backward flowing of ingesta through the esophagus; however, regurgitation is a relatively effortless act in contrast to the retching and abdominal pressure characteristic of vomiting.", [["esophagus", "ANATOMY", 80, 89], ["abdominal", "ANATOMY", 177, 186], ["vomiting", "DISEASE", 23, 31], ["retching", "DISEASE", 164, 172], ["vomiting", "DISEASE", 214, 222], ["esophagus", "ORGAN", 80, 89], ["abdominal", "ORGANISM_SUBDIVISION", 177, 186], ["Both regurgitation", "PROBLEM", 0, 18], ["vomiting", "PROBLEM", 23, 31], ["a backward flowing of ingesta through the esophagus", "PROBLEM", 38, 89], ["regurgitation", "PROBLEM", 100, 113], ["the retching", "PROBLEM", 160, 172], ["abdominal pressure", "TEST", 177, 195], ["vomiting", "PROBLEM", 214, 222], ["regurgitation", "OBSERVATION", 5, 18], ["backward", "OBSERVATION_MODIFIER", 40, 48], ["flowing", "OBSERVATION_MODIFIER", 49, 56], ["esophagus", "ANATOMY", 80, 89], ["regurgitation", "OBSERVATION", 100, 113], ["retching", "OBSERVATION", 164, 172], ["abdominal", "ANATOMY", 177, 186], ["vomiting", "OBSERVATION", 214, 222]]], ["Regurgitation localizes the problem to Note: Pain management has become increasingly recognized as an essential part of clinical practice today.", [["Regurgitation", "DISEASE", 0, 13], ["Pain", "DISEASE", 45, 49], ["Regurgitation", "PROBLEM", 0, 13], ["Pain management", "TREATMENT", 45, 60]]], ["Section 1 (Tables 1-16 to 1-23) addresses indications of the drugs and doses most commonly employed in pain management in dogs and cats.definitionthe esophagus.", [["esophagus", "ANATOMY", 150, 159], ["pain", "DISEASE", 103, 107], ["dogs", "ORGANISM", 122, 126], ["cats", "ORGANISM", 131, 135], ["esophagus", "ORGAN", 150, 159], ["dogs", "SPECIES", 122, 126], ["cats", "SPECIES", 131, 135], ["the drugs", "TREATMENT", 57, 66], ["pain management", "TREATMENT", 103, 118], ["esophagus", "ANATOMY", 150, 159]]], ["Both acquired (e.g., foreign body) and congenital (e.g., familial megaesophagus) forms and esophageal disease can lead to regurgitation.", [["body", "ANATOMY", 29, 33], ["megaesophagus", "ANATOMY", 66, 79], ["esophageal", "ANATOMY", 91, 101], ["congenital (e.g., familial megaesophagus", "DISEASE", 39, 79], ["esophageal disease", "DISEASE", 91, 109], ["megaesophagus", "CANCER", 66, 79], ["esophageal", "ORGAN", 91, 101], ["congenital (e.g., familial megaesophagus) forms", "PROBLEM", 39, 86], ["esophageal disease", "PROBLEM", 91, 109], ["regurgitation", "PROBLEM", 122, 135], ["foreign body", "OBSERVATION", 21, 33], ["congenital", "OBSERVATION", 39, 49], ["esophageal", "ANATOMY", 91, 101], ["disease", "OBSERVATION", 102, 109], ["regurgitation", "OBSERVATION", 122, 135]]], ["Many esophageal problems remain undiagnosed if regurgitation is not present.AssociAted signsPhysical signs accompanying regurgitation that are recognized by owners of dogs or cats include dysphagia characterized by difficulty swallowing food, frequent attempts to swallow food, and hypersalivation.", [["esophageal", "ANATOMY", 5, 15], ["esophageal problems", "DISEASE", 5, 24], ["dysphagia", "DISEASE", 188, 197], ["hypersalivation", "DISEASE", 282, 297], ["esophageal", "ORGAN", 5, 15], ["dogs", "ORGANISM", 167, 171], ["cats", "ORGANISM", 175, 179], ["dogs", "SPECIES", 167, 171], ["cats", "SPECIES", 175, 179], ["Many esophageal problems", "PROBLEM", 0, 24], ["regurgitation", "PROBLEM", 47, 60], ["AssociAted signsPhysical signs accompanying regurgitation", "PROBLEM", 76, 133], ["dysphagia", "PROBLEM", 188, 197], ["difficulty swallowing food", "PROBLEM", 215, 241], ["hypersalivation", "PROBLEM", 282, 297], ["esophageal", "ANATOMY", 5, 15], ["problems", "OBSERVATION", 16, 24], ["undiagnosed", "OBSERVATION", 32, 43], ["regurgitation", "OBSERVATION", 47, 60], ["not present", "UNCERTAINTY", 64, 75], ["regurgitation", "OBSERVATION", 120, 133]]], ["Belching may also be reported subsequent to the entrapment of air in the esophagus.", [["esophagus", "ANATOMY", 73, 82], ["esophagus", "ORGAN", 73, 82], ["Belching", "PROBLEM", 0, 8], ["air in the esophagus", "PROBLEM", 62, 82], ["entrapment", "OBSERVATION", 48, 58], ["air", "OBSERVATION", 62, 65], ["esophagus", "ANATOMY", 73, 82]]], ["Inappetence and weight loss subsequently develop.", [["Inappetence", "DISEASE", 0, 11], ["weight loss", "DISEASE", 16, 27], ["Inappetence", "PROBLEM", 0, 11], ["weight loss", "PROBLEM", 16, 27], ["weight loss", "OBSERVATION", 16, 27]]], ["Esophageal dilatation may be observed at the level of the lower cervical esophagus or thoracic inlet.", [["Esophageal", "ANATOMY", 0, 10], ["lower cervical esophagus", "ANATOMY", 58, 82], ["thoracic inlet", "ANATOMY", 86, 100], ["Esophageal", "ORGAN", 0, 10], ["cervical esophagus", "ORGAN", 64, 82], ["thoracic inlet", "MULTI-TISSUE_STRUCTURE", 86, 100], ["Esophageal dilatation", "TREATMENT", 0, 21], ["dilatation", "OBSERVATION", 11, 21], ["lower", "ANATOMY_MODIFIER", 58, 63], ["cervical esophagus", "ANATOMY", 64, 82], ["thoracic", "ANATOMY", 86, 94], ["inlet", "ANATOMY_MODIFIER", 95, 100]]], ["Owners may report expulsion of blood-tinged saliva subsequent to esophageal mucosal injury.", [["blood", "ANATOMY", 31, 36], ["esophageal mucosal", "ANATOMY", 65, 83], ["esophageal mucosal injury", "DISEASE", 65, 90], ["blood", "ORGANISM_SUBSTANCE", 31, 36], ["saliva", "ORGANISM_SUBSTANCE", 44, 50], ["esophageal mucosal", "MULTI-TISSUE_STRUCTURE", 65, 83], ["expulsion of blood-tinged saliva", "PROBLEM", 18, 50], ["esophageal mucosal injury", "PROBLEM", 65, 90], ["esophageal mucosal", "ANATOMY", 65, 83], ["injury", "OBSERVATION", 84, 90]]], ["Paroxysms of coughing and retching, particularly when eating, may be present, along with difficult breathing in animals with significant pneumonia.", [["coughing", "DISEASE", 13, 21], ["retching", "DISEASE", 26, 34], ["pneumonia", "DISEASE", 137, 146], ["Paroxysms", "PROBLEM", 0, 9], ["coughing", "PROBLEM", 13, 21], ["retching", "PROBLEM", 26, 34], ["difficult breathing", "PROBLEM", 89, 108], ["significant pneumonia", "PROBLEM", 125, 146], ["coughing", "OBSERVATION", 13, 21], ["retching", "OBSERVATION", 26, 34], ["significant", "OBSERVATION_MODIFIER", 125, 136], ["pneumonia", "OBSERVATION", 137, 146]]], ["Nasal discharge may consist of mucoid to mucopurulent exudates or of food and liquid recently consumed.AssociAted signsRarely, affected animals have swollen joints, lameness, and severe weakness associated with hypertrophic osteodystrophy subsequent to an intrathoracic lesion.", [["Nasal", "ANATOMY", 0, 5], ["mucoid", "ANATOMY", 31, 37], ["exudates", "ANATOMY", 54, 62], ["swollen joints", "ANATOMY", 149, 163], ["intrathoracic lesion", "ANATOMY", 256, 276], ["swollen joints", "DISEASE", 149, 163], ["lameness", "DISEASE", 165, 173], ["weakness", "DISEASE", 186, 194], ["hypertrophic osteodystrophy", "DISEASE", 211, 238], ["Nasal", "ORGAN", 0, 5], ["joints", "MULTI-TISSUE_STRUCTURE", 157, 163], ["intrathoracic lesion", "PATHOLOGICAL_FORMATION", 256, 276], ["mucoid to mucopurulent exudates", "PROBLEM", 31, 62], ["swollen joints", "PROBLEM", 149, 163], ["lameness", "PROBLEM", 165, 173], ["severe weakness", "PROBLEM", 179, 194], ["hypertrophic osteodystrophy", "PROBLEM", 211, 238], ["an intrathoracic lesion", "PROBLEM", 253, 276], ["swollen", "OBSERVATION_MODIFIER", 149, 156], ["joints", "ANATOMY", 157, 163], ["lameness", "OBSERVATION_MODIFIER", 165, 173], ["severe", "OBSERVATION_MODIFIER", 179, 185], ["weakness", "OBSERVATION", 186, 194], ["hypertrophic", "OBSERVATION_MODIFIER", 211, 223], ["osteodystrophy", "OBSERVATION", 224, 238], ["intrathoracic", "ANATOMY", 256, 269], ["lesion", "OBSERVATION", 270, 276]]], ["Atypical signs include dyspnea (aspiration pneumonia or foreign body penetration through the intrathoracic esophagus), regurgitation unrelated to eating, and recurrent gastric bloating associated with aerophagia. differentiAl diAgnosis diAgnostic PlAns 1.", [["body", "ANATOMY", 64, 68], ["intrathoracic esophagus", "ANATOMY", 93, 116], ["gastric", "ANATOMY", 168, 175], ["dyspnea", "DISEASE", 23, 30], ["pneumonia", "DISEASE", 43, 52], ["regurgitation unrelated to eating", "DISEASE", 119, 152], ["gastric bloating", "DISEASE", 168, 184], ["aerophagia", "DISEASE", 201, 211], ["body", "ORGANISM_SUBDIVISION", 64, 68], ["intrathoracic esophagus", "ORGAN", 93, 116], ["gastric", "ORGAN", 168, 175], ["Atypical signs", "PROBLEM", 0, 14], ["dyspnea", "PROBLEM", 23, 30], ["aspiration pneumonia", "PROBLEM", 32, 52], ["foreign body penetration through the intrathoracic esophagus", "PROBLEM", 56, 116], ["regurgitation", "PROBLEM", 119, 132], ["recurrent gastric bloating", "PROBLEM", 158, 184], ["aerophagia", "PROBLEM", 201, 211], ["dyspnea", "OBSERVATION", 23, 30], ["aspiration", "OBSERVATION_MODIFIER", 32, 42], ["pneumonia", "OBSERVATION", 43, 52], ["foreign body", "OBSERVATION", 56, 68], ["intrathoracic esophagus", "ANATOMY", 93, 116], ["regurgitation", "OBSERVATION", 119, 132], ["gastric", "ANATOMY", 168, 175], ["bloating", "OBSERVATION", 176, 184], ["aerophagia", "OBSERVATION", 201, 211]]], ["History and physical examination, to characterize the nature of the problem, to distinguish between vomiting and regurgitation, and to establish the character of the regurgitated material.", [["vomiting", "DISEASE", 100, 108], ["physical examination", "TEST", 12, 32], ["vomiting", "PROBLEM", 100, 108], ["regurgitation", "PROBLEM", 113, 126], ["the regurgitated material", "PROBLEM", 162, 187], ["regurgitation", "OBSERVATION", 113, 126]]], ["Laboratory database, to assess patient status, particularly if secondary complications are present.", [["patient", "ORGANISM", 31, 38], ["patient", "SPECIES", 31, 38], ["Laboratory database", "TEST", 0, 19], ["secondary complications", "PROBLEM", 63, 86]]], ["Survey thoracic and cervical radiography, to assess presence of megaesophagus, radiopaque intraesophageal lesion, or both.", [["thoracic", "ANATOMY", 7, 15], ["cervical", "ANATOMY", 20, 28], ["megaesophagus", "ANATOMY", 64, 77], ["intraesophageal lesion", "ANATOMY", 90, 112], ["megaesophagus", "DISEASE", 64, 77], ["radiopaque intraesophageal lesion", "DISEASE", 79, 112], ["thoracic", "MULTI-TISSUE_STRUCTURE", 7, 15], ["cervical", "ORGAN", 20, 28], ["megaesophagus", "CANCER", 64, 77], ["Survey thoracic and cervical radiography", "TEST", 0, 40], ["megaesophagus", "PROBLEM", 64, 77], ["radiopaque intraesophageal lesion", "PROBLEM", 79, 112], ["thoracic", "ANATOMY", 7, 15], ["cervical", "ANATOMY", 20, 28], ["megaesophagus", "OBSERVATION", 64, 77], ["radiopaque", "OBSERVATION_MODIFIER", 79, 89], ["intraesophageal", "ANATOMY", 90, 105], ["lesion", "OBSERVATION", 106, 112]]], ["Contrast esophagram, to confirm any interference with normal bolus transport at the point of obstruction, changes in mucosal integrity or luminal displacement, and the presence of extraluminal gas.", [["mucosal", "ANATOMY", 117, 124], ["luminal", "ANATOMY", 138, 145], ["obstruction", "DISEASE", 93, 104], ["luminal", "CHEMICAL", 138, 145], ["mucosal", "MULTI-TISSUE_STRUCTURE", 117, 124], ["luminal", "MULTI-TISSUE_STRUCTURE", 138, 145], ["Contrast esophagram", "TEST", 0, 19], ["normal bolus transport", "TREATMENT", 54, 76], ["obstruction", "PROBLEM", 93, 104], ["changes in mucosal integrity", "PROBLEM", 106, 134], ["luminal displacement", "PROBLEM", 138, 158], ["extraluminal gas", "PROBLEM", 180, 196], ["obstruction", "OBSERVATION", 93, 104], ["mucosal integrity", "OBSERVATION", 117, 134], ["luminal displacement", "OBSERVATION", 138, 158], ["extraluminal", "ANATOMY_MODIFIER", 180, 192], ["gas", "OBSERVATION", 193, 196]]], ["(Oral suspension of barium sulfate is recommended over other contrast materials.)", [["Oral", "ANATOMY", 1, 5], ["barium sulfate", "CHEMICAL", 20, 34], ["barium sulfate", "CHEMICAL", 20, 34], ["barium sulfate", "SIMPLE_CHEMICAL", 20, 34], ["Oral suspension of barium sulfate", "TREATMENT", 1, 34]]], ["Note: Contrast medium retention in the esophagus is the hallmark of a motor disorder and often localizes the site of dysmotility.", [["esophagus", "ANATOMY", 39, 48], ["site", "ANATOMY", 109, 113], ["motor disorder", "DISEASE", 70, 84], ["dysmotility", "DISEASE", 117, 128], ["esophagus", "ORGAN", 39, 48], ["Contrast medium retention in the esophagus", "PROBLEM", 6, 48], ["a motor disorder", "PROBLEM", 68, 84], ["dysmotility", "PROBLEM", 117, 128], ["medium retention", "OBSERVATION", 15, 31], ["esophagus", "ANATOMY", 39, 48], ["hallmark", "OBSERVATION_MODIFIER", 56, 64], ["motor disorder", "OBSERVATION", 70, 84], ["dysmotility", "OBSERVATION", 117, 128]]], ["Endoscopy and, as indicated, biopsy, to determine the cause of megaesophagus rather than to diagnose megaesophagus.", [["megaesophagus", "ANATOMY", 63, 76], ["megaesophagus", "ANATOMY", 101, 114], ["megaesophagus", "DISEASE", 101, 114], ["megaesophagus", "CANCER", 63, 76], ["megaesophagus", "CANCER", 101, 114], ["Endoscopy", "TEST", 0, 9], ["biopsy", "TEST", 29, 35], ["megaesophagus", "PROBLEM", 63, 76], ["diagnose megaesophagus", "PROBLEM", 92, 114], ["megaesophagus", "OBSERVATION", 63, 76]]], ["In some instances, especially foreign body obstruction, endoscopy may be therapeutic.", [["body", "ANATOMY", 38, 42], ["obstruction", "DISEASE", 43, 54], ["foreign body obstruction", "PROBLEM", 30, 54], ["endoscopy", "TEST", 56, 65], ["obstruction", "OBSERVATION", 43, 54]]], ["Special procedures, to include contrast esophagram during fluoroscopy, CT, and exploratory laparotomy.", [["Special procedures", "TREATMENT", 0, 18], ["contrast esophagram", "TEST", 31, 50], ["fluoroscopy", "TEST", 58, 69], ["CT", "TEST", 71, 73], ["exploratory laparotomy", "TEST", 79, 101], ["laparotomy", "OBSERVATION", 91, 101]]], ["The terms seizure, convulsion, epilepsy, epileptic attack, and \"fit\" all describe a clinical sign that is characterized by paroxysmal involuntary contraction of a series of voluntary muscles with a generally short duration, typically followed by a change in behavior.", [["muscles", "ANATOMY", 183, 190], ["seizure", "DISEASE", 10, 17], ["convulsion", "DISEASE", 19, 29], ["epilepsy", "DISEASE", 31, 39], ["epileptic", "DISEASE", 41, 50], ["muscles", "ORGANISM_SUBDIVISION", 183, 190], ["The terms seizure", "PROBLEM", 0, 17], ["convulsion", "PROBLEM", 19, 29], ["epilepsy", "PROBLEM", 31, 39], ["epileptic attack", "PROBLEM", 41, 57], ["paroxysmal involuntary contraction", "PROBLEM", 123, 157], ["a change in behavior", "PROBLEM", 246, 266], ["seizure", "OBSERVATION", 10, 17], ["epileptic attack", "OBSERVATION", 41, 57], ["paroxysmal", "OBSERVATION_MODIFIER", 123, 133], ["involuntary contraction", "OBSERVATION", 134, 157], ["muscles", "ANATOMY", 183, 190]]], ["Epileptic seizure, the most common form of seizure disorder in dogs, has been described as having four component phases: (1) prodromal phase, the period of time immediately before a seizure; (2) aura, behavior suggesting that the patient is aware that seizure activity is impending; (3) ictal phase, characterized by actual seizure activity, and (4) postictal phase, the period after cessation of seizure activity, often manifesting as increased anxiety, water or food consumption, and/or transient blindness.", [["Epileptic seizure", "DISEASE", 0, 17], ["seizure disorder", "DISEASE", 43, 59], ["seizure", "DISEASE", 182, 189], ["aura", "DISEASE", 195, 199], ["seizure", "DISEASE", 252, 259], ["seizure", "DISEASE", 324, 331], ["seizure", "DISEASE", 397, 404], ["anxiety", "DISEASE", 446, 453], ["blindness", "DISEASE", 499, 508], ["dogs", "ORGANISM", 63, 67], ["patient", "ORGANISM", 230, 237], ["dogs", "SPECIES", 63, 67], ["patient", "SPECIES", 230, 237], ["Epileptic seizure", "PROBLEM", 0, 17], ["seizure disorder", "PROBLEM", 43, 59], ["a seizure", "PROBLEM", 180, 189], ["aura", "PROBLEM", 195, 199], ["seizure activity", "PROBLEM", 252, 268], ["ictal phase", "TEST", 287, 298], ["actual seizure activity", "PROBLEM", 317, 340], ["seizure activity", "PROBLEM", 397, 413], ["increased anxiety", "PROBLEM", 436, 453], ["transient blindness", "PROBLEM", 489, 508], ["most common", "OBSERVATION_MODIFIER", 23, 34], ["seizure", "OBSERVATION", 43, 50], ["transient", "OBSERVATION_MODIFIER", 489, 498], ["blindness", "OBSERVATION", 499, 508]]], ["Seizure activity may be self-limiting (one or two seizures per 24-hour period) or continuous (status epilepticus), which can be life-threatening and warrants immediate therapeutic intervention.", [["Seizure", "DISEASE", 0, 7], ["seizures", "DISEASE", 50, 58], ["status epilepticus", "DISEASE", 94, 112], ["Seizure activity", "PROBLEM", 0, 16], ["two seizures", "PROBLEM", 46, 58], ["continuous (status epilepticus", "PROBLEM", 82, 112], ["immediate therapeutic intervention", "TREATMENT", 158, 192]]], ["In addition, seizures are classified as focal (facial twitching or bizarre behavioral manifestations) or generalized; generalized seizures are further characterized as tonic-clonic, clonic, myoclonic, atonic, or absence types.", [["facial", "ANATOMY", 47, 53], ["seizures", "DISEASE", 13, 21], ["seizures", "DISEASE", 130, 138], ["clonic", "DISEASE", 182, 188], ["myoclonic", "DISEASE", 190, 199], ["atonic", "DISEASE", 201, 207], ["seizures", "PROBLEM", 13, 21], ["focal (facial twitching", "PROBLEM", 40, 63], ["bizarre behavioral manifestations", "PROBLEM", 67, 100], ["generalized seizures", "PROBLEM", 118, 138], ["tonic-clonic", "PROBLEM", 168, 180], ["clonic", "PROBLEM", 182, 188], ["myoclonic", "PROBLEM", 190, 199], ["atonic", "PROBLEM", 201, 207], ["absence types", "PROBLEM", 212, 225], ["focal", "OBSERVATION_MODIFIER", 40, 45], ["facial", "ANATOMY", 47, 53], ["generalized", "OBSERVATION_MODIFIER", 118, 129], ["seizures", "OBSERVATION", 130, 138]]], ["Seizures result from disorders of the brain that cause spontaneous depolarizations and excitation of cerebral neurons.", [["brain", "ANATOMY", 38, 43], ["cerebral neurons", "ANATOMY", 101, 117], ["Seizures", "DISEASE", 0, 8], ["disorders of the brain", "DISEASE", 21, 43], ["brain", "ORGAN", 38, 43], ["cerebral neurons", "CELL", 101, 117], ["cerebral neurons", "CELL_TYPE", 101, 117], ["Seizures", "PROBLEM", 0, 8], ["disorders of the brain", "PROBLEM", 21, 43], ["spontaneous depolarizations", "PROBLEM", 55, 82], ["excitation of cerebral neurons", "PROBLEM", 87, 117], ["brain", "ANATOMY", 38, 43], ["spontaneous depolarizations", "OBSERVATION", 55, 82], ["cerebral neurons", "ANATOMY", 101, 117]]], ["As a presenting problem, seizures are much more common in the dog than in the cat.", [["seizures", "DISEASE", 25, 33], ["dog", "ORGANISM", 62, 65], ["cat", "ORGANISM", 78, 81], ["dog", "SPECIES", 62, 65], ["cat", "SPECIES", 78, 81], ["a presenting problem", "PROBLEM", 3, 23], ["seizures", "PROBLEM", 25, 33]]], ["Such disorders may originate from extracranial causes, metabolic or toxic diseases, and intracranial causes (e.g., organic brain disease).", [["extracranial", "ANATOMY", 34, 46], ["intracranial", "ANATOMY", 88, 100], ["brain", "ANATOMY", 123, 128], ["metabolic or toxic diseases", "DISEASE", 55, 82], ["intracranial causes", "DISEASE", 88, 107], ["organic brain disease", "DISEASE", 115, 136], ["brain", "ORGAN", 123, 128], ["Such disorders", "PROBLEM", 0, 14], ["extracranial causes", "PROBLEM", 34, 53], ["toxic diseases", "PROBLEM", 68, 82], ["intracranial causes (e.g., organic brain disease)", "PROBLEM", 88, 137], ["extracranial", "ANATOMY", 34, 46], ["toxic", "OBSERVATION_MODIFIER", 68, 73], ["intracranial", "ANATOMY", 88, 100], ["organic brain disease", "OBSERVATION", 115, 136]]], ["When seizures occur in the absence of detectable organic or metabolic CNS abnormalities, the seizures are described as idiopathic.", [["CNS", "ANATOMY", 70, 73], ["seizures", "DISEASE", 5, 13], ["seizures", "DISEASE", 93, 101], ["CNS", "ANATOMICAL_SYSTEM", 70, 73], ["seizures", "PROBLEM", 5, 13], ["detectable organic or metabolic CNS abnormalities", "PROBLEM", 38, 87], ["the seizures", "PROBLEM", 89, 101], ["idiopathic", "PROBLEM", 119, 129], ["metabolic CNS", "OBSERVATION", 60, 73], ["idiopathic", "OBSERVATION_MODIFIER", 119, 129]]], ["Idiopathic epilepsy is the most common type of seizure reported in companion animal species.AssociAted signsGeneralized motor seizures are the most prevalent type of seizure encountered in veterinary medicine.", [["Idiopathic epilepsy", "DISEASE", 0, 19], ["seizure", "DISEASE", 47, 54], ["motor seizures", "DISEASE", 120, 134], ["seizure", "DISEASE", 166, 173], ["Idiopathic epilepsy", "PROBLEM", 0, 19], ["seizure", "PROBLEM", 47, 54], ["AssociAted signs", "PROBLEM", 92, 108], ["Generalized motor seizures", "PROBLEM", 108, 134], ["seizure", "PROBLEM", 166, 173], ["epilepsy", "OBSERVATION", 11, 19], ["most common", "OBSERVATION_MODIFIER", 27, 38], ["seizure", "OBSERVATION", 47, 54], ["signs", "OBSERVATION_MODIFIER", 103, 108], ["Generalized", "OBSERVATION_MODIFIER", 108, 119], ["motor seizures", "OBSERVATION", 120, 134], ["most prevalent", "OBSERVATION_MODIFIER", 143, 157]]], ["Most cases are diagnosed as idiopathic epilepsy on the basis that organic causes of seizure activity cannot be identified.", [["idiopathic epilepsy", "DISEASE", 28, 47], ["seizure", "DISEASE", 84, 91], ["idiopathic epilepsy", "PROBLEM", 28, 47], ["seizure activity", "PROBLEM", 84, 100], ["idiopathic", "OBSERVATION_MODIFIER", 28, 38], ["epilepsy", "OBSERVATION", 39, 47]]], ["The time between seizures (interictal period) in animals with a history of generalized motor seizures is characteristically described by owners as normal.", [["seizures", "DISEASE", 17, 25], ["seizures", "DISEASE", 93, 101], ["seizures", "PROBLEM", 17, 25], ["generalized motor seizures", "PROBLEM", 75, 101], ["motor seizures", "OBSERVATION", 87, 101], ["normal", "OBSERVATION", 147, 153]]], ["The immediate postictal period, regardless of the cause of the seizure activity, is often associated with transient disorientation, blindness, stumbling, PD, or polyphagia.AssociAted signsThe spectrum of possible clinical signs associated with seizure activity is extensive.", [["seizure", "DISEASE", 63, 70], ["disorientation", "DISEASE", 116, 130], ["blindness", "DISEASE", 132, 141], ["stumbling", "DISEASE", 143, 152], ["PD", "DISEASE", 154, 156], ["polyphagia", "DISEASE", 161, 171], ["seizure", "DISEASE", 244, 251], ["the seizure activity", "PROBLEM", 59, 79], ["transient disorientation", "PROBLEM", 106, 130], ["blindness", "PROBLEM", 132, 141], ["stumbling", "PROBLEM", 143, 152], ["PD", "PROBLEM", 154, 156], ["polyphagia", "PROBLEM", 161, 171], ["AssociAted signs", "PROBLEM", 172, 188], ["clinical signs", "PROBLEM", 213, 227], ["seizure activity", "PROBLEM", 244, 260], ["disorientation", "OBSERVATION", 116, 130], ["blindness", "OBSERVATION", 132, 141], ["extensive", "OBSERVATION_MODIFIER", 264, 273]]], ["Before a diagnosis of idiopathic epilepsy is reached, it is important that the patient be evaluated for cardiovascular disease, trauma, toxicity, infectious disease, parasites, neoplasia, and metabolic disorders, particularly those affecting the kidney, liver, and endocrine pancreas.agE oF animalSeizures in young animals (< 1year old) are commonly caused by developmental abnormalities, hydrocephalus, lissencephaly, encephalitis (infectious), lead poisoning, severe intestinal parasitism, portacaval shunt abnormalities, and juvenile hypoglycemia.", [["cardiovascular", "ANATOMY", 104, 118], ["neoplasia", "ANATOMY", 177, 186], ["kidney", "ANATOMY", 246, 252], ["liver", "ANATOMY", 254, 259], ["endocrine pancreas", "ANATOMY", 265, 283], ["intestinal", "ANATOMY", 469, 479], ["idiopathic epilepsy", "DISEASE", 22, 41], ["cardiovascular disease", "DISEASE", 104, 126], ["trauma", "DISEASE", 128, 134], ["toxicity", "DISEASE", 136, 144], ["infectious disease", "DISEASE", 146, 164], ["neoplasia", "DISEASE", 177, 186], ["metabolic disorders", "DISEASE", 192, 211], ["developmental abnormalities", "DISEASE", 360, 387], ["hydrocephalus", "DISEASE", 389, 402], ["lissencephaly", "DISEASE", 404, 417], ["encephalitis", "DISEASE", 419, 431], ["poisoning", "DISEASE", 451, 460], ["intestinal parasitism", "DISEASE", 469, 490], ["portacaval shunt abnormalities", "DISEASE", 492, 522], ["juvenile hypoglycemia", "DISEASE", 528, 549], ["patient", "ORGANISM", 79, 86], ["cardiovascular", "ANATOMICAL_SYSTEM", 104, 118], ["neoplasia", "CANCER", 177, 186], ["kidney", "ORGAN", 246, 252], ["liver", "ORGAN", 254, 259], ["endocrine pancreas", "ORGAN", 265, 283], ["intestinal", "ORGAN", 469, 479], ["patient", "SPECIES", 79, 86], ["idiopathic epilepsy", "PROBLEM", 22, 41], ["cardiovascular disease", "PROBLEM", 104, 126], ["trauma", "PROBLEM", 128, 134], ["toxicity", "PROBLEM", 136, 144], ["infectious disease", "PROBLEM", 146, 164], ["parasites", "PROBLEM", 166, 175], ["neoplasia", "PROBLEM", 177, 186], ["metabolic disorders", "PROBLEM", 192, 211], ["developmental abnormalities", "PROBLEM", 360, 387], ["hydrocephalus", "PROBLEM", 389, 402], ["lissencephaly", "PROBLEM", 404, 417], ["encephalitis", "PROBLEM", 419, 431], ["lead poisoning", "PROBLEM", 446, 460], ["severe intestinal parasitism", "PROBLEM", 462, 490], ["portacaval shunt abnormalities", "PROBLEM", 492, 522], ["juvenile hypoglycemia", "PROBLEM", 528, 549], ["idiopathic", "OBSERVATION_MODIFIER", 22, 32], ["epilepsy", "OBSERVATION", 33, 41], ["infectious", "OBSERVATION_MODIFIER", 146, 156], ["neoplasia", "OBSERVATION", 177, 186], ["metabolic disorders", "OBSERVATION", 192, 211], ["kidney", "ANATOMY", 246, 252], ["liver", "ANATOMY", 254, 259], ["endocrine pancreas", "ANATOMY", 265, 283], ["hydrocephalus", "OBSERVATION", 389, 402], ["lissencephaly", "OBSERVATION", 404, 417], ["encephalitis", "OBSERVATION", 419, 431], ["severe", "OBSERVATION_MODIFIER", 462, 468], ["intestinal", "ANATOMY", 469, 479], ["parasitism", "OBSERVATION", 480, 490], ["portacaval shunt", "OBSERVATION", 492, 508], ["juvenile", "OBSERVATION_MODIFIER", 528, 536], ["hypoglycemia", "OBSERVATION", 537, 549]]], ["Idiopathic epilepsy usually begins when animals are 1 to 3 years of age.", [["Idiopathic epilepsy", "DISEASE", 0, 19], ["Idiopathic epilepsy", "PROBLEM", 0, 19], ["epilepsy", "OBSERVATION", 11, 19]]], ["Animals older than 5 years of age are more likely to have CNS tumors or hypoglycemia from insulin-secreting beta cell pancreatic neoplasms.BrEEd PrEdisPositionSome basic knowledge about breed predisposition to seizure disorders may be helpful in establishing a diagnosis.", [["CNS tumors", "ANATOMY", 58, 68], ["beta cell pancreatic neoplasms", "ANATOMY", 108, 138], ["tumors", "DISEASE", 62, 68], ["hypoglycemia", "DISEASE", 72, 84], ["beta cell pancreatic neoplasms", "DISEASE", 108, 138], ["seizure disorders", "DISEASE", 210, 227], ["Animals", "ORGANISM", 0, 7], ["CNS tumors", "CANCER", 58, 68], ["insulin", "GENE_OR_GENE_PRODUCT", 90, 97], ["beta cell pancreatic neoplasms", "CANCER", 108, 138], ["CNS tumors", "PROBLEM", 58, 68], ["hypoglycemia", "PROBLEM", 72, 84], ["insulin", "TREATMENT", 90, 97], ["secreting beta cell pancreatic neoplasms", "PROBLEM", 98, 138], ["seizure disorders", "PROBLEM", 210, 227], ["CNS", "ANATOMY", 58, 61], ["tumors", "OBSERVATION", 62, 68], ["hypoglycemia", "OBSERVATION", 72, 84], ["secreting beta cell", "OBSERVATION", 98, 117], ["pancreatic", "ANATOMY", 118, 128], ["neoplasms", "OBSERVATION", 129, 138]]], ["Idiopathic epilepsy has been seen in numerous dog breeds, particularly German Shepherd Dogs, Belgian Tervurens, Keeshonds, Saint Bernards, Standard and Miniature Poodles, Beagles, Irish Setters, Cocker Spaniels, Alaskan Malamutes, Siberian Huskies, and Labrador and Golden Retrievers.", [["Idiopathic epilepsy", "DISEASE", 0, 19], ["dog", "ORGANISM", 46, 49], ["Idiopathic epilepsy", "PROBLEM", 0, 19], ["epilepsy", "OBSERVATION", 11, 19], ["Golden Retrievers", "OBSERVATION", 266, 283]]], ["Juvenile hypoglycemia is most prevalent in toy breeds.", [["hypoglycemia", "DISEASE", 9, 21], ["Juvenile hypoglycemia", "PROBLEM", 0, 21], ["hypoglycemia", "OBSERVATION", 9, 21], ["most prevalent", "OBSERVATION_MODIFIER", 25, 39]]], ["Hydrocephalus is common in the toy and brachycephalic breeds.", [["Hydrocephalus", "DISEASE", 0, 13], ["Hydrocephalus", "PROBLEM", 0, 13], ["brachycephalic breeds", "OBSERVATION", 39, 60]]], ["Neoplastic diseases are common in dogs of brachycephalic breeds older than 5 years of age.3Disorders of CNS metabolism include leukodystrophy (Cairn and West Highland White Terriers), lipodystrophy (German Short-Haired Pointers and English Setters), lissencephaly (Lhasa Apso), portosystemic shunts (Yorkshire Terriers), and hyperlipidemic states (Miniature Schnauzers).", [["Neoplastic", "ANATOMY", 0, 10], ["CNS", "ANATOMY", 104, 107], ["Neoplastic diseases", "DISEASE", 0, 19], ["leukodystrophy", "DISEASE", 127, 141], ["lipodystrophy", "DISEASE", 184, 197], ["lissencephaly", "DISEASE", 250, 263], ["portosystemic shunts", "DISEASE", 278, 298], ["hyperlipidemic states", "DISEASE", 325, 346], ["dogs", "ORGANISM", 34, 38], ["CNS", "ANATOMICAL_SYSTEM", 104, 107], ["dogs", "SPECIES", 34, 38], ["Neoplastic diseases", "PROBLEM", 0, 19], ["brachycephalic breeds", "PROBLEM", 42, 63], ["CNS metabolism", "PROBLEM", 104, 118], ["leukodystrophy", "PROBLEM", 127, 141], ["lipodystrophy", "PROBLEM", 184, 197], ["lissencephaly", "PROBLEM", 250, 263], ["portosystemic shunts (Yorkshire Terriers", "PROBLEM", 278, 318], ["hyperlipidemic states", "PROBLEM", 325, 346], ["brachycephalic breeds", "OBSERVATION", 42, 63], ["CNS", "ANATOMY", 104, 107], ["lipodystrophy", "OBSERVATION", 184, 197], ["portosystemic shunts", "OBSERVATION", 278, 298], ["hyperlipidemic", "OBSERVATION", 325, 339]]], ["A unique, usually fatal, encephalitis is described in Pugs.EnvironmEntExposure to infectious agents or other sick animals may be important, as is exposure to sources of intoxicants, such as lead in paints, linoleum, tar, batteries, or roofing material; hexachlorophene soap; ethylene glycol (antifreeze); metaldehyde snail bait; and various other insecticides, including chlorinated hydrocarbons, organophosphates, and rodenticides.", [["encephalitis", "DISEASE", 25, 37], ["linoleum", "CHEMICAL", 206, 214], ["tar", "CHEMICAL", 216, 219], ["hexachlorophene", "CHEMICAL", 253, 268], ["ethylene glycol", "CHEMICAL", 275, 290], ["metaldehyde", "CHEMICAL", 305, 316], ["chlorinated hydrocarbons", "CHEMICAL", 371, 395], ["organophosphates", "CHEMICAL", 397, 413], ["linoleum", "CHEMICAL", 206, 214], ["hexachlorophene", "CHEMICAL", 253, 268], ["ethylene glycol", "CHEMICAL", 275, 290], ["metaldehyde", "CHEMICAL", 305, 316], ["chlorinated hydrocarbons", "CHEMICAL", 371, 395], ["organophosphates", "CHEMICAL", 397, 413], ["linoleum", "SIMPLE_CHEMICAL", 206, 214], ["hexachlorophene", "SIMPLE_CHEMICAL", 253, 268], ["ethylene glycol", "SIMPLE_CHEMICAL", 275, 290], ["metaldehyde", "SIMPLE_CHEMICAL", 305, 316], ["chlorinated hydrocarbons", "SIMPLE_CHEMICAL", 371, 395], ["organophosphates", "SIMPLE_CHEMICAL", 397, 413], ["rodenticides", "SIMPLE_CHEMICAL", 419, 431], ["encephalitis", "PROBLEM", 25, 37], ["EnvironmEntExposure", "TREATMENT", 59, 78], ["infectious agents", "TREATMENT", 82, 99], ["intoxicants", "PROBLEM", 169, 180], ["roofing material", "PROBLEM", 235, 251], ["hexachlorophene soap", "TREATMENT", 253, 273], ["ethylene glycol (antifreeze)", "TREATMENT", 275, 303], ["metaldehyde snail bait", "TREATMENT", 305, 327], ["various other insecticides", "TREATMENT", 333, 359], ["chlorinated hydrocarbons", "TREATMENT", 371, 395], ["organophosphates", "TREATMENT", 397, 413], ["rodenticides", "TREATMENT", 419, 431], ["encephalitis", "OBSERVATION", 25, 37], ["infectious", "OBSERVATION", 82, 92]]], ["Dogs and cats on the same premises with swine may be exposed to suid herpesvirus (pseudorabies, or Aujeszky disease).", [["Aujeszky disease", "DISEASE", 99, 115], ["Dogs", "ORGANISM", 0, 4], ["cats", "ORGANISM", 9, 13], ["swine", "ORGANISM", 40, 45], ["herpesvirus", "ORGANISM", 69, 80], ["pseudorabies", "ORGANISM", 82, 94], ["Aujeszky", "ORGANISM", 99, 107], ["Dogs", "SPECIES", 0, 4], ["cats", "SPECIES", 9, 13], ["swine", "SPECIES", 40, 45], ["pseudorabies", "SPECIES", 82, 94], ["Aujeszky", "SPECIES", 99, 107], ["swine", "SPECIES", 40, 45], ["pseudorabies", "SPECIES", 82, 94], ["Aujeszky", "SPECIES", 99, 107], ["suid herpesvirus (pseudorabies", "PROBLEM", 64, 94], ["Aujeszky disease", "PROBLEM", 99, 115]]], ["A high-protein diet exacerbates hepatic encephalopathy.", [["hepatic", "ANATOMY", 32, 39], ["hepatic encephalopathy", "DISEASE", 32, 54], ["hepatic", "ORGAN", 32, 39], ["A high-protein diet", "TREATMENT", 0, 19], ["hepatic encephalopathy", "PROBLEM", 32, 54], ["protein diet", "OBSERVATION", 7, 19], ["hepatic", "ANATOMY", 32, 39], ["encephalopathy", "OBSERVATION", 40, 54]]], ["Thiamine deficiency may result from long-term consumption of certain fish diets or from cooking pet food.", [["Thiamine", "CHEMICAL", 0, 8], ["Thiamine", "CHEMICAL", 0, 8], ["Thiamine", "SIMPLE_CHEMICAL", 0, 8], ["Thiamine deficiency", "PROBLEM", 0, 19], ["deficiency", "OBSERVATION", 9, 19], ["long-term", "OBSERVATION_MODIFIER", 36, 45]]], ["Thorough physical examination, to include careful neurologic examination, with particular attention to cranial nerves, funduscopic examination, and cardiac auscultation.", [["neurologic", "ANATOMY", 50, 60], ["cranial nerves", "ANATOMY", 103, 117], ["cardiac", "ANATOMY", 148, 155], ["cranial nerves", "MULTI-TISSUE_STRUCTURE", 103, 117], ["cardiac", "ORGAN", 148, 155], ["Thorough physical examination", "TEST", 0, 29], ["careful neurologic examination", "TEST", 42, 72], ["cranial nerves", "TEST", 103, 117], ["funduscopic examination", "TEST", 119, 142], ["cardiac auscultation", "TEST", 148, 168], ["cranial nerves", "ANATOMY", 103, 117], ["cardiac", "ANATOMY", 148, 155], ["auscultation", "OBSERVATION", 156, 168]]], ["Laboratory database, essential to rule out metabolic causes.", [["Laboratory database", "TEST", 0, 19], ["metabolic causes", "PROBLEM", 43, 59], ["metabolic causes", "OBSERVATION", 43, 59]]], ["In addition to a CBC, biochemistry profile, urinalysis, and fecal culture, any or all of the following tests are indicated: serum ammonia, bile acids, serum insulin in hypoglycemic patients, blood lead test, and serial blood cultures.", [["serum", "ANATOMY", 124, 129], ["serum", "ANATOMY", 151, 156], ["blood", "ANATOMY", 191, 196], ["blood cultures", "ANATOMY", 219, 233], ["ammonia", "CHEMICAL", 130, 137], ["bile acids", "CHEMICAL", 139, 149], ["insulin", "CHEMICAL", 157, 164], ["hypoglycemic", "DISEASE", 168, 180], ["ammonia", "CHEMICAL", 130, 137], ["bile acids", "CHEMICAL", 139, 149], ["serum", "ORGANISM_SUBSTANCE", 124, 129], ["ammonia", "SIMPLE_CHEMICAL", 130, 137], ["bile acids", "SIMPLE_CHEMICAL", 139, 149], ["serum", "ORGANISM_SUBSTANCE", 151, 156], ["insulin", "GENE_OR_GENE_PRODUCT", 157, 164], ["patients", "ORGANISM", 181, 189], ["blood", "ORGANISM_SUBSTANCE", 191, 196], ["blood", "ORGANISM_SUBSTANCE", 219, 224], ["serum insulin", "PROTEIN", 151, 164], ["patients", "SPECIES", 181, 189], ["a CBC", "TEST", 15, 20], ["biochemistry profile", "TEST", 22, 42], ["urinalysis", "TEST", 44, 54], ["fecal culture", "TEST", 60, 73], ["the following tests", "TEST", 89, 108], ["serum ammonia", "TEST", 124, 137], ["bile acids", "TEST", 139, 149], ["serum insulin", "TEST", 151, 164], ["hypoglycemic patients", "TEST", 168, 189], ["blood lead test", "TEST", 191, 206], ["serial blood cultures", "TEST", 212, 233], ["fecal", "ANATOMY", 60, 65]]], ["Serum should be assessed for the presence of lipid (triglyceride).", [["Serum", "ANATOMY", 0, 5], ["triglyceride", "CHEMICAL", 52, 64], ["triglyceride", "CHEMICAL", 52, 64], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["lipid", "SIMPLE_CHEMICAL", 45, 50], ["triglyceride", "SIMPLE_CHEMICAL", 52, 64], ["Serum", "TEST", 0, 5], ["lipid (triglyceride", "TEST", 45, 64]]], ["Survey radiographs of the skull.", [["skull", "ANATOMY", 26, 31], ["skull", "ORGAN", 26, 31], ["Survey radiographs of the skull", "TEST", 0, 31], ["skull", "ANATOMY", 26, 31]]], ["These are rarely helpful, as intracranial neoplasms are not detectable on conventional skull radiographs.", [["intracranial neoplasms", "ANATOMY", 29, 51], ["skull", "ANATOMY", 87, 92], ["intracranial neoplasms", "DISEASE", 29, 51], ["intracranial neoplasms", "CANCER", 29, 51], ["skull", "ORGAN", 87, 92], ["intracranial neoplasms", "PROBLEM", 29, 51], ["conventional skull radiographs", "TEST", 74, 104], ["intracranial", "ANATOMY", 29, 41], ["neoplasms", "OBSERVATION", 42, 51]]], ["In special circumstances, limited ultrasound examination of the brain may be possible in young dogs through a cranial fontanelle.", [["brain", "ANATOMY", 64, 69], ["cranial", "ANATOMY", 110, 117], ["brain", "ORGAN", 64, 69], ["dogs", "ORGANISM", 95, 99], ["cranial fontanelle", "MULTI-TISSUE_STRUCTURE", 110, 128], ["dogs", "SPECIES", 95, 99], ["limited ultrasound examination of the brain", "TEST", 26, 69], ["brain", "ANATOMY", 64, 69], ["may be possible", "UNCERTAINTY", 70, 85], ["cranial fontanelle", "ANATOMY", 110, 128]]], ["Evidence of hydrocephalus may be seen.", [["hydrocephalus", "DISEASE", 12, 25], ["hydrocephalus", "PROBLEM", 12, 25], ["hydrocephalus", "OBSERVATION", 12, 25], ["may be seen", "UNCERTAINTY", 26, 37]]], ["CT or MRI (special facilities required).", [["CT", "TEST", 0, 2], ["MRI", "TEST", 6, 9]]], ["ECG or echocardiogram, if indicated.", [["ECG", "TEST", 0, 3], ["echocardiogram", "TEST", 7, 21]]], ["Abdominal ultrasound (portosystemic shunt).", [["Abdominal", "ANATOMY", 0, 9], ["Abdominal", "ORGAN", 0, 9], ["portosystemic", "MULTI-TISSUE_STRUCTURE", 22, 35], ["Abdominal ultrasound", "TEST", 0, 20], ["portosystemic shunt", "TREATMENT", 22, 41], ["portosystemic shunt", "OBSERVATION", 22, 41]]], ["Serologic studies for canine distemper, rabies, FIP, FeLV, FIV, toxoplasmosis, and systemic (deep) mycoses.", [["canine distemper", "DISEASE", 22, 38], ["rabies", "DISEASE", 40, 46], ["FIP, FeLV, FIV, toxoplasmosis", "DISEASE", 48, 77], ["mycoses", "DISEASE", 99, 106], ["canine distemper", "ORGANISM", 22, 38], ["rabies", "ORGANISM", 40, 46], ["FIP", "ORGANISM", 48, 51], ["FeLV", "ORGANISM", 53, 57], ["FIV", "ORGANISM", 59, 62], ["canine distemper", "SPECIES", 22, 38], ["canine distemper", "SPECIES", 22, 38], ["rabies", "SPECIES", 40, 46], ["FeLV", "SPECIES", 53, 57], ["FIV", "SPECIES", 59, 62], ["Serologic studies", "TEST", 0, 17], ["canine distemper", "PROBLEM", 22, 38], ["rabies", "PROBLEM", 40, 46], ["FIP", "PROBLEM", 48, 51], ["FeLV", "PROBLEM", 53, 57], ["FIV", "PROBLEM", 59, 62], ["toxoplasmosis", "PROBLEM", 64, 77], ["systemic (deep) mycoses", "PROBLEM", 83, 106], ["mycoses", "OBSERVATION", 99, 106]]], ["CSF analysis, including biochemistries, antibody titers, and cytologic parameters.", [["CSF", "GENE_OR_GENE_PRODUCT", 0, 3], ["CSF", "PROTEIN", 0, 3], ["CSF analysis", "TEST", 0, 12], ["biochemistries", "TEST", 24, 38], ["antibody titers", "TEST", 40, 55], ["cytologic parameters", "TEST", 61, 81]]], ["EEG.", [["EEG", "TEST", 0, 3]]], ["Although limited in availability, the EEG may be useful in detecting inflammatory brain disease and congenital intracranial abnormalities (e.g., hydrocephalus).", [["brain", "ANATOMY", 82, 87], ["intracranial", "ANATOMY", 111, 123], ["brain disease", "DISEASE", 82, 95], ["congenital intracranial abnormalities", "DISEASE", 100, 137], ["hydrocephalus", "DISEASE", 145, 158], ["brain", "ORGAN", 82, 87], ["the EEG", "TEST", 34, 41], ["inflammatory brain disease", "PROBLEM", 69, 95], ["congenital intracranial abnormalities", "PROBLEM", 100, 137], ["hydrocephalus", "PROBLEM", 145, 158], ["inflammatory", "OBSERVATION", 69, 81], ["congenital", "OBSERVATION_MODIFIER", 100, 110], ["intracranial", "ANATOMY", 111, 123], ["abnormalities", "OBSERVATION", 124, 137], ["hydrocephalus", "OBSERVATION", 145, 158]]], ["Contrast studies, requiring special equipment or facilities: radioisotope brain scan, cerebral angiography, pneumoencephalography, and CT scan.sneezing And nAsAl dischArge definitionSneezing is a protective reflex described as a sudden, involuntary, and forceful, even violent, expulsion of air from the upper respiratory tract; it may or may not be accompanied by nasal secretions.", [["brain", "ANATOMY", 74, 79], ["cerebral", "ANATOMY", 86, 94], ["upper respiratory tract", "ANATOMY", 304, 327], ["nasal secretions", "ANATOMY", 365, 381], ["sneezing", "DISEASE", 143, 151], ["brain", "ORGAN", 74, 79], ["cerebral", "MULTI-TISSUE_STRUCTURE", 86, 94], ["upper respiratory", "ORGANISM_SUBDIVISION", 304, 321], ["tract", "ORGANISM_SUBDIVISION", 322, 327], ["nasal secretions", "ORGANISM_SUBSTANCE", 365, 381], ["Contrast studies", "TEST", 0, 16], ["radioisotope brain scan", "TEST", 61, 84], ["cerebral angiography", "TEST", 86, 106], ["pneumoencephalography", "TEST", 108, 129], ["CT scan", "TEST", 135, 142], ["sneezing", "PROBLEM", 143, 151], ["a sudden, involuntary, and forceful", "PROBLEM", 227, 262], ["expulsion of air from the upper respiratory tract", "PROBLEM", 278, 327], ["nasal secretions", "PROBLEM", 365, 381], ["brain", "ANATOMY", 74, 79], ["cerebral", "ANATOMY", 86, 94], ["nAsAl", "ANATOMY", 156, 161], ["air", "OBSERVATION", 291, 294], ["upper", "ANATOMY_MODIFIER", 304, 309], ["respiratory tract", "ANATOMY", 310, 327], ["may not be", "UNCERTAINTY", 339, 349], ["nasal", "ANATOMY", 365, 370], ["secretions", "OBSERVATION", 371, 381]]], ["Clients easily recognize sneezing.", [["sneezing", "DISEASE", 25, 33], ["sneezing", "PROBLEM", 25, 33], ["sneezing", "OBSERVATION", 25, 33]]], ["Although sneezing is a physiologic response to irritating stimuli, increased frequency and paroxysmal sneezing episodes are readily recognized as abnormal.", [["sneezing", "DISEASE", 9, 17], ["paroxysmal sneezing", "DISEASE", 91, 110], ["sneezing", "PROBLEM", 9, 17], ["irritating stimuli", "PROBLEM", 47, 65], ["increased frequency", "PROBLEM", 67, 86], ["paroxysmal sneezing episodes", "PROBLEM", 91, 119], ["increased", "OBSERVATION_MODIFIER", 67, 76]]], ["Like sneezing, a nasal discharge, regardless of its consistency, is a clinical sign that clients accurately interpret and reliably describe to the clinician.", [["nasal", "ANATOMY", 17, 22], ["sneezing", "DISEASE", 5, 13], ["sneezing", "PROBLEM", 5, 13], ["a nasal discharge", "PROBLEM", 15, 32], ["sneezing", "OBSERVATION", 5, 13]]], ["Sneezing is the outward manifestation of nasal passage irritation by extraneous agents (foreign material) or endogenous agents (antigen-antibody interaction).", [["nasal", "ANATOMY", 41, 46], ["Sneezing", "DISEASE", 0, 8], ["nasal", "ORGANISM_SUBDIVISION", 41, 46], ["antigen-antibody", "GENE_OR_GENE_PRODUCT", 128, 144], ["Sneezing", "PROBLEM", 0, 8], ["nasal passage irritation", "PROBLEM", 41, 65], ["extraneous agents", "TREATMENT", 69, 86], ["foreign material", "TREATMENT", 88, 104], ["endogenous agents", "TREATMENT", 109, 126], ["nasal", "ANATOMY", 41, 46], ["passage irritation", "OBSERVATION", 47, 65]]], ["Afferent impulses travel via the fifth cranial nerve to the medulla, where the initial reflex is triggered.", [["cranial nerve", "ANATOMY", 39, 52], ["medulla", "ANATOMY", 60, 67], ["cranial nerve", "MULTI-TISSUE_STRUCTURE", 39, 52], ["medulla", "MULTI-TISSUE_STRUCTURE", 60, 67], ["fifth", "ANATOMY_MODIFIER", 33, 38], ["cranial nerve", "ANATOMY", 39, 52], ["medulla", "ANATOMY", 60, 67], ["reflex", "OBSERVATION", 87, 93]]], ["Chronic nasal discharge is a clinical sign that localizes a disorder to the upper respiratory passages, particularly the nasal cavity and frontal sinuses.AssociAted signsImportant associated signs suggesting systemic involvement include facial asymmetry (neoplasia or fungal infection), atrophy of the masseter and temporal muscles, difficulty prehending or masticating food, conjunctivitis, and ocular discharge.", [["nasal", "ANATOMY", 8, 13], ["respiratory", "ANATOMY", 82, 93], ["nasal cavity", "ANATOMY", 121, 133], ["frontal sinuses", "ANATOMY", 138, 153], ["facial", "ANATOMY", 237, 243], ["neoplasia", "ANATOMY", 255, 264], ["masseter", "ANATOMY", 302, 310], ["temporal muscles", "ANATOMY", 315, 331], ["ocular", "ANATOMY", 396, 402], ["facial asymmetry", "DISEASE", 237, 253], ["neoplasia", "DISEASE", 255, 264], ["fungal infection", "DISEASE", 268, 284], ["atrophy of the masseter and temporal muscles", "DISEASE", 287, 331], ["conjunctivitis", "DISEASE", 376, 390], ["ocular discharge", "DISEASE", 396, 412], ["nasal", "ORGAN", 8, 13], ["nasal cavity", "MULTI-TISSUE_STRUCTURE", 121, 133], ["frontal sinuses", "MULTI-TISSUE_STRUCTURE", 138, 153], ["neoplasia", "CANCER", 255, 264], ["masseter", "ORGAN", 302, 310], ["ocular", "ORGAN", 396, 402], ["Chronic nasal discharge", "PROBLEM", 0, 23], ["a disorder to the upper respiratory passages", "PROBLEM", 58, 102], ["AssociAted signsImportant associated signs", "PROBLEM", 154, 196], ["systemic involvement", "PROBLEM", 208, 228], ["facial asymmetry (neoplasia", "PROBLEM", 237, 264], ["fungal infection", "PROBLEM", 268, 284], ["atrophy of the masseter and temporal muscles", "PROBLEM", 287, 331], ["difficulty prehending or masticating food", "PROBLEM", 333, 374], ["conjunctivitis", "PROBLEM", 376, 390], ["ocular discharge", "PROBLEM", 396, 412], ["nasal", "ANATOMY", 8, 13], ["discharge", "OBSERVATION", 14, 23], ["upper", "ANATOMY_MODIFIER", 76, 81], ["respiratory passages", "OBSERVATION", 82, 102], ["nasal cavity", "ANATOMY", 121, 133], ["frontal sinuses", "ANATOMY", 138, 153], ["suggesting", "UNCERTAINTY", 197, 207], ["systemic", "OBSERVATION_MODIFIER", 208, 216], ["facial", "ANATOMY", 237, 243], ["asymmetry", "OBSERVATION", 244, 253], ["neoplasia", "OBSERVATION", 255, 264], ["fungal", "OBSERVATION_MODIFIER", 268, 274], ["infection", "OBSERVATION", 275, 284], ["atrophy", "OBSERVATION", 287, 294], ["masseter", "ANATOMY", 302, 310], ["temporal muscles", "ANATOMY", 315, 331], ["conjunctivitis", "OBSERVATION", 376, 390], ["ocular", "ANATOMY", 396, 402]]], ["Epistaxis, which is distinguished from blood-tinged nasal discharge, is an important associated sign that further supports intranasal disease or coagulopathy.", [["blood", "ANATOMY", 39, 44], ["nasal", "ANATOMY", 52, 57], ["Epistaxis", "DISEASE", 0, 9], ["coagulopathy", "DISEASE", 145, 157], ["blood", "ORGANISM_SUBSTANCE", 39, 44], ["nasal", "ORGANISM_SUBDIVISION", 52, 57], ["Epistaxis", "PROBLEM", 0, 9], ["blood-tinged nasal discharge", "PROBLEM", 39, 67], ["intranasal disease", "PROBLEM", 123, 141], ["coagulopathy", "PROBLEM", 145, 157], ["tinged", "OBSERVATION_MODIFIER", 45, 51], ["nasal", "ANATOMY", 52, 57], ["coagulopathy", "OBSERVATION", 145, 157]]], ["Cleft palate is a common cause of nasal discharge in neonates.", [["Cleft palate", "ANATOMY", 0, 12], ["nasal", "ANATOMY", 34, 39], ["Cleft palate", "DISEASE", 0, 12], ["palate", "ORGAN", 6, 12], ["nasal", "ORGANISM_SUBDIVISION", 34, 39], ["neonates", "ORGANISM", 53, 61], ["Cleft palate", "PROBLEM", 0, 12], ["nasal discharge in neonates", "PROBLEM", 34, 61], ["palate", "OBSERVATION", 6, 12], ["nasal", "ANATOMY", 34, 39], ["discharge", "OBSERVATION", 40, 49]]], ["Erosion and depigmentation of the planum nasale is often associated with nasal aspergillosis in dogs, whereas cats with nasal cryptococcosis may have a detectable granuloma at the rostral aspect of the nose.", [["planum nasale", "ANATOMY", 34, 47], ["nasal aspergillosis", "ANATOMY", 73, 92], ["nasal", "ANATOMY", 120, 125], ["granuloma", "ANATOMY", 163, 172], ["rostral aspect", "ANATOMY", 180, 194], ["nose", "ANATOMY", 202, 206], ["depigmentation of the planum nasale", "DISEASE", 12, 47], ["nasal aspergillosis", "DISEASE", 73, 92], ["nasal cryptococcosis", "DISEASE", 120, 140], ["granuloma", "DISEASE", 163, 172], ["nasal aspergillosis", "PATHOLOGICAL_FORMATION", 73, 92], ["dogs", "ORGANISM", 96, 100], ["cats", "ORGANISM", 110, 114], ["granuloma", "PATHOLOGICAL_FORMATION", 163, 172], ["rostral aspect", "MULTI-TISSUE_STRUCTURE", 180, 194], ["nose", "ORGAN", 202, 206], ["dogs", "SPECIES", 96, 100], ["cats", "SPECIES", 110, 114], ["Erosion", "PROBLEM", 0, 7], ["depigmentation", "PROBLEM", 12, 26], ["the planum nasale", "PROBLEM", 30, 47], ["nasal aspergillosis in dogs", "PROBLEM", 73, 100], ["nasal cryptococcosis", "PROBLEM", 120, 140], ["a detectable granuloma", "PROBLEM", 150, 172], ["depigmentation", "OBSERVATION", 12, 26], ["planum", "ANATOMY_MODIFIER", 34, 40], ["often associated with", "UNCERTAINTY", 51, 72], ["nasal", "ANATOMY", 73, 78], ["aspergillosis", "OBSERVATION", 79, 92], ["nasal", "ANATOMY", 120, 125], ["cryptococcosis", "OBSERVATION", 126, 140], ["detectable", "OBSERVATION_MODIFIER", 152, 162], ["granuloma", "OBSERVATION", 163, 172], ["rostral", "ANATOMY_MODIFIER", 180, 187], ["nose", "ANATOMY", 202, 206]]], ["Occasionally, cough is associated with purulent nasal discharges and sneezing.", [["nasal", "ANATOMY", 48, 53], ["cough", "DISEASE", 14, 19], ["sneezing", "DISEASE", 69, 77], ["nasal", "ORGANISM_SUBDIVISION", 48, 53], ["cough", "PROBLEM", 14, 19], ["purulent nasal discharges", "PROBLEM", 39, 64], ["sneezing", "PROBLEM", 69, 77], ["cough", "OBSERVATION", 14, 19], ["purulent", "OBSERVATION_MODIFIER", 39, 47], ["nasal", "ANATOMY", 48, 53], ["discharges", "OBSERVATION", 54, 64], ["sneezing", "OBSERVATION", 69, 77]]], ["(Figure 3-4) sPontAneous bleeding: hemorrhAge definition Spontaneous or prolonged bleeding is the visible, abnormal discharge of blood resulting from a failure of one or more hemostatic mechanisms.", [["blood", "ANATOMY", 129, 134], ["bleeding", "DISEASE", 25, 33], ["hemorrhAge", "DISEASE", 35, 45], ["bleeding", "DISEASE", 82, 90], ["blood", "ORGANISM_SUBSTANCE", 129, 134], ["sPontAneous bleeding", "PROBLEM", 13, 33], ["hemorrhAge definition", "PROBLEM", 35, 56], ["prolonged bleeding", "PROBLEM", 72, 90], ["abnormal discharge of blood", "PROBLEM", 107, 134], ["a failure of one or more hemostatic mechanisms", "PROBLEM", 150, 196], ["bleeding", "OBSERVATION", 25, 33], ["hemorrhAge", "OBSERVATION", 35, 45], ["prolonged", "OBSERVATION_MODIFIER", 72, 81], ["bleeding", "OBSERVATION", 82, 90], ["failure", "OBSERVATION", 152, 159]]], ["It may result from deficiencies in platelet numbers or function, in the extrinsic or intrinsic coagulation cascades, or in vascular integrity.differentiAl diAgnosis diAgnostic PlAnsThe hemostatic response is a complex defense system that fulfills three basic functions: ensures that blood is confined to the vascular system of the normal animal (vascular integrity), causes the arrest of bleeding at sites of vascular injury, and maintains the patency of the vascular network.differentiAl diAgnosis diAgnostic PlAnsThese functions are accomplished through complex interactions among blood platelets, the blood vessel wall, and a variety of plasma enzyme systems.", [["platelet", "ANATOMY", 35, 43], ["vascular", "ANATOMY", 123, 131], ["blood", "ANATOMY", 283, 288], ["vascular system", "ANATOMY", 308, 323], ["vascular", "ANATOMY", 346, 354], ["sites", "ANATOMY", 400, 405], ["vascular", "ANATOMY", 409, 417], ["vascular network", "ANATOMY", 459, 475], ["blood platelets", "ANATOMY", 583, 598], ["blood vessel wall", "ANATOMY", 604, 621], ["plasma", "ANATOMY", 640, 646], ["bleeding", "DISEASE", 388, 396], ["vascular injury", "DISEASE", 409, 424], ["platelet", "CELL", 35, 43], ["vascular", "MULTI-TISSUE_STRUCTURE", 123, 131], ["blood", "ORGANISM_SUBSTANCE", 283, 288], ["vascular system", "MULTI-TISSUE_STRUCTURE", 308, 323], ["vascular", "MULTI-TISSUE_STRUCTURE", 346, 354], ["vascular", "MULTI-TISSUE_STRUCTURE", 409, 417], ["vascular network", "MULTI-TISSUE_STRUCTURE", 459, 475], ["blood platelets", "CELL", 583, 598], ["blood vessel wall", "MULTI-TISSUE_STRUCTURE", 604, 621], ["plasma", "ORGANISM_SUBSTANCE", 640, 646], ["blood platelets", "CELL_TYPE", 583, 598], ["deficiencies in platelet numbers", "PROBLEM", 19, 51], ["intrinsic coagulation cascades", "PROBLEM", 85, 115], ["a complex defense system", "PROBLEM", 208, 232], ["the arrest", "PROBLEM", 374, 384], ["bleeding", "PROBLEM", 388, 396], ["vascular injury", "PROBLEM", 409, 424], ["blood platelets", "TEST", 583, 598], ["the blood vessel wall", "TEST", 600, 621], ["plasma enzyme systems", "TEST", 640, 661], ["platelet numbers", "OBSERVATION", 35, 51], ["coagulation cascades", "OBSERVATION", 95, 115], ["vascular", "ANATOMY", 123, 131], ["vascular system", "ANATOMY", 308, 323], ["normal", "OBSERVATION", 331, 337], ["vascular", "ANATOMY", 346, 354], ["bleeding", "OBSERVATION", 388, 396], ["vascular", "ANATOMY", 409, 417], ["injury", "OBSERVATION", 418, 424], ["patency", "OBSERVATION_MODIFIER", 444, 451], ["vascular", "ANATOMY", 459, 467], ["blood vessel", "ANATOMY", 604, 616], ["wall", "ANATOMY_MODIFIER", 617, 621]]], ["Disorders affecting these interactions can result in spontaneous or prolonged bleeding.differentiAl diAgnosis diAgnostic PlAnsThe primary phase of hemostasis occurs with platelet aggregation and the formation of the relatively unstable platelet plug.", [["platelet", "ANATOMY", 170, 178], ["platelet", "ANATOMY", 236, 244], ["bleeding", "DISEASE", 78, 86], ["platelet aggregation", "DISEASE", 170, 190], ["platelet", "CELL", 170, 178], ["platelet", "CELL", 236, 244], ["Disorders", "PROBLEM", 0, 9], ["spontaneous or prolonged bleeding", "PROBLEM", 53, 86], ["hemostasis", "TREATMENT", 147, 157], ["platelet aggregation", "PROBLEM", 170, 190], ["the relatively unstable platelet plug", "PROBLEM", 212, 249], ["prolonged", "OBSERVATION_MODIFIER", 68, 77], ["bleeding", "OBSERVATION", 78, 86], ["hemostasis", "OBSERVATION", 147, 157], ["platelet aggregation", "OBSERVATION", 170, 190], ["relatively", "OBSERVATION_MODIFIER", 216, 226], ["unstable", "OBSERVATION_MODIFIER", 227, 235], ["platelet plug", "OBSERVATION", 236, 249]]], ["The secondary phase of hemostasis, essential to complete hemostasis, reinforces the platelet plug with fibrin.", [["platelet", "ANATOMY", 84, 92], ["platelet", "CELL", 84, 92], ["fibrin", "GENE_OR_GENE_PRODUCT", 103, 109], ["fibrin", "PROTEIN", 103, 109], ["hemostasis", "TREATMENT", 23, 33], ["the platelet plug", "TREATMENT", 80, 97], ["fibrin", "TREATMENT", 103, 109], ["secondary", "OBSERVATION_MODIFIER", 4, 13], ["phase", "OBSERVATION_MODIFIER", 14, 19], ["hemostasis", "OBSERVATION", 23, 33], ["platelet plug", "OBSERVATION", 84, 97], ["fibrin", "OBSERVATION", 103, 109]]], ["Secondary hemostasis depends on adequate plasma concentration of procoagulant proteins and on their proper interaction.", [["plasma", "ANATOMY", 41, 47], ["plasma", "ORGANISM_SUBSTANCE", 41, 47], ["procoagulant proteins", "GENE_OR_GENE_PRODUCT", 65, 86], ["procoagulant proteins", "PROTEIN", 65, 86], ["Secondary hemostasis", "PROBLEM", 0, 20], ["procoagulant proteins", "TREATMENT", 65, 86], ["hemostasis", "OBSERVATION", 10, 20], ["procoagulant proteins", "OBSERVATION", 65, 86]]], ["Coagulation can be initiated through an intrinsic pathway, which involves intranasal causEsSerous Nasal DischargeAcute viral upper respiratory infection (feline) Feline chlamydiosis Intranasal parasites Oronasal fistula (canine tooth) Rhinosporidiosis (canine, rare)PurulEnt nasal dischargE Viral upper respiratory infection with secondary bacterial infection (dog and cat)Bacterial rhinitis (especially Bordetella bronchiseptica) Mycotic nasal disease Foreign body rhinitis Traumatic rhinitis or sinusitis Cleft palate Neoplasia (several types possible) Nasopharyngeal polyps (feline, rare) Benign nasal polyps (canine, rare) Oronasal fistula (occasionally associated with small amounts of blood)Mucoid to Mucopurulent Nasal DischargeMycotic nasal disease (e.g., aspergillosis, cryptococcosis, blastomycosis)3components normally found within the vasculature and which is activated by contact with a foreign surface.", [["tooth", "ANATOMY", 228, 233], ["nasal", "ANATOMY", 439, 444], ["Nasopharyngeal polyps", "ANATOMY", 555, 576], ["Benign nasal polyps", "ANATOMY", 592, 611], ["Oronasal fistula", "ANATOMY", 627, 643], ["blood", "ANATOMY", 691, 696], ["nasal", "ANATOMY", 743, 748], ["vasculature", "ANATOMY", 847, 858], ["surface", "ANATOMY", 908, 915], ["upper respiratory infection", "DISEASE", 125, 152], ["Feline chlamydiosis", "DISEASE", 162, 181], ["Oronasal fistula", "DISEASE", 203, 219], ["Rhinosporidiosis", "DISEASE", 235, 251], ["respiratory infection", "DISEASE", 303, 324], ["bacterial infection", "DISEASE", 340, 359], ["Bacterial rhinitis", "DISEASE", 373, 391], ["Bordetella bronchiseptica", "DISEASE", 404, 429], ["Mycotic nasal disease", "DISEASE", 431, 452], ["rhinitis", "DISEASE", 466, 474], ["Traumatic rhinitis", "DISEASE", 475, 493], ["sinusitis", "DISEASE", 497, 506], ["Cleft palate Neoplasia", "DISEASE", 507, 529], ["Nasopharyngeal polyps", "DISEASE", 555, 576], ["nasal polyps", "DISEASE", 599, 611], ["Oronasal fistula", "DISEASE", 627, 643], ["DischargeMycotic nasal disease", "DISEASE", 726, 756], ["aspergillosis", "DISEASE", 764, 777], ["cryptococcosis", "DISEASE", 779, 793], ["blastomycosis", "DISEASE", 795, 808], ["feline", "ORGANISM", 154, 160], ["Feline", "ORGANISM", 162, 168], ["canine", "ORGANISM", 221, 227], ["tooth", "ORGAN", 228, 233], ["canine", "ORGANISM", 253, 259], ["dog", "ORGANISM_SUBDIVISION", 361, 364], ["cat", "ORGANISM_SUBDIVISION", 369, 372], ["Bordetella bronchiseptica", "ORGANISM", 404, 429], ["Nasopharyngeal polyps", "CANCER", 555, 576], ["feline", "ORGANISM", 578, 584], ["nasal polyps", "PATHOLOGICAL_FORMATION", 599, 611], ["canine", "ORGANISM", 613, 619], ["blood", "ORGANISM_SUBSTANCE", 691, 696], ["vasculature", "MULTI-TISSUE_STRUCTURE", 847, 858], ["surface", "CELLULAR_COMPONENT", 908, 915], ["feline", "SPECIES", 154, 160], ["Feline", "SPECIES", 162, 168], ["canine", "SPECIES", 221, 227], ["canine", "SPECIES", 253, 259], ["dog", "SPECIES", 361, 364], ["cat", "SPECIES", 369, 372], ["Bordetella bronchiseptica", "SPECIES", 404, 429], ["canine", "SPECIES", 253, 259], ["dog", "SPECIES", 361, 364], ["Bordetella bronchiseptica", "SPECIES", 404, 429], ["Coagulation", "TEST", 0, 11], ["an intrinsic pathway", "TEST", 37, 57], ["intranasal causEsSerous Nasal DischargeAcute viral upper respiratory infection (feline)", "PROBLEM", 74, 161], ["Feline chlamydiosis", "PROBLEM", 162, 181], ["Intranasal parasites Oronasal fistula", "PROBLEM", 182, 219], ["Rhinosporidiosis (canine, rare)", "PROBLEM", 235, 266], ["PurulEnt nasal dischargE", "PROBLEM", 266, 290], ["Viral upper respiratory infection", "PROBLEM", 291, 324], ["secondary bacterial infection", "PROBLEM", 330, 359], ["Bacterial rhinitis (especially Bordetella bronchiseptica)", "PROBLEM", 373, 430], ["Mycotic nasal disease", "PROBLEM", 431, 452], ["Foreign body rhinitis", "PROBLEM", 453, 474], ["Traumatic rhinitis", "PROBLEM", 475, 493], ["sinusitis Cleft palate Neoplasia", "PROBLEM", 497, 529], ["Nasopharyngeal polyps (feline", "PROBLEM", 555, 584], ["Benign nasal polyps (canine, rare)", "PROBLEM", 592, 626], ["Oronasal fistula", "PROBLEM", 627, 643], ["small amounts of blood)", "PROBLEM", 674, 697], ["Mucoid to Mucopurulent Nasal DischargeMycotic nasal disease", "PROBLEM", 697, 756], ["aspergillosis", "PROBLEM", 764, 777], ["cryptococcosis", "PROBLEM", 779, 793], ["blastomycosis)3components", "PROBLEM", 795, 820], ["Nasal", "ANATOMY", 98, 103], ["upper", "ANATOMY_MODIFIER", 125, 130], ["respiratory", "ANATOMY", 131, 142], ["infection", "OBSERVATION", 143, 152], ["fistula", "OBSERVATION", 212, 219], ["PurulEnt", "OBSERVATION_MODIFIER", 266, 274], ["nasal", "ANATOMY", 275, 280], ["upper", "ANATOMY_MODIFIER", 297, 302], ["respiratory", "ANATOMY", 303, 314], ["infection", "OBSERVATION", 315, 324], ["bacterial", "OBSERVATION_MODIFIER", 340, 349], ["infection", "OBSERVATION", 350, 359], ["Bacterial rhinitis", "OBSERVATION", 373, 391], ["nasal", "ANATOMY", 439, 444], ["disease", "OBSERVATION", 445, 452], ["Foreign body rhinitis", "OBSERVATION", 453, 474], ["Traumatic", "OBSERVATION_MODIFIER", 475, 484], ["rhinitis", "OBSERVATION", 485, 493], ["sinusitis", "OBSERVATION", 497, 506], ["palate", "ANATOMY", 513, 519], ["Neoplasia", "OBSERVATION", 520, 529], ["Nasopharyngeal", "ANATOMY", 555, 569], ["polyps", "OBSERVATION", 570, 576], ["Benign", "OBSERVATION_MODIFIER", 592, 598], ["nasal", "ANATOMY", 599, 604], ["polyps", "OBSERVATION", 605, 611], ["Oronasal", "ANATOMY", 627, 635], ["fistula", "OBSERVATION", 636, 643], ["Mucopurulent", "OBSERVATION_MODIFIER", 707, 719], ["Nasal", "ANATOMY", 720, 725], ["DischargeMycotic", "ANATOMY_MODIFIER", 726, 742], ["nasal", "ANATOMY", 743, 748], ["disease", "OBSERVATION", 749, 756], ["aspergillosis", "OBSERVATION", 764, 777], ["cryptococcosis", "OBSERVATION", 779, 793], ["blastomycosis", "OBSERVATION", 795, 808], ["vasculature", "ANATOMY", 847, 858], ["foreign surface", "OBSERVATION", 900, 915]]], ["Secondary hemostasis is regulated by inhibitory products that limit the extent of enzymatic reaction and prevent their dissemination: antithrombin III, a potent inhibitor of kallikrein; factors IXa, XIa, XIIa, and Xa; and thrombin.", [["antithrombin III", "GENE_OR_GENE_PRODUCT", 134, 150], ["kallikrein", "GENE_OR_GENE_PRODUCT", 174, 184], ["IXa", "GENE_OR_GENE_PRODUCT", 194, 197], ["XIa", "GENE_OR_GENE_PRODUCT", 199, 202], ["XIIa", "GENE_OR_GENE_PRODUCT", 204, 208], ["Xa", "GENE_OR_GENE_PRODUCT", 214, 216], ["thrombin", "GENE_OR_GENE_PRODUCT", 222, 230], ["antithrombin III", "PROTEIN", 134, 150], ["kallikrein", "PROTEIN", 174, 184], ["IXa", "PROTEIN", 194, 197], ["XIa", "PROTEIN", 199, 202], ["XIIa", "PROTEIN", 204, 208], ["Xa", "PROTEIN", 214, 216], ["thrombin", "PROTEIN", 222, 230], ["Secondary hemostasis", "PROBLEM", 0, 20], ["inhibitory products", "TREATMENT", 37, 56], ["enzymatic reaction", "PROBLEM", 82, 100], ["antithrombin III", "TREATMENT", 134, 150], ["a potent inhibitor of kallikrein", "TREATMENT", 152, 184], ["factors IXa", "TREATMENT", 186, 197], ["XIIa", "TREATMENT", 204, 208], ["Xa", "TREATMENT", 214, 216], ["thrombin", "TREATMENT", 222, 230], ["hemostasis", "OBSERVATION", 10, 20], ["enzymatic reaction", "OBSERVATION", 82, 100]]], ["The fibrinolytic system, another plasma protein-enzyme system, removes the hemostatic plug once its function has been served.AssociAted signsBleeding disorders are most apparent when bleeding develops spontaneously from one or more body orifices and is prolonged.", [["plasma", "ANATOMY", 33, 39], ["body orifices", "ANATOMY", 232, 245], ["Bleeding disorders", "DISEASE", 141, 159], ["bleeding", "DISEASE", 183, 191], ["plasma", "ORGANISM_SUBSTANCE", 33, 39], ["body orifices", "MULTI-TISSUE_STRUCTURE", 232, 245], ["plasma protein", "PROTEIN", 33, 47], ["The fibrinolytic system", "TEST", 0, 23], ["another plasma protein", "TEST", 25, 47], ["the hemostatic plug", "TREATMENT", 71, 90], ["AssociAted signsBleeding disorders", "PROBLEM", 125, 159], ["bleeding", "PROBLEM", 183, 191], ["hemostatic plug", "OBSERVATION", 75, 90], ["signs", "OBSERVATION_MODIFIER", 136, 141], ["Bleeding", "OBSERVATION", 141, 149], ["most apparent", "UNCERTAINTY", 164, 177], ["more body", "OBSERVATION_MODIFIER", 227, 236], ["orifices", "ANATOMY_MODIFIER", 237, 245], ["prolonged", "OBSERVATION_MODIFIER", 253, 262]]], ["Bleeding from the nose (epistaxis; see Figure 3 -4) is perhaps the most commonly reported outward manifestation of a bleeding disorder in dogs.", [["nose", "ANATOMY", 18, 22], ["Bleeding", "DISEASE", 0, 8], ["epistaxis", "DISEASE", 24, 33], ["bleeding disorder", "DISEASE", 117, 134], ["nose", "ORGANISM_SUBDIVISION", 18, 22], ["dogs", "ORGANISM", 138, 142], ["dogs", "SPECIES", 138, 142], ["Bleeding from the nose", "PROBLEM", 0, 22], ["epistaxis", "PROBLEM", 24, 33], ["a bleeding disorder in dogs", "PROBLEM", 115, 142], ["nose", "ANATOMY", 18, 22], ["epistaxis", "OBSERVATION", 24, 33], ["bleeding", "OBSERVATION", 117, 125]]], ["Bleeding into the skin or mucous membranes (e.g., petechiation) may not be immediately apparent to even the most observant owner.", [["skin", "ANATOMY", 18, 22], ["mucous membranes", "ANATOMY", 26, 42], ["Bleeding", "DISEASE", 0, 8], ["skin", "ORGAN", 18, 22], ["mucous membranes", "MULTI-TISSUE_STRUCTURE", 26, 42], ["Bleeding into the skin or mucous membranes", "PROBLEM", 0, 42], ["skin", "ANATOMY", 18, 22], ["mucous membranes", "ANATOMY", 26, 42]]], ["Excessive or prolonged bleeding into soft tissues (hematoma) or joints (hemarthrosis) may be seen as physical enlargement of the affected tissues, with pain and lameness.AssociAted signsThere may be a history of recurrent minor bleeding episodes in some animals.", [["soft tissues", "ANATOMY", 37, 49], ["hematoma", "ANATOMY", 51, 59], ["joints", "ANATOMY", 64, 70], ["tissues", "ANATOMY", 138, 145], ["bleeding", "DISEASE", 23, 31], ["hematoma", "DISEASE", 51, 59], ["hemarthrosis", "DISEASE", 72, 84], ["pain", "DISEASE", 152, 156], ["lameness", "DISEASE", 161, 169], ["bleeding", "DISEASE", 228, 236], ["soft tissues", "TISSUE", 37, 49], ["joints", "MULTI-TISSUE_STRUCTURE", 64, 70], ["tissues", "TISSUE", 138, 145], ["Excessive or prolonged bleeding into soft tissues (hematoma", "PROBLEM", 0, 59], ["joints (hemarthrosis", "PROBLEM", 64, 84], ["physical enlargement of the affected tissues", "PROBLEM", 101, 145], ["pain", "PROBLEM", 152, 156], ["lameness", "PROBLEM", 161, 169], ["AssociAted signs", "PROBLEM", 170, 186], ["recurrent minor bleeding episodes", "PROBLEM", 212, 245], ["prolonged", "OBSERVATION_MODIFIER", 13, 22], ["bleeding", "OBSERVATION", 23, 31], ["soft tissues", "ANATOMY", 37, 49], ["hematoma", "OBSERVATION", 51, 59], ["joints", "ANATOMY", 64, 70], ["hemarthrosis", "OBSERVATION", 72, 84], ["enlargement", "OBSERVATION", 110, 121], ["affected tissues", "ANATOMY", 129, 145], ["lameness", "OBSERVATION", 161, 169], ["recurrent", "OBSERVATION_MODIFIER", 212, 221], ["minor", "OBSERVATION_MODIFIER", 222, 227], ["bleeding", "OBSERVATION", 228, 236]]], ["The severity of clinical signs depends on such factors as type of defect, degree of clotting factor activity, and individual variation.", [["clotting factor", "GENE_OR_GENE_PRODUCT", 84, 99], ["clotting factor", "PROTEIN", 84, 99], ["clinical signs", "PROBLEM", 16, 30], ["type of defect", "PROBLEM", 58, 72], ["clotting factor activity", "PROBLEM", 84, 108], ["severity", "OBSERVATION_MODIFIER", 4, 12], ["defect", "OBSERVATION", 66, 72], ["clotting factor activity", "OBSERVATION", 84, 108], ["variation", "OBSERVATION_MODIFIER", 125, 134]]], ["Moderately to severely affected animals are typically young at the time of presentation.", [["Moderately to severely affected animals", "PROBLEM", 0, 39], ["severely", "OBSERVATION_MODIFIER", 14, 22], ["affected", "OBSERVATION", 23, 31]]], ["Prolonged bleeding during or after elective surgical procedures may be the first sign of a bleeding disorder.strAining to defecAte: dyscheziA definitionDyschezia is painful or difficult evacuation of feces from the rectum.", [["feces", "ANATOMY", 200, 205], ["rectum", "ANATOMY", 215, 221], ["bleeding", "DISEASE", 10, 18], ["bleeding disorder", "DISEASE", 91, 108], ["feces", "ORGANISM_SUBSTANCE", 200, 205], ["rectum", "ORGAN", 215, 221], ["Prolonged bleeding", "PROBLEM", 0, 18], ["elective surgical procedures", "TREATMENT", 35, 63], ["a bleeding disorder", "PROBLEM", 89, 108], ["dyscheziA definitionDyschezia", "PROBLEM", 132, 161], ["painful", "PROBLEM", 165, 172], ["difficult evacuation of feces from the rectum", "PROBLEM", 176, 221], ["bleeding", "OBSERVATION", 10, 18], ["bleeding", "OBSERVATION", 91, 99], ["painful", "OBSERVATION_MODIFIER", 165, 172], ["feces", "OBSERVATION", 200, 205], ["rectum", "ANATOMY", 215, 221]]], ["In the clinical setting, dyschezia may be a difficult problem to ascertain in cats and female dogs unless the owner is particularly astute and is able to distinguish effort to urinate (see Straining to Urinate: Dysuria) from effort to defecate.", [["dyschezia", "DISEASE", 25, 34], ["cats", "ORGANISM", 78, 82], ["dogs", "ORGANISM", 94, 98], ["cats", "SPECIES", 78, 82], ["dogs", "SPECIES", 94, 98], ["dyschezia", "PROBLEM", 25, 34], ["a difficult problem", "PROBLEM", 42, 61], ["Dysuria", "PROBLEM", 211, 218], ["Dysuria", "OBSERVATION", 211, 218]]], ["Therefore a concerted effort on the part of the clinician is usually necessary to differentiate disorders affecting the urinary outflow tract and micturition from disorders affecting defecation.", [["urinary outflow tract", "ANATOMY", 120, 141], ["disorders affecting the urinary outflow tract", "DISEASE", 96, 141], ["urinary outflow", "ORGANISM_SUBDIVISION", 120, 135], ["tract", "ORGANISM_SUBDIVISION", 136, 141], ["differentiate disorders", "PROBLEM", 82, 105], ["the urinary outflow tract", "PROBLEM", 116, 141], ["micturition from disorders affecting defecation", "PROBLEM", 146, 193], ["urinary outflow tract", "ANATOMY", 120, 141]]], ["Rectal or perianal pain is among the most common causes for dyschezia.", [["Rectal", "ANATOMY", 0, 6], ["perianal", "ANATOMY", 10, 18], ["Rectal or perianal pain", "DISEASE", 0, 23], ["dyschezia", "DISEASE", 60, 69], ["Rectal", "MULTI-TISSUE_STRUCTURE", 0, 6], ["Rectal or perianal pain", "PROBLEM", 0, 23], ["dyschezia", "PROBLEM", 60, 69], ["perianal", "ANATOMY", 10, 18], ["pain", "OBSERVATION", 19, 23]]], ["The origin of the pain may be mucosal, mucocutaneous (anal), or extraluminal (rectal).", [["mucosal", "ANATOMY", 30, 37], ["mucocutaneous", "ANATOMY", 39, 52], ["anal", "ANATOMY", 54, 58], ["extraluminal", "ANATOMY", 64, 76], ["rectal", "ANATOMY", 78, 84], ["pain", "DISEASE", 18, 22], ["mucosal", "PATHOLOGICAL_FORMATION", 30, 37], ["anal", "ORGANISM_SUBDIVISION", 54, 58], ["rectal", "ORGAN", 78, 84], ["the pain", "PROBLEM", 14, 22], ["mucosal, mucocutaneous (anal), or extraluminal (rectal)", "PROBLEM", 30, 85], ["origin", "ANATOMY_MODIFIER", 4, 10], ["pain", "OBSERVATION", 18, 22], ["may be", "UNCERTAINTY", 23, 29], ["mucosal", "ANATOMY", 30, 37], ["mucocutaneous", "OBSERVATION", 39, 52], ["anal", "ANATOMY", 54, 58], ["extraluminal", "ANATOMY_MODIFIER", 64, 76], ["rectal", "ANATOMY", 78, 84]]], ["Rectal strictures are uncommon but may contribute to constipation and associated dyschezia.", [["Rectal", "ANATOMY", 0, 6], ["Rectal strictures", "DISEASE", 0, 17], ["constipation", "DISEASE", 53, 65], ["dyschezia", "DISEASE", 81, 90], ["Rectal strictures", "PATHOLOGICAL_FORMATION", 0, 17], ["Rectal strictures", "PROBLEM", 0, 17], ["constipation", "PROBLEM", 53, 65], ["associated dyschezia", "PROBLEM", 70, 90], ["strictures", "OBSERVATION", 7, 17], ["constipation", "OBSERVATION", 53, 65], ["dyschezia", "OBSERVATION", 81, 90]]], ["Strictures typically develop subsequent to neoplasia or deep, nonpenetrating injury to the rectum.", [["neoplasia", "ANATOMY", 43, 52], ["rectum", "ANATOMY", 91, 97], ["Strictures", "DISEASE", 0, 10], ["neoplasia", "DISEASE", 43, 52], ["injury to the rectum", "DISEASE", 77, 97], ["neoplasia", "CANCER", 43, 52], ["rectum", "ORGAN", 91, 97], ["Strictures", "PROBLEM", 0, 10], ["neoplasia", "PROBLEM", 43, 52], ["deep, nonpenetrating injury to the rectum", "PROBLEM", 56, 97], ["neoplasia", "OBSERVATION", 43, 52], ["deep", "ANATOMY_MODIFIER", 56, 60], ["nonpenetrating", "OBSERVATION_MODIFIER", 62, 76], ["injury", "OBSERVATION", 77, 83], ["rectum", "ANATOMY", 91, 97]]], ["Although uncommon, dyschezia may also occur subsequent to lesions in the lumbar spinal cord or sacrum.AssociAted signsThe most common response to dyschezia is constipation, although many owners do not recognize this as a primary problem.", [["lesions", "ANATOMY", 58, 65], ["lumbar spinal cord", "ANATOMY", 73, 91], ["sacrum", "ANATOMY", 95, 101], ["dyschezia", "DISEASE", 19, 28], ["dyschezia", "DISEASE", 146, 155], ["constipation", "DISEASE", 159, 171], ["dyschezia", "CANCER", 19, 28], ["lesions", "PATHOLOGICAL_FORMATION", 58, 65], ["lumbar", "MULTI-TISSUE_STRUCTURE", 73, 79], ["spinal cord", "ORGAN", 80, 91], ["sacrum", "ORGAN", 95, 101], ["dyschezia", "PROBLEM", 19, 28], ["lesions in the lumbar spinal cord or sacrum", "PROBLEM", 58, 101], ["AssociAted signs", "PROBLEM", 102, 118], ["dyschezia", "PROBLEM", 146, 155], ["constipation", "PROBLEM", 159, 171], ["lesions", "OBSERVATION", 58, 65], ["lumbar", "ANATOMY_MODIFIER", 73, 79], ["spinal cord", "ANATOMY", 80, 91], ["sacrum", "ANATOMY", 95, 101], ["most common", "OBSERVATION_MODIFIER", 122, 133], ["constipation", "OBSERVATION", 159, 171]]], ["Not uncommonly, the pain associated with rectal lesions is intense during attempts to defecate.", [["rectal lesions", "ANATOMY", 41, 55], ["pain", "DISEASE", 20, 24], ["rectal lesions", "PATHOLOGICAL_FORMATION", 41, 55], ["the pain", "PROBLEM", 16, 24], ["rectal lesions", "PROBLEM", 41, 55], ["rectal", "ANATOMY", 41, 47], ["lesions", "OBSERVATION", 48, 55], ["intense", "OBSERVATION_MODIFIER", 59, 66]]], ["The animal may cry or turn abruptly and lick the anus in response to the pain.", [["anus", "ANATOMY", 49, 53], ["pain", "DISEASE", 73, 77], ["anus", "ORGAN", 49, 53], ["the pain", "PROBLEM", 69, 77], ["anus", "ANATOMY", 49, 53]]], ["Dogs may circle while assuming the position to defecate.", [["Dogs", "ORGANISM", 0, 4]]], ["Cats are more likely to make many attempts at defecation or may manifest inappropriate defecation in locations outside of the litter box.", [["defecation", "PROBLEM", 46, 56], ["inappropriate defecation", "PROBLEM", 73, 97], ["more likely", "UNCERTAINTY", 9, 20], ["defecation", "OBSERVATION", 87, 97], ["litter box", "OBSERVATION", 126, 136]]], ["Unless attempting defecation, the animal is likely not to manifest pain at all.AssociAted signsPhysical examination should include digital examination of the rectum and inspection of the perineum and each anal sac for evidence of lesions.", [["rectum", "ANATOMY", 158, 164], ["perineum", "ANATOMY", 187, 195], ["anal sac", "ANATOMY", 205, 213], ["lesions", "ANATOMY", 230, 237], ["pain", "DISEASE", 67, 71], ["rectum", "ORGAN", 158, 164], ["perineum", "ORGAN", 187, 195], ["anal sac", "MULTI-TISSUE_STRUCTURE", 205, 213], ["lesions", "PATHOLOGICAL_FORMATION", 230, 237], ["defecation", "PROBLEM", 18, 28], ["pain", "PROBLEM", 67, 71], ["AssociAted signsPhysical examination", "TEST", 79, 115], ["digital examination of the rectum and inspection of the perineum", "TEST", 131, 195], ["lesions", "PROBLEM", 230, 237], ["likely not", "UNCERTAINTY", 44, 54], ["rectum", "ANATOMY", 158, 164], ["perineum", "ANATOMY", 187, 195], ["anal sac", "ANATOMY", 205, 213], ["lesions", "OBSERVATION", 230, 237]]], ["It is important to consider shaving the perineum to assess the integrity of the skin for evidence of lesions, particularly neoplasia. b.", [["perineum", "ANATOMY", 40, 48], ["skin", "ANATOMY", 80, 84], ["lesions", "ANATOMY", 101, 108], ["neoplasia", "ANATOMY", 123, 132], ["neoplasia", "DISEASE", 123, 132], ["perineum", "ORGAN", 40, 48], ["skin", "ORGAN", 80, 84], ["lesions", "PATHOLOGICAL_FORMATION", 101, 108], ["neoplasia", "CANCER", 123, 132], ["lesions", "PROBLEM", 101, 108], ["neoplasia", "PROBLEM", 123, 132], ["perineum", "ANATOMY", 40, 48], ["skin", "ANATOMY", 80, 84], ["lesions", "OBSERVATION", 101, 108], ["neoplasia", "OBSERVATION", 123, 132]]], ["Rectal examination, carefully expressing both anal glands and assessing the character of the discharge (sedation may be required) c.", [["Rectal", "ANATOMY", 0, 6], ["anal glands", "ANATOMY", 46, 57], ["Rectal", "ORGAN", 0, 6], ["anal glands", "ORGAN", 46, 57], ["Rectal examination", "TEST", 0, 18], ["sedation", "TREATMENT", 104, 112], ["anal glands", "ANATOMY", 46, 57]]], ["Evaluation of the perianal skin (carefully shaving the perineum is recommended) 2.", [["perianal skin", "ANATOMY", 18, 31], ["perineum", "ANATOMY", 55, 63], ["skin", "ORGAN", 27, 31], ["perineum", "ORGANISM_SUBDIVISION", 55, 63], ["Evaluation", "TEST", 0, 10], ["the perianal skin", "PROBLEM", 14, 31], ["perianal skin", "ANATOMY", 18, 31], ["perineum", "ANATOMY", 55, 63]]], ["Abdominal radiographs or abdominal ultrasound to assess prostate size (in male dogs), presence of intraabdominal masses, or presence of fecalith formation.", [["Abdominal", "ANATOMY", 0, 9], ["abdominal", "ANATOMY", 25, 34], ["prostate", "ANATOMY", 56, 64], ["intraabdominal masses", "ANATOMY", 98, 119], ["intraabdominal masses", "DISEASE", 98, 119], ["abdominal", "ORGANISM_SUBDIVISION", 25, 34], ["prostate", "CANCER", 56, 64], ["dogs", "ORGANISM", 79, 83], ["intraabdominal masses", "PATHOLOGICAL_FORMATION", 98, 119], ["fecalith", "PATHOLOGICAL_FORMATION", 136, 144], ["dogs", "SPECIES", 79, 83], ["Abdominal radiographs", "TEST", 0, 21], ["abdominal ultrasound", "TEST", 25, 45], ["intraabdominal masses", "PROBLEM", 98, 119], ["fecalith formation", "PROBLEM", 136, 154], ["abdominal", "ANATOMY", 25, 34], ["prostate", "ANATOMY", 56, 64], ["size", "OBSERVATION_MODIFIER", 65, 69], ["intraabdominal", "ANATOMY", 98, 112], ["masses", "OBSERVATION", 113, 119], ["fecalith formation", "OBSERVATION", 136, 154]]], ["Colonoscopy or proctoscopy, with rigid or flexible endoscope and biopsy of any obvious lesions.", [["lesions", "ANATOMY", 87, 94], ["lesions", "CANCER", 87, 94], ["Colonoscopy", "TEST", 0, 11], ["proctoscopy", "TEST", 15, 26], ["rigid or flexible endoscope", "TEST", 33, 60], ["biopsy", "TEST", 65, 71], ["any obvious lesions", "PROBLEM", 75, 94], ["obvious", "OBSERVATION_MODIFIER", 79, 86], ["lesions", "OBSERVATION", 87, 94]]], ["Recovered tissues should be examined cytologically and by histopathology.", [["tissues", "ANATOMY", 10, 17], ["tissues", "TISSUE", 10, 17]]], ["Anesthesia is rarely required for this procedure unless the integrity of the rectal mucosa is substantially compromised or pain is significant.", [["rectal mucosa", "ANATOMY", 77, 90], ["pain", "DISEASE", 123, 127], ["rectal mucosa", "MULTI-TISSUE_STRUCTURE", 77, 90], ["Anesthesia", "TREATMENT", 0, 10], ["this procedure", "TREATMENT", 34, 48], ["substantially compromised", "PROBLEM", 94, 119], ["pain", "PROBLEM", 123, 127], ["rectal mucosa", "ANATOMY", 77, 90], ["substantially", "OBSERVATION_MODIFIER", 94, 107], ["compromised", "OBSERVATION", 108, 119]]], ["Rarely, exploratory laparotomy, to further elucidate the nature of abnormal intraabdominal findings.strAining to urinAte: dysuriA definitionDysuria is painful or difficult urination.", [["intraabdominal", "ANATOMY", 76, 90], ["urinAte", "CHEMICAL", 113, 120], ["definitionDysuria", "DISEASE", 130, 147], ["intraabdominal", "IMMATERIAL_ANATOMICAL_ENTITY", 76, 90], ["urinAte", "SIMPLE_CHEMICAL", 113, 120], ["exploratory laparotomy", "TEST", 8, 30], ["abnormal intraabdominal findings", "PROBLEM", 67, 99], ["dysuriA definitionDysuria", "PROBLEM", 122, 147], ["painful", "PROBLEM", 151, 158], ["difficult urination", "PROBLEM", 162, 181], ["laparotomy", "OBSERVATION", 20, 30], ["abnormal", "OBSERVATION_MODIFIER", 67, 75], ["intraabdominal", "ANATOMY", 76, 90], ["dysuriA", "OBSERVATION", 122, 129]]], ["A relatively common presenting sign in both dogs and cats, dysuria should be regarded as an urgent situation worthy of immediate attention.strAining to urinAte: dysuriA definitionOwner observations are not entirely reliable in describing dysuria.", [["dysuria", "DISEASE", 59, 66], ["dysuria", "DISEASE", 238, 245], ["dogs", "ORGANISM", 44, 48], ["cats", "ORGANISM", 53, 57], ["urinAte", "SIMPLE_CHEMICAL", 152, 159], ["dysuria", "PATHOLOGICAL_FORMATION", 238, 245], ["dogs", "SPECIES", 44, 48], ["cats", "SPECIES", 53, 57], ["dysuria", "PROBLEM", 59, 66], ["strAining to urinAte", "PROBLEM", 139, 159], ["dysuriA", "PROBLEM", 161, 168], ["dysuria", "PROBLEM", 238, 245], ["dysuriA", "OBSERVATION", 161, 168], ["dysuria", "OBSERVATION", 238, 245]]], ["Therefore physical examination is usually necessary to differentiate attempts to defecate from attempts to urinate and to distinguish between incontinence and dysuria.", [["incontinence", "DISEASE", 142, 154], ["dysuria", "DISEASE", 159, 166], ["physical examination", "TEST", 10, 30], ["attempts to urinate", "PROBLEM", 95, 114], ["incontinence", "PROBLEM", 142, 154], ["dysuria", "PROBLEM", 159, 166], ["dysuria", "OBSERVATION", 159, 166]]], ["Dysuria generally results from disorders of the lower urinary tract (bladder or urethra), genital tract (prostate or vagina), or both that induce an impediment to urinary outflow resulting in abnormal micturition or inappropriate urination.", [["lower urinary tract", "ANATOMY", 48, 67], ["bladder", "ANATOMY", 69, 76], ["urethra", "ANATOMY", 80, 87], ["genital tract", "ANATOMY", 90, 103], ["prostate", "ANATOMY", 105, 113], ["vagina", "ANATOMY", 117, 123], ["urinary", "ANATOMY", 163, 170], ["Dysuria", "DISEASE", 0, 7], ["disorders of the lower urinary tract", "DISEASE", 31, 67], ["abnormal micturition", "DISEASE", 192, 212], ["inappropriate urination", "DISEASE", 216, 239], ["lower", "ORGANISM_SUBDIVISION", 48, 53], ["urinary tract", "ORGANISM_SUBDIVISION", 54, 67], ["bladder", "ORGAN", 69, 76], ["urethra", "ORGAN", 80, 87], ["genital tract", "ORGANISM_SUBDIVISION", 90, 103], ["prostate", "ORGAN", 105, 113], ["vagina", "ORGAN", 117, 123], ["urinary", "ORGANISM_SUBDIVISION", 163, 170], ["Dysuria", "PROBLEM", 0, 7], ["disorders of the lower urinary tract (bladder or urethra", "PROBLEM", 31, 87], ["genital tract (prostate or vagina", "PROBLEM", 90, 123], ["urinary outflow", "PROBLEM", 163, 178], ["abnormal micturition", "PROBLEM", 192, 212], ["inappropriate urination", "PROBLEM", 216, 239], ["lower", "ANATOMY_MODIFIER", 48, 53], ["urinary tract", "ANATOMY", 54, 67], ["bladder", "ANATOMY", 69, 76], ["urethra", "ANATOMY", 80, 87], ["genital tract", "ANATOMY", 90, 103], ["prostate", "ANATOMY", 105, 113], ["vagina", "ANATOMY", 117, 123], ["urinary outflow", "ANATOMY", 163, 178]]], ["However, a variety of neurologic lesions, particularly lesions in the caudal lumbar spine and sacrum affecting either parasympathetic or sympathetic innervation to the lower urinary tract, can result in dysuria.", [["neurologic lesions", "ANATOMY", 22, 40], ["lesions", "ANATOMY", 55, 62], ["caudal lumbar spine", "ANATOMY", 70, 89], ["sacrum", "ANATOMY", 94, 100], ["sympathetic innervation", "ANATOMY", 137, 160], ["lower urinary tract", "ANATOMY", 168, 187], ["neurologic lesions", "DISEASE", 22, 40], ["dysuria", "DISEASE", 203, 210], ["neurologic lesions", "PATHOLOGICAL_FORMATION", 22, 40], ["lesions", "CANCER", 55, 62], ["caudal lumbar spine", "MULTI-TISSUE_STRUCTURE", 70, 89], ["sacrum", "ORGAN", 94, 100], ["sympathetic innervation", "MULTI-TISSUE_STRUCTURE", 137, 160], ["lower", "ORGANISM_SUBDIVISION", 168, 173], ["urinary tract", "ORGANISM_SUBDIVISION", 174, 187], ["neurologic lesions", "PROBLEM", 22, 40], ["lesions in the caudal lumbar spine and sacrum", "PROBLEM", 55, 100], ["parasympathetic or sympathetic innervation to the lower urinary tract", "PROBLEM", 118, 187], ["dysuria", "PROBLEM", 203, 210], ["variety", "OBSERVATION_MODIFIER", 11, 18], ["neurologic", "OBSERVATION_MODIFIER", 22, 32], ["lesions", "OBSERVATION", 33, 40], ["lesions", "OBSERVATION", 55, 62], ["caudal", "ANATOMY_MODIFIER", 70, 76], ["lumbar spine", "ANATOMY", 77, 89], ["sacrum", "ANATOMY", 94, 100], ["sympathetic innervation", "OBSERVATION", 137, 160], ["lower", "ANATOMY_MODIFIER", 168, 173], ["urinary tract", "ANATOMY", 174, 187], ["dysuria", "OBSERVATION", 203, 210]]], ["Neurologic dysurias are among the most difficult to characterize and to treat.AssociAted signsClinical signs associated with dysuria can often be localized to the point of the primary lesion in the lower genitourinary tract.", [["primary lesion", "ANATOMY", 176, 190], ["lower genitourinary tract", "ANATOMY", 198, 223], ["Neurologic dysurias", "DISEASE", 0, 19], ["dysuria", "DISEASE", 125, 132], ["lesion", "CANCER", 184, 190], ["lower", "ORGANISM_SUBDIVISION", 198, 203], ["genitourinary tract", "ORGANISM_SUBDIVISION", 204, 223], ["Neurologic dysurias", "PROBLEM", 0, 19], ["AssociAted signsClinical signs", "PROBLEM", 78, 108], ["dysuria", "PROBLEM", 125, 132], ["the primary lesion in the lower genitourinary tract", "PROBLEM", 172, 223], ["dysurias", "OBSERVATION", 11, 19], ["most difficult to characterize", "OBSERVATION_MODIFIER", 34, 64], ["dysuria", "OBSERVATION", 125, 132], ["primary", "OBSERVATION_MODIFIER", 176, 183], ["lesion", "OBSERVATION", 184, 190], ["lower", "ANATOMY_MODIFIER", 198, 203], ["genitourinary tract", "ANATOMY", 204, 223]]], ["Dysuria is commonly associated with discolored urine (particularly hematuria), pyuria, or both, subsequent to mucosal inflammation and infection.", [["urine", "ANATOMY", 47, 52], ["mucosal", "ANATOMY", 110, 117], ["Dysuria", "DISEASE", 0, 7], ["hematuria", "DISEASE", 67, 76], ["pyuria", "DISEASE", 79, 85], ["inflammation", "DISEASE", 118, 130], ["infection", "DISEASE", 135, 144], ["urine", "ORGANISM_SUBSTANCE", 47, 52], ["mucosal", "PATHOLOGICAL_FORMATION", 110, 117], ["Dysuria", "PROBLEM", 0, 7], ["discolored urine", "PROBLEM", 36, 52], ["hematuria", "PROBLEM", 67, 76], ["pyuria", "PROBLEM", 79, 85], ["mucosal inflammation", "PROBLEM", 110, 130], ["infection", "PROBLEM", 135, 144], ["pyuria", "OBSERVATION", 79, 85], ["mucosal", "ANATOMY", 110, 117], ["inflammation", "OBSERVATION", 118, 130], ["infection", "OBSERVATION", 135, 144]]], ["Certain causes of urinary incontinence may also result in dysuria.", [["urinary", "ANATOMY", 18, 25], ["urinary incontinence", "DISEASE", 18, 38], ["dysuria", "DISEASE", 58, 65], ["urinary", "ORGANISM_SUBDIVISION", 18, 25], ["urinary incontinence", "PROBLEM", 18, 38], ["dysuria", "PROBLEM", 58, 65], ["urinary", "ANATOMY", 18, 25], ["incontinence", "OBSERVATION", 26, 38], ["dysuria", "OBSERVATION", 58, 65]]], ["The owner may also report frequent attempts at urination by the animal.AssociAted signsDistinguish between two additional clinical signs associated with dysuria: PU (increased volume) versus pollakiuria (increased frequency).", [["dysuria", "DISEASE", 153, 160], ["PU", "DISEASE", 162, 164], ["pollakiuria", "DISEASE", 191, 202], ["frequent attempts at urination", "PROBLEM", 26, 56], ["two additional clinical signs", "PROBLEM", 107, 136], ["dysuria", "PROBLEM", 153, 160], ["PU (increased volume)", "PROBLEM", 162, 183], ["pollakiuria (increased frequency)", "PROBLEM", 191, 224], ["dysuria", "OBSERVATION", 153, 160], ["PU", "OBSERVATION", 162, 164], ["increased", "OBSERVATION_MODIFIER", 204, 213]]], ["Patients with dysuria may also manifest strangury, defined as a slow, painful discharge of urine caused by spasm of the bladder and urethra.", [["urine", "ANATOMY", 91, 96], ["bladder", "ANATOMY", 120, 127], ["urethra", "ANATOMY", 132, 139], ["dysuria", "DISEASE", 14, 21], ["strangury", "DISEASE", 40, 49], ["spasm of the bladder", "DISEASE", 107, 127], ["Patients", "ORGANISM", 0, 8], ["urine", "ORGANISM_SUBSTANCE", 91, 96], ["bladder", "ORGAN", 120, 127], ["urethra", "ORGAN", 132, 139], ["Patients", "SPECIES", 0, 8], ["dysuria", "PROBLEM", 14, 21], ["a slow, painful discharge of urine", "PROBLEM", 62, 96], ["spasm of the bladder and urethra", "PROBLEM", 107, 139], ["dysuria", "OBSERVATION", 14, 21], ["spasm", "OBSERVATION", 107, 112], ["bladder", "ANATOMY", 120, 127], ["urethra", "ANATOMY", 132, 139]]], ["In male dogs, dysuria caused by an enlarged prostate may also be associated with constipation.swelling of the limbs: PeriPherAl edemA definitionPeripheral edema is a pathologic increase in the fluid volume of the interstitium of soft tissue typically affecting the head and neck, forelimbs, or hindlimbs.", [["prostate", "ANATOMY", 44, 52], ["limbs", "ANATOMY", 110, 115], ["fluid", "ANATOMY", 193, 198], ["interstitium", "ANATOMY", 213, 225], ["soft tissue", "ANATOMY", 229, 240], ["head", "ANATOMY", 265, 269], ["neck", "ANATOMY", 274, 278], ["forelimbs", "ANATOMY", 280, 289], ["hindlimbs", "ANATOMY", 294, 303], ["dysuria", "DISEASE", 14, 21], ["constipation", "DISEASE", 81, 93], ["PeriPherAl", "CHEMICAL", 117, 127], ["edema", "DISEASE", 155, 160], ["dogs", "ORGANISM", 8, 12], ["prostate", "ORGAN", 44, 52], ["limbs", "ORGANISM_SUBDIVISION", 110, 115], ["fluid", "ORGANISM_SUBSTANCE", 193, 198], ["interstitium", "TISSUE", 213, 225], ["soft tissue", "TISSUE", 229, 240], ["head", "ORGANISM_SUBDIVISION", 265, 269], ["neck", "ORGAN", 274, 278], ["forelimbs", "ORGAN", 280, 289], ["hindlimbs", "ORGAN", 294, 303], ["dogs", "SPECIES", 8, 12], ["dysuria", "PROBLEM", 14, 21], ["an enlarged prostate", "PROBLEM", 32, 52], ["constipation", "PROBLEM", 81, 93], ["swelling of the limbs", "PROBLEM", 94, 115], ["PeriPherAl edemA definitionPeripheral edema", "PROBLEM", 117, 160], ["a pathologic increase", "PROBLEM", 164, 185], ["the fluid volume", "TEST", 189, 205], ["soft tissue", "PROBLEM", 229, 240], ["dysuria", "OBSERVATION", 14, 21], ["enlarged", "OBSERVATION", 35, 43], ["prostate", "ANATOMY", 44, 52], ["may also be associated with", "UNCERTAINTY", 53, 80], ["constipation", "OBSERVATION", 81, 93], ["limbs", "ANATOMY", 110, 115], ["edemA", "OBSERVATION", 128, 133], ["definitionPeripheral", "OBSERVATION_MODIFIER", 134, 154], ["edema", "OBSERVATION", 155, 160], ["pathologic", "OBSERVATION_MODIFIER", 166, 176], ["increase", "OBSERVATION_MODIFIER", 177, 185], ["fluid volume", "OBSERVATION", 193, 205], ["interstitium", "ANATOMY_MODIFIER", 213, 225], ["soft tissue", "ANATOMY_MODIFIER", 229, 240], ["head", "ANATOMY", 265, 269], ["neck", "ANATOMY", 274, 278], ["forelimbs", "ANATOMY", 280, 289], ["hindlimbs", "ANATOMY", 294, 303]]], ["The distribution pattern of peripheral edema can be characterized as generalized, regional, or focal.", [["peripheral edema", "ANATOMY", 28, 44], ["peripheral edema", "DISEASE", 28, 44], ["peripheral edema", "PATHOLOGICAL_FORMATION", 28, 44], ["peripheral edema", "PROBLEM", 28, 44], ["distribution", "OBSERVATION_MODIFIER", 4, 16], ["pattern", "OBSERVATION_MODIFIER", 17, 24], ["peripheral", "ANATOMY_MODIFIER", 28, 38], ["edema", "OBSERVATION", 39, 44], ["generalized", "OBSERVATION_MODIFIER", 69, 80], ["regional", "OBSERVATION_MODIFIER", 82, 90], ["focal", "OBSERVATION_MODIFIER", 95, 100]]], ["Peripheral edema may or may not be associated with other forms of edema, such as cerebral edema or pulmonary edema.", [["Peripheral edema", "ANATOMY", 0, 16], ["edema", "ANATOMY", 66, 71], ["cerebral", "ANATOMY", 81, 89], ["pulmonary", "ANATOMY", 99, 108], ["Peripheral edema", "DISEASE", 0, 16], ["edema", "DISEASE", 66, 71], ["cerebral edema", "DISEASE", 81, 95], ["pulmonary edema", "DISEASE", 99, 114], ["edema", "PATHOLOGICAL_FORMATION", 66, 71], ["cerebral edema", "PATHOLOGICAL_FORMATION", 81, 95], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 99, 114], ["Peripheral edema", "PROBLEM", 0, 16], ["edema", "PROBLEM", 66, 71], ["cerebral edema", "PROBLEM", 81, 95], ["pulmonary edema", "PROBLEM", 99, 114], ["edema", "OBSERVATION", 11, 16], ["may not be associated with", "UNCERTAINTY", 24, 50], ["edema", "OBSERVATION", 66, 71], ["cerebral", "ANATOMY", 81, 89], ["edema", "OBSERVATION", 90, 95], ["pulmonary", "ANATOMY", 99, 108], ["edema", "OBSERVATION", 109, 114]]], ["The distinction between normal and abnormal increases in interstitial fluid volumes is difficult to establish clinically.", [["interstitial fluid", "ANATOMY", 57, 75], ["interstitial fluid", "TISSUE", 57, 75], ["abnormal increases in interstitial fluid volumes", "PROBLEM", 35, 83], ["normal", "OBSERVATION", 24, 30], ["abnormal", "OBSERVATION_MODIFIER", 35, 43], ["increases", "OBSERVATION_MODIFIER", 44, 53], ["interstitial", "ANATOMY_MODIFIER", 57, 69], ["fluid volumes", "OBSERVATION", 70, 83]]], ["Moderate to severe increases (30%) in interstitial fluid volume are evident on visual examination of the patient as a result of the physical changes in the tissue caused by the fluid.", [["interstitial fluid", "ANATOMY", 38, 56], ["tissue", "ANATOMY", 156, 162], ["fluid", "ANATOMY", 177, 182], ["interstitial fluid", "MULTI-TISSUE_STRUCTURE", 38, 56], ["patient", "ORGANISM", 105, 112], ["tissue", "TISSUE", 156, 162], ["fluid", "ORGANISM_SUBSTANCE", 177, 182], ["patient", "SPECIES", 105, 112], ["Moderate to severe increases", "PROBLEM", 0, 28], ["interstitial fluid volume", "TEST", 38, 63], ["visual examination", "TEST", 79, 97], ["the physical changes in the tissue", "PROBLEM", 128, 162], ["severe", "OBSERVATION_MODIFIER", 12, 18], ["increases", "OBSERVATION_MODIFIER", 19, 28], ["30%", "OBSERVATION_MODIFIER", 30, 33], ["interstitial", "ANATOMY_MODIFIER", 38, 50], ["fluid volume", "OBSERVATION", 51, 63], ["fluid", "OBSERVATION", 177, 182]]], ["Any increase in the interstitial fluid volume identified by any means (e.g., histopathology, physical examination) constitutes peripheral edema.swelling of the limbs: PeriPherAl edemA definitionAlbumin is the smallest plasma protein and is the primary source of plasma colloidal oncotic pressure.", [["interstitial fluid", "ANATOMY", 20, 38], ["peripheral edema", "ANATOMY", 127, 143], ["limbs", "ANATOMY", 160, 165], ["plasma", "ANATOMY", 218, 224], ["plasma", "ANATOMY", 262, 268], ["peripheral edema", "DISEASE", 127, 143], ["interstitial fluid", "TISSUE", 20, 38], ["peripheral edema", "PATHOLOGICAL_FORMATION", 127, 143], ["limbs", "ORGANISM_SUBDIVISION", 160, 165], ["PeriPherAl", "GENE_OR_GENE_PRODUCT", 167, 177], ["plasma", "ORGANISM_SUBSTANCE", 218, 224], ["plasma", "ORGANISM_SUBSTANCE", 262, 268], ["PeriPherAl edemA definitionAlbumin", "PROTEIN", 167, 201], ["plasma protein", "PROTEIN", 218, 232], ["the interstitial fluid volume", "TEST", 16, 45], ["physical examination", "TEST", 93, 113], ["peripheral edema", "PROBLEM", 127, 143], ["swelling of the limbs", "PROBLEM", 144, 165], ["PeriPherAl edemA definitionAlbumin", "PROBLEM", 167, 201], ["the smallest plasma protein", "TEST", 205, 232], ["plasma colloidal oncotic pressure", "TEST", 262, 295], ["increase", "OBSERVATION_MODIFIER", 4, 12], ["interstitial", "ANATOMY_MODIFIER", 20, 32], ["fluid volume", "OBSERVATION", 33, 45], ["peripheral", "ANATOMY_MODIFIER", 127, 137], ["edema", "OBSERVATION", 138, 143], ["limbs", "ANATOMY", 160, 165], ["PeriPherAl", "ANATOMY_MODIFIER", 167, 177], ["edemA", "OBSERVATION", 178, 183], ["colloidal oncotic pressure", "OBSERVATION", 269, 295]]], ["Edema may become clinically evident as the serum albumin concentration falls below 2 g/dL.", [["serum", "ANATOMY", 43, 48], ["Edema", "DISEASE", 0, 5], ["serum", "ORGANISM_SUBSTANCE", 43, 48], ["albumin", "GENE_OR_GENE_PRODUCT", 49, 56], ["Edema", "PROBLEM", 0, 5], ["the serum albumin concentration", "TEST", 39, 70]]], ["However, other factors are also involved in the formation of edema, such as decreased plasma volume and increased extracellular space associated with decreased renal excretion of sodium.AssociAted signsPatients that are presented with peripheral edema may manifest other signs.", [["edema", "ANATOMY", 61, 66], ["plasma", "ANATOMY", 86, 92], ["extracellular space", "ANATOMY", 114, 133], ["renal", "ANATOMY", 160, 165], ["peripheral edema", "ANATOMY", 235, 251], ["edema", "DISEASE", 61, 66], ["sodium", "CHEMICAL", 179, 185], ["peripheral edema", "DISEASE", 235, 251], ["sodium", "CHEMICAL", 179, 185], ["edema", "PATHOLOGICAL_FORMATION", 61, 66], ["plasma", "ORGANISM_SUBSTANCE", 86, 92], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 114, 127], ["renal", "ORGAN", 160, 165], ["sodium", "SIMPLE_CHEMICAL", 179, 185], ["edema", "PROBLEM", 61, 66], ["decreased plasma volume", "PROBLEM", 76, 99], ["increased extracellular space", "PROBLEM", 104, 133], ["decreased renal excretion of sodium", "PROBLEM", 150, 185], ["AssociAted signsPatients", "PROBLEM", 186, 210], ["peripheral edema", "PROBLEM", 235, 251], ["edema", "OBSERVATION", 61, 66], ["decreased", "OBSERVATION_MODIFIER", 76, 85], ["plasma volume", "OBSERVATION", 86, 99], ["increased", "OBSERVATION_MODIFIER", 104, 113], ["extracellular space", "OBSERVATION", 114, 133], ["decreased", "OBSERVATION_MODIFIER", 150, 159], ["renal", "ANATOMY", 160, 165], ["excretion", "OBSERVATION", 166, 175], ["peripheral", "ANATOMY_MODIFIER", 235, 245], ["edema", "OBSERVATION", 246, 251]]], ["Evidence of chronic inflammatory disease, vasculitis, ecchymoses, cardiac disease, allergy, or trauma (including burns) should be considered.", [["cardiac", "ANATOMY", 66, 73], ["chronic inflammatory disease", "DISEASE", 12, 40], ["vasculitis", "DISEASE", 42, 52], ["ecchymoses", "DISEASE", 54, 64], ["cardiac disease", "DISEASE", 66, 81], ["allergy", "DISEASE", 83, 90], ["trauma", "DISEASE", 95, 101], ["burns", "DISEASE", 113, 118], ["cardiac", "ORGAN", 66, 73], ["chronic inflammatory disease", "PROBLEM", 12, 40], ["vasculitis", "PROBLEM", 42, 52], ["ecchymoses", "PROBLEM", 54, 64], ["cardiac disease", "PROBLEM", 66, 81], ["allergy", "PROBLEM", 83, 90], ["trauma", "PROBLEM", 95, 101], ["burns", "PROBLEM", 113, 118], ["chronic", "OBSERVATION_MODIFIER", 12, 19], ["inflammatory", "OBSERVATION", 20, 32], ["vasculitis", "OBSERVATION", 42, 52], ["ecchymoses", "OBSERVATION", 54, 64], ["cardiac", "ANATOMY", 66, 73], ["disease", "OBSERVATION", 74, 81]]], ["Patients with peripheral edema may also have primary protein-losing (renal or GI) disorders.", [["peripheral edema", "ANATOMY", 14, 30], ["renal", "ANATOMY", 69, 74], ["GI", "ANATOMY", 78, 80], ["peripheral edema", "DISEASE", 14, 30], ["primary protein-losing (renal or GI) disorders", "DISEASE", 45, 91], ["Patients", "ORGANISM", 0, 8], ["renal", "CANCER", 69, 74], ["Patients", "SPECIES", 0, 8], ["peripheral edema", "PROBLEM", 14, 30], ["primary protein-losing (renal or GI) disorders", "PROBLEM", 45, 91], ["peripheral", "ANATOMY_MODIFIER", 14, 24], ["edema", "OBSERVATION", 25, 30], ["renal", "ANATOMY", 69, 74], ["GI", "ANATOMY", 78, 80]]], ["These patients may be presented with increased water consumption or urination or diarrhea and weight loss.", [["urination", "DISEASE", 68, 77], ["diarrhea", "DISEASE", 81, 89], ["weight loss", "DISEASE", 94, 105], ["patients", "ORGANISM", 6, 14], ["water", "SIMPLE_CHEMICAL", 47, 52], ["patients", "SPECIES", 6, 14], ["increased water consumption", "PROBLEM", 37, 64], ["urination", "PROBLEM", 68, 77], ["diarrhea", "PROBLEM", 81, 89], ["weight loss", "PROBLEM", 94, 105]]], ["Severe hepatic disease may result in diminished synthesis of albumin, thereby contributing to the formation of edema.", [["hepatic", "ANATOMY", 7, 14], ["edema", "ANATOMY", 111, 116], ["hepatic disease", "DISEASE", 7, 22], ["edema", "DISEASE", 111, 116], ["hepatic", "ORGAN", 7, 14], ["albumin", "GENE_OR_GENE_PRODUCT", 61, 68], ["edema", "PATHOLOGICAL_FORMATION", 111, 116], ["albumin", "PROTEIN", 61, 68], ["Severe hepatic disease", "PROBLEM", 0, 22], ["diminished synthesis of albumin", "PROBLEM", 37, 68], ["edema", "PROBLEM", 111, 116], ["hepatic", "ANATOMY", 7, 14], ["disease", "OBSERVATION", 15, 22], ["diminished", "OBSERVATION_MODIFIER", 37, 47], ["synthesis", "OBSERVATION_MODIFIER", 48, 57], ["edema", "OBSERVATION", 111, 116]]], ["Congenital (primary) lymphedema-an autosomal dominant trait primarily affecting the hindlimbs by 3 to 6 months of age Acquired (secondary) lymphedema (focal or regional) Infectious, granulomatous, neoplastic, traumatic injury, or compression of lymphatics incrEasEd intErstitial gEl matrix Myxedema (hypothyroidism)-rare 8.", [["hindlimbs", "ANATOMY", 84, 93], ["granulomatous", "ANATOMY", 182, 195], ["neoplastic", "ANATOMY", 197, 207], ["lymphatics", "ANATOMY", 245, 255], ["Congenital (primary) lymphedema", "DISEASE", 0, 31], ["autosomal dominant trait primarily affecting the hindlimbs", "DISEASE", 35, 93], ["lymphedema", "DISEASE", 139, 149], ["traumatic injury", "DISEASE", 209, 225], ["hypothyroidism", "DISEASE", 300, 314], ["hindlimbs", "ORGAN", 84, 93], ["lymphatics", "MULTI-TISSUE_STRUCTURE", 245, 255], ["Congenital (primary) lymphedema", "PROBLEM", 0, 31], ["autosomal dominant trait", "PROBLEM", 35, 59], ["Acquired (secondary) lymphedema (focal or regional) Infectious, granulomatous", "PROBLEM", 118, 195], ["neoplastic", "PROBLEM", 197, 207], ["traumatic injury", "PROBLEM", 209, 225], ["compression of lymphatics incrEasEd intErstitial gEl matrix Myxedema (hypothyroidism)", "PROBLEM", 230, 315], ["lymphedema", "OBSERVATION", 21, 31], ["autosomal", "OBSERVATION_MODIFIER", 35, 44], ["dominant trait", "OBSERVATION", 45, 59], ["hindlimbs", "ANATOMY", 84, 93], ["lymphedema", "OBSERVATION", 139, 149], ["focal", "OBSERVATION_MODIFIER", 151, 156], ["regional", "OBSERVATION_MODIFIER", 160, 168], ["Infectious", "OBSERVATION_MODIFIER", 170, 180], ["granulomatous", "OBSERVATION_MODIFIER", 182, 195], ["neoplastic", "OBSERVATION_MODIFIER", 197, 207], ["traumatic", "OBSERVATION_MODIFIER", 209, 218], ["injury", "OBSERVATION", 219, 225], ["lymphatics", "ANATOMY", 245, 255], ["incrEasEd", "OBSERVATION_MODIFIER", 256, 265], ["intErstitial", "ANATOMY_MODIFIER", 266, 278], ["gEl matrix Myxedema", "OBSERVATION", 279, 298], ["hypothyroidism", "OBSERVATION", 300, 314]]], ["Edema fluid analysis.", [["Edema fluid", "ANATOMY", 0, 11], ["Edema", "DISEASE", 0, 5], ["Edema fluid analysis", "TEST", 0, 20], ["fluid", "OBSERVATION", 6, 11]]], ["Collect by direct insertion of a 22-gauge needle into edematous tissue.", [["edematous tissue", "ANATOMY", 54, 70], ["edematous tissue", "TISSUE", 54, 70], ["a 22-gauge needle", "TREATMENT", 31, 48], ["edematous tissue", "PROBLEM", 54, 70], ["edematous tissue", "OBSERVATION", 54, 70]]], ["A sample is collected into plain and ethylenediaminetetraacetic acid (EDTA)containing tubes.", [["sample", "ANATOMY", 2, 8], ["ethylenediaminetetraacetic acid", "CHEMICAL", 37, 68], ["EDTA", "CHEMICAL", 70, 74], ["ethylenediaminetetraacetic acid", "CHEMICAL", 37, 68], ["EDTA", "CHEMICAL", 70, 74], ["ethylenediaminetetraacetic acid", "SIMPLE_CHEMICAL", 37, 68], ["EDTA", "SIMPLE_CHEMICAL", 70, 74], ["A sample", "TEST", 0, 8], ["ethylenediaminetetraacetic acid (EDTA)containing tubes", "TREATMENT", 37, 91]]], ["Fluid is analyzed for color, consistency, and turbidity as well as protein and cellularity.", [["Fluid", "TREATMENT", 0, 5], ["color", "TEST", 22, 27], ["cellularity", "OBSERVATION", 79, 90]]], ["Postcapillary venous pressure and oxygen saturation, to confirm proximal obstruction to venous drainage or an arteriovenous fistula.", [["Postcapillary venous", "ANATOMY", 0, 20], ["venous", "ANATOMY", 88, 94], ["arteriovenous fistula", "ANATOMY", 110, 131], ["oxygen", "CHEMICAL", 34, 40], ["obstruction", "DISEASE", 73, 84], ["arteriovenous fistula", "DISEASE", 110, 131], ["oxygen", "CHEMICAL", 34, 40], ["venous", "MULTI-TISSUE_STRUCTURE", 14, 20], ["oxygen", "SIMPLE_CHEMICAL", 34, 40], ["venous", "MULTI-TISSUE_STRUCTURE", 88, 94], ["arteriovenous fistula", "PATHOLOGICAL_FORMATION", 110, 131], ["Postcapillary venous pressure", "TEST", 0, 29], ["oxygen saturation", "TEST", 34, 51], ["proximal obstruction", "PROBLEM", 64, 84], ["venous drainage", "TREATMENT", 88, 103], ["an arteriovenous fistula", "PROBLEM", 107, 131], ["venous", "ANATOMY", 14, 20], ["pressure", "OBSERVATION_MODIFIER", 21, 29], ["oxygen saturation", "OBSERVATION", 34, 51], ["proximal", "OBSERVATION_MODIFIER", 64, 72], ["obstruction", "OBSERVATION", 73, 84], ["venous", "ANATOMY", 88, 94], ["drainage", "OBSERVATION", 95, 103], ["arteriovenous", "ANATOMY", 110, 123], ["fistula", "OBSERVATION", 124, 131]]], ["(Normal postcapillary venous pressure is 13 \u00b1 4 mm Hg.) 10.", [["postcapillary venous", "ANATOMY", 8, 28], ["postcapillary venous", "MULTI-TISSUE_STRUCTURE", 8, 28], ["postcapillary venous pressure", "TEST", 8, 37], ["postcapillary venous", "ANATOMY", 8, 28]]], ["Cytology and histopathology.", [["Cytology", "TEST", 0, 8], ["histopathology", "TEST", 13, 27], ["histopathology", "OBSERVATION", 13, 27]]], ["Studies are useful in evaluating mass lesions associated with edematous tissue.uncontrolled urinAtion: urinAry incontinence definitionUrinary incontinence is the lack of normal ability to prevent discharge of urine from the bladder.", [["mass lesions", "ANATOMY", 33, 45], ["edematous tissue", "ANATOMY", 62, 78], ["Urinary", "ANATOMY", 134, 141], ["urine", "ANATOMY", 209, 214], ["bladder", "ANATOMY", 224, 231], ["incontinence", "DISEASE", 111, 123], ["Urinary incontinence", "DISEASE", 134, 154], ["mass lesions", "CANCER", 33, 45], ["edematous tissue", "TISSUE", 62, 78], ["Urinary", "ORGANISM_SUBSTANCE", 134, 141], ["urine", "ORGANISM_SUBSTANCE", 209, 214], ["bladder", "ORGAN", 224, 231], ["Studies", "TEST", 0, 7], ["mass lesions", "PROBLEM", 33, 45], ["edematous tissue", "PROBLEM", 62, 78], ["uncontrolled urinAtion", "PROBLEM", 79, 101], ["urinAry incontinence definition", "PROBLEM", 103, 134], ["Urinary incontinence", "PROBLEM", 134, 154], ["discharge of urine from the bladder", "PROBLEM", 196, 231], ["mass", "OBSERVATION", 33, 37], ["edematous tissue", "OBSERVATION", 62, 78], ["urinAtion", "OBSERVATION", 92, 101], ["urin", "ANATOMY", 103, 107], ["incontinence", "OBSERVATION", 111, 123], ["incontinence", "OBSERVATION", 142, 154], ["urine", "OBSERVATION", 209, 214], ["bladder", "ANATOMY", 224, 231]]], ["Urinary incontinence should be suspected when an animal that previously exhibited normal control of urination begins passing urine at times or in places that are inappropriate.", [["Urinary", "ANATOMY", 0, 7], ["urine", "ANATOMY", 125, 130], ["Urinary incontinence", "DISEASE", 0, 20], ["Urinary", "ORGANISM_SUBSTANCE", 0, 7], ["urine", "ORGANISM_SUBSTANCE", 125, 130], ["Urinary incontinence", "PROBLEM", 0, 20], ["passing urine", "PROBLEM", 117, 130], ["incontinence", "OBSERVATION", 8, 20]]], ["Determining whether or not the presenting complaint of inappropriate urinary behavior is involuntary can be a formidable task in a dog or cat.", [["urinary", "ANATOMY", 69, 76], ["inappropriate urinary behavior", "DISEASE", 55, 85], ["urinary", "ORGANISM_SUBDIVISION", 69, 76], ["dog", "ORGANISM", 131, 134], ["cat", "ORGANISM", 138, 141], ["dog", "SPECIES", 131, 134], ["inappropriate urinary behavior", "PROBLEM", 55, 85]]], ["Distinguishing between voluntary and involuntary urination is fundamental to the diagnostic plan.", [["involuntary urination", "DISEASE", 37, 58], ["voluntary and involuntary urination", "PROBLEM", 23, 58]]], ["The normal micturition reflex is a result of the complex interaction of the autonomic and somatic nervous systems.", [["autonomic", "ANATOMY", 76, 85], ["somatic nervous systems", "ANATOMY", 90, 113], ["somatic nervous systems", "ANATOMICAL_SYSTEM", 90, 113], ["the autonomic and somatic nervous systems", "PROBLEM", 72, 113], ["normal", "OBSERVATION", 4, 10], ["micturition reflex", "OBSERVATION", 11, 29], ["somatic nervous", "OBSERVATION", 90, 105]]], ["Normal control of micturition can be divided into a series of nervous pathways: 1.", [["nervous", "ANATOMY", 62, 69], ["nervous", "ANATOMICAL_SYSTEM", 62, 69]]], ["Sensory neurons have stretch receptors in the bladder wall that relay information through ascending spinal cord tracts to the brainstem and somesthetic cortex of the frontoparietal lobes.", [["Sensory neurons", "ANATOMY", 0, 15], ["bladder wall", "ANATOMY", 46, 58], ["spinal cord", "ANATOMY", 100, 111], ["brainstem", "ANATOMY", 126, 135], ["somesthetic cortex", "ANATOMY", 140, 158], ["frontoparietal lobes", "ANATOMY", 166, 186], ["Sensory neurons", "CELL", 0, 15], ["bladder wall", "MULTI-TISSUE_STRUCTURE", 46, 58], ["spinal cord", "ORGAN", 100, 111], ["brainstem", "ANATOMICAL_SYSTEM", 126, 135], ["somesthetic cortex", "CANCER", 140, 158], ["frontoparietal lobes", "MULTI-TISSUE_STRUCTURE", 166, 186], ["Sensory neurons", "CELL_TYPE", 0, 15], ["stretch receptors", "PROTEIN", 21, 38], ["stretch receptors in the bladder wall", "PROBLEM", 21, 58], ["stretch receptors", "OBSERVATION", 21, 38], ["bladder", "ANATOMY", 46, 53], ["wall", "ANATOMY_MODIFIER", 54, 58], ["ascending", "ANATOMY_MODIFIER", 90, 99], ["spinal cord", "ANATOMY", 100, 111], ["tracts", "ANATOMY_MODIFIER", 112, 118], ["brainstem", "ANATOMY", 126, 135], ["somesthetic", "ANATOMY_MODIFIER", 140, 151], ["cortex", "ANATOMY_MODIFIER", 152, 158], ["frontoparietal lobes", "ANATOMY", 166, 186]]], ["This pathway is the basis for the perception of a full bladder.", [["bladder", "ANATOMY", 55, 62], ["bladder", "ORGAN", 55, 62], ["bladder", "ANATOMY", 55, 62]]], ["The frontoparietal motor cortex projects to the brainstem reticular formation centers for micturition, which are responsible for storage and evacuation of urine.", [["frontoparietal motor cortex", "ANATOMY", 4, 31], ["brainstem reticular", "ANATOMY", 48, 67], ["urine", "ANATOMY", 155, 160], ["frontoparietal motor cortex", "CANCER", 4, 31], ["brainstem reticular", "MULTI-TISSUE_STRUCTURE", 48, 67], ["urine", "ORGANISM_SUBSTANCE", 155, 160], ["evacuation of urine", "TEST", 141, 160], ["frontoparietal", "ANATOMY_MODIFIER", 4, 18], ["motor cortex", "ANATOMY", 19, 31], ["brainstem", "ANATOMY", 48, 57], ["reticular", "ANATOMY_MODIFIER", 58, 67], ["urine", "OBSERVATION", 155, 160]]], ["From these centers, reticulospinal tracts descend the spinal cord to influence gray matter centers responsible for the storage or evacuation of urine.", [["reticulospinal tracts", "ANATOMY", 20, 41], ["spinal cord", "ANATOMY", 54, 65], ["gray matter", "ANATOMY", 79, 90], ["urine", "ANATOMY", 144, 149], ["reticulospinal tracts", "MULTI-TISSUE_STRUCTURE", 20, 41], ["spinal cord", "ORGAN", 54, 65], ["urine", "ORGANISM_SUBSTANCE", 144, 149], ["evacuation of urine", "TEST", 130, 149], ["reticulospinal", "ANATOMY_MODIFIER", 20, 34], ["tracts", "ANATOMY_MODIFIER", 35, 41], ["spinal cord", "ANATOMY", 54, 65], ["urine", "OBSERVATION", 144, 149]]], ["For evacuation, the visceral efferent neurons in the sacral segments that innervate the detrusor muscle via the pelvic nerves are facilitated.", [["visceral efferent neurons", "ANATOMY", 20, 45], ["sacral segments", "ANATOMY", 53, 68], ["detrusor muscle", "ANATOMY", 88, 103], ["pelvic nerves", "ANATOMY", 112, 125], ["visceral efferent neurons", "CELL", 20, 45], ["sacral segments", "MULTI-TISSUE_STRUCTURE", 53, 68], ["detrusor muscle", "TISSUE", 88, 103], ["pelvic nerves", "MULTI-TISSUE_STRUCTURE", 112, 125], ["visceral efferent neurons", "CELL_TYPE", 20, 45], ["evacuation", "TREATMENT", 4, 14], ["evacuation", "OBSERVATION", 4, 14], ["visceral", "ANATOMY_MODIFIER", 20, 28], ["efferent", "ANATOMY_MODIFIER", 29, 37], ["neurons", "ANATOMY_MODIFIER", 38, 45], ["sacral", "ANATOMY_MODIFIER", 53, 59], ["segments", "ANATOMY_MODIFIER", 60, 68], ["detrusor muscle", "ANATOMY", 88, 103], ["pelvic nerves", "ANATOMY", 112, 125]]], ["The somatic efferent neurons in the sacral segments that innervate the striated urethralis muscle via the pudendal nerve are inhibited.", [["somatic efferent neurons", "ANATOMY", 4, 28], ["sacral segments", "ANATOMY", 36, 51], ["striated urethralis muscle", "ANATOMY", 71, 97], ["pudendal nerve", "ANATOMY", 106, 120], ["somatic efferent neurons", "CELL", 4, 28], ["sacral segments", "MULTI-TISSUE_STRUCTURE", 36, 51], ["striated urethralis muscle", "TISSUE", 71, 97], ["pudendal nerve", "MULTI-TISSUE_STRUCTURE", 106, 120], ["somatic efferent neurons", "CELL_TYPE", 4, 28], ["somatic", "OBSERVATION_MODIFIER", 4, 11], ["efferent neurons", "OBSERVATION", 12, 28], ["sacral", "ANATOMY_MODIFIER", 36, 42], ["segments", "ANATOMY_MODIFIER", 43, 51], ["striated", "ANATOMY_MODIFIER", 71, 79], ["urethralis muscle", "ANATOMY", 80, 97], ["pudendal nerve", "ANATOMY", 106, 120]]], ["Facilitation of these pudendal somatic neurons prevents urination.", [["pudendal somatic neurons", "ANATOMY", 22, 46], ["pudendal somatic neurons", "CELL", 22, 46], ["pudendal somatic neurons", "CELL_TYPE", 22, 46], ["these pudendal somatic neurons", "PROBLEM", 16, 46], ["urination", "PROBLEM", 56, 65], ["pudendal", "ANATOMY", 22, 30]]], ["Urinary incontinence is the physical manifestation of any one of several disorders affecting voluntary urine retention in the bladder.", [["Urinary", "ANATOMY", 0, 7], ["urine", "ANATOMY", 103, 108], ["bladder", "ANATOMY", 126, 133], ["Urinary incontinence", "DISEASE", 0, 20], ["urine retention", "DISEASE", 103, 118], ["Urinary", "ORGANISM_SUBSTANCE", 0, 7], ["urine", "ORGANISM_SUBSTANCE", 103, 108], ["bladder", "ORGAN", 126, 133], ["Urinary incontinence", "PROBLEM", 0, 20], ["several disorders", "PROBLEM", 65, 82], ["voluntary urine retention in the bladder", "PROBLEM", 93, 133], ["incontinence", "OBSERVATION", 8, 20], ["urine retention", "OBSERVATION", 103, 118], ["bladder", "ANATOMY", 126, 133]]], ["Neurologic lesions involving either upper motor or lower motor neuron segments of the micturition reflex arc result in urinary incontinence.", [["Neurologic lesions", "ANATOMY", 0, 18], ["upper motor", "ANATOMY", 36, 47], ["lower motor neuron", "ANATOMY", 51, 69], ["urinary", "ANATOMY", 119, 126], ["urinary incontinence", "DISEASE", 119, 139], ["Neurologic lesions", "PATHOLOGICAL_FORMATION", 0, 18], ["motor neuron", "MULTI-TISSUE_STRUCTURE", 57, 69], ["urinary", "ORGANISM_SUBDIVISION", 119, 126], ["Neurologic lesions", "PROBLEM", 0, 18], ["the micturition reflex", "TEST", 82, 104], ["urinary incontinence", "PROBLEM", 119, 139], ["lesions", "OBSERVATION", 11, 18], ["upper", "ANATOMY_MODIFIER", 36, 41], ["lower", "ANATOMY_MODIFIER", 51, 56], ["motor neuron", "ANATOMY", 57, 69], ["urinary", "ANATOMY", 119, 126], ["incontinence", "OBSERVATION", 127, 139]]], ["A paralytic bladder usually results in bladder overdistension and urine dribbling.", [["bladder", "ANATOMY", 12, 19], ["bladder", "ANATOMY", 39, 46], ["urine", "ANATOMY", 66, 71], ["paralytic bladder", "DISEASE", 2, 19], ["bladder overdistension and urine dribbling", "DISEASE", 39, 81], ["bladder", "ORGAN", 12, 19], ["bladder", "ORGAN", 39, 46], ["urine", "ORGANISM_SUBSTANCE", 66, 71], ["A paralytic bladder", "PROBLEM", 0, 19], ["bladder overdistension", "PROBLEM", 39, 61], ["urine dribbling", "PROBLEM", 66, 81], ["paralytic", "OBSERVATION", 2, 11], ["bladder", "ANATOMY", 12, 19], ["bladder", "ANATOMY", 39, 46], ["overdistension", "OBSERVATION", 47, 61], ["urine dribbling", "OBSERVATION", 66, 81]]], ["Urine can be easily expressed by manual compression of the bladder in affected patients.", [["Urine", "ANATOMY", 0, 5], ["bladder", "ANATOMY", 59, 66], ["compression of the bladder", "DISEASE", 40, 66], ["Urine", "ORGANISM_SUBSTANCE", 0, 5], ["bladder", "ORGAN", 59, 66], ["patients", "ORGANISM", 79, 87], ["patients", "SPECIES", 79, 87], ["Urine", "TEST", 0, 5], ["manual compression of the bladder", "PROBLEM", 33, 66], ["manual", "OBSERVATION_MODIFIER", 33, 39], ["compression", "OBSERVATION", 40, 51], ["bladder", "ANATOMY", 59, 66]]], ["A \"cord bladder\" is caused by a lesion between the brain and the spinal reflex center of micturition.", [["cord bladder", "ANATOMY", 3, 15], ["lesion", "ANATOMY", 32, 38], ["brain", "ANATOMY", 51, 56], ["spinal", "ANATOMY", 65, 71], ["cord bladder", "DISEASE", 3, 15], ["cord bladder", "ORGAN", 3, 15], ["brain", "ORGAN", 51, 56], ["A \"cord bladder", "PROBLEM", 0, 15], ["a lesion between the brain", "PROBLEM", 30, 56], ["cord bladder", "ANATOMY", 3, 15], ["lesion", "OBSERVATION", 32, 38], ["brain", "ANATOMY", 51, 56], ["spinal reflex", "ANATOMY", 65, 78]]], ["There is usually temporary bladder paralysis followed by involuntary reflex micturition subsequent to manual compression.uncontrolled urinAtion: urinAry incontinence definitionNonneurogenic urinary incontinence may be caused by anatomic or functional disorders (e.g., ectopic ureters) affecting the storage phase of micturition.", [["bladder", "ANATOMY", 27, 34], ["urinary", "ANATOMY", 190, 197], ["ureters", "ANATOMY", 276, 283], ["bladder paralysis", "DISEASE", 27, 44], ["involuntary reflex micturition", "DISEASE", 57, 87], ["incontinence", "DISEASE", 153, 165], ["urinary incontinence", "DISEASE", 190, 210], ["ectopic ureters", "DISEASE", 268, 283], ["bladder", "ORGAN", 27, 34], ["ureters", "ORGAN", 276, 283], ["usually temporary bladder paralysis", "PROBLEM", 9, 44], ["involuntary reflex micturition", "TREATMENT", 57, 87], ["manual compression", "TREATMENT", 102, 120], ["uncontrolled urinAtion", "PROBLEM", 121, 143], ["urinAry incontinence", "PROBLEM", 145, 165], ["Nonneurogenic urinary incontinence", "PROBLEM", 176, 210], ["anatomic or functional disorders", "PROBLEM", 228, 260], ["ectopic ureters", "PROBLEM", 268, 283], ["temporary", "ANATOMY_MODIFIER", 17, 26], ["bladder", "ANATOMY", 27, 34], ["paralysis", "OBSERVATION", 35, 44], ["compression", "OBSERVATION", 109, 120], ["urinAtion", "OBSERVATION", 134, 143], ["urinary", "ANATOMY", 190, 197], ["incontinence", "OBSERVATION", 198, 210], ["functional disorders", "OBSERVATION", 240, 260], ["ureters", "ANATOMY", 276, 283]]], ["Hormone-responsive incontinence is also a common form of nonneurogenic urinary incontinence.", [["urinary", "ANATOMY", 71, 78], ["incontinence", "DISEASE", 19, 31], ["urinary incontinence", "DISEASE", 71, 91], ["Hormone", "SIMPLE_CHEMICAL", 0, 7], ["urinary", "ORGANISM_SUBDIVISION", 71, 78], ["Hormone-responsive incontinence", "PROBLEM", 0, 31], ["nonneurogenic urinary incontinence", "PROBLEM", 57, 91], ["responsive incontinence", "OBSERVATION", 8, 31], ["urinary", "ANATOMY", 71, 78], ["incontinence", "OBSERVATION", 79, 91]]], ["In these patients (usually dogs), the detrusor reflex is normal; normal urination behavior, in addition to urine dribbling, occurs.uncontrolled urinAtion: urinAry incontinence definitionA number of disorders of micturition are associated with excessive outlet resistance (e.g., urethral calculi, neoplasia) during voiding.", [["detrusor", "ANATOMY", 38, 46], ["urine", "ANATOMY", 107, 112], ["urethral calculi", "ANATOMY", 278, 294], ["neoplasia", "ANATOMY", 296, 305], ["urine dribbling", "DISEASE", 107, 122], ["incontinence", "DISEASE", 163, 175], ["disorders of micturition", "DISEASE", 198, 222], ["urethral calculi", "DISEASE", 278, 294], ["neoplasia", "DISEASE", 296, 305], ["patients", "ORGANISM", 9, 17], ["dogs", "ORGANISM", 27, 31], ["detrusor", "MULTI-TISSUE_STRUCTURE", 38, 46], ["urine", "ORGANISM_SUBSTANCE", 107, 112], ["urethral calculi", "PATHOLOGICAL_FORMATION", 278, 294], ["neoplasia", "CANCER", 296, 305], ["patients", "SPECIES", 9, 17], ["dogs", "SPECIES", 27, 31], ["the detrusor reflex", "TEST", 34, 53], ["urine dribbling", "PROBLEM", 107, 122], ["uncontrolled urinAtion", "PROBLEM", 131, 153], ["urinAry incontinence", "PROBLEM", 155, 175], ["disorders of micturition", "PROBLEM", 198, 222], ["excessive outlet resistance", "PROBLEM", 243, 270], ["urethral calculi", "PROBLEM", 278, 294], ["neoplasia", "PROBLEM", 296, 305], ["detrusor", "ANATOMY", 38, 46], ["reflex", "OBSERVATION", 47, 53], ["normal", "OBSERVATION", 57, 63], ["urinAtion", "OBSERVATION", 144, 153], ["urinAry", "ANATOMY", 155, 162], ["incontinence", "OBSERVATION", 163, 175], ["excessive", "OBSERVATION_MODIFIER", 243, 252], ["outlet resistance", "OBSERVATION", 253, 270], ["urethral", "ANATOMY", 278, 286], ["calculi", "OBSERVATION", 287, 294], ["neoplasia", "OBSERVATION", 296, 305]]], ["Bladder overdistension and urine dribbling are frequently accompanied by dysuria and hematuria.AssociAted signsEvidence of urine or blood-tinged urine on the hair coat around the genitalia or on the patient's sleeping surface is frequently the first sign of a micturition disorder that owners recognize.", [["Bladder", "ANATOMY", 0, 7], ["urine", "ANATOMY", 27, 32], ["urine", "ANATOMY", 123, 128], ["blood", "ANATOMY", 132, 137], ["urine", "ANATOMY", 145, 150], ["hair coat", "ANATOMY", 158, 167], ["genitalia", "ANATOMY", 179, 188], ["Bladder overdistension", "DISEASE", 0, 22], ["urine dribbling", "DISEASE", 27, 42], ["dysuria", "DISEASE", 73, 80], ["hematuria", "DISEASE", 85, 94], ["micturition disorder", "DISEASE", 260, 280], ["Bladder", "ORGAN", 0, 7], ["urine", "ORGANISM_SUBSTANCE", 27, 32], ["urine", "ORGANISM_SUBSTANCE", 123, 128], ["blood", "ORGANISM_SUBSTANCE", 132, 137], ["urine", "ORGANISM_SUBSTANCE", 145, 150], ["hair coat", "MULTI-TISSUE_STRUCTURE", 158, 167], ["genitalia", "ORGAN", 179, 188], ["patient", "ORGANISM", 199, 206], ["patient", "SPECIES", 199, 206], ["Bladder overdistension", "PROBLEM", 0, 22], ["urine dribbling", "PROBLEM", 27, 42], ["dysuria", "PROBLEM", 73, 80], ["hematuria", "PROBLEM", 85, 94], ["urine or blood-tinged urine", "PROBLEM", 123, 150], ["a micturition disorder", "PROBLEM", 258, 280], ["overdistension", "OBSERVATION", 8, 22], ["urine dribbling", "OBSERVATION", 27, 42], ["dysuria", "OBSERVATION", 73, 80], ["hematuria", "OBSERVATION", 85, 94], ["urine", "OBSERVATION", 123, 128], ["tinged", "OBSERVATION_MODIFIER", 138, 144], ["urine", "OBSERVATION", 145, 150], ["genitalia", "ANATOMY", 179, 188]]], ["Patients with neurogenic urinary incontinence may show evidence of spinal cord disease with conscious proprioceptive deficits in the hindlimbs, foot drag, and abrasions on the dorsal aspect of the hindfeet.", [["neurogenic urinary", "ANATOMY", 14, 32], ["spinal cord", "ANATOMY", 67, 78], ["hindlimbs", "ANATOMY", 133, 142], ["foot", "ANATOMY", 144, 148], ["dorsal aspect", "ANATOMY", 176, 189], ["hindfeet", "ANATOMY", 197, 205], ["neurogenic urinary incontinence", "DISEASE", 14, 45], ["cord disease", "DISEASE", 74, 86], ["conscious proprioceptive deficits", "DISEASE", 92, 125], ["abrasions", "DISEASE", 159, 168], ["Patients", "ORGANISM", 0, 8], ["urinary", "ORGANISM_SUBDIVISION", 25, 32], ["spinal cord", "ORGAN", 67, 78], ["hindlimbs", "ORGANISM_SUBDIVISION", 133, 142], ["foot", "ORGANISM_SUBDIVISION", 144, 148], ["dorsal aspect", "MULTI-TISSUE_STRUCTURE", 176, 189], ["Patients", "SPECIES", 0, 8], ["neurogenic urinary incontinence", "PROBLEM", 14, 45], ["spinal cord disease", "PROBLEM", 67, 86], ["conscious proprioceptive deficits in the hindlimbs", "PROBLEM", 92, 142], ["foot drag", "TEST", 144, 153], ["abrasions", "PROBLEM", 159, 168], ["neurogenic", "ANATOMY_MODIFIER", 14, 24], ["urinary", "ANATOMY", 25, 32], ["incontinence", "OBSERVATION", 33, 45], ["may show evidence of", "UNCERTAINTY", 46, 66], ["spinal cord", "ANATOMY", 67, 78], ["disease", "OBSERVATION", 79, 86], ["conscious", "OBSERVATION_MODIFIER", 92, 101], ["proprioceptive deficits", "OBSERVATION", 102, 125], ["hindlimbs", "ANATOMY", 133, 142], ["foot", "ANATOMY", 144, 148], ["drag", "OBSERVATION_MODIFIER", 149, 153], ["abrasions", "OBSERVATION", 159, 168], ["dorsal", "ANATOMY_MODIFIER", 176, 182], ["hindfeet", "ANATOMY", 197, 205]]], ["However, lesions involving the cerebral cortex and cerebellum may also be associated with incontinence, as can behavioral disorders.AssociAted signsObvious straining to urinate, particularly if associated with an enlarged abdomen, may indicate obstructive disease.", [["lesions", "ANATOMY", 9, 16], ["cerebral cortex", "ANATOMY", 31, 46], ["cerebellum", "ANATOMY", 51, 61], ["abdomen", "ANATOMY", 222, 229], ["incontinence", "DISEASE", 90, 102], ["behavioral disorders", "DISEASE", 111, 131], ["obstructive disease", "DISEASE", 244, 263], ["lesions", "PATHOLOGICAL_FORMATION", 9, 16], ["cerebral cortex", "MULTI-TISSUE_STRUCTURE", 31, 46], ["cerebellum", "ORGAN", 51, 61], ["abdomen", "ORGAN", 222, 229], ["lesions involving the cerebral cortex and cerebellum", "PROBLEM", 9, 61], ["incontinence", "PROBLEM", 90, 102], ["behavioral disorders", "PROBLEM", 111, 131], ["AssociAted signsObvious straining to urinate", "PROBLEM", 132, 176], ["an enlarged abdomen", "PROBLEM", 210, 229], ["obstructive disease", "PROBLEM", 244, 263], ["lesions", "OBSERVATION", 9, 16], ["cerebral cortex", "ANATOMY", 31, 46], ["cerebellum", "ANATOMY", 51, 61], ["may also be", "UNCERTAINTY", 62, 73], ["incontinence", "OBSERVATION", 90, 102], ["straining", "OBSERVATION", 156, 165], ["enlarged", "OBSERVATION", 213, 221], ["abdomen", "ANATOMY", 222, 229], ["may indicate", "UNCERTAINTY", 231, 243], ["obstructive", "OBSERVATION_MODIFIER", 244, 255], ["disease", "OBSERVATION", 256, 263]]], ["Affected patients may be uremic, manifesting characteristic signs of lethargy, anorexia, and vomiting. differentiAl diAgnosis diAgnostic PlAns 1.", [["uremic", "DISEASE", 25, 31], ["lethargy", "DISEASE", 69, 77], ["anorexia", "DISEASE", 79, 87], ["vomiting", "DISEASE", 93, 101], ["patients", "ORGANISM", 9, 17], ["patients", "SPECIES", 9, 17], ["uremic", "PROBLEM", 25, 31], ["lethargy", "PROBLEM", 69, 77], ["anorexia", "PROBLEM", 79, 87], ["vomiting", "PROBLEM", 93, 101], ["may be", "UNCERTAINTY", 18, 24], ["uremic", "OBSERVATION", 25, 31], ["lethargy", "OBSERVATION", 69, 77], ["anorexia", "OBSERVATION", 79, 87]]], ["History and physical examination.", [["physical examination", "TEST", 12, 32]]], ["The size of the urinary bladder must also be determined.", [["urinary bladder", "ANATOMY", 16, 31], ["urinary bladder", "ORGAN", 16, 31], ["size", "OBSERVATION_MODIFIER", 4, 8], ["urinary bladder", "ANATOMY", 16, 31], ["must also be determined", "UNCERTAINTY", 32, 55]]], ["Neurologic examination.", [["Neurologic examination", "TEST", 0, 22]]], ["A thorough neurologic examination should be performed in an attempt to establish or rule out a neurogenic cause.", [["neurologic", "ANATOMY", 11, 21], ["A thorough neurologic examination", "TEST", 0, 33], ["a neurogenic cause", "PROBLEM", 93, 111], ["neurogenic", "OBSERVATION", 95, 105]]], ["Particular emphasis is given to the spinal cord and sacral nerve roots.", [["spinal cord", "ANATOMY", 36, 47], ["sacral nerve roots", "ANATOMY", 52, 70], ["spinal cord", "ORGAN", 36, 47], ["sacral nerve roots", "MULTI-TISSUE_STRUCTURE", 52, 70], ["spinal cord", "ANATOMY", 36, 47], ["sacral", "ANATOMY_MODIFIER", 52, 58], ["nerve roots", "ANATOMY", 59, 70]]], ["The bulbourethral and perineal reflexes should be assessed.", [["bulbourethral", "ANATOMY", 4, 17], ["perineal", "ANATOMY", 22, 30], ["bulbourethral", "MULTI-TISSUE_STRUCTURE", 4, 17], ["perineal", "ORGANISM_SUBDIVISION", 22, 30], ["The bulbourethral and perineal reflexes", "TEST", 0, 39], ["perineal reflexes", "ANATOMY", 22, 39]]], ["Catheterization of urinary bladder, to determine residual urine (normal < 0.2 to 0.4 mL/ kg in the dog and cat).", [["urinary bladder", "ANATOMY", 19, 34], ["urine", "ANATOMY", 58, 63], ["urinary bladder", "ORGAN", 19, 34], ["urine", "ORGANISM_SUBSTANCE", 58, 63], ["dog", "ORGANISM", 99, 102], ["cat", "ORGANISM", 107, 110], ["dog", "SPECIES", 99, 102], ["Catheterization", "TEST", 0, 15], ["residual urine", "PROBLEM", 49, 63], ["urinary bladder", "ANATOMY", 19, 34]]], ["Urine collected is submitted for urinalysis and, as indicated, for culture and sensitivity.", [["Urine", "ANATOMY", 0, 5], ["Urine", "ORGANISM_SUBSTANCE", 0, 5], ["Urine", "TEST", 0, 5], ["urinalysis", "TEST", 33, 43], ["culture", "TEST", 67, 74], ["sensitivity", "TEST", 79, 90]]], ["Laboratory database, to evaluate patient health status.", [["patient", "ORGANISM", 33, 40], ["patient", "SPECIES", 33, 40], ["Laboratory database", "TEST", 0, 19]]], ["Survey radiographs of the caudal abdomen and spinal cord.", [["caudal abdomen", "ANATOMY", 26, 40], ["spinal cord", "ANATOMY", 45, 56], ["caudal abdomen", "MULTI-TISSUE_STRUCTURE", 26, 40], ["spinal cord", "ORGAN", 45, 56], ["Survey radiographs of the caudal abdomen and spinal cord", "TEST", 0, 56], ["caudal", "ANATOMY_MODIFIER", 26, 32], ["abdomen", "ANATOMY", 33, 40], ["spinal cord", "ANATOMY", 45, 56]]], ["Contrast studies, as needed, including pneumocystogram (only in the absence of hematuria), contrast urethrogram, and excretory urogram (also called intravenous pyelogram).", [["intravenous", "ANATOMY", 148, 159], ["hematuria", "DISEASE", 79, 88], ["Contrast studies", "TEST", 0, 16], ["pneumocystogram", "TEST", 39, 54], ["hematuria", "PROBLEM", 79, 88], ["contrast urethrogram", "TEST", 91, 111], ["excretory urogram", "TEST", 117, 134], ["intravenous pyelogram", "TEST", 148, 169], ["hematuria", "OBSERVATION", 79, 88]]], ["Cystometrogram.", [["Cystometrogram", "TEST", 0, 14]]], ["Special equipment is required.vision loss: totAl blindness definitionBlindness is the inability to perceive visual stimuli.", [["vision loss", "DISEASE", 30, 41], ["blindness", "DISEASE", 49, 58], ["Blindness", "DISEASE", 69, 78], ["Special equipment", "TREATMENT", 0, 17], ["vision loss", "PROBLEM", 30, 41], ["totAl blindness definition", "PROBLEM", 43, 69], ["Blindness", "PROBLEM", 69, 78], ["visual stimuli", "TEST", 108, 122], ["totAl", "OBSERVATION_MODIFIER", 43, 48], ["blindness", "OBSERVATION", 49, 58]]], ["Because loss of visual function in animals is typically characterized by a change in behavior, the ability of pet owners to detect vision loss depends on their perception of changes in the animal's awareness of and interaction with its surroundings.", [["loss of visual function", "DISEASE", 8, 31], ["vision loss", "DISEASE", 131, 142], ["loss of visual function", "PROBLEM", 8, 31], ["a change in behavior", "PROBLEM", 73, 93], ["vision loss", "PROBLEM", 131, 142], ["visual function", "OBSERVATION", 16, 31]]], ["Vision loss is likely to be apparent to owners only when there is complete loss of vision.", [["Vision loss", "DISEASE", 0, 11], ["loss of vision", "DISEASE", 75, 89], ["Vision loss", "PROBLEM", 0, 11], ["complete loss of vision", "PROBLEM", 66, 89], ["likely to be", "UNCERTAINTY", 15, 27]]], ["An owner is unlikely to detect visual deficits, such as partial vision loss or unilateral blindness, because of the animal's ability to compensate.vision loss: totAl blindness definitionBlindness can occur in any of four ways: (1) lesions causing opacification of clear ocular media (e.g., cornea, aqueous humor, or lens); (2) failure of the retina to process visual images; (3) failure of neurologic transmission; and (4) failure in the final image processing (i.e., cortical blindness).", [["lesions", "ANATOMY", 231, 238], ["ocular", "ANATOMY", 270, 276], ["cornea", "ANATOMY", 290, 296], ["aqueous humor", "ANATOMY", 298, 311], ["lens", "ANATOMY", 316, 320], ["retina", "ANATOMY", 342, 348], ["neurologic", "ANATOMY", 390, 400], ["cortical", "ANATOMY", 468, 476], ["visual deficits", "DISEASE", 31, 46], ["partial vision loss", "DISEASE", 56, 75], ["blindness", "DISEASE", 90, 99], ["vision loss", "DISEASE", 147, 158], ["blindness", "DISEASE", 166, 175], ["Blindness", "DISEASE", 186, 195], ["cortical blindness", "DISEASE", 468, 486], ["lesions", "PATHOLOGICAL_FORMATION", 231, 238], ["cornea", "TISSUE", 290, 296], ["aqueous humor", "ORGANISM_SUBSTANCE", 298, 311], ["lens", "TISSUE", 316, 320], ["retina", "MULTI-TISSUE_STRUCTURE", 342, 348], ["cortical", "MULTI-TISSUE_STRUCTURE", 468, 476], ["visual deficits", "PROBLEM", 31, 46], ["partial vision loss", "PROBLEM", 56, 75], ["unilateral blindness", "PROBLEM", 79, 99], ["vision loss", "PROBLEM", 147, 158], ["totAl blindness definition", "PROBLEM", 160, 186], ["Blindness", "PROBLEM", 186, 195], ["lesions", "PROBLEM", 231, 238], ["opacification of clear ocular media (e.g., cornea, aqueous humor, or lens)", "PROBLEM", 247, 321], ["failure of the retina", "PROBLEM", 327, 348], ["visual images", "TEST", 360, 373], ["failure of neurologic transmission", "PROBLEM", 379, 413], ["failure", "PROBLEM", 423, 430], ["cortical blindness", "PROBLEM", 468, 486], ["unilateral", "OBSERVATION_MODIFIER", 79, 89], ["blindness", "OBSERVATION", 90, 99], ["totAl", "OBSERVATION_MODIFIER", 160, 165], ["blindness", "OBSERVATION", 166, 175], ["lesions", "OBSERVATION", 231, 238], ["opacification", "OBSERVATION", 247, 260], ["clear", "ANATOMY_MODIFIER", 264, 269], ["ocular media", "ANATOMY", 270, 282], ["cornea", "ANATOMY", 290, 296], ["lens", "ANATOMY", 316, 320], ["failure", "OBSERVATION", 327, 334], ["retina", "ANATOMY", 342, 348], ["failure", "OBSERVATION", 423, 430], ["cortical blindness", "OBSERVATION", 468, 486]]], ["When an animal is presented with acute visual loss, the owner is usually describing a bilateral ocular disease problem or the possibility of a CNS disorder.", [["ocular", "ANATOMY", 96, 102], ["CNS", "ANATOMY", 143, 146], ["acute visual loss", "DISEASE", 33, 50], ["ocular disease", "DISEASE", 96, 110], ["CNS disorder", "DISEASE", 143, 155], ["ocular", "ORGAN", 96, 102], ["CNS", "ANATOMICAL_SYSTEM", 143, 146], ["acute visual loss", "PROBLEM", 33, 50], ["a bilateral ocular disease problem", "PROBLEM", 84, 118], ["a CNS disorder", "PROBLEM", 141, 155], ["acute", "OBSERVATION_MODIFIER", 33, 38], ["visual loss", "OBSERVATION", 39, 50], ["bilateral", "ANATOMY_MODIFIER", 86, 95], ["ocular", "ANATOMY", 96, 102], ["disease", "OBSERVATION", 103, 110], ["CNS", "ANATOMY", 143, 146], ["disorder", "OBSERVATION", 147, 155]]], ["Acute unilateral visual loss problems are not often recognized except by the very astute animal owner or observer.", [["visual loss", "DISEASE", 17, 28], ["Acute unilateral visual loss problems", "PROBLEM", 0, 37], ["unilateral", "OBSERVATION_MODIFIER", 6, 16], ["visual loss", "OBSERVATION", 17, 28]]], ["For the veterinarian, initial assessment of the animal with acute visual loss depends initially on confirming that the ocular media are clear and allow light to pass from the anterior ocular segment and reach the photoreceptor cells (rods and cones) in the posterior ocular segment.", [["ocular", "ANATOMY", 119, 125], ["anterior ocular", "ANATOMY", 175, 190], ["photoreceptor cells", "ANATOMY", 213, 232], ["rods", "ANATOMY", 234, 238], ["cones", "ANATOMY", 243, 248], ["ocular", "ANATOMY", 267, 273], ["acute visual loss", "DISEASE", 60, 77], ["anterior ocular segment", "MULTI-TISSUE_STRUCTURE", 175, 198], ["photoreceptor cells", "CELL", 213, 232], ["rods", "MULTI-TISSUE_STRUCTURE", 234, 238], ["cones", "MULTI-TISSUE_STRUCTURE", 243, 248], ["posterior ocular segment", "MULTI-TISSUE_STRUCTURE", 257, 281], ["photoreceptor cells", "CELL_TYPE", 213, 232], ["initial assessment", "TEST", 22, 40], ["acute visual loss", "PROBLEM", 60, 77], ["acute", "OBSERVATION_MODIFIER", 60, 65], ["visual loss", "OBSERVATION", 66, 77], ["ocular media", "ANATOMY", 119, 131], ["clear", "OBSERVATION", 136, 141], ["anterior", "ANATOMY_MODIFIER", 175, 183], ["ocular segment", "ANATOMY", 184, 198], ["photoreceptor cells", "OBSERVATION", 213, 232], ["rods", "OBSERVATION_MODIFIER", 234, 238], ["posterior", "ANATOMY_MODIFIER", 257, 266], ["ocular", "ANATOMY", 267, 273], ["segment", "ANATOMY_MODIFIER", 274, 281]]], ["Transillumination should be used to evaluate the ocular media.", [["ocular", "ANATOMY", 49, 55], ["Transillumination", "TREATMENT", 0, 17], ["ocular media", "ANATOMY", 49, 61]]], ["Such conditions as acute bilateral uveitis, severe corneal edema, bilateral acute keratitis, rapidly developing metabolic cataracts, or acute cyclitis with vitreous involvement may alter the ocular media to interfere with light transmission.", [["corneal", "ANATOMY", 51, 58], ["vitreous", "ANATOMY", 156, 164], ["ocular", "ANATOMY", 191, 197], ["uveitis", "DISEASE", 35, 42], ["corneal edema", "DISEASE", 51, 64], ["keratitis", "DISEASE", 82, 91], ["metabolic cataracts", "DISEASE", 112, 131], ["cyclitis", "DISEASE", 142, 150], ["corneal edema", "PATHOLOGICAL_FORMATION", 51, 64], ["vitreous", "MULTI-TISSUE_STRUCTURE", 156, 164], ["Such conditions", "PROBLEM", 0, 15], ["acute bilateral uveitis", "PROBLEM", 19, 42], ["severe corneal edema", "PROBLEM", 44, 64], ["bilateral acute keratitis", "PROBLEM", 66, 91], ["metabolic cataracts", "PROBLEM", 112, 131], ["acute cyclitis", "PROBLEM", 136, 150], ["vitreous involvement", "PROBLEM", 156, 176], ["light transmission", "TEST", 222, 240], ["acute", "OBSERVATION_MODIFIER", 19, 24], ["bilateral", "ANATOMY_MODIFIER", 25, 34], ["uveitis", "OBSERVATION", 35, 42], ["severe", "OBSERVATION_MODIFIER", 44, 50], ["corneal", "ANATOMY", 51, 58], ["edema", "OBSERVATION", 59, 64], ["bilateral", "ANATOMY_MODIFIER", 66, 75], ["acute", "OBSERVATION_MODIFIER", 76, 81], ["keratitis", "OBSERVATION", 82, 91], ["rapidly", "OBSERVATION_MODIFIER", 93, 100], ["metabolic cataracts", "OBSERVATION", 112, 131], ["acute", "OBSERVATION_MODIFIER", 136, 141], ["cyclitis", "OBSERVATION", 142, 150], ["vitreous", "OBSERVATION", 156, 164]]], ["Both direct and indirect pupillary responses should be evaluated while evaluating the anterior ocular media.", [["anterior ocular", "ANATOMY", 86, 101], ["anterior ocular", "MULTI-TISSUE_STRUCTURE", 86, 101], ["anterior", "ANATOMY_MODIFIER", 86, 94], ["ocular media", "ANATOMY", 95, 107]]], ["Once it has been determined that light can reach the posterior ocular segment, a fundus evaluation should be done.", [["ocular", "ANATOMY", 63, 69], ["fundus", "ANATOMY", 81, 87], ["posterior ocular segment", "MULTI-TISSUE_STRUCTURE", 53, 77], ["fundus", "MULTI-TISSUE_STRUCTURE", 81, 87], ["a fundus evaluation", "TEST", 79, 98], ["posterior", "ANATOMY_MODIFIER", 53, 62], ["ocular segment", "ANATOMY", 63, 77]]], ["Fundic abnormalities associated with acute visual loss may include acute chorioretinitis, often with exudative retinal detachments; acute choroidal hemorrhages, often associated with abnormal blood pressure in chronic renal disease; and acute optic neuritis.", [["retinal", "ANATOMY", 111, 118], ["choroidal", "ANATOMY", 138, 147], ["blood", "ANATOMY", 192, 197], ["renal", "ANATOMY", 218, 223], ["Fundic abnormalities", "DISEASE", 0, 20], ["acute visual loss", "DISEASE", 37, 54], ["chorioretinitis", "DISEASE", 73, 88], ["retinal detachments", "DISEASE", 111, 130], ["choroidal hemorrhages", "DISEASE", 138, 159], ["abnormal blood pressure", "DISEASE", 183, 206], ["chronic renal disease", "DISEASE", 210, 231], ["optic neuritis", "DISEASE", 243, 257], ["retinal", "MULTI-TISSUE_STRUCTURE", 111, 118], ["choroidal", "MULTI-TISSUE_STRUCTURE", 138, 147], ["blood", "ORGANISM_SUBSTANCE", 192, 197], ["renal", "ORGAN", 218, 223], ["Fundic abnormalities", "PROBLEM", 0, 20], ["acute visual loss", "PROBLEM", 37, 54], ["acute chorioretinitis", "PROBLEM", 67, 88], ["exudative retinal detachments", "PROBLEM", 101, 130], ["acute choroidal hemorrhages", "PROBLEM", 132, 159], ["abnormal blood pressure", "PROBLEM", 183, 206], ["chronic renal disease", "PROBLEM", 210, 231], ["acute optic neuritis", "PROBLEM", 237, 257], ["abnormalities", "OBSERVATION", 7, 20], ["associated with", "UNCERTAINTY", 21, 36], ["acute", "OBSERVATION_MODIFIER", 37, 42], ["visual loss", "OBSERVATION", 43, 54], ["may include", "UNCERTAINTY", 55, 66], ["acute", "OBSERVATION_MODIFIER", 67, 72], ["chorioretinitis", "OBSERVATION", 73, 88], ["exudative", "OBSERVATION_MODIFIER", 101, 110], ["retinal", "ANATOMY", 111, 118], ["detachments", "OBSERVATION", 119, 130], ["acute", "OBSERVATION_MODIFIER", 132, 137], ["choroidal", "ANATOMY", 138, 147], ["hemorrhages", "OBSERVATION", 148, 159], ["abnormal", "OBSERVATION_MODIFIER", 183, 191], ["blood pressure", "OBSERVATION", 192, 206], ["chronic", "OBSERVATION_MODIFIER", 210, 217], ["renal", "ANATOMY", 218, 223], ["disease", "OBSERVATION", 224, 231], ["acute", "OBSERVATION_MODIFIER", 237, 242], ["optic neuritis", "OBSERVATION", 243, 257]]], ["Acute visual loss in the dog without accompanying fundic lesions that can be seen on ophthalmoscopic examination may be associated with a retrobulbar optic neuritis or with the syndrome of sudden acquired retinal degeneration syndrome (SARDS) in the dog.", [["fundic lesions", "ANATOMY", 50, 64], ["retinal", "ANATOMY", 205, 212], ["Acute visual loss", "DISEASE", 0, 17], ["retrobulbar optic neuritis", "DISEASE", 138, 164], ["retinal degeneration syndrome", "DISEASE", 205, 234], ["SARDS", "DISEASE", 236, 241], ["dog", "ORGANISM", 25, 28], ["fundic lesions", "PATHOLOGICAL_FORMATION", 50, 64], ["retinal", "MULTI-TISSUE_STRUCTURE", 205, 212], ["dog", "ORGANISM", 250, 253], ["dog", "SPECIES", 25, 28], ["dog", "SPECIES", 250, 253], ["Acute visual loss in the dog", "PROBLEM", 0, 28], ["accompanying fundic lesions", "PROBLEM", 37, 64], ["ophthalmoscopic examination", "TEST", 85, 112], ["a retrobulbar optic neuritis", "PROBLEM", 136, 164], ["the syndrome", "PROBLEM", 173, 185], ["sudden acquired retinal degeneration syndrome", "PROBLEM", 189, 234], ["visual loss", "OBSERVATION", 6, 17], ["fundic", "ANATOMY", 50, 56], ["lesions", "OBSERVATION", 57, 64], ["may be associated with", "UNCERTAINTY", 113, 135], ["retrobulbar optic", "ANATOMY", 138, 155], ["neuritis", "OBSERVATION", 156, 164], ["retinal", "ANATOMY", 205, 212], ["degeneration syndrome", "OBSERVATION", 213, 234]]], ["SARDS is poorly understood.", [["SARDS", "DISEASE", 0, 5]]], ["The syndrome appears to involve middle-aged to old female dogs, and there is a breed predilection for the dachshund.", [["dogs", "ORGANISM", 58, 62], ["dogs", "SPECIES", 58, 62], ["The syndrome", "PROBLEM", 0, 12], ["a breed predilection", "PROBLEM", 77, 97], ["the dachshund", "PROBLEM", 102, 115], ["syndrome", "OBSERVATION", 4, 12], ["appears to involve", "UNCERTAINTY", 13, 31], ["middle", "ANATOMY_MODIFIER", 32, 38], ["dogs", "OBSERVATION", 58, 62]]], ["The visual loss may first start as nyctalopia and progress over a period of weeks to complete visual loss.", [["visual loss", "DISEASE", 4, 15], ["nyctalopia", "DISEASE", 35, 45], ["visual loss", "DISEASE", 94, 105], ["The visual loss", "PROBLEM", 0, 15], ["complete visual loss", "PROBLEM", 85, 105], ["visual loss", "OBSERVATION", 4, 15], ["visual loss", "OBSERVATION", 94, 105]]], ["In some cases the visual loss is generalized and acute.", [["visual loss", "DISEASE", 18, 29], ["the visual loss", "PROBLEM", 14, 29], ["visual loss", "OBSERVATION", 18, 29], ["generalized", "OBSERVATION_MODIFIER", 33, 44], ["acute", "OBSERVATION_MODIFIER", 49, 54]]], ["Associated systemic signs of PD, PU, polyphagia, obesity, and hepatomegaly may be present.", [["PD", "DISEASE", 29, 31], ["PU", "DISEASE", 33, 35], ["polyphagia", "DISEASE", 37, 47], ["obesity", "DISEASE", 49, 56], ["hepatomegaly", "DISEASE", 62, 74], ["PD", "PROBLEM", 29, 31], ["PU", "PROBLEM", 33, 35], ["polyphagia", "PROBLEM", 37, 47], ["obesity", "PROBLEM", 49, 56], ["hepatomegaly", "PROBLEM", 62, 74], ["PD", "OBSERVATION", 29, 31], ["PU", "OBSERVATION_MODIFIER", 33, 35], ["polyphagia", "OBSERVATION", 37, 47], ["obesity", "OBSERVATION", 49, 56], ["hepatomegaly", "OBSERVATION", 62, 74], ["may be", "UNCERTAINTY", 75, 81]]], ["Laboratory profiles may show abnormal differentials in the WBC count, elevated liver enzymes, an abnormal response to ACTH stimulation testing, or an abnormal response to low-dose dexamethasone suppression testing.", [["WBC", "ANATOMY", 59, 62], ["liver", "ANATOMY", 79, 84], ["dexamethasone", "CHEMICAL", 180, 193], ["dexamethasone", "CHEMICAL", 180, 193], ["WBC", "CELL", 59, 62], ["liver", "ORGAN", 79, 84], ["ACTH", "GENE_OR_GENE_PRODUCT", 118, 122], ["dexamethasone", "SIMPLE_CHEMICAL", 180, 193], ["liver enzymes", "PROTEIN", 79, 92], ["Laboratory profiles", "TEST", 0, 19], ["abnormal differentials", "PROBLEM", 29, 51], ["the WBC count", "TEST", 55, 68], ["elevated liver enzymes", "PROBLEM", 70, 92], ["an abnormal response", "PROBLEM", 94, 114], ["ACTH stimulation testing", "TEST", 118, 142], ["an abnormal response", "PROBLEM", 147, 167], ["low-dose dexamethasone suppression testing", "TREATMENT", 171, 213], ["abnormal", "OBSERVATION_MODIFIER", 29, 37], ["differentials", "OBSERVATION_MODIFIER", 38, 51], ["liver", "ANATOMY", 79, 84]]], ["The fundus may appear absolutely normal, or early signs of retinal thinning and atrophy may be evident.", [["fundus", "ANATOMY", 4, 10], ["retinal", "ANATOMY", 59, 66], ["retinal thinning", "DISEASE", 59, 75], ["atrophy", "DISEASE", 80, 87], ["fundus", "MULTI-TISSUE_STRUCTURE", 4, 10], ["retinal", "MULTI-TISSUE_STRUCTURE", 59, 66], ["retinal thinning", "PROBLEM", 59, 75], ["atrophy", "PROBLEM", 80, 87], ["fundus", "ANATOMY", 4, 10], ["may appear", "UNCERTAINTY", 11, 21], ["absolutely", "OBSERVATION_MODIFIER", 22, 32], ["normal", "OBSERVATION", 33, 39], ["early", "OBSERVATION_MODIFIER", 44, 49], ["signs", "OBSERVATION_MODIFIER", 50, 55], ["retinal", "ANATOMY", 59, 66], ["thinning", "OBSERVATION", 67, 75], ["atrophy", "OBSERVATION", 80, 87], ["may be evident", "UNCERTAINTY", 88, 102]]], ["Differential diagnosis with optic neuritis is based on electroretinographic (ERG) testing; the ERG response is flat in SARDS but is normal in optic neuritis.", [["optic neuritis", "DISEASE", 28, 42], ["optic neuritis", "DISEASE", 142, 156], ["SARDS", "CANCER", 119, 124], ["optic neuritis", "PROBLEM", 28, 42], ["electroretinographic (ERG) testing", "TEST", 55, 89], ["the ERG response", "TEST", 91, 107], ["flat in SARDS", "PROBLEM", 111, 124], ["optic neuritis", "PROBLEM", 142, 156], ["optic neuritis", "OBSERVATION", 28, 42], ["flat", "OBSERVATION_MODIFIER", 111, 115], ["normal", "OBSERVATION", 132, 138], ["optic neuritis", "OBSERVATION", 142, 156]]], ["The cause of SARDS is unknown.vision loss: totAl blindness definitionAcute visual loss associated with tumors of the CNS, particularly CNS tumors that involve the optic chiasm, are infrequently reported in the dog.", [["tumors", "ANATOMY", 103, 109], ["CNS", "ANATOMY", 117, 120], ["CNS tumors", "ANATOMY", 135, 145], ["optic chiasm", "ANATOMY", 163, 175], ["SARDS", "DISEASE", 13, 18], ["vision loss", "DISEASE", 30, 41], ["blindness", "DISEASE", 49, 58], ["Acute visual loss", "DISEASE", 69, 86], ["tumors of the CNS", "DISEASE", 103, 120], ["tumors", "DISEASE", 139, 145], ["optic chiasm", "DISEASE", 163, 175], ["SARDS", "CANCER", 13, 18], ["tumors", "CANCER", 103, 109], ["CNS", "ANATOMICAL_SYSTEM", 117, 120], ["CNS tumors", "CANCER", 135, 145], ["optic chiasm", "MULTI-TISSUE_STRUCTURE", 163, 175], ["dog", "ORGANISM", 210, 213], ["dog", "SPECIES", 210, 213], ["SARDS", "PROBLEM", 13, 18], ["vision loss", "PROBLEM", 30, 41], ["totAl blindness definition", "PROBLEM", 43, 69], ["Acute visual loss", "PROBLEM", 69, 86], ["tumors of the CNS", "PROBLEM", 103, 120], ["CNS tumors", "PROBLEM", 135, 145], ["totAl", "OBSERVATION_MODIFIER", 43, 48], ["blindness", "OBSERVATION", 49, 58], ["Acute", "OBSERVATION_MODIFIER", 69, 74], ["visual loss", "OBSERVATION", 75, 86], ["tumors", "OBSERVATION", 103, 109], ["CNS", "ANATOMY", 117, 120], ["CNS", "ANATOMY", 135, 138], ["tumors", "OBSERVATION", 139, 145], ["optic chiasm", "ANATOMY", 163, 175]]], ["Pituitary tumors are most likely to be the source.", [["Pituitary tumors", "ANATOMY", 0, 16], ["Pituitary tumors", "DISEASE", 0, 16], ["Pituitary tumors", "CANCER", 0, 16], ["Pituitary tumors", "PROBLEM", 0, 16], ["tumors", "OBSERVATION", 10, 16], ["most likely", "UNCERTAINTY", 21, 32]]], ["Pituitary tumors must become macroadenomas before invading and involving midbrain structures and the optic chiasm region.", [["Pituitary tumors", "ANATOMY", 0, 16], ["midbrain structures", "ANATOMY", 73, 92], ["optic chiasm region", "ANATOMY", 101, 120], ["Pituitary tumors", "DISEASE", 0, 16], ["macroadenomas", "DISEASE", 29, 42], ["Pituitary tumors", "CANCER", 0, 16], ["macroadenomas", "CANCER", 29, 42], ["midbrain structures", "TISSUE", 73, 92], ["optic chiasm", "MULTI-TISSUE_STRUCTURE", 101, 113], ["Pituitary tumors", "PROBLEM", 0, 16], ["macroadenomas", "PROBLEM", 29, 42], ["tumors", "OBSERVATION", 10, 16], ["macroadenomas", "OBSERVATION", 29, 42], ["midbrain", "ANATOMY_MODIFIER", 73, 81], ["optic chiasm", "ANATOMY", 101, 113], ["region", "ANATOMY_MODIFIER", 114, 120]]], ["It is not uncommon for macroadenomas to be nonfunctional; thus the affected animal may not develop any clinical metabolic abnormalities.", [["macroadenomas", "DISEASE", 23, 36], ["metabolic abnormalities", "DISEASE", 112, 135], ["macroadenomas", "CANCER", 23, 36], ["macroadenomas", "PROBLEM", 23, 36], ["any clinical metabolic abnormalities", "PROBLEM", 99, 135], ["not uncommon for", "UNCERTAINTY", 6, 22], ["macroadenomas", "OBSERVATION", 23, 36], ["nonfunctional", "OBSERVATION", 43, 56]]], ["Papilledema is rarely observed with brain tumors in dogs.", [["brain tumors", "ANATOMY", 36, 48], ["Papilledema", "DISEASE", 0, 11], ["brain tumors", "DISEASE", 36, 48], ["brain tumors", "CANCER", 36, 48], ["dogs", "ORGANISM", 52, 56], ["dogs", "SPECIES", 52, 56], ["Papilledema", "PROBLEM", 0, 11], ["brain tumors in dogs", "PROBLEM", 36, 56], ["rarely observed", "UNCERTAINTY", 15, 30], ["brain", "ANATOMY", 36, 41], ["tumors", "OBSERVATION", 42, 48]]], ["Although pituitary macroadenomas that produce chiasmal compression and visual loss are rare in dogs, the differential diagnosis must still be considered.vision loss: totAl blindness definitionThe availability of CT has provided the ability to diagnose tumors of the hypophysis that may be associated with acute visual loss.", [["pituitary macroadenomas", "ANATOMY", 9, 32], ["chiasmal", "ANATOMY", 46, 54], ["tumors", "ANATOMY", 252, 258], ["hypophysis", "ANATOMY", 266, 276], ["pituitary macroadenomas", "DISEASE", 9, 32], ["chiasmal compression", "DISEASE", 46, 66], ["visual loss", "DISEASE", 71, 82], ["vision loss", "DISEASE", 153, 164], ["blindness", "DISEASE", 172, 181], ["tumors of the hypophysis", "DISEASE", 252, 276], ["acute visual loss", "DISEASE", 305, 322], ["pituitary macroadenomas", "CANCER", 9, 32], ["dogs", "ORGANISM", 95, 99], ["tumors", "CANCER", 252, 258], ["hypophysis", "ORGAN", 266, 276], ["dogs", "SPECIES", 95, 99], ["pituitary macroadenomas", "PROBLEM", 9, 32], ["chiasmal compression", "PROBLEM", 46, 66], ["visual loss", "PROBLEM", 71, 82], ["vision loss", "PROBLEM", 153, 164], ["totAl blindness definition", "PROBLEM", 166, 192], ["CT", "TEST", 212, 214], ["diagnose tumors of the hypophysis", "PROBLEM", 243, 276], ["acute visual loss", "PROBLEM", 305, 322], ["pituitary", "ANATOMY", 9, 18], ["macroadenomas", "OBSERVATION", 19, 32], ["chiasmal compression", "OBSERVATION", 46, 66], ["visual loss", "OBSERVATION", 71, 82], ["totAl", "OBSERVATION_MODIFIER", 166, 171], ["blindness", "OBSERVATION", 172, 181], ["hypophysis", "ANATOMY", 266, 276], ["may be associated with", "UNCERTAINTY", 282, 304], ["acute", "OBSERVATION_MODIFIER", 305, 310], ["visual loss", "OBSERVATION", 311, 322]]], ["In addition, the use of the same technique has made visualization of the adrenal glands and the ability to diagnose bilateral adrenal gland hyperplasia easier.", [["adrenal glands", "ANATOMY", 73, 87], ["adrenal gland", "ANATOMY", 126, 139], ["adrenal gland hyperplasia", "DISEASE", 126, 151], ["adrenal glands", "ORGAN", 73, 87], ["adrenal gland", "MULTI-TISSUE_STRUCTURE", 126, 139], ["bilateral adrenal gland hyperplasia", "PROBLEM", 116, 151], ["adrenal glands", "ANATOMY", 73, 87], ["bilateral", "ANATOMY_MODIFIER", 116, 125], ["adrenal gland", "ANATOMY", 126, 139], ["hyperplasia", "OBSERVATION", 140, 151]]], ["Pituitary macroadenomas are larger than 1 cm in diameter.vision loss: totAl blindness definitionOptic neuritis may manifest as an acute visual loss problem.", [["Pituitary macroadenomas", "ANATOMY", 0, 23], ["Pituitary macroadenomas", "DISEASE", 0, 23], ["vision loss", "DISEASE", 57, 68], ["blindness", "DISEASE", 76, 85], ["neuritis", "DISEASE", 102, 110], ["acute visual loss", "DISEASE", 130, 147], ["Pituitary macroadenomas", "CANCER", 0, 23], ["Pituitary macroadenomas", "PROBLEM", 0, 23], ["vision loss", "PROBLEM", 57, 68], ["totAl blindness definitionOptic neuritis", "PROBLEM", 70, 110], ["an acute visual loss problem", "PROBLEM", 127, 155], ["macroadenomas", "OBSERVATION", 10, 23], ["larger", "OBSERVATION_MODIFIER", 28, 34], ["than 1 cm", "OBSERVATION_MODIFIER", 35, 44], ["diameter", "OBSERVATION_MODIFIER", 48, 56], ["totAl", "OBSERVATION_MODIFIER", 70, 75], ["blindness", "OBSERVATION", 76, 85], ["acute", "OBSERVATION_MODIFIER", 130, 135], ["visual loss", "OBSERVATION", 136, 147]]], ["There may or may not be observable ophthalmoscopic changes of the optic nerve.", [["optic nerve", "ANATOMY", 66, 77], ["optic nerve", "MULTI-TISSUE_STRUCTURE", 66, 77], ["observable ophthalmoscopic changes of the optic nerve", "PROBLEM", 24, 77], ["may not be", "UNCERTAINTY", 13, 23], ["optic nerve", "ANATOMY", 66, 77]]], ["Ophthalmoscopic abnormalities are characterized by edema of the disk, hemorrhages in and around the disk, edema, and inflammation of the surrounding retinal tissue.", [["disk", "ANATOMY", 64, 68], ["edema", "ANATOMY", 106, 111], ["retinal tissue", "ANATOMY", 149, 163], ["Ophthalmoscopic abnormalities", "DISEASE", 0, 29], ["edema of the disk", "DISEASE", 51, 68], ["hemorrhages", "DISEASE", 70, 81], ["edema", "DISEASE", 106, 111], ["inflammation", "DISEASE", 117, 129], ["edema", "PATHOLOGICAL_FORMATION", 51, 56], ["edema", "PATHOLOGICAL_FORMATION", 106, 111], ["retinal tissue", "TISSUE", 149, 163], ["Ophthalmoscopic abnormalities", "PROBLEM", 0, 29], ["edema of the disk", "PROBLEM", 51, 68], ["hemorrhages", "PROBLEM", 70, 81], ["the disk", "PROBLEM", 96, 104], ["edema", "PROBLEM", 106, 111], ["inflammation of the surrounding retinal tissue", "PROBLEM", 117, 163], ["edema", "OBSERVATION", 51, 56], ["disk", "ANATOMY", 64, 68], ["hemorrhages", "OBSERVATION", 70, 81], ["disk", "ANATOMY", 100, 104], ["edema", "OBSERVATION", 106, 111], ["inflammation", "OBSERVATION", 117, 129], ["surrounding", "ANATOMY_MODIFIER", 137, 148], ["retinal tissue", "ANATOMY", 149, 163]]], ["Acute optic neuritis often persists as a retrobulbar lesion without any ophthalmoscopically observable lesions.", [["retrobulbar lesion", "ANATOMY", 41, 59], ["lesions", "ANATOMY", 103, 110], ["optic neuritis", "DISEASE", 6, 20], ["retrobulbar lesion", "DISEASE", 41, 59], ["retrobulbar lesion", "PATHOLOGICAL_FORMATION", 41, 59], ["lesions", "CANCER", 103, 110], ["Acute optic neuritis", "PROBLEM", 0, 20], ["a retrobulbar lesion", "PROBLEM", 39, 59], ["any ophthalmoscopically observable lesions", "PROBLEM", 68, 110], ["optic", "OBSERVATION_MODIFIER", 6, 11], ["neuritis", "OBSERVATION", 12, 20], ["retrobulbar", "ANATOMY", 41, 52], ["lesion", "OBSERVATION", 53, 59], ["lesions", "OBSERVATION", 103, 110]]], ["Pupils are widely dilated and nonresponsive or poorly responsive to light.", [["widely dilated", "PROBLEM", 11, 25], ["nonresponsive", "PROBLEM", 30, 43], ["widely", "OBSERVATION_MODIFIER", 11, 17], ["dilated", "OBSERVATION", 18, 25], ["nonresponsive", "OBSERVATION_MODIFIER", 30, 43]]], ["In suspected acute optic neuritis, a complete physical examination, including a neurologic evaluation, peripheral blood count, and CSF analysis, should be performed, if possible.", [["neurologic", "ANATOMY", 80, 90], ["peripheral blood", "ANATOMY", 103, 119], ["optic neuritis", "DISEASE", 19, 33], ["blood", "ORGANISM_SUBSTANCE", 114, 119], ["acute optic neuritis", "PROBLEM", 13, 33], ["a complete physical examination", "TEST", 35, 66], ["a neurologic evaluation", "TEST", 78, 101], ["peripheral blood count", "TEST", 103, 125], ["CSF analysis", "TEST", 131, 143], ["suspected", "UNCERTAINTY", 3, 12], ["acute", "OBSERVATION_MODIFIER", 13, 18], ["optic neuritis", "OBSERVATION", 19, 33]]], ["The presence of pleocytosis and increased protein content in the CSF is of significance.", [["pleocytosis", "DISEASE", 16, 27], ["CSF", "GENE_OR_GENE_PRODUCT", 65, 68], ["CSF", "PROTEIN", 65, 68], ["pleocytosis", "PROBLEM", 16, 27], ["increased protein content in the CSF", "PROBLEM", 32, 68], ["pleocytosis", "OBSERVATION", 16, 27], ["increased", "OBSERVATION_MODIFIER", 32, 41], ["protein content", "OBSERVATION", 42, 57]]], ["It may be difficult to specifically diagnose the cause of acute optic neuritis.definitionVomiting is forceful ejection of food or fluid through the mouth from the stomach and occasionally the proximal duodenum.", [["fluid", "ANATOMY", 130, 135], ["mouth", "ANATOMY", 148, 153], ["stomach", "ANATOMY", 163, 170], ["proximal duodenum", "ANATOMY", 192, 209], ["optic neuritis", "DISEASE", 64, 78], ["mouth", "ORGANISM_SUBDIVISION", 148, 153], ["stomach", "ORGAN", 163, 170], ["duodenum", "ORGAN", 201, 209], ["acute optic neuritis", "PROBLEM", 58, 78], ["acute", "OBSERVATION_MODIFIER", 58, 63], ["optic neuritis", "OBSERVATION", 64, 78], ["forceful", "OBSERVATION_MODIFIER", 101, 109], ["ejection", "OBSERVATION", 110, 118], ["fluid", "OBSERVATION", 130, 135], ["mouth", "ANATOMY", 148, 153], ["stomach", "ANATOMY", 163, 170], ["proximal", "ANATOMY_MODIFIER", 192, 200], ["duodenum", "ANATOMY", 201, 209]]], ["The term applies to those animals with overt evidence of effort associated with the expulsion of food and is characterized by vigorous abdominal pressing, arched back, gagging or retching, and hypersalivation.", [["abdominal", "ANATOMY", 135, 144], ["retching", "DISEASE", 179, 187], ["hypersalivation", "DISEASE", 193, 208], ["abdominal", "ORGANISM_SUBDIVISION", 135, 144], ["the expulsion of food", "PROBLEM", 80, 101], ["vigorous abdominal pressing", "PROBLEM", 126, 153], ["arched back", "PROBLEM", 155, 166], ["gagging", "PROBLEM", 168, 175], ["retching", "PROBLEM", 179, 187], ["hypersalivation", "PROBLEM", 193, 208], ["vigorous", "OBSERVATION_MODIFIER", 126, 134], ["abdominal", "ANATOMY", 135, 144], ["pressing", "OBSERVATION", 145, 153], ["retching", "OBSERVATION", 179, 187]]], ["Projectile vomiting is the term used to describe the violent ejection of stomach contents without nausea or retching.", [["stomach", "ANATOMY", 73, 80], ["vomiting", "DISEASE", 11, 19], ["nausea", "DISEASE", 98, 104], ["retching", "DISEASE", 108, 116], ["stomach", "ORGAN", 73, 80], ["Projectile vomiting", "PROBLEM", 0, 19], ["nausea", "PROBLEM", 98, 104], ["retching", "PROBLEM", 108, 116], ["stomach", "ANATOMY", 73, 80], ["retching", "OBSERVATION", 108, 116]]], ["Regurgitation, on the other hand, denotes expulsion of food or fluid from the esophagus and is a considerably more passive act than vomiting.definitionVomiting is a complex reflex that entails coordination of the GI tract, musculoskeletal system, and nervous system.", [["fluid", "ANATOMY", 63, 68], ["esophagus", "ANATOMY", 78, 87], ["GI tract", "ANATOMY", 213, 221], ["musculoskeletal system", "ANATOMY", 223, 245], ["nervous system", "ANATOMY", 251, 265], ["Regurgitation", "DISEASE", 0, 13], ["vomiting", "DISEASE", 132, 140], ["fluid", "ORGANISM_SUBSTANCE", 63, 68], ["esophagus", "ORGAN", 78, 87], ["GI tract", "ORGANISM_SUBDIVISION", 213, 221], ["musculoskeletal", "ANATOMICAL_SYSTEM", 223, 238], ["system", "ANATOMICAL_SYSTEM", 239, 245], ["nervous system", "ANATOMICAL_SYSTEM", 251, 265], ["Regurgitation", "PROBLEM", 0, 13], ["expulsion of food", "PROBLEM", 42, 59], ["fluid from the esophagus", "PROBLEM", 63, 87], ["vomiting", "PROBLEM", 132, 140], ["a complex reflex", "PROBLEM", 163, 179], ["expulsion", "OBSERVATION", 42, 51], ["fluid", "OBSERVATION", 63, 68], ["esophagus", "ANATOMY", 78, 87], ["GI tract", "ANATOMY", 213, 221], ["musculoskeletal system", "ANATOMY", 223, 245], ["nervous system", "ANATOMY", 251, 265]]], ["Although the CNS vomiting center initiates vomiting, it must first be stimulated.", [["CNS", "ANATOMY", 13, 16], ["vomiting", "DISEASE", 17, 25], ["vomiting", "DISEASE", 43, 51], ["CNS", "ANATOMICAL_SYSTEM", 13, 16], ["the CNS vomiting", "PROBLEM", 9, 25], ["vomiting", "PROBLEM", 43, 51], ["CNS", "ANATOMY", 13, 16]]], ["Even when vomiting is drug induced, stimulation of the vomiting center is accomplished subsequent to stimulation of a medullary chemoreceptor trigger zone that forwards impulses to the vomiting center.", [["medullary chemoreceptor", "ANATOMY", 118, 141], ["vomiting", "DISEASE", 10, 18], ["vomiting", "DISEASE", 55, 63], ["vomiting", "DISEASE", 185, 193], ["medullary", "ORGAN", 118, 127], ["vomiting", "PROBLEM", 10, 18], ["the vomiting", "PROBLEM", 51, 63], ["a medullary chemoreceptor trigger zone", "PROBLEM", 116, 154]]], ["Many sensory nerves can mediate emetic impulses.", [["sensory nerves", "ANATOMY", 5, 19], ["sensory nerves", "MULTI-TISSUE_STRUCTURE", 5, 19], ["sensory nerves", "ANATOMY", 5, 19]]], ["Therefore, intense pain (especially abdominal); nervous (psychogenic) stimuli; disagreeable odors, tastes, and smells; sensations from the labyrinth and pharyngeal areas; various toxins and drugs; and presumably the retention of metabolic waste products all may lead to vomiting.", [["abdominal", "ANATOMY", 36, 45], ["nervous", "ANATOMY", 48, 55], ["labyrinth", "ANATOMY", 139, 148], ["pharyngeal areas", "ANATOMY", 153, 169], ["pain", "DISEASE", 19, 23], ["vomiting", "DISEASE", 270, 278], ["abdominal", "ORGANISM_SUBDIVISION", 36, 45], ["nervous", "ANATOMICAL_SYSTEM", 48, 55], ["labyrinth", "ORGANISM_SUBDIVISION", 139, 148], ["pharyngeal", "ORGANISM_SUBDIVISION", 153, 163], ["intense pain (especially abdominal)", "PROBLEM", 11, 46], ["nervous (psychogenic) stimuli", "PROBLEM", 48, 77], ["disagreeable odors", "PROBLEM", 79, 97], ["smells", "PROBLEM", 111, 117], ["sensations from the labyrinth and pharyngeal areas", "PROBLEM", 119, 169], ["various toxins", "TREATMENT", 171, 185], ["drugs", "TREATMENT", 190, 195], ["metabolic waste products", "TREATMENT", 229, 253], ["vomiting", "PROBLEM", 270, 278], ["intense", "OBSERVATION_MODIFIER", 11, 18], ["pain", "OBSERVATION", 19, 23], ["abdominal", "ANATOMY", 36, 45], ["labyrinth", "ANATOMY", 139, 148], ["pharyngeal", "ANATOMY", 153, 163], ["metabolic waste", "OBSERVATION", 229, 244]]], ["Numerous receptors for vomiting are located in the abdominal viscera, especially the duodenum.", [["abdominal viscera", "ANATOMY", 51, 68], ["duodenum", "ANATOMY", 85, 93], ["vomiting", "DISEASE", 23, 31], ["abdominal viscera", "ORGAN", 51, 68], ["duodenum", "ORGAN", 85, 93], ["vomiting", "PROBLEM", 23, 31], ["vomiting", "OBSERVATION", 23, 31], ["abdominal viscera", "ANATOMY", 51, 68], ["duodenum", "ANATOMY", 85, 93]]], ["Afferent nerve fibers are found in the vagal and sympathetic nerves.definitionVomiting can be quite debilitating.", [["Afferent nerve fibers", "ANATOMY", 0, 21], ["vagal", "ANATOMY", 39, 44], ["sympathetic nerves", "ANATOMY", 49, 67], ["nerve fibers", "MULTI-TISSUE_STRUCTURE", 9, 21], ["vagal", "MULTI-TISSUE_STRUCTURE", 39, 44], ["sympathetic nerves", "MULTI-TISSUE_STRUCTURE", 49, 67], ["Afferent nerve fibers", "PROBLEM", 0, 21], ["quite debilitating", "PROBLEM", 94, 112], ["nerve fibers", "OBSERVATION", 9, 21], ["vagal", "ANATOMY", 39, 44], ["sympathetic nerves", "ANATOMY", 49, 67]]], ["When excessive, it causes severe extracellular fluid deficits, particularly of sodium, potassium, and chloride ions and water.", [["extracellular fluid", "ANATOMY", 33, 52], ["extracellular fluid deficits", "DISEASE", 33, 61], ["sodium", "CHEMICAL", 79, 85], ["potassium", "CHEMICAL", 87, 96], ["chloride ions", "CHEMICAL", 102, 115], ["sodium", "CHEMICAL", 79, 85], ["potassium", "CHEMICAL", 87, 96], ["chloride", "CHEMICAL", 102, 110], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 33, 46], ["fluid", "IMMATERIAL_ANATOMICAL_ENTITY", 47, 52], ["sodium", "SIMPLE_CHEMICAL", 79, 85], ["potassium", "SIMPLE_CHEMICAL", 87, 96], ["chloride ions", "SIMPLE_CHEMICAL", 102, 115], ["water", "SIMPLE_CHEMICAL", 120, 125], ["severe extracellular fluid deficits", "PROBLEM", 26, 61], ["sodium", "TEST", 79, 85], ["potassium", "TREATMENT", 87, 96], ["chloride ions", "TREATMENT", 102, 115], ["severe", "OBSERVATION_MODIFIER", 26, 32], ["extracellular", "OBSERVATION_MODIFIER", 33, 46], ["fluid deficits", "OBSERVATION", 47, 61]]], ["Loss of mainly gastric contents results in loss of hydrogen ions, a high serum bicarbonate concentration, and metabolic alkalosis.", [["gastric", "ANATOMY", 15, 22], ["serum", "ANATOMY", 73, 78], ["hydrogen ions", "CHEMICAL", 51, 64], ["bicarbonate", "CHEMICAL", 79, 90], ["metabolic alkalosis", "DISEASE", 110, 129], ["hydrogen", "CHEMICAL", 51, 59], ["bicarbonate", "CHEMICAL", 79, 90], ["gastric", "ORGAN", 15, 22], ["hydrogen ions", "SIMPLE_CHEMICAL", 51, 64], ["serum", "ORGANISM_SUBSTANCE", 73, 78], ["bicarbonate", "SIMPLE_CHEMICAL", 79, 90], ["Loss of mainly gastric contents", "PROBLEM", 0, 31], ["loss of hydrogen ions", "PROBLEM", 43, 64], ["a high serum bicarbonate concentration", "PROBLEM", 66, 104], ["metabolic alkalosis", "PROBLEM", 110, 129], ["mainly", "OBSERVATION_MODIFIER", 8, 14], ["gastric", "ANATOMY", 15, 22], ["contents", "OBSERVATION", 23, 31], ["loss", "OBSERVATION_MODIFIER", 43, 47], ["hydrogen ions", "OBSERVATION", 51, 64], ["metabolic alkalosis", "OBSERVATION", 110, 129]]], ["Vomited material from the proximal intestinal tract contains high concentrations of bicarbonate.definitionClinically, vomiting should be addressed as a problem that originates from the GI tract (primary causes) or from causes outside the GI tract (i.e., metabolic causes [secondary]).AssociAted signsDepending on the underlying cause, vomiting may be associated with a number of significant clinical signs.", [["proximal intestinal tract", "ANATOMY", 26, 51], ["GI tract", "ANATOMY", 185, 193], ["GI tract", "ANATOMY", 238, 246], ["bicarbonate", "CHEMICAL", 84, 95], ["vomiting", "DISEASE", 118, 126], ["vomiting", "DISEASE", 335, 343], ["bicarbonate", "CHEMICAL", 84, 95], ["intestinal tract", "ORGANISM_SUBDIVISION", 35, 51], ["bicarbonate", "SIMPLE_CHEMICAL", 84, 95], ["GI tract", "ORGANISM_SUBDIVISION", 185, 193], ["GI tract", "ORGANISM_SUBDIVISION", 238, 246], ["Vomited material from the proximal intestinal tract", "PROBLEM", 0, 51], ["high concentrations of bicarbonate", "TREATMENT", 61, 95], ["vomiting", "PROBLEM", 118, 126], ["the GI tract", "PROBLEM", 181, 193], ["vomiting", "PROBLEM", 335, 343], ["significant clinical signs", "PROBLEM", 379, 405], ["proximal", "ANATOMY_MODIFIER", 26, 34], ["intestinal tract", "ANATOMY", 35, 51], ["high concentrations", "OBSERVATION", 61, 80], ["GI tract", "ANATOMY", 185, 193], ["GI tract", "ANATOMY", 238, 246], ["significant", "OBSERVATION_MODIFIER", 379, 390]]], ["Primary causes of vomiting are generally associated with other GI signs, such as diarrhea, abdominal pain, obvious foreign bodies (e.g., a linear foreign body entrapped proximally under the tongue), ingestion of known irritant materials or drugs, hematochezia, or palpable abdominal tumors.", [["GI", "ANATOMY", 63, 65], ["abdominal", "ANATOMY", 91, 100], ["body", "ANATOMY", 154, 158], ["tongue", "ANATOMY", 190, 196], ["palpable abdominal tumors", "ANATOMY", 264, 289], ["vomiting", "DISEASE", 18, 26], ["diarrhea", "DISEASE", 81, 89], ["abdominal pain", "DISEASE", 91, 105], ["hematochezia", "DISEASE", 247, 259], ["abdominal tumors", "DISEASE", 273, 289], ["abdominal", "ORGANISM_SUBDIVISION", 91, 100], ["tongue", "ORGAN", 190, 196], ["palpable abdominal tumors", "CANCER", 264, 289], ["vomiting", "PROBLEM", 18, 26], ["other GI signs", "PROBLEM", 57, 71], ["diarrhea", "PROBLEM", 81, 89], ["abdominal pain", "PROBLEM", 91, 105], ["obvious foreign bodies", "PROBLEM", 107, 129], ["a linear foreign body", "PROBLEM", 137, 158], ["known irritant materials", "PROBLEM", 212, 236], ["hematochezia", "PROBLEM", 247, 259], ["palpable abdominal tumors", "PROBLEM", 264, 289], ["vomiting", "OBSERVATION", 18, 26], ["abdominal", "ANATOMY", 91, 100], ["foreign bodies", "OBSERVATION", 115, 129], ["tongue", "ANATOMY", 190, 196], ["irritant materials", "OBSERVATION", 218, 236], ["abdominal", "ANATOMY", 273, 282], ["tumors", "OBSERVATION", 283, 289]]], ["Animals with metabolic or secondary causes of vomiting may appear lethargic, anorexic, and weak, particularly when the vomiting episodes have been sustained for several days.", [["vomiting", "DISEASE", 46, 54], ["anorexic", "DISEASE", 77, 85], ["vomiting", "DISEASE", 119, 127], ["Animals", "ORGANISM", 0, 7], ["vomiting", "PROBLEM", 46, 54], ["lethargic", "PROBLEM", 66, 75], ["anorexic", "PROBLEM", 77, 85], ["weak", "PROBLEM", 91, 95], ["the vomiting episodes", "PROBLEM", 115, 136], ["weak", "OBSERVATION_MODIFIER", 91, 95]]], ["In some animals, PU or PD, anuria, icterus, cough, and anemia are present.", [["PD", "DISEASE", 23, 25], ["anuria", "DISEASE", 27, 33], ["icterus", "DISEASE", 35, 42], ["cough", "DISEASE", 44, 49], ["anemia", "DISEASE", 55, 61], ["PU", "PROBLEM", 17, 19], ["PD", "PROBLEM", 23, 25], ["anuria", "PROBLEM", 27, 33], ["icterus", "PROBLEM", 35, 42], ["cough", "PROBLEM", 44, 49], ["anemia", "PROBLEM", 55, 61], ["anuria", "OBSERVATION", 27, 33], ["icterus", "OBSERVATION", 35, 42], ["cough", "OBSERVATION", 44, 49], ["anemia", "OBSERVATION", 55, 61]]], ["Note: Cough-induced gagging associated with tracheitis or tracheobronchitis is often accompanied by the expulsion of mucus from the respiratory tract and can be a forceful act.", [["tracheitis", "ANATOMY", 44, 54], ["mucus", "ANATOMY", 117, 122], ["respiratory tract", "ANATOMY", 132, 149], ["Cough", "DISEASE", 6, 11], ["gagging", "DISEASE", 20, 27], ["tracheitis", "DISEASE", 44, 54], ["tracheobronchitis", "DISEASE", 58, 75], ["mucus", "ORGANISM_SUBSTANCE", 117, 122], ["respiratory tract", "ORGANISM_SUBDIVISION", 132, 149], ["Cough", "PROBLEM", 6, 11], ["gagging", "PROBLEM", 20, 27], ["tracheitis", "PROBLEM", 44, 54], ["tracheobronchitis", "PROBLEM", 58, 75], ["the expulsion of mucus from the respiratory tract", "PROBLEM", 100, 149], ["Cough", "OBSERVATION", 6, 11], ["tracheitis", "OBSERVATION", 44, 54], ["tracheobronchitis", "OBSERVATION", 58, 75], ["expulsion", "OBSERVATION", 104, 113], ["mucus", "OBSERVATION", 117, 122], ["respiratory tract", "ANATOMY", 132, 149]]], ["As such, productive coughs may appear to the owner to be vomiting.AssociAted signsfrom the upper respiratory tract may be swallowed and subsequently vomited, giving the appearance that bleeding is from the stomach.AssociAted signsAnorexia and vomiting are the most common associated, but nonspecific, signs.", [["upper respiratory tract", "ANATOMY", 91, 114], ["stomach", "ANATOMY", 206, 213], ["coughs", "DISEASE", 20, 26], ["vomiting", "DISEASE", 57, 65], ["bleeding", "DISEASE", 185, 193], ["Anorexia", "DISEASE", 230, 238], ["vomiting", "DISEASE", 243, 251], ["upper respiratory", "ORGANISM_SUBDIVISION", 91, 108], ["tract", "ORGANISM_SUBDIVISION", 109, 114], ["stomach", "ORGAN", 206, 213], ["productive coughs", "PROBLEM", 9, 26], ["vomiting", "PROBLEM", 57, 65], ["AssociAted signsfrom the upper respiratory tract", "PROBLEM", 66, 114], ["bleeding", "PROBLEM", 185, 193], ["AssociAted signs", "PROBLEM", 214, 230], ["Anorexia", "PROBLEM", 230, 238], ["vomiting", "PROBLEM", 243, 251], ["upper", "ANATOMY_MODIFIER", 91, 96], ["respiratory tract", "ANATOMY", 97, 114], ["swallowed", "OBSERVATION", 122, 131], ["bleeding", "OBSERVATION", 185, 193], ["stomach", "ANATOMY", 206, 213], ["signs", "OBSERVATION_MODIFIER", 225, 230], ["Anorexia", "OBSERVATION", 230, 238], ["vomiting", "OBSERVATION", 243, 251], ["most common", "OBSERVATION_MODIFIER", 260, 271], ["nonspecific", "OBSERVATION_MODIFIER", 288, 299]]], ["Weight loss, weakness, dark stool (melena), dehydration, and inactivity are other related signs having low diagnostic yield.", [["Weight loss", "DISEASE", 0, 11], ["weakness", "DISEASE", 13, 21], ["melena", "DISEASE", 35, 41], ["dehydration", "DISEASE", 44, 55], ["Weight loss", "PROBLEM", 0, 11], ["weakness", "PROBLEM", 13, 21], ["dark stool", "PROBLEM", 23, 33], ["melena", "PROBLEM", 35, 41], ["dehydration", "PROBLEM", 44, 55], ["inactivity", "PROBLEM", 61, 71], ["low diagnostic yield", "PROBLEM", 103, 123], ["loss", "OBSERVATION", 7, 11], ["weakness", "OBSERVATION", 13, 21], ["dark", "OBSERVATION_MODIFIER", 23, 27], ["stool", "OBSERVATION", 28, 33], ["dehydration", "OBSERVATION", 44, 55]]], ["Severe anemia can result from sustained gastric hemorrhage and if acute may justify exploratory laparotomy to identify the source of the bleeding.AssociAted signsIncreased water consumption and urination may suggest underlying renal or hepatic disease.", [["gastric", "ANATOMY", 40, 47], ["renal", "ANATOMY", 227, 232], ["hepatic", "ANATOMY", 236, 243], ["anemia", "DISEASE", 7, 13], ["gastric hemorrhage", "DISEASE", 40, 58], ["bleeding", "DISEASE", 137, 145], ["renal or hepatic disease", "DISEASE", 227, 251], ["gastric", "ORGAN", 40, 47], ["water", "SIMPLE_CHEMICAL", 172, 177], ["renal", "ORGAN", 227, 232], ["hepatic", "ORGAN", 236, 243], ["Severe anemia", "PROBLEM", 0, 13], ["sustained gastric hemorrhage", "PROBLEM", 30, 58], ["exploratory laparotomy", "TEST", 84, 106], ["the bleeding", "PROBLEM", 133, 145], ["AssociAted signs", "PROBLEM", 146, 162], ["Increased water consumption", "PROBLEM", 162, 189], ["urination", "PROBLEM", 194, 203], ["underlying renal or hepatic disease", "PROBLEM", 216, 251], ["anemia", "OBSERVATION", 7, 13], ["sustained", "OBSERVATION_MODIFIER", 30, 39], ["gastric", "ANATOMY", 40, 47], ["hemorrhage", "OBSERVATION", 48, 58], ["bleeding", "OBSERVATION", 137, 145], ["signs", "OBSERVATION_MODIFIER", 157, 162], ["Increased", "OBSERVATION_MODIFIER", 162, 171], ["water consumption", "OBSERVATION", 172, 189], ["renal", "ANATOMY", 227, 232], ["hepatic", "ANATOMY", 236, 243], ["disease", "OBSERVATION", 244, 251]]], ["Intracutaneous or subcutaneous tumors, specifically mast cell tumors, can be associated with severe gastric ulceration and bleeding.", [["Intracutaneous", "ANATOMY", 0, 14], ["subcutaneous tumors", "ANATOMY", 18, 37], ["mast cell tumors", "ANATOMY", 52, 68], ["gastric", "ANATOMY", 100, 107], ["tumors", "DISEASE", 31, 37], ["mast cell tumors", "DISEASE", 52, 68], ["gastric ulceration", "DISEASE", 100, 118], ["bleeding", "DISEASE", 123, 131], ["subcutaneous tumors", "CANCER", 18, 37], ["mast cell tumors", "CANCER", 52, 68], ["gastric", "ORGAN", 100, 107], ["Intracutaneous or subcutaneous tumors", "PROBLEM", 0, 37], ["mast cell tumors", "PROBLEM", 52, 68], ["severe gastric ulceration", "PROBLEM", 93, 118], ["bleeding", "PROBLEM", 123, 131], ["subcutaneous", "ANATOMY", 18, 30], ["tumors", "OBSERVATION", 31, 37], ["mast cell tumors", "OBSERVATION", 52, 68], ["severe", "OBSERVATION_MODIFIER", 93, 99], ["gastric", "ANATOMY", 100, 107], ["ulceration", "OBSERVATION", 108, 118], ["bleeding", "OBSERVATION", 123, 131]]], ["Ulcerative lesions in the mouth may indicate recent ingestion of caustic or toxic compounds.", [["Ulcerative lesions", "ANATOMY", 0, 18], ["mouth", "ANATOMY", 26, 31], ["Ulcerative lesions in the mouth", "DISEASE", 0, 31], ["Ulcerative lesions", "PATHOLOGICAL_FORMATION", 0, 18], ["mouth", "ORGAN", 26, 31], ["Ulcerative lesions in the mouth", "PROBLEM", 0, 31], ["caustic or toxic compounds", "PROBLEM", 65, 91], ["lesions", "OBSERVATION", 11, 18], ["mouth", "ANATOMY", 26, 31], ["caustic", "OBSERVATION_MODIFIER", 65, 72], ["toxic compounds", "OBSERVATION", 76, 91]]], ["The frenulum in the mouth should always be examined to rule out linear foreign bodies. differentiAl diAgnosis diAgnostic PlAns 3 weAkness, lethArgy, fAtigue definition Weakness is a term commonly used by owners to describe a pet that manifests a behavior change characterized by episodic (intermittent) or continuous decline in endurance or the ability to perform routine physical tasks (walking, running, fetching).", [["frenulum", "ANATOMY", 4, 12], ["mouth", "ANATOMY", 20, 25], ["Weakness", "DISEASE", 168, 176], ["frenulum", "CANCER", 4, 12], ["mouth", "ORGAN", 20, 25], ["linear foreign bodies", "PROBLEM", 64, 85], ["3 weAkness", "PROBLEM", 127, 137], ["lethArgy", "PROBLEM", 139, 147], ["fAtigue definition Weakness", "PROBLEM", 149, 176], ["a behavior change", "PROBLEM", 244, 261], ["episodic (intermittent)", "PROBLEM", 279, 302], ["continuous decline in endurance", "PROBLEM", 306, 337], ["frenulum", "ANATOMY", 4, 12], ["mouth", "ANATOMY", 20, 25], ["linear", "OBSERVATION_MODIFIER", 64, 70], ["foreign bodies", "OBSERVATION", 71, 85]]], ["However, the cause of true weakness in a dog or cat can be difficult to characterize and even more difficult to diagnose.", [["weakness", "DISEASE", 27, 35], ["dog", "ORGANISM", 41, 44], ["cat", "ORGANISM", 48, 51], ["dog", "SPECIES", 41, 44], ["true weakness", "PROBLEM", 22, 35], ["true", "OBSERVATION_MODIFIER", 22, 26], ["weakness", "OBSERVATION", 27, 35]]], ["Most authors today consider conventional terms such as fatigue and lethargy to be interchangeable with weakness.", [["fatigue", "DISEASE", 55, 62], ["lethargy", "DISEASE", 67, 75], ["fatigue", "PROBLEM", 55, 62], ["lethargy", "PROBLEM", 67, 75], ["weakness", "PROBLEM", 103, 111]]], ["The terms depressed and depression, although sometimes used in describing weakness, are less appropriate terms, as they are conventionally reserved for describing mood or psychomotor disorders in humans.AssociAted signsCharacterizing weakness can be complicated by the fact that the patient appears normal during physical examination.", [["depressed", "DISEASE", 10, 19], ["depression", "DISEASE", 24, 34], ["psychomotor disorders", "DISEASE", 171, 192], ["humans", "ORGANISM", 196, 202], ["patient", "ORGANISM", 283, 290], ["humans", "SPECIES", 196, 202], ["patient", "SPECIES", 283, 290], ["humans", "SPECIES", 196, 202], ["The terms depressed", "PROBLEM", 0, 19], ["depression", "PROBLEM", 24, 34], ["weakness", "PROBLEM", 74, 82], ["psychomotor disorders in humans", "PROBLEM", 171, 202], ["AssociAted signsCharacterizing weakness", "PROBLEM", 203, 242], ["physical examination", "TEST", 313, 333], ["depressed", "OBSERVATION_MODIFIER", 10, 19], ["depression", "OBSERVATION", 24, 34], ["weakness", "OBSERVATION", 234, 242], ["normal", "OBSERVATION", 299, 305]]], ["The clinician must carefully discern any pertinent events that either precede or follow intermittent weakness.", [["intermittent weakness", "PROBLEM", 88, 109]]], ["Age, breed, consumption of food, inappropriate water consumption, activity or exertion, conformation, underlying medical disorders, and concurrent drug therapy must be considered.", [["underlying medical disorders", "PROBLEM", 102, 130], ["concurrent drug therapy", "TREATMENT", 136, 159]]], ["Although frequently implicated in the cause of weakness, advanced age is not necessarily the primary underlying cause.", [["weakness", "DISEASE", 47, 55], ["weakness", "PROBLEM", 47, 55], ["weakness", "OBSERVATION", 47, 55]]], ["Because of the extensive list of potential differential diagnoses, patients with either intermittent or continuous weakness warrant a comprehensive physical and laboratory assessment.", [["patients", "ORGANISM", 67, 75], ["patients", "SPECIES", 67, 75], ["intermittent or continuous weakness", "PROBLEM", 88, 123], ["laboratory assessment", "TEST", 161, 182]]], ["Multiple drugs may be involved, especially anticonvulsants, corticosteroids, antitussives, cardiovascular drugs, and some antimicrobials.mEtaBolic disEasERenal and hepatic diseases predominate Electrolyte disorders (e.g., hypokalemia, hyperkalemia, hypercalcemia, hypernatremia) Acidosis or alkalosis (pulmonary and/or renal mechanisms may be involved) Hypertriglyceridemia (sustained)inFEctious disEasEAny acute-onset or sustained infection involving any pathogenic organism, especially in young dogs and catshEmatologic disordErsAnemia predominates (acute-onset or gradual onset) Bone marrow neoplasia (e.g., leukemia-multiple types, myeloma)EndocrinE disordErs (multiPlE disordErs)Hypothyroidism (especially in dogs) Hyperthyroidism (feline, apathetic form) Hyperadrenocorticism (Cushing syndrome) Hypoadrenocorticism (Addison disease) Parathyroid disorders Diabetes mellitus Neoplasia (insulinoma) (hypermetabolic), inadequate consumption or assimilation of nutrient, or excessive nutrient loss contributes to significant weight loss.AssociAted signsThe clinical history should center on diet, appetite, and known health status (i.e., evidence of vomiting, diarrhea, and so on).", [["cardiovascular", "ANATOMY", 91, 105], ["hepatic", "ANATOMY", 164, 171], ["pulmonary", "ANATOMY", 302, 311], ["renal", "ANATOMY", 319, 324], ["Bone marrow neoplasia", "ANATOMY", 582, 603], ["leukemia", "ANATOMY", 611, 619], ["myeloma", "ANATOMY", 636, 643], ["insulinoma", "ANATOMY", 890, 900], ["hepatic diseases", "DISEASE", 164, 180], ["Electrolyte disorders", "DISEASE", 193, 214], ["hypokalemia", "DISEASE", 222, 233], ["hyperkalemia", "DISEASE", 235, 247], ["hypercalcemia", "DISEASE", 249, 262], ["hypernatremia", "DISEASE", 264, 277], ["Acidosis", "DISEASE", 279, 287], ["alkalosis", "DISEASE", 291, 300], ["pulmonary and/or renal mechanisms", "DISEASE", 302, 335], ["Hypertriglyceridemia", "DISEASE", 353, 373], ["infection", "DISEASE", 432, 441], ["ErsAnemia", "DISEASE", 528, 537], ["Bone marrow neoplasia", "DISEASE", 582, 603], ["leukemia", "DISEASE", 611, 619], ["myeloma", "DISEASE", 636, 643], ["Hypothyroidism", "DISEASE", 684, 698], ["Hyperthyroidism", "DISEASE", 720, 735], ["feline, apathetic form", "DISEASE", 737, 759], ["Hyperadrenocorticism", "DISEASE", 761, 781], ["Cushing syndrome", "DISEASE", 783, 799], ["Hypoadrenocorticism", "DISEASE", 801, 820], ["Addison disease", "DISEASE", 822, 837], ["Parathyroid disorders", "DISEASE", 839, 860], ["Diabetes mellitus Neoplasia", "DISEASE", 861, 888], ["insulinoma", "DISEASE", 890, 900], ["nutrient loss", "DISEASE", 985, 998], ["weight loss", "DISEASE", 1026, 1037], ["vomiting", "DISEASE", 1151, 1159], ["diarrhea", "DISEASE", 1161, 1169], ["corticosteroids", "CHEMICAL", 60, 75], ["hepatic", "ORGAN", 164, 171], ["pulmonary", "ORGAN", 302, 311], ["renal", "ORGAN", 319, 324], ["dogs", "ORGANISM", 497, 501], ["Bone marrow neoplasia", "CANCER", 582, 603], ["leukemia", "CANCER", 611, 619], ["myeloma", "CANCER", 636, 643], ["dogs", "ORGANISM", 714, 718], ["feline", "ORGANISM", 737, 743], ["Parathyroid", "ORGAN", 839, 850], ["insulinoma", "CANCER", 890, 900], ["dogs", "SPECIES", 497, 501], ["dogs", "SPECIES", 714, 718], ["Multiple drugs", "TREATMENT", 0, 14], ["anticonvulsants", "TREATMENT", 43, 58], ["corticosteroids", "TREATMENT", 60, 75], ["antitussives", "TREATMENT", 77, 89], ["cardiovascular drugs", "TREATMENT", 91, 111], ["some antimicrobials", "TREATMENT", 117, 136], ["mEtaBolic disEasERenal and hepatic diseases", "PROBLEM", 137, 180], ["Electrolyte disorders", "PROBLEM", 193, 214], ["hypokalemia", "PROBLEM", 222, 233], ["hyperkalemia", "PROBLEM", 235, 247], ["hypercalcemia", "PROBLEM", 249, 262], ["hypernatremia)", "PROBLEM", 264, 278], ["Acidosis", "PROBLEM", 279, 287], ["alkalosis", "PROBLEM", 291, 300], ["renal mechanisms", "PROBLEM", 319, 335], ["Hypertriglyceridemia (sustained)inFEctious disEasEAny", "PROBLEM", 353, 406], ["sustained infection", "PROBLEM", 422, 441], ["any pathogenic organism", "PROBLEM", 452, 475], ["catshEmatologic disordErsAnemia", "PROBLEM", 506, 537], ["Bone marrow neoplasia", "PROBLEM", 582, 603], ["leukemia", "PROBLEM", 611, 619], ["myeloma", "PROBLEM", 636, 643], ["EndocrinE disordErs", "PROBLEM", 644, 663], ["multiPlE disordErs", "PROBLEM", 665, 683], ["Hypothyroidism", "PROBLEM", 684, 698], ["Hyperthyroidism (feline, apathetic form)", "PROBLEM", 720, 760], ["Hyperadrenocorticism (Cushing syndrome)", "PROBLEM", 761, 800], ["Hypoadrenocorticism (Addison disease)", "PROBLEM", 801, 838], ["Parathyroid disorders", "PROBLEM", 839, 860], ["Diabetes mellitus Neoplasia (insulinoma) (hypermetabolic)", "PROBLEM", 861, 918], ["inadequate consumption", "PROBLEM", 920, 942], ["excessive nutrient loss", "PROBLEM", 975, 998], ["significant weight loss", "PROBLEM", 1014, 1037], ["AssociAted signs", "PROBLEM", 1038, 1054], ["vomiting", "PROBLEM", 1151, 1159], ["diarrhea", "PROBLEM", 1161, 1169], ["hepatic", "ANATOMY", 164, 171], ["diseases", "OBSERVATION", 172, 180], ["Electrolyte disorders", "OBSERVATION", 193, 214], ["hypercalcemia", "OBSERVATION", 249, 262], ["hypernatremia", "OBSERVATION", 264, 277], ["Acidosis", "OBSERVATION", 279, 287], ["alkalosis", "OBSERVATION", 291, 300], ["pulmonary", "ANATOMY", 302, 311], ["renal", "ANATOMY", 319, 324], ["inFEctious", "OBSERVATION_MODIFIER", 385, 395], ["sustained", "OBSERVATION_MODIFIER", 422, 431], ["infection", "OBSERVATION", 432, 441], ["acute", "OBSERVATION_MODIFIER", 552, 557], ["marrow", "ANATOMY", 587, 593], ["neoplasia", "OBSERVATION", 594, 603], ["leukemia", "OBSERVATION", 611, 619], ["myeloma", "OBSERVATION", 636, 643], ["Hypothyroidism", "OBSERVATION", 684, 698], ["Hyperthyroidism", "OBSERVATION", 720, 735], ["Parathyroid", "ANATOMY", 839, 850], ["Neoplasia", "OBSERVATION", 879, 888], ["nutrient loss", "OBSERVATION", 985, 998], ["significant", "OBSERVATION_MODIFIER", 1014, 1025], ["weight loss", "OBSERVATION", 1026, 1037]]], ["The duration of time over which the owner perceives weight loss occurring is important.", [["weight loss", "DISEASE", 52, 63], ["weight loss", "PROBLEM", 52, 63]]], ["Emaciation developing within a month (e.g., with neoplasia) may carry a poorer prognosis than emaciation developing over several months.", [["neoplasia", "ANATOMY", 49, 58], ["neoplasia", "DISEASE", 49, 58], ["emaciation", "DISEASE", 94, 104], ["neoplasia", "CANCER", 49, 58], ["Emaciation", "PROBLEM", 0, 10], ["neoplasia", "PROBLEM", 49, 58], ["emaciation", "PROBLEM", 94, 104], ["neoplasia", "OBSERVATION", 49, 58]]], ["The physical examination should focus on the presence of fever, GI disease, and overt changes in size and consistency of internal organs.differentiAl diAgnosisA spectrum of differential diagnoses must be considered in the patient with emaciation or cachexia.", [["GI", "ANATOMY", 64, 66], ["organs", "ANATOMY", 130, 136], ["fever", "DISEASE", 57, 62], ["GI disease", "DISEASE", 64, 74], ["emaciation", "DISEASE", 235, 245], ["cachexia", "DISEASE", 249, 257], ["organs", "ORGAN", 130, 136], ["patient", "ORGANISM", 222, 229], ["cachexia", "CANCER", 249, 257], ["patient", "SPECIES", 222, 229], ["The physical examination", "TEST", 0, 24], ["fever", "PROBLEM", 57, 62], ["GI disease", "PROBLEM", 64, 74], ["overt changes in size and consistency of internal organs", "PROBLEM", 80, 136], ["emaciation", "PROBLEM", 235, 245], ["cachexia", "PROBLEM", 249, 257], ["fever", "OBSERVATION", 57, 62], ["GI", "ANATOMY", 64, 66], ["disease", "OBSERVATION", 67, 74], ["size", "OBSERVATION_MODIFIER", 97, 101], ["internal organs", "ANATOMY", 121, 136], ["cachexia", "OBSERVATION", 249, 257]]], ["Several categories of illness should be considered when emaciation or cachexia is associated with the following: Malnutrition.", [["illness", "DISEASE", 22, 29], ["emaciation", "DISEASE", 56, 66], ["cachexia", "DISEASE", 70, 78], ["Malnutrition", "DISEASE", 113, 125], ["cachexia", "CANCER", 70, 78], ["illness", "PROBLEM", 22, 29], ["emaciation", "PROBLEM", 56, 66], ["cachexia", "PROBLEM", 70, 78], ["Malnutrition", "PROBLEM", 113, 125], ["illness", "OBSERVATION", 22, 29], ["Malnutrition", "OBSERVATION", 113, 125]]], ["Quality and quantity of food, availability of food, evidence of neglect or abuse Polyphagia.", [["neglect", "DISEASE", 64, 71], ["abuse Polyphagia", "DISEASE", 75, 91], ["neglect", "PROBLEM", 64, 71], ["Polyphagia", "PROBLEM", 81, 91], ["neglect", "OBSERVATION", 64, 71]]], ["Malassimilation (i.e., either maldigestion or malabsorption), hypermetabolic states (e.g., hyperthyroidism, pregnancy), excessive nutrient losses (e.g., diabetes mellitus, glomerulonephropathy) Anorexia.", [["Malassimilation", "DISEASE", 0, 15], ["malabsorption", "DISEASE", 46, 59], ["hyperthyroidism", "DISEASE", 91, 106], ["excessive nutrient losses", "DISEASE", 120, 145], ["diabetes mellitus", "DISEASE", 153, 170], ["glomerulonephropathy", "DISEASE", 172, 192], ["Anorexia", "DISEASE", 194, 202], ["Malassimilation", "PROBLEM", 0, 15], ["maldigestion", "PROBLEM", 30, 42], ["malabsorption)", "PROBLEM", 46, 60], ["hypermetabolic states", "PROBLEM", 62, 83], ["hyperthyroidism", "PROBLEM", 91, 106], ["pregnancy)", "PROBLEM", 108, 118], ["excessive nutrient losses", "PROBLEM", 120, 145], ["diabetes mellitus", "PROBLEM", 153, 170], ["glomerulonephropathy)", "PROBLEM", 172, 193], ["Anorexia", "PROBLEM", 194, 202], ["malabsorption", "OBSERVATION", 46, 59], ["nutrient losses", "OBSERVATION", 130, 145], ["Anorexia", "OBSERVATION", 194, 202]]], ["Infectious diseases, neoplasia, neurologic disease, toxicity (e.g., chronic lead poisoning), dental disease (pseudoanorexia) GI signs.", [["neoplasia", "ANATOMY", 21, 30], ["neurologic", "ANATOMY", 32, 42], ["Infectious diseases", "DISEASE", 0, 19], ["neoplasia", "DISEASE", 21, 30], ["neurologic disease", "DISEASE", 32, 50], ["toxicity", "DISEASE", 52, 60], ["poisoning", "DISEASE", 81, 90], ["dental disease", "DISEASE", 93, 107], ["pseudoanorexia", "DISEASE", 109, 123], ["neoplasia", "CANCER", 21, 30], ["Infectious diseases", "PROBLEM", 0, 19], ["neoplasia", "PROBLEM", 21, 30], ["neurologic disease", "PROBLEM", 32, 50], ["toxicity", "PROBLEM", 52, 60], ["chronic lead poisoning", "PROBLEM", 68, 90], ["dental disease (pseudoanorexia)", "PROBLEM", 93, 124], ["GI signs", "TEST", 125, 133], ["neoplasia", "OBSERVATION", 21, 30], ["neurologic disease", "OBSERVATION", 32, 50]]], ["Malassimilation (i.e., either maldigestion or malabsorption); parasitism Urinary tract signs.", [["Urinary tract", "ANATOMY", 73, 86], ["Malassimilation", "DISEASE", 0, 15], ["malabsorption", "DISEASE", 46, 59], ["Urinary tract signs", "DISEASE", 73, 92], ["Urinary tract", "ORGANISM_SUBDIVISION", 73, 86], ["Malassimilation", "PROBLEM", 0, 15], ["maldigestion", "PROBLEM", 30, 42], ["malabsorption)", "PROBLEM", 46, 60], ["parasitism Urinary tract signs", "PROBLEM", 62, 92], ["malabsorption", "OBSERVATION", 46, 59], ["Urinary tract", "ANATOMY", 73, 86]]], ["Excess renal loss of fluid and nutrients (polyuric states) Fever.", [["renal", "ANATOMY", 7, 12], ["fluid", "ANATOMY", 21, 26], ["Fever", "DISEASE", 59, 64], ["renal", "ORGAN", 7, 12], ["fluid", "ORGANISM_SUBSTANCE", 21, 26], ["Excess renal loss of fluid", "PROBLEM", 0, 26], ["Fever", "PROBLEM", 59, 64], ["renal", "ANATOMY", 7, 12], ["loss", "OBSERVATION", 13, 17], ["fluid", "OBSERVATION", 21, 26]]], ["Infectious diseases diAgnostic PlAns (Figure 3-6) yellow skin or mucous membrAnes: icterus (or JAundice) definition Icterus, or jaundice, is a yellow discoloration of tissue (especially skin, mucous membranes, and sclera) caused by an increased serum concentration of bilirubin.", [["skin", "ANATOMY", 57, 61], ["mucous membrAnes", "ANATOMY", 65, 81], ["tissue", "ANATOMY", 167, 173], ["skin", "ANATOMY", 186, 190], ["mucous membranes", "ANATOMY", 192, 208], ["sclera", "ANATOMY", 214, 220], ["serum", "ANATOMY", 245, 250], ["Infectious diseases", "DISEASE", 0, 19], ["mucous membrAnes", "DISEASE", 65, 81], ["icterus", "DISEASE", 83, 90], ["Icterus", "DISEASE", 116, 123], ["jaundice", "DISEASE", 128, 136], ["bilirubin", "CHEMICAL", 268, 277], ["bilirubin", "CHEMICAL", 268, 277], ["skin", "ORGAN", 57, 61], ["mucous membrAnes", "PATHOLOGICAL_FORMATION", 65, 81], ["tissue", "TISSUE", 167, 173], ["skin", "ORGAN", 186, 190], ["mucous membranes", "MULTI-TISSUE_STRUCTURE", 192, 208], ["sclera", "MULTI-TISSUE_STRUCTURE", 214, 220], ["serum", "ORGANISM_SUBSTANCE", 245, 250], ["bilirubin", "GENE_OR_GENE_PRODUCT", 268, 277], ["bilirubin", "PROTEIN", 268, 277], ["Figure", "TEST", 38, 44], ["icterus", "PROBLEM", 83, 90], ["JAundice)", "PROBLEM", 95, 104], ["Icterus", "PROBLEM", 116, 123], ["jaundice", "PROBLEM", 128, 136], ["a yellow discoloration of tissue", "PROBLEM", 141, 173], ["an increased serum concentration of bilirubin", "PROBLEM", 232, 277], ["skin", "ANATOMY", 57, 61], ["mucous membrAnes", "ANATOMY", 65, 81], ["icterus", "OBSERVATION", 83, 90], ["Icterus", "OBSERVATION", 116, 123], ["jaundice", "OBSERVATION", 128, 136], ["yellow", "OBSERVATION_MODIFIER", 143, 149], ["discoloration", "OBSERVATION", 150, 163], ["tissue", "OBSERVATION", 167, 173], ["skin", "ANATOMY", 186, 190], ["mucous membranes", "ANATOMY", 192, 208], ["sclera", "ANATOMY", 214, 220], ["increased", "OBSERVATION", 235, 244]]], ["It is indicative of underlying hepatocellular disease or intravascular hemolytic disease.", [["hepatocellular", "ANATOMY", 31, 45], ["intravascular", "ANATOMY", 57, 70], ["hepatocellular disease", "DISEASE", 31, 53], ["intravascular hemolytic disease", "DISEASE", 57, 88], ["hepatocellular", "CANCER", 31, 45], ["underlying hepatocellular disease", "PROBLEM", 20, 53], ["intravascular hemolytic disease", "PROBLEM", 57, 88], ["indicative of", "UNCERTAINTY", 6, 19], ["hepatocellular disease", "OBSERVATION", 31, 53], ["intravascular hemolytic disease", "OBSERVATION", 57, 88]]], ["Hyperbilirubinemia is required for icterus to develop but may not occur concurrently with icterus.differentiAl diAgnosisIn practice, icterus is an uncommon presenting complaint, because the dense hair coat of cats and dogs precludes early detection of bile pigment in skin.", [["hair coat", "ANATOMY", 196, 205], ["bile pigment", "ANATOMY", 252, 264], ["skin", "ANATOMY", 268, 272], ["Hyperbilirubinemia", "DISEASE", 0, 18], ["icterus", "DISEASE", 35, 42], ["icterus", "DISEASE", 90, 97], ["icterus", "DISEASE", 133, 140], ["hair coat", "MULTI-TISSUE_STRUCTURE", 196, 205], ["cats", "ORGANISM", 209, 213], ["dogs", "ORGANISM", 218, 222], ["bile pigment", "TISSUE", 252, 264], ["skin", "ORGAN", 268, 272], ["cats", "SPECIES", 209, 213], ["dogs", "SPECIES", 218, 222], ["Hyperbilirubinemia", "PROBLEM", 0, 18], ["icterus", "PROBLEM", 35, 42], ["icterus", "PROBLEM", 90, 97], ["icterus", "PROBLEM", 133, 140], ["the dense hair coat of cats and dogs", "PROBLEM", 186, 222], ["bile pigment in skin", "PROBLEM", 252, 272], ["icterus", "OBSERVATION", 35, 42], ["icterus", "OBSERVATION", 90, 97], ["icterus", "OBSERVATION", 133, 140], ["bile", "ANATOMY", 252, 256], ["pigment", "OBSERVATION", 257, 264], ["skin", "ANATOMY", 268, 272]]], ["Icteric tissues are most evident in the sclera and in the oral, vaginal, and preputial mucous membranes, particularly in anemic patients.", [["Icteric tissues", "ANATOMY", 0, 15], ["sclera", "ANATOMY", 40, 46], ["oral", "ANATOMY", 58, 62], ["vaginal", "ANATOMY", 64, 71], ["preputial mucous membranes", "ANATOMY", 77, 103], ["anemic", "DISEASE", 121, 127], ["Icteric tissues", "TISSUE", 0, 15], ["sclera", "TISSUE", 40, 46], ["oral", "ORGANISM_SUBDIVISION", 58, 62], ["vaginal", "ORGANISM_SUBDIVISION", 64, 71], ["preputial mucous membranes", "MULTI-TISSUE_STRUCTURE", 77, 103], ["patients", "ORGANISM", 128, 136], ["patients", "SPECIES", 128, 136], ["Icteric tissues", "PROBLEM", 0, 15], ["the oral, vaginal, and preputial mucous membranes", "PROBLEM", 54, 103], ["tissues", "OBSERVATION", 8, 15], ["sclera", "ANATOMY", 40, 46], ["oral", "ANATOMY", 58, 62], ["vaginal", "ANATOMY", 64, 71], ["preputial mucous membranes", "ANATOMY", 77, 103], ["anemic", "OBSERVATION", 121, 127]]], ["Icterus can occur subsequent to the accumulation of either unconjugated (lipid-soluble) or conjugated (water-soluble) bilirubin in the blood.differentiAl diAgnosisIcterus can originate at any of three levels: prehepatic (hemolytic disease), hepatic (hepatocellular disease), posthepatic (obstructive or reduced bile flow).differentiAl diAgnosisUnconjugated hyperbilirubinemia results from rapid hemolysis (a common cause in the dog and cat), ineffective erythropoiesis, impaired hepatic uptake of conjugated bilirubin, or impaired conjugation.", [["blood", "ANATOMY", 135, 140], ["hepatic", "ANATOMY", 241, 248], ["hepatocellular", "ANATOMY", 250, 264], ["posthepatic", "ANATOMY", 275, 286], ["bile", "ANATOMY", 311, 315], ["hepatic", "ANATOMY", 479, 486], ["Icterus", "DISEASE", 0, 7], ["bilirubin", "CHEMICAL", 118, 127], ["hemolytic disease", "DISEASE", 221, 238], ["hepatic (hepatocellular disease", "DISEASE", 241, 272], ["obstructive or reduced bile flow", "DISEASE", 288, 320], ["hyperbilirubinemia", "DISEASE", 357, 375], ["hemolysis", "DISEASE", 395, 404], ["erythropoiesis", "DISEASE", 454, 468], ["bilirubin", "CHEMICAL", 508, 517], ["bilirubin", "CHEMICAL", 118, 127], ["bilirubin", "CHEMICAL", 508, 517], ["unconjugated", "SIMPLE_CHEMICAL", 59, 71], ["lipid", "SIMPLE_CHEMICAL", 73, 78], ["conjugated", "SIMPLE_CHEMICAL", 91, 101], ["water", "SIMPLE_CHEMICAL", 103, 108], ["bilirubin", "SIMPLE_CHEMICAL", 118, 127], ["blood", "ORGANISM_SUBSTANCE", 135, 140], ["hepatic", "ORGAN", 241, 248], ["hepatocellular", "ORGAN", 250, 264], ["bile", "MULTI-TISSUE_STRUCTURE", 311, 315], ["dog", "ORGANISM", 428, 431], ["cat", "ORGANISM", 436, 439], ["hepatic", "MULTI-TISSUE_STRUCTURE", 479, 486], ["bilirubin", "SIMPLE_CHEMICAL", 508, 517], ["bilirubin", "PROTEIN", 118, 127], ["dog", "SPECIES", 428, 431], ["Icterus", "PROBLEM", 0, 7], ["the accumulation", "PROBLEM", 32, 48], ["unconjugated (lipid-soluble)", "TREATMENT", 59, 87], ["conjugated (water-soluble)", "TREATMENT", 91, 117], ["bilirubin in the blood", "TEST", 118, 140], ["differentiAl diAgnosisIcterus", "PROBLEM", 141, 170], ["prehepatic (hemolytic disease)", "PROBLEM", 209, 239], ["hepatic (hepatocellular disease)", "PROBLEM", 241, 273], ["posthepatic (obstructive or reduced bile flow)", "PROBLEM", 275, 321], ["Unconjugated hyperbilirubinemia", "PROBLEM", 344, 375], ["rapid hemolysis", "PROBLEM", 389, 404], ["ineffective erythropoiesis", "PROBLEM", 442, 468], ["impaired hepatic uptake of conjugated bilirubin", "PROBLEM", 470, 517], ["impaired conjugation", "PROBLEM", 522, 542], ["blood", "ANATOMY", 135, 140], ["hemolytic disease", "OBSERVATION", 221, 238], ["hepatic", "ANATOMY", 241, 248], ["hepatocellular", "ANATOMY", 250, 264], ["obstructive", "OBSERVATION", 288, 299], ["reduced", "OBSERVATION_MODIFIER", 303, 310], ["bile flow", "OBSERVATION", 311, 320], ["rapid", "OBSERVATION_MODIFIER", 389, 394], ["hemolysis", "OBSERVATION", 395, 404], ["ineffective", "OBSERVATION_MODIFIER", 442, 453], ["erythropoiesis", "OBSERVATION", 454, 468], ["impaired", "OBSERVATION_MODIFIER", 470, 478], ["hepatic", "ANATOMY", 479, 486], ["uptake", "OBSERVATION", 487, 493], ["conjugated bilirubin", "OBSERVATION", 497, 517], ["impaired", "OBSERVATION_MODIFIER", 522, 530], ["conjugation", "OBSERVATION_MODIFIER", 531, 542]]], ["Conjugated (water-soluble) hyperbilirubinemia is generally the result of disorders intrinsic to the liver that affect bilirubin transport.", [["liver", "ANATOMY", 100, 105], ["hyperbilirubinemia", "DISEASE", 27, 45], ["disorders intrinsic to the liver", "DISEASE", 73, 105], ["bilirubin", "CHEMICAL", 118, 127], ["bilirubin", "CHEMICAL", 118, 127], ["liver", "ORGAN", 100, 105], ["bilirubin", "SIMPLE_CHEMICAL", 118, 127], ["Conjugated (water-soluble)", "TREATMENT", 0, 26], ["hyperbilirubinemia", "PROBLEM", 27, 45], ["disorders intrinsic to the liver", "PROBLEM", 73, 105], ["bilirubin transport", "TEST", 118, 137], ["hyperbilirubinemia", "OBSERVATION", 27, 45], ["liver", "ANATOMY", 100, 105]]], ["Cholestatic disease is associated with reduced bile flow and can be characterized by significant bile acidemia and icterus.AssociAted signsIcterus can be detected in a dog or cat without overt clinical signs; however, RBC values and hepatic function should be assessed.", [["bile", "ANATOMY", 47, 51], ["bile", "ANATOMY", 97, 101], ["RBC", "ANATOMY", 218, 221], ["hepatic", "ANATOMY", 233, 240], ["Cholestatic disease", "DISEASE", 0, 19], ["reduced bile flow", "DISEASE", 39, 56], ["bile acidemia", "DISEASE", 97, 110], ["icterus", "DISEASE", 115, 122], ["bile", "ORGANISM_SUBSTANCE", 47, 51], ["bile", "ORGAN", 97, 101], ["dog", "ORGANISM", 168, 171], ["cat", "ORGANISM", 175, 178], ["RBC", "CELL", 218, 221], ["hepatic", "ORGAN", 233, 240], ["RBC", "CELL_TYPE", 218, 221], ["dog", "SPECIES", 168, 171], ["cat", "SPECIES", 175, 178], ["Cholestatic disease", "PROBLEM", 0, 19], ["reduced bile flow", "PROBLEM", 39, 56], ["significant bile acidemia", "PROBLEM", 85, 110], ["icterus", "PROBLEM", 115, 122], ["AssociAted signsIcterus", "PROBLEM", 123, 146], ["overt clinical signs", "PROBLEM", 187, 207], ["RBC values", "TEST", 218, 228], ["hepatic function", "TEST", 233, 249], ["disease", "OBSERVATION", 12, 19], ["reduced", "OBSERVATION_MODIFIER", 39, 46], ["bile flow", "OBSERVATION", 47, 56], ["significant", "OBSERVATION_MODIFIER", 85, 96], ["bile", "ANATOMY", 97, 101], ["acidemia", "OBSERVATION", 102, 110], ["icterus", "OBSERVATION", 115, 122], ["hepatic", "ANATOMY", 233, 240]]], ["Prehepatic icterus is characteristically associated with rapid-onset anemia and with generalized weakness, lassitude, or acute collapse (caval syndrome), and bright orange urine.", [["caval", "ANATOMY", 137, 142], ["urine", "ANATOMY", 172, 177], ["Prehepatic icterus", "DISEASE", 0, 18], ["anemia", "DISEASE", 69, 75], ["weakness", "DISEASE", 97, 105], ["lassitude", "DISEASE", 107, 116], ["acute collapse (caval syndrome", "DISEASE", 121, 151], ["urine", "ORGANISM_SUBSTANCE", 172, 177], ["Prehepatic icterus", "PROBLEM", 0, 18], ["rapid-onset anemia", "PROBLEM", 57, 75], ["generalized weakness", "PROBLEM", 85, 105], ["lassitude", "PROBLEM", 107, 116], ["acute collapse (caval syndrome", "PROBLEM", 121, 151], ["bright orange urine", "PROBLEM", 158, 177], ["icterus", "OBSERVATION", 11, 18], ["rapid", "OBSERVATION_MODIFIER", 57, 62], ["-onset", "OBSERVATION_MODIFIER", 62, 68], ["anemia", "OBSERVATION", 69, 75], ["generalized", "OBSERVATION_MODIFIER", 85, 96], ["weakness", "OBSERVATION", 97, 105], ["acute", "OBSERVATION_MODIFIER", 121, 126], ["collapse", "OBSERVATION", 127, 135], ["caval syndrome", "OBSERVATION", 137, 151]]], ["Pallor can be difficult to assess in patients with marked icterus.", [["icterus", "DISEASE", 58, 65], ["patients", "ORGANISM", 37, 45], ["patients", "SPECIES", 37, 45], ["Pallor", "PROBLEM", 0, 6], ["marked icterus", "PROBLEM", 51, 65], ["marked", "OBSERVATION_MODIFIER", 51, 57], ["icterus", "OBSERVATION", 58, 65]]], ["Hepatic icterus and posthepatic icterus are generally associated with lethargy and decreased appetite and are therefore difficult to distinguish clinically.", [["Hepatic icterus", "ANATOMY", 0, 15], ["Hepatic icterus", "DISEASE", 0, 15], ["icterus", "DISEASE", 32, 39], ["lethargy", "DISEASE", 70, 78], ["Hepatic icterus", "PROBLEM", 0, 15], ["posthepatic icterus", "PROBLEM", 20, 39], ["lethargy", "PROBLEM", 70, 78], ["decreased appetite", "PROBLEM", 83, 101], ["icterus", "OBSERVATION", 8, 15], ["posthepatic", "ANATOMY", 20, 31], ["icterus", "OBSERVATION", 32, 39], ["lethargy", "OBSERVATION", 70, 78], ["decreased", "OBSERVATION_MODIFIER", 83, 92], ["appetite", "OBSERVATION", 93, 101]]], ["Depending on the type of hepatic injury or the level of obstruction, episodic vomiting or diarrhea, weight loss, abdominal distension, PU or PD, peripheral edema associated with hypoproteinemia, and prolonged bleeding (uncommon) may be reported.", [["hepatic", "ANATOMY", 25, 32], ["abdominal", "ANATOMY", 113, 122], ["peripheral edema", "ANATOMY", 145, 161], ["hepatic injury", "DISEASE", 25, 39], ["obstruction", "DISEASE", 56, 67], ["episodic vomiting", "DISEASE", 69, 86], ["diarrhea", "DISEASE", 90, 98], ["weight loss", "DISEASE", 100, 111], ["abdominal distension", "DISEASE", 113, 133], ["PU", "DISEASE", 135, 137], ["PD", "DISEASE", 141, 143], ["peripheral edema", "DISEASE", 145, 161], ["hypoproteinemia", "DISEASE", 178, 193], ["bleeding", "DISEASE", 209, 217], ["hepatic", "ORGAN", 25, 32], ["abdominal", "ORGANISM_SUBDIVISION", 113, 122], ["hepatic injury", "PROBLEM", 25, 39], ["obstruction", "PROBLEM", 56, 67], ["episodic vomiting", "PROBLEM", 69, 86], ["diarrhea", "PROBLEM", 90, 98], ["weight loss", "PROBLEM", 100, 111], ["abdominal distension", "PROBLEM", 113, 133], ["PU", "PROBLEM", 135, 137], ["PD", "PROBLEM", 141, 143], ["peripheral edema", "PROBLEM", 145, 161], ["hypoproteinemia", "PROBLEM", 178, 193], ["prolonged bleeding", "PROBLEM", 199, 217], ["hepatic", "ANATOMY", 25, 32], ["injury", "OBSERVATION", 33, 39], ["obstruction", "OBSERVATION", 56, 67], ["abdominal", "ANATOMY", 113, 122], ["distension", "OBSERVATION", 123, 133], ["PU", "OBSERVATION", 135, 137], ["peripheral", "ANATOMY_MODIFIER", 145, 155], ["edema", "OBSERVATION", 156, 161], ["hypoproteinemia", "OBSERVATION", 178, 193], ["prolonged", "OBSERVATION_MODIFIER", 199, 208], ["bleeding", "OBSERVATION", 209, 217]]]], "PMC7178863": [], "PMC7472979": [["Tidy Past and Messy PresentClassically, immunologists thought of mononuclear phagocytes, including tissue macrophages and circulating monocytes, as bone marrow (BM)-derived cells that act as sentinels against pathogens and damage [1].", [["mononuclear phagocytes", "ANATOMY", 65, 87], ["tissue macrophages", "ANATOMY", 99, 117], ["monocytes", "ANATOMY", 134, 143], ["bone marrow", "ANATOMY", 148, 159], ["BM)-derived cells", "ANATOMY", 161, 178], ["mononuclear phagocytes", "CELL", 65, 87], ["tissue macrophages", "CELL", 99, 117], ["monocytes", "CELL", 134, 143], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 148, 159], ["BM)-derived cells", "CELL", 161, 178], ["mononuclear phagocytes", "CELL_TYPE", 65, 87], ["tissue macrophages", "CELL_TYPE", 99, 117], ["circulating monocytes", "CELL_TYPE", 122, 143], ["bone marrow (BM)-derived cells", "CELL_TYPE", 148, 178], ["mononuclear phagocytes", "PROBLEM", 65, 87], ["tissue macrophages", "PROBLEM", 99, 117], ["circulating monocytes", "PROBLEM", 122, 143], ["bone marrow", "TEST", 148, 159], ["derived cells", "PROBLEM", 165, 178], ["pathogens", "PROBLEM", 209, 218], ["mononuclear phagocytes", "OBSERVATION", 65, 87], ["circulating monocytes", "OBSERVATION", 122, 143], ["bone", "ANATOMY", 148, 152]]], ["Myeloid cells (see Glossary) were considered relatively short lived [2] and therefore unable to maintain over a long period of time any functional changes that arose as a consequence of prior stimulus.", [["Myeloid cells", "ANATOMY", 0, 13], ["Myeloid cells", "CELL", 0, 13], ["Myeloid cells", "CELL_TYPE", 0, 13], ["Myeloid cells", "PROBLEM", 0, 13]]], ["With advances in lineage tracing and cell-type-specific depletion methods in recent years, these views were challenged on several levels: First, steady-state tissue-resident macrophages are often long-lived, self-replenishing cell populations of embryonic origin rather than offspring from BM-derived cells [3., 4., 5.].", [["cell", "ANATOMY", 37, 41], ["tissue", "ANATOMY", 158, 164], ["macrophages", "ANATOMY", 174, 185], ["cell", "ANATOMY", 226, 230], ["embryonic", "ANATOMY", 246, 255], ["BM-derived cells", "ANATOMY", 290, 306], ["lineage", "CELL", 17, 24], ["cell", "CELL", 37, 41], ["tissue", "CELL", 158, 164], ["macrophages", "CELL", 174, 185], ["cell populations", "CELL", 226, 242], ["embryonic", "DEVELOPING_ANATOMICAL_STRUCTURE", 246, 255], ["BM-derived cells", "CELL", 290, 306], ["resident macrophages", "CELL_TYPE", 165, 185], ["BM-derived cells", "CELL_TYPE", 290, 306], ["lineage tracing", "TEST", 17, 32], ["these views", "TEST", 91, 102], ["macrophages", "ANATOMY", 174, 185], ["embryonic origin", "OBSERVATION_MODIFIER", 246, 262], ["BM", "ANATOMY", 290, 292]]], ["Second, tissue-resident macrophages are heavily involved in tissue maintenance and repair processes, sometimes at the expense of their immune function [6., 7., 8., 9.].", [["tissue", "ANATOMY", 8, 14], ["macrophages", "ANATOMY", 24, 35], ["tissue", "ANATOMY", 60, 66], ["tissue-resident macrophages", "CELL", 8, 35], ["tissue", "TISSUE", 60, 66], ["resident macrophages", "CELL_TYPE", 15, 35], ["repair processes", "TREATMENT", 83, 99], ["tissue", "ANATOMY", 8, 14], ["macrophages", "OBSERVATION", 24, 35], ["repair", "OBSERVATION", 83, 89]]], ["Third, when the steady state is perturbed \u2013 for instance, by infection \u2013 recruitment of additional monocyte-derived cells is crucial to accelerate the immune response [10,11].", [["monocyte", "ANATOMY", 99, 107], ["cells", "ANATOMY", 116, 121], ["infection", "DISEASE", 61, 70], ["monocyte", "CELL", 99, 107], ["cells", "CELL", 116, 121], ["monocyte-derived cells", "CELL_TYPE", 99, 121], ["infection", "PROBLEM", 61, 70], ["additional monocyte-derived cells", "TREATMENT", 88, 121], ["infection", "OBSERVATION", 61, 70]]], ["At the end of the perturbation, recruited cells may remain in the tissue to contribute long term to the pool of macrophages that live permanently in that organ [12].", [["cells", "ANATOMY", 42, 47], ["tissue", "ANATOMY", 66, 72], ["macrophages", "ANATOMY", 112, 123], ["organ", "ANATOMY", 154, 159], ["cells", "CELL", 42, 47], ["tissue", "TISSUE", 66, 72], ["macrophages", "CELL", 112, 123], ["organ", "ORGAN", 154, 159], ["macrophages", "CELL_TYPE", 112, 123], ["recruited cells", "PROBLEM", 32, 47]]], ["Finally, a range of long-term changes in the reactivity of innate immune cells following a stimulus have been described under the notion of trained immunity [13].Tidy Past and Messy PresentThese novel concepts and observations highlight the notion that mammalian tissue-resident and recruited macrophages are not only of different origins (embryonic versus BM) but can also be functionally different.", [["immune cells", "ANATOMY", 66, 78], ["tissue", "ANATOMY", 263, 269], ["macrophages", "ANATOMY", 293, 304], ["embryonic", "ANATOMY", 340, 349], ["BM", "ANATOMY", 357, 359], ["innate immune cells", "CELL", 59, 78], ["macrophages", "CELL", 293, 304], ["embryonic", "DEVELOPING_ANATOMICAL_STRUCTURE", 340, 349], ["BM", "CELL", 357, 359], ["innate immune cells", "CELL_TYPE", 59, 78], ["macrophages", "CELL_TYPE", 293, 304], ["long-term changes", "PROBLEM", 20, 37], ["innate immune cells", "TREATMENT", 59, 78], ["long-term", "OBSERVATION_MODIFIER", 20, 29], ["immune cells", "OBSERVATION", 66, 78], ["macrophages", "OBSERVATION", 293, 304]]], ["Besides their origin, important determinants of macrophage responsiveness are the tissue where they reside [14], the time spent in that tissue, and how inflamed or quiescent this environment is.", [["macrophage", "ANATOMY", 48, 58], ["tissue", "ANATOMY", 82, 88], ["tissue", "ANATOMY", 136, 142], ["macrophage", "CELL", 48, 58], ["tissue", "TISSUE", 82, 88], ["tissue", "TISSUE", 136, 142], ["macrophage responsiveness", "PROBLEM", 48, 73], ["macrophage responsiveness", "OBSERVATION", 48, 73]]], ["What role does each of these factors play and how do they combine to ultimately fine-tune macrophage function at a given moment in time?", [["macrophage", "ANATOMY", 90, 100], ["macrophage", "CELL", 90, 100]]], ["Recent studies on murine AMs have started to shed light on some of these questions, through the identification of subsets and their role in health and disease.", [["murine", "ORGANISM", 18, 24], ["AMs", "CELL", 25, 28], ["murine AMs", "CELL_TYPE", 18, 28], ["murine", "SPECIES", 18, 24], ["Recent studies", "TEST", 0, 14], ["disease", "PROBLEM", 151, 158]]], ["We propose here an overarching model in which most of the functional alterations to lung immunity derive from recruitment or changes in monocyte-derived AMs, while resident AMs are terminally differentiated and largely unable to modify their function: the old dogs that do not learn new tricks.The Complexity of AM SubsetsAfter years of debate, a clear picture of murine tissue macrophage origin is now emerging, with macrophage populations in organs such as the brain (microglia), liver (Kupffer cells), and lung (AMs) being seeded early in ontogeny from an embryonic precursor [15].", [["lung", "ANATOMY", 84, 88], ["monocyte", "ANATOMY", 136, 144], ["AMs", "ANATOMY", 153, 156], ["AMs", "ANATOMY", 173, 176], ["tissue macrophage", "ANATOMY", 371, 388], ["macrophage", "ANATOMY", 418, 428], ["organs", "ANATOMY", 444, 450], ["brain", "ANATOMY", 463, 468], ["microglia", "ANATOMY", 470, 479], ["liver", "ANATOMY", 482, 487], ["Kupffer cells", "ANATOMY", 489, 502], ["lung", "ANATOMY", 509, 513], ["AMs", "ANATOMY", 515, 518], ["embryonic precursor", "ANATOMY", 559, 578], ["lung", "ORGAN", 84, 88], ["monocyte", "CELL", 136, 144], ["AMs", "CELL", 153, 156], ["AMs", "CELL", 173, 176], ["dogs", "ORGANISM", 260, 264], ["murine", "ORGANISM", 364, 370], ["tissue macrophage", "CELL", 371, 388], ["macrophage populations", "CELL", 418, 440], ["organs", "ORGAN", 444, 450], ["brain", "ORGAN", 463, 468], ["microglia", "CELL", 470, 479], ["liver", "ORGAN", 482, 487], ["Kupffer cells", "CELL", 489, 502], ["lung", "ORGAN", 509, 513], ["AMs", "CELL", 515, 518], ["embryonic", "DEVELOPING_ANATOMICAL_STRUCTURE", 559, 568], ["monocyte", "CELL_TYPE", 136, 144], ["AMs", "CELL_TYPE", 153, 156], ["AMs", "CELL_TYPE", 173, 176], ["macrophage populations", "CELL_TYPE", 418, 440], ["microglia", "CELL_TYPE", 470, 479], ["Kupffer cells", "CELL_TYPE", 489, 502], ["AMs", "CELL_TYPE", 515, 518], ["dogs", "SPECIES", 260, 264], ["murine", "SPECIES", 364, 370], ["murine tissue macrophage origin", "PROBLEM", 364, 395], ["macrophage populations in organs", "PROBLEM", 418, 450], ["lung (AMs)", "PROBLEM", 509, 519], ["lung", "ANATOMY", 84, 88], ["immunity", "OBSERVATION", 89, 97], ["Complexity", "OBSERVATION_MODIFIER", 298, 308], ["murine tissue", "OBSERVATION_MODIFIER", 364, 377], ["macrophage origin", "OBSERVATION", 378, 395], ["macrophage populations", "OBSERVATION", 418, 440], ["brain", "ANATOMY", 463, 468], ["microglia", "ANATOMY", 470, 479], ["liver", "ANATOMY", 482, 487], ["Kupffer cells", "ANATOMY", 489, 502], ["lung", "ANATOMY", 509, 513]]], ["These organs are considered \u2018closed\u2019, as there is almost no steady-state recruitment of monocyte-derived macrophages [3,5,15].", [["organs", "ANATOMY", 6, 12], ["monocyte", "ANATOMY", 88, 96], ["macrophages", "ANATOMY", 105, 116], ["organs", "ORGAN", 6, 12], ["monocyte", "CELL", 88, 96], ["macrophages", "CELL", 105, 116], ["monocyte-derived macrophages", "CELL_TYPE", 88, 116]]], ["Other tissues are thought to be \u2018open\u2019 for replacement with blood monocytes at either slow (i.e., heart) or fast (i.e., dermis and gut) rates [5,15,16].", [["tissues", "ANATOMY", 6, 13], ["blood monocytes", "ANATOMY", 60, 75], ["heart", "ANATOMY", 98, 103], ["dermis", "ANATOMY", 120, 126], ["gut", "ANATOMY", 131, 134], ["tissues", "TISSUE", 6, 13], ["blood monocytes", "CELL", 60, 75], ["heart", "ORGAN", 98, 103], ["dermis", "TISSUE", 120, 126], ["gut", "ORGANISM_SUBDIVISION", 131, 134], ["blood monocytes", "CELL_TYPE", 60, 75], ["replacement", "TREATMENT", 43, 54], ["blood monocytes", "PROBLEM", 60, 75], ["slow (i.e., heart) or fast (i.e., dermis and gut) rates", "PROBLEM", 86, 141], ["thought to be", "UNCERTAINTY", 18, 31], ["replacement", "OBSERVATION", 43, 54], ["heart", "ANATOMY", 98, 103], ["dermis", "ANATOMY", 120, 126], ["gut", "ANATOMY", 131, 134]]], ["Lineage-tracing experiments and BM-chimeric mice (Table 1) have shown that tissue-resident AMs self-maintain without further input from monocytes in the steady-state lung [3., 4., 5.], whereas in situations of lung insult, BM-derived cells can contribute to the AM pool [10,12].", [["tissue", "ANATOMY", 75, 81], ["AMs", "ANATOMY", 91, 94], ["monocytes", "ANATOMY", 136, 145], ["lung", "ANATOMY", 166, 170], ["lung", "ANATOMY", 210, 214], ["BM-derived cells", "ANATOMY", 223, 239], ["lung insult", "DISEASE", 210, 221], ["mice", "ORGANISM", 44, 48], ["tissue", "TISSUE", 75, 81], ["AMs", "CELL", 91, 94], ["monocytes", "CELL", 136, 145], ["lung", "ORGAN", 166, 170], ["lung", "ORGAN", 210, 214], ["BM-derived cells", "CELL", 223, 239], ["AM", "GENE_OR_GENE_PRODUCT", 262, 264], ["AMs", "CELL_TYPE", 91, 94], ["monocytes", "CELL_TYPE", 136, 145], ["BM-derived cells", "CELL_TYPE", 223, 239], ["mice", "SPECIES", 44, 48], ["mice", "SPECIES", 44, 48], ["lung insult", "PROBLEM", 210, 221], ["BM", "TEST", 223, 225], ["lung", "ANATOMY", 166, 170], ["lung", "ANATOMY", 210, 214], ["insult", "OBSERVATION", 215, 221]]], ["Embryonic precursors and blood monocytes are considered highly \u2018plastic\u2019 as they are capable of differentiating into many myeloid cell subtypes; by contrast, terminally differentiated tissue macrophages are committed to the phenotype imposed by their specific organ of residence and do not fully acquire the characteristics of AMs when transplanted into the lung [14,17].The Complexity of AM SubsetsUntil recently, in neither the mouse nor human datasets was it possible to determine AM origin (Table 1).", [["Embryonic precursors", "ANATOMY", 0, 20], ["blood monocytes", "ANATOMY", 25, 40], ["myeloid cell", "ANATOMY", 122, 134], ["tissue macrophages", "ANATOMY", 184, 202], ["organ", "ANATOMY", 260, 265], ["AMs", "ANATOMY", 327, 330], ["lung", "ANATOMY", 358, 362], ["Embryonic precursors", "CELL", 0, 20], ["blood monocytes", "CELL", 25, 40], ["myeloid cell", "CELL", 122, 134], ["tissue macrophages", "CELL", 184, 202], ["organ", "ORGAN", 260, 265], ["AMs", "CELL", 327, 330], ["lung", "ORGAN", 358, 362], ["mouse", "ORGANISM", 430, 435], ["human", "ORGANISM", 440, 445], ["Embryonic precursors", "CELL_TYPE", 0, 20], ["blood monocytes", "CELL_TYPE", 25, 40], ["myeloid cell subtypes", "CELL_TYPE", 122, 143], ["terminally differentiated tissue macrophages", "CELL_TYPE", 158, 202], ["AMs", "CELL_TYPE", 327, 330], ["mouse", "SPECIES", 430, 435], ["human", "SPECIES", 440, 445], ["mouse", "SPECIES", 430, 435], ["human", "SPECIES", 440, 445], ["Embryonic precursors", "PROBLEM", 0, 20], ["blood monocytes", "TEST", 25, 40], ["many myeloid cell subtypes", "PROBLEM", 117, 143], ["terminally differentiated tissue macrophages", "PROBLEM", 158, 202], ["blood monocytes", "OBSERVATION", 25, 40], ["myeloid cell subtypes", "OBSERVATION", 122, 143], ["terminally differentiated", "OBSERVATION_MODIFIER", 158, 183], ["tissue macrophages", "OBSERVATION", 184, 202], ["lung", "ANATOMY", 358, 362], ["Complexity", "OBSERVATION_MODIFIER", 375, 385]]], ["The absence of reliable markers of origin limits our understanding of AM pool composition in healthy humans, but studies in lung transplant recipients use human leukocyte antigen (HLA) or sex mismatch between donor and recipient as markers for the distinction between AMs that were present in the lung prior to the transplantation (resident) or that migrated in later (recruited).", [["AM pool", "ANATOMY", 70, 77], ["lung", "ANATOMY", 124, 128], ["AMs", "ANATOMY", 268, 271], ["lung", "ANATOMY", 297, 301], ["AM", "GENE_OR_GENE_PRODUCT", 70, 72], ["humans", "ORGANISM", 101, 107], ["lung", "ORGAN", 124, 128], ["human leukocyte antigen", "GENE_OR_GENE_PRODUCT", 155, 178], ["HLA", "GENE_OR_GENE_PRODUCT", 180, 183], ["AMs", "CELL", 268, 271], ["lung", "ORGAN", 297, 301], ["human leukocyte antigen", "PROTEIN", 155, 178], ["AMs", "CELL_TYPE", 268, 271], ["humans", "SPECIES", 101, 107], ["human", "SPECIES", 155, 160], ["humans", "SPECIES", 101, 107], ["human", "SPECIES", 155, 160], ["studies", "TEST", 113, 120], ["lung transplant recipients", "TREATMENT", 124, 150], ["human leukocyte antigen", "TEST", 155, 178], ["sex mismatch between donor", "PROBLEM", 188, 214], ["AMs", "PROBLEM", 268, 271], ["the transplantation", "TREATMENT", 311, 330], ["lung", "ANATOMY", 124, 128], ["transplant", "OBSERVATION", 129, 139], ["lung", "ANATOMY", 297, 301]]], ["These studies have shown that lung macrophages comprise both resident (donor) cells and newly recruited BM-derived (recipient) cells [18., 19., 20.].", [["lung macrophages", "ANATOMY", 30, 46], ["donor) cells", "ANATOMY", 71, 83], ["BM-derived (recipient) cells", "ANATOMY", 104, 132], ["lung macrophages", "CELL", 30, 46], ["(donor) cells", "CELL", 70, 83], ["BM-derived (recipient) cells", "CELL", 104, 132], ["lung macrophages", "CELL_TYPE", 30, 46], ["resident (donor) cells", "CELL_TYPE", 61, 83], ["BM-derived (recipient) cells", "CELL_TYPE", 104, 132], ["These studies", "TEST", 0, 13], ["lung macrophages", "PROBLEM", 30, 46], ["lung", "ANATOMY", 30, 34], ["macrophages", "OBSERVATION", 35, 46]]], ["In humans, being surrounded by pollutants and undergoing infections or other lung insults multiple times during our lifetime, the AM pool will comprise a mix of macrophages, some of embryonic origin and others of BM origin, with differing arrival times and duration of residence in the lung.", [["lung", "ANATOMY", 77, 81], ["macrophages", "ANATOMY", 161, 172], ["embryonic", "ANATOMY", 182, 191], ["BM", "ANATOMY", 213, 215], ["lung", "ANATOMY", 286, 290], ["infections", "DISEASE", 57, 67], ["lung insults", "DISEASE", 77, 89], ["humans", "ORGANISM", 3, 9], ["lung", "ORGAN", 77, 81], ["macrophages", "CELL", 161, 172], ["embryonic", "DEVELOPING_ANATOMICAL_STRUCTURE", 182, 191], ["BM", "TISSUE", 213, 215], ["lung", "ORGAN", 286, 290], ["macrophages", "CELL_TYPE", 161, 172], ["humans", "SPECIES", 3, 9], ["humans", "SPECIES", 3, 9], ["infections", "PROBLEM", 57, 67], ["other lung insults", "PROBLEM", 71, 89], ["infections", "OBSERVATION", 57, 67], ["lung", "ANATOMY", 77, 81], ["insults", "OBSERVATION", 82, 89], ["macrophages", "OBSERVATION", 161, 172], ["embryonic origin", "OBSERVATION", 182, 198], ["BM origin", "OBSERVATION", 213, 222], ["lung", "ANATOMY", 286, 290]]], ["Laboratory mice living under specific-pathogen-free (SPF) conditions will not have experienced major lung insults, so the predominance of embryonically derived AMs has not been lost and, as a consequence, na\u00efve laboratory mice contain mostly, if not only, AMs of embryonic origin [3., 4., 5.].The Complexity of AM SubsetsRNA-seq of bulk cell populations in mice have shown a unique tissue-specific transcriptional profile for macrophages, which is distinct from blood monocytes [14].", [["lung", "ANATOMY", 101, 105], ["AMs", "ANATOMY", 160, 163], ["AMs", "ANATOMY", 256, 259], ["embryonic", "ANATOMY", 263, 272], ["bulk cell", "ANATOMY", 332, 341], ["tissue", "ANATOMY", 382, 388], ["macrophages", "ANATOMY", 426, 437], ["blood monocytes", "ANATOMY", 462, 477], ["lung insults", "DISEASE", 101, 113], ["mice", "ORGANISM", 11, 15], ["lung", "ORGAN", 101, 105], ["AMs", "CELL", 160, 163], ["mice", "ORGANISM", 222, 226], ["AMs", "CELL", 256, 259], ["embryonic", "DEVELOPING_ANATOMICAL_STRUCTURE", 263, 272], ["AM", "GENE_OR_GENE_PRODUCT", 311, 313], ["bulk cell populations", "CELL", 332, 353], ["mice", "ORGANISM", 357, 361], ["tissue", "TISSUE", 382, 388], ["macrophages", "CELL", 426, 437], ["blood", "ORGANISM_SUBSTANCE", 462, 467], ["monocytes", "ORGANISM_SUBSTANCE", 468, 477], ["AMs", "CELL_TYPE", 160, 163], ["AMs", "CELL_TYPE", 256, 259], ["macrophages", "CELL_TYPE", 426, 437], ["blood monocytes", "CELL_TYPE", 462, 477], ["mice", "SPECIES", 11, 15], ["mice", "SPECIES", 222, 226], ["mice", "SPECIES", 357, 361], ["mice", "SPECIES", 11, 15], ["mice", "SPECIES", 222, 226], ["mice", "SPECIES", 357, 361], ["major lung insults", "PROBLEM", 95, 113], ["embryonic origin", "PROBLEM", 263, 279], ["SubsetsRNA", "TEST", 314, 324], ["bulk cell populations", "PROBLEM", 332, 353], ["macrophages", "PROBLEM", 426, 437], ["blood monocytes", "TEST", 462, 477], ["lung", "ANATOMY", 101, 105], ["insults", "OBSERVATION", 106, 113], ["bulk cell populations", "OBSERVATION", 332, 353]]], ["Recent single-cell transcriptional analyses have indicated a vast variety of lung macrophage clusters in lung cancer patients with their biography of varied lung insults [21,22], but also in mice living under SPF conditions [22].", [["cell", "ANATOMY", 14, 18], ["lung macrophage", "ANATOMY", 77, 92], ["lung cancer", "ANATOMY", 105, 116], ["lung", "ANATOMY", 157, 161], ["lung cancer", "DISEASE", 105, 116], ["lung insults", "DISEASE", 157, 169], ["cell", "CELL", 14, 18], ["lung macrophage", "CELL", 77, 92], ["lung cancer", "CANCER", 105, 116], ["patients", "ORGANISM", 117, 125], ["lung", "ORGAN", 157, 161], ["mice", "ORGANISM", 191, 195], ["patients", "SPECIES", 117, 125], ["mice", "SPECIES", 191, 195], ["mice", "SPECIES", 191, 195], ["Recent single-cell transcriptional analyses", "TEST", 0, 43], ["lung macrophage clusters in lung cancer", "PROBLEM", 77, 116], ["varied lung insults", "PROBLEM", 150, 169], ["lung", "ANATOMY", 77, 81], ["macrophage clusters", "OBSERVATION", 82, 101], ["lung", "ANATOMY", 105, 109], ["cancer", "OBSERVATION", 110, 116], ["lung", "ANATOMY", 157, 161]]], ["While there are similarities between mouse and human macrophage populations, these cannot be unequivocally mapped onto each other [22].", [["macrophage populations", "ANATOMY", 53, 75], ["mouse", "ORGANISM", 37, 42], ["human", "ORGANISM", 47, 52], ["macrophage populations", "CELL", 53, 75], ["mouse and human macrophage populations", "CELL_TYPE", 37, 75], ["mouse", "SPECIES", 37, 42], ["human", "SPECIES", 47, 52], ["mouse", "SPECIES", 37, 42], ["human", "SPECIES", 47, 52], ["mouse and human macrophage populations", "TREATMENT", 37, 75], ["macrophage", "OBSERVATION_MODIFIER", 53, 63]]], ["As these studies have not determined the embryonic or BM origin of macrophage subsets, future single-cell analysis should be combined with models employing fate-mapping tracing techniques [16] to broaden our understanding of the impact of origin or differing sojourns in the lung on AM functionality.Increased AM Reactivity Post-Influenza Virus Infection (IVI) May Emerge from Monocyte-Derived CellsRecent results have shed new light on the link between origin and AM functionality.", [["embryonic", "ANATOMY", 41, 50], ["BM", "ANATOMY", 54, 56], ["macrophage", "ANATOMY", 67, 77], ["single-cell", "ANATOMY", 94, 105], ["lung", "ANATOMY", 275, 279], ["embryonic", "DEVELOPING_ANATOMICAL_STRUCTURE", 41, 50], ["BM", "CELL", 54, 56], ["macrophage", "CELL", 67, 77], ["lung", "ORGAN", 275, 279], ["AM", "MULTI-TISSUE_STRUCTURE", 283, 285], ["AM Reactivity Post-Influenza Virus", "ORGANISM", 310, 344], ["Monocyte", "CELL", 377, 385], ["AM", "GENE_OR_GENE_PRODUCT", 465, 467], ["macrophage subsets", "CELL_TYPE", 67, 85], ["Influenza Virus", "SPECIES", 329, 344], ["these studies", "TEST", 3, 16], ["macrophage subsets", "PROBLEM", 67, 85], ["single-cell analysis", "TEST", 94, 114], ["differing sojourns in the lung", "PROBLEM", 249, 279], ["Increased AM Reactivity", "PROBLEM", 300, 323], ["Influenza Virus Infection", "PROBLEM", 329, 354], ["Monocyte", "TEST", 377, 385], ["macrophage subsets", "OBSERVATION", 67, 85], ["differing", "OBSERVATION_MODIFIER", 249, 258], ["sojourns", "OBSERVATION", 259, 267], ["lung", "ANATOMY", 275, 279], ["Influenza Virus", "OBSERVATION", 329, 344]]], ["Using chimeric mice that provide markers to distinguish between adult BM and embryonic origin, our group showed that, following recovery from IVI, the AM pool comprised both embryonically derived \u2018resident\u2019 AMs and CCR2-dependent, BM-derived \u2018recruited\u2019 AMs, most likely of monocyte origin [10].", [["adult BM", "ANATOMY", 64, 72], ["embryonic", "ANATOMY", 77, 86], ["AM pool", "ANATOMY", 151, 158], ["AMs", "ANATOMY", 207, 210], ["BM", "ANATOMY", 231, 233], ["AMs", "ANATOMY", 254, 257], ["monocyte", "ANATOMY", 274, 282], ["mice", "ORGANISM", 15, 19], ["BM", "CELL", 70, 72], ["embryonic", "DEVELOPING_ANATOMICAL_STRUCTURE", 77, 86], ["AM", "GENE_OR_GENE_PRODUCT", 151, 153], ["AMs", "CELL", 207, 210], ["CCR2", "GENE_OR_GENE_PRODUCT", 215, 219], ["BM", "CELL", 231, 233], ["\u2018", "CELL", 242, 243], ["AMs", "CELL", 254, 257], ["monocyte", "CELL", 274, 282], ["AMs", "CELL_TYPE", 207, 210], ["CCR2", "PROTEIN", 215, 219], ["BM-derived \u2018recruited\u2019 AMs", "CELL_TYPE", 231, 257], ["mice", "SPECIES", 15, 19], ["mice", "SPECIES", 15, 19], ["chimeric mice", "TREATMENT", 6, 19], ["IVI", "TREATMENT", 142, 145], ["embryonic origin", "OBSERVATION_MODIFIER", 77, 93], ["most likely", "UNCERTAINTY", 259, 270]]], ["The two AM subsets were indistinguishable by surface phenotype and morphology but showed significant transcriptional, epigenetic, and functional differences.", [["surface", "ANATOMY", 45, 52], ["AM", "GENE_OR_GENE_PRODUCT", 8, 10], ["AM subsets", "CELL_LINE", 8, 18], ["significant transcriptional, epigenetic, and functional differences", "PROBLEM", 89, 156], ["significant", "OBSERVATION_MODIFIER", 89, 100], ["transcriptional", "OBSERVATION", 101, 116], ["epigenetic", "OBSERVATION_MODIFIER", 118, 128]]], ["While IVI had no impact on the transcriptional profile or functional phenotype of resident AMs, recruited AMs maintained open chromatin at loci controlling the expression of inflammatory genes, including Il6, which made these cells significantly more responsive to stimulation with bacterial Toll-like receptor (TLR) agonists [10] (Figure 1A).", [["AMs", "ANATOMY", 91, 94], ["AMs", "ANATOMY", 106, 109], ["chromatin", "ANATOMY", 126, 135], ["cells", "ANATOMY", 226, 231], ["AMs", "CELL", 91, 94], ["AMs", "CELL", 106, 109], ["chromatin", "CELLULAR_COMPONENT", 126, 135], ["Il6", "GENE_OR_GENE_PRODUCT", 204, 207], ["cells", "CELL", 226, 231], ["Toll-like receptor", "GENE_OR_GENE_PRODUCT", 292, 310], ["TLR", "GENE_OR_GENE_PRODUCT", 312, 315], ["IVI", "PROTEIN", 6, 9], ["resident AMs", "CELL_TYPE", 82, 94], ["AMs", "CELL_TYPE", 106, 109], ["open chromatin", "DNA", 121, 135], ["inflammatory genes", "DNA", 174, 192], ["Il6", "DNA", 204, 207], ["bacterial Toll-like receptor", "PROTEIN", 282, 310], ["TLR", "PROTEIN", 312, 315], ["open chromatin", "PROBLEM", 121, 135], ["inflammatory genes", "PROBLEM", 174, 192], ["Il6", "PROBLEM", 204, 207], ["these cells", "PROBLEM", 220, 231], ["bacterial Toll-like receptor (TLR) agonists", "TREATMENT", 282, 325], ["inflammatory genes", "OBSERVATION", 174, 192]]], ["It should be noted that resident AMs can be important producers of type I interferons (IFNs) and cytokines post-viral infection [23., 24., 25., 26.], but this response is most prominent on day 1 and is short-lived.", [["AMs", "ANATOMY", 33, 36], ["infection", "DISEASE", 118, 127], ["AMs", "CELL", 33, 36], ["type I interferons", "GENE_OR_GENE_PRODUCT", 67, 85], ["IFNs", "GENE_OR_GENE_PRODUCT", 87, 91], ["resident AMs", "CELL_TYPE", 24, 36], ["type I interferons", "PROTEIN", 67, 85], ["IFNs", "PROTEIN", 87, 91], ["cytokines", "PROTEIN", 97, 106], ["type I interferons (IFNs)", "TREATMENT", 67, 92], ["cytokines post-viral infection", "PROBLEM", 97, 127], ["most prominent", "OBSERVATION_MODIFIER", 171, 185]]], ["On days 3\u20139 post-infection, resident AMs are often found to be depleted, and monocytes are recruited into the inflamed tissue [10,26., 27., 28., 29.].", [["AMs", "ANATOMY", 37, 40], ["monocytes", "ANATOMY", 77, 86], ["tissue", "ANATOMY", 119, 125], ["infection", "DISEASE", 17, 26], ["AMs", "CELL", 37, 40], ["monocytes", "CELL", 77, 86], ["tissue", "TISSUE", 119, 125], ["AMs", "CELL_TYPE", 37, 40], ["monocytes", "CELL_TYPE", 77, 86], ["infection", "PROBLEM", 17, 26], ["monocytes", "TEST", 77, 86], ["infection", "OBSERVATION", 17, 26], ["depleted", "OBSERVATION", 63, 71], ["monocytes", "ANATOMY", 77, 86], ["inflamed tissue", "ANATOMY", 110, 125]]], ["In the case of severe IVI, monocytes destined to become recruited AMs arrive in the lung between day 3 and 7 of infection [10].", [["monocytes", "ANATOMY", 27, 36], ["AMs", "ANATOMY", 66, 69], ["lung", "ANATOMY", 84, 88], ["IVI", "DISEASE", 22, 25], ["infection", "DISEASE", 112, 121], ["monocytes", "CELL", 27, 36], ["AMs", "CELL", 66, 69], ["lung", "ORGAN", 84, 88], ["monocytes", "CELL_TYPE", 27, 36], ["AMs", "CELL_TYPE", 66, 69], ["severe IVI", "PROBLEM", 15, 25], ["monocytes", "PROBLEM", 27, 36], ["infection", "PROBLEM", 112, 121], ["severe", "OBSERVATION_MODIFIER", 15, 21], ["IVI", "OBSERVATION", 22, 25], ["lung", "ANATOMY", 84, 88], ["infection", "OBSERVATION", 112, 121]]], ["Even after a 1-month residence in the lung, these BM-derived AMs have not acquired the relatively unresponsive profile of resident AMs as determined by transcriptional and functional analysis [10].", [["lung", "ANATOMY", 38, 42], ["BM", "ANATOMY", 50, 52], ["AMs", "ANATOMY", 61, 64], ["AMs", "ANATOMY", 131, 134], ["lung", "ORGAN", 38, 42], ["BM", "CELL", 50, 52], ["AMs", "CELL", 61, 64], ["AMs", "CELL", 131, 134], ["AMs", "CELL_TYPE", 61, 64], ["resident AMs", "CELL_TYPE", 122, 134], ["lung", "ANATOMY", 38, 42], ["BM", "OBSERVATION", 50, 52]]], ["These results highlight a differential responsiveness between resident and recruited AMs and reconcile functional changes at the population level with a lack of functional changes in resident AMs; the new functionality comes in with the newly recruited cells [10].", [["AMs", "ANATOMY", 85, 88], ["AMs", "ANATOMY", 192, 195], ["cells", "ANATOMY", 253, 258], ["AMs", "CELL", 85, 88], ["AMs", "CELL", 192, 195], ["cells", "CELL", 253, 258], ["AMs", "CELL_TYPE", 85, 88], ["AMs", "CELL_TYPE", 192, 195], ["functional changes", "PROBLEM", 103, 121]]], ["Similar observations with regard to BM-derived AMs have been made in other lung-insult models, showing that BM-derived AMs provide protection against murine house dust mite (HDM)-induced asthma [11] or can be a driving force for lung fibrosis following mouse lung injury [12,30,31].", [["BM", "ANATOMY", 36, 38], ["AMs", "ANATOMY", 47, 50], ["lung", "ANATOMY", 75, 79], ["BM", "ANATOMY", 108, 110], ["AMs", "ANATOMY", 119, 122], ["lung", "ANATOMY", 229, 233], ["lung", "ANATOMY", 259, 263], ["HDM", "CHEMICAL", 174, 177], ["asthma", "DISEASE", 187, 193], ["fibrosis", "DISEASE", 234, 242], ["lung injury", "DISEASE", 259, 270], ["BM", "CELL", 36, 38], ["AMs", "CELL", 47, 50], ["lung", "ORGAN", 75, 79], ["BM-derived AMs", "CELL", 108, 122], ["murine", "ORGANISM", 150, 156], ["lung", "ORGAN", 229, 233], ["mouse", "ORGANISM", 253, 258], ["lung", "ORGAN", 259, 263], ["AMs", "CELL_TYPE", 47, 50], ["AMs", "CELL_TYPE", 119, 122], ["murine", "SPECIES", 150, 156], ["mouse", "SPECIES", 253, 258], ["house dust mite", "SPECIES", 157, 172], ["mouse", "SPECIES", 253, 258], ["BM", "TEST", 36, 38], ["BM", "PROBLEM", 108, 110], ["asthma", "PROBLEM", 187, 193], ["lung fibrosis", "PROBLEM", 229, 242], ["mouse lung injury", "PROBLEM", 253, 270], ["lung", "ANATOMY", 75, 79], ["lung", "ANATOMY", 229, 233], ["fibrosis", "OBSERVATION", 234, 242], ["lung", "ANATOMY", 259, 263], ["injury", "OBSERVATION", 264, 270]]], ["Also, similar to IVI, tissue-resident AMs have been reported to remain mostly unchanged following bleomycin treatment [12], consistent with the notion that resident AMs of embryonic origin can play important roles in tissue homeostasis and exhibit reduced functional plasticity [17,32].Why Is Proliferation of Resident AMs Not Sufficient to Replenish the AM Pool?Resident AMs are known to be able to proliferate and contribute to the repopulation of the lung, but some of the AMs found after IVI and other insults are monocyte derived [10., 11., 12.].", [["tissue", "ANATOMY", 22, 28], ["AMs", "ANATOMY", 38, 41], ["AMs", "ANATOMY", 165, 168], ["embryonic origin", "ANATOMY", 172, 188], ["tissue", "ANATOMY", 217, 223], ["AMs", "ANATOMY", 372, 375], ["lung", "ANATOMY", 454, 458], ["AMs", "ANATOMY", 476, 479], ["monocyte", "ANATOMY", 518, 526], ["bleomycin", "CHEMICAL", 98, 107], ["bleomycin", "CHEMICAL", 98, 107], ["tissue", "TISSUE", 22, 28], ["AMs", "CELL", 38, 41], ["bleomycin", "SIMPLE_CHEMICAL", 98, 107], ["AMs", "CELL", 165, 168], ["embryonic", "DEVELOPING_ANATOMICAL_STRUCTURE", 172, 181], ["tissue", "TISSUE", 217, 223], ["AMs", "CELL", 372, 375], ["lung", "ORGAN", 454, 458], ["AMs", "CELL", 476, 479], ["monocyte", "CELL", 518, 526], ["AMs", "CELL_TYPE", 38, 41], ["AMs", "CELL_TYPE", 165, 168], ["AMs", "CELL_TYPE", 372, 375], ["AMs", "CELL_TYPE", 476, 479], ["bleomycin treatment", "TREATMENT", 98, 117], ["reduced functional plasticity", "PROBLEM", 248, 277], ["the repopulation of the lung", "PROBLEM", 430, 458], ["the AMs", "PROBLEM", 472, 479], ["IVI", "TREATMENT", 492, 495], ["unchanged", "OBSERVATION_MODIFIER", 78, 87], ["Proliferation", "OBSERVATION_MODIFIER", 293, 306], ["repopulation", "OBSERVATION", 434, 446], ["lung", "ANATOMY", 454, 458]]], ["Why do resident AMs not fully repopulate the AM pool during recovery from IVI in mice?", [["IVI", "DISEASE", 74, 77], ["AMs", "CELL", 16, 19], ["mice", "ORGANISM", 81, 85], ["AMs", "CELL_TYPE", 16, 19], ["mice", "SPECIES", 81, 85], ["mice", "SPECIES", 81, 85]]], ["Why is the contribution of a monocyte-derived AM population needed?", [["monocyte", "ANATOMY", 29, 37], ["monocyte", "CELL", 29, 37], ["AM", "CELL", 46, 48], ["a monocyte", "TEST", 27, 37]]], ["The niche model [33] may provide a framework to explain AM dynamics.", [["AM", "GENE_OR_GENE_PRODUCT", 56, 58]]], ["At the steady state, the lung epithelium can prevent access by monocytes to engraft in this niche.", [["lung epithelium", "ANATOMY", 25, 40], ["monocytes", "ANATOMY", 63, 72], ["lung epithelium", "TISSUE", 25, 40], ["monocytes", "CELL", 63, 72], ["monocytes", "CELL_TYPE", 63, 72], ["the lung epithelium", "PROBLEM", 21, 40], ["lung", "ANATOMY", 25, 29], ["epithelium", "ANATOMY_MODIFIER", 30, 40]]], ["Moreover, the AM niche is unavailable, already occupied with embryonically derived resident cells.", [["AM niche", "ANATOMY", 14, 22], ["cells", "ANATOMY", 92, 97], ["cells", "CELL", 92, 97], ["embryonically derived resident cells", "CELL_TYPE", 61, 97]]], ["Injury such as IVI would lead to AM depletion and render the niche temporarily available.", [["Injury", "DISEASE", 0, 6], ["Injury", "PROBLEM", 0, 6], ["IVI", "TREATMENT", 15, 18], ["AM depletion", "PROBLEM", 33, 45]]], ["The empty niche may instruct resident AMs to proliferate locally or, if necessary, allow recruited monocytes to engraft [3,10,17].", [["niche", "ANATOMY", 10, 15], ["AMs", "ANATOMY", 38, 41], ["monocytes", "ANATOMY", 99, 108], ["AMs", "CELL", 38, 41], ["monocytes", "CELL", 99, 108], ["AMs", "CELL_TYPE", 38, 41], ["monocytes", "CELL_TYPE", 99, 108]]], ["In vivo studies in mice have highlighted the capacity of resident AMs to self-sustain via proliferation at the steady state and expand after targeted depletion [3].", [["AMs", "ANATOMY", 66, 69], ["mice", "ORGANISM", 19, 23], ["AMs", "CELL", 66, 69], ["AMs", "CELL_TYPE", 66, 69], ["mice", "SPECIES", 19, 23], ["mice", "SPECIES", 19, 23], ["vivo studies", "TEST", 3, 15], ["targeted depletion", "PROBLEM", 141, 159]]], ["For instance, accumulation of pleural macrophages was demonstrated in a type 2 immune response induced by infection with the nematode Litomosoides sigmodontis.", [["pleural macrophages", "ANATOMY", 30, 49], ["infection", "DISEASE", 106, 115], ["pleural macrophages", "CELL", 30, 49], ["Litomosoides sigmodontis", "ORGANISM", 134, 158], ["pleural macrophages", "CELL_TYPE", 30, 49], ["Litomosoides sigmodontis", "SPECIES", 134, 158], ["Litomosoides sigmodontis", "SPECIES", 134, 158], ["pleural macrophages", "PROBLEM", 30, 49], ["a type 2 immune response", "PROBLEM", 70, 94], ["infection", "PROBLEM", 106, 115], ["the nematode Litomosoides sigmodontis", "PROBLEM", 121, 158], ["accumulation", "OBSERVATION_MODIFIER", 14, 26], ["pleural", "ANATOMY", 30, 37], ["macrophages", "OBSERVATION", 38, 49], ["infection", "OBSERVATION", 106, 115], ["nematode Litomosoides sigmodontis", "OBSERVATION", 125, 158]]], ["Here, local proliferation of alternatively activated macrophages was driven via IL-4 signaling, given that it was absent in IL-4-deficient mice, with minimal contribution from recruited macrophages [34,35].", [["macrophages", "ANATOMY", 53, 64], ["macrophages", "ANATOMY", 186, 197], ["macrophages", "CELL", 53, 64], ["IL-4", "GENE_OR_GENE_PRODUCT", 80, 84], ["IL-4", "GENE_OR_GENE_PRODUCT", 124, 128], ["mice", "ORGANISM", 139, 143], ["macrophages", "CELL", 186, 197], ["alternatively activated macrophages", "CELL_TYPE", 29, 64], ["IL", "PROTEIN", 80, 82], ["IL-4", "PROTEIN", 124, 128], ["recruited macrophages", "CELL_TYPE", 176, 197], ["mice", "SPECIES", 139, 143], ["mice", "SPECIES", 139, 143], ["activated macrophages", "PROBLEM", 43, 64], ["IL", "TEST", 124, 126], ["proliferation", "OBSERVATION_MODIFIER", 12, 25], ["macrophages", "OBSERVATION", 53, 64], ["minimal", "OBSERVATION_MODIFIER", 150, 157], ["macrophages", "OBSERVATION", 186, 197]]], ["It should be noted that monocyte-derived macrophages could also be driven to proliferate by IL-4 activation, as shown by BrdU incorporation by recruited peritoneal macrophages after IL-4 treatment [34].", [["monocyte", "ANATOMY", 24, 32], ["macrophages", "ANATOMY", 41, 52], ["peritoneal macrophages", "ANATOMY", 153, 175], ["BrdU", "CHEMICAL", 121, 125], ["BrdU", "CHEMICAL", 121, 125], ["monocyte", "CELL", 24, 32], ["macrophages", "CELL", 41, 52], ["IL-4", "GENE_OR_GENE_PRODUCT", 92, 96], ["BrdU", "SIMPLE_CHEMICAL", 121, 125], ["peritoneal macrophages", "CELL", 153, 175], ["IL-4", "GENE_OR_GENE_PRODUCT", 182, 186], ["macrophages", "CELL_TYPE", 41, 52], ["IL-4", "PROTEIN", 92, 96], ["peritoneal macrophages", "CELL_TYPE", 153, 175], ["monocyte", "TEST", 24, 32], ["IL-4 treatment", "TREATMENT", 182, 196], ["peritoneal", "ANATOMY", 153, 163]]], ["The infection-site-restricted IL-4-dependent proliferation of resident macrophages was independent of the M-CSF receptor, in contrast to M-CSF-dependent proliferation at the steady state [35].", [["macrophages", "ANATOMY", 71, 82], ["infection", "DISEASE", 4, 13], ["IL-4", "GENE_OR_GENE_PRODUCT", 30, 34], ["macrophages", "CELL", 71, 82], ["M-CSF receptor", "GENE_OR_GENE_PRODUCT", 106, 120], ["M-CSF", "GENE_OR_GENE_PRODUCT", 137, 142], ["infection-site", "DNA", 4, 18], ["IL-4", "PROTEIN", 30, 34], ["resident macrophages", "CELL_TYPE", 62, 82], ["M-CSF receptor", "PROTEIN", 106, 120], ["CSF", "PROTEIN", 139, 142], ["The infection", "PROBLEM", 0, 13], ["restricted IL", "TREATMENT", 19, 32], ["CSF receptor", "TEST", 108, 120], ["dependent proliferation", "PROBLEM", 143, 166], ["infection", "OBSERVATION", 4, 13], ["site", "OBSERVATION_MODIFIER", 14, 18], ["dependent", "OBSERVATION_MODIFIER", 35, 44], ["proliferation", "OBSERVATION_MODIFIER", 45, 58], ["macrophages", "OBSERVATION", 71, 82], ["dependent", "OBSERVATION_MODIFIER", 143, 152], ["proliferation", "OBSERVATION", 153, 166]]], ["In the mouse lung, IL-4-dependent AM proliferation is enhanced by surfactant protein A (SP-A), potentially produced by alveolar epithelial type II cells [36].", [["lung", "ANATOMY", 13, 17], ["AM", "ANATOMY", 34, 36], ["alveolar epithelial type II cells", "ANATOMY", 119, 152], ["SP-A", "CHEMICAL", 88, 92], ["mouse", "ORGANISM", 7, 12], ["lung", "ORGAN", 13, 17], ["IL-4", "GENE_OR_GENE_PRODUCT", 19, 23], ["AM", "CELL", 34, 36], ["surfactant protein A", "GENE_OR_GENE_PRODUCT", 66, 86], ["SP-A", "GENE_OR_GENE_PRODUCT", 88, 92], ["alveolar epithelial type II cells", "CELL", 119, 152], ["surfactant protein A", "PROTEIN", 66, 86], ["SP", "PROTEIN", 88, 90], ["alveolar epithelial type II cells", "CELL_TYPE", 119, 152], ["mouse", "SPECIES", 7, 12], ["mouse", "SPECIES", 7, 12], ["dependent AM proliferation", "PROBLEM", 24, 50], ["surfactant protein", "TEST", 66, 84], ["alveolar epithelial type II cells", "PROBLEM", 119, 152], ["mouse", "ANATOMY_MODIFIER", 7, 12], ["lung", "ANATOMY", 13, 17], ["IL", "OBSERVATION_MODIFIER", 19, 21], ["dependent", "OBSERVATION_MODIFIER", 24, 33], ["AM proliferation", "OBSERVATION", 34, 50], ["alveolar epithelial", "ANATOMY", 119, 138]]], ["By contrast, repopulation of lung macrophages after genotoxic depletion is dependent on both M-CSF and GM-CSF, but independent of IL-4 [3].", [["lung macrophages", "ANATOMY", 29, 45], ["GM", "CHEMICAL", 103, 105], ["lung macrophages", "CELL", 29, 45], ["M-CSF", "GENE_OR_GENE_PRODUCT", 93, 98], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 103, 109], ["IL-4", "GENE_OR_GENE_PRODUCT", 130, 134], ["lung macrophages", "CELL_TYPE", 29, 45], ["CSF", "PROTEIN", 95, 98], ["CSF", "PROTEIN", 106, 109], ["IL", "PROTEIN", 130, 132], ["repopulation of lung macrophages", "TREATMENT", 13, 45], ["genotoxic depletion", "PROBLEM", 52, 71], ["lung", "ANATOMY", 29, 33], ["macrophages", "OBSERVATION", 34, 45], ["genotoxic depletion", "OBSERVATION", 52, 71]]], ["Together, these data suggest that proliferative capacity may not be restricted to macrophage precursors, but resident macrophages may be capable of expansion in situ for maintenance in type 2 responses or when restoring tissue homeostasis in situations where the tissue-damage potential of inflammatory cell recruitment is to be avoided.Why Is Proliferation of Resident AMs Not Sufficient to Replenish the AM Pool?In contrast to our findings describing how depleted AMs are repopulated with both resident AMs and highly immunoreactive recruited AMs following IVI [10], another IVI study in mice found that the reduction of AMs was recovered by local repopulation with resident AMs, independent of monocyte contribution [3].", [["macrophage precursors", "ANATOMY", 82, 103], ["macrophages", "ANATOMY", 118, 129], ["situ", "ANATOMY", 161, 165], ["tissue", "ANATOMY", 220, 226], ["tissue", "ANATOMY", 263, 269], ["cell", "ANATOMY", 303, 307], ["AMs", "ANATOMY", 466, 469], ["AMs", "ANATOMY", 505, 508], ["AMs", "ANATOMY", 545, 548], ["AMs", "ANATOMY", 623, 626], ["AMs", "ANATOMY", 677, 680], ["monocyte", "ANATOMY", 697, 705], ["macrophage", "CELL", 82, 92], ["macrophages", "CELL", 118, 129], ["tissue", "TISSUE", 220, 226], ["tissue", "TISSUE", 263, 269], ["inflammatory cell", "CELL", 290, 307], ["AMs", "CELL", 466, 469], ["AMs", "CELL", 505, 508], ["AMs", "CELL", 545, 548], ["mice", "ORGANISM", 590, 594], ["AMs", "CELL", 623, 626], ["AMs", "CELL", 677, 680], ["monocyte", "CELL", 697, 705], ["macrophage precursors", "CELL_TYPE", 82, 103], ["resident macrophages", "CELL_TYPE", 109, 129], ["AMs", "CELL_TYPE", 466, 469], ["AMs", "CELL_TYPE", 505, 508], ["AMs", "CELL_TYPE", 545, 548], ["AMs", "CELL_TYPE", 623, 626], ["resident AMs", "CELL_TYPE", 668, 680], ["mice", "SPECIES", 590, 594], ["mice", "SPECIES", 590, 594], ["proliferative capacity", "PROBLEM", 34, 56], ["restoring tissue homeostasis in situations", "PROBLEM", 210, 252], ["inflammatory cell recruitment", "TREATMENT", 290, 319], ["another IVI study", "TEST", 569, 586], ["AMs", "PROBLEM", 623, 626], ["inflammatory cell recruitment", "OBSERVATION", 290, 319], ["Proliferation", "OBSERVATION_MODIFIER", 344, 357]]], ["Similar patterns of AM depletion and proliferation in situ were observed with poly I:C and clodronate liposome administration [3], confirming the ability of resident macrophages to expand in inflammatory settings.", [["macrophages", "ANATOMY", 166, 177], ["poly I:C", "CHEMICAL", 78, 86], ["clodronate", "CHEMICAL", 91, 101], ["poly I:C", "CHEMICAL", 78, 86], ["clodronate", "CHEMICAL", 91, 101], ["AM", "GENE_OR_GENE_PRODUCT", 20, 22], ["poly I:C", "SIMPLE_CHEMICAL", 78, 86], ["clodronate liposome", "SIMPLE_CHEMICAL", 91, 110], ["macrophages", "CELL", 166, 177], ["resident macrophages", "CELL_TYPE", 157, 177], ["AM depletion", "PROBLEM", 20, 32], ["proliferation in situ", "PROBLEM", 37, 58], ["C and clodronate liposome administration", "TREATMENT", 85, 125], ["inflammatory settings", "TREATMENT", 191, 212], ["AM depletion", "OBSERVATION", 20, 32], ["proliferation", "OBSERVATION_MODIFIER", 37, 50], ["macrophages", "OBSERVATION", 166, 177], ["inflammatory", "OBSERVATION", 191, 203]]], ["Most likely, the contribution of embryonically derived versus monocyte-derived cells to the AM pool post-IVI may depend on the degree of AM depletion during infection, which in turn may depend on the severity of inflammation.", [["monocyte", "ANATOMY", 62, 70], ["cells", "ANATOMY", 79, 84], ["AM pool", "ANATOMY", 92, 99], ["AM", "CHEMICAL", 137, 139], ["infection", "DISEASE", 157, 166], ["inflammation", "DISEASE", 212, 224], ["monocyte", "CELL", 62, 70], ["-derived cells", "CELL", 70, 84], ["AM", "CELL", 92, 94], ["AM", "GENE_OR_GENE_PRODUCT", 137, 139], ["embryonically derived versus monocyte-derived cells", "CELL_TYPE", 33, 84], ["IVI", "TREATMENT", 105, 108], ["AM depletion", "PROBLEM", 137, 149], ["infection", "PROBLEM", 157, 166], ["inflammation", "PROBLEM", 212, 224], ["AM depletion", "OBSERVATION", 137, 149], ["infection", "OBSERVATION", 157, 166], ["inflammation", "OBSERVATION", 212, 224]]], ["This might also contribute to explaining why, in another IVI study, AMs were desensitized for TLR signaling 1\u20132 months post-recovery [37], reminiscent of the lipopolysaccharide (LPS) tolerance previously described [38].Is There Trained Immunity of Resident AMs?Trained immunity in monocytes and macrophages has been described as a stimulus-induced epigenetic alteration leading to long-term functional changes.", [["AMs", "ANATOMY", 68, 71], ["monocytes", "ANATOMY", 281, 290], ["macrophages", "ANATOMY", 295, 306], ["lipopolysaccharide", "CHEMICAL", 158, 176], ["LPS", "CHEMICAL", 178, 181], ["AMs", "CELL", 68, 71], ["TLR", "GENE_OR_GENE_PRODUCT", 94, 97], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 158, 176], ["LPS", "SIMPLE_CHEMICAL", 178, 181], ["AMs", "CELL", 257, 260], ["monocytes", "CELL", 281, 290], ["macrophages", "CELL", 295, 306], ["AMs", "CELL_TYPE", 68, 71], ["TLR", "PROTEIN", 94, 97], ["Resident AMs", "CELL_TYPE", 248, 260], ["monocytes", "CELL_TYPE", 281, 290], ["macrophages", "CELL_TYPE", 295, 306], ["another IVI study", "TEST", 49, 66], ["AMs", "PROBLEM", 68, 71], ["the lipopolysaccharide (LPS", "TREATMENT", 154, 181], ["macrophages", "PROBLEM", 295, 306], ["epigenetic alteration", "PROBLEM", 348, 369], ["long-term functional changes", "PROBLEM", 381, 409], ["macrophages", "OBSERVATION", 295, 306], ["long-term functional", "OBSERVATION_MODIFIER", 381, 401]]], ["Where does trained immunity come into play and where is macrophage origin sufficient to explain functional differences?", [["macrophage", "ANATOMY", 56, 66], ["macrophage", "CELL", 56, 66]]], ["The above results [10., 11., 12.] demonstrate that resident AMs do not change during certain lung insults, in line with their status as terminally differentiated, tissue-adapted cells.", [["AMs", "ANATOMY", 60, 63], ["lung", "ANATOMY", 93, 97], ["tissue", "ANATOMY", 163, 169], ["cells", "ANATOMY", 178, 183], ["AMs", "CELL", 60, 63], ["lung", "ORGAN", 93, 97], ["tissue", "TISSUE", 163, 169], ["cells", "CELL", 178, 183], ["AMs", "CELL_TYPE", 60, 63], ["terminally differentiated, tissue-adapted cells", "CELL_TYPE", 136, 183], ["certain lung insults", "PROBLEM", 85, 105], ["lung", "ANATOMY", 93, 97], ["insults", "OBSERVATION", 98, 105]]], ["However, in other experimental settings, long-lived resident AMs can also show long-term functional alterations (Figure 1Ba).", [["AMs", "ANATOMY", 61, 64], ["AMs", "CELL", 61, 64], ["AMs", "CELL_TYPE", 61, 64], ["long-term functional alterations", "PROBLEM", 79, 111]]], ["For instance, the Pseudomonas aeruginosa vaccine induces expansion of local AMs independent of monocyte recruitment, providing protection against bacterial challenge in a mouse model of chemotherapy-induced depletion of BM-derived immune cells [39].", [["AMs", "ANATOMY", 76, 79], ["monocyte", "ANATOMY", 95, 103], ["BM-derived immune cells", "ANATOMY", 220, 243], ["Pseudomonas aeruginosa", "ORGANISM", 18, 40], ["AMs", "CELL", 76, 79], ["monocyte", "CELL", 95, 103], ["mouse", "ORGANISM", 171, 176], ["BM-derived immune cells", "CELL", 220, 243], ["AMs", "CELL_TYPE", 76, 79], ["BM-derived immune cells", "CELL_TYPE", 220, 243], ["Pseudomonas aeruginosa", "SPECIES", 18, 40], ["mouse", "SPECIES", 171, 176], ["Pseudomonas aeruginosa", "SPECIES", 18, 40], ["mouse", "SPECIES", 171, 176], ["the Pseudomonas aeruginosa vaccine", "TREATMENT", 14, 48], ["monocyte recruitment", "TREATMENT", 95, 115], ["protection", "TREATMENT", 127, 137], ["bacterial challenge", "TREATMENT", 146, 165], ["a mouse model of chemotherapy", "TREATMENT", 169, 198], ["induced depletion of BM", "PROBLEM", 199, 222], ["immune cells", "PROBLEM", 231, 243], ["monocyte recruitment", "OBSERVATION", 95, 115], ["BM", "ANATOMY", 220, 222]]], ["Similarly, resident trained AMs provide prolonged antibacterial protection after adenoviral infection independent of monocytes and BM progenitors, as shown in BM chimeras and parabiotic mice ([40]; Table 1).", [["AMs", "ANATOMY", 28, 31], ["monocytes", "ANATOMY", 117, 126], ["BM progenitors", "ANATOMY", 131, 145], ["BM chimeras", "ANATOMY", 159, 170], ["infection", "DISEASE", 92, 101], ["AMs", "CELL", 28, 31], ["adenoviral", "ORGANISM", 81, 91], ["monocytes", "CELL", 117, 126], ["BM progenitors", "CELL", 131, 145], ["BM chimeras", "CELL", 159, 170], ["parabiotic mice", "ORGANISM", 175, 190], ["AMs", "CELL_TYPE", 28, 31], ["monocytes", "CELL_TYPE", 117, 126], ["BM progenitors", "CELL_TYPE", 131, 145], ["BM chimeras", "CELL_TYPE", 159, 170], ["mice", "SPECIES", 186, 190], ["adenoviral", "SPECIES", 81, 91], ["mice", "SPECIES", 186, 190], ["prolonged antibacterial protection", "TREATMENT", 40, 74], ["adenoviral infection", "PROBLEM", 81, 101], ["BM progenitors", "TREATMENT", 131, 145]]], ["Here, the induction of trained AMs required priming by CD8+ T cells via IFN-\u03b3 production [40].", [["AMs", "ANATOMY", 31, 34], ["CD8+ T cells", "ANATOMY", 55, 67], ["AMs", "CELL", 31, 34], ["CD8", "GENE_OR_GENE_PRODUCT", 55, 58], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 72, 77], ["AMs", "CELL_TYPE", 31, 34], ["CD8", "PROTEIN", 55, 58], ["T cells", "CELL_TYPE", 60, 67], ["IFN", "PROTEIN", 72, 75], ["\u03b3", "PROTEIN", 76, 77], ["trained AMs", "TREATMENT", 23, 34], ["IFN", "TEST", 72, 75]]], ["In these studies, increased lung macrophage reactivity did not require newly recruited monocyte-derived cells as it was independent of the monocyte chemoattractant CCL2; instead, increased reactivity was deemed to be dependent on resident cells having changed their functionality [39,40].", [["lung macrophage", "ANATOMY", 28, 43], ["monocyte", "ANATOMY", 87, 95], ["cells", "ANATOMY", 104, 109], ["cells", "ANATOMY", 239, 244], ["lung macrophage", "CELL", 28, 43], ["monocyte", "CELL", 87, 95], ["cells", "CELL", 104, 109], ["monocyte", "CELL", 139, 147], ["CCL2", "GENE_OR_GENE_PRODUCT", 164, 168], ["cells", "CELL", 239, 244], ["derived cells", "CELL_TYPE", 96, 109], ["monocyte chemoattractant", "PROTEIN", 139, 163], ["CCL2", "PROTEIN", 164, 168], ["resident cells", "CELL_TYPE", 230, 244], ["these studies", "TEST", 3, 16], ["increased lung macrophage reactivity", "PROBLEM", 18, 54], ["the monocyte chemoattractant CCL2", "TREATMENT", 135, 168], ["increased reactivity", "PROBLEM", 179, 199], ["increased", "OBSERVATION_MODIFIER", 18, 27], ["lung", "ANATOMY", 28, 32], ["macrophage reactivity", "OBSERVATION", 33, 54]]], ["It is currently unclear whether this effect is restricted to certain challenge models; also, it is unclear why other viral infections or bleomycin-induced lung insult might instead lead to the strong presence of monocyte-derived AMs with changed functionality.", [["lung", "ANATOMY", 155, 159], ["monocyte", "ANATOMY", 212, 220], ["AMs", "ANATOMY", 229, 232], ["infections", "DISEASE", 123, 133], ["bleomycin", "CHEMICAL", 137, 146], ["lung insult", "DISEASE", 155, 166], ["bleomycin", "CHEMICAL", 137, 146], ["bleomycin", "SIMPLE_CHEMICAL", 137, 146], ["lung", "ORGAN", 155, 159], ["monocyte", "CELL", 212, 220], ["AMs", "CELL", 229, 232], ["AMs", "CELL_TYPE", 229, 232], ["other viral infections", "PROBLEM", 111, 133], ["bleomycin-induced lung insult", "PROBLEM", 137, 166], ["unclear why", "UNCERTAINTY", 99, 110], ["viral", "OBSERVATION_MODIFIER", 117, 122], ["infections", "OBSERVATION", 123, 133], ["lung", "ANATOMY", 155, 159], ["insult", "OBSERVATION", 160, 166], ["monocyte", "OBSERVATION", 212, 220]]], ["In addition, not all lung insults will lead to strong CD8+ T cell-derived IFN-\u03b3, which appears to be a key cytokine in the imprinting of increased macrophage reactivity in the abovementioned mouse model of adenovirus infection [40].", [["lung", "ANATOMY", 21, 25], ["T cell", "ANATOMY", 59, 65], ["macrophage", "ANATOMY", 147, 157], ["lung insults", "DISEASE", 21, 33], ["adenovirus infection", "DISEASE", 206, 226], ["lung", "ORGAN", 21, 25], ["CD8", "GENE_OR_GENE_PRODUCT", 54, 57], ["T cell", "CELL", 59, 65], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 74, 79], ["macrophage", "CELL", 147, 157], ["mouse", "ORGANISM", 191, 196], ["adenovirus", "ORGANISM", 206, 216], ["CD8", "PROTEIN", 54, 57], ["IFN-\u03b3", "PROTEIN", 74, 79], ["cytokine", "PROTEIN", 107, 115], ["mouse", "SPECIES", 191, 196], ["mouse", "SPECIES", 191, 196], ["adenovirus", "SPECIES", 206, 216], ["all lung insults", "PROBLEM", 17, 33], ["T cell", "TEST", 59, 65], ["increased macrophage reactivity", "PROBLEM", 137, 168], ["adenovirus infection", "PROBLEM", 206, 226], ["lung", "ANATOMY", 21, 25], ["insults", "OBSERVATION", 26, 33], ["appears to be", "UNCERTAINTY", 87, 100], ["increased", "OBSERVATION_MODIFIER", 137, 146], ["macrophage reactivity", "OBSERVATION", 147, 168], ["adenovirus infection", "OBSERVATION", 206, 226]]], ["Given the variety of results obtained in different systems, the jury is still out on the circumstances under which embryonically derived resident AMs adopt long-term functional changes (Table 2).", [["AMs", "ANATOMY", 146, 149], ["AMs", "CELL", 146, 149], ["embryonically derived resident AMs", "CELL_TYPE", 115, 149]]], ["It is possible that, depending on the type of insult (e.g., whether it is more local or systemic), different processes may lead to changed reactivity of macrophages, some relying on long-term changes in resident populations, others on recruitment of new cells of differing reactivity.Why Are Recruited AMs More Immunoreactive Than Resident AMs?We argue that the simplest explanation for the increased reactivity of monocyte-derived AMs is that this represents a \u2018legacy\u2019 of their former monocyte profile.", [["macrophages", "ANATOMY", 153, 164], ["cells", "ANATOMY", 254, 259], ["monocyte", "ANATOMY", 415, 423], ["AMs", "ANATOMY", 432, 435], ["monocyte", "ANATOMY", 487, 495], ["macrophages", "CELL", 153, 164], ["cells", "CELL", 254, 259], ["AMs", "CELL", 340, 343], ["monocyte", "CELL", 415, 423], ["AMs", "CELL", 432, 435], ["monocyte", "CELL", 487, 495], ["macrophages", "CELL_TYPE", 153, 164], ["AMs", "CELL_TYPE", 302, 305], ["AMs", "CELL_TYPE", 340, 343], ["monocyte", "CELL_TYPE", 415, 423], ["AMs", "CELL_TYPE", 432, 435], ["insult", "PROBLEM", 46, 52], ["macrophages", "PROBLEM", 153, 164], ["the increased reactivity", "PROBLEM", 387, 411], ["macrophages", "OBSERVATION", 153, 164], ["long-term", "OBSERVATION_MODIFIER", 182, 191], ["new cells", "OBSERVATION_MODIFIER", 250, 259], ["Immunoreactive", "OBSERVATION_MODIFIER", 311, 325]]], ["Recruited monocytes seeded the mouse lung niches early post IVI to contribute to the AM pool [10,28,29].", [["monocytes", "ANATOMY", 10, 19], ["lung niches", "ANATOMY", 37, 48], ["monocytes", "CELL", 10, 19], ["mouse", "ORGANISM", 31, 36], ["lung", "ORGAN", 37, 41], ["monocytes", "CELL_TYPE", 10, 19], ["mouse", "SPECIES", 31, 36], ["mouse", "SPECIES", 31, 36], ["monocytes", "OBSERVATION", 10, 19], ["lung", "ANATOMY", 37, 41]]], ["Nevertheless, when recruited AMs were analyzed 28 days post-infection, they showed great similarities to blood monocytes from na\u00efve animals, transcriptionally and in terms of global chromatin accessibility [10].", [["AMs", "ANATOMY", 29, 32], ["blood monocytes", "ANATOMY", 105, 120], ["chromatin", "ANATOMY", 182, 191], ["AMs", "CELL", 29, 32], ["blood monocytes", "CELL", 105, 120], ["chromatin", "CELLULAR_COMPONENT", 182, 191], ["AMs", "CELL_TYPE", 29, 32], ["blood monocytes", "CELL_TYPE", 105, 120], ["chromatin", "DNA", 182, 191], ["blood monocytes", "TEST", 105, 120], ["chromatin accessibility", "OBSERVATION", 182, 205]]], ["A prominent example is the regulation of Il6 gene expression: more IL-6 protein is produced on a bacterial stimulus in recruited AMs than in resident AMs, and this is reflected in open chromatin regions found upstream of the Il6 gene in recruited AMs.", [["AMs", "ANATOMY", 129, 132], ["AMs", "ANATOMY", 150, 153], ["chromatin", "ANATOMY", 185, 194], ["AMs", "ANATOMY", 247, 250], ["Il6", "GENE_OR_GENE_PRODUCT", 41, 44], ["IL-6", "GENE_OR_GENE_PRODUCT", 67, 71], ["AMs", "CELL", 129, 132], ["AMs", "CELL", 150, 153], ["chromatin", "CELLULAR_COMPONENT", 185, 194], ["Il6", "GENE_OR_GENE_PRODUCT", 225, 228], ["AMs", "CELL", 247, 250], ["Il6 gene", "DNA", 41, 49], ["IL-6 protein", "PROTEIN", 67, 79], ["AMs", "CELL_TYPE", 129, 132], ["AMs", "CELL_TYPE", 150, 153], ["open chromatin regions", "DNA", 180, 202], ["Il6 gene", "DNA", 225, 233], ["AMs", "CELL_TYPE", 247, 250], ["a bacterial stimulus", "TREATMENT", 95, 115], ["open chromatin regions", "PROBLEM", 180, 202], ["prominent", "OBSERVATION_MODIFIER", 2, 11], ["bacterial stimulus", "OBSERVATION", 97, 115], ["open chromatin", "OBSERVATION", 180, 194]]], ["The open regions are similar to those in blood monocytes, and absent in resident AMs [10].", [["blood monocytes", "ANATOMY", 41, 56], ["AMs", "ANATOMY", 81, 84], ["blood monocytes", "CELL", 41, 56], ["AMs", "CELL", 81, 84], ["blood monocytes", "CELL_TYPE", 41, 56], ["AMs", "CELL_TYPE", 81, 84], ["blood monocytes", "TEST", 41, 56], ["open", "OBSERVATION", 4, 8], ["similar", "OBSERVATION_MODIFIER", 21, 28]]], ["In addition, another study in mice found enrichment of genes belonging to the IL-6 signaling pathway after stimulation of inflammatory monocytes and interstitial macrophages, but not of AMs [32].", [["inflammatory monocytes", "ANATOMY", 122, 144], ["interstitial macrophages", "ANATOMY", 149, 173], ["mice", "ORGANISM", 30, 34], ["IL-6", "GENE_OR_GENE_PRODUCT", 78, 82], ["monocytes", "CELL", 135, 144], ["interstitial macrophages", "CELL", 149, 173], ["IL-6", "PROTEIN", 78, 82], ["inflammatory monocytes", "CELL_TYPE", 122, 144], ["interstitial macrophages", "CELL_TYPE", 149, 173], ["AMs", "CELL_TYPE", 186, 189], ["mice", "SPECIES", 30, 34], ["mice", "SPECIES", 30, 34], ["another study", "TEST", 13, 26], ["the IL", "TEST", 74, 80], ["inflammatory monocytes", "PROBLEM", 122, 144], ["interstitial macrophages", "PROBLEM", 149, 173], ["AMs", "PROBLEM", 186, 189], ["inflammatory monocytes", "OBSERVATION", 122, 144], ["interstitial macrophages", "OBSERVATION", 149, 173]]], ["As interstitial macrophages are located in an open niche, they resemble more blood monocytes, in contrast to the closed niche of AMs, which sets them apart [5,15].", [["interstitial macrophages", "ANATOMY", 3, 27], ["blood monocytes", "ANATOMY", 77, 92], ["AMs", "ANATOMY", 129, 132], ["interstitial macrophages", "CELL", 3, 27], ["blood monocytes", "CELL", 77, 92], ["AMs", "CELL", 129, 132], ["interstitial macrophages", "CELL_TYPE", 3, 27], ["blood monocytes", "CELL_TYPE", 77, 92], ["AMs", "CELL_TYPE", 129, 132], ["interstitial macrophages", "PROBLEM", 3, 27], ["blood monocytes", "TEST", 77, 92], ["interstitial", "ANATOMY_MODIFIER", 3, 15], ["macrophages", "OBSERVATION", 16, 27], ["blood monocytes", "OBSERVATION", 77, 92]]], ["This suggests that the heterogeneous AM population post-IVI in mice [10] might not require major transcriptional, epigenetic, or functional changes of any of the constituent cell subsets.", [["cell", "ANATOMY", 174, 178], ["AM", "GENE_OR_GENE_PRODUCT", 37, 39], ["mice", "ORGANISM", 63, 67], ["cell", "CELL", 174, 178], ["constituent cell subsets", "CELL_TYPE", 162, 186], ["mice", "SPECIES", 63, 67], ["mice", "SPECIES", 63, 67], ["the heterogeneous AM population", "PROBLEM", 19, 50], ["heterogeneous", "OBSERVATION_MODIFIER", 23, 36], ["constituent cell subsets", "OBSERVATION", 162, 186]]], ["Resident AMs may be programmed to be hyporesponsive; hence, the low IL-6 production.", [["AMs", "ANATOMY", 9, 12], ["AMs", "CELL", 9, 12], ["IL-6", "GENE_OR_GENE_PRODUCT", 68, 72], ["AMs", "CELL_TYPE", 9, 12], ["IL", "PROTEIN", 68, 70], ["hyporesponsive", "PROBLEM", 37, 51]]], ["By contrast, recruited AMs, due to their monocyte legacy, might still transcriptionally resemble the blood monocytes they once were, with key proinflammatory genes prone for expression (Figure 1A,C).Why Are Recruited AMs More Immunoreactive Than Resident AMs?However, these findings in IVI do not exclude the possibility that in other situations, greater reactivity of recruited AMs is imprinted.", [["AMs", "ANATOMY", 23, 26], ["monocyte", "ANATOMY", 41, 49], ["blood monocytes", "ANATOMY", 101, 116], ["AMs", "ANATOMY", 379, 382], ["AMs", "CELL", 23, 26], ["monocyte", "CELL", 41, 49], ["blood monocytes", "CELL", 101, 116], ["AMs", "CELL", 255, 258], ["AMs", "CELL", 379, 382], ["AMs", "CELL_TYPE", 23, 26], ["blood monocytes", "CELL_TYPE", 101, 116], ["proinflammatory genes", "DNA", 142, 163], ["AMs", "CELL_TYPE", 255, 258], ["AMs", "CELL_TYPE", 379, 382], ["the blood monocytes", "TEST", 97, 116]]], ["One possibility is that inflammatory conditions in the lung during the monocyte-to-macrophage transition imprint enhanced reactivity onto these cells (Figure 1Bb), similar to what has been described in vitro when human blood monocytes were kept in culture for time periods of several days [41].", [["lung", "ANATOMY", 55, 59], ["monocyte", "ANATOMY", 71, 79], ["macrophage", "ANATOMY", 83, 93], ["cells", "ANATOMY", 144, 149], ["blood monocytes", "ANATOMY", 219, 234], ["lung", "ORGAN", 55, 59], ["monocyte", "CELL", 71, 79], ["macrophage", "CELL", 83, 93], ["cells", "CELL", 144, 149], ["human", "ORGANISM", 213, 218], ["blood monocytes", "CELL", 219, 234], ["human blood monocytes", "CELL_TYPE", 213, 234], ["human", "SPECIES", 213, 218], ["human", "SPECIES", 213, 218], ["inflammatory conditions in the lung", "PROBLEM", 24, 59], ["the monocyte", "TEST", 67, 79], ["macrophage transition", "PROBLEM", 83, 104], ["human blood monocytes", "TEST", 213, 234], ["culture", "TEST", 248, 255], ["inflammatory", "OBSERVATION", 24, 36], ["lung", "ANATOMY", 55, 59], ["monocyte", "ANATOMY", 71, 79]]], ["Alternatively, prior to arrival in the lung, monocytes might receive a cytokine-mediated signal in the blood imprinting their functionality (Figure 1Bc), or monocyte precursors might be imprinted even earlier in the BM (Figure 1Bd,e).", [["lung", "ANATOMY", 39, 43], ["monocytes", "ANATOMY", 45, 54], ["blood", "ANATOMY", 103, 108], ["monocyte", "ANATOMY", 157, 165], ["BM", "ANATOMY", 216, 218], ["lung", "ORGAN", 39, 43], ["monocytes", "CELL", 45, 54], ["blood", "ORGANISM_SUBSTANCE", 103, 108], ["monocyte", "CELL", 157, 165], ["BM", "TISSUE", 216, 218], ["monocytes", "CELL_TYPE", 45, 54], ["cytokine", "PROTEIN", 71, 79], ["monocyte precursors", "CELL_TYPE", 157, 176], ["a cytokine", "TEST", 69, 79], ["the blood", "TEST", 99, 108], ["Figure 1Bc", "TEST", 141, 151], ["monocyte precursors", "PROBLEM", 157, 176], ["lung", "ANATOMY", 39, 43], ["monocytes", "ANATOMY", 45, 54]]], ["The latter hypotheses are testable as they predict that, post-lung injury, the function of monocytes or monocyte-derived macrophages might be changed in peripheral organs in addition to the lung, because presumably, blood monocytes or their precursors would be trained.", [["lung", "ANATOMY", 62, 66], ["monocytes", "ANATOMY", 91, 100], ["monocyte", "ANATOMY", 104, 112], ["macrophages", "ANATOMY", 121, 132], ["peripheral organs", "ANATOMY", 153, 170], ["lung", "ANATOMY", 190, 194], ["blood monocytes", "ANATOMY", 216, 231], ["lung injury", "DISEASE", 62, 73], ["lung", "ORGAN", 62, 66], ["monocytes", "CELL", 91, 100], ["monocyte", "CELL", 104, 112], ["macrophages", "CELL", 121, 132], ["peripheral organs", "MULTI-TISSUE_STRUCTURE", 153, 170], ["lung", "ORGAN", 190, 194], ["blood monocytes", "CELL", 216, 231], ["monocytes", "CELL_TYPE", 91, 100], ["monocyte", "CELL_TYPE", 104, 112], ["macrophages", "CELL_TYPE", 121, 132], ["blood monocytes", "CELL_TYPE", 216, 231], ["post-lung injury", "PROBLEM", 57, 73], ["monocytes", "PROBLEM", 91, 100], ["monocyte-derived macrophages", "PROBLEM", 104, 132], ["blood monocytes", "PROBLEM", 216, 231], ["lung", "ANATOMY", 62, 66], ["injury", "OBSERVATION", 67, 73], ["peripheral", "ANATOMY_MODIFIER", 153, 163], ["organs", "ANATOMY", 164, 170], ["lung", "ANATOMY", 190, 194]]], ["Inversely, how systemic insults such as sepsis and trauma modify monocyte and macrophage function locally [42] is an important area of research that we do not cover here.Why Are Recruited AMs More Immunoreactive Than Resident AMs?", [["monocyte", "ANATOMY", 65, 73], ["macrophage", "ANATOMY", 78, 88], ["sepsis", "DISEASE", 40, 46], ["trauma", "DISEASE", 51, 57], ["monocyte", "CELL", 65, 73], ["macrophage", "CELL", 78, 88], ["AMs", "CELL", 226, 229], ["AMs", "CELL_TYPE", 226, 229], ["systemic insults", "PROBLEM", 15, 31], ["sepsis", "PROBLEM", 40, 46], ["trauma", "PROBLEM", 51, 57], ["sepsis", "OBSERVATION", 40, 46]]]], "PMC7445509": [["IntroductionTuberculosis (TB) remains a major public health problem globally, accounting 10 millioncases (range: 9.0\u201311.1 million); surprisingly two-thirds represents the developing country.1 Moreover, in 2017, TB remained one of the top 10 causes of death and the leading cause from a single infectious agent, with an estimated 1.3 million deaths (range: 1.2\u20131.4 million), worldwide.1 Emergence of drug-resistant TB continues to be a significant public health crisis, and has further worsened the situation and become a significant obstacle to effective TB control.2 According to global tuberculosis reports, worldwide in 2017, 558,000 people (range: 483,000\u2013639,000) developed TB that was resistant to rifampicin (RR-TB), the most effective \ufb01rst line drug, and of these, 82% had multidrug-resistant TB (MDR-TB).", [["IntroductionTuberculosis", "CHEMICAL", 0, 24], ["TB", "DISEASE", 26, 28], ["TB", "DISEASE", 211, 213], ["death", "DISEASE", 251, 256], ["deaths", "DISEASE", 341, 347], ["TB", "DISEASE", 414, 416], ["tuberculosis", "DISEASE", 588, 600], ["TB", "DISEASE", 679, 681], ["rifampicin", "CHEMICAL", 704, 714], ["RR-TB", "CHEMICAL", 716, 721], ["TB", "DISEASE", 801, 803], ["MDR-TB", "DISEASE", 805, 811], ["rifampicin", "CHEMICAL", 704, 714], ["people", "ORGANISM", 637, 643], ["rifampicin", "SIMPLE_CHEMICAL", 704, 714], ["people", "SPECIES", 637, 643], ["death", "PROBLEM", 251, 256], ["an estimated 1.3 million deaths", "PROBLEM", 316, 347], ["drug", "TREATMENT", 399, 403], ["resistant TB", "PROBLEM", 404, 416], ["effective TB control", "TREATMENT", 545, 565], ["TB", "PROBLEM", 679, 681], ["rifampicin", "TREATMENT", 704, 714], ["RR", "TEST", 716, 718], ["TB", "PROBLEM", 719, 721], ["multidrug-resistant TB", "PROBLEM", 781, 803], ["significant", "OBSERVATION_MODIFIER", 435, 446], ["worsened", "OBSERVATION_MODIFIER", 485, 493], ["significant", "OBSERVATION_MODIFIER", 521, 532], ["tuberculosis", "OBSERVATION", 588, 600], ["TB", "OBSERVATION", 679, 681]]], ["Globally, 3.5% of new TB cases and 18% of previously treated cases had MDR/RR-TB1IntroductionTB remains one of the leading public health problems in Nepal.", [["TB", "DISEASE", 22, 24], ["TB1IntroductionTB", "DISEASE", 78, 95], ["new TB cases", "PROBLEM", 18, 30], ["MDR", "PROBLEM", 71, 74], ["RR", "TEST", 75, 77], ["TB1IntroductionTB", "TREATMENT", 78, 95]]], ["According to the 2016/17 national tuberculosis programme, a total of 31,764 cases of TB were identified.", [["tuberculosis", "DISEASE", 34, 46], ["TB", "DISEASE", 85, 87], ["TB", "PROBLEM", 85, 87], ["tuberculosis", "OBSERVATION", 34, 46]]], ["The estimated annual incidence rate of all forms of TB is 111/100,000, whereas the incidence rate of new and relapse is 108/100,000 population.3IntroductionOne of the greatest risk factors for drug-resistant TB is problems in treatment and diagnosis, especially in developing countries.", [["TB", "DISEASE", 52, 54], ["TB", "DISEASE", 208, 210], ["The estimated annual incidence rate", "PROBLEM", 0, 35], ["TB", "PROBLEM", 52, 54], ["resistant TB", "PROBLEM", 198, 210], ["annual", "OBSERVATION_MODIFIER", 14, 20], ["incidence", "OBSERVATION_MODIFIER", 21, 30], ["new", "OBSERVATION_MODIFIER", 101, 104]]], ["If TB is identified and treated early, drug resistance can be avoided.", [["TB", "DISEASE", 3, 5], ["TB", "PROBLEM", 3, 5], ["drug resistance", "TREATMENT", 39, 54], ["TB", "OBSERVATION", 3, 5]]], ["The rapid detection of Mycobacterium tuberculosis (MTB) is crucial for early diagnosis and management of disease to minimize the high risk of disease transmission from person to person and emergence of MDR-TB.", [["Mycobacterium tuberculosis", "DISEASE", 23, 49], ["MTB", "DISEASE", 51, 54], ["MDR-TB", "DISEASE", 202, 208], ["Mycobacterium tuberculosis", "ORGANISM", 23, 49], ["Mycobacterium tuberculosis", "SPECIES", 23, 49], ["person", "SPECIES", 168, 174], ["person", "SPECIES", 178, 184], ["Mycobacterium tuberculosis", "SPECIES", 23, 49], ["The rapid detection", "TEST", 0, 19], ["Mycobacterium tuberculosis", "PROBLEM", 23, 49], ["disease", "PROBLEM", 105, 112], ["disease transmission", "PROBLEM", 142, 162], ["MDR", "PROBLEM", 202, 205], ["TB", "PROBLEM", 206, 208], ["Mycobacterium tuberculosis", "OBSERVATION", 23, 49], ["disease", "OBSERVATION", 142, 149], ["TB", "OBSERVATION", 206, 208]]], ["Xpert MTB/Rif assay, endorsed by WHO, is able to assess simultaneously detection of M. tuberculosis and rifampicin resistance mutation in the rpoB gene within two hours.4,5 The Xpert assay is highly rapid, sensitive and specific in diagnosis of both pulmonary and extra pulmonary tuberculosis.6\u20138 Additionally, it was shown to be cost-effective for TB diagnosis compared to microscopy in resource limited countries.9IntroductionMoreover, the prevalence of MTB and RR/MTB and its contributing factors described in literature vary largely across countries, which may also differ from Nepal.", [["pulmonary", "ANATOMY", 250, 259], ["pulmonary", "ANATOMY", 270, 279], ["tuberculosis", "DISEASE", 87, 99], ["rifampicin", "CHEMICAL", 104, 114], ["pulmonary and extra pulmonary tuberculosis", "DISEASE", 250, 292], ["TB", "DISEASE", 349, 351], ["MTB", "DISEASE", 456, 459], ["MTB", "DISEASE", 467, 470], ["rifampicin", "CHEMICAL", 104, 114], ["M. tuberculosis", "ORGANISM", 84, 99], ["rifampicin", "SIMPLE_CHEMICAL", 104, 114], ["rpoB", "GENE_OR_GENE_PRODUCT", 142, 146], ["pulmonary", "ORGAN", 250, 259], ["pulmonary", "ORGAN", 270, 279], ["rpoB gene", "DNA", 142, 151], ["M. tuberculosis", "SPECIES", 84, 99], ["M. tuberculosis", "SPECIES", 84, 99], ["M. tuberculosis", "PROBLEM", 84, 99], ["rifampicin resistance mutation", "PROBLEM", 104, 134], ["The Xpert assay", "TEST", 173, 188], ["both pulmonary and extra pulmonary tuberculosis", "PROBLEM", 245, 292], ["TB diagnosis", "TEST", 349, 361], ["microscopy", "TEST", 374, 384], ["MTB", "PROBLEM", 456, 459], ["RR/MTB", "TREATMENT", 464, 470], ["tuberculosis", "OBSERVATION", 87, 99], ["rifampicin resistance", "OBSERVATION", 104, 125], ["both", "ANATOMY_MODIFIER", 245, 249], ["pulmonary", "ANATOMY", 250, 259], ["extra", "OBSERVATION_MODIFIER", 264, 269], ["pulmonary", "ANATOMY", 270, 279], ["tuberculosis", "OBSERVATION", 280, 292], ["MTB", "OBSERVATION", 467, 470]]], ["However, to date, the prevalence of MTB and RR-MTB has not been addressed extensively in the Nepalese setting.", [["MTB", "DISEASE", 36, 39], ["MTB", "PROBLEM", 36, 39], ["RR", "TEST", 44, 46], ["MTB", "TREATMENT", 47, 50]]], ["Therefore, the present study was aimed at assessing the rate of RR-MTB using the Xpert MTB/Rif assay, and further to identify the influencing factors associated with it.Study Design ::: MethodsThis was a retrospective cross-sectional study where data were evaluated retrospectively from the patients over a one year period from February 2018 to January 2019.Study Setting ::: MethodsThis study was conducted at National Tuberculosis Center (NTC), Bhaktpur Nepal.", [["Tuberculosis", "DISEASE", 420, 432], ["patients", "ORGANISM", 291, 299], ["patients", "SPECIES", 291, 299], ["the present study", "TEST", 11, 28], ["RR", "TEST", 64, 66], ["Methods", "TREATMENT", 186, 193], ["a retrospective cross-sectional study", "TEST", 202, 239], ["Methods", "TREATMENT", 376, 383], ["This study", "TEST", 383, 393]]], ["This is a referral governmental hospital where the referral patients from different health services across the country visit the hospital for diagnosis and treatment of the disease.Outcome Variables ::: MethodsThe core variable used for the study was MTB and RR-MTB.", [["patients", "ORGANISM", 60, 68], ["patients", "SPECIES", 60, 68], ["treatment", "TREATMENT", 156, 165], ["the disease", "PROBLEM", 169, 180], ["Methods", "TREATMENT", 203, 210], ["the study", "TEST", 237, 246], ["MTB", "PROBLEM", 251, 254], ["RR", "TEST", 259, 261], ["disease", "OBSERVATION", 173, 180]]], ["The covariates included in this study were: age, sex, ethnic group, geographic diversity, TB treatment history.Study Population and Selection ::: MethodsPresumptive TB patients who visited NTCTuberculosis Center for the diagnosis and treatment of the disease, who met the inclusion criteria were enrolled in the study.", [["TB", "DISEASE", 90, 92], ["TB", "DISEASE", 165, 167], ["patients", "ORGANISM", 168, 176], ["patients", "SPECIES", 168, 176], ["this study", "TEST", 27, 37], ["TB treatment history", "TREATMENT", 90, 110], ["treatment", "TREATMENT", 234, 243], ["the disease", "PROBLEM", 247, 258], ["the study", "TEST", 308, 317], ["disease", "OBSERVATION", 251, 258]]], ["To be eligible, all age groups with signs and symptoms suggestive of TB underwent the GeneXpert Rif/MTB assay test and smear test.", [["TB", "DISEASE", 69, 71], ["signs and symptoms", "PROBLEM", 36, 54], ["TB", "PROBLEM", 69, 71], ["the GeneXpert Rif/MTB assay test", "TEST", 82, 114], ["smear test", "TEST", 119, 129]]], ["Patients with insufficient demographic and clinical information were excluded from the study.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["the study", "TEST", 83, 92]]], ["A total 197 records of study participants who had no records of smear test were excluded from 1187 subjects, resulting in 990.Data Collection ::: MethodsA structured questionnaire and checklist was used for the data collection.", [["participants", "ORGANISM", 29, 41], ["participants", "SPECIES", 29, 41], ["smear test", "TEST", 64, 74], ["the data collection", "TEST", 207, 226]]], ["Patient\u2019s demographic including age, sex, ethnicity, TB treatment history, geographic diversity and results of smear test for bacteriological presentation or not, rifampicin resistance using the GeneXpert/MTB assay was assessed retrospectively from the patient\u2019s medical chart as well as from laboratory chart.Laboratory investigation ::: MethodsFrom the respiratory specimen collected, acid fast bacilli microscopy and Xpert MTB/RIF assay was performed.", [["respiratory specimen", "ANATOMY", 355, 375], ["TB", "DISEASE", 53, 55], ["rifampicin", "CHEMICAL", 163, 173], ["rifampicin", "CHEMICAL", 163, 173], ["rifampicin", "SIMPLE_CHEMICAL", 163, 173], ["patient", "ORGANISM", 253, 260], ["Patient", "SPECIES", 0, 7], ["patient", "SPECIES", 253, 260], ["smear test", "TEST", 111, 121], ["bacteriological presentation", "TEST", 126, 154], ["rifampicin resistance", "TREATMENT", 163, 184], ["the GeneXpert/MTB assay", "TEST", 191, 214], ["the respiratory specimen", "TEST", 351, 375], ["acid fast bacilli microscopy", "TEST", 387, 415], ["Xpert MTB/RIF assay", "TEST", 420, 439], ["respiratory", "ANATOMY", 355, 366]]], ["If the presence of MTB was detected, GeneXpert was also used to look for evidence of rifampicin resistance.Laboratory investigation ::: MethodsFrom the sample, MTB bacilli was purified and concentrated by the Xpert MTB/RIF.", [["MTB", "DISEASE", 19, 22], ["rifampicin", "CHEMICAL", 85, 95], ["RIF", "CHEMICAL", 219, 222], ["rifampicin", "CHEMICAL", 85, 95], ["rifampicin", "SIMPLE_CHEMICAL", 85, 95], ["MTB", "PROBLEM", 19, 22], ["GeneXpert", "TEST", 37, 46], ["rifampicin resistance", "PROBLEM", 85, 106], ["MTB bacilli", "TEST", 160, 171], ["MTB", "OBSERVATION", 19, 22], ["rifampicin resistance", "OBSERVATION", 85, 106], ["MTB", "OBSERVATION_MODIFIER", 160, 163], ["bacilli", "OBSERVATION", 164, 171]]], ["Genomic material was isolated from the captured bacteria by sonication and the genomic DNA subsequently amplified by PCR.", [["DNA", "CELLULAR_COMPONENT", 87, 90], ["genomic DNA", "DNA", 79, 90], ["Genomic material", "PROBLEM", 0, 16], ["the captured bacteria", "PROBLEM", 35, 56], ["the genomic DNA", "PROBLEM", 75, 90], ["PCR", "TEST", 117, 120]]], ["Furthermore, all the clinically relevant rifampicin resistance, inducing mutations in the rpoB gene in the MTB genome in a real-time format using fluorescent probes called molecular beacons were identified.", [["rifampicin", "CHEMICAL", 41, 51], ["rifampicin", "CHEMICAL", 41, 51], ["rifampicin", "SIMPLE_CHEMICAL", 41, 51], ["rpoB", "GENE_OR_GENE_PRODUCT", 90, 94], ["rpoB gene", "DNA", 90, 99], ["MTB genome", "DNA", 107, 117], ["rifampicin resistance", "TREATMENT", 41, 62], ["inducing mutations", "PROBLEM", 64, 82], ["fluorescent probes", "TEST", 146, 164], ["molecular beacons", "PROBLEM", 172, 189], ["rifampicin resistance", "OBSERVATION", 41, 62], ["MTB genome", "OBSERVATION", 107, 117]]], ["Internal quality controls (sample processing control and probe check control) were used during the assay.GeneXpert MTB/RIF Assay ::: MethodsGeneXpert analysis was performed in accordance to the protocol provided by its manufacturer (Cepheid, Sunnyvale, CA, USA), module GX-IV-4.", [["sample", "ANATOMY", 27, 33], ["Internal quality controls", "TREATMENT", 0, 25], ["sample processing control", "TREATMENT", 27, 52], ["probe check control)", "TREATMENT", 57, 77], ["the assay", "TEST", 95, 104], ["MethodsGeneXpert analysis", "TEST", 133, 158]]], ["Sputum specimens were used directly for the test.", [["Sputum specimens", "ANATOMY", 0, 16], ["Sputum specimens", "CANCER", 0, 16], ["Sputum specimens", "TEST", 0, 16], ["the test", "TEST", 40, 48]]], ["Briefly, the sample-reagent (SR) (Cepheid) was added at a 2:1 ratio to the sputum sample and incubated for 15 min at room temperature.", [["sputum sample", "ANATOMY", 75, 88], ["Cepheid", "SIMPLE_CHEMICAL", 34, 41], ["the sample", "TEST", 9, 19], ["the sputum sample", "TEST", 71, 88]]], ["The treated sample was shaken gently during incubation and then transferred into the cartridge.Data Processing and Analysis ::: MethodsThe data collected from TB registration book were entered into an excel spreadsheet and then exported to SPSS version 20 (IBM Corporation, Armonk, NY, USA) for analysis.", [["sample", "ANATOMY", 12, 18], ["Methods", "TREATMENT", 128, 135], ["The data", "TEST", 135, 143], ["SPSS version", "TEST", 240, 252], ["analysis", "TEST", 295, 303], ["cartridge", "ANATOMY", 85, 94]]], ["Rifampicin resistance was the outcome variable.", [["Rifampicin", "CHEMICAL", 0, 10], ["Rifampicin", "CHEMICAL", 0, 10], ["Rifampicin", "SIMPLE_CHEMICAL", 0, 10], ["Rifampicin resistance", "TREATMENT", 0, 21]]], ["The association between the outcome variable test status and independent variables were computed using Chi-square test and where applicable Fisher\u2019s exact test.", [["Chi-square test", "TEST", 103, 118], ["exact test", "TEST", 149, 159]]], ["Confidence interval was set at 95% and P value less than 0.05% considered to be statistically significant for all tests.Ethical Aspects ::: MethodsStudy protocol was approved by the NTC for commencement of the study.", [["Confidence interval", "TEST", 0, 19], ["P value", "TEST", 39, 46], ["all tests", "TEST", 110, 119], ["MethodsStudy protocol", "TREATMENT", 140, 161], ["the study", "TEST", 206, 215]]], ["To ensure the confidentiality of the participants' information, data were anonymously used; and any other confidential information was highly secured.", [["participants", "SPECIES", 37, 49]]], ["Since we used secondary data, informed consent was not sought from the study participants.ResultsThe estimated prevalence of MTB among presumptive TB patients was 13.8%, with lower limit 11.88% and upper limit 16.16% (Table 1)", [["MTB", "DISEASE", 125, 128], ["TB", "DISEASE", 147, 149], ["patients", "ORGANISM", 150, 158], ["participants", "SPECIES", 77, 89], ["patients", "SPECIES", 150, 158], ["the study", "TEST", 67, 76], ["MTB", "PROBLEM", 125, 128], ["upper limit", "TEST", 198, 209]]]], "PMC7152105": [["Etiologic AgentThe infectious vector may be any microorganism capable of causing infection.", [["infection", "DISEASE", 81, 90], ["The infectious vector", "PROBLEM", 15, 36], ["any microorganism", "PROBLEM", 44, 61], ["infection", "PROBLEM", 81, 90], ["infectious", "OBSERVATION", 19, 29], ["infection", "OBSERVATION", 81, 90]]], ["The pathogenicity is the ability to induce disease, which is characterized by its virulence (infection severity, determined by the germ morbidity and mortality rates) and the level of invasiveness (capacity to invade tissues).", [["germ", "ANATOMY", 131, 135], ["tissues", "ANATOMY", 217, 224], ["infection", "DISEASE", 93, 102], ["germ", "TISSUE", 131, 135], ["tissues", "TISSUE", 217, 224], ["disease", "PROBLEM", 43, 50], ["its virulence (infection severity", "PROBLEM", 78, 111], ["the germ morbidity", "PROBLEM", 127, 145], ["mortality rates", "TEST", 150, 165], ["disease", "OBSERVATION", 43, 50], ["virulence", "OBSERVATION_MODIFIER", 82, 91]]], ["No microorganism is completely avirulent.", [["microorganism", "PROBLEM", 3, 16], ["avirulent", "PROBLEM", 31, 40], ["microorganism", "OBSERVATION", 3, 16], ["completely", "OBSERVATION_MODIFIER", 20, 30], ["avirulent", "OBSERVATION", 31, 40]]], ["An organism may have a very low level of virulence, but if the host (patient or health care provider) is highly susceptible, infection by the organism may cause disease.", [["infection", "DISEASE", 125, 134], ["patient", "ORGANISM", 69, 76], ["patient", "SPECIES", 69, 76], ["An organism", "PROBLEM", 0, 11], ["a very low level of virulence", "PROBLEM", 21, 50], ["infection", "PROBLEM", 125, 134], ["disease", "PROBLEM", 161, 168], ["very", "OBSERVATION_MODIFIER", 23, 27], ["low level", "OBSERVATION_MODIFIER", 28, 37], ["infection", "OBSERVATION", 125, 134]]], ["The risk of infection increases with the infecting dose (i.e., the number of organisms available to induce disease), the reservoir (i.e., the site where the organisms reside and multiply), and the infection source (i.e., the site from where it is transmitted to a susceptible host either directly or indirectly through an intermediary object).", [["infection", "DISEASE", 12, 21], ["infection", "DISEASE", 197, 206], ["infection", "PROBLEM", 12, 21], ["the infecting dose", "TREATMENT", 37, 55], ["organisms", "PROBLEM", 77, 86], ["disease", "PROBLEM", 107, 114], ["the reservoir", "TREATMENT", 117, 130], ["the infection source", "PROBLEM", 193, 213], ["infection", "OBSERVATION", 12, 21], ["infection", "OBSERVATION", 197, 206], ["intermediary object", "OBSERVATION", 322, 341]]], ["The infection source may be a human (e.g., health care providers, children, visitors, housekeeping personnel) with a symptomatic or an asymptomatic infection during the incubation period.", [["infection", "DISEASE", 4, 13], ["infection", "DISEASE", 148, 157], ["human", "ORGANISM", 30, 35], ["children", "ORGANISM", 66, 74], ["human", "SPECIES", 30, 35], ["children", "SPECIES", 66, 74], ["human", "SPECIES", 30, 35], ["The infection source", "PROBLEM", 0, 20], ["an asymptomatic infection", "PROBLEM", 132, 157], ["infection", "OBSERVATION", 4, 13], ["asymptomatic", "OBSERVATION_MODIFIER", 135, 147], ["infection", "OBSERVATION", 148, 157]]], ["The source may also be temporarily or permanently colonized (the most frequently colonized tissues are the skin and digestive and respiratory tracts).HostThe presence of a susceptible host is an increasingly important element in the chain of infection that paradoxically results from advances in current medical therapies and technology (e.g., children undergoing organ transplantation, chemotherapy, or extremely premature neonates) and the presence of children with diseases that compromise their immune systems (e.g., acquired immunodeficiency syndrome [AIDS], tuberculosis, malnutrition, burns).", [["tissues", "ANATOMY", 91, 98], ["skin", "ANATOMY", 107, 111], ["digestive", "ANATOMY", 116, 125], ["respiratory tracts", "ANATOMY", 130, 148], ["organ", "ANATOMY", 364, 369], ["infection", "DISEASE", 242, 251], ["acquired immunodeficiency syndrome", "DISEASE", 521, 555], ["AIDS", "DISEASE", 557, 561], ["tuberculosis", "DISEASE", 564, 576], ["malnutrition", "DISEASE", 578, 590], ["burns", "DISEASE", 592, 597], ["tissues", "TISSUE", 91, 98], ["skin", "ORGAN", 107, 111], ["digestive", "ORGAN", 116, 125], ["respiratory tracts", "MULTI-TISSUE_STRUCTURE", 130, 148], ["children", "ORGANISM", 344, 352], ["organ", "ORGAN", 364, 369], ["neonates", "ORGANISM", 424, 432], ["children", "ORGANISM", 454, 462], ["children", "SPECIES", 344, 352], ["children", "SPECIES", 454, 462], ["permanently colonized", "PROBLEM", 38, 59], ["a susceptible host", "PROBLEM", 170, 188], ["infection", "PROBLEM", 242, 251], ["current medical therapies", "TREATMENT", 296, 321], ["organ transplantation", "TREATMENT", 364, 385], ["chemotherapy", "TREATMENT", 387, 399], ["extremely premature neonates", "PROBLEM", 404, 432], ["diseases", "PROBLEM", 468, 476], ["their immune systems", "PROBLEM", 493, 513], ["acquired immunodeficiency syndrome", "PROBLEM", 521, 555], ["AIDS", "PROBLEM", 557, 561], ["tuberculosis", "PROBLEM", 564, 576], ["malnutrition", "PROBLEM", 578, 590], ["burns", "PROBLEM", 592, 597], ["may also be", "UNCERTAINTY", 11, 22], ["colonized", "OBSERVATION", 50, 59], ["skin", "ANATOMY", 107, 111], ["digestive", "ANATOMY", 116, 125], ["respiratory tracts", "ANATOMY", 130, 148], ["susceptible", "OBSERVATION_MODIFIER", 172, 183], ["host", "OBSERVATION", 184, 188], ["increasingly", "OBSERVATION_MODIFIER", 195, 207], ["important element", "OBSERVATION_MODIFIER", 208, 225], ["infection", "OBSERVATION", 242, 251]]], ["The organism may enter the host through the skin, mucous membranes, lungs, gastrointestinal tract, genitourinary tract, or the bloodstream via intravenous solutions, following laryngoscopy, or from surgical wounds.", [["skin", "ANATOMY", 44, 48], ["mucous membranes", "ANATOMY", 50, 66], ["lungs", "ANATOMY", 68, 73], ["gastrointestinal tract", "ANATOMY", 75, 97], ["genitourinary tract", "ANATOMY", 99, 118], ["bloodstream", "ANATOMY", 127, 138], ["intravenous", "ANATOMY", 143, 154], ["wounds", "ANATOMY", 207, 213], ["skin", "ORGAN", 44, 48], ["mucous membranes", "MULTI-TISSUE_STRUCTURE", 50, 66], ["lungs", "ORGAN", 68, 73], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 75, 97], ["genitourinary tract", "ORGANISM_SUBDIVISION", 99, 118], ["bloodstream", "IMMATERIAL_ANATOMICAL_ENTITY", 127, 138], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 143, 154], ["wounds", "PATHOLOGICAL_FORMATION", 207, 213], ["mucous membranes, lungs, gastrointestinal tract, genitourinary tract", "PROBLEM", 50, 118], ["intravenous solutions", "TREATMENT", 143, 164], ["laryngoscopy", "TEST", 176, 188], ["surgical wounds", "PROBLEM", 198, 213], ["skin", "ANATOMY", 44, 48], ["mucous membranes", "ANATOMY", 50, 66], ["lungs", "ANATOMY", 68, 73], ["gastrointestinal tract", "ANATOMY", 75, 97], ["genitourinary tract", "ANATOMY", 99, 118], ["wounds", "OBSERVATION", 207, 213]]], ["Organisms may also infect the individual as a result of work accidents with cutting or piercing devices.", [["accidents", "DISEASE", 61, 70], ["Organisms", "PROBLEM", 0, 9], ["cutting or piercing devices", "TREATMENT", 76, 103]]], ["The development of infection is influenced by the host defense mechanisms that may be classified as either nonspecific or specific:\u2022Nonspecific defense mechanisms include the skin, mucous membranes, secretions, excretions, enzymes, inflammatory responses, genetic factors, hormonal responses, nutritional status, behavior patterns, and the presence of other diseases.\u2022Specific defense mechanisms or immunity may occur as a result of exposure to an infectious agent (antibody formation) or through placental transfer of antibodies; artificial defense may be acquired through vaccines, toxoids, or exogenously administered immunoglobulins.", [["skin", "ANATOMY", 175, 179], ["mucous membranes", "ANATOMY", 181, 197], ["secretions", "ANATOMY", 199, 209], ["placental", "ANATOMY", 497, 506], ["infection", "DISEASE", 19, 28], ["skin", "ORGAN", 175, 179], ["mucous membranes", "MULTI-TISSUE_STRUCTURE", 181, 197], ["placental", "ORGAN", 497, 506], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 621, 636], ["antibodies", "PROTEIN", 519, 529], ["immunoglobulins", "PROTEIN", 621, 636], ["infection", "PROBLEM", 19, 28], ["Nonspecific defense mechanisms", "PROBLEM", 132, 162], ["secretions", "PROBLEM", 199, 209], ["enzymes", "TEST", 223, 230], ["inflammatory responses", "PROBLEM", 232, 254], ["genetic factors", "PROBLEM", 256, 271], ["other diseases", "PROBLEM", 352, 366], ["an infectious agent (antibody formation", "PROBLEM", 445, 484], ["antibodies", "PROBLEM", 519, 529], ["artificial defense", "PROBLEM", 531, 549], ["vaccines", "TREATMENT", 574, 582], ["toxoids", "TREATMENT", 584, 591], ["exogenously administered immunoglobulins", "TREATMENT", 596, 636], ["infection", "OBSERVATION", 19, 28], ["host defense", "OBSERVATION_MODIFIER", 50, 62], ["skin", "ANATOMY", 175, 179], ["mucous membranes", "ANATOMY", 181, 197], ["secretions", "OBSERVATION", 199, 209], ["inflammatory", "OBSERVATION_MODIFIER", 232, 244], ["diseases", "OBSERVATION", 358, 366], ["infectious", "OBSERVATION", 448, 458]]]]}